<SEC-DOCUMENT>0001493152-26-005827.txt : 20260209
<SEC-HEADER>0001493152-26-005827.hdr.sgml : 20260209
<ACCEPTANCE-DATETIME>20260209173145
ACCESSION NUMBER:		0001493152-26-005827
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		93
FILED AS OF DATE:		20260209
DATE AS OF CHANGE:		20260209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioRestorative Therapies, Inc.
		CENTRAL INDEX KEY:			0001505497
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				301341024
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-293322
		FILM NUMBER:		26612635

	BUSINESS ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		(631) 760-8100

	MAIL ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stem Cell Assurance, Inc.
		DATE OF NAME CHANGE:	20101110
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>forms-1.htm
<DESCRIPTION>S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:BRTX="http://biorestorative.com/20250930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_BRTX_biorestorative.com_20250930 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20250101_20250930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001505497 -->
<!-- Field: Set; Name: xdx; ID: xdx_079_SO_Z%2D%2D\2026 OPERATIONS\EDGAR\02 FEBRUARY\BIORESTORATIVE THERAPIES, INC\02%2D05%2D2026\Form S%2D1\Draft\Production\form10%2Dq.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000004" name="dei:EntityCentralIndexKey">0001505497</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-09-30" id="xdx2ixbrl0096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2025-07-012025-09-30" id="xdx2ixbrl0216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueAbeyanceShares" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueAbeyanceShares" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueAbeyanceShares" contextRef="From2025-01-012025-03-31" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueAbeyanceShares" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueAbeyanceShares" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0528" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:NoncashLeaseExpense" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0594" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0615" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0675" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0676" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0679" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0684" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:ReclassificationOfDeferredOfferingCosts" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0691" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:DeferredOfferingCostsIncludedInAccountsPayable" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0694" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-07-012025-09-30_us-gaap_ProductMember" id="xdx2ixbrl0754" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0973" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1012" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1013" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1014" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1110" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1124" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1130" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:DeferredOfferingCost" contextRef="AsOf2023-12-31" id="xdx2ixbrl1186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="xdx2ixbrl1191" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl1212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl1224" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl1225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GrantIncome" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl1477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1576" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1579" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1583" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:PaymentsForProceedsFromDeferredOfferingCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:IssuanceOfCommonStockHeldInAbeyance" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_us-gaap_ProductMember" id="xdx2ixbrl1657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1741" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31_custom_PatentsAndTrademarkMember" id="xdx2ixbrl1846" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_PatentsAndTrademarkMember" id="xdx2ixbrl1858" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2097" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl2109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31" id="xdx2ixbrl2117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20515187" id="xdx2ixbrl2181" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20515187" id="xdx2ixbrl2185" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl2187" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:DeferredTaxAssetsRightOfUseAsset" contextRef="AsOf2024-12-31" id="xdx2ixbrl2240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2024-12-31" id="xdx2ixbrl2258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl2273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl2274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2327" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="xdx2ixbrl2362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl2366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31" id="xdx2ixbrl2369" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2025#OperatingLeaseLiabilityCurrent</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl2370" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2025#OperatingLeaseLiabilityCurrent</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl2372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl2374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl2459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl2461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl2467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl2469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl2473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl2475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl2481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl2483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="brtx-20250930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ATMSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BRTX:ATMSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_custom_ATMSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BRTX:ATMSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BRTX:TwoThousandTwentyFourATMProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-082025-10-08_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-08</xbrli:startDate>
        <xbrli:endDate>2025-10-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-08_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-08_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-062024-11-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-06</xbrli:startDate>
        <xbrli:endDate>2024-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-06_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-062024-02-06_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-06</xbrli:startDate>
        <xbrli:endDate>2024-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_AuctusFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-20_us-gaap_CommonStockMember_custom_AuctusFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-062024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-06</xbrli:startDate>
        <xbrli:endDate>2024-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-052024-02-05_us-gaap_CommonStockMember_custom_RothCapitalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-05</xbrli:startDate>
        <xbrli:endDate>2024-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-142025-02-14_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-14</xbrli:startDate>
        <xbrli:endDate>2025-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-052025-06-05_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-05</xbrli:startDate>
        <xbrli:endDate>2025-06-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-13</xbrli:startDate>
        <xbrli:endDate>2025-10-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BRTX:TwoThousandTwentyFourATMProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-162025-06-16_custom_BoardOfDirectorMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:BoardOfDirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-16</xbrli:startDate>
        <xbrli:endDate>2025-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-302025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-30</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-08</xbrli:startDate>
        <xbrli:endDate>2022-09-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-08</xbrli:startDate>
        <xbrli:endDate>2022-09-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-24</xbrli:startDate>
        <xbrli:endDate>2022-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-24</xbrli:startDate>
        <xbrli:endDate>2022-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-22_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-23_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_DemandSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:DemandSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-122023-07-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-12</xbrli:startDate>
        <xbrli:endDate>2023-07-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_ATMProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-062024-02-06_us-gaap_CommonStockMember_custom_AuctusFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-06</xbrli:startDate>
        <xbrli:endDate>2024-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NewWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:NewWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:NewWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember20509234">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember20509593">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember20509640">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember20509859">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_EmployeeStockOptionMember20510484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember20510484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-302025-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-30</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-312024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-31</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_custom_ExistingWarrantMember_custom_BlackScholesOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BlackScholesOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BlackScholesOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BlackScholesOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BlackScholesOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-062025-10-06_us-gaap_CommonStockMember_custom_SubscriptionAgreementsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:SubscriptionAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-06</xbrli:startDate>
        <xbrli:endDate>2025-10-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-06_us-gaap_SubsequentEventMember_custom_SubscriptionAgreementsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:SubscriptionAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-06_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-062025-10-06_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-06</xbrli:startDate>
        <xbrli:endDate>2025-10-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-112025-08-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-11</xbrli:startDate>
        <xbrli:endDate>2025-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-272025-10-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-27</xbrli:startDate>
        <xbrli:endDate>2025-10-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ComputerSoftwareAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ComputerSoftwareAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ManufacturingEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20515187">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SectionThreeHundredAndEightyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:SectionThreeHundredAndEightyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MelvilleLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>BRTX:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="xdx2ixbrl0286" toRefs="Footnote000551"/>
  <ix:relationship fromRefs="Fact000287" toRefs="Footnote000551"/>
  <ix:relationship fromRefs="Fact000288" toRefs="Footnote000551"/>
  <ix:relationship fromRefs="xdx2ixbrl0289" toRefs="Footnote000551"/>
  <ix:relationship fromRefs="Fact000290" toRefs="Footnote000551"/>
  <ix:relationship fromRefs="Fact000292" toRefs="Footnote000551"/>
  <ix:relationship fromRefs="xdx2ixbrl0342" toRefs="Footnote000558"/>
  <ix:relationship fromRefs="Fact000343" toRefs="Footnote000558"/>
  <ix:relationship fromRefs="Fact000344" toRefs="Footnote000558"/>
  <ix:relationship fromRefs="xdx2ixbrl0345" toRefs="Footnote000558"/>
  <ix:relationship fromRefs="Fact000346" toRefs="Footnote000558"/>
  <ix:relationship fromRefs="Fact000348" toRefs="Footnote000558"/>
  <ix:relationship fromRefs="xdx2ixbrl0416" toRefs="Footnote000565"/>
  <ix:relationship fromRefs="Fact000417" toRefs="Footnote000565"/>
  <ix:relationship fromRefs="Fact000418" toRefs="Footnote000565"/>
  <ix:relationship fromRefs="Fact000420" toRefs="Footnote000565"/>
  <ix:relationship fromRefs="Fact000422" toRefs="Footnote000565"/>
  <ix:relationship fromRefs="xdx2ixbrl1433" toRefs="Footnote001502"/>
  <ix:relationship fromRefs="Fact001434" toRefs="Footnote001502"/>
  <ix:relationship fromRefs="Fact001435" toRefs="Footnote001502"/>
  <ix:relationship fromRefs="xdx2ixbrl1436" toRefs="Footnote001502"/>
  <ix:relationship fromRefs="Fact001437" toRefs="Footnote001502"/>
  <ix:relationship fromRefs="Fact001439" toRefs="Footnote001502"/>
  <ix:relationship fromRefs="Fact001582" toRefs="Footnote001620"/>
  <ix:relationship fromRefs="xdx2ixbrl1583" toRefs="Footnote001620"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
filed with the Securities and Exchange Commission on February 9, 2026.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
No. 333-_________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_903_edei--DocumentType_c20250101__20250930_zcjqimZY2rnl"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000013" name="dei:DocumentType">S-1</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
SECURITIES ACT OF 1933</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_904_edei--EntityRegistrantName_c20250101__20250930_zFdosG8dofL3"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000014" name="dei:EntityRegistrantName">BIORESTORATIVE
THERAPIES, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20250101__20250930_z7N02VsyFn5"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:stateprovnameen" id="Fact000015" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8099</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20250101__20250930_z82PDLe81k98"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000016" name="dei:EntityTaxIdentificationNumber">30-1341024</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
Standard Industrial </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    Code Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20250101__20250930_zpFRbDVYtmFe"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000017" name="dei:EntityAddressAddressLine1">40
Marcus Drive</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20250101__20250930_zKqNwqrhf1nd"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000018" name="dei:EntityAddressAddressLine2">Suite One</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20250101__20250930_zAqDIRFgyod3"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000019" name="dei:EntityAddressCityOrTown">Melville</ix:nonNumeric></span>,
<span id="xdx_903_edei--EntityAddressStateOrProvince_c20250101__20250930_zSCH0x3UTL28"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20250101__20250930_z6l3qYrEsY08"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000021" name="dei:EntityAddressPostalZipCode">11747</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--CityAreaCode_c20250101__20250930_zL9Ahm7dolz3"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000022" name="dei:CityAreaCode">(631)</ix:nonNumeric>
</span><span id="xdx_90B_edei--LocalPhoneNumber_c20250101__20250930_zCBCWINON5Y3"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000023" name="dei:LocalPhoneNumber">760-8100</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--ContactPersonnelName_c20250101__20250930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zqDU8bRquuy7"><ix:nonNumeric contextRef="From2025-01-012025-09-30_dei_BusinessContactMember" id="Fact000024" name="dei:ContactPersonnelName">Lance
Alstodt</ix:nonNumeric></span>, President and Chief Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioRestorative
Therapies, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20250101__20250930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zObWgErm2pTl"><ix:nonNumeric contextRef="From2025-01-012025-09-30_dei_BusinessContactMember" id="Fact000025" name="dei:EntityAddressAddressLine1">40
Marcus Drive</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20250101__20250930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zrc1Ei4hvol6"><ix:nonNumeric contextRef="From2025-01-012025-09-30_dei_BusinessContactMember" id="Fact000026" name="dei:EntityAddressAddressLine2">Suite One</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20250101__20250930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z5ugLcHIZoGg"><ix:nonNumeric contextRef="From2025-01-012025-09-30_dei_BusinessContactMember" id="Fact000027" name="dei:EntityAddressCityOrTown">Melville</ix:nonNumeric></span>,
<span id="xdx_90D_edei--EntityAddressStateOrProvince_c20250101__20250930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zjD2yO5Pp6I7"><ix:nonNumeric contextRef="From2025-01-012025-09-30_dei_BusinessContactMember" format="ixt-sec:stateprovnameen" id="Fact000028" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20250101__20250930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zeNJCLgct7M8"><ix:nonNumeric contextRef="From2025-01-012025-09-30_dei_BusinessContactMember" id="Fact000029" name="dei:EntityAddressPostalZipCode">11747</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--CityAreaCode_c20250101__20250930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_ztF1ss7iOsqi"><ix:nonNumeric contextRef="From2025-01-012025-09-30_dei_BusinessContactMember" id="Fact000030" name="dei:CityAreaCode">(631)</ix:nonNumeric></span>
<span id="xdx_90F_edei--LocalPhoneNumber_c20250101__20250930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zeu602LVLIu7"><ix:nonNumeric contextRef="From2025-01-012025-09-30_dei_BusinessContactMember" id="Fact000031" name="dei:LocalPhoneNumber">760-8100</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>With
copies to:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fred
                                            Skolnik, Esq.</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certilman
    Balin Adler &amp; Hyman, LLP</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>90
    Merrick Avenue</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>East
    Meadow, New York 11554</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(516)
    296-7048</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Matthew
                                            Bernstein, Esq. </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Justin
    Grossman, Esq.</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ellenoff
    Grossman &amp; Schole LLP</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1345
    Avenue of the Americas</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
    York, New York 10105</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(212)
    370-1300</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public: <b>As soon as practicable after the effective date of this registration statement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityFilerCategory_c20250101__20250930_zU9e5vXJLNZc"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:entityfilercategoryen" id="Fact000032" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_909_edei--EntitySmallBusiness_c20250101__20250930_zi69QTOOlQx2"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleantrue" id="Fact000033" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20250101__20250930_zP5bhtMGVRza"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact000034" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">The
information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission relating to these securities is effective. This preliminary prospectus is
not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale
is not permitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">PRELIMINARY
PROSPECTUS SUBJECT TO COMPLETION, DATED FEBRUARY 9, 2026</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><img src="forms-1_006.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Up
to 9,708,738 Units, each consisting of:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>One
Share of Common Stock or One Pre-Funded Warrant to Purchase One</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
of Common Stock and One Common Stock Warrant to Purchase up to</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>One
Share of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Up
to 9,708,738 Shares of Common Stock or Shares of Common Stock Underlying Pre-Funded Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Up
9,708,738 Shares of Common Stock Underlying</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering on a reasonable best efforts basis up to 9,708,738 units (&#8220;Units&#8221;), each consisting of one share of our
common stock, par value $0.0001 per share (our &#8220;common stock&#8221;), and one warrant (each a &#8220;Common Stock Warrant&#8221;
or &#8220;warrant&#8221;), each warrant to purchase one share of our common stock, at an assumed public offering price of $1.03
per Unit, for gross proceeds of approximately $10,000,000. The public offering price per Unit will be determined between us and
the placement agent based on market conditions at the time of pricing, and may be at a discount to the then current market price of our
common stock. Therefore, the recent market price of our common stock referenced in this preliminary prospectus may not be indicative
of the final offering price per Unit. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities.
The common stock or Pre-Funded Warrants (as defined below) and Common Stock Warrants are immediately separable and will be issued separately
in this offering. Each warrant will be immediately exercisable for one share of common stock at an assumed exercise price of
$1.03 per share (100% of the assumed public offering price per Unit) and will expire on the fifth anniversary of the original
issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;BRTX&#8221;. On February 4,
2026, the last reported sale price of our common stock was $1.03 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also offering to investors in Units that would otherwise result in the investor&#8217;s beneficial ownership exceeding 4.99% of
our outstanding common stock immediately following the consummation of this offering the opportunity to invest in Units consisting
of one pre-funded warrant to purchase one share of our common stock (&#8220;Pre-Funded Warrant&#8221;) (in lieu of one share of our
common stock), and one Common Stock Warrant. Subject to limited exceptions, a holder of Pre-Funded Warrants will not have the right
to exercise any portion of its Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own in excess of
4.99% (or, at the election of the holder, such limit may be increased to up to 9.99%) of our common stock outstanding immediately
after giving effect to such exercise. Each Pre-Funded Warrant will be exercisable for one share of our common stock. The purchase
price of each Unit including a Pre-Funded Warrant will be equal to the price per Unit including one share of our common stock, minus
$0.0001, and the exercise price of each Pre-Funded Warrant will equal $0.0001 per share. The Pre-Funded Warrants will be immediately
exercisable (subject to the beneficial ownership cap) and may be exercised at any time until all of the Pre-Funded Warrants are
exercised in full. For each Unit including a Pre-Funded Warrant purchased (without regard to any limitation on exercise set forth
therein), the number of Units including a share of our common stock we are offering will be decreased on a one-for-one
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities will be offered at a fixed price and are expected to be issued in a single closing. We expect this offering to be completed
not later than one business day following the commencement of sales in this offering (after the effective date of the registration statement
of which this prospectus forms a part) and we will deliver all securities to be issued in connection with this offering delivery versus
payment or receipt versus payment, as the case may be, upon our receipt of investor funds. Accordingly, neither we nor the placement
agent have made any arrangements to place investor funds in an escrow account or trust account since the placement agent will not receive
investor funds in connection with the sale of the securities offered hereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged Rodman &amp; Renshaw LLC (the &#8220;placement agent&#8221; or &#8220;Rodman&#8221;) to act as our exclusive placement agent
in connection with this offering. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities
offered by this prospectus. The placement agent is not purchasing or selling any of the securities we are offering and the placement
agent is not required to arrange the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay to
the placement agent the fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus.
There is no arrangement for funds to be received in escrow, trust or similar arrangement. There is no minimum offering requirement as
a condition of closing of this offering. We may sell fewer than all of the Units offered hereby, which may significantly reduce the amount
of proceeds received by us. Because there is no escrow account and no minimum number of securities or amount of proceeds, investors could
be in a position where they have invested in us, but we have not raised sufficient proceeds in this offering to adequately fund the intended
uses of the proceeds as described in this prospectus. See &#8220;Risk Factors&#8221; for more information regarding risks related to
this offering. We will bear all costs associated with the offering. See &#8220;Plan of Distribution&#8221; for more information regarding
these arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    Unit Consisting of Common Stock and Warrant</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    Unit Consisting of Pre-Funded Warrant and Warrant</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<sup>(2)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    offering price</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    agent fees<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    to us, before expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    placement agent fees shall equal 7% of the gross proceeds of the securities sold by us in this offering. The placement agent will
    receive compensation in addition to the placement agent fees described above. See &#8220;Plan of Distribution&#8221; for a description
    of the compensation payable to the placement agent.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    foregoing assumes that no Pre-Funded Warrants are issued as part of the Units.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established trading market for the Pre-Funded Warrants or the Common Stock Warrants and we do not expect an active trading market
to develop. We do not intend to list the Pre-Funded Warrants or the Common Stock Warrants on any securities exchange or other trading
market. Without an active trading market, the liquidity of these securities will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a smaller reporting company under the federal securities laws and, as such, have elected to comply with certain reduced public company
reporting requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
in our securities involves a high degree of risk. You should carefully read and consider the risks that are described in the &#8220;Risk
Factors&#8221; section beginning on page 6 of this prospectus before making a decision to invest in our securities. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that delivery of the securities against payment will be made on or about , 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 16pt"><b>Rodman
&amp; Renshaw LLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is dated &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 93%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sd_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sd_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sd_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sd_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_001">CAPITALIZATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_002">DILUTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_003">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_004">USE OF PROCEEDS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_005">BUSINESS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_001">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#am_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#am_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE COMPENSATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#am_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS; DIRECTOR INDEPENDENCE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#am_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BENEFICIAL OWNERSHIP OF SECURITIES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#am_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MARKET FOR OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#am_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGE IN CERTIFYING ACCOUNTANTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#am_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#am_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF OUR SECURITIES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#YV-001">LEGAL MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#YV-002">EXPERTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>113</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#YV-003">WHERE YOU CAN FIND MORE INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">113</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#YV-004">INDEX TO FINANCIAL STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-1</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus includes references to our federally registered trademarks, <i>BioRestorative Therapies and Dragonfly design</i>, <i>BRTX-100,
ThermoStem and BRTX</i>. The <i>Dragonfly logo</i> is also registered with the U.S. Copyright Office. This prospectus also includes
references to trademarks, trade names and service marks that are the property of other organizations. Solely for convenience,
trademarks and trade names referred to in this prospectus appear without the &#174;, &#8480; or &#8482; symbols, and copyrighted
content appears without the use of the symbol &#169;, but the absence of use of these symbols does not reflect upon the validity or
enforceability of the intellectual property owned by us or third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_001"></span>ABOUT
THIS PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus. Neither we nor the placement agent has authorized any other person
to provide you with any information that is different. If anyone provides you with different or inconsistent information, you should
not rely on it. We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted.
The distribution of this prospectus and the offering of our securities in certain jurisdictions may be restricted by law. Persons outside
the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to,
the offering of our securities and the distribution of this prospectus outside the United States. This prospectus does not constitute,
and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus
by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this
prospectus or of any sale of our securities. Our business, financial condition, results of operations and prospects may have changed
since that date. It is important for you to read and consider all information contained in this prospectus in making your investment
decision. You should read this prospectus and the additional information described under &#8220;Where You Can Find More Information&#8221;
in this prospectus before investing in our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade
names included in this prospectus are the property of their respective owners. Solely for convenience, trademarks and trade names referred
to in this prospectus, including logos, artwork and other visual displays, may appear without the &#174; or <sup>TM</sup> symbols, but
such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable
law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship
with, or endorsement or sponsorship of us by, any other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus includes estimates regarding market and industry data that we prepared based on our management&#8217;s knowledge and experience
in the markets in which we operate, together with information obtained from various sources, including publicly available information,
industry reports and publications, surveys, our customers and consultants, trade and business organizations and other contacts in the
markets in which we operate. In some cases, we do not expressly refer to the sources from which this data is derived. Management estimates
are derived from publicly available information released by independent industry analysts and third-party sources, as well as data from
our internal research, and are based on assumptions made by us upon reviewing such data and our knowledge of such industry and markets
which we believe to be reasonable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context of this prospectus indicates otherwise, the terms &#8220;BioRestorative,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221;
&#8220;us&#8221; or &#8220;our&#8221; refer to BioRestorative Therapies, Inc. and its consolidated subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_002"></span>PROSPECTUS
SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights information contained elsewhere in this prospectus. This summary is not complete and does not contain all of the information
that you should consider in making your investment decision. Before investing in our securities, you should carefully read the entire
prospectus carefully, including &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations,&#8221; our financial statements and related notes included in this prospectus and the exhibits to the registration
statement of which this prospectus is a part.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core
programs relate to the treatment of disc/spine disease and metabolic disorders. We also operate a commercial biocosmeceutical platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Disc/Spine Program (brtxDisc)</i>. Our lead cell therapy candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a
person&#8217;s own) cultured mesenchymal stem cells collected from the patient&#8217;s bone marrow. We intend that the product will be
used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure.
The <i>BRTX-100</i> production process utilizes proprietary technology and involves collecting a patient&#8217;s bone marrow, isolating
and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, <i>BRTX-100</i> is injected by
a physician into the patient&#8217;s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-surgical
procedures and who potentially face the prospect of surgery. We are conducting a Phase 2 clinical trial using <i>BRTX-100</i> to treat
chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (&#8220;FDA&#8221;)
Investigational New Drug (&#8220;IND&#8221;) clearance to evaluate <i>BRTX-100</i> in the treatment of chronic cervical discogenic pain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Metabolic Program (ThermoStem)</i>. We are developing cell-based therapy candidates to target obesity and metabolic disorders using
brown adipose (fat) derived stem cells (&#8220;BADSC&#8221;) to generate brown adipose tissue (&#8220;BAT&#8221;), as well as exosomes
secreted by BADSC. We refer to this as our <i>ThermoStem Program</i>. BAT is intended to mimic naturally occurring brown adipose depots
that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals
may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with
higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss. Patents
related to the <i>ThermoStem Program</i> have been issued in the United States and other jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>BioCosmeceuticals.</i> We operate a commercial biocosmeceutical platform. Our current commercial product, formulated and manufactured
using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary
biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas
of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a
broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals
in the emerging biocosmeceuticals space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being a Smaller Reporting Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company,&#8221; meaning that the market value of our shares held by non-affiliates plus the proposed aggregate
amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue was less than $100 million
during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i) the
market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during
the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. For as long
as we remain a smaller reporting company, we may continue to rely on exemptions from certain disclosure requirements that are available
to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal
years of audited financial statements in our Annual Report on Form 10-K. Also, smaller reporting companies have reduced disclosure obligations
regarding executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Nevada corporation. Our headquarters are located at 40 Marcus Drive, Suite One, Melville, New York 11747. Our telephone number
is (631) 760-8100. We maintain certain information on our website at <span style="text-decoration: underline">www.biorestorative.com</span>. The information on our website is
not (and should not be considered) part of this prospectus and is not incorporated in this prospectus by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<div style="border: Black 1pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_003"></span>THE
OFFERING </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    offered by us</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 68%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
                                            to 9,708,738 Units, consisting of one share of our common stock and one Common
                                            Stock Warrant, each Common Stock Warrant to purchase one share of common stock.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also offering to investors in Units that would otherwise result in the investor&#8217;s beneficial ownership exceeding 4.99% of our
outstanding common stock immediately following the consummation of this offering the opportunity to invest in Units consisting of one
Pre-Funded Warrant to purchase one share of common stock in lieu of one share of common stock. For each Unit that includes a Pre-Funded
Warrant purchased (without regard to any limitation on exercise set forth therein), the number of Units including a share of common stock
we are offering will be decreased on a one-for-one basis. Subject to limited exceptions, a holder of Pre-Funded Warrants will not have
the right to exercise any portion of its Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own in excess
of 4.99% (or, at the election of the holder, such limit may be increased to up to 9.99%) of the common stock outstanding immediately
after giving effect to such exercise. Each Pre-Funded Warrant will be exercisable for one share of common stock. The purchase price of
each Unit including a Pre-Funded Warrant (and accompanying Common Stock Warrant) will be equal to the price per Unit including one share
of common stock, minus $0.0001, and the exercise price of each Pre-Funded Warrant will equal $0.0001 per share. The Pre-Funded Warrants
will be immediately exercisable (subject to the beneficial ownership cap) and may be exercised at any time in perpetuity or until all
of the Pre-Funded Warrants are exercised in full. This offering also relates to the shares of common stock issuable upon the exercise
of the Pre-Funded Warrants.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Units will not be certificated or issued in stand-alone form. The shares of our common stock (or Pre-Funded Warrants) and the Common
Stock Warrant comprising the Units are immediately separable upon issuance and will be issued separately in this offering.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Common Stock Warrants will have an exercise price per share of 100% of the public offering price per Unit, will be exercisable
    immediately and will expire on the fifth anniversary of the original issuance date. Each Common Stock Warrant is exercisable for one
    share of common stock, subject to adjustment in the event of stock dividends, stock splits, stock combinations, reclassifications,
    reorganizations or similar events affecting our common stock as described herein. Each holder of Common Stock Warrants will be
    prohibited from exercising its warrant for shares of our common stock if, as a result of such exercise, the holder, together with
    its affiliates, would own more than 4.99% of the total number of shares of our common stock then issued and outstanding. However,
    any holder may increase such percentage to any other percentage not in excess of 9.99%. This offering also relates to the offering
    of the shares of common stock issuable upon the exercise of the Common Stock Warrants. For more information regarding the warrants,
    you should carefully read the section entitled &#8220;Description of Our Securities &#8212; Warrants&#8221; in this
    prospectus.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of common stock outstanding as of the date of this prospectus</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,876,242
    shares</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of common stock to be outstanding immediately after this offering</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 18,584,980 shares (assuming the maximum number of Units covered by this prospectus, no issuance of Pre-Funded Warrants,
    and no exercise of Common Stock Warrants issued in this offering).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    estimate that the net proceeds to us from the sale of 9,708,738 Units in this offering will be approximately $9.0 million
    (assuming all the securities covered by this prospectus are sold), based on the assumed public offering price of $1.03 per
    Unit, the last reported sale price of our common stock on Nasdaq on February 4, 2026, and after deducting placement agent
    fees and estimated offering expenses payable by us. We currently intend to use the net proceeds from this offering in connection
    with our clinical trials with respect to <i>BRTX-100</i>, pre-clinical research and development with respect to our <i>ThermoStem
    Program,</i> the development of our commercial biocosmeceuticals platform and for general corporate purposes and working capital.
    We may also use a portion of the net proceeds from this offering to acquire or invest in complementary businesses, technologies,
    product candidates or other intellectual property, although we have no present commitments or agreements to do so. See &#8220;Use
    of Proceeds.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our securities involves a high degree of risk. See the &#8220;Risk Factors&#8221; section of this prospectus beginning on page
    6.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonable
    best efforts:</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to offer and sell the securities offered hereby directly to the purchasers. We have retained the placement agent to act
    as our exclusive placement agent to use its reasonable best efforts to solicit offers to purchase the securities offered by this
    prospectus. The placement agent is not required to buy or sell any specific number or dollar amount of the securities offered hereby.
    See &#8220;Plan of Distribution.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-up
    agreements</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our officers and directors have agreed with the
    placement agent, subject to certain exceptions, for a period of 90 days following the closing of this offering, not to sell,
    transfer or otherwise dispose of, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable
    or exchangeable for shares of capital stock for such applicable period. See &#8220;Plan of Distribution.&#8221;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    for common stock</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock is listed on Nasdaq under the symbol &#8220;BRTX&#8221;.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock to be outstanding after this offering is based on 8,876,242 shares of our common stock outstanding as
of February 4, 2026 and excludes, as of that date, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,398,158
                                            shares of our common stock issuable upon the conversion of 1,398,158 shares of Series B preferred
                                            stock;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">918,055
                                            shares of our common stock held in abeyance in connection with a warrant exercise (due to
                                            a beneficial ownership limitation) and issuable at the request of the securityholder;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,495,038
                                            shares of our common stock issuable upon the exercise of outstanding warrants with a weighted
                                            average exercise price of $4.91 per share;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,252,319
                                            shares of our common stock issuable upon the exercise of outstanding stock options,
                                            with a weighted average exercise price of $2.58 per share; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,248,635
                                            shares of our common stock reserved for future issuance pursuant to future awards granted
                                            under our 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, all information in this prospectus assumes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            of the securities covered by this prospectus are sold, there is no issuance of Pre-Funded
                                            Warrants and there is no exercise of the Common Stock Warrants;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            assumed public offering price of $1.03 per Unit, which is the last reported sale price
                                            of our common stock on Nasdaq on February 4, 2026;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            conversion of the outstanding Series B preferred stock;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            issuance of the shares of common stock held in abeyance;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            exercise of the outstanding warrants;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            exercise of the outstanding stock options; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            grants of awards under the 2021 Plan.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_004"></span>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should consider carefully the risks described below, together with other information in this prospectus, before you make a decision to
invest in our common stock. If any of the events described below actually occur, our business, operating results, prospects or financial
condition could be materially and adversely affected. This could cause the trading price of our common stock to decline and you may lose
all or part of your investment. The risks described below are not the only ones that we face. Additional risks not presently known to
us or that we currently deem immaterial may also affect our business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preceding
the full risk factors is a list of certain of the risk factors that follow. Reference is made to the complete risk factors for a full
description of the risks involved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Business Generally</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a limited operating history; we have incurred substantial losses since inception; we expect to continue to incur losses for
    the near term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on our executive officers and on our ability to attract and retain additional qualified personnel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the event that we are unable to utilize our current premises and need to relocate, we will be required to comply with regulatory
    requirements as to the operation of our laboratory, which could have had a material adverse effect on the conduct of our clinical
    trials and on our business. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Cell Therapy Product Development Efforts</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    future success is significantly dependent on the timely and successful development and commercialization of <i>BRTX-100</i>, our
    lead product candidate for the treatment of chronic lumbar disc disease; if we encounter delays or difficulties in the development
    of this product candidate, as well as any other product candidates, our business prospects would be significantly harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    disruption to our access to the media (including cell culture media) and reagents we are using in the clinical development of our
    cell therapy product candidates could adversely affect our ability to perform clinical trials and seek future regulatory submissions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which would prevent or delay
    regulatory approval and commercialization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize
    a product candidate, and the approval may be for a narrower indication than we seek.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    presently lack manufacturing capabilities to produce our product candidates at commercial scale quantities and do not have an alternate
    manufacturing supply at this time, which could negatively impact our ability to meet any future demand for the products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may have difficulties in sourcing brown adipose (fat) tissue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    safety problems are encountered by us or others developing new stem cell-based therapies, our stem cell initiatives could be materially
    and adversely affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are vulnerable to competition and technological change, and also to physicians&#8217; inertia.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited experience in the development and marketing of cell therapies and may be unsuccessful in our efforts to establish a
    profitable business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    cell therapy business is based on novel technologies that are inherently expensive, risky and may not be understood by or accepted
    in the marketplace, which could adversely affect our future value.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to significant product liability claims and litigation, including potential exposure from the use of our product candidates
    in human subjects, and our insurance may be inadequate to cover claims that may arise.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    inability to obtain reimbursement for our products and services from private and governmental insurers could negatively impact demand
    for our products and services.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Intellectual Property</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to protect our proprietary rights.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    to United States patent law may have a material adverse effect on our intellectual property rights.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    certain countries, patent holders may be required to grant compulsory licenses, which would likely have a significant and detrimental
    effect on any future revenues in such country.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Government Regulation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    failure to receive regulatory approvals for our cell therapy product candidates would likely have a material and adverse effect on
    our business and prospects.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to conduct clinical studies in accordance with regulations and accepted standards, we may be delayed in receiving,
    or may never receive, regulatory approvals of our product candidates from the FDA and other regulatory authorities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    is uncertain to what extent the government, private health insurers and third-party payors will approve coverage or provide reimbursement
    for the therapies and products to which our services relate. Availability for such reimbursement may be further limited by reductions
    in Medicare, Medicaid and other federal healthcare program funding in the United States.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitor
    companies or hospitals in the European Union (&#8220;EU&#8221;) may be able to take advantage of EU rules permitting sales of unlicensed
    medicines for individual patients to sell competing products without a marketing authorization.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock is classified as a &#8220;penny stock;&#8221; the restrictions of the penny stock regulations of the SEC may result
    in less liquidity for our common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-takeover
    provisions and the regulations to which we may be subject may make it more difficult for a third party to acquire control of us,
    even if the change in control would be beneficial to our securityholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Associated with Our Nasdaq Listing</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    cannot assure you that we will be able to continue to comply with the minimum bid price requirement of Nasdaq.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to this Offering</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    is a reasonable best efforts offering, with no minimum amount of Units required to be sold, and we may sell fewer than all of the
    Units offered hereby.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Following this offering, we will still need to raise substantial
additional funding, which may not be available on acceptable terms, if at all, to be able to continue as a going concern and advance
our business plan.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have broad discretion as to the use of proceeds from this offering and may not use the proceeds effectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    will experience immediate and substantial dilution in net tangible book value.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    may be significant future issuances or resales of our common stock which may materially and adversely dilute your ownership interest
    and affect the market price of our shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Business Generally</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history; we have incurred substantial losses since inception; we expect to continue to incur losses for the
near term.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a limited operating history. Since our inception, we have incurred net losses. As of September 30, 2025, our accumulated deficit
was $166,713,054. For the nine months ended September 30, 2025, we had a net loss of $11.0 million and negative cash flows from operations
of $8.4 million and, as of September 30, 2025, we had working capital of $1.3 million. We anticipate that we will continue to incur net
losses and negative cash flows from operations as we execute our development plans for 2026 and beyond, as well as other potential strategic
and business development initiatives. These conditions raise substantial doubt about our ability to continue as a going concern for at
least twelve months after the issuance date of the financial statements included herein. Our current funds will not be sufficient to
enable us to fully complete our development activities or attain profitable operations. If we are unable to obtain such needed additional
financing on a timely basis, we may have to curtail our development, marketing and promotional activities, which would have a material
adverse effect on our business, financial condition and results of operations, and ultimately we could be forced to discontinue our operations
and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business strategy is high risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focusing our resources and efforts primarily on the development of cellular-based products and services which will require extensive
cash for research, development and commercialization activities. This is a high-risk strategy because there is no assurance that our
products and services, including our <i>Disc/Spine Program</i> and our <i>ThermoStem</i> metabolic brown fat research initiative, will
ever become commercially viable (commercial risk), that we will prevent other companies from depriving us of market share and profit
margins by offering services and products based on our inventions and developments (legal risk), that we will successfully manage a company
in a new area of business, regenerative medicine, and on a different scale than we have operated in the past (operational risk), that
we will be able to achieve the desired therapeutic results using stem and regenerative cells (scientific risk), or that our cash resources
will be adequate to develop our products and services until we become profitable, if ever (financial risk). We are using our cash in
one of the riskiest industries in the economy (strategic risk). This may make our securities an unsuitable investment for many investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to enter into agreements in order to implement our business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for a certain license agreement with Regenerative Sciences, LLC and agreements relating to the conduct of our Phase 2 clinical trial,
we do not have any material agreements or understandings in place with respect to the implementation of our business strategy. No assurances
can be given that we will be able to enter into any necessary agreements with respect to the development of our business. Our inability
to enter into any such agreements would have a material adverse effect on our results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on our executive officers and on our ability to attract and retain additional qualified personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
performance is substantially dependent on the performance of Lance Alstodt, our Chief Executive Officer. We rely upon him for strategic
business decisions and guidance. We are also dependent on the performance of Francisco Silva, our Vice President of Research and Development.
Each of Messrs. Alstodt and Silva is subject to an employment agreement with us that is scheduled to expire on March 18, 2026. We do
not have any key-man insurance policies on the lives of either of our executive officers. We believe that our future success in developing
marketable products and services and achieving a competitive position will depend in large part upon whether we can attract and retain
additional qualified management and scientific personnel. Competition for such personnel is intense, and there can be no assurance that
we will be able to attract and retain such personnel. The loss of the services of Mr. Alstodt and/or Mr. Silva or the inability to attract
and retain additional personnel and develop expertise as needed would have a substantial negative effect on our results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
the event that we are unable to utilize our current premises and need to relocate, we will be required to comply with regulatory requirements
as to the operation of our laboratory, which could have had a material adverse effect on the conduct of our clinical trials and on our
business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are utilizing our laboratory, which includes a cGMP ISO-7 certified clean room, to provide the cell processing services necessary for
the clinical production of <i>BRTX-100 </i>for our Phase 2 disc clinical trial and to manufacture our commercial product. In the event
that we are required to relocate our premises, whether due to a casualty event or otherwise, we will be required to comply with regulatory
requirements as to the operation of our laboratory which could have a material adverse effect on the conduct of our clinical trials and
on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Cell Therapy Product Development Efforts</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success is significantly dependent on the timely and successful development and commercialization of BRTX-100, our lead product
candidate for the treatment of chronic lumbar disc disease; if we encounter delays or difficulties in the development of this product
candidate, as well as any other product candidates, our business prospects would be significantly harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent upon the successful development, approval and commercialization of our product candidates. Before we are able to seek regulatory
approval of our product candidates, we must conduct and complete extensive clinical trials to demonstrate their safety and efficacy in
humans. We are currently conducting a Phase 2 clinical trial using <i>BRTX-100</i> to treat chronic lower back pain due to degenerative
disc disease related to protruding/bulging discs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive, difficult to design and implement, and can take many years to complete. Importantly, a failure of one or more of
these or any other clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result
of, clinical trials that could delay or prevent our ability to complete our clinical studies, receive regulatory approval or commercialize
our cell therapy product candidates, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspensions,
    delays or changes in the design, initiation, enrollment, implementation or completion of required clinical trials; adverse changes
    in our financial position or significant and unexpected increases in the cost of our clinical development program; changes or uncertainties
    in, or additions to, the regulatory approval process that require us to alter our current development strategy; clinical trial results
    that are negative, inconclusive or less than desired as to safety and/or efficacy, which could result in the need for additional
    clinical studies or the termination of the product&#8217;s development; delays in our ability to manufacture the product in quantities
    or in a form that is suitable for any required clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intellectual
    property constraints that prevent us from making, using, or commercializing any of our cell therapy product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply or quality of our product candidates or other materials necessary to conduct clinical trials of these product candidates may
    be insufficient or inadequate; the inability to generate sufficient pre-clinical, toxicology, or other in vivo or in vitro data,
    to support the initiation of clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective clinical study sites, the terms of which can be subject to extensive negotiation
    and may vary significantly among different clinical study sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining required Institutional Review Board (&#8220;IRB&#8221;) approval at each clinical study site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application
    or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical
    trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials
    conducted by competitors or approved products post-market for related technology that raise FDA concerns about risk to patients of
    the technology broadly; or if the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    collaborating with patient groups and investigators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by our contract research organization (&#8220;CRO&#8221;), other third parties, or us to adhere to clinical study requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to perform in accordance with the FDA&#8217;s current Good Clinical Practices or (&#8220;GCP&#8221;) requirements, or applicable
    regulatory guidelines in other countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in having patients qualify for or complete participation in a study or return for post-treatment follow-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    dropping out of a study;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer
    of manufacturing processes from any academic collaborators to larger-scale facilities operated by either a contract manufacturing
    organization (&#8220;CMO&#8221;), or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing
    process;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in our clinical trials caused by health emergencies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for
    use in clinical studies or the inability to do any of the foregoing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA not accepting clinical data from trials that are conducted at clinical sites in countries where the standard of care is potentially
    different from the United States; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to raise sufficient funds to complete our clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
inability to successfully complete pre-clinical and clinical development could result in additional costs to us or impair our ability
to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required, or we
may elect, to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also
shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before
we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are able to successfully complete our clinical development program for our product candidates, and ultimately receive regulatory
approval to market one or more of the products, we may, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    approval for indications that are not as broad as the indications we sought;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
    the product removed from the market after obtaining marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">encounter
    issues with respect to the manufacturing of commercial supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    subject to additional post-marketing testing requirements; and/or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    subject to restrictions on how the product is distributed or used.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will not be able to commercialize our <i>BRTX-100</i> product candidate for at least five years; however, due to the
unknowns relating to the FDA regulatory process, such time period may be longer or shorter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may experience delays and other difficulties in enrolling a sufficient number of patients in our clinical trials which could delay or
prevent the receipt of necessary regulatory approvals.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to initiate or complete as planned any clinical trials if we are unable to identify and enroll a sufficient number of
eligible patients to participate in the clinical trials required by the FDA or other regulatory authorities. We also may be unable to
engage a sufficient number of clinical trial sites to conduct our trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may face challenges in enrolling patients to participate in our clinical trials due to the novelty of our cell-based therapies, the size
of the patient populations and the eligibility criteria for enrollment in the trial. In addition, some patients may have concerns regarding
cell therapy that may negatively affect their perception of therapies under development and their decision to enroll in the trials. Furthermore,
patients suffering from diseases within target indications may enroll in competing clinical trials, which could negatively affect our
ability to complete enrollment of our trials. Enrollment challenges in clinical trials often result in increased development costs for
a product candidate, significant delays and potentially the abandonment of the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have other delays in completing our clinical trials and we may not complete them at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we lack significant experience in completing clinical trials and bringing a drug through commercialization, we have hired outside consultants
with such experience. Clinical trials for <i>BRTX-100 </i>and other product candidates in development may be delayed or terminated as
a result of many factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    failing to complete clinical trials due to dissatisfaction with the treatment, side effects, or other reasons;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by regulators to authorize us to commence a clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or termination by regulators of clinical research for many reasons, including concerns about patient safety, the failure of study
    sites and/or investigators in our clinical research program to comply with GCP requirements, or our failure, or the failure of our
    contract manufacturers, to comply with current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure to obtain clinical supply for our products necessary to conduct clinical trials from contract manufacturers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">treatment
    candidates demonstrating a lack of efficacy during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">treatment
    candidates demonstrating significant safety signals; and/or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to continue to fund clinical trials or to find a partner to fund the clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or failure to complete clinical trials and obtain FDA approval for our product candidates could have a material adverse effect
on our cost to develop and commercialize, and our ability to generate revenue from, a particular product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
development of our cell therapy product candidates is subject to uncertainty because autologous cell therapy is inherently variable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
manufacturing an autologous cell therapy, the number and composition of the cell population varies from patient to patient. Such variability
in the number and composition of these cells could adversely affect our ability to manufacture autologous cell therapies in a cost-effective
or profitable manner and meet acceptable product release specifications for use in a clinical trial or, if approved, for commercial sale.
As a consequence, the development and regulatory approval process for autologous cell therapy products could be delayed or may never
be completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
disruption to our access to the media (including cell culture media) and reagents we are using in the clinical development of our cell
therapy product candidates could adversely affect our ability to perform clinical trials and seek future regulatory submissions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
media (including cell culture media) and reagents, as well as devices, materials and systems, that we intend to use in our clinical trials,
and that we may need or use in commercial production, are provided by unaffiliated third parties. Any lack of continued availability
of these media, reagents, devices, materials and systems for any reason would have a material adverse effect on our ability to complete
these studies and could adversely impact our ability to achieve commercial manufacture of our planned therapeutic products. Although
other available sources for these media, reagents, devices, materials and systems may exist in the marketplace, we have not evaluated
their cost, effectiveness, or intellectual property foundation and therefore cannot guarantee the suitability or availability of such
other potential sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Products
that appear promising in research and development may be delayed or may fail to reach later stages of clinical development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development of cellular based products is highly uncertain. Product candidates that appear promising in preclinical and early
research and development may be delayed or fail to reach later stages of development. Decisions regarding the further development of
product candidates must be made with limited and incomplete data, which makes it difficult to ensure or even accurately predict whether
the allocation of limited resources and the expenditure of additional capital on specific product candidates will result in desired outcomes.
Pre-clinical and clinical data can be interpreted in different ways, and negative or inconclusive results or adverse events during a
clinical trial could delay, limit or prevent the development of a product candidate. Positive preclinical data may not continue or occur
for future subjects in our clinical studies and may not be repeated or observed in ongoing or future studies involving our product candidates.
Furthermore, our product candidates may also fail to show the desired safety and efficacy in later stages of clinical development despite
having successfully advanced through initial clinical studies. In addition, regulatory delays or rejections may be encountered as a result
of many factors, including changes in regulatory policy during the period of product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which would prevent or delay regulatory
approval and commercialization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trials of our product candidates are, and the manufacturing and marketing of our products will be, subject to extensive and
rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test
and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we
must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both
safe and effective for use in each target indication. In particular, because some of our product candidates are subject to regulation
as biological drug products, we will need to demonstrate that those products are safe, pure, and potent for use in their target indications.
Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended
use. The risk/benefit profile required for product licensure will vary depending on these factors and may include decrease or elimination
of pain, adequate duration of response, a delay in the progression of the disease, an improvement in function and/or decrease in disability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if such trials are successfully completed, we cannot guarantee that the FDA will interpret the results as we do or that
the FDA will apply the policies and standards that we expect due to rapid and unpredictable regulatory policy changes associated with
the Trump Administration, and more trials could be required before we submit our product candidates for approval. To the extent that
the results of the trials are not satisfactory to the FDA for support of a marketing application, we may be required to expend significant
resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product
candidate, and the approval may be for a narrower indication than we seek.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate.
Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete
their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA
Advisory Committee or other regulatory authority recommends non-approval or restrictions or conditions on approval. In addition, we may
experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes
in regulatory authority policy during the period of product development, clinical trials and the review process. For example, executive
orders and other government cost-saving measures may result in reductions in the number of FDA personnel available to review our applications
or conduct necessary pre-approval inspections of our manufacturing sites resulting in delays in the approvals of our product candidates.
Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant
limitations in the form of narrow indications, contraindications or a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;). These
regulatory authorities may require warnings or precautions with respect to conditions of use or they may grant approval subject to the
performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims or allow
the promotional claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing
scenarios could materially harm the commercial prospects for our product candidates and materially and adversely affect our business,
financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may never obtain FDA approval for any of our product candidates in the United States and, even if we do, we may never obtain approval
for or commercialize any of our product candidates in any foreign jurisdiction, which would limit our ability to realize our full market
potential.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to eventually market any of our product candidates in any particular foreign jurisdiction, we must establish and comply with numerous
and varying regulatory requirements regarding safety and efficacy on a jurisdiction-by-jurisdiction basis. Approval by the FDA in the
United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, preclinical
studies and clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory
approval in one country does not guarantee regulatory approval in any other country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
processes vary among countries and can involve additional product testing and validation and additional administrative review periods.
Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical
trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent
the introduction of our product candidates in those countries. The foreign regulatory approval process involves similar risks to those
associated with FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including international markets,
nor have we attempted to obtain such approval. If we fail to comply with regulatory requirements in international markets or to obtain
and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and
our ability to realize the full market potential of our products may be unrealized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
presently lack manufacturing capabilities to produce our product candidates at commercial scale quantities and do not have an alternate
manufacturing supply at this time, which could negatively impact our ability to meet any future demand for the products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have utilized our laboratory to provide the cell processing services necessary for clinical production of <i>BRTX-100 </i>for our Phase
2 disc clinical trial. We believe that we have sufficient laboratory capacity to provide such services with regard to the balance of
the Phase 2 trial; however, we would need to significantly expand our manufacturing capabilities to provide such cell processing services
to meet potential commercial demand for <i>BRTX-100</i> and any other of our product candidates, if approved, as well as any of our other
product candidates that might attain regulatory approval. Such expansion would require additional regulatory approvals. Even if we increase
our manufacturing capabilities, it is possible that we may still lack sufficient capacity to meet demand. Ultimately, if we are unable
to supply our products to meet commercial demand, whether because of processing constraints or other disruptions, delays or difficulties
that we experience, sales of the products and their long-term commercial prospects could be significantly damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek to utilize a third-party manufacturer for <i>BRTX-100</i> or any of our other product candidates; however, we do not have any
arrangements in place with a third-party manufacturer. If our facilities at which these product candidates would be manufactured or our
equipment were significantly damaged or destroyed, or if there were other disruptions, delays or difficulties affecting manufacturing
capacity, our planned and future clinical studies and commercial production for these product candidates would likely be significantly
disrupted and delayed. It would be both time consuming and expensive to replace this capacity with third parties, particularly since
any new facility would need to comply with the regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ultimately,
if we are unable to supply our cell therapy product candidates to meet commercial demand (assuming commercial approval is obtained),
whether because of processing constraints or other disruptions, delays or difficulties that we experience, our production costs could
dramatically increase and sales of the product and its long-term commercial prospects could be significantly damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
commercial potential and profitability of our products are unknown and subject to significant risk and uncertainty.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we successfully develop and obtain regulatory approval for our cell therapy product candidates, the market may not understand or accept
the products, which could adversely affect both the timing and level of future sales. Ultimately, the degree of market acceptance of
our product candidates (or any of our future product candidates) will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical effectiveness, safety and convenience of the product particularly in relation to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to distinguish our products (which involve adult cells) from any ethical and political controversies associated with stem
    cell products derived from human embryonic or fetal tissue; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of the product, the reimbursement policies of government and third-party payors and our ability to obtain sufficient third-party
    coverage or reimbursement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are successful in achieving sales of our product candidates, it is not clear to what extent, if any, the products will be profitable.
The costs of goods associated with production of cell therapy products are significant. In addition, some changes in manufacturing processes
or procedures generally require FDA or foreign regulatory authority review and approval prior to implementation. We may need to conduct
additional pre-clinical studies and clinical trials to support approval of any such changes. Furthermore, this review process could be
costly and time-consuming and could delay or prevent the commercialization of product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have difficulties in sourcing brown adipose (fat) tissue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use brown adipose (fat) tissue to identify and characterize brown adipose derived stem cells for use in our pre-clinical <i>ThermoStem
Program. </i>There is no certainty that we will be able to continue to collect brown adipose samples through any relationships that we
have, have had or may establish with potential sources of brown adipose tissue. The inability to procure brown fat tissue would have
a material adverse effect upon our ability to advance our <i>ThermoStem Program.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
safety problems are encountered by us or others developing new stem cell-based therapies, our stem cell initiatives could be materially
and adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of stem cells for therapeutic indications is still in the very early stages of development. If an adverse event occurs during clinical
trials related to one of our proposed products and/or services or those of others, the FDA and other regulatory authorities may halt
clinical trials or require additional studies. The occurrence of any of these events would delay, and increase the cost of, our development
efforts and may render the commercialization of our proposed products and/or services impractical or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are vulnerable to competition and technological change, and also to physicians&#8217; inertia.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will compete with many domestic and foreign companies in developing our technology and products, including biotechnology, medical device
and pharmaceutical companies. Many current and potential competitors have substantially greater financial, technological, research and
development, marketing, and personnel resources. There is no assurance that our competitors will not succeed in developing alternative
products and/or services that are more effective, easier to use, or more economical than those which we may develop, or that would render
our products and/or services obsolete and non-competitive. In general, we may not be able to prevent others from developing and marketing
competitive products and/or services similar to ours or which perform similar functions or which are marketed before ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may have greater experience in developing products, therapies or devices, conducting clinical trials, obtaining regulatory clearances
or approvals, manufacturing and commercialization. It is possible that competitors may obtain patent protection, approval or clearance
from the FDA or achieve commercialization earlier than we can, any of which could have a substantial negative effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will compete against cell-based therapies derived from alternate sources, such as bone marrow, adipose tissue, umbilical cord blood and
potentially embryos. Doctors historically are slow to adopt new technologies like ours, whatever the merits, when older technologies
continue to be supported by established providers. Overcoming such inertia often requires very significant marketing expenditures or
definitive product performance and/or pricing superiority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that physicians&#8217; inertia and skepticism will also be a significant barrier as we attempt to gain market penetration with
our future products and services. We may need to finance lengthy time-consuming clinical studies (so as to provide convincing evidence
of the medical benefit) in order to overcome this inertia and skepticism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
recent extensive use of both FDA-approved and compounded versions of glucagon-like peptide-1 (GLP-1) receptor agonist drug products,
such as Wegovy and Ozempic (semaglutide), including the launch of FDA-approved oral Wegovy in January 2026, for the treatment of obesity
has significantly increased the competition in the obesity market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not
realize the benefits of such alliances or licensing arrangements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates
and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges,
increase our near and long-term expenditures, issue securities that dilute the shares of our existing stockholders, or disrupt our management
and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming
and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements
for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third
parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. To date, such efforts
have not been successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
collaborations involving our product candidates, such as our collaborations with third-party research institutions, are subject to numerous
risks, which may include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization
    programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability
    of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate,
    repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing
    and distribution;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information
    in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary
    information or expose us to potential liability;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of
    our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
    may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
    of the applicable product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we
    would not have the exclusive right to commercialize such intellectual property.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, if we enter into collaboration agreements and strategic partnerships or license our products or businesses, we may not be able
to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company
culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic
transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into
new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization
of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition,
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited experience in the development and marketing of cell therapies and may be unsuccessful in our efforts to establish a profitable
business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business plan has been focused historically on capturing a piece of the burgeoning field of cell therapy. We have limited experience
in the areas of cell therapy product development and marketing, and in the related regulatory issues and processes. Although we have
recruited a team that has experience with designing and conducting clinical trials and have hired FDA consultants, as a company, we have
limited experience in conducting clinical trials and no experience in conducting clinical trials through to regulatory approval of any
product candidate. In part because of this lack of experience, we cannot be certain that planned clinical trials will begin or be completed
on time, if at all. We cannot assure that we will successfully achieve our clinical development goals or fulfill our plans to capture
a piece of the cell therapy market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
cell therapy business is based on novel technologies that are inherently expensive, risky and may not be understood by or accepted in
the marketplace, which could adversely affect our future value.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical development, commercialization and marketing of cell and tissue-based therapies are at an early-stage, substantially research-oriented,
and financially speculative. To date, very few companies have been successful in their efforts to develop and commercialize a cell therapy
product. In general, cell-based or tissue-based products may be susceptible to various risks, including undesirable and unintended side
effects, unintended immune system responses, inadequate therapeutic efficacy, or other characteristics that may prevent or limit their
approval or commercial use. In addition, <i>BRTX-100</i> is a cell-based candidate that is produced by using a patient&#8217;s own stem
cells derived from bone marrow. Regulatory approval of novel product candidates such as <i>BRTX-100</i>, which is manufactured using
novel manufacturing processes, can be more complex and expensive and take longer than other, more well-known or extensively studied pharmaceutical
or biopharmaceutical products, due to the FDA&#8217;s lack of experience with them. To our knowledge, the FDA has not yet approved a
disc related stem cell therapy product. This lack of experience may lengthen the regulatory review process, require us to conduct additional
studies or clinical trials, which would increase our development costs, lead to changes in regulatory positions and interpretations,
delay or prevent approval and commercialization of these product candidates or lead to significant post-approval limitations or restrictions.
Furthermore, the number of people who may use cell or tissue-based therapies is difficult to forecast with accuracy. Our future success
is dependent on the establishment of a large global market for cell- and tissue-based therapies and our ability to capture a share of
this market with our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
cell therapy product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
enactment of the Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCIA&#8221;) created an abbreviated regulatory pathway
for the approval of products demonstrated to be biosimilar, or &#8220;highly similar,&#8221; to or &#8220;interchangeable&#8221; with
an FDA-approved innovator (original) biologic product. The abbreviated regulatory pathway establishes legal authority for the FDA to
review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on
its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA
until 12 years after the original branded product is approved under a BLA. The FDA has developed considerable experience with the biosimilar
and interchangeable biosimilar processes since the enactment of the BPCIA in 2009. Should any of our product candidates be approved via
the BLA pathway, we expect that biosimilar applicants will seek approval of biosimilar, and/or interchangeable, versions of our product
that could result in lower prices for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that, if any of our product candidates are approved as a biological product under a BLA, it should qualify for the 12-year period
of exclusivity. However, there is a risk that the FDA could approve biosimilar applicants for other reference products that no longer
have such exclusivity, thus potentially creating the opportunity for greater competition sooner than anticipated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also face competition from unapproved stem cell therapies performed by treatment centers that do not comply with FDA requirements.
Despite the FDA&#8217;s successful enforcement against unapproved stem cell treatments in the federal courts (<i>United States v. Regenerative
Sciences, LLC </i>(2014 D.C. Cir.), <i>United States v. U.S. Stem Cell Clinic LLC </i>(2021 11<sup>th</sup> Cir.) and <i>United States
v. California Stem Cell Treatment Center, Inc.</i> (2024 9<sup>th</sup> Cir. <i>cert. denied</i>), thousands of clinics continue to offer
unapproved stem cell therapies due to high demand, FDA enforcement limitations, and tactical rebranding to avoid FDA enforcement action.
The FDA lacks the resources to bring enforcement actions against thousands of individual small-office clinics simultaneously. Therefore,
we could face competition from stem cell clinics that would not be required to undergo the costly and time-consuming FDA approval and
compliance process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA&#8217;s regulation of regenerative medicine products remains unpredictable and we are not certain what impact this will have on the
potential approval of our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s regulation of therapies derived from stem cell products and technologies is evolving and may continue to evolve. In December
2016, the 21st Century Cures Act (the &#8220;Cures Act&#8221;) was signed into law in the United States to advance access to medical
innovations. Among other things, the Cures Act established a new FDA regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation.
This designation offers a variety of benefits to product candidates, including enhanced FDA support during clinical development, priority
review on application filing, accelerated approval based on potential surrogate endpoints, and the potential use of patient registry
data and other forms of real world evidence for post-approval confirmatory studies. There is no certainty that any of our product candidates
will receive RMAT designation or any other type of expedited review program designation from the FDA. In any event, the receipt of an
FDA RMAT designation or other expedited review program designation may not result in a faster development process, review or approval
compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to significant product liability claims and litigation, including potential exposure from the use of our product candidates
in human subjects, and our insurance may be inadequate to cover claims that may arise.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to potential product liability risks inherent in the testing, processing and marketing of cell therapy products.
Such liability claims may be expensive to defend and result in large judgments against us. We face an inherent risk of product liability
exposure related to the testing of our current and any future product candidates in human clinical trials and will face an even greater
risk with respect to any commercial sales of our products should they be approved. No product candidate has been widely used over an
extended period of time, and therefore safety data is limited. Cell therapy companies derive the raw materials for manufacturing of product
candidates from human cell sources, and therefore the manufacturing process and handling requirements are extensive, which increases
the risk of quality failures and subsequent product liability claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to maintain insurance coverage adequate to cover our clinical trials and increase that coverage before commercializing product
candidates, if ever. At any time during our clinical trials or after commercialization, if that occurs, we may not be able to obtain
or maintain product liability insurance on acceptable terms with adequate coverage or at all, or if claims against us substantially exceed
our coverage, then our financial position could be significantly impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we are ultimately successful in any product liability litigation that may arise, such litigation could consume substantial amounts
of our financial and managerial resources, result in decreased demand for our products and injure our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to maintain errors and omissions, directors and officers, workers&#8217; compensation and other insurance at levels we believe to
be appropriate to our business activities. If, however, we were subject to a claim in excess of this coverage or to a claim not covered
by our insurance and the claim succeeded, we would be required to pay the claim from our own limited resources, which could have a material
adverse effect on our financial condition, results of operations and business. Additionally, liability or alleged liability could harm
our business by diverting the attention and resources of our management and damaging our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those that are expected to be used by our clinical investigators, clinical research organizations or other
contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of development programs
for our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on information technology systems to keep financial records, maintain laboratory and corporate records, communicate with staff and
external parties and operate other critical functions. Any significant degradation or failure of these computer systems could cause us
to inaccurately calculate or lose data. Despite the implementation of security measures, these internal computer systems and those used
by our clinical investigators, clinical research organizations, and other contractors and consultants are vulnerable to damage from computer
viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. The techniques that could
be used by criminal elements or foreign governments to attack these computer systems are sophisticated, change frequently and may originate
from less regulated and remote areas of the world. While we have not experienced any such system failure, theft of information, accident
or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption
of our clinical development activities. For example, the loss of clinical trial data from historical or future clinical trials could
result in delays in regulatory approval efforts and significantly increase costs to recover or reproduce the data. To the extent that
any disruption, theft of information, or security breach were to result in a loss of or damage to data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the clinical development and future development of
our product candidates could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
operate and sell in international markets carries great risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to market our products and services both domestically and in foreign markets. A number of risks are inherent in international
transactions. In order for us to market our products and services in non-U.S. jurisdictions, we need to obtain and maintain required
regulatory approvals or clearances in these countries and must comply with the country specific regulations regarding safety, manufacturing
processes and quality. These regulations, including the requirements for approvals or clearances to market, may differ from the FDA regulatory
scheme. International operations and sales also may be limited or disrupted by political instability, price controls, trade restrictions
and changes in tariffs. Additionally, fluctuations in currency exchange rates may adversely affect demand for our services and products
by increasing the price of our products and services in the currency of the countries in which the products and services are offered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will obtain regulatory approvals or clearances in all of the countries where we intend to market our products
and services, that we will not incur significant costs in obtaining or maintaining foreign regulatory approvals or clearances, or that
we will be able to successfully commercialize our products and services in various foreign markets. Delays in receipt of approvals or
clearances to market our products and services in foreign countries, failure to receive such approvals or clearances or the future loss
of previously received approvals or clearances could have a substantial negative effect on our results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
inability to obtain reimbursement for our products and services from private and governmental insurers could negatively impact demand
for our products and services.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
acceptance and sales of our product candidates may depend on coverage and reimbursement policies and health care reform measures. Decisions
about formulary coverage as well as levels at which government authorities and third-party payors, such as private health insurers and
health maintenance organizations, reimburse patients for the price they pay for our product candidates, as well as levels at which these
payors pay directly for our product candidates, where applicable, could affect whether we are able to successfully commercialize these
products. We cannot guarantee that reimbursement will be available for any of our product candidates. We also cannot guarantee that coverage
or reimbursement amounts will not reduce the demand for, or the price of, our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize
our products. The Patient Protection and Affordable Care Act (the &#8220;PPACA&#8221;), as well as the Inflation Reduction Act, passed
in August 2022, and other health reforms include measures that would limit or prohibit payments for certain medical treatments or subject
the pricing of drugs and biologics to government control. In addition, in many foreign countries, particularly the countries of the EU,
the pricing of drugs and biologics is subject to government control. If our products are or become subject to government regulation that
limits or prohibits payment for our products, or that subjects the price of our products to government control, we may not be able to
generate revenue, attain profitability or commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, third-party payors are increasingly limiting both coverage and the level of reimbursement of new drugs and biologics. They
may also impose strict prior authorization requirements and/or refuse to provide any coverage of uses of approved products for medical
indications other than those for which the FDA has granted market approvals. As a result, significant uncertainty exists as to whether
and how much third-party payors will reimburse patients for their use of newly-approved drugs and biologics. If we are unable to obtain
adequate levels of reimbursement for our product candidates, our ability to successfully market and sell our product candidates will
be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
activity as a contract manufacturer of biologic-based cosmetics could result in FDA enforcement for reasons outside of our control, which
could disrupt the development of our own product candidates or harm our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
manufactured a commercial product as a contract manufacturer for a third-party company. While we believe the product we manufactured
for the third party was intended for cosmetic uses, we (as the contract manufacturer) did not ultimately have control over how the product
was marketed. It is possible that the FDA could determine, based on how the product was marketed (among other considerations), that it
was intended for unapproved therapeutic use(s), which could result in the temporary or permanent suspension of manufacturing and/or commercialization
of the product and/or a wide range of enforcement actions, such as warning letters, recall, &#8216;dear doctor&#8217; letters, and others.
If the FDA takes enforcement action against the third party or us in connection with this product, or against others for whom we may
serve in the future as a contract manufacturer, it could have an adverse impact on our operations and/or harm our reputation as a biologics
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Intellectual Property</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our proprietary rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend in large part upon our ability to protect our proprietary rights. There is no assurance, for example,
that any additional patents will be issued based on our or our licensor&#8217;s pending applications or, if issued, that such patents
will not become the subject of a re-examination, will provide us with competitive advantages, will not be challenged by any third parties,
or that the patents of others will not prevent the commercialization of products and services incorporating our technology. Furthermore,
there can be no guarantee that others will not independently develop similar products and services, duplicate any of our products and
services, or design around any patents we obtain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will also depend upon our ability to avoid infringing patents issued to others. If we were judicially determined to
be infringing on any third-party patent, we could be required to pay damages, alter our products, services or processes, obtain licenses,
or cease certain activities. If we are required in the future to obtain any licenses from third parties for some of our products and/or
services, there can be no guarantee that we would be able to do so on commercially favorable terms, if at all. United States and foreign
patent applications are not immediately made public, so we might be surprised by the grant to someone else of a patent on a technology
we are actively using. Although we conducted a freedom to operate (&#8220;FTO&#8221;) search years ago on the licensed technology associated
with our <i>Disc/Spine Program</i>, modifications made, and/or further developments that may be made, to that technology may not be covered
by the initial FTO. No FTO has been undertaken with respect to our <i>ThermoStem </i>brown fat initiative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation,
which would result in substantial costs to us and the diversion of effort on our part, may be necessary to enforce or confirm the ownership
of any patents issued or licensed to us, or to determine the scope and validity of third-party proprietary rights. If our competitors
claim technology also claimed by us and prepare and file patent applications in the United States, we may have to participate in interference
proceedings declared by the U.S. Patent and Trademark Office (the &#8220;Patent Office&#8221;) or a foreign patent office to determine
priority of invention, which could result in substantial costs and diversion of effort, even if the eventual outcome is favorable to
us. Any such litigation or interference proceeding, regardless of outcome, could be expensive and time-consuming.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
challenges to our patents through oppositions, re-examination proceedings or interference proceedings could result in a loss of patent
rights in the relevant jurisdiction. If we are unsuccessful in actions we bring against the patents of other parties, and it is determined
that we infringe upon the patents of third parties, we may be subject to litigation, or otherwise prevented from commercializing potential
products and/or services in the relevant jurisdiction, or may be required to obtain licenses to those patents or develop or obtain alternative
technologies, any of which could harm our business. Furthermore, if such challenges to our patent rights are not resolved in our favor,
we could be delayed or prevented from entering into new collaborations or from commercializing certain products and/or services, which
could adversely affect our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential or sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course
of litigation there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If
securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on unpatented trade secrets and proprietary technological expertise. Some of our intended future cell-related
therapeutic products and/or services may fit into this category. We also rely, in part, on confidentiality agreements with our partners,
employees, advisors, vendors, and consultants to protect our trade secrets and proprietary technological expertise. There can be no guarantee
that these agreements will not be breached, or that we will have adequate remedies for any breach, or that our unpatented trade secrets
and proprietary technological expertise will not otherwise become known or be independently discovered by competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to obtain or maintain patent protection, failure to protect trade secrets, third-party claims against our patents, trade secrets, or
proprietary rights or our involvement in disputes over our patents, trade secrets, or proprietary rights, including involvement in litigation,
could divert our efforts and attention from other aspects of our business and have a substantial negative effect on our results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property in countries outside of the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
property law outside the United States is uncertain and, in many countries, is currently undergoing review and revisions. The laws of
some countries do not protect our patent and other intellectual property rights to the same extent as United States laws. Third parties
may attempt to oppose the issuance of patents to us in foreign countries by initiating opposition proceedings. Opposition proceedings
against any of our patent filings in a foreign country could have an adverse effect on our corresponding patents that are issued or pending
in the United States. It may be necessary or useful for us to participate in proceedings to determine the validity of our patents or
our competitors&#8217; patents that have been issued in countries other than the United States. This could result in substantial costs,
divert our efforts and attention from other aspects of our business, and could have a material adverse effect on our results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to United States patent law may have a material adverse effect on our intellectual property rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Leahy-Smith America Invents Act (the &#8220;AIA&#8221;), which was signed into law in 2011, significantly changes United States patent
law. It may take some time to establish what the law means, since it is just being interpreted by the lower courts, Federal Circuit Courts
of Appeal, and the Supreme Court. The effects of these decisions are still not known. The first major change is that AIA switches the
United States patent system from a &#8220;first to invent&#8221; system to a &#8220;first to file&#8221; system. Now that the first to
file system is in effect, there is a risk that another company may independently develop identical or similar patents at approximately
the same time, and be awarded the patents instead of us. Further, for the second major change, AIA abolished interference proceedings,
and establishes derivation proceedings to replace interference proceedings in all cases in which the time period for instituting an interference
proceeding has not lapsed where an inventor named in an earlier application derived the claimed invention from a named inventor. Now
that the derivation proceedings are in effect, there is a risk that the inventorship of any pending patent application can be challenged
for reasons of derivation. The third major change is that AIA established post-grant opposition proceedings that will apply only to patent
applications filed after &#8220;first to file&#8221; became effective. Post-grant opposition will enable a person who is not the patent
owner to initiate proceedings in the Patent Office within nine months after the grant of a patent that can result in cancellation of
a patent as invalid. In addition to AIA, recent court decisions have created uncertainty with regard to our ability to obtain and maintain
patents. Therefore, there is a risk that any of our patents once granted may be subject to post-grant opposition, which will increase
uncertainty on the validity of any newly granted patent or may ultimately result in cancellation of the patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Supreme Court has recently taken more limiting positions as to what constitutes patentable subject matter. As a result,
many patents covering what were previously patentable inventions are now determined to cover inventions which are deemed non-statutory
subject matter and are now invalid. As a result of this and subsequent opinions by the Court of Appeals for the Federal Circuit, the
Patent Office is now applying more stringent limitations to claims in patent applications and is refusing to grant patents in areas of
technology where patents were previously deemed available. Therefore, there is a risk that we will be unable to acquire patents to cover
our products and, if such patents are granted, they may subsequently be found to be invalid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
certain countries, patent holders may be required to grant compulsory licenses, which would likely have a significant and detrimental
effect on any future revenues in such country.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries, including some countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses
to third parties. In addition, most countries limit the enforceability of patents against government agencies or government contractors.
In these countries, the patent owner may be limited to monetary relief and may be unable to enjoin infringement, which could materially
diminish the value of the patent. Compulsory licensing of life-saving products is also becoming increasingly common in developing countries,
either through direct legislation or international initiatives. Such compulsory licenses could be extended to our product candidates,
which may limit our potential revenue opportunities, including with respect to any future revenues that may result from our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Government Regulation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates for which we obtain regulatory approval will be subject to ongoing regulatory requirements for manufacturing, labeling,
packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information. Any regulatory
approvals that we receive for our product candidates also may be subject to a REMS or the specific obligations imposed as a condition
for marketing authorization by equivalent authorities in a foreign jurisdiction, limitations on the approved indicated uses for which
the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing,
including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, in the United
States, the holder of an approved new drug application (&#8220;NDA&#8221;) or BLA is obligated to monitor and report adverse events and
any failure of a product to meet the specifications in the NDA or BLA. The holder of an approved NDA or BLA also must submit new or supplemental
applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising
and promotional materials must comply with the Federal Food, Drug and Cosmetic Act (the &#8220;FDCA&#8221;) and implementing regulations
and are subject to FDA oversight and post-marketing reporting obligations, in addition to other potentially applicable federal and state
laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, product manufacturers and their facilities may be subject to payment of application and program fees and are subject to continual
review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments
made in the NDA, BLA or foreign marketing application. If we or a regulatory authority discover previously unknown problems with a product,
such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or if
a regulatory authority disagrees with the promotion, marketing or labeling of our product, a regulatory authority may impose restrictions
relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or
suspension of manufacturing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable regulatory requirements for any product candidate following approval, a regulatory authority may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    a warning or untitled letter asserting that we are in violation of the law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic
    partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict
    the marketing or manufacturing of the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain the product or otherwise demand or require the withdrawal or recall of the product from the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to permit the import or export of products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">request
    and publicize a voluntary recall of the product; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to allow us to enter into supply contracts, including government contracts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government enforcement action or investigation of alleged violations of law could require us to expend significant time and resources
in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to
commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the research, manufacturing, distribution, sale, and promotion of drugs and biologic products are subject to regulation
by various federal, state, and local authorities, including the FDA, the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;),
other divisions the Department of Health and Human Services (&#8220;HHS&#8221;) (e.g., the Office of Inspector General), the United States
Department of Justice offices of the United States Attorney, the Federal Trade Commission and state and local governments. Our operations
are directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws
and regulations, including the federal Anti-Kickback Statute (&#8220;AKS&#8221;), the federal civil and criminal False Claims Act (&#8220;FCA&#8221;)
the Physician Payments Sunshine Act and regulations and equivalent provisions in other countries. In addition, we may be subject to patient
privacy laws by both the federal government and the states in which we conduct our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
and federal regulatory and enforcement agencies continue actively to investigate violations of health care laws and regulations, and
the United States Congress continues to strengthen the arsenal of enforcement tools. For example, the Bipartisan Budget Act of 2018 increased
the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the AKS. Enforcement agencies
also continue to pursue novel theories of liability under these laws. Government agencies have recently increased regulatory scrutiny
and enforcement activity with respect to programs supported or sponsored by pharmaceutical companies, including reimbursement and co-pay
support, funding of independent charitable foundations and other programs that offer benefits for patients. Several investigations into
these programs have resulted in significant civil and criminal settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any
of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and
criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment
and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our
results of operations. Even if we are not determined to have violated these laws, government investigations into these issues typically
require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert
the attention of our management from operating our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in the event we determine to operate in foreign jurisdictions, including conducting clinical trials, we will need to comply with the
United States Foreign Corrupt Practices Act of 1977, (the &#8220;FCPA&#8221;). The FCPA prohibits a corporation, including its subsidiaries,
third-party contractors, distributors, consultants and employees, from corruptly making or offering to make payments to foreign officials
for the purpose of obtaining or enhancing business. Under the law, &#8220;foreign officials&#8221; include employees of health systems
operated by government entities. The FCPA also establishes specific record-keeping and internal accounting controls. Violations of the
FCPA can result in the imposition of civil penalties or criminal prosecution. Failure to comply with the FCPA will adversely affect our
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the FCPA, we will also need to comply with the foreign government laws and regulations of each individual country in which
any therapy centers that we may establish are located and products are to be distributed and sold. These regulations vary in complexity
and can be as stringent, and on occasion even more stringent, than FDA regulations in the United States. Due to the fact that there are
new and emerging stem cell and cell therapy regulations that have recently been drafted and/or implemented in various countries around
the world, the application and subsequent implementation of these new and emerging regulations have little to no precedence. Therefore,
the level of complexity and stringency is not always precisely understood today for each country, creating greater uncertainty for the
international regulatory process. Furthermore, there can be no guarantee that laws and regulations will not be implemented, amended and/or
reinterpreted in a way that will negatively affect our business. Likewise, there can be no assurance that we will be able, or will have
the resources, to maintain compliance with all such healthcare laws and regulations. Failure to comply with such healthcare laws and
regulations, as well as the costs associated with such compliance or with enforcement of such healthcare laws and regulations, may have
a material adverse effect on our operations or may require restructuring of our operations or impair our ability to operate profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current and future employees, consultants and advisors and our future principal investigators, medical institutions and commercial partners
may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of fraud or other misconduct by our current and future employees, consultants, advisors, principal investigators,
medical institutions and commercial partners, including contract laboratories, and CROs. Misconduct by these parties could include intentional
failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA
and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report
financial information or data accurately or disclose unauthorized activities to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not and in the future may not independently conduct all aspects of our product candidate research and preclinical and clinical
testing and product candidate manufacturing. If we rely on third parties, including CROs, medical institutions, and contract laboratories
to monitor and manage data for our ongoing preclinical and clinical programs, we will still maintain responsibility for ensuring their
activities are conducted in accordance with the applicable study protocol, legal, regulatory and scientific standards. We and our third-party
vendors will be required to comply with current cGMP, GCP, and Good Laboratory Practice (&#8220;GLP&#8221;) requirements, which are a
collection of laws and regulations enforced by the FDA, the EU and comparable foreign authorities for all of our product candidates in
clinical development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended
to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.
Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the
FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
precautions we take to detect and prevent employee and third-party misconduct may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with
these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting
our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects,
including the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
failure to receive regulatory approvals for our cell therapy product candidates would likely have a material and adverse effect on our
business and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not received regulatory approval to market any of our product candidates in any jurisdiction. If we seek approval of any
of our cell therapy product candidates, we will be required to submit to the FDA and potentially other regulatory authorities extensive
pre-clinical and clinical data supporting its safety and efficacy, as well as information about the manufacturing process and to undergo
inspection of our manufacturing facility or other contract manufacturing facilities, if utilized, among other things. The process of
obtaining FDA and other regulatory approvals is expensive, generally takes many years and is subject to numerous risks and uncertainties,
particularly with complex and/or novel product candidates such as our cell-based product candidates. Changes in regulatory approval requirements,
policies, or court decisions may cause delays in the approval or rejection of an application, make it easier for our competitors to gain
regulatory approval to enter the marketplace, or allow competitors to enter the market without having to obtain FDA approval. Executive
orders and other government cost-saving measures may result in reductions in the number of FDA personnel available to review our applications
or conduct necessary pre-approval inspections of our manufacturing sites resulting in delays in the approvals of our product candidates.
Ultimately, the FDA and other regulatory agencies have substantial discretion in the approval process and may refuse to accept any application
or may decide that our product candidate data are insufficient for approval without the submission of additional preclinical, clinical
or other studies. In addition, varying agency interpretations of the data obtained from preclinical and clinical testing could delay,
limit or prevent regulatory approval of a product candidate. Any difficulties or failures that we encounter in securing regulatory approval
for our product candidates would likely have a substantial adverse impact on our ability to generate product sales, and could make any
search for a collaborative partner more difficult. Similarly, any regulatory approval we ultimately obtain may be limited or subject
to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to conduct clinical studies in accordance with regulations and accepted standards, we may be delayed in receiving, or may
never receive, regulatory approvals of our product candidates from the FDA and other regulatory authorities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain marketing approvals for our product candidates in the United States and abroad, we must, among other requirements, complete adequate
and well-controlled clinical trials sufficient to demonstrate to the FDA and other regulatory bodies that the product candidate is safe
and effective for each indication for which approval is sought. If the FDA finds that patients enrolled in the trial are or would be
exposed to an unreasonable and significant risk of illness or injury, due to, among other things, occurrence of a serious adverse event
in an ongoing clinical trial, the FDA can place one or more of our clinical trials on hold. If safety concerns develop, we may, or the
FDA or an institutional review board may require us to, stop the affected trials before completion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
completion of our clinical trials also may be delayed or terminated for a number of other reasons, including if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    clinical investigators do not perform the clinical trials on the anticipated schedule or consistent with the clinical trial protocol,
    good clinical practices required by the FDA and other regulatory requirements, or other third parties do not perform data collection
    and analysis in a timely or accurate manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspections
    of clinical trial sites by the FDA or other regulatory authorities reveal violations that require us to undertake corrective action,
    suspend or terminate one or more sites, or prohibit use of some or all of the data in support of marketing applications; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or one or more institutional review boards suspends or terminates the trial at an investigational site, or precludes enrollment
    of additional subjects.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development costs will increase if there are material delays in our clinical trials, or if we are required to modify, suspend, terminate
or repeat a clinical trial. If we are unable to conduct our clinical trials properly, we may never receive regulatory approval to market
our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Health
care companies have been the subjects of federal and state investigations, and we could become subject to investigations in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
federal and state government agencies have heightened civil and criminal enforcement efforts. There are numerous ongoing investigations
of health care companies, as well as their executives and managers. In addition, amendments to the federal FCA, including under healthcare
reform legislation, have made it easier for private parties to bring &#8220;<i>qui tam</i>&#8221; (or whistleblower) lawsuits against
companies under which the whistleblower may be entitled to receive a percentage of any money paid to the government. The FCA provides,
in part, that an action can be brought against any person or entity that has knowingly presented, or caused to be presented, a false
or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim
approved. The government has taken the position that claims presented in violation of the federal AKS, Stark Law or other healthcare-related
laws, including laws enforced by the FDA, may be considered a violation of the FCA. Penalties include substantial fines for each false
claim, plus three times the amount of damages that the federal government sustained because of the act of that person or entity and/or
exclusion from the Medicare and Medicaid programs. In addition, a majority of states have adopted similar state whistleblower and false
claims provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any government investigations involving any of our facilities or management. While we believe that we are in compliance
with applicable governmental healthcare laws and regulations, any future investigations of our business or executives could cause us
to incur substantial costs, and result in significant liabilities or penalties, as well as damage to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
is uncertain to what extent the government, private health insurers and third-party payors will approve coverage or provide reimbursement
for the therapies and products to which our services relate. Availability for such reimbursement may be further limited by reductions
in Medicare, Medicaid and other federal healthcare program funding in the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that health care providers cannot obtain coverage or reimbursement for our products and therapies, they may elect not to provide
such products and therapies to their patients and, thus, may not need our services. Further, as cost containment pressures are increasing
in the health care industry, government and private payors may adopt strategies designed to limit the amount of reimbursement paid to
health care providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
the trend toward managed health care and bundled pricing for health care services in the United States, could significantly influence
the purchase of healthcare products and services, resulting in lower prices and reduced demand for our therapeutic products under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may directly or indirectly receive revenues from federal health care programs, such as Medicare. Federal health care programs are subject
to changes in coverage and reimbursement rules and procedures, including retroactive rate adjustments. These contingencies could materially
decrease the range of services covered by such programs or the reimbursement rates paid directly or indirectly for our products and services.
To the extent that any health care reform favors the reimbursement of other therapies over our therapeutic products under development,
such reform could affect our ability to sell our services, which may have a material adverse effect on our revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
limitation on reimbursement available from private and government payors may reduce the demand for, or the price of, our products and
services, which could have a material adverse effect on our revenues. Additional legislation or regulation relating to the health care
industry or third-party coverage and reimbursement may be enacted in the future which could adversely affect the revenues generated from
the sale of our products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
there has been a trend in recent years towards reductions in overall funding for Medicare, Medicaid and other federal health care programs.
The reduced funding of governmental programs could have a negative impact on the demand for our services to the extent it relates to
products and services which are reimbursed by government and private payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unintended
consequences of healthcare reform in the United States may adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare industry is undergoing fundamental changes resulting from political, economic and regulatory influences. In the United States,
the PPACA was signed into law in 2010 under the Obama administration. By implementing comprehensive reforms, the law seeks to, among
other things, increase access to healthcare for the uninsured and control the escalation of healthcare expenditures within the economy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been adopted since the PPACA was enacted. These changes include aggregate reductions in Medicare
payments to providers of 2% per fiscal year, which went into effect in April 2013 and, following passage of the Bipartisan Budget Act
of 2018, will remain in effect through 2030 unless additional Congressional action is taken. In January 2013, President Obama signed
into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Congress
has since considered additional reductions in Medicare reimbursement for drugs and devices as part of legislation to reduce the budget
deficit. Similar legislation could be enacted in the future. The Medicare regulations and interpretive determinations that determine
how drugs, devices and services are covered and reimbursed also are subject to change. These laws, regulations, and interpretive determinations
may result in additional reductions in Medicare and other health care funding, which could impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, President Biden signed the Inflation Reduction Act (the &#8220;IRA&#8221;), which provides for (i) the government to set
or negotiate prices for select high-cost Medicare Part D (beginning in 2026) and Medicare Part B drugs (beginning in 2028) that are more
than nine years (for small-molecule drugs) or 13 years (for biological products) from their FDA approval, (ii) manufacturers to pay a
rebate for Medicare Part B and Part D drugs when prices increase faster than inflation beginning in 2022 for Medicare Part D and 2023
for Medicare Part B drugs, and (iii) Medicare Part D redesign which replaces the current coverage gap provisions and establishes a $2,000
cap for out-of-pocket limits costs for Medicare beneficiaries beginning in 2025, with manufacturers being responsible for 10% of costs
up to the $2,000 cap and 20% after that cap is reached. Implementation of the IRA is expected to be carried out through upcoming actions
by regulatory authorities, the outcome of which is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
reform measures that may be adopted in the future, may result in more rigorous coverage criteria and decreased reimbursement. The implementation
of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize our product candidates. It is difficult to predict how enforcement initiatives under the PPACA, the IRA, and/or additional
legislation or regulation enacted in the future may impact our business. If the PPACA, the IRA, and/or additional legislation or regulation
enacted in the future cause such unintended consequences or indirect impact, they could have a material adverse effect on our business,
financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Competitor
companies or hospitals in the EU may be able to take advantage of EU rules permitting sales of unlicensed medicines for individual patients
to sell competing products without a marketing authorization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU medicines rules allow individual member states to permit the supply of a medicinal product without a marketing authorization to fulfill
special needs, where the product is supplied in response to a bona fide unsolicited order, formulated in accordance with the specifications
of a healthcare professional and for use by an individual patient under his direct personal responsibility. This may, in certain countries,
also apply to products manufactured in a country outside the EU and imported to treat specific patients or small groups of patients.
In addition, advanced therapy medicinal products do not need a marketing authorization if they are prepared on a non-routine basis and
are used within the same EU member state in a hospital in accordance with a medical prescription for an individual patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
exemptions could allow our competitors to make sales in the EU without having obtained a marketing authorization and without undergoing
the expense of clinical trials, especially if those competitors have cell processing facilities in the relevant EU member state. Similarly,
certain hospitals may be able to compete with us on the basis of these rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
pay no dividends.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends in the past, and currently do not intend to pay any cash dividends in the foreseeable future. We intend
to retain earnings, if any, to finance the development and expansion of our business. Our future dividend policy will be subject to the
discretion of our Board of Directors and will be contingent upon future earnings, if any, our financial condition, capital requirements,
general business conditions, and other factors. Therefore, we can give no assurance that any dividends of any kind will ever be paid
to holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is no assurance that an active trading market for our common stock will be sustained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq. However, no assurance can be given that an active market for our common stock will be sustained. In
addition, although there have been market makers in our common stock, we cannot assure that these market makers will continue to make
a market in our securities or that other factors outside of our control will not cause them to stop market making in our securities.
Making a market in securities involves maintaining bid and ask quotations and being able to effect transactions in reasonable quantities
at those quoted prices, subject to various securities laws and other regulatory requirements. Furthermore, the development and maintenance
of a public trading market depends upon the existence of willing buyers and sellers, the presence of which is not within our control
or that of any market maker. Market makers are not required to maintain a continuous two-sided market, are required to honor firm quotations
for only a limited number of securities, and are free to withdraw firm quotations at any time. Even with a market maker, factors such
as our past losses from operations and the small size of our company mean that there can be no assurance of an active and liquid market
for our securities developing in the foreseeable future. Even if there is a market for our securities, we cannot assure that securityholders
will be able to resell their securities at any price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stockholders
who hold unregistered shares of our common stock are subject to resale restrictions pursuant to Rule 144 due to our former status as
a &#8220;shell company.&#8221;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
previously were a &#8220;shell company&#8221; pursuant to Rule 144, promulgated under the Securities Act, or Rule 144, and, as such,
sales of our securities pursuant to Rule 144 cannot be made unless, among other things, we continue to remain subject to Section 13 or
15(d) of the Exchange Act, and we file all of our required periodic reports with the SEC under the Exchange Act. Because our unregistered
securities cannot be sold pursuant to Rule 144 unless we continue to meet such requirements, any unregistered securities we sell in the
future or issue to consultants or employees, in consideration for services rendered or for any other purpose, will have no liquidity
unless we continue to comply with such requirements. As a result, it may be more difficult for us to obtain financing to fund our operations
and pay our consultants and employees with our securities instead of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 37; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred, and will continue to incur, increased costs as a result of being an SEC reporting company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), as well as a variety of related rules implemented by the SEC, have
required changes in corporate governance practices and generally increased the disclosure requirements of public companies. As a reporting
company, we incur significant legal, accounting and other expenses in connection with our public disclosure and other obligations. Based
upon SEC regulations currently in effect, we are required to establish, evaluate and report on our internal control over financial reporting.
We believe that compliance with the myriad of rules and regulations applicable to reporting companies and related compliance issues will
continue to require a significant amount of time and attention from our management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Material
weaknesses in our internal control over financial reporting have caused and may cause us to fail to timely and accurately report our
financial results or result in a material misstatement of our consolidated financial statements. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified control deficiencies in the design and operation of our internal control over financial reporting that constituted material
weaknesses. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such
that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or
detected on a timely basis. Our material weaknesses related to the following control deficiencies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of adherence to formal policies and procedures;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of risk assessment procedures on internal controls to detect financial reporting risks on a timely manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of design and implementation of effective controls to achieve complete and accurate financial reporting and disclosures, including
    documented controls over the preparation and review of journal entries, account reconciliations and income taxes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of design and implementation of effective controls over the accounting for warrants issued in connection with equity financings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deficiencies described above resulted in a past misstatement and, if not remedied, could result in a misstatement of one or more account
balances or disclosures in our annual or interim consolidated financial statements that would not be prevented or detected, and, accordingly,
we determined that these control deficiencies constituted material weaknesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address our material weaknesses, we have engaged an external financial consulting firm to assist us with implementing enhancements and
controls within our accounting systems, and further evolving our accounting and quarterly and annual close processes. We will not be
able to remediate these control deficiencies until these steps have been completed and have been operating effectively for a sufficient
period of time and management has concluded, through testing, that the controls are operating effectively. The redesign and implementation
of improvements to our accounting and proprietary systems and controls may be costly and time consuming and the cost to remediate may
impair our results of operations in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to remediate our material weakness, identify future material weaknesses in our internal control over financial reporting or fail
to meet the demands that have been placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be
unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations.
Failure to comply with Section 404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the
SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are unable to remediate
any such material weakness, our reputation, results of operations and financial condition could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stock price may fluctuate significantly and be highly volatile and this may make it difficult for a securityholder to resell our securities
at the volume, prices and times the securityholder finds attractive.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock may be subject to significant fluctuations and be highly volatile, which may make it difficult for a
securityholder to resell our securities at the volume, prices and times the securityholder finds attractive. There are many factors that
will impact our stock price and trading volume, including, but not limited to, the factors listed above under &#8220;Risks Related to
Our Business Generally,&#8221; &#8220;Risks Related to Our Cell Therapy Product Development Efforts,&#8221; &#8220;Risks Related to Our
Intellectual Property,&#8221; &#8220;Risks Related to Government Regulation,&#8221; &#8220;Risks Related to Our Common Stock&#8221; and
&#8220;Risks Associated with Our Nasdaq Listing.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
markets, in general, experience significant price and volume volatility, and the market price of our securities may continue to be subject
to such market fluctuations that may be unrelated to our operating performance and prospects. Increased market volatility and fluctuations
could result in a substantial decline in the market price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
common stock is classified as a &#8220;penny stock;&#8221; the restrictions of the penny stock regulations of the SEC may result in less
liquidity for our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted regulations which define a &#8220;penny stock&#8221; to be any equity security that has a market price (as therein defined)
of less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. Unless exempt, the rules
require the delivery, prior to any transaction involving a penny stock by a retail customer, of a disclosure schedule prepared by the
SEC relating to the penny stock market. Disclosure is also required to be made about commissions payable to both the broker/dealer and
the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing
recent price information for the penny stock held in the account and information on the limited market in penny stocks. The market price
for shares of our common stock is currently below $5.00 and we do not satisfy any of the exceptions to the SEC&#8217;s definition of
penny stock. Accordingly, our common stock is currently classified as a penny stock. As a result of the penny stock restrictions, brokers
or potential investors may be reluctant to trade in our securities, which may result in less liquidity for our shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 39; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions and the regulations to which we may be subject may make it more difficult for a third party to acquire control of us, even
if the change in control would be beneficial to our securityholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated in Nevada. Anti-takeover provisions in Nevada law and our articles of incorporation and bylaws could make it more difficult
for a third party to acquire control of us and may prevent stockholders from receiving a premium for their securities. Our certificate
of incorporation provides that our Board of Directors may issue up to 20,000,000 shares of preferred stock, in one or more series, without
stockholder approval and with such terms, preferences, rights and privileges as the Board of Directors may deem appropriate. Of such
20,000,000 authorized shares, 1,398,158 shares of Series B preferred stock are issued and outstanding. These provisions and other factors
may hinder or prevent a change in control, even if the change in control would be perceived as beneficial to, or sought by, our other
stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Associated with Our Nasdaq Listing</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
cannot assure you that we will be able to continue to comply with the minimum bid price requirement of Nasdaq</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the market price of our common stock satisfied the initial listing minimum bid price requirement for Nasdaq, there can be no assurance
that the market price of our common stock will remain at the $1.00 per share level required for continuing compliance with that requirement.
There are many factors, such as negative financial or operational results, that could adversely affect the market price of our common
stock and jeopardize our ability to maintain Nasdaq&#8217;s minimum bid price requirement. On February 4, 2026, the last reported
sale price of our common stock was $1.03 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock may not attract new investors, including institutional investors, and may not satisfy the investing
requirements of those investors. Consequently, the trading liquidity of our common stock may not improve</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that our Nasdaq listing has helped generate greater and broader investor interest, including institutional investors, there
can be no assurances in that regard. In addition, there can be no assurance that the market price of our common stock will satisfy the
investing requirements of those investors. As a result, the trading liquidity of our common stock may not necessarily improve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Relating To This Offering</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>This
is a reasonable best efforts offering, with no minimum amount of Units required to be sold, and we may sell fewer than all of the Units
offered hereby.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
placement agent has agreed to use its reasonable best efforts to solicit offers to purchase the Units in this offering. The placement
agent has no obligation to buy any of the Units from us or to arrange for the purchase or sale of any specific number or dollar amount
of the Units. There is no required minimum number of Units that must be sold as a condition to complete this offering. As there is no
minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement agent fees and
proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth in this prospectus. We
may sell fewer than all of the Units offered hereby, which would significantly reduce the amount of proceeds received by us, and investors
in this offering will not receive a refund in the event that we do not sell all of the Units offered in this offering. The success of
this offering will impact our ability to use the proceeds to execute our business plans. We may have insufficient capital to implement
our business plans, potentially resulting in greater operating losses or dilution unless we are able to raise capital from alternative
sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 40; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is substantial doubt regarding our ability to continue as a going concern. Following this offering, we will still need to raise substantial
additional funding, which may not be available on acceptable terms, if at all, to be able to continue as a going concern and advance
our business plan. The report of our independent registered public accounting firm contains an explanatory paragraph that expresses substantial
doubt about our ability to continue as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is substantial doubt regarding our ability to continue as a going concern. Our existence in our current form is dependent upon our ability
to obtain additional capital. Our cash and cash equivalents and investments held in marketable securities following this offering will
not be sufficient to fund our long-term operations. Raising funds in the current economic environment is challenging and financing may
not be available in sufficient amounts or on acceptable terms, if at all. The issuance of additional securities, whether equity or debt,
or the possibility of such issuance, may cause the market price of our common stock to decline. The sale of additional equity or convertible
debt securities may dilute the ownership of existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to raise adequate funds, we may have to delay, reduce the scope of or eliminate some or all of our business plan expenditures,
and the failure to procure such required financing could have a material and adverse effect on our business, liquidity, financial condition
and results of operations as well as our ability to continue as a going concern. If we are unable to continue as a going concern, we
might have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower
than the values reflected in our financial statements. The inclusion of the going concern explanatory paragraph by our auditors, our
lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our business, share
price, and our ability to raise new capital or to enter into critical contractual relations with third parties due to concerns about
our ability to meet our contractual obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of our independent registered public accounting firms with respect to our financial statements as of December 31, 2024 and 2023
and for the years then ended indicates that our financial statements have been prepared assuming that we will continue as a going concern.
The report states that, as of December 31, 2024 there is substantial doubt about our ability to continue as a going concern within one
year after the issuance date of such financial statements. Our plans in regard to these matters are described in footnote 1 to such financial
statements. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Following
this offering, we will need to obtain additional financing to continue our ongoing development and proposed operations. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
this offering, even if we sell all of the securities covered by this prospectus, we will still require significant additional funds in
the future through equity or debt financings, government funding or grants, private capital, royalty agreements, customer payments, or
other strategic alliances with third parties, either alone or in combination, to fund our business plan and to complete our initiatives.
Our business plan, which includes the conduct of a Phase 3 clinical trial for <i>BRTX-100</i> and the development of our <i>ThermoStem
Program</i> and biocosmeceuticals platform, has required and will continue to require substantial capital expenditures. We will require
financing to fund our research and development, and initial commercial production activities, including the legal, operational set-up,
general and administrative, marketing, employee salaries and other related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
additional funding will be subject to various additional factors, including investor acceptance of our business plan, the status of our
development program and ongoing results from our biocosmeceuticals efforts. If we are not able to secure adequate additional funding
when needed, we will need to re-evaluate our operating plan and may be forced to make significant reductions in spending, extend payment
terms with suppliers, liquidate assets where possible, limit, suspend or curtail planned development programs and cease operations entirely.
Having insufficient funds may also require us to relinquish rights to assets and technology that we would otherwise prefer to develop
ourselves, or on less favorable terms than we would otherwise choose. The foregoing actions and circumstances could materially adversely
impact our business, liquidity, results of operations and future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 41; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such required financing may not be available in amounts or on terms acceptable to us or at all, and the failure to procure such required
financing could have a material and adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
on the type and the terms of any financing we pursue, stockholders&#8217; rights and the value of their investment in our common stock
could be reduced. Any additional equity financing will dilute stockholdings, and debt financing, if available, may involve restrictions
on financing and operating activities. In addition, if we issue secured debt securities, the holders of the debt would have a claim to
our assets that would be prior to the rights of stockholders until the debt is paid. Interest on such debt securities would increase
costs and negatively impact operating results. If the issuance of new securities results in diminished rights to holders of our common
stock, the market price of our common stock could be negatively impacted. Any sale of securities will also need to comply with the applicable
rules of the stock exchanges on which our securities are listed or quoted for trading. Further, strategic collaboration or royalty agreements
may provide us with non-dilutive or minimally dilutive financing but adversely impact our future results of operations or capital resources.
Following this offering, there is no guarantee that we will be able to secure any additional funding or be able to secure funding which
will provide us with sufficient funds to meet our objectives, which may adversely affect our business and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have broad discretion as to the use of proceeds from this offering and may not use the proceeds effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds of this offering in connection with our clinical trials with respect to <i>BRTX-100</i>, pre-clinical
research and development with respect to our <i>ThermoStem Program</i>, the development of our commercial biocosmeceuticals platform
and for general corporate purposes and working capital. We may also use a portion of the net proceeds from this offering to acquire or
invest in complementary businesses, technologies, product candidates or other intellectual property, although we have no present commitments
or agreements to do so. We have not allocated any specific portion of the net proceeds to any particular purpose, and our management
will have the discretion to allocate the proceeds as it determines. We will have significant flexibility and broad discretion in applying
the net proceeds of this offering, and we may not apply these proceeds effectively. Our management might not be able to yield a significant
return, if any, on any investment of these net proceeds, and you will not have the opportunity to influence our decisions on how to use
our net proceeds from this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
will experience immediate and substantial dilution in net tangible book value.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price will be substantially higher than the as adjusted net tangible book value per share of our outstanding shares of
common stock as of September 30, 2025. As a result, investors in this offering will incur immediate dilution of $0.43 per share,
based upon an assumed public offering price of $1.03 per Unit, the last reported sale price of our common stock on Nasdaq on February
4, 2026, and assuming that all of the securities covered by this prospectus are sold. Investors in this offering will pay a price
per share that substantially exceeds the book value of our tangible assets after subtracting our liabilities. See &#8220;Dilution&#8221;
for a more complete description of how the value of your investment will be diluted upon the completion of this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 42; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
may experience future dilution as a result of future equity offerings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into,
or exercisable or exchangeable for, our common stock at prices that may not be the same as the price per share in this offering. We may
sell shares of our common stock or other securities in any other offering at a price per share that is less than the price per share
paid by investors in this offering, and investors purchasing shares of common stock or other securities in the future could have rights
superior to existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
may be significant future issuances or resales of our common stock which may materially and adversely dilute your ownership interest
and affect the market price of our shares. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have authorization to issue up to 75,000,000 shares of common stock of which, as of February 4, 2026, 8,876,242 shares
were issued and outstanding. We are not restricted from issuing additional shares of our common stock in the future, including securities
convertible into, or exchangeable or exercisable for, shares of our common stock. In addition, there are 1,398,158 shares of Series B
preferred stock issued and outstanding. Such shares are convertible under certain circumstances into an equal number of shares of common
stock. Pursuant to our November 2021 public offering of securities, we issued warrants for the purchase of an aggregate of 2,645,000
shares of common stock (of which warrants for the purchase of 970,000 shares of common stock remain outstanding) as well as underwriter
warrants for the purchase of 235,970 shares of common stock. We have an effective registration statement on Form S-3 under the Securities
Act registering the issuance of such shares. The shares issuable pursuant to the registration statement on Form S-3 will be freely tradable
in the public market, except for shares held by affiliates. In addition, pursuant to agreements entered into with the holders of certain
warrants, we have issued an aggregate of 2,433,525 shares of common stock and warrants for the purchase of an aggregate of 2,513,686
shares of common stock and are obligated to issue an additional 918,055 shares of common stock that are being held in abeyance due to
the holder&#8217;s maximum beneficial ownership limitation. We have registered the resale of the shares of common stock issuable upon
the exercise of such warrants. The issuance of shares of common stock upon exercise of the above warrants would dilute the ownership
of our stockholders. We also have effective registration statements on Form S-8 under the Securities Act registering an aggregate of
9,850,000 shares of our common stock issuable under our 2021 Stock Incentive Plan. As of February 4, 2026, options to purchase
5,252,319 shares of our common stock were outstanding under the 2021 Plan. The shares issuable pursuant to the registration statements
on Form S-8 will be freely tradable in the public market, except for shares held by affiliates. We may include a resale prospectus in
our registration statement on Form S-8 with regard to the 2021 Plan covering the resale of the shares issuable to Lance Alstodt and Francisco
Silva, our Chief Executive Officer and Vice President, Research and Development, respectively (and other affiliates), upon their exercise
of options held by them and with regard to shares of our common stock issued to them upon the vesting of restricted stock units. The
resale of such shares will be currently subject to the volume limitations imposed by Rule 144. The issuance of shares of our common stock
pursuant to the 2021 Plan would dilute the ownership of our stockholders. We also have an effective registration statement on Form S-1
with regard to the resale of up to 508,592 shares of our common stock issuable upon the exercise of warrants. Further, we have an effective
shelf registration statement on Form S-3 under the Securities Act registering $75,000,000 of our equity and debt securities. Pursuant
to the requirements of Form S-3, we currently may sell pursuant to such Form S-3, during any 12 month period, securities having an aggregate
market value of not more than one-third of the aggregate market value of the shares of our common stock held by non-affiliates. As of
January 31, 2026, the aggregate market value of shares of our common stock held by non-affiliates pursuant to General Instruction I.B.6
of Form S-3 was $9,239,458. In addition, our Board of Directors (our &#8220;Board&#8221;) is authorized to designate and issue
18,456,842 shares of preferred stock without further stockholder approval, containing such rights and preferences as our Board shall
determine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 43; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of a substantial number of shares of our common stock or securities convertible into, or exchangeable or exercisable for, shares
of our common stock, whether directly by us in future offerings or by our existing securityholders in the secondary market, the perception
that such issuances or resales could occur or the availability for future issuances or resale of shares of our common stock or securities
convertible into, or exchangeable or exercisable for, shares of our common stock could materially and adversely affect the market price
of our securities and our ability to raise capital through future offerings of equity or equity-related securities on attractive terms
or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Common Stock Warrants and the Pre-Funded Warrants are speculative in nature and there is not expected to be an active trading market
for the warrants.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock Warrants and the Pre-Funded Warrants offered in this offering do not confer any rights of common stock ownership on their
holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire shares of our common
stock at a fixed price for a limited period of time. Specifically, commencing on the date of issuance, holders of the Common Stock Warrants
may exercise their right to acquire the common stock and pay an exercise price of $1.03 per share (100% of the public offering
price of a Unit), prior to five years from the date of issuance, after which date any unexercised warrants will expire and have no further
value. In the case of Pre-Funded Warrants, holders may exercise their right to acquire the common stock and pay an exercise price of
$0.0001 per share. The Pre-Funded Warrants do not expire. In addition, there is no established trading market for the Common Stock Warrants
or Pre-Funded Warrants and we do not expect an active trading market to develop. Without an active trading market, the liquidity of the
Common Stock Warrants and Pre-Funded Warrants will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holders
of the Common Stock Warrants or Pre-Funded Warrants will have no rights as a holder of Common Stock until they acquire our Common Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
holders of the Common Stock Warrants or Pre-Funded Warrants acquire shares of our common stock upon exercise of the Common Stock Warrants
or Pre-Funded Warrants, the holders will have no rights with respect to shares of our common stock issuable upon exercise of the Common
Stock Warrants or Pre-Funded Warrants. Upon exercise of the Common Stock Warrants or Pre-Funded Warrants, the holder will be entitled
to exercise the rights of a holder of common stock as to the security exercised only as to matters for which the record date occurs after
the exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
of the Common Stock Warrants could discourage an acquisition of us by a third party.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of the Common Stock Warrants could make it more difficult or expensive for a third party to acquire us. The Common Stock Warrants
prohibit us from engaging in certain transactions constituting &#8220;fundamental transactions&#8221; unless, among other things, the
surviving entity assumes our obligations under the Common Stock Warrants. These and other provisions of the warrants offered by this
prospectus could prevent or deter a third party from acquiring us even where the acquisition could be beneficial to you.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="D_001"></span>CAPITALIZATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and cash equivalents, investments held in marketable securities and capitalization as of September
30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            an actual basis; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            an as adjusted basis to give effect to our issuance and sale of up to (i) 9,708,738
                                            Units in this offering at an assumed public offering price of $1.03 per Unit, the
                                            last reported sale price of our common stock on Nasdaq on February 4, 2026, after
                                            deducting the estimated placement agent fees and estimated offering expenses payable by us,
                                            (ii) 75% of the maximum offering amount after deducting the estimated placement agent fees
                                            and estimated offering expenses payable by us, (iii) 50% of the maximum offering amount after
                                            deducting the estimated placement agent fees and estimated offering expenses payable by us
                                            and (iv) 25% of the maximum offering amount after deducting the estimated placement agent
                                            fees and estimated offering expenses payable by us.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
as adjusted information below is illustrative only, and our cash and cash equivalents, investments held in marketable securities and
capitalization following the closing of this offering will be adjusted based on the actual public offering price and other terms of this
offering determined at pricing. You should read this information in conjunction with our financial statements and related notes and the
section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in
this prospectus and other financial information contained in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center">As of September 30, 2025</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Actual</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$2,500,000 (25% of the maximum offering)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$5,000,000 (50% of the maximum offering)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$7,500,000 (75% of the maximum offering)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$10,000,000 (100% of the maximum offering)</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">602,444</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,659,444</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,984,444</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,309,444</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,634,444</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investments held in marketable securities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,887,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,887,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,887,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,887,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,887,383</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred stock, $0.01 par value; 20,000,000 shares authorized; Series B Convertible Preferred</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,982</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock, $0.0001 par value; 75,000,000 shares authorized, 7,978,117 shares issued and outstanding,
    actual;  10,405,302, 12,832,486, 15,259,671 and 17,686,855 shares issued and outstanding, as adjusted, based on the
    sale of 25%, 50%, 75% and 100%, respectively, of the Units offered hereby</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">797</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,768</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">168,905,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">170,892,945</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">173,217,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">175,542,460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">177,867,217</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(166,713,054</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(166,713,054</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(166,713,054</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(166,713,054</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(166,713,054</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,206,979</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">4,194,913</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6,519,913</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,844,913</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">11,169,913</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total capitalization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,206,979</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,194,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,519,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,844,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,169,913</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock outstanding after this offering is based on 7,978,117 shares of our common stock outstanding as
of September 30, 2025, and excludes as of that date the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; 1,398,158
shares of our common stock issuable upon the conversion of 1,398,158 shares of Series B preferred stock;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; 1,138,055
shares of our common stock held in abeyance in connection with a warrant exercise (due to a beneficial ownership limitation) and issuable
at the request of the securityholder;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; 3,951,384
shares of our common stock issuable upon the exercise of outstanding warrants with a weighted average exercise price of $5.21 per share;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; 5,262,973
shares of our common stock issuable upon the exercise of outstanding stock options, with a weighted average exercise price of $2.58 per
share; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; 4,237,981
shares of our common stock reserved for future issuance pursuant to future awards granted under the 2021 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="D_002"></span>DILUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price
per Unit and the as adjusted net tangible book value per share after giving effect to this offering. We calculate net tangible book value
per share by dividing the net tangible book value, which is tangible assets less total liabilities, by the number of outstanding shares
of our common stock. Dilution represents the difference between the amount per share paid by purchasers of the securities in this offering
and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering. Our net tangible
book value as of September 30, 2025 was approximately $1.65 million, or approximately $0.21 per share of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the sale of our securities pursuant to this prospectus in the aggregate amount of $10,000,000 at an assumed offering
price of $1.03 per Unit, the last reported sale price of our common stock on Nasdaq on February 4, 2026 (assuming that
all of the securities covered by this prospectus are sold and there are no issuances of Pre-Funded Warrants), and after deducting the
estimated placement agent fees and estimated aggregate offering expenses payable by us, our net tangible book value as of September 30,
2025 would have been approximately $10.61 million, or $0.60 per share of common stock. This represents an increase in the
net tangible book value per share to our existing stockholders of approximately $0.39 per share and an immediate dilution in the
net tangible book value of approximately $0.43 per share to new investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this per share dilution to new investors based on the amount of funds we expect to receive on a sliding
scale as a percentage of the total offering amount:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Offering Level</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$2,500,000 <br/>(25% of the maximum offering)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$5,000,000 <br/>(50% of the maximum offering)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$7,500,000 <br/>(75% of the maximum offering)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$10,000,000 <br/>(100% of the maximum offering)</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Assumed public offering price per Unit</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1.03</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1.03</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1.03</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1.03</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Net tangible book value per share as of September 30, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Increase per share attributable to this offering</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.14</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.39</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">As adjusted net tangible book value per share as of September 30, 2025, after giving effect to this offering</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.35</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.54</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.60</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Dilution per share to new investors purchasing Units in this offering</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.68</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.49</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.43</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilution information above is for illustration purposes only. Our as adjusted net tangible book value following the closing of this offering
will depend on the actual public offering price and other terms of this offering determined at pricing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing table and discussion are based on 7,978,117 shares of our common stock outstanding as of September 30, 2025 and excludes, as
of September 30, 2025, (i) outstanding warrants to purchase up to 3,951,384 shares of our common stock at a weighted average exercise
price of $5.21 per share; (ii) outstanding options to purchase up to 5,262,973 shares of our common stock at a weighted average exercise
price of $2.58 per share; (iii) 1,398,158 shares of Series B preferred stock convertible into an equal number of shares of our common
stock at a conversion price of $10.00 per share; and (iv) 1,138,055 shares of our common stock held in abeyance in connection with a
warrant exercise (due to a beneficial ownership limitation) and issuable at the request of the securityholder. To the extent that warrants
and options are exercised, Series B preferred stock is converted and shares held in abeyance are issued, there may be further dilution
to new investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="D_003"></span>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements regarding future events and our future results that are based on our current expectations,
estimates, forecasts and projections as well as the current beliefs and assumptions of our management, including about our business,
our financial condition, our results of operations, our operating requirements and utilization of our capital resources, and the industry
and environment in which we operate. Statements that include words such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221;
&#8220;intend&#8221; and &#8220;expect,&#8221; variations of these words, and similar expressions, are intended to identify forward-looking
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements may include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements
    relating to projected growth and management&#8217;s long-term performance goals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements
    relating to the anticipated effects on results of operations or our financial condition from expected developments or events;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements
    relating to our business and growth strategies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other statements which are not historical facts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements speak only as of the date of this prospectus and are subject to risks, uncertainties and assumptions that
are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements.
Factors that might cause or contribute to such differences, and other factors that we believe affect our performance, include those discussed
in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Conditions and
Results of Operations&#8221; in this prospectus, and in other reports we file with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors include without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    current and anticipated cash needs and our need for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal,
    state and foreign regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to conduct clinical trials with respect to our products and services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to develop and commercialize our products and services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to enter into agreements to implement our business strategy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    acceptance of our products and services by patients and the medical community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure necessary media and reagents, as well as devices, materials and systems, for our clinical trials and commercial
    production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    manufacturing capabilities to produce our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain brown adipose (fat) tissue in connection with our <i>ThermoStem Program</i>;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our intellectual property;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain an adequate level of product liability insurance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain third party reimbursement for our products and services from private and governmental insurers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effects of competition in our market areas;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on certain key personnel; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">further
    sales or other dilution of our equity, which may adversely affect the market price of our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
forward-looking statements are based on the reasonable expectations of our management at the time that they are made, you should not
rely on them. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, whether as a result
of new information, future events or otherwise, except as may be required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="D_004"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds from this offering, after deducting the estimated placement agent fees and offering expenses, payable
by us, will be approximately $9.0 million (assuming that all of the securities covered by this prospectus are sold and there are
no issuances of Pre-Funded Warrants) based on an assumed public offering price of $1.03 per Unit, which is the last reported sale
price of our common stock on Nasdaq on February 4, 2026. However, because this is a reasonable best efforts offering and there is no
minimum offering amount required as a condition to the closing of this offering, the actual offering amount, the placement agent&#8217;s
fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover
page of this prospectus. Based on the assumed public offering price set forth above, we estimate that our net proceeds from the sale
of 75%, 50%, and 25% of the securities offered in this offering would be approximately $6.7 million, $4.4 million, and $2.1 million,
respectively, after deducting the estimated placement agent fees and estimated offering expenses payable by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents and investments held
in marketable securities, in connection with our clinical trials with respect to <i>BRTX-100</i>, pre-clinical research and development
with respect to our <i>ThermoStem Program</i>, the development of our commercial biocosmeceuticals platform and for general corporate
purposes and working capital. We may also use a portion of the net proceeds from this offering to acquire or invest in complementary
businesses, technologies, product candidates or other intellectual property, although we have no present commitments or agreements to
do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts and timing of our actual expenditures will depend on numerous factors, including the factors described under &#8220;Risk Factors&#8221;
in this prospectus, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds
for other purposes, and our management will have broad discretion in the application of the net proceeds to us from this offering, including
for any of the purposes described above. Pending the use of the net proceeds from this offering, we intend to invest the net proceeds
in interest-bearing, investment-grade securities, certificates of deposit or government securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="D_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop therapeutic products, using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core
programs relate to the treatment of disc/spine disease and metabolic disorders. We also operate a commercial biocosmeceutical platform:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disc/Spine
    Program (brtxDisc). </i></b>Our lead cell therapy candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a person&#8217;s
    own) cultured mesenchymal stem cells (&#8220;MSCs&#8221;) collected from the patient&#8217;s bone marrow. We intend that the product
    will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical
    procedure. The <i>BRTX-100</i> production process utilizes proprietary technology and involves collecting a patient&#8217;s bone
    marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, <i>BRTX-100
    </i>is injected by a physician into the patient&#8217;s damaged disc. The treatment is intended for patients whose pain has not been
    alleviated by non-surgical procedures and who potentially face the prospect of surgery. We are conducting a Phase 2 clinical trial
    using <i>BRTX-100</i> to treat chronic lower back pain arising from degenerative disc disease. We have also obtained FDA IND clearance
    to evaluate <i>BRTX-</i>100 in the treatment of chronic cervical discogenic pain. See &#8220;Disc/Spine Program&#8221; below.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Metabolic
    Program (ThermoStem)</i></b>. We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown
    adipose (fat) derived stem cells (&#8220;BADSC&#8221;) to generate brown adipose tissue (&#8220;BAT&#8221;) as well as exosomes secreted
    by BADSC. We refer to this as our <i>ThermoStem Program</i>. BAT is intended to mimic naturally occurring brown adipose depots that
    regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may
    be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with
    higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
    Patents related to the <i>ThermoStem Program</i> have been issued in the United States and other jurisdictions. See &#8220;Metabolic
    Brown Adipose (Fat) Program&#8221; below.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>BioCosmeceuticals</i></b>:
    We operate a commercial biocosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7
    certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum
    has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic
    effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader
    family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals
    in the emerging biocosmeceuticals space.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to
the spine and discs (and other parts of the body). We anticipate that FDA approval or clearance will be necessary for this device prior
to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard to <i>BRTX-100</i>.
See &#8220;Curved Needle Device&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patents and patent applications for the <i>Disc/Spine Program</i>, the <i>ThermoStem Program</i> and the curved needle device are described
below under &#8220;Technology; Research and Development.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
human being has stem cells in his or her body. These cells exist from the early stages of human development until the end of a person&#8217;s
life. Throughout our lives, our body continues to produce stem cells that regenerate to produce differentiated cells that make up various
aspects of the body such as skin, blood, muscle and nerves. These are generally referred to as adult (non-embryonic) stem cells. These
cells are important for the purpose of medical therapies aiming to replace lost or damaged cells or tissues or to otherwise treat disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regenerative
cell therapy relies on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones or repairing damaged or diseased
tissue. A great range of cells can serve in cell therapy, including cells found in peripheral and umbilical cord blood, bone marrow and
adipose (fat) tissue. Physicians have been using adult stem cells from bone marrow to treat various blood cancers for 70 years (the first
successful bone marrow transplant was performed in 1956). Recently, physicians have begun to use stem cells to treat various other diseases.
We intend to develop cell and tissue products and regenerative therapy protocols, primarily involving adult stem cells, to allow patients
to undergo cellular-based treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are concentrating initially on therapeutic areas in which risk to the patient is low, recovery is relatively easy, results can be demonstrated
through sufficient clinical data, and patients and physicians will be comfortable with the procedure. We believe that there will be readily
identifiable groups of patients who will benefit from these procedures. We also believe that these procedures will be significantly less
expensive than the most common surgical procedure alternatives and will compare favorably, over the long-term, to conservative treatment
costs which may persist for years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we have focused our initial developmental efforts on cellular-based therapeutic products and clinical development programs in selective
areas of medicine for which the treatment protocol is minimally invasive. Such areas include the treatment of the disc and spine and
metabolic-related disorders. Upon regulatory approval, we will seek to obtain third party reimbursement for our products and procedures;
however; if we are not successful, patients may be required to pay for our products and procedures out of pocket in full and without
the ability to be reimbursed by any governmental and other third party payers, which would adversely impact our prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have undertaken research and development efforts in connection with the development of investigational therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. See &#8220;Disc/Spine Program,&#8221; &#8220;Metabolic
Brown Adipose (Fat) Program&#8221; and &#8220;Curved Needle Device&#8221; below. As a result of these programs, we have seven United
States patents, eighteen foreign patents and one United States patent application related to research regarding our <i>ThermoStem Program.</i>
We have also obtained licenses for two United States patent applications related to our <i>Disc/Spine Program, </i>one United States
patent related to our <i>Disc/Spine Program,</i> and a license for one United States patent related to a curved needle device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a research laboratory facility with cGMP capabilities to produce clinical grade products and we will seek to further
develop cellular-based treatments, products and protocols, stem cell-related intellectual property (&#8220;IP&#8221;) and translational
research applications. See &#8220;Laboratory&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any significant revenues to date. In November 2021, we completed a $23,000,000 public offering of our securities.
In 2023, we raised approximately $2,680,000 in additional gross proceeds through public offerings of our securities. In February 2024,
we received approximately $8,100,000 in gross proceeds pursuant to the exercise of warrants. During 2025, we received approximately $2,000,000
of gross proceeds pursuant to what is commonly is referred to as an &#8220;at-the-market&#8221; program with Rodman &amp; Renshaw, LLC
(the &#8220;2024 ATM&#8221;). As of January 31, 2026, we had the ability to raise an additional approximately $1,017,040 under the 2024
ATM. In October 2025, we received approximately $1,100,000 in gross proceeds pursuant to a registered direct public offering of our common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
BRTX-100 program has been granted a fast track designation by the FDA which may result in a reduction in the length of time required
to complete our Phase 2 clinical trial and consequently a reduction in the costs involved. However, notwithstanding the above, we believe
that our current funds may not be sufficient for us to complete our Phase 2 clinical trial investigating the use of <i>BRTX</i>-<i>100</i>
in the treatment of chronic lower back pain arising from degenerative disc disease, as further described in this section, continue our
pre-clinical research and development efforts with respect to our <i>ThermoStem Program</i> and satisfy our current working capital needs
through the end of the 12 month period following the date of the financial statements included in this prospectus. In addition, the implementation
of our business plan, as discussed below, will require the receipt of significant additional financing to fund our research and development
efforts, including our contemplated Phase 3 clinical trial with regard to <i>BRTX-100</i> and our contemplated clinical trials relating
to our <i>ThermoStem Program</i>, and otherwise fund our operations. We intend to seek to raise capital through our 2024 ATM and warrant
exercises as well as through investment bankers and from biotech funds, strategic partners and other financial institutions. No assurance
can be given that the amount of funding that we anticipate may be required for the above purposes is correct or that we will be able
to accomplish our goals within the timeframes projected. In addition, no assurance can be given that we will be able to obtain any required
financing on commercially reasonable terms or otherwise. If we are unable to obtain adequate funding, we may be required to significantly
curtail or discontinue our proposed operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disc/Spine
Program</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the initiatives that we are currently pursuing is our <i>Disc/Spine Program</i>, with our initial product candidate being called <i>BRTX-100</i>.
We have obtained an exclusive license (see &#8220;<i>Exclusive License</i>&#8221; below) that permits us to use technology for adult
stem cell treatment of disc and spine conditions. The technology is an advanced stem cell culture and injection procedure into the intervertebral
disc (&#8220;IVD&#8221;) that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
back pain is the most common, most disabling, and most costly musculoskeletal ailment faced worldwide. According to a 2016 market report
from Trinity Partners, a global life sciences consulting firm, of the 250 million American adults, nearly 25 million have chronic lower
back pain of which approximately 12 million have been diagnosed with and treated for disc degeneration and approximately 5.6 million
have pain caused by a protruding or injured disc. We believe that between 500,000 and one million invasive surgical procedures are performed
each year to try to alleviate the pain associated with these lower back conditions and that such procedures cost approximately $40 billion.
Clinical studies have documented that the source of the pain is most frequently damage to the IVD. This can occur when forces, whether
a single load or repetitive microtrauma, exceed the IVD&#8217;s inherent capacity to resist those loads. Aging, obesity, smoking, lifestyle,
and certain genetic factors may predispose one to an IVD injury. Current surgical approaches to back pain are extremely invasive (often
altering the spine&#8217;s biomechanics unfavorably and predisposing it to further disc degeneration) and are associated with unacceptably
low success rates (with a second operation occurring 10% to 20% of the time). In addition, current surgical approaches are costly with
spinal fusion surgery costing approximately $110,000, discectomy costing approximately $20,000 to $50,000 and disc replacement surgery
costing approximately $80,000 to $150,000. Even conservative treatments can be costly, with oral medications costing between $1,000 and
$2,000 per year, injection treatments costing approximately $8,000 per year and physical therapy costing approximately $20,000 annually.
We anticipate that the cost of a single treatment using <i>BRTX-100</i> will compare favorably to conservative treatments which may continue
for years and will be less expensive than the most common surgical procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
once thought to be benign, the natural history of lower back pain is often one of chronic recurrent episodes of pain leading to progressive
disability. This is believed to be a direct result of the IVD&#8217;s poor healing capacity after injury. The IVD is the largest avascular
(having few or no blood vessels) structure in the body and is low in cellularity. Therefore, its inherent capacity to heal after injury
is poor. The clinical rationale of <i>BRTX-100</i> is to deliver a high concentration of the patient&#8217;s own cultured MSCs into the
site of pathology to promote healing and relieve pain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed a mesenchymal stem cell product candidate, <i>BRTX-100, </i>derived from autologous (or a person&#8217;s own) human bone
marrow, cultured and formulated, in a proprietary method, specifically for introduction into a painful lumbar disc. The product candidate
was developed utilizing in part the exclusive license described below under &#8220;<i>Exclusive License</i>.&#8221; As described below
under &#8220;<i>BRTX-100</i>&#8221; and &#8220;<i>Production and Delivery</i>,&#8221; <i>BRTX-100</i> is a hypoxic (low oxygen) stem
cell product developed through a culturing process. In order to enhance the survivability of our bone marrow-derived MSCs in the avascular
environment of the damaged disc, <i>BRTX-100 </i>is designed to expand under hypoxic conditions. This process is intended to result in
a large cell count population with enhanced viability and therapeutic potential following injection into the injured disc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, pursuant to an IND application, we received authorization from the FDA to commence a Phase 2 clinical trial investigating
the use of <i>BRTX-100</i>, our lead cell therapy candidate, in the treatment of chronic lower back pain arising from degenerative disc
disease. We are conducting our Phase 2 clinical trial as described below under &#8220;<i>Clinical Trial</i>.&#8221; We believe that,
based upon our periodic reports to the FDA as to our clinical trial, the existing IND remains effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to developing <i>BRTX-100</i>, we may also seek to sublicense the technology to a strategic third party, who may assist in gaining
FDA approval for a lumbar disc indication, or third parties for use in connection with cellular-based developmental programs with regard
to disc and spine related conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a laboratory, which includes a clean room facility, to perform the production of cell products (including <i>BRTX-100</i>)
for use in our clinical trials, for third party cell products or for general research purposes. We may also use this laboratory to develop
our pipeline of future products and expand our stem cell-related IP. See &#8220;Laboratory&#8221; and &#8220;Technology; Research and
Development&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, a United States patent related to <i>BRTX-100</i> was issued. We have been granted exclusive license rights with respect
to the patent. See &#8220;<i>Exclusive License</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BRTX-100
</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidate<i>, BRTX-100,</i> is an autologous hypoxic (low oxygen) cultured mesenchymal stem cell product derived from a
patient&#8217;s own bone marrow and formulated with a proprietary biomaterial carrier (platelet lysate) to increase potency, viability
and survivability. We have designed the cryopreserved sterile cellular product candidate to be provided in vials for injection into painful
lumbar discs. We anticipate the product candidate will be delivered using a standard 20 gauge 3.5 inch introducer needle and a 25 gauge
6 inch needle that will extend into the disc center upon delivery. Upon regulatory approval, we plan to provide training to medical practitioners
with regard to the approved injection procedure. It is anticipated that the delivery of the product candidate will be a 30 minute procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mesenchymal
stem cells used in <i>BRTX-100 </i>are similar to other MSCs under development by others; however, in order to enhance the survivability
of our bone marrow-derived MSCs in the avascular environment of the damaged disc, <i>BRTX-100 </i>is designed to expand under hypoxic
conditions for a period of approximately three weeks. This process is intended to result in an approximate 40 million cell count population
with enhanced viability and therapeutic potential following injection locally into injured spinal discs. Publications and scientific
literature have indicated that MSCs preconditioned in a hypoxic environment show enhanced skeletal muscle regeneration properties and
improved impacts upon circulation and vascular formation compared to MSCs cultured under normoxic (normal oxygen) conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the <i>Journal of Translational Medicine</i> published the results of our study evaluating the benefits of long-term hypoxic
culturing of human bone marrow-derived MSCs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2021, we were awarded a National Institutes of Health Small Business Technology Transfer (STTR) Phase 1 grant for $256,000
to evaluate the therapeutic effects on our hypoxic cultured bone marrow derived mesenchymal stem cells (<i>BRTX-100</i>) after encapsulation
with a PEG-peptide hydrogel. The work was done in collaboration with Washington University of St. Louis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
June 2022, we have entered into clinical trial agreements with 16 sites to conduct our Phase 2 clinical trial targeting chronic lumbar
disc disease. See &#8220;<i>Clinical Trial</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Production
and Delivery</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production of our product candidate, <i>BRTX-100, </i>begins with the physician collecting bone marrow from the patient under local anesthesia.
Peripheral blood is also collected from the patient. The physician will then send the patient&#8217;s bone marrow and blood samples to
our laboratory (or a contract laboratory) for culturing and formulation. The hypoxic culturing process is intended to result in the selection
of a cell population that is suitable for an improved possibility of survival in the internal disc environment. We anticipate that the
cell culturing process and product formulation will take approximately three weeks, with an additional two weeks required for quality
control testing required to meet product release criteria. We will then send the therapeutic cryopreserved stem cells (<i>BRTX-100</i>)
in a sterile vial back to the physician&#8217;s offices where it will undergo a controlled thaw prior to the procedure. The price structure
for the procedure and our services has not been determined and no assurances can be given as to the effect that such price structure
will have on the marketability of such procedure and services. The following illustrates the process:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_001.jpg" alt="" style="height: 393px; width: 700px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exclusive
License</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our license agreement with Regenerative Sciences, LLC (&#8220;Regenerative&#8221;) that became effective in April 2012 (the &#8220;Regenerative
License Agreement&#8221;), we have obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing
license from Regenerative to utilize or sublicense a certain method for culturing cells for use in our developmental program involving
disc and spine conditions, including protruding or painful discs and the treatment of avascular zones. The investigational technology
that has been licensed is an advanced stem cell culture and injection procedure that may offer relief from lower back pain, buttock and
leg pain, and numbness and tingling in the leg and foot. Pursuant to the Regenerative License Agreement, we have also obtained a worldwide,
exclusive, royalty-bearing license from Regenerative to utilize or sublicense a certain investigational curved needle device for the
administration of specific cells and/or cell products to the disc and/or spine (and other parts of the body). It will be necessary to
advance the design of this investigational device to facilitate the delivery of substances, including living cells, to specific locations
within the body and minimize the potential for damage to nearby structures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patents that are the subject of the Regenerative License Agreement have been assigned to Regenexx, LLC which we have been advised by
Regenerative is an affiliate of Regenerative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Animal
Study</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
efficacy and safety of our product candidate, <i>BRTX-100,</i> has been tested in a degenerative intervertebral rabbit disc model. In
this study, 80 rabbits underwent surgery to create a puncture in the discs. Four weeks post-surgery, each rabbit had either contrast,
a biomaterial carrier or <i>BRTX-100</i> injected into the discs. In order to study the biodistribution and efficacy of <i>BRTX-100</i>,
the rabbits were evaluated at day 56 and day 120.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key safety findings of the animal study are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    was no evidence or observation of gross toxicity related to the administration of <i>BRTX-100</i> at either time point. The clinical
    pathology across both groups and time points were within expected normal historical ranges and under the conditions of the test.
    No abnormalities (including fractures or overt signs of lumbar disc disease) were identified after review of the radiographic images
    taken at both endpoints for both groups. No toxicity or adverse finding was evident in the systemic tissues or the discs of animals
    receiving <i>BRTX-100</i>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    was no detectable presence of human cells (<i>BRTX-100</i>) observed at the day 56 interim time point. This is consistent with the
    proposed mechanism of action that <i>BRTX-100</i> acts through a paracrine effect of secreted growth and immunomodulation factors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key efficacy findings of the animal study are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BRTX-100
    </i>showed a statistically significant DHI (disc height increase) over the control group at day 120.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BRTX-100
    </i>showed a statistically significant improvement in disc histology over the control group at day 120 as graded by a validated histology
    scale. <i>BRTX-100</i> showed a significant improvement in the cellularity and matrix of the disc when compared to the control group
    at day 120.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to an IND application we submitted to the FDA, we have obtained authorization to conduct a Phase 2 clinical trial investigating the use
of <i>BRTX-100</i>, our lead cell therapy candidate, in the treatment of chronic lower back pain arising from degenerative disc disease.
We are conducting our Phase 2 clinical trial as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following describes the Phase 2 clinical trial authorized by the FDA:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 2 Prospective, Double-Blinded, Placebo Controlled, Randomized Study</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 55; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99
    patients; randomized 2:1, <i>BRTX-100</i> to control, 40 million cells/dose</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20
    clinical trial sites (we intend to utilize up to 16 clinical trial sites)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
    efficacy endpoint at 12 months</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
    safety and efficacy follow up at 24 months</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
    subjects must have only one symptomatic diseased disc</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
    subjects must have current diagnosis of chronic lumbar disc disease typical pain with degeneration of a single disc confirmed by
    history, exam, radiography, or other acceptable means</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
    subjects must have exhausted previous conservative non-operative therapies</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
    Efficacy Endpoint</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Responder
    endpoint - percentage of patients that meet the improvement in function and reduction in pain threshold</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
    in function defined as at least a 30% increase in function based on the Oswestry questionnaires (ODI)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
    of pain defined as at least a 30% decrease in pain as measured using the Visual Analogue Scale (VAS)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    or Secondary Endpoints</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    response at 12 months</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline in pain as assessed with the VAS score and ODI at weeks 2, 12, 26, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline in function as assessed with the ODI at weeks 2, 12, 26, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline in function as assessed by Roland Morris Disability Questionnaire (RMDQ) at weeks 26, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline function as assessed by Functional Rating Index (FRI) at weeks 12, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline Quality of Life assessment (SF-12 questionnaire) scores at weeks 2, 12, 26, 52 and 104</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, we entered into a Master Service Agreement with Professional Research Consulting Inc. d/b/a PRC Clinical, a CRO specializing
in clinical trial management, to conduct our Phase 2 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, we announced that we had completed enrollment for the safety run-in component of our Phase 2 clinical study of <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, we announced that we had signed a clinical trial agreement with Northwell Health, New York State&#8217;s largest health care
provider and private employer, pursuant to which Northwell Health is participating in our Phase 2 clinical study of <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, we announced that the final subject in our <i>BRTX-100</i> Phase 2 clinical trial safety cohort had been dosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, we announced that the independent Data Safety Monitoring Board, which is overseeing our Phase 2 clinical trial, unanimously
recommended the continuation of our study in accordance with the version of the protocol with no changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, we announced that the FDA cleared an important amendment to the protocol of our ongoing Phase 2 study investigating the use
of <i>BRTX-100</i>. The protocol amendment removed saline injection in the control arm of the study and replaced it with a sham injection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, we announced new preliminary 26&#8211;52 week blinded data from the first 10 patients with cLDD enrolled in our ongoing
Phase 2 clinical trial of <i>BRTX-100</i>. No serious adverse events were reported in any of the 10 safety run-in subjects. In addition,
there was no dose limiting toxicity at 26-52 weeks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, we announced new preliminary 26&#8211;52 week blinded data from the first 15 patients with cLDD enrolled in our ongoing
Phase 2 clinical trial of <i>BRTX-100</i>. No serious adverse events were reported in any of the 15 subjects. In addition, there was
no dose limiting toxicity at 26-52 weeks. Further, we announced certain positive preliminary data analyses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025, we announced that preliminary 26-, 52- and 104- week blinded data from the first 15 patients with cLDD enrolled in our ongoing
Phase 2 clinical trial of <i>BRTX-100</i> was presented by our Vice President of Research and Development at the International Society
for Cell and Gene Therapy 2025 Annual meeting. No serious adverse events were reported and there was no dose limiting toxicity at 26-104
weeks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2025, we announced that new preliminary blinded clinical data from 36 patients enrolled in our ongoing Phase 2 trial of <i>BRTX-100</i>
for the treatment of cLDD was presented by our Vice President of Research and Development at the International Society for Stem Cell
Research 2025 Annual Meeting. Over 74% of the subjects showed greater than 50% improvement in function by 52 weeks and over 72% of the
subjects reported greater than 50% in reduction in pain by 52 weeks. No serious adverse events or dose limiting toxicities were reported
between 26 and 104 weeks at the target dose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, we announced that we were granted a Type B meeting with the FDA to discuss a potential accelerated biologics license application
(&#8220;BLA&#8221;) approval pathway for the Fast-Track-Designated <i>BRTX-100</i> program for the treatment of cLDD. The meeting took
place in December 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA approval process can be lengthy, expensive and uncertain and there is no guarantee that the clinical trial(s) will be completed or
that the product will ultimately receive approval or clearance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an alternative to undertaking any necessary clinical trials ourselves, we may explore the licensing of our rights with respect to our
product candidate, <i>BRTX-100,</i> to a strategic partner. Such an arrangement could possibly eliminate or significantly reduce the
need to raise the substantial capital needed to commence and complete the clinical trials and undertake the commercialization of <i>BRTX-100
</i>and would provide licensing-related revenue to us in lieu of product sales revenue. No assurance can be given that any licensing
agreement will be entered into, whether upon commercially reasonable terms or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Defined
Health Report</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, we engaged Defined Health, a business development and strategy consulting firm, to conduct an independent review of <i>BRTX-100</i>.
Defined Health has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
review was intended to collect informed, independent opinions regarding <i>BRTX-100</i> among key opinion leaders (&#8220;KOLs&#8221;)
(i.e., orthopedic surgeons specializing in back and spine surgery with experience in stem cell therapy), who, upon studying applicable
clinical material, could offer opinions regarding the future therapeutic potential of <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted in the Defined Health report, the KOLs indicated that stem cell therapies have great potential to treat chronic lumbar disc disease
and other therapeutic areas. The KOLs reacted positively to the value proposition of our product candidate, <i>BRTX-100, </i>and were
optimistic that the clinical data presented to date is likely to be mirrored in future clinical investigations. Given the opportunity,
the KOLs indicated that they would likely participate in a clinical trial should it be offered at their center and that they would recommend
the study to appropriately eligible patients. The report indicated that, if <i>BRTX-100</i> were to be granted FDA approval, the KOLs
anticipate that it would be integrated into the standard of care for eligible chronic lumbar disc disease patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Similar
Therapies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
data from studies of therapies comparative to <i>BRTX-100</i> have shown reduced pain, increased function, and an absence of significant
safety issues with a durable response, as shown below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_002.jpg" alt="" style="height: 362px; width: 700px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impact
on Public Health </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States is the world&#8217;s leading consumer of hydrocodone (99%) and oxycodone (83%) and leads the world in per capital consumption
of such drugs (twice as much as second ranked Canada). In 2020, 91,000 persons in the United States died from overdoses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
annual healthcare and lost productivity costs in the United States related to pain, including headache, back pain and neck pain, are
estimated to be $600 billion, which is twice the annual costs related to heart disease and greater than the combined annual costs related
to cancer and diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metabolic
Brown Adipose (Fat) Program</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
June 2011, we have been engaging in pre-clinical research efforts with respect to an investigational platform technology utilizing brown
adipose (fat) derived stem cells (&#8220;BADSCs&#8221;) for therapeutic purposes. We have labeled this initiative our <i>ThermoStem Program</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brown
fat is a specialized adipose (fat) tissue found in the human body that plays a key role in the evolutionarily conserved mechanisms underlying
thermogenesis (generation of non-shivering body heat) and energy homeostasis in mammals - long known to be present at high levels in
hibernating mammals and human newborns. Recent studies have demonstrated that brown fat is present in the adult human body and may be
correlated with the maintenance and regulation of healthy metabolism, thus potentially being involved in caloric regulation. The pre-clinical
<i>ThermoStem Program</i> involves the use of a cell-based (brown adipose tissue construct) treatment for metabolic disease, such as
type 2 diabetes, obesity, hypertension and other metabolic disorders, as well as cardiac deficiencies. The diseases, disorders and syndromes
that may be targeted by our <i>ThermoStem Program</i> are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_003.jpg" alt="" style="height: 323.25pt; width: 447.75pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have had initial success in transplanting the brown adipose tissue construct in animals, and we are currently exploring ways to deliver
into humans. Even though present, BAT mass is very low in healthy adults and even lower in obese populations. Therefore, it may not be
sufficient to either naturally impact whole body metabolism, or to be targeted by drugs intended to increase its activity in the majority
of the population. Increasing BAT mass is crucial in order to benefit from its metabolic activity and this is what our <i>ThermoStem
Program</i> seeks to accomplish. We may also identify other naturally occurring biologics and chemically engineered molecules that may
enhance brown adipose tissue performance and activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obesity,
the abnormal accumulation of white fat tissue, leads to a number of metabolic disorders and is the driving force behind the rise of type
2 diabetes and cardiovascular diseases worldwide. Pharmacological efforts to alter metabolic homeostasis through modulating central control
of appetite and satiety have had limited market penetration due to significant psychological and physiological safety concerns directly
attributed to modulating these brain centers. Adipose tissue is one of the largest organs in the human body and plays a key role in central
energy balance and lipid homeostasis. White and brown adipose tissues are found in mammals. White adipose tissue&#8217;s function is
to store energy, whereas BAT specializes in energy expenditure. As discussed in a 2020 article published in the <i>International Journal
of Molecular Sciences</i>, recent advancements in unraveling the mechanisms that control the induction, differentiation, proliferation,
and thermogenic activity of BAT, along with the application of imaging technologies for human BAT visualization, have generated optimism
that these advances may provide novel strategies for targeting BAT activation/thermogenesis, leading to efficacious and safe obesity
targeted therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing cell-based product candidates to target obesity and metabolic disorders using BADSCs. Our goal is to develop a bioengineered
implantable brown adipose tissue construct intended to mimic ones naturally occurring in the human body. We have isolated and characterized
a human multipotent stem cell population that resides within BAT depots. We have expanded these stem cells to clinically relevant numbers
and successfully differentiated them into functional brown adipocytes. We intend to use adult stem cells that may be differentiated into
progenitor or fully differentiated brown adipocytes, or a related cell type, which can be used therapeutically in patients. We are focusing
on the development of treatment protocols that utilize allogeneic cells (i.e., stem cells from a genetically similar but not identical
donor).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to deliver these differentiated cells into target locations <i>in vivo</i>, we seeded BADSCs onto 3-dimensional biological scaffolds.
Pre-clinical animal models of diet-induced obesity, that were transplanted with differentiated BADSCs supported by a biological scaffold,
presented significant reductions in weight and blood glucose levels compared to scaffold only controls. We are identifying technology
for <i>in vivo</i> delivery in small animal models. Having completed our proof of concept using our BAT in small animals, we are currently
developing our next generation BAT. It is anticipated that this next version will contain a higher purity of BADSC and a greater percent
of functional brown adipocytes, which is expected to increase the therapeutic effect compared to our first-generation product. In addition,
we are exploring the delivery of the therapeutic using encapsulation technology, which will only allow for reciprocal exchange of small
molecules between the host circulation and the BAT implant. We expect that encapsulation may present several advantages over our current
biological scaffolds, including prevention of any immune response or implant rejection that might occur in an immunocompetent host and
an increase in safety by preventing the implanted cells from invading the host tissues. We have developed promising data on the loading
of human stem cell-derived tissue engineered brown fat into an encapsulation device to be used as a cell delivery system for our metabolic
platform program for the treatment of type 2 diabetes, obesity, hyperlipidemia and hypertension. This advancement may lead to successful
transplantation of brown fat in humans. We are evaluating the next generation of BAT constructs that will first be tested in small animal
models. No assurance can be given that this delivery system will be effective <i>in vivo</i> in animals or humans. Our allogeneic brown
adipose derived stem cell platform potentially provides a therapeutic and commercial model for the cell-based treatment of obesity and
related metabolic disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2014, our research with regard to the identification of a population of brown adipose derived stem cells was published in <i>Stem
Cells</i>, a respected stem cell journal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2014, we entered into a Research Agreement with Pfizer Inc., a global pharmaceutical company. Pursuant to the Research Agreement
with Pfizer, we were engaged to provide research and development services with regard to a joint study of the development and validation
of a human brown adipose cell model. The Research Agreement with Pfizer provided for an initial payment to us of $250,000 and the payment
of up to an additional $525,000 during the two-year term of the Agreement, all of which has been received. The Research Agreement expired
upon completion of the services provided for therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2015, we entered into a one year research collaboration agreement with the University of Pennsylvania with regard to the understanding
of brown adipose biology and its role in metabolic disorders. In September 2018, we entered into a one year research collaboration agreement
with the University of Pennsylvania pursuant to which the university was provided access to our proprietary brown adipose tissue cells
for research purposes. No amounts were payable by or to us pursuant to either agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2015, a United States patent related to the <i>ThermoStem Program </i>was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2017, an Australian patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2017, a Japanese patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019, a United States patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, an Australian patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, an Israeli patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, a United States patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, our collaboration with the University of Pennsylvania resulted in a publication in <i>Cell Reports</i>, a respected peer
reviewed journal, with regard to our <i>ThermoStem Program</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, a European patent related to our <i>ThermoStem Program</i> was issued to us. This European patent was validated in Belgium,
France, Germany, Italy, Poland, Spain, Sweden, Switzerland, and the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, an Israeli patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, a European patent related to our <i>ThermoStem Program</i> was issued to us. This European patent was validated in France,
Germany, Italy, Spain, and the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, a United States patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2021, a Japanese patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2021, a United States patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2021, an Australian patent related to our <i>ThermoStem Program </i>was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, a Japanese patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, an Israeli patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, we announced that we were awarded a Small Business Innovation Research (SBIR) Phase 1 grant from Eunice Kennedy Shriver
National Institute of Child Health &amp; Human Development of the National Institutes of Health to enable the development and the evaluation
of our <i>ThermoStem Program</i> for the treatment of polycystic ovary syndrome (PCOS). The work is to be done in collaboration with
Dr. Sheng Wu, Associate Professor, Center for Metabolic Disease Research at Temple University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, a Japanese patent related to our <i>ThermoStem Program </i>was issued to us<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, a United States patent related to our <i>ThermoStem Program </i>was issued to us<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, a European patent related to our <i>ThermoStem Program </i>was issued to us<i>. </i>This European patent was validated in
France, Germany, Italy, Spain, and the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, a United States patent related to our <i>ThermoStem Program </i>was issued to us<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, a Japanese patent related to our <i>ThermoStem</i> program was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, a European patent related to our <i>ThermoStem Program </i>was issued to us<i>.</i> This European patent was validated in
France, Germany, Italy, Spain and the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, an Israeli patent related to our <i>ThermoStem Program </i>was issued to us<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, a Japanese patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, a notice of allowance was issued for an Australian patent application related to our <i>ThermoStem Program</i>. This application
is expected to issue as an Australian patent in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed proof of concept preclinical animal studies using our first generation brown adipose derived stem cells. We intend to
undertake additional preclinical animal studies in order to optimize delivery and explore the feasibility of targeting additional indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that much of our development work in this area will take place at our laboratory facility, outside core facilities at academic,
research or medical institutions, or contractors. See &#8220;Laboratory&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioCosmeceuticals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate a commercial biocosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified
clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically
engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward,
we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic
products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging biocosmeceuticals space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market our biocosmeceutical products to distributors, medical spas and direct to consumers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2025, we announced the hiring of Sandy Lipkins whose responsibilities focus on technology commercialization and business development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2025, we announced that we hired Crystal Romano as our Head of Global Commercial Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Curved
Needle Device</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Regenerative License Agreement discussed under &#8220;Disc/Spine Program-<i>Exclusive License</i>&#8221; above, we have licensed
and further developed an investigational curved needle device (&#8220;CND&#8221;) that is a needle system with a curved inner cannula
to allow access to difficult-to-locate regions for the delivery or removal of fluids and other substances. The investigational CND is
intended to deliver stem cells and/or other therapeutic products or material to the interior of a human intervertebral disc, the spine
region, or potentially other areas of the body. The device is designed to rely on the use of pre-curved nested cannulae that allow the
cells or material to be deposited in the posterior and lateral aspects of the disc to which direct access is not possible due to outlying
structures such as vertebra, spinal cord and spinal nerves. We anticipate that the use of the investigational CND will facilitate the
delivery of substances, including living cells, to specific locations within the body and minimize the potential for damage to nearby
structures. The investigational device may also have more general use applications. In August 2015, a United States patent for the CND
was issued to the licensor, Regenerative. We anticipate that FDA approval or clearance will be necessary for the investigational CND
prior to commercialization. We do not intend to utilize the CND in connection with our Phase 2 clinical trial with regard to <i>BRTX-100</i>.
The FDA review and approval process can be lengthy, expensive and uncertain and there is no guarantee of ultimate approval or clearance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Laboratory</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a laboratory in Melville, New York for research purposes and have built a cleanroom within the laboratory for the production
of cell-based product candidates, such as <i>BRTX-100</i>, for use in a clinical trial, for third party cell products or for general
research purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have expanded our laboratory to include capabilities for the clinical production of our pipeline of clinical and investigational cell
therapy candidates. Our expanded cGMP facility includes process development space, ISO 7 cleanrooms and state-of-the-art equipment. We
have expanded our research and development operations to include clinical manufacturing, a necessary step for our Phase 2 clinical trial
for <i>BRTX-100</i>. The new facility has been designed to provide cGMP manufacturing according to FDA and European Medicines Agency
regulations and guidelines to support clinical grade cell production. In May 2023, we announced that we had received a license from the
New York State Department of Health (the &#8220;NYSDOH&#8221;) to act as a tissue bank for the processing of mesenchymal stem cells from
autologous donors. In November 2024, we announced that we received a provisional license from the NYSDOH for the processing of allogeneic
(non-autologous) donor tissue material for the isolation, expansion and cryopreservation of various cell types, including stem cells,
for medical research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we develop our business and our stem cell product candidates, and we obtain regulatory approval, we will seek to establish ourselves
as a key provider of adult stem cells for therapies and expand to provide cells in other market areas for stem cell therapy. We may also
use outside laboratories specializing in cell therapy services and manufacturing of cell products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technology;
Research and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to utilize our laboratory or a third party laboratory in connection with cellular research activities. We also intend to obtain
cellular-based therapeutic technology licenses and increase our IP portfolio. We intend to seek to develop potential stem cell delivery
systems or devices. The goal of these specialized delivery systems or devices is to deliver cells into specific areas of the body, control
the rate, amount and types of cells used in a treatment, and populate these areas of the body with sufficient stem cells so that there
is a successful therapeutic result.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also intend to perform research to develop certain stem cell optimization compounds, media designed to enhance cellular growth and regeneration
for the purpose of improving pre-treatment and post-treatment outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our <i>Disc/Spine Program</i>, fourteen patent applications have been filed with regard to technology that is the subject of the Regenerative
License Agreement (see &#8220;Disc/Spine Program-<i>Exclusive License</i>&#8221; above). Regenerative has been issued a patent from one
of these applications with regard to its curved needle therapeutic delivery device. This patent expires in March 2031. In addition, in
March 2022, a United States patent related to <i>BRTX-</i>100 was issued. This patent expires in December 2029. Of the other twelve applications
that were filed, one application remains pending. The patents that are the subject of the Regenerative License Agreement have been assigned
to Regenexx, LLC which we have been advised is an affiliate of Regenerative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our <i>ThermoStem Program</i>, we have one pending United States patent application and seven United States patents within three patent
families. Four of the patents expire in June 2032 and three of the patents expire in April 2034. With regard to the first patent family
in the <i>ThermoStem Program, </i>patent applications have been filed in five foreign jurisdictions (of which four applications have
been granted as foreign patents and one application has lapsed). The patents expire in June 2032. With regard to the second patent family
in the <i>ThermoStem Program,</i> patent applications have been filed in four foreign jurisdictions (of which four applications have
been granted as foreign patents). The patents expire in April 2034. With regard to the third patent family in the <i>ThermoStem Program</i>,
patent applications have been filed in four foreign jurisdictions (of which four applications have been granted as foreign patents).
The patents expire in April 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2014, we entered into a Research and Development Agreement with Rohto Pharmaceutical Co., Ltd., a Japanese pharmaceutical company
(&#8220;Rohto&#8221;). Pursuant to the Research and Development Agreement with Rohto, we were engaged to provide research and development
services with regard to stem cells. The agreement with Rohto expired upon the completion of the services provided for therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have secured registrations in the U.S. Patent and Trademark Office for the following trademarks:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_004.jpg" alt="" style="height: 74.25pt; width: 180pt"/></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRTX-100</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THERMOSTEM</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRTX</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<i>Dragonfly Logo</i> is also registered with the U.S. Copyright Office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have federal common law rights in the trademark <i>BioRestorative Therapies</i> and other trademarks and trade names used in the
conduct of our business that are not registered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in large part on our ability to develop and protect our proprietary technology. We intend to rely on a combination
of patent, trade secret and know-how, copyright and trademark laws, as well as confidentiality agreements, licensing agreements, non-compete
agreements and other agreements, to establish and protect our proprietary rights. Our success will also depend upon our ability to avoid
infringing upon the proprietary rights of others, for if we are judicially determined to have infringed such rights, we may be required
to pay damages, alter our services, products or processes, obtain licenses or cease certain activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, we incurred $5,348,709 and $4,034,591, respectively, in research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisors </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a Scientific Advisory Board whose purpose is to provide advice and guidance in connection with scientific matters relating
to our business. The Scientific Advisory Board has established a Disc Advisory Committee which focuses on matters relating to our <i>Disc/Spine
Program</i>. Our Scientific Advisory Board members are Dr. Wayne Marasco (Chairman), Dr. Jason Lipetz, Dr. Wayne Olan, Dr. Joy Cavagnaro,
Dr. Harvinder Sandhu and Dr. Christopher Plastaras. The Disc Advisory Committee members are Dr. Lipetz (Chairman), Dr. Olan, Dr. Sandhu
and Dr. Plastaras. See &#8220;Management&#8221; for a listing of the principal positions for Drs. Marasco, Lipetz, Olan, Cavagnaro, Sandhu
and Plastaras.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will compete with many pharmaceutical, biotechnology and medical device companies, as well as other private and public stem cell companies
involved in the development and commercialization of cell-based medical technologies and therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regenerative
medicine is rapidly progressing, in large part through the development of cell-based therapies or devices designed to isolate cells from
human tissues. Most efforts involve cell sources, such as bone marrow, adipose tissue, embryonic and fetal tissue, umbilical cord and
peripheral blood and skeletal muscle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
working in the area of regenerative medicine with regard to the disc and spine include, among others, Mesoblast, Fibrogenesis, DiscGenics
and Isto Biologics. Companies that are developing products and therapies to combat obesity and diabetes include Novo Nordisk, Sanofi,
Merck, Eli Lilly, Roche, Pfizer, Regeneron and Altimmune. The recent extensive use of both FDA-approved and compounded versions of glucagon-like
peptide-1 (GLP-1) receptor agonist drug products, such as Wegovy and Ozempic (semaglutide), including the launch of FDA-approved oral
Wegovy in January 2026, for the treatment of obesity has significantly increased the competition in the obesity market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors and potential competitors have substantially greater financial, technological, research and development, marketing
and personnel resources than we do. We cannot, with any accuracy, forecast when or if these companies are likely to bring their products
and therapies to market in competition with those that we are pursuing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biologics Price Competition and Innovation Act (the &#8220;BPCIA&#8221;) sets forth an abbreviated pathway for the approval of biosimilar
and interchangeable biological products that could be used by future competitors, if any, of our product candidates that are approved
by the FDA as a biologic. For the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences
between the reference product and the proposed biosimilar product. Interchangeability requires that a product is biosimilar to the reference
product, and the product must be expected to produce the same clinical results as the reference product and, for products administered
multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing
safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Under the BPCIA, an application for
a biosimilar product cannot be submitted to the FDA until four years following approval of the reference product, and it may not be approved
by the FDA until 12 years after the original branded product is approved under a BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that, if any of our product candidates are approved as a biological product under a BLA, it should qualify for the 12-year period
of exclusivity. However, there is a risk that the FDA could permit biosimilar applicants to reference approved biologics other than our
therapeutic candidates, thus circumventing our exclusivity and potentially creating the opportunity for competition sooner than anticipated.
Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional
BLA, rather than via the abbreviated pathway. Moreover, it is possible that a biosimilar product could be approved as &#8220;interchangeable&#8221;
with our product and therefore substitutable for our product by a healthcare professional under applicable state laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also face competition from unapproved stem cell therapies performed by treatment centers that do not comply with FDA requirements.
Despite the FDA&#8217;s successful enforcement against unapproved stem cell treatments in the federal courts (<i>United States v. Regenerative
Sciences, LLC </i>(2014 D.C. Cir.), <i>United States v. U.S. Stem Cell Clinic LLC </i>(2021 11<sup>th</sup> Cir.) and <i>United States
v. California Stem Cell Treatment Center, Inc.</i> (2024 9<sup>th</sup> Cir. <i>cert. denied</i>), thousands of clinics continue to offer
unapproved stem cell therapies due to high demand, FDA enforcement limitations, and tactical rebranding to avoid FDA enforcement action.
The FDA lacks the resources to bring enforcement actions against thousands of individual small-office clinics simultaneously. Therefore,
we could face competition from stem cell clinics that would not be required to undergo the costly and time-consuming FDA approval and
compliance process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a comparison of <i>BRTX-100</i> to Mesoblast&#8217;s adult stem cell biologic:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_005.jpg" alt="" style="height: 511px; width: 700px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that <i>BRTX-100</i> has competitive advantages to Mesoblast&#8217;s product for the following reasons:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    use of autologous cells results in low to no risk of rejection, greater safety profile (introduction of viral/genetic) and potentially
    a streamlined regulatory path</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hypoxic
    culturing creates increased cell proliferation, greater plasticity, increased paracrine effect and increased cell survival after
    application</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Autologous
    platelet lysate provides growth factors that interact with the cells, allowing for better cell survival</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
    to no risk of safety concerns related to immunological and zoonotic (animal to human) transmission</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
regulatory approval, our cell product candidates are intended to be marketed to physicians, other health care professionals, hospitals,
research institutions, pharmaceutical companies and the military. It is anticipated that physicians who are trained and skilled in performing
spinal injections will be the physicians most likely to treat discs with injections of <i>BRTX-100</i> upon regulatory approval. These
physicians would include interventional physiatrists (physical medicine physicians), pain management anesthesiologists, interventional
radiologists and neurosurgeons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governmental
Regulation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Government Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health care industry is highly regulated in the United States. The federal government, through various departments and agencies, state
and local governments, and private third-party accreditation organizations, regulate and monitor the health care industry, associated
products, and operations. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose
substantial requirements upon the clinical development, approval, manufacture, distribution and marketing of medical products, including
drugs, biologics, and medical devices. These agencies and other federal, state and local entities regulate research and development activities
and the testing, manufacture, quality control, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval,
post-approval monitoring, advertising, promotion, sampling and import and export of medical products. The following is a general overview
of the laws and regulations pertaining to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FDA
Regulation of Stem Cell Treatment and Products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA regulates the manufacture of human stem cell treatments and associated products under the authority of the Public Health Service
Act (&#8220;PHSA&#8221;) and the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;). Stem cells can be regulated under the
FDA&#8217;s Human Cells, Tissues, and Cellular and Tissue-Based Products Regulations (&#8220;HCT/Ps&#8221;) or may also be subject to
the FDA&#8217;s drug, biologic, or medical device regulations, each as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Human
Cells, Tissues, and Cellular and Tissue-Based Products Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 361 of the PHSA, the FDA issued specific regulations governing the use of HCT/Ps in humans. Pursuant to Part 1271 of Title 21
of the Code of Federal Regulations (&#8220;CFR&#8221;) (the &#8220;HCT/P Regulations&#8221;), the FDA established a unified registration
and listing system for establishments that manufacture and process HCT/Ps. The regulations also include provisions pertaining to donor
eligibility determinations; current good tissue practices covering all stages of production, including harvesting, processing, manufacture,
storage, labeling, packaging, and distribution; and other procedures to prevent the introduction, transmission, and spread of communicable
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
HCT/P Regulations define HCT/Ps as articles &#8220;containing or consisting of human cells or tissues that are intended for implantation,
transplantation, infusion or transfer into a human recipient.&#8221; The HCT/P Regulations strictly constrain the types of products that
may be regulated solely as HCT/P. Factors considered include the degree of manipulation, whether the product is intended for a homologous
function, whether the product has been combined with noncellular or non-tissue components, and the product&#8217;s effect or dependence
on the body&#8217;s metabolic function. In those instances where cells, tissues, and cellular and tissue-based products have been only
minimally manipulated, are intended strictly for homologous use, have not been combined with noncellular or nontissue substances, and
do not depend on or have any effect on the body&#8217;s metabolism, the manufacturer is only required to register with the FDA, submit
a list of manufactured products, and adopt and implement procedures for the control of communicable diseases. If one or more of the above
factors has been exceeded, the product would be regulated as a drug, biological product, or medical device rather than an HCT/P.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are an enterprise in the early stages of operations and have not generated significant revenues from operations, it is difficult to
anticipate the likely regulatory status of the array of products and services that we may offer. We believe that some of the adult autologous
(self-derived) stem cells that will be used in our cellular therapy products and services, including the brown adipose (fat) tissue that
we intend to use in our <i>ThermoStem Program</i>, may be regulated by the FDA as HCT/Ps under the HCT/P Regulations. However, the FDA
may disagree with this position or conclude that some or all of our stem cell therapy products or services do not meet the applicable
definitions and exemptions to the regulation. If we are not regulated solely under the HCT/P Regulations, we would need to expend significant
resources to comply with the FDA&#8217;s broad regulatory authority under the FDCA. Historically, the U.S. federal courts have upheld
the FDA&#8217;s authority to regulate stem cell products under the FDCA that do not comply with the FDA&#8217;s interpretations of the
HCT/P Regulations. In October 2025, the United States Supreme Court refused to hear an appeal of the FDA&#8217;s enforcement victory
in <i>United States v. California Stem Cell Treatment Center, Inc.</i>, leaving in place the federal appellate court decision upholding
the FDA&#8217;s regulation of stem cell treatments as biological products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulated solely under the FDA&#8217;s HCT/P statutory and regulatory provisions, once our laboratory in the United States becomes operational,
it will need to satisfy the following requirements, among others, to process and store stem cells:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">registration
    and listing of HCT/Ps with the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">donor
    eligibility determinations, including donor screening and donor testing requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">current
    good tissue practices, specifically including requirements for the facilities, environmental controls, equipment, supplies and reagents,
    recovery of HCT/Ps from the patient, processing, storage, labeling and document controls, and distribution and shipment of the HCT/Ps
    to the laboratory, storage, or other facility;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tracking
    and traceability of HCT/Ps and equipment, supplies, and reagents used in the manufacture of HCT/Ps;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    event reporting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    inspection; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abiding
    by any FDA order of retention, recall, destruction, and cessation of manufacturing of HCT/Ps.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-reproductive
HCT/Ps and non-peripheral blood stem/progenitor cells that are offered for import into the United States and regulated solely under Section
361 of the PHSA must also satisfy the requirements under 21 C.F.R. &#167; 1271.420. Section 1271.420 requires that the importer of record
of HCT/Ps notify the FDA prior to, or at the time of, importation and provide sufficient information for the FDA to make an admissibility
decision. In addition, the importer must hold the HCT/P intact and under conditions necessary to prevent transmission of communicable
disease until an admissibility decision is made by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions
including public warning letters, fines, consent decrees, orders of retention, recall or destruction of product, orders to cease manufacturing,
and criminal prosecution. If any of these events were to occur, it could materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that our cellular therapy activities are limited to developing products and services outside the United States, as described
in detail below, the products and services would not be subject to FDA regulation, but will be subject to the applicable requirements
of the foreign jurisdiction. We intend to comply with all applicable foreign governmental requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Drug
and Biological Product Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
HCT/P product that does not meet the criteria for being solely regulated under Section 361 of the PHSA will be regulated as a drug, device
or biological product under the FDCA and/or Section 351 of the PHSA, and applicable FDA regulations. The FDA has broad regulatory authority
over drugs and biologics marketed for sale in the United States. The FDA regulates the research, clinical testing, manufacturing, safety,
effectiveness, labeling, storage, recordkeeping, promotion, distribution, and production of drugs and biological products. The FDA also
regulates the export of drugs and biological products manufactured in the United States to international markets in certain situations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug or biologic may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
completion of non-clinical laboratory tests, animal studies and formulation studies conducted according to GLP or other applicable regulations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
submission of an IND, which allows clinical trials to begin unless the FDA objects within 30 days;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug or biologic
for its intended use or uses conducted in accordance with FDA regulations and GCP, which are international ethical and scientific quality
standards meant to ensure that the rights, safety and well-being of trial participants are protected and that the integrity of the data
is maintained;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
registration of clinical trials of FDA-regulated products and certain clinical trial information;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
preparation and submission to the FDA of an NDA, in the case of a drug or BLA in the case of a biologic;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
review of the product by an FDA advisory committee, where appropriate or if applicable;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
satisfactory completion of pre-approval inspection of manufacturing facilities and clinical trial sites at which the product, or components
thereof, are produced to assess compliance with cGMP requirements and of selected clinical trial sites to assess compliance with GCP
requirements; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
FDA approval of an NDA or BLA which must occur before a drug or biologic can be marketed or sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
of an NDA requires a showing that the drug is safe and effective for its intended use and that the methods, facilities, and controls
used for the manufacturing, processing, and packaging of the drug are adequate to preserve its identity, strength, quality, and purity.
To obtain a BLA, a manufacturer must show that the proposed product is safe, pure, and potent and that the facility in which the product
is manufactured, processed, packed, or held meets established quality control standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of an NDA or BLA approval by the FDA, human clinical trials are typically conducted in the following phases (which may overlap):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Phase 1: The investigational product is initially given to healthy human subjects or patients and tested for safety, dosage tolerance,
absorption, metabolism, distribution and excretion. These trials may also provide early evidence on effectiveness. During Phase 1 clinical
trials, sufficient information about the investigational product&#8217;s pharmacokinetics and pharmacologic effects may be obtained to
permit the design of well-controlled and scientifically valid Phase 2 clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Phase 2: These clinical trials are conducted in a limited number of human subjects in the target population to identify possible adverse
effects and safety risks, to determine the efficacy of the investigational product for specific targeted diseases and to determine dosage
tolerance and dosage levels. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning
larger and more costly Phase 3 clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Phase 3: Phase 3 clinical trials are undertaken after Phase 2 clinical trials demonstrate that a dosage range of the investigational
product appears effective and has a tolerable safety profile. The Phase 2 clinical trials must also provide sufficient information for
the design of Phase 3 clinical trials. Phase 3 clinical trials are conducted to provide statistically significant evidence of clinical
efficacy and to further test for safety risks in an expanded human subject population at multiple clinical trial sites. These clinical
trials are intended to further evaluate dosage, effectiveness and safety, to establish the overall benefit-risk profile of the investigational
product and to provide an adequate basis for product labeling and approval by the FDA. In most cases, the FDA requires two adequate and
well-controlled Phase 3 clinical trials to demonstrate the efficacy of an investigational drug or biologic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted in accordance with FDA regulations, GCP requirements and their protocols in order for the data to be
considered reliable for regulatory purposes. Progress reports detailing the results of the clinical trials must be submitted at least
annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed
successfully within any specified period, or at all. These government regulations may delay or prevent approval of product candidates
for a considerable period of time and impose costly procedures upon our business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may require, or companies may pursue, additional clinical trials, referred to as Phase 4 clinical trials, after a product is approved.
Such trials may be made a condition to be satisfied for continuing drug approval. The results of Phase 4 clinical trials can confirm
the effectiveness of a product candidate and can provide important safety information. In addition, the FDA has authority to require
sponsors to conduct post-marketing trials to specifically address safety issues identified by the agency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Pediatric Research Equity Act (&#8220;PREA&#8221;), certain NDAs and BLAs and certain supplements to an NDA or BLA must contain data
to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing
and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission
of pediatric data or full or partial waivers. A sponsor who is planning to submit a marketing application for a drug that includes a
new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration submit an initial Pediatric
Study Plan (&#8220;PSP&#8221;) to the FDA within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable
before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that
the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification
for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the
requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement
on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered
based on data collected from preclinical studies, early phase clinical trials, and/or other clinical development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to some of the conditions established in an approved application, including changes in indications, labeling, manufacturing processes
or facilities, require submission and FDA approval of a new NDA or BLA, or an NDA or BLA supplement, before the change can be implemented.
An NDA or BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA
uses the same procedures and actions in reviewing NDA and BLA supplements as it does in reviewing NDAs and BLAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
and biological products must also comply with applicable requirements, including monitoring and recordkeeping activities, manufacturing
requirements, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities
with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising
requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or
in patient populations that are not described in the drug&#8217;s approved labeling, or off-label use, limitations on industry-sponsored
scientific and educational activities and requirements for promotional activities involving the internet. Although physicians may, in
their independent professional medical judgment, prescribe legally available drugs for off-label uses, manufacturers typically may not
market or promote such off-label uses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have determined that, under the FDA&#8217;s current interpretation of the applicable law, our <i>BRTX-100</i> product candidate will
be regulated as a biological product under the PHSA. Therefore, we will need to expend significant resources to ensure regulatory compliance.
There is no assurance as to whether or when we will receive FDA approval of the <i>BRTX-100 </i>product candidate. The process of designing,
conducting, compiling and submitting the non-clinical and clinical studies required for BLA approval is time-consuming, expensive and
unpredictable. The process can take many years, depending on the product and the FDA&#8217;s requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if a product candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations
and dosages, or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form
of onerous risk management plans, restrictions on distribution or use, or post-marketing trial requirements. Further, even after regulatory
approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product, including
safety labeling or imposition of a Risk Evaluation and Mitigation Strategy, the requirement to conduct post-market studies or clinical
trials or even complete withdrawal of the product from the market. Delay in obtaining, or failure to obtain, regulatory approval for
our products, or obtaining approval but for significantly limited use, would harm our business. Further, we cannot predict what adverse
governmental regulations may arise from future United States or foreign governmental action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions
from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals,
seizure of our products, total or partial shutdown of our production, withdrawal of approvals, and criminal prosecutions. If any of these
events were to occur, it could materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FDA
Expedited Review Programs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is authorized to expedite the review of NDAs and BLAs in several ways. Under the Fast Track program, the sponsor of a drug or biologic
product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after
the filing of the IND. Drug and biologic products are eligible for Fast Track designation if they are intended to treat a serious or
life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies
to the combination of the product candidate and the specific indication for which it is being studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of
a Fast Track NDA or BLA before the application is complete, a process known as rolling review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product submitted to the FDA for marketing, including under a Fast Track program, may also be eligible for the following other types
of FDA programs intended to expedite development and review:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Breakthrough therapy designation. To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence must indicate that such product candidates may demonstrate
substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor
of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement
of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review, and rolling review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Priority review. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a
significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition compared to marketed
products. The FDA aims to complete its review of priority review applications within six months as opposed to ten months for standard
review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 73; Options: NewSection; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Accelerated approval. Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses
and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means
that a product candidate may be approved on the basis of adequate and well-controlled clinical trials establishing that the product candidate
has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical
endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity
and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require
that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well-controlled post-marketing
clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.
As a result of the FDA&#8217;s controversial use of the accelerated approval pathway for an Alzheimer&#8217;s drug (aducanumab), Congress
revised the accelerated approval process as a part of the Food and Drug Omnibus Reform Act of 2022 to provide the FDA with additional
authorities to enforce the post-approval study requirements and to withdraw approvals when those requirements are not met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
Track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval
but may expedite the development or approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the FDA is authorized to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible
for this designation if it is a regenerative medicine advanced therapy (&#8220;RMAT&#8221;) (which may include a cell therapy) that is
intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates
that the drug has the potential to address unmet medical needs for such disease or condition. The benefits of a RMAT designation include
early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility
for priority review and accelerated approval based on surrogate or intermediate endpoints.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Medical
Device Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also has broad authority over the regulation of medical devices marketed for sale in the United States. The FDA regulates the research,
clinical testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, promotion, distribution,
and production of medical devices. The FDA also regulates the export of medical devices manufactured in the United States to international
markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA, medical devices are classified into one of three classes, Class I, Class II, or Class III, depending upon the degree of risk
associated with the medical device and the extent of control needed to ensure safety and effectiveness. Class I devices are subject to
the lowest degree of regulatory scrutiny because they are considered low risk devices and need only comply with the FDA&#8217;s General
Controls. The General Controls include compliance with the registration, listing, adverse event reporting requirements, and applicable
portions of the Quality System Regulation as well as the general misbranding and adulteration prohibitions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
II devices are subject to the General Controls as well as certain Special Controls such as 510(k) premarket notification. Class III devices
are subject to the highest degree of regulatory scrutiny and typically include life supporting and life sustaining devices and implants.
They are subject to the General Controls and Special Controls that include a premarket approval application (&#8220;PMA&#8221;). &#8220;New&#8221;
devices are automatically regulated as Class III devices unless they are shown to be low risk, in which case they may be subject to de
novo review to be moved to Class I or Class II. Clinical research of an investigational device is subject to the FDA&#8217;s Investigational
Device Exemption (&#8220;IDE&#8221;) regulations. Nonsignificant risk devices are subject to abbreviated requirements that do not require
a submission to the FDA but must have Institutional Review Board (IRB) approval and comply with other requirements pertaining to informed
consent, labeling, recordkeeping, reporting, and monitoring. Significant risk devices require the submission of an IDE application to
the FDA and the FDA&#8217;s approval of the IDE application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 74; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA premarket clearance and approval process can be lengthy, expensive and uncertain. It generally takes three to twelve months from
submission to obtain 510(k) premarket clearance, although it may take longer. Approval of a PMA could take one to four years, or more,
from the time the application is submitted and there is no guarantee of ultimate clearance or approval. Securing FDA clearances and approvals
may require the submission of extensive clinical data and supporting information to the FDA. Additionally, the FDA actively enforces
regulations prohibiting marketing and promotion of devices for indications or uses that have not been cleared or approved by the FDA.
In addition, modifications or enhancements of products that could affect the safety or effectiveness or effect a major change in the
intended use of a device that was either cleared through the 510(k) process or approved through the PMA process may require further FDA
review through new 510(k) or PMA submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we develop processes, products or services which qualify as medical devices subject to FDA regulation, we intend to comply
with such regulations. If the FDA determines that our products are regulated as medical devices and we have failed to comply with applicable
regulatory requirements, it can impose a variety of enforcement actions from public warning letters, application integrity proceedings,
fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure of our products, total
or partial shutdown of our production, withdrawal of approvals, and criminal prosecutions. If any of these events were to occur, it could
materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Current
Good Manufacturing Practices and other FDA Regulations of Cellular Therapy Products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
that fall outside of the HCT/P regulations and are regulated as drugs, biological products, or devices must comply with applicable cGMP
regulations. These cGMPs and related quality standards are designed to ensure the products that are processed at a facility meet the
FDA&#8217;s applicable requirements for identity, strength, quality, sterility, purity, and safety. In the event that our domestic United
States operations are subject to the FDA&#8217;s drug, biological product, or device regulations, we intend to comply with the applicable
cGMPs and quality regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions
from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals,
seizure of our products, total or partial shutdown of our production, withdrawal of approvals, and criminal prosecutions. If any of these
events were to occur, it could materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Promotion
of Foreign-Based Cellular Therapy Treatment&#8212; &#8220;Medical Tourism&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 75; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may establish, or license technology to third parties in connection with their establishment of, adult stem cell therapy facilities outside
the United States. We also intend to work with hospitals and physicians to make the stem cell-based therapies available for patients
who travel outside the United States for treatment. &#8220;Medical tourism&#8221; is defined as the practice of traveling across international
borders to obtain health care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Federal Trade Commission (the &#8220;FTC&#8221;) has the authority to regulate and police advertising of medical treatments, procedures,
and regimens in the United States under the Federal Trade Commission Act (the &#8220;FTCA&#8221;). The FTC has regulatory authority to
prevent unfair and deceptive practices and false advertising. Specifically, the FTC requires advertisers and promoters to have a reasonable
basis to substantiate and support claims. The FTC has many enforcement powers, one of which is the power to order disgorgement by promoters
deemed in violation of the FTCA of any profits made from the promoted business and can order injunctions from further violative promotion.
Advertising that we may utilize in connection with our medical tourism operations will be subject to FTC regulatory authority, and we
intend to comply with such regulatory r&#233;gime. Similar laws and requirements are likely to exist in other countries and we intend
to comply with such requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Federal
Regulation of Clinical Laboratories</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) provides the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;)
authority over all laboratory testing, except research, that is performed on humans in the United States. The Division of Laboratory
Services, within the Survey and Certification Group, under the Center for Medicaid and State Operations (&#8220;CMSO&#8221;), has the
responsibility for implementing the CLIA program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CLIA program is designed to establish quality laboratory testing by ensuring the accuracy, reliability, and timeliness of patient test
results. Under CLIA, a laboratory is a facility that does laboratory testing on specimens derived from humans and used to provide information
for the diagnosis, prevention, treatment of disease, or impairment of, or assessment of health. Laboratories that handle stem cells and
other biologic matter are, therefore, included under the CLIA program. Under the CLIA program, laboratories must be certified by the
government, satisfy governmental quality and personnel standards, undergo proficiency testing, be subject to inspections, and pay fees.
To the extent that our business activities require CLIA certification, we intend to obtain and maintain such certification. If we are
subject to CLIA, the failure to comply with CLIA standards could result in suspension, revocation, or limitation of a laboratory&#8217;s
CLIA certificate. In addition, fines or criminal penalties could also be levied. If any of these events were to occur, it could impact
our business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Health
Insurance Portability and Accountability Act&#8212;Protection of Patient Health Information</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business.
The Health Insurance Portability Act of 1996 (&#8220;HIPAA&#8221;) as amended by the Health Information Technology for Economic and Clinical
Health Act (&#8220;HITECH&#8221;), and their respective implementing regulations imposes specified requirements relating to the privacy,
security and transmission of individually identifiable health information on certain types of individuals and organizations. In addition,
certain state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other
and from HIPAA in significant ways and may not have the same effect, thus complicating compliance efforts. Further, we may need to also
comply with additional federal or state privacy laws and regulations that may apply to certain diagnoses, such as HIV/AIDS, to the extent
that they apply to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 76; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Department of Health and Human Services (&#8220;HHS&#8221;), through its Office for Civil Rights, investigates breach reports and determines
whether administrative or technical modifications are required and whether civil or criminal sanctions should be imposed. Companies failing
to comply with HIPAA and the implementing regulations may also be subject to civil money penalties or in the case of knowing violations,
potential criminal penalties, including monetary fines, imprisonment, or both. In some cases, the State Attorneys General may seek enforcement
and appropriate sanctions in federal court.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Applicable U.S. Laws</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above-described regulation by United States federal and state government, the following are other federal and state laws
and regulations that could directly or indirectly affect our ability to operate the business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local licensure, registration, and regulation of the development of pharmaceuticals and biologics;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local licensure of medical professionals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    statutes and regulations related to the corporate practice of medicine;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laws
    and regulations administered by U.S. Customs and Border Protection related to the importation of biological material into the United
    States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    laws and regulations administered by the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    laws and regulations administered by HHS;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local laws and regulations governing human subject research and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal physician self-referral prohibition, also known as Stark Law, and any state equivalents to Stark Law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal False Claims Act (&#8220;FCA&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute (&#8220;AKS&#8221;) and any state equivalent statutes and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    and state coverage and reimbursement laws and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local laws and regulations for the disposal and handling of medical waste and biohazardous material;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occupational
    Safety and Health Administration (&#8220;OSHA&#8221;) regulations and requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Intermediate Sanctions rules of the IRS providing for potential financial sanctions with respect to &#8220;excess benefit transactions&#8221;
    with tax-exempt organizations;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 77; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Physician Payments Sunshine Act (in the event that our products are classified as drugs, biologics, devices or medical supplies and
    are reimbursed by Medicare, Medicaid or the Children&#8217;s Health Insurance Program);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and other federal laws addressing the privacy of health information; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items
    or services reimbursed by any third-party payer, including commercial insurers, state laws that require pharmaceutical companies
    to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated
    by the federal government or otherwise restrict payments that may be made to healthcare professionals and other potential referral
    sources, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians
    and other healthcare professionals or marketing expenditures, and state laws governing the privacy and security of health information
    in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating
    compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violation
of any of the laws described above or any other governmental laws and regulations may result in penalties, including civil and criminal
penalties, damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare
programs and imprisonment. Furthermore, efforts to ensure that business activities and business arrangements comply with applicable healthcare
laws and regulations can be costly for manufacturers of branded prescription products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Government Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, we will need to comply with the government regulations of each individual country in which our therapy centers are located and
products are to be distributed and sold. These regulations vary in complexity and can be as stringent, and on occasion even more stringent,
than FDA regulations in the United States. Due to the fact that there are new and emerging cell therapy regulations that have recently
been drafted and/or implemented in various countries around the world, the application and subsequent implementation of these new and
emerging regulations have little to no precedence. Therefore, the level of complexity and stringency is not always precisely understood
for each country, creating greater uncertainty for the international regulatory process. Furthermore, government regulations can change
with little to no notice and may result in up-regulation of our product(s), thereby creating a greater regulatory burden for our cell
processing technology products. We have not yet thoroughly explored the applicable laws and regulations that we will need to comply with
in foreign jurisdictions. It is possible that we may not be permitted to expand our business into one or more foreign jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any definitive plans or arrangements with respect to the establishment by us of stem cell therapy clinics in any country.
We intend to explore any such opportunities as they arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offices</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices and laboratory are located at 40 Marcus Drive, Suite One, Melville, New York, and our telephone number is
(631) 760-8100. We occupy 6,800 square feet of space at the premises pursuant to a lease that expired in December 2024. The lease provided
for a current annual base rental of $173,060. We currently occupy the premises on a month-to-month basis at a monthly rental of $14,422
and are negotiating an extension of the term of the lease. Our premises are suitable and adequate for our current operations. Our website
is www.biorestorative.com. Our internet website and the information contained therein or connected thereto are not intended to be incorporated
by reference into this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have 14 employees, 13 of whom are full-time employees. We believe that our employee relations are good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 78; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="am_001"></span><b>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion and analysis of the consolidated results of operations and financial condition of BioRestorative Therapies, Inc.
as of December 31, 2024 and 2023 and for the years ended December 31, 2024 and 2023 and as of September 30, 2025 and for the nine months
ended September 30, 2025 and 2024 should be read in conjunction with our financial statements and the notes to those financial statements
that are included elsewhere in this prospectus. References in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; to &#8220;us,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and similar terms refer to BioRestorative
Therapies, Inc. This prospectus contains forward-looking statements as that term is defined in the federal securities laws. The events
described in forward-looking statements contained in this prospectus may not occur. Generally, these statements relate to business plans
or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits
from acquisitions that may be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating results.
The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221;
&#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; and &#8220;continue,&#8221; and their opposites and similar expressions,
are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or
events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence
the accuracy of the statements and the projections upon which the statements are based. Reference is made to &#8220;Risk Factors&#8221;
for a discussion of some of the uncertainties, risks and assumptions associated with these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
risks and factors include, by way of example and without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financing needed to complete our clinical trials and implement our business plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully develop and commercialize BRTX-100, our lead product candidate for the treatment of chronic lumbar disc disease,
    as well as our metabolic ThermoStem Program and commercial biocosmeceuticals platform;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our proprietary rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to achieve and sustain profitability of the existing lines of business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain world-class research and development talent;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain key science, technology and management personnel and to expand our management team;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of estimates regarding expenses, future revenue, capital requirements, profitability, and needs for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from geo-political actions, including war and terrorism or disease outbreaks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain customers;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 79; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to navigate through the increasingly complex therapeutic regulatory environment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully engage in any new business lines that we pursue; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    related to the restatement of our previously issued financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity or performance. Except as required by applicable law, including the securities laws of the United States, we do not intend
to update any of the forward-looking statements to conform these statements to actual results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Readers
are urged to carefully review and consider the various disclosures made by us in this prospectus and in our other reports filed with
the SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of
unanticipated events or changes in the future operating results over time, except as required by law. We believe that our assumptions
are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of
operations or the results of our future activities will not differ materially from our assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently pursuing our <i>Disc/Spine Program</i> with our initial investigational therapeutic product being called <i>BRTX-100</i>.
In March 2022, a United States patent issued in our <i>Disc/Spine Program</i> Phase 2 clinical trial investigating the use of <i>BRTX-100</i>
in the treatment of chronic lower back pain arising from degenerative disc disease. We have obtained an exclusive license to use technology
for investigational adult stem cell treatment of disc and spine conditions, including protruding and bulging lumbar discs. The technology
is an advanced stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling
in the leg and foot. We are investigating the expansion of the clinic application of <i>BRTX-100</i> to other indications within the
body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also developing our <i>ThermoStem Program</i>. This pre-clinical program involves the use of brown adipose (fat) in connection with
the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
United States patents related to the <i>ThermoStem Program</i> were issued in September 2015, January 2019, March 2020, March 2021, July
2021, June 2023 and December 2023; Australian patents related to the <i>ThermoStem Program</i> were issued in April 2017, October 2019
and August 2021; Japanese patents related to the <i>ThermoStem Program</i> were issued in December 2017, June 2021, February 2022 June
2023, July 2024 and September 2025; Israeli patents related to our <i>ThermoStem Program</i> were issued in October 2019, May 2020, March
2022 and March 2025; and European patents related to the <i>ThermoStem Program </i>were issued in April 2020, January 2021, July 2023
and March 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate a commercial biocosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified
clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically
engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward,
we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic
products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging biocosmeceuticals space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 80; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also licensed a patented curved needle device that is a needle system designed to deliver cells and/or other therapeutic products
or materials to the spine and discs or other potential sites. We anticipate that FDA approval or clearance will be necessary for this
device prior to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard
to <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
offices are located in Melville, New York where we have established a laboratory facility in order to increase our capabilities for the
further development of possible cellular-based treatments, products and protocols, stem cell-related intellectual property and translational
research applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, our accumulated deficit was $166,713,054. We have historically only generated a modest amount of revenue, and
our losses have principally been operating expenses incurred in research and development, marketing and promotional activities in order
to commercialize our products and services, plus costs associated with meeting the requirements of being a public company. We expect
to continue to incur substantial costs for these activities over at least the next year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, we entered into an At The Market Offering Agreement with Rodman under which we currently have the ability to issue and
sell shares of our common stock, from time to time, through Rodman, up to an aggregate offering price of approximately $3,614,000 in
an at-the-market (&#8220;ATM&#8221;) program. During the nine months ended September 30, 2025, we sold 965,424 shares of our common stock
under the ATM program with Rodman at a weighted-average gross price of approximately $2.08 per share and raised approximately $2,011,000
of gross proceeds. The total commissions and related legal and accounting fees were approximately $222,000 and we received
net proceeds of approximately $1,789,000. We did not sell any shares of our common stock under the ATM program during the year ended
December 31, 2024. As of January 31, 2026, we had remaining capacity to sell up to an additional $1,017,040 of common stock
under the ATM program with Rodman.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2025, we sold 678,125 shares of our common stock in a registered direct offering. We received net proceeds of approximately $900,000
from the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024 and nine months ended September 30, 2025, we had a net loss of $9.0 million and $11.0 million, respectively,
and negative cash flows from operations of $8.2 million and $8.4 million, respectively, and, as of September 30, 2025, we had working
capital of $1.3 million. We anticipate that we will continue to incur net losses and negative cash flows from operations as we execute
our development plans for 2026 and beyond, as well as other potential strategic and business development initiatives. These conditions
raise substantial doubt about our ability to continue as a going concern for at least twelve months after the issuance date of the financial
statements included in this prospectus. We will require significant additional funding to complete our clinical trials using <i>BRTX-100.
</i>We will require a substantial amount of additional funding to implement our other programs as discussed in this prospectus under
&#8220;Business&#8221;, including our metabolic <i>ThermoStem Program</i>, and fund general operations. No assurance can be given that
the amount of funding that we anticipate may be required for such purposes is correct or that we will be able to accomplish our goals
within the timeframes projected. In addition, no assurance can be given that we will be able to obtain any required financing on commercially
reasonable terms or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 81; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
derive revenue pursuant to a license agreement with a stem cell treatment company (the &#8220;SCTC&#8221;) entered into in January 2012,
as amended in November 2015 and November 2022. Pursuant to the license agreement, the SCTC has granted to us an exclusive license to
use certain intellectual property related to, among other things, stem cell disc procedures and we have granted to the SCTC a sublicense
to use, and the right to sublicense to third parties the right to use, in certain locations in the United States and the Cayman Islands,
certain of the licensed intellectual property. In consideration of the sublicense, the SCTC has agreed to pay us royalties on a per disc
procedure basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also derive product revenue from our biocosmeceuticals commercial product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2025, our Board of Directors authorized a common stock repurchase program under which we may repurchase up to $2,000,000 of
our outstanding common stock through June 16, 2026. No repurchases have been made to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
Months Ended September 30, 2025 Compared With Nine Months Ended September 30, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents selected items in our consolidated statements of operations for the nine months ended September 30, 2025 and
2024, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: justify">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">340,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">357,700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Cost of goods sold</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,208</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,733</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">317,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">332,967</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,467,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,004,794</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,672,192</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,193,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,139,724</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,198,019</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Loss From Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,821,832</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,865,052</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other (Expense) Income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">231,621</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">497,089</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,498</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Gain on exchange of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,711,698</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Change in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">552,536</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(837,466</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Total Other Income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">787,493</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,521,819</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,034,339</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,343,233</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2025 and 2024, we generated $40,100 and $57,700, respectively, of royalty revenue in connection with
our sublicense agreement with the SCTC. The decrease was primarily due to a decrease in disc procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 82; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2025 and 2024, we generated $300,000 in each period of cosmetic product sales revenue in connection
with our exclusive supply agreement with Cartessa.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific
Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives and biocosmeceuticals
program. Research and development expenses are expensed as they are incurred. For the nine months ended September 30, 2025, research
and development expenses increased by $2,462,738, or 49.2%, as compared to the nine months ended September 30, 2024. The increase was
primarily the result of an increase in recruitment and other costs for our Phase 2 clinical trial of $2,010,122, an increase in lab supply
expense of $438,183, and an increase in headcount costs of $19,290, partially offset by a decrease in bonus expense of $86,372 and a
decrease in stock-based compensation expense of $5,976. We expect that our research and development expenses will continue to increase
in subsequent fiscal periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees, as well
as corporate expenses such as legal and professional fees, investor relations and occupancy-related expenses. For the nine months ended
September 30, 2025, general and administrative expenses increased by $478,967, or 11.4%, as compared to the nine months ended September
30, 2024, primarily driven by an increase in stock-based compensation expense of $246,803 related to the vesting of awards, an increase
in consulting expense of $127,621, and an increase in payroll of $91,274, partially offset by a decrease in professional fees of $20,748.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2025, interest income was $231,621, as compared to interest income of $497,089 for the nine months
ended September 30, 2024. The change was primarily due to a decrease in interest income from the investments held in marketable securities
due to a lower average balance of the marketable securities during the 2025 period as compared to the 2024 period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2025, other income was $3,336, as compared to other income of $150,498 for the nine months ended
September 30, 2024. The change was primarily due to a one-time payment received in the 2024 period in connection with the development
of our biocosmeceuticals product line.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gain
on Exchange of Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2024, we recognized a gain on exchange of $1,711,698 related to the issuance of warrants and common
stock in exchange for the cancellation of existing warrants. There was no gain on exchange of warrants for the nine months ended September
30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<!-- Field: Page; Sequence: 83; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Warrant Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2025, we recognized a gain on the change in fair value of warrant liabilities of $552,536 related
to the decrease in fair value of warrants that are accounted for as warrant liabilities. For the nine months ended September 30, 2024,
we recognized a loss on the change in fair value of warrant liabilities of $837,466 related to the increase in fair value of warrants
that are accounted for as warrant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
Ended December 31, 2024 Compared with Year Ended December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents selected items in our consolidated statements of operations for the years ended December 31, 2024 and 2023,
respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: justify">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">401,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">145,800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: justify; padding-bottom: 1pt">Cost of goods sold</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28,072</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">372,928</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,348,709</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,034,591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,579,413</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,331,983</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,928,122</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,366,574</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Loss From Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,555,194</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,220,774</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other Income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">616,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">552,293</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Grant income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,664</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Gain on exchange of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,711,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Change in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">97,188</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,997,780</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Total Other Income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,575,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,803,070</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,979,381</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,417,404</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, we generated $401,000 and $145,800, respectively, of royalty revenue in connection with our
sublicense agreement and sales revenue in connection with our cosmeceuticals business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific
Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development
expenses are expensed as they are incurred. For the year ended December 31, 2024, research and development expenses increased by $1,314,118,
or 33%, to $5,348,709 compared to $4,034,591 for the year ended December 31, 2023. The increase was primarily driven by headcount costs
of $323,025 and general lab supplies expense of $1,041,952, partially offset by the reversal of a 2023 bonus accrual of $257,873.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 84; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our research and development expenses will continue to increase with the continuation of the aforementioned initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and administrative</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees (excluding
any cash or non-cash compensation of our Vice President of Research and Development and our laboratory staff), as well as corporate expenses
such as legal and professional fees, investor relations and occupancy related expenses. For the year ended December 31, 2024, general
and administrative expenses decreased by $4,752,570, or 42% to $6,579,413 from $11,331,983 for the year ended December 31, 2023. The
decrease was primarily driven by a decrease in stock-based compensation expense of $4,970,401 and a decrease in headcount costs of $111,363,
offset by an increase in professional fees of $229,273.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our general and administrative expenses related to operations will increase as we expand our staff, develop our infrastructure
and incur additional costs to support the growth of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, interest income increased $63,784, or 12%, to $616,077 from $552,293 for the year ended December 31,
2023. The increase was due to the interest and dividend income of the investments held in marketable securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Grant
income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no grant income for the year ended December 31, 2024. Grant income of $83,333 during the year ended December 31, 2023 consisted of
funding received under a National Institutes of Health Small Business Technology Transfer (STTR) Phase 1 grant, offset by related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, other income of $150,850 primarily related to investment dividend income and other miscellaneous income.
For the year ended December 31, 2023, other income of $169,664 primarily related to an Employee Retention Tax Credit, gains from settlements
of certain accrued expenses and realized and unrealized gain on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gain
on Exchange of Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, we recognized a gain on exchange of $1,711,698 related to the issuance of warrants and common stock
in exchange for the cancellation of existing warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in fair value of derivative liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, we recognized a gain on the change in fair value of warrant liabilities of $97,188 related to the reduction
in the fair value of the warrants that are accounted for as warrant liabilities. For the year ended December 31, 2023, we recognized
a gain on the change in fair value of warrant liabilities of $3,997,780 related to the reduction in the fair value of the warrants that
are accounted for as warrant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 85; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure our liquidity in a number of ways, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">602,444</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">547,890</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">884,377</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Investments held in marketable securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,887,383</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,184,701</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,181,618</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Working capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,271,781</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,395,815</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,783,181</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Availability
of Additional Funds</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2025, we had a net loss of $11.0 million and negative cash flows from operations of $8.4 million,
and, as of September 30, 2025, we had working capital of $1.3 million. For the year ended December 31, 2024, we had a net loss of $9.0
million and negative cash flows from operations of $8.2 million and, as of December 31, 2024, we had working capital of $7.4 million.
We anticipate that we will continue to incur net losses and negative cash flows from operations as we execute our development plans for
2026 and beyond, as well as other potential strategic and business development initiatives. Based on these conditions, we believe we
may not have sufficient cash for at least twelve months after the issuance date of the financial statements included in this prospectus
which raises substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating needs include the planned costs to operate our business, including amounts required to fund our clinical trials, working capital
and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including
our ability to successfully commercialize our products and services, competing technological and market developments, and the need to
enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service
offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to raise sufficient additional capital when we need it or raise capital on favorable terms. Future financing may require
us to pledge certain assets and enter into covenants that could restrict certain business activities or our ability to incur further
indebtedness and may contain other terms that are not favorable to our stockholders or us. If we are unable to obtain adequate funds
on reasonable terms, we may be required to significantly curtail or discontinue operations or obtain funds by entering into financing
agreements on unattractive terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#8220;At-the-Market&#8221;
Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, we entered into an At The Market Offering Agreement with Rodman, under which we currently have the ability to issue and
sell shares of our common stock, from time to time, through Rodman, up to an aggregate offering price of approximately $3,614,000 in
an ATM, program. During the nine months ended September 30, 2025, we sold 965,424 shares of our common stock under the ATM program with
Rodman at a weighted-average gross price of approximately $2.08 per share and raised approximately $2,011,000 of gross proceeds. The
total commissions and related legal and accounting fees were approximately $222,000 and we received net proceeds of approximately
$1,789,000. As of January 31, 2026, we had remaining capacity to sell up to an additional $1,017,040 of common stock under the
ATM program with Rodman.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 86; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrant
Exercises</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, we received gross proceeds of approximately $8,100,000 pursuant to the exercise of outstanding warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine
Months Ended September 30, 2025 Compared With Nine Months Ended September 30, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2025 and 2024, our sources and uses of cash were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-bottom: 2.5pt">Net Cash Used In Operating Activities</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(8.373.790</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(5,882,501</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net Cash Provided By (Used In) Investing Activities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,496,796</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,018,078</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net Cash Provided By Financing Activities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,931,548</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,505,646</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net Increase in Cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">54,554</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">605,067</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Used in Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $8,373,790 for the nine months ended September 30, 2025, primarily due to cash used to fund the
net loss of $11,034,339, adjusted for net non-cash expenses of $2,246,501, and $414,048 of cash provided by changes in operating assets
and liabilities. Net cash used in operating activities was $5,882,501 for the nine months ended September 30, 2024, primarily due to
cash used to fund the net loss of $7,343,233, adjusted for net non-cash expenses of $1,520,670, and $59,938 of cash used in changes in
operating assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Provided by (Used in) Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities was $6,496,796 for the nine months ended September 30, 2025 primarily due to a sale of marketable
securities which provided $9,212,343 of cash, offset by a purchase of marketable securities which used $2,679,147 of cash and a purchase
of equipment which used $36,400 of cash. Net cash used in investing activities was $1,018,078 for the nine months ended September 30,
2024 primarily due to a purchase of marketable securities which used $18,294,566 of cash and a purchase of equipment which used $93,755
of cash, offset by a sale of marketable securities which provided $17,370,243 of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Provided by Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $1,931,548 for the nine months ended September 30, 2025 due to net proceeds of $1,938,445 received
in connection with the issuance of common stock for the 2024 ATM offering and $42,411 due to the exercise of stock options, partially
offset by deferred offering costs of $49,308, compared to $7,505,646 net cash provided by financing activities for the nine months ended
September 30, 2024 due to net proceeds of $7,528,027 received in connection with the exercise and issuance of warrants, partially offset
by deferred offering costs of $22,381.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 87; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
Ended December 31, 2024 Compared with Year Ended December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, our sources and uses of cash were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Net Cash Used In Operating Activities</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(8,230,346</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(6,430,211</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Cash Provided By Investing Activities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">514,529</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,252,043</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Cash Provided By Financing Activities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,379,330</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,348,773</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Decrease in Cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(336,487</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(829,395</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Used in Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $8,230,346 for the year ended December 31, 2024, primarily due to cash used to fund the net loss
of $8,979,381 which gives effect to net non-cash expenses of $720,382, partially offset by $28,653 of cash provided by changes in operating
assets and liabilities. Net cash used in operating activities was $6,430,211 for the year ended December 31, 2023, primarily due to cash
used to fund the net loss of $10,417,704 which gives effect to net non-cash expenses of $3,472,167, partially offset by $515,326 of cash
provided by changes in our operating assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Provided by Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities decreased by $2,737,514 for the year ended December 31, 2024 compared to the year ended December
31, 2023, primarily due to the purchase of marketable securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Provided by Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities increased by $5,030,557 for the year ended December 31, 2024 compared to the year ended December
31, 2023 due to the gross proceeds from the exchange and issuance of warrants of $8,123,391, less issuance costs of $595,364, all partially
offset by $2,348,773 of gross proceeds from the sale of common stock pursuant to an ATM and direct offering undertaken during the year
ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effects
of Inflation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that inflation had a material impact on our business, revenues or operating results during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 88; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, which require
our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities
at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that
there are material differences between these estimates and actual results, our financial condition or results of operations would be
affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account
of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were
highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from
period to period or the use of different estimates that we reasonably could have used in the current period would have a material impact
on our financial condition or results of operations. There are items within our financial statements that require estimation but are
not deemed critical, as defined above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a detailed discussion of our significant accounting policies and related judgments, see Note 2 of the Notes to Consolidated Financial
Statements and Note 2 of the Notes to Unaudited Condensed Consolidated Financial Statements included in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our consolidated financial statements for the years ended December 31, 2024 and 2023 and Note 2 to our unaudited condensed
consolidated financial statements for the three and nine months ended September 30, 2025 and 2024 included elsewhere in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that
is material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 89; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="am_002"></span><b>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding our directors and executive officers is set forth below. Each of our officers devotes his full business time in providing services
on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 61%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Positions
    Held</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Research and Development, Secretary and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E. Kristal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Compensation Committee Chair</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Audit Committee Chair</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Nominating Committee Chair</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lance
Alstodt</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
Alstodt has served as our Chief Executive Officer, President and Chairman of the Board since November 2020. He served as our Executive
Vice President and Chief Strategy Officer from October 2018 to February 2020. Since 2013, Mr. Alstodt has served as Chief Executive Officer
of MedVest Consulting Corporation, an advisory and capital firm that focuses exclusively on the healthcare industry. Prior to MedVest,
he was an investment banker with over 23 years of experience with respect to healthcare investment banking, including mergers and acquisitions.
From 2011 to 2013, Mr. Alstodt was a Managing Director at Leerink Partners where he helped lead its medical technology sector. From 2009
to 2011, he was a Managing Director and Head of Medical Technology at Oppenheimer &amp; Co. From 2000 to 2009, Mr. Alstodt was a Managing
Director in the Healthcare Group and Global Mergers and Acquisitions Group at Bank of America Merrill Lynch. He previously spent seven
years as a Vice President in the Global Mergers and Acquisitions Group at J.P. Morgan Chase, where he worked extensively on acquisitions,
leveraged buyouts, private and public financings, exclusive sales and general advisory assignments. Mr. Alstodt received a degree in
Economics from the State University of New York at Albany, with a secondary concentration in Finance and Marketing. We believe that Mr.
Alstodt&#8217;s executive-level management experience with us and other healthcare businesses and his extensive experience in the investment
banking field relating to the healthcare sector give him the qualifications to serve as one of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Francisco
Silva</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
Silva has served as our Vice President of Research and Development since March 2013, having also previously served in such position from
April 2011 until March 2012. Mr. Silva was elected our Secretary and a director in November 2020. He served as our Research Scientist
from March 2012 to June 2012 and as our Chief Scientist from June 2012 to March 2013. From 2007 to 2011, Mr. Silva served as Chief Executive
Officer of DV Biologics LLC, and as President of DaVinci Biosciences, LLC, companies engaged in the commercialization of human based
biologics for both research and therapeutic applications. From 2003 to 2007, Mr. Silva served as Vice President of Research and Development
for PrimeGen Biotech LLC, a company engaged in the development of cell based platforms. From 2002 to 2003, he was a Research Scientist
with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell
platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He
has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research. Mr.
Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship
and MBRS Fellowship from California State Polytechnic University. We believe that Mr. Silva&#8217;s executive-level management experience
with us since April 2011 and his extensive knowledge of the science related to our business give him the qualifications to serve as one
of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 90; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Robert
E. Kristal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
E. Kristal has served as our Chief Financial Officer since November 2021. Mr. Kristal is an experienced Wall Street and Bay Street professional
who has served in various management roles within multiple business lines of investment banks. From 2016 to 2020, he was Head of Equity
Research at H.C. Wainwright. Mr. Kristal provided investment banking and merchant banking services from 2013 to 2016 at H.C. Wainwright
and T.R. Winston. He is a Charted Financial Analyst. Mr. Kristal received a Bachelor of Arts degree in Economics from Wilfrid Laurier
University and a Bachelor of Commerce (Honors) degree in Finance from the University of Windsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nickolay
Kukekov, Ph.D.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
Kukekov, Ph.D. has served as one of our directors since March 2021 and Chair of our Board&#8217;s Compensation Committee since November
2021. For more than the past fifteen years, Dr. Kukekov has held a number of healthcare investment banking positions. He has served as
Senior Managing Director of Paulson Investment Company, LLC since 2020. From 2012 to 2020, Dr. Kukekov was a founding partner of Highline
Research Advisors LLC. He served as a Managing Director of Summer Street Research Partners from 2010 to 2012. From 2007 to 2009, Dr.
Kukekov was a Managing Director of Paramount Capital. He served as a Vice President of Rodman &amp; Renshaw from 2006 to 2007. He serves
as a director of Brain Scientific, Inc. and Omnia Wellness Inc. whose shares are publicly traded. Dr. Kukekov received a Bachelor of
Arts degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and a Ph.D. in neuroscience from
Columbia University College of Physicians and Surgeons. We believe that Dr. Kukekov&#8217;s extensive experience in the investment banking
field relating to the healthcare sector and his strong background in regenerative medicine give him the qualifications to serve as one
of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patrick
F. Williams</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
F. Williams has served as one of our directors and Chair of our Board&#8217;s Audit Committee since November 2021. Mr. Williams has more
than 25 years of experience across medical device, consumer product goods and technology sectors. Appointed as Chief Financial Officer
of NeuroPace Inc., or NeuroPace, in June 2025, Mr. Williams is responsible for optimizing the financial performance of NeuroPace and
ensuring the scalability of various functions to support high growth expansion. Mr. Williams served as Chief Financial Officer of STAAR
Surgical Company from July 2020 to March 2025. From 2016 to 2019, he served as the Chief Financial Officer of Sientra, Inc. before transitioning
to General Manager for its miraDry&#174; business unit. From 2012 to 2016, Mr. Williams served as Chief Financial Officer of ZELTIQ Aesthetics,
Inc., a publicly-traded medical device company that was acquired by Allergan. Previously, he served as Vice President in finance, strategy
and investor relations roles from 2007 to 2012 at NuVasive, Inc., a San-Diego based medical device company servicing the spine sector.
He has also held finance roles with Callaway Golf and Kyocera Wireless. Mr. Williams received an MBA in Finance and Management from San
Diego State University and a Bachelor of Arts in Economics from the University of California, San Diego. We believe that Mr. Williams&#8217;
executive-level management experience with healthcare-related businesses, including his financial management expertise, give him the
qualifications to serve as one of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 91; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>David
Rosa</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Rosa has served as one of our directors and Chair of our Board&#8217;s Nominating Committee since November 2021. Mr. Rosa has served
as the Chief Executive Officer, President and a director of NeuroOne Medical Technologies Corporation, or NeuroOne (Nasdaq: NMTC), since
July 2017 and served as Chief Executive Officer and a director of NeuroOne, Inc., formerly its wholly-owned subsidiary, from October
2016 until December 2019, when NeuroOne, Inc. merged with and into NeuroOne. NeuroOne is committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#8217;s
disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve
patient outcomes and reduce procedural costs. From November 2009 to November 2015, Mr. Rosa served as the Chief Executive Officer and
President of Sunshine Heart, Inc., n/k/a CHF Solutions, Inc. (Nasdaq: CHFS), a publicly-held early-stage medical device company. From
2008 to November 2009, he served as Chief Executive Officer of Milksmart, Inc., a company that specializes in medical devices for animals.
From 2004 to 2008, Mr. Rosa served as the Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical,
Inc. He serves as a director on the board of directors of Biotricity Inc. (Nasdaq:BTCY) and Healthcare Triangle, Inc. (Nasdaq:HCTI).
Mr. Rosa previously served as Chairman of Neuro Event Labs, a privately-held company in Finland, and is an Advisory Board member of SYNAPS
Dx, a privately-held company in Bethesda, Maryland. We believe that Mr. Rosa&#8217;s senior leadership experience in the medical device
industry and his strong technical, strategic, and operational expertise give him the qualifications to serve as one of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following persons are the members of our Scientific Advisory Board:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Positions</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne
                                            Marasco, M.D., Ph.D.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor,
                                            Department of Cancer Immunology &amp; AIDS, Dana-Farber Cancer Institute;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor
    of Medicine, Harvard Medical School;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Faculty Member, Harvard Stem Cell Institute</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jason
                                            Lipetz, M.D.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    Disc Advisory Committee</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founder,
                                            Long Island Spine Rehabilitation Medicine;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    of Spine Medicine, Northwell Health Spine Center;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Assistant Professor, Department of Physical Medicine and Rehabilitation, Zucker School of Medicine at Hofstra/Northwell</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 92; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne
    J. Olan, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
                                            Interventional and Endovascular Neurosurgery;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associate
    Professor, Neurosurgery and Radiology, George Washington University Medical Center;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    Physician, Department of Radiology, National Institutes of Health</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joy
                                            Cavagnaro, Ph.D.,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DABT,
    RAC</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
                                            and Founder, Access BIO, L.C.; Fellow, Academy of Toxicological Sciences and the Regulatory
                                            Professional Society;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Senior Pharmacologist and Director of Quality Assurance, Food and Drug Administration&#8217;s Center for Biologics Evaluation and
    Research</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harvinder
    Sandhu, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orthopedic
                                            Spine Surgeon, Hospital for Special Surgery;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Chief of Spinal Surgery Service, UCLA Medical Center</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Plastaras, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            Director of Musculoskeletal Spine and Sports Rehabilitation Medicine and Physiatrist, MossRehab;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Director of The Penn Spine and Rehabilitation Center;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Director of Spine, Sports and Musculoskeletal Medicine Fellowship, University of Pennsylvania</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our executive officers, directors and Scientific Advisory Board members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
of Office</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a classified Board of Directors. The directors will hold office until the respective annual meetings of stockholders indicated below
and until their respective successors are elected and qualified or until their earlier resignation or removal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    Expires</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
executive officer will hold office until the initial meeting of the Board of Directors following the next annual meeting of stockholders
and until his successor is elected and qualified or until his or her earlier resignation or removal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 93; Options: NewSection; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="am_003"></span><b>EXECUTIVE
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following Summary Compensation Table sets forth all compensation earned in all capacities during the fiscal years ended December 31,
2025 and 2024 by (i) our principal executive officer, and (ii) our two most highly compensated executive officers, other than our principal
executive officer, who were serving as an executive officer as of December 31, 2025 and whose total compensation for the 2025 fiscal
year, as determined by Regulation S-K, Item 402, exceeded $100,000 (the individuals falling within categories (i) and (ii) are collectively
referred to as the Named Executive Officers):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Lance Alstodt</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">2025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">596,666</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,512,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">2,109,167</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">539,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">275,000</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,314,583</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">566,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,468,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,035,416</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">VP, Research and Development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">514,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">262,500</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,227,083</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Kristal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">343,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">318,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">661,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">293,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">90,000</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">683,752</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reflect the aggregate grant date fair value of grants made in the fiscal year computed in accordance with stock-based accounting
    rules (FASB ASC Topic 718-Stock Compensation). Assumptions used in the calculations of these amounts are included in Note 8 to our
    consolidated financial statements included in this Annual Report.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">No determination has yet been made as to the amount
    of the discretionary bonus in consideration of 2025 services.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2024 Bonus amount represents a discretionary bonus in consideration of 2024 services which was paid in 2025.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 94; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information on outstanding equity awards as of December 31, 2025 to the Named Executive Officers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="16" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="16" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities underlying unexercised options exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities underlying unexercised options unexercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity incentive plan awards: Number of securities underlying unexercised unearned options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option expiration date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares or units of stock that have not vested</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Market value of shares of units that have not vested</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left">Lance Alstodt</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">293,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">5.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">3/18/31</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lance Alstodt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,059</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">11/4/31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lance Alstodt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,762</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/17/33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lance Alstodt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,649</td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/13/34</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lance Alstodt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395,942</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/14/35</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">6/10/26</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">7/12/27</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">10/29/28</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">293,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">3/18/31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,059</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">11/4/31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,762</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/17/33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,684</td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/13/34</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">384,490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">384,489</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/14/35</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>S</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Kristal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">11/4/31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Kristal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/17/33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Kristal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,789</td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/13/34</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Kristal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,246</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,246</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/14/35</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    becomes exercisable in four nearly equal quarterly installments beginning on February 13, 2026.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    becomes exercisable in eight nearly equal quarterly installments beginning on February 14, 2026.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 95; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lance
Alstodt</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 16, 2020, Mr. Alstodt was elected our Chief Executive Officer, President and Chairman of the Board. On March 18, 2021, we entered
into an employment agreement with Mr. Alstodt which provides for a term ending on March 18, 2026. Pursuant to the employment agreement,
Mr. Alstodt currently is entitled to receive an annual salary of $600,000 (giving effect to a $150,000 performance salary increase received
in November 2021 and $50,000 annual increases in salary pursuant to his employment agreement). Concurrently with the execution of the
employment agreement, we granted to Mr. Alstodt pursuant to the 2021 Plan (i) a ten year option for the purchase of 293,479 shares of
our common stock at an exercise price of $47.60 per share (which exercise price was subsequently reduced to $13.50 per share and further
reduced to $5.08 per share) and (ii) 146,740 RSUs. The option vested to the extent of 50% thereof on the date of grant, 12.5% on November
4, 2021 and the balance in six equal quarterly installments commencing on December 18, 2021. The RSUs vested in three equal annual installments
on the first, second and third anniversaries of the date of grant. In the event that Mr. Alstodt&#8217;s employment is terminated by
us without &#8220;cause&#8221;, or Mr. Alstodt terminates his employment for &#8220;good reason&#8221; (each as defined in the employment
agreement), Mr. Alstodt will be entitled to receive severance in an amount up to one time his then annual base salary. If Mr. Alstodt&#8217;s
employment with us is terminated without cause, the option granted to Mr. Alstodt will remain exercisable until its expiration date notwithstanding
such termination of employment with us. In March 2022, we and Mr. Alstodt agreed that, in lieu of a $50,000 increase in his annual salary
(as provided for in his employment agreement), we issued to Mr. Alstodt 12,438 RSUs (having a value of $50,000), which RSUs vested in
twelve equal monthly installments. Such grant was in consideration of Mr. Alstodt deferring his right to receive the $50,000 increase
in his salary for one year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Francisco
Silva</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, we and Mr. Silva entered into an employment agreement which provides for a term ending on March 18, 2026. Pursuant to
the employment agreement, Mr. Silva is currently entitled to receive an annual salary of $575,000 (giving effect to a $150,000 performance
salary increase received in November 2021 and $50,000 annual increases in salary pursuant to his employment agreement). Concurrently
with the execution of the employment agreement, we granted to Mr. Silva pursuant to the 2021 Plan (i) a ten year option for the purchase
of 293,479 shares of our common stock at an exercise price of $47.60 per share (which exercise price was subsequently reduced to $13.50
per share and further reduced to $5.08 per share) and (ii) 146,740 RSUs. The option vested to the extent of 50% thereof on the date of
grant, 12.5% on November 4, 2021 and the balance in six equal quarterly installments commencing on December 18, 2021. The RSUs vested
in three equal annual installments on the first, second and third anniversaries of the date of grant. In the event that Mr. Silva&#8217;s
employment is terminated by us without &#8220;cause&#8221;, or Mr. Silva terminates his employment for &#8220;good reason&#8221; (each
as defined in the employment agreement), Mr. Silva will be entitled to receive severance in an amount up to one time his then annual
base salary. If Mr. Silva&#8217;s employment with us is terminated without cause, the option granted to Mr. Silva will remain exercisable
until its expiration date notwithstanding such termination of employment with us. In March 2022, we and Mr. Silva agreed that, in lieu
of a $50,000 increase in his annual salary (as provided for in his employment agreement), we issued to Mr. Silva 12,438 RSUs (having
a value of $50,000), which RSUs vested in twelve equal monthly installments. Such grant was in consideration of Mr. Silva deferring his
right to receive the $50,000 increase in his salary for one year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 96; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information concerning the compensation of our non-employee directors for the fiscal year ended December
31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonqualified Deferred Compensation Earnings</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Nickolay Kukekov</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">35,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">100,001</td><td style="width: 1%; text-align: left"><sup>(1)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">135,001</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patrick F. Williams</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,001</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">135,001</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Rosa</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,001</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">135,001</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2025, Dr. Kukekov held options for the purchase of 189,542 shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2025, Mr. Williams held options for the purchase of 174,796 shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2025, Mr. Rosa held options for the purchase of 174,796 shares of common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kukekov and Messrs. Williams and Rosa, our non-employee directors, as compensation for their services as a director, are entitled to
receive per annum $35,000 in cash and $100,000 in option grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Award Grant Practices</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
awards are discretionary and are generally granted to our named executive officers in the second or third week of February each year.
In certain circumstances, including the hiring or promotion of an officer, the Compensation Committee may approve grants to be effective
at other times. The Compensation Committee did not take material nonpublic information into account when determining the timing and terms
of equity awards in 2025, and we do not time the disclosure of material nonpublic information for the purpose of affecting the value
of executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 97; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="am_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS; DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is comprised of Lance Alstodt (Chair), Francisco Silva, Nickolay Kukekov, Patrick F. Williams and David Rosa. Each
of Dr. Kukekov, Mr. Williams and Mr. Rosa is an &#8220;independent director&#8221; based on the definition of independence in Listing
Rule 5605(a)(2) of The Nasdaq Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Williams (Chair), Dr. Kukekov and Mr. Rosa are the members of our Board&#8217;s Audit Committee. Each of Mr. Williams, Dr. Kukekov and
Mr. Rosa is an &#8220;independent director&#8221; based on the definition of independence in Listing Rule 5605(a)(2) of The Nasdaq Stock
Market and Rule 10A-3(b)(1) under the Exchange Act. Our Board of Directors has determined that Mr. Williams qualifies as an &#8220;audit
committee financial expert,&#8221; as that term is defined in Item 407(d)(5) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Rosa (Chair), Dr. Kukekov and Mr. Williams are the members of our Board&#8217;s Nominating Committee. Each of Mr. Rosa, Dr. Kukekov and
Mr. Williams is an &#8220;independent director&#8221; based on the definition of independence in Listing Rule 5605(a)(2) of The Nasdaq
Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kukekov (Chair), Mr. Williams and Mr. Rosa are the members of our Board&#8217;s Compensation Committee. Each of Dr. Kukekov, Mr. Williams
and Mr. Rosa is an &#8220;independent director&#8221; based on the definition of independence in Listing Rule 5605(a)(2) of The Nasdaq
Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 98; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_005"></span>BENEFICIAL
OWNERSHIP OF SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the beneficial ownership of our common stock, as of February 4, 2026,
known by us, through transfer agent records and reports filed with the SEC, to be held by: (i) each person who beneficially owns 5% or
more of the shares of common stock then outstanding; (ii) each of our directors; (iii) each of our Named Executive Officers (as defined
above); and (iv) all of our directors and executive officers as a group. The following table also sets forth certain information regarding
the beneficial ownership of our Series B preferred stock as of February 4,  2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this table reflects &#8220;beneficial ownership&#8221; as defined in Rule 13d-3 of the Exchange Act. To our knowledge,
and unless otherwise indicated, each stockholder has sole voting power and investment power over the shares listed as beneficially owned
by such stockholder, subject to community property laws where applicable. Percentage ownership prior to this offering is based on 8,876,242
shares of common stock (exclusive of the shares of common stock issuable to Auctus Fund, LLC, or Auctus, as discussed in footnote (11)
to the following table) and 1,398,158 shares of Series B preferred stock outstanding as of February 4, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
                                            and Address of Beneficial</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owner</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of<br/>
                                            Shares of<br/>
                                            Common Stock<br/>
                                            Beneficially</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate<br/>
    Percent of<br/>
    Class Prior to this Offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate
Percent of Class After this Offering<sup>(12)</sup></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    Shares of Series<br/>
    B Preferred<br/>
    Stock<br/>
    Beneficially<br/>
    Owned</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate<br/>
    Percent of Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
    and Executive Officers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,431,592</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><p style="margin: 0">14.1</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">7.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,379,155</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">13.7</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">7.0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Kristal<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">414,920</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">4.5</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">2.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">189,542</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">2.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">1.0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">174,796</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">1.9</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">174,796</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">1.9</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    directors and executive officers as a group (6 persons)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,764,801</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">30.7</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">17.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certain
    Beneficial Owners</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dale
    Broadrick<sup>(7)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">923,905</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(8)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">10.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">5.0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd
    Hale Morrison</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">685,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(9)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">7.7</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">3.7</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auctus
    Fund, LLC<sup>(10)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auctus
    Fund Management LLC<sup>(10)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred
    Sollami<sup>(10)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Louis
    Posner<sup>(10)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">894,387</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(11)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">9.99</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">4.8</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%<sup>(13)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,398,158</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(14)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 1%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    is c/o BioRestorative Therapies, Inc., 40 Marcus Drive, Suite One, Melville, New York 11747.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 99; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,244,095 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,195,635 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days and 12,136
    shares of common stock held by Mr. Silva in a retirement account.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    406,926 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    3,385,790 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    is 3003 Brick Church Pike, Nashville, Tennessee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    upon Amendment No. 9 to Schedule 13D and Forms 4 filed with the SEC. Includes 477,972 shares of common stock held by Fleetco Inc.
    of which Mr. Broadrick is a 93% stockholder.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    upon Schedule 13G, as amended, filed with the SEC, Mr. Morrison has shared voting and dispositive power with respect to the 685,000
    shares of common stock. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    is 545 Boylston Street, 2<sup>nd</sup> Floor, Boston, Massachusetts 02116.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    upon Amendment No. 5 to Schedule 13G filed with the SEC on August 14, 2025, other filings made by Auctus with the SEC
    and other information of which we are aware. Auctus holds warrants for the purchase of up to 1,613,685 shares of our
    common stock. In addition, Auctus&#8217; shares of Series B preferred stock are convertible into an aggregate of 1,398,158
    shares of our common stock. In connection with the transaction in which certain of the above warrants were issued, we issued
    to Auctus certain shares of our common stock and have agreed to issue to Auctus, upon receipt of notice from Auctus, subject to the
    limitation discussed below, 918,055 shares of our common stock (the &#8220;Additional Shares&#8221;). However, such
    warrants are not exercisable for the purchase of our common stock, such Series B preferred stock is not convertible into shares of
    our common stock and the Additional Shares are not issuable to the extent Auctus would beneficially own, after such exercise, conversion
    or issuance, more than 9.99% of our outstanding shares of common stock. Auctus has advised that, as of October 31, 2025, it
    owned 817,792 shares of common stock, which represented approximately 9.2% of the then 8,876,242 outstanding
    shares of common stock, and that the Additional Shares are issuable to it, upon notice from it, to the extent that such issuances
    would not result in Auctus beneficially owning after such issuances more than 9.99% of our outstanding shares of common stock. Based
    upon the foregoing, as of such date, 76,595 Additional Shares were issuable to Auctus (to comply with the 9.99% beneficial
    ownership limitation), the remaining Additional Shares were not issuable, Auctus&#8217; warrants were not then
    currently exercisable for the purchase of shares of common stock and its Series B preferred stock was not currently convertible
    into shares of common stock. The number of shares of common stock beneficially owned by Auctus includes the 76,595 Additional
    Shares currently issuable to it. Without the 9.99% limitation discussed above, as of October 31, 2025, Auctus would have beneficial
    ownership of 4,560,190 shares of common stock.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes
    that (a) all of the securities offered by this prospectus are sold, (b) there are no issuances of Pre-Funded Warrants and (c) none
    of the Common Stock Warrants or Placement Agent Warrants are exercised.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(13)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Subject to upward adjustment to the extent that, due
    to the offering and the reduction in Auctus&#8217; percentage ownership of our common stock, a portion of Auctus&#8217; warrants
    would become exercisable, its Series B preferred stock would be convertible and/or the Additional Shares would be issuable.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to the Certificate of Designations of Preferred Stock with regard to the Series B preferred stock, Auctus, as the sole holder of
    the 1,398,158 outstanding shares of Series B preferred stock, is entitled to vote such shares based on the number of shares of common
    stock into which such shares are convertible (currently 1,398,158); however, pursuant to such Certificate of Designations of Preferred
    Stock, as indicated in footnote (10), such Series B preferred stock is not convertible into shares of common stock to the extent
    Auctus would beneficially own, after such conversion, more than 9.99% of our then outstanding shares of common stock. Since Auctus
    has advised that, as of October 31, 2025, it owned 817,792 shares of common stock, which represented approximately
    9.2% of the outstanding shares of common stock, and, as indicated in footnote (11) above, 76,595 Additional Shares
    were issuable to it, Auctus&#8217; Series B preferred stock was not currently convertible into shares of common stock.
    Accordingly, as of October 31, 2025, Auctus, as the sole holder of the Series B preferred stock, was not entitled to
    any votes for such shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information as of December 31, 2025 with respect to compensation plans (including individual compensation
arrangements) under which our common stock are authorized for issuance, aggregated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    compensation plans previously approved by security holders; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    compensation plans not previously approved by security holders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="margin: 0"></p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 100; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY
COMPENSATION PLAN INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> securities to be<br/> issued upon<br/> exercise of<br/> outstanding<br/> options (a)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-average<br/> exercise price of<br/> outstanding options<br/> (b)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> securities<br/> remaining<br/> available for future<br/> issuance under<br/> equity<br/> compensation<br/> plans (excluding<br/> securities reflected<br/> in column (a))</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1pt">Equity compensation plans approved by security holders</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">5,266,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2.57</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">4,234,354</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,266,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,234,354</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="am_006"></span><b>MARKET
FOR OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
in our common stock are currently reported under the symbol &#8220;BRTX&#8221; on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 4, 2026, there were 343 record holders of our shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our shares of common stock are entitled to dividends when, as and if declared by our Board of Directors out of funds legally available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not declared or paid any dividends in the past to the holders of our common stock and do not currently anticipate declaring or paying
any dividends in the foreseeable future. We intend to retain earnings, if any, to finance the development and expansion of our business.
Future dividend policy will be subject to the discretion of our Board of Directors and will be contingent upon future earnings, if any,
our financial condition, capital requirements, general business conditions, and other factors. Therefore, we can give no assurance that
any dividends of any kind will ever be paid to holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 101; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="am_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CHANGE
IN CERTIFYING ACCOUNTANTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Resignation
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2024, CBIZ CPAs P.C. acquired the attest business of Marcum LLP (&#8220;Marcum&#8221;). On April 16, 2025, Marcum informed
us that Marcum resigned as our independent registered public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
of Marcum&#8217;s reports on our financial statements for either of the two fiscal years ended December 31, 2024 and December 31, 2023,
respectively, contained an adverse opinion or a disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope, or
accounting principles, except for including in its report on our financial statements for the fiscal year ended December 31, 2024 an
explanatory paragraph as to substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
our fiscal years ended December 31, 2024 and December 31, 2023, respectively, and the subsequent interim period through April 16, 2025,
there were no disagreements with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure, which disagreement(s), if not resolved to the satisfaction of Marcum, would have caused it to make reference to the
subject matter of the disagreement(s) in connection with its report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
our fiscal years ended December 31, 2024 and December 31, 2023, respectively, and the subsequent interim period through April 16, 2025,
we had the following &#8220;reportable events&#8221; (as such term is defined in Item 304(a)(1)(v) of Regulation S-K): As disclosed in
Part II, Item 9A of our Form 10-Ks for the fiscal years ended December 31, 2024 and 2023, there were material weaknesses identified in
internal control over financial reporting related to lack of adherence to formal policies and procedures, lack of risk assessment procedures
on internal controls to detect financial reporting risks in a timely manner, lack of design and implementation of effective controls
to achieve complete and accurate financial reporting and disclosures, including documented controls over the preparation and review of
journal entries, account reconciliations and income taxes, and lack of design and implementation of effective controls over the accounting
for warrants issued in connection with equity financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provided Marcum with a copy of the above disclosures prior to our filing of the above with the SEC. A letter to the SEC, dated April
21, 2025, from Marcum regarding its concurrence with the statements made by us concerning the resignation of Marcum as our independent
registered public accounting firm was filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Appointment
of New Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2025, the Audit Committee of our Board of Directors engaged CBIZ CPAs P.C. as our independent registered public accounting
firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
our fiscal years ended December 31, 2024 and December 31, 2023, respectively, and the subsequent interim period through April 16, 2025,
neither we nor anyone on our behalf consulted with CBIZ CPAs P.C. with respect to either (i) the application of accounting principles
to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our consolidated financial
statements, and neither a written report nor oral advice was provided to us that CBIZ CPAs P.C. concluded was an important factor considered
by us in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject
of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or
a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 102; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_008"></span>PLAN
OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering on a reasonable best efforts basis up to 9,708,738 Units, based on an assumed public offering price of $1.03
per Unit for gross proceeds of up to approximately $10 million before deduction of placement agent fees and offering expenses.
There is no minimum amount of proceeds that is a condition to closing of this offering. The actual amount of gross proceeds, if any,
in this offering could vary substantially from the gross proceeds from the sale of the maximum amount of securities being offered in
this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to an engagement agreement, dated as of February 4, 2026, we have engaged Rodman to act as our exclusive placement agent
to solicit offers to purchase the securities offered by this prospectus. The placement agent is not purchasing or selling any securities,
nor is it required to arrange for the purchase and sale of any specific number or dollar amount of securities, other than to use its
&#8220;reasonable best efforts&#8221; to arrange for the sale of the securities by us. Therefore, we may not sell the entire amount of
securities being offered. Investors purchasing securities offered hereby will have the option to execute a securities purchase agreement
with us. In addition to the rights and remedies available to all investors in this offering under federal and state securities laws,
the investors who enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. Investors
who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities
in this offering. The placement agency agreement provides that the placement agent&#8217;s obligations are subject to conditions contained
in the placement agency agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Units will be offered at a fixed price and are expected to be issued in a single closing. There is no minimum number of Units to be sold
or minimum aggregate offering proceeds for this offering to close. We expect this offering to be completed not later than one trading
day following the commencement of this offering and we will deliver all securities issued in connection with this offering delivery versus
payment (&#8220;DVP&#8221;)/receipt versus payment (&#8220;RVP&#8221;) upon our receipt of investor funds. Accordingly, neither we nor
the placement agent has made any arrangements to place investor funds in an escrow account or trust account since the placement agent
will not receive investor funds in connection with the sale of securities offered hereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will deliver the securities being issued to the investors upon receipt of investor funds for the purchase of the securities offered pursuant
to this prospectus. We expect to deliver the securities being offered pursuant to this prospectus on or about , 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placement
Agent Fees and Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, we will pay the placement agent a cash transaction fee equal to 7.0% of the aggregate gross cash
proceeds to us from the sale of the securities in the offering. In addition, we will reimburse the placement agent for certain of its
out-of-pocket expenses incurred in connection with this offering, including the placement agent&#8217;s legal fees, and actual travel
and reasonable out-of-pocket expenses if this offering is completed, in an amount not to exceed $100,000, subject to reduction under
certain circumstances, and up to $15,950 for the placement agent&#8217;s closing costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 103; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the public offering price, placement agent fees and proceeds, before expenses, to us, assuming the sale of all
Units in this offering and no sale of any Pre-Funded Warrants in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Unit</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consisting of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>and Warrant</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Unit</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consisting of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Funded</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<sup>(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Public offering price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement agent fees<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds to us, before expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    placement agent fees shall equal 7.0% of the gross proceeds of the securities sold by us in this offering.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    foregoing assumes that no Pre-Funded Warrants are issued as part of the Units.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the total expenses of the offering, including registration and filing fees, printing fees and legal and accounting expenses,
but excluding the placement agent fees, will be approximately $268,000, all of which are payable by us. This figure includes,
among other things, the placement agent&#8217;s expenses (including the legal fees, costs and expenses for the placement agent&#8217;s
legal counsel) that we have agreed to reimburse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placement
Agent Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to issue to Rodman (or its permitted assignees) warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase a number
of shares of common stock equal to 7.0% of the total number of shares of common stock and/or Pre-Funded Warrants being sold in this offering.
The Placement Agent Warrants will be substantially similar to the Common Stock Warrants issued hereunder. See the form of Placement Agent
Warrant filed as an exhibit to the registration statement of which this prospectus forms a part for a complete description of the terms.
The Placement Agent Warrants and the shares of common stock underlying the warrants are being registered on the registration statement
of which this prospectus is a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of common stock are listed on Nasdaq under the symbol &#8220;BRTX.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
last reported sale price of our common stock on Nasdaq on February 4, 2026, was $1.03 per share. The actual public offering
price was determined between us and the underwriters, and may be at a discount to the current market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lock-Up
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors and
officers will enter into lock-up agreements in connection with this offering. Under these agreements, these individuals will agree, subject
to specified exceptions, not to sell or transfer any shares of common stock or securities convertible into, or exchangeable or exercisable
for, our common stock during a period ending 90 days following the closing of this offering. Specifically, these individuals have
agreed, in part, not to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might
reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement
or otherwise), or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning
of Section 16 of the Exchange Act, with respect to, any shares of our common stock or securities convertible, exchangeable or exercisable
into shares of our common stock beneficially owned by them. Notwithstanding these limitations, these shares of common stock may be transferred
under limited circumstances, including, without limitation, by gift, will or intestate succession.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 104; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have agreed that, subject to certain exceptions, we will not issue, enter into any agreement to issue or announce the issuance
or proposed issuance of any shares of common stock or common stock equivalents for a period of 90 days following the closing of this
offering or effect or enter into an agreement to effect any issuance by us or our subsidiaries of any securities that involve a variable
rate transaction (as defined in the securities purchase agreement) for a period of nine months following the closing
date of this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tail</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, if, within twelve months following such time, we, or any of our affiliates, complete any public or private
offering of equity, or other financing or capital-raising, then, to the extent we receive any capital or funds from any of the investors
who were contacted by the placement agent in connection with this offering or introduced to us by the placement agent during the term
of our engagement agreement with the placement agent, then we will pay the placement agent, upon the closing of such financing, compensation
equal to 7.0% of the gross proceeds of such financing received from such investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent for our common stock is Transhare Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Determination
of Offering Price</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price of the securities offered by this prospectus, and the exercise price of the Common Stock Warrants included in the
Units we are offering, were determined by negotiation among us, the placement agent and the investors in this offering. Among the factors
that were considered in determining the public offering price were the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.5in">&#160;</td>
  <td style="width: 0.5in">&#9679;</td>
  <td>our history and our prospects;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#9679;</td>
  <td>the industry in which we operate;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#9679;</td>
  <td>our past and present operating results;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#9679;</td>
  <td>the previous experience of our executive officers; and</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#9679;</td>
  <td>the general condition of the securities markets at the time of this offering.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price stated on the cover page of this prospectus should not be considered an indication of the actual value of the shares
of common stock sold in this offering. That price is subject to change as a result of market conditions and other factors and we cannot
assure you that the shares of common stock sold in this offering can be resold at or above the public offering price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 105; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Electronic
Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on a website maintained by the placement agent or an affiliate. Other than this
prospectus, the information on the placement agent&#8217;s website and any information contained in any other website maintained by the
placement agent is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved
and/or endorsed by us or the placement agent, and should not be relied upon by investors. In connection with the offering, the placement
agent or selected dealers may distribute prospectuses electronically. No forms of electronic prospectus other than prospectuses that
are printable as Adobe&#174; PDF will be used in connection with this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of their business activities, the placement agent and its affiliates may make or hold a broad array of investments
and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for
their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments
of ours or our affiliates. The placement agent and its affiliates may also make investment recommendations and/or publish or express
independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the placement agent against certain liabilities, including certain liabilities arising under the Securities
Act, or to contribute to payments that the placement agent may be required to make for these liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
M</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting
discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to comply with the requirements
of the Securities Act and the Exchange Act, including, without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These
rules and regulations may limit the timing of purchases and sales of our securities by the placement agent acting as principal. Under
these rules and regulations, the placement agent (i) may not engage in any stabilization activity in connection with our securities and
(ii) may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than
as permitted under the Exchange Act, until it has completed its participation in the distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 106; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="am_009"></span><b>DESCRIPTION
OF OUR SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains a summary description of our capital stock and the warrants we are offering pursuant to this prospectus. This summary
description does not purport to be complete and is subject to, and qualified in its entirety by reference to, the more complete descriptions
thereof set forth in our amended and restated articles of incorporation (&#8220;our charter&#8221;) and our bylaws, each as amended to
date, and the forms of the warrants, which are included as exhibits to the registration statement of which this prospectus forms a part
and are incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Authorization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 95,000,000 shares of capital stock. We are authorized to issue 75,000,000 shares of common stock,
par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.01 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Rights. </i>Subject to preferences that may be applicable to any shares of our preferred stock that may be outstanding, the holders of
our common stock are entitled to share ratably in such dividends as may be declared by our Board out of funds legally available therefor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting
Rights. </i>Each share of our common stock entitles its holder to one vote in the election of directors as well as all other matters
to be voted on by stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No
Preemptive Rights. </i>Holders of our common stock do not have any preemptive rights to subscribe for additional shares on a pro rata
basis or otherwise when additional shares are offered for sale by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation
Rights. </i>Subject to preferences that may be applicable to any shares of our preferred stock that may be outstanding, in the event
of our liquidation, dissolution or winding up, the holders of our common stock would be entitled to receive, pro rata, after payment
of all of our debts and liabilities, all of our remaining assets available for distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Rights</i>. Holders of our common stock have no preferences or conversion or exchange rights. Shares of our common stock will not be
liable for further calls or assessments by us and are not subject to redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is authorized to provide, out of the unissued shares of preferred stock, for one or more series of preferred stock and, with respect
to each such series, to fix the number of shares constituting such series and the designation of such series, the voting powers, if any,
of the shares of such series, and the preferences and relative, participating, optional or other special rights, if any, and any qualifications,
limitations or restrictions thereof, of the shares of such series, as are stated in the resolution or resolutions providing for the issuance
of such series adopted by our Board. The authority of our Board with respect to each series of preferred stock includes determination
of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            designation of the series;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 107; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of shares of the series;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            dividend rate or rates on the shares of that series, whether dividends will be cumulative
                                            and, if so, from which date or dates, and the relative rights of priority, if any, of payment
                                            of dividends on shares of that series;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the series will have voting rights in addition to the voting rights provided by law and,
                                            if so, the terms of such voting rights;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the series will have conversion privileges and, if so, the terms and conditions of such conversion,
                                            including provision for adjustment of the conversion rate in such events as our Board determines;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            or not the shares of that series will be redeemable, in whole or in part, at our option or
                                            at the option of the holder thereof and, if made subject to such redemption, the terms and
                                            conditions of such redemption, including the date or dates upon or after which they will
                                            be redeemable, and the amount per share payable in case of redemptions, which amount may
                                            vary under different conditions and at different redemption rates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            terms and amount of any sinking fund provided for the purchase or redemption of the shares
                                            of such series;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            rights of the shares of that series in the event of voluntary or involuntary liquidation,
                                            dissolution or winding up of our company, and the relative rights of priority, if any, of
                                            payment of shares of that series;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            restrictions, if any, on the issue or reissue of any additional preferred stock; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            other relative rights, preferences and limitations of that series.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Overview</i>.
The following summary of certain terms and provisions of the Common Stock Warrants offered hereby is not complete and is subject to,
and qualified in its entirety by, the provisions of the form of Common Stock Warrant which is filed as an exhibit to the registration
statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the
warrant agency agreement, including the annexes thereto and the form of Common Stock Warrant. Each Common Stock Warrant issued
in this offering entitles the registered holder to purchase one share of our common stock at a price equal to $&#160;&#160;&#160;&#160;&#160;
per share, subject to adjustment as discussed below, immediately following the issuance of such warrant and terminating at 5:00 p.m.,
New York City time, on the fifth anniversary of the original issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 108; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercisability</i>.
The Common Stock Warrants are exercisable at any time after their original issuance date until the fifth anniversary of the original
issuance date. The Common Stock Warrants may be exercised upon surrender of the warrant on or prior to the expiration date at the offices
of the Company, with the exercise form included with the Common Stock Warrant completed and executed as indicated. If we fail
to maintain the effectiveness of the registration statement and current prospectus relating to the common stock issuable upon exercise
of the Common Stock Warrants, the holders of the warrants shall have the right to exercise the warrants via a cashless exercise feature
provided for in the Common Stock Warrants, until such time as there is an effective registration statement and current prospectus. See
&#8220;&#8212; Cashless Exercise&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
Limitation</i>. A holder (together with its affiliates) may not exercise any portion of the Common Stock Warrants to the extent that
the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after exercise,
except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding
stock after exercising the holder&#8217;s Common Stock Warrants up to 9.99% of the number of shares of our common stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Common Stock Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
Price</i>. The exercise price per whole share of our common stock purchasable upon the exercise of the Common Stock Warrants is $&#160;&#160;&#160;&#160;&#160;
per share of common stock. The warrants will be immediately exercisable and may be exercised at any time up to the date that is the fifth
anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise of the warrants
may be adjusted in certain circumstances, including in the event of a stock dividend or recapitalization, reorganization, merger or consolidation.
However, the Common Stock Warrants will not be adjusted for issuances of common stock at prices below their exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cashless
Exercise</i>. If, at any time after the issuance of the Common Stock Warrants, a holder of the warrants exercises the warrants and a
registration statement registering the issuance of the shares of common stock underlying the warrants under the Securities Act is not
then effective or available (or a prospectus is not available for the resale of the shares of common stock underlying the warrants),
then, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise
price, the holder shall instead receive upon such exercise (either in whole or in part) only the net number of shares of common stock
determined according to a formula set forth in the Common Stock Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fractional
Shares</i>. No fractional shares of Common Stock will be issued upon exercise of the warrants. If, upon exercise of a Common Stock Warrant,
the holder would be entitled to receive a fractional interest in a share, we will, in our discretion and upon exercise, either pay a
cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price or round up to
the next whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability</i>.
Subject to applicable laws, the Common Stock Warrants may be offered for sale, sold, transferred or assigned at the option of the holder
without our consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certificated
Form</i>. The Common Stock Warrants shall be issued solely in certificated (physical) form, with each Common Stock Warrant represented
by a duly executed warrant certificate delivered to the Holder, and shall not be issued in book-entry or uncertificated form without
the prior written consent of the Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 109; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fundamental
Transactions</i>. In the event of a &#8220;fundamental transaction,&#8221; as described in the Common Stock Warrants and generally including
any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially
all of our properties or assets, our consolidation or merger with or into another person, or any person or group becoming the beneficial
owner of greater than 50% of the voting power represented by our outstanding equity, the holders of the Common Stock Warrants
will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property that the holders
would have received had they exercised the warrants immediately prior to such fundamental transaction. Notwithstanding the foregoing,
in the event of a fundamental transaction, under certain circumstances, the holders of the Common Stock Warrants have the right
to require us or a successor entity to redeem the Common Stock Warrants for cash in the amount of the Black-Scholes Value (as defined
in the Common Stock Warrants) of the unexercised portion of the Common Stock Warrants concurrently with or within 30 days following the
consummation of a fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rights
as a Stockholder</i>. Except by virtue of such holder&#8217;s ownership of shares of our common stock, the holder of a Common Stock Warrant
does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pre-Funded
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Overview</i>.
The following summary of certain terms and provisions of the Pre-Funded Warrants offered hereby is not complete and is subject to the
form of Pre-Funded Warrant, which is filed as an exhibit to the registration statement of which this prospectus is a part. Prospective
investors should carefully review the terms and provisions set forth in the form of Pre-Funded Warrant. Each Pre-Funded Warrant issued
in this offering entitles the registered holder to purchase one share of our common stock at a purchase price of $0.0001, subject to
adjustment as discussed below, immediately following the issuance of such warrant and terminating at the time no Pre-Funded Warrants
are outstanding. The Pre-Funded Warrants will be issued in certificated form.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercisability</i>.
The Pre-Funded Warrants are exercisable at any time after their original issuance date until the Pre-Funded Warrants are exercised in
full. The Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed
exercise notice accompanied by payment in full for the number of shares of common stock purchased upon such exercise (except in the case
of a cashless exercise as discussed below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
Limitation</i>. A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrants to the extent that the
holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after exercise,
except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding
stock after exercising the holder&#8217;s Pre-Funded Warrants up to 9.99% of the number of shares of our common stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
Price</i>. The exercise price per whole share of our common stock purchasable upon the exercise of the Pre-Funded Warrants is $0.0001
per share of common stock. The warrants will be immediately exercisable and may be exercised at any time until the Pre-Funded Warrants
are exercised in full. The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted
in certain circumstances, including in the event of a stock dividend or recapitalization, reorganization, merger or consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 110; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cashless
Exercise</i>. If, at any time after the issuance of the Pre-Funded Warrants, a holder of the warrants exercises the warrants and a registration
statement registering the issuance of the shares of common stock underlying the warrants under the Securities Act is not then effective
or available (or a prospectus is not available for the resale of shares of common stock underlying the warrants), then, in lieu of making
the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder shall
instead receive upon such exercise (either in whole or in part) only the net number of shares of common stock determined according to
a formula set forth in the Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fractional
Shares</i>. No fractional shares of common stock will be issued upon exercise of the warrants. If, upon exercise of a Pre-Funded Warrant,
the holder would be entitled to receive a fractional interest in a share, we will, in our discretion and upon exercise, either pay a
cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price or round up to
the next whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability</i>.
Subject to applicable laws, the Pre-Funded Warrants may be offered for sale, sold, transferred or assigned at the option of the holder
without our consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fundamental
Transactions</i>. In the event of a &#8220;fundamental transaction,&#8221; as described in the Pre-Funded Warrants and generally including
any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially
all of our properties or assets, our consolidation or merger with or into another person, or any person or group becoming the beneficial
owner of greater than 50% of the voting power represented by our outstanding equity, the holders of the Pre-Funded Warrants
will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property that the holders
would have received had they exercised the warrants immediately prior to such fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rights
as a Stockholder</i>. Except by virtue of such holder&#8217;s ownership of shares of our common stock, the holder of a Pre-Funded Warrant
does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Provisions Having Potential Anti-Takeover Effects</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General.
</i>The following is a summary of the material provisions of the Nevada Revised Statues (the &#8220;NRS&#8221;) and our charter and bylaws
that address matters of corporate governance and the rights of stockholders. Certain of these provisions may delay or prevent takeover
attempts not first approved by our Board (including takeovers which certain stockholders may deem to be in their best interests). These
provisions also could delay or frustrate the removal of incumbent directors or the assumption of control by stockholders. The primary
purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring control of our company.
All references to the charter and bylaws are to our charter and bylaws in effect on the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 111; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.2pt"><i>Combinations
with Interested Stockholder.</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">Sections
78.411-78.444, inclusive, of the NRS contain provisions governing combinations with an interested stockholder. For purposes of the NRS,
&#8220;combinations&#8221; include: (i) any merger or consolidation with any interested stockholder, (ii) any sale, lease, exchange,
mortgage, pledge, transfer or other disposition to any interested stockholder of corporate assets with an aggregate market value equal
to more than 5% of the aggregate market value of the corporation&#8217;s consolidated assets, more than 5% of the aggregate market value
of outstanding shares of the corporation or more than 10% of the earning power or net income of the corporation, (iii) the issuance to
any interested stockholder of voting shares (except pursuant to a share dividend or similar proportionate distribution) with an aggregate
market value equal to 5% or more of the aggregate market value of all the outstanding shares of the corporation, (iv) the adoption of
the dissolution of the corporation if proposed by or on behalf of any interested stockholder, (v) any reclassification of securities,
recapitalization or corporate reorganization that will have the effect of increasing the proportionate share of the corporation&#8217;s
outstanding voting shares held by any interested stockholder and (vi) any receipt by the interested stockholder of the benefit (except
proportionately as a stockholder) of any loan, advance, guarantee, pledge or other financial assistance. For purposes of the NRS, an
&#8220;interested stockholder&#8221; is defined to include any beneficial owner of more than 10% of any class of the voting securities
of a Nevada corporation and any person who is an affiliate or associate of the corporation and was at any time during the preceding two
years the beneficial owner of more than 10% of any class of the voting securities of the Nevada corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">Subject
to certain exceptions, the provisions of the NRS statute governing combinations with interested stockholders provide that a Nevada corporation
may not engage in a combination with an interested stockholder for two years after the date that the person first became an interested
stockholder unless the combination or the transaction by which the person first became an interested stockholder is approved by the Board
of Directors before the person first became an interested stockholder, or unless the combination is approved by the Board of Directors
and 60% of the corporation&#8217;s voting power not beneficially owned by the interested stockholder, its affiliates and associates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.2pt; background-color: white"><i>Control
Share Acquisitions.</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt; background-color: white">The
NRS also contains a &#8220;control share acquisitions statute.&#8221; If applicable to a Nevada corporation, this statute restricts the
voting rights of certain stockholders referred to as &#8220;acquiring persons,&#8221; that acquire or offer to acquire ownership of a
&#8220;controlling interest&#8221; in the outstanding voting stock of an &#8220;issuing corporation.&#8221; For purposes of these provisions,
a &#8220;controlling interest&#8221; means with certain exceptions the ownership of outstanding voting stock sufficient to enable the
acquiring person to exercise one-fifth or more but less than <span style="color: #3D3D3D">one</span>-<span style="color: #3D3D3D">third</span>,
<span style="color: #3D3D3D">one</span>-<span style="color: #3D3D3D">third</span> or more but less than a majority, or a majority or
more of all voting power in the election of directors; &#8220;issuing corporation&#8221; means a Nevada corporation that has 200 or more
stockholders of record, at least 100 of whom have addresses in Nevada appearing on the stock ledger of the corporation at all times during
the 90 days immediately preceding such date, and which does business in Nevada directly or through an affiliated corporation. The voting
rights of an acquiring person in the affected shares will be restored only if such restoration is approved by the holders of a majority
of the voting power of the corporation. The NRS allows a corporation to &#8220;opt-out&#8221; of the control share acquisitions statute
by providing in such corporation&#8217;s articles of incorporation or bylaws that the control share acquisitions statute does not apply
to the corporation or to an acquisition of a controlling interest specifically by types of existing or future stockholders, whether or
not identified. The Company has not opted out of this statute.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 112; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Authorized
But Unissued Shares. </i>Nevada law does not require stockholder approval for any issuance of authorized shares. Authorized but unissued
shares may be used for a variety of corporate purposes, including future public or private offerings to raise additional capital or to
facilitate corporate acquisitions. One of the effects of the existence of authorized but unissued shares may be to enable our Board to
issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain
control of our company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management
and possibly deprive the stockholders of opportunities to sell their shares of common stock at prices higher than prevailing market prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock</i>. Under the terms of our charter, our Board is authorized to issue shares of preferred stock in one or more series without stockholder
approval. Our Board has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend
rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. The purpose of authorizing
our Board to issue preferred stock and determine its rights and preferences is to provide flexibility and eliminate delays associated
with a stockholder vote on specific issues. However, the ability of our Board to issue preferred stock and determine its rights and preferences
may have the effect of delaying or preventing a change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Classified
Board. </i>We have a classified Board of Directors consisting of three classes of directors. A classified board is one in which a certain
number, but not all, of the directors are elected on a rotating basis each year. This method of electing directors makes changes in the
composition of our Board more difficult, and thus a potential change in control may be a lengthier process. The existence of our classified
Board reduces the possibility that a third party could effect an unsolicited change in control of our Board. Since our classified Board
will increase the amount of time required for a takeover bidder to obtain control of us without the cooperation of our Board, even if
the takeover bidder were to acquire a majority of our outstanding common stock, the existence of our classified Board could tend to discourage
certain tender offers which stockholders might feel would be in their best interests. Our classified Board will likely allow management,
if confronted by a proposal from a third party who has acquired a block of our common stock, sufficient time to review the proposal and
appropriate alternatives to the proposal and to attempt to negotiate a better transaction, if possible, for our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Special
Meetings of Stockholders.</i> Our bylaws provide that special meetings of stockholders may be called only by our Board or the Chairman
of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Filling
Vacancies.</i> Vacancies occurring in our Board and newly created directorships resulting from an increase in the authorized number of
directors may be filled by a majority of the remaining directors, even if less than a quorum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Removal
of Directors by Stockholders. </i>Under the terms of our charter, stockholders may remove directors with or without cause with the affirmative
vote of holders of 75% of the voting power of all of the then-outstanding shares of our capital stock then entitled to vote at an election
of directors, voting together as a single class.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment
of Bylaws.</i> Our bylaws may be amended by our Board or by the holders of at least 75% of the voting power of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment
of Certain Charter Provisions. </i>Under the terms of our charter, amending certain charter provisions requires the affirmative vote
of the holders of at least 75% of the voting power of all of the then-outstanding shares of our capital stock entitled to vote thereon,
voting together as a single class. The provisions subject to such heightened requirement include those relating to stockholder action
by written consent, the calling of special meetings, board classification, the filling of board vacancies, the removal of directors and
the ability to amend our bylaws, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Advance
Notification of Stockholder Nominations and Proposals</i>. Our bylaws establish advance notice procedures with respect to the nomination
of persons for election as directors, other than nominations made by or at the direction of our Board, and stockholder proposals for
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 113; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stockholder
Nominees; Stockholder Proposals.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order for a stockholder to nominate a candidate for director at, or bring any business before, an annual meeting of stockholders, under
our bylaws, timely notice of the nomination or business must be received by us in advance of the meeting. To be timely, a stockholder&#8217;s
notice must be delivered to or mailed and received by our Secretary at our principal executive offices not less than 90 days nor more
than 120 days prior to the one-year anniversary of the date on which we first mailed the proxy materials for the preceding year&#8217;s
annual meeting of stockholders; provided, however, that if the meeting is convened more than 30 days prior to or delayed more than 60
days after the anniversary of the preceding year&#8217;s annual meeting, to be timely a stockholder&#8217;s notice must be received not
earlier than the close of business on the 120th day prior to the date of such annual meeting and not later than the close of business
on the later of the 90th day prior to the date of such annual meeting or, if the first public announcement of the date of such annual
meeting is less than 100 days prior to the date of such annual meeting, the 10th day following the day on which public announcement of
the date of such meeting is first made by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stockholder sending the notice of nomination or proposed business must describe various matters, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    to each person whom the stockholder proposes to nominate for election as a director, all information relating to such person as would
    be required to be disclosed in solicitations of proxies for election of such nominee as a director pursuant to Regulation 14A under
    the Exchange Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
    the name and address of such stockholder, as they appear on our books and of such beneficial owner or Control Person (as defined
    in our bylaws), if any, (ii) the number of our shares which are, directly or indirectly, owned beneficially and of record by such
    stockholder and such beneficial owner or Control Person, if any (iii) a representation that the stockholder intends to appear at
    the meeting in person or by proxy to submit the business specified in such notice, (iv) if the notice relates to any business other
    than a nomination of director(s), a brief description of the business desired to be brought before the meeting, including the complete
    text of any resolutions proposed for consideration, and the reasons for conducting such business at the meeting, (v) any direct or
    indirect personal or other interest of the stockholder in the business to be submitted, (vi) a description of any agreement, arrangement
    or understanding (including any derivative or short positions, profit interests, options, hedging transactions, and borrowed or loaned
    shares) that has been entered into as of the date of the stockholder&#8217;s notice by, or on behalf of, such stockholder or beneficial
    owner and by any Control Person or any other person acting in concert with any of the foregoing, the effect or intent of which is
    to mitigate loss, manage risk or benefit from changes in the share price of any class of our stock, or maintain, increase or decrease
    the voting power of the stockholder or beneficial owner with respect to shares of our stock, and a representation that the stockholder
    will notify us in writing within five business days after the record date for such meeting of any such agreement, arrangement or
    understanding in effect as of the record date for the meeting, (vii) a representation whether the stockholder or the beneficial owner,
    if any, and any Control Person will engage in a solicitation with respect to the nomination or business and, if so, the name of each
    participant (as defined in Item 4 of Schedule 14A under the Exchange Act) in such solicitation and whether such person intends or
    is part of a group which intends to deliver a proxy statement and/or form of proxy to holders of at least the percentage of our outstanding
    stock required to approve or adopt the business to be proposed (in person or by proxy) by the stockholder and (viii) any other information
    relating to such stockholder, beneficial owner or Control Person, if any, that would be required to be disclosed in a proxy statement
    and form of proxy or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal
    and/or for the election of directors in a contested election pursuant to Section 14 of the Exchange Act and the rules and regulations
    promulgated thereunder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions are intended to enhance the likelihood of continuity and stability in the composition of our Board and in policies formulated
by our Board and to discourage certain types of transactions that may involve an actual or threatened change of control of our company.
These provisions are designed to reduce our vulnerability to an unsolicited proposal for a takeover that does not contemplate the acquisition
of all of our outstanding shares or an unsolicited proposal for the restructuring or sale of all or part of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 114; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
on Director Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
charter provides that our directors shall generally not be liable to us or any of our stockholders for damages for breach of duty as
a director. This provision will eliminate such liability except for (i) any breach of the director&#8217;s duty of loyalty to us or to
our stockholders, (ii) acts and omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)
liability for unlawful payment of dividends or unlawful stock purchases or redemptions in violation of the NRS, and (iv) any transaction
from which the director derived an improper personal benefit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
of Directors and Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
78.7502(1) of the NRS provides that a corporation may, and our charter and bylaws provide that we shall, indemnify any person who was
or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative (an &#8220;Action&#8221;), by reason of the fact that he is or was our director, officer, employee
or agent or is or was serving at our request in such capacity in another corporation, partnership, joint venture, trust or other enterprise
(the &#8220;Indemnified Party&#8221;), against expenses (including attorney&#8217;s fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with such Action if he acted in good faith and in a manner he reasonably believed
to be in or not opposed to our best interests, and, with respect to any criminal Action, had no reasonable cause to believe his conduct
was unlawful; provided, however, no indemnification shall be made in respect of any Action by or in our right if the Indemnified Party
shall have been adjudged by a court of competent jurisdiction, after exhaustion of any appeals, to be liable to us, unless and only to
the extent that the court shall determine that, despite the adjudication of liability but in view of all circumstances, such person is
fairly and reasonably entitled to indemnity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the NRS, the directors have a fiduciary duty to us that is not eliminated by this provision of our charter and, in appropriate circumstances,
equitable remedies such as injunctive or other forms of non-monetary relief will remain available. In addition, each director will continue
to be subject to liability under the NRS for breach of the director&#8217;s duty of loyalty to us for acts or omissions which are found
by a court of competent jurisdiction to not be in good faith or involve intentional misconduct, for knowing violations of law, for actions
leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases or redemptions that
are prohibited by the NRS. This provision also does not affect the directors&#8217; responsibilities under any other laws, such as the
federal securities laws or state or federal environmental laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Section 78.7502(3) of the NRS provides that determination of an Indemnified Party&#8217;s eligibility for indemnification by us shall
be made on a case-by-case basis by: (i) the stockholders; (ii) the Board of Directors by a majority vote of a quorum consisting of directors
who were not parties to the Action; or (iii) independent legal counsel&#8217;s written opinion if: (1) a majority vote of a quorum consisting
of directors who were not parties to the Action so orders; or (2) a quorum consisting of directors who were not parties to the Action
cannot be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
Section 78.752(1) of the NRS empowers a corporation to purchase and maintain insurance or make other financial arrangements with respect
to liability arising out of the actions or omissions of directors, officers, employees or agents in their capacity or status as such,
whether or not the corporation has the authority to indemnify him against such liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
charter provides that, to the fullest extent permitted by the NRS, no director or officer shall be personally liable to us or to our
stockholders for monetary damages for breach of fiduciary duty as a director or an officer, except to the extent that such exemption
from liability or limitation thereof is not permitted under the NRS currently in effect or as the same may be amended. If the NRS is
amended to further eliminate or limit or authorize corporate action to further eliminate or limit the liability of directors or officers,
the liability of our directors and officers shall be eliminated or limited to the fullest extent permitted by the NRS, as so amended
from time to time. No repeal or modification of this provision of our charter will apply to or have any effect on the liability or alleged
liability of any of our directors or officers for or with respect to any acts or omissions of such directors or officers occurring prior
to such repeal or modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws provide that we will indemnify and hold harmless any person who was <span style="background-color: white">or is a party or is
threatened to be made a party to any threatened, pending or completed Action in such manner, under such circumstances and to the fullest
extent permitted by our charter and the NRS.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons
under the provisions discussed above or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 115; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="YV-001"></span>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the issuance of the securities offered hereby will be passed upon by our counsel, Certilman Balin Adler &amp; Hyman, LLP.
The placement agent is being represented in connection with this offering by Ellenoff Grossman &amp; Schole LLP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="YV-002"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements as of December 31, 2023 and 2024 and for the years then ended have been included in this prospectus
in reliance upon the report of Marcum LLP, an independent registered public accounting firm, which report includes an explanatory paragraph
regarding our ability to continue as a going concern, included herein, and upon the authority of said firm as experts in accounting and
auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="YV-003"></span>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information
statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is <span style="text-decoration: underline">http://www.sec.gov</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website address is <span style="text-decoration: underline">www.biorestorative.com</span>. This website address, and the website addresses included in any documents incorporated
by reference herein, are not intended to function as hyperlinks, and the information contained on such websites and on the SEC&#8217;s
website is not incorporated by reference in this prospectus and you should not consider it a part of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 116; Value: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="YV-004"></span>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Y-003">Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Y-004">Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Y-005">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity for the Nine Months Ended September 30, 2025 and 2024 (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Y-006">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Y-007">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aud_001">Report
    of Independent Registered Public Accounting Firm</a></span> (PCAOB ID 688)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-18</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">Consolidated Statements of Operations For the Years Ended December 31, 2024 and December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">Consolidated Statements of Stockholders&#8217; Equity For the Years Ended December 31, 2024 and December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_005">Consolidated Statements of Cash Flows For the Years Ended December 31, 2024 and December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_006">Notes to Consolidated Financial Statements For the Years Ended December 31, 2024 and December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-23</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 117; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Y-003"></span>BIORESTORATIVE THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED CONSOLIDATED BALANCE SHEETS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_zYQb1TN9GQ32" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20250930_zdb5GbzDIC7j" style="padding-bottom: 1pt; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zg0kXm2Jsi81" style="padding-bottom: 1pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_z2DNZPIUWXp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrentAbstract_i01B_zka06K6ilLp" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzH4H_zMxa41emplh6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-09-30" id="Fact000042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">602,444</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,890</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--MarketableSecuritiesCurrent_i02I_maACzH4H_zNVOvbXE8WEg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investments held in marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2025-09-30" id="Fact000045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,887,383</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-12-31" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,184,701</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzH4H_zdP3Og6EXp1e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-09-30" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzH4H_zy11YnYXZVPg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-09-30" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,237</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,230</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrent_i02TI_mtACzH4H_maAzouh_zjry9SDFHPZ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-09-30" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,707,464</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,144,221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredOfferingCost_i01I_maAzouh_zrNOKq1mCOo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:DeferredOfferingCost" contextRef="AsOf2025-09-30" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,066</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:DeferredOfferingCost" contextRef="AsOf2024-12-31" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzouh_zE6ZS7oeDXxk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-09-30" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">309,498</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,936</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0d_maAzouh_zWXPXQ5Mb4mj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Right-of-use assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maAzouh_ztCgBwDk1LBg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2025-09-30" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">556,634</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623,945</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i01TI_mtAzouh_zC8iktJF3NW" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-09-30" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,642,662</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,279,799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z3oxhIxBOXl1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zoAzY7u5h1rh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccountsPayableCurrent_i02I_maLCzB4b_zA9o9wMXNJa8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-09-30" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">859,898</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">483,070</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAccruedLiabilitiesCurrent_i02I_maLCzB4b_ztTOb3FW0Tg1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">607,470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">744,485</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0d_maLCzB4b_zPxTioL5c7eg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLCzB4b_zt2UK2kbQXl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,968,315</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzB4b_maLz7WG_zucwiTqwJO1a" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left">Total Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,435,683</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,748,406</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Liabilities_i01TI_mtLz7WG_maLASEztsq_zv3cZLNd9LR" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left">Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CommitmentsAndContingencies_i01I_maLASEztsq_zDe7dfViyn7h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0096">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0097">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockholdersEquityAbstract_i01B_z3Ff8gFfOZMk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PreferredStockValue_i02I_maSEzLYl_zq9YnnvhCuh4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Preferred stock, $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930_zzAbFBGN3Obc" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_z1YSJqntMbl5" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000105" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250930_zIWbZYot4uZg" title="Preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zP1CIlkeDrdc" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; Series B Convertible Preferred Stock;
    <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z0dTuWacxpT6" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z1fQSSIMtYU3" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000113" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000115" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></ix:nonFraction></span></span> shares designated, <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zkDFPByD9mug" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z7ynBaicjRs8" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zLrD9Dqlteal" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zuY2zBMq5x2l" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000117" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000119" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000121" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000123" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at September 30, 2025 and December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-09-30" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommonStockValue_i02I_maSEzLYl_zZ4bCBnLA792" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Common stock, $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250930_zlEBtSlimIUb" title="Common stock, par value"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zaHn3IyeCwzb" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000128" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000130" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250930_zOdlPVWgQXVd" title="Common stock, shares authorized"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zDx3WydnqRkc" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000132" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20250930_z5A6xbFyt7Y9" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250930_zEaDhDESuQ4c" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-09-30" id="Fact000136" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-09-30" id="Fact000138" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,978,117</ix:nonFraction></ix:nonFraction></span></span> and
    <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zZh1qwXBFYY8" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zreytU12ngFl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-09-30" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdditionalPaidInCapital_i02I_maSEzLYl_zx9lkhKkoUY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-09-30" id="Fact000144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,905,254</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,195,434</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzLYl_zSNTwiotgn25" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-09-30" id="Fact000147" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">166,713,054</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,678,715</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquity_i02TI_mtSEzLYl_maLASEztsq_zTyb6ORiYaG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,206,979</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,531,393</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEztsq_zgIJiuWZAu4k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,642,662</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,279,799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Y-004"></span>BIORESTORATIVE THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_zZIWzgmMNygd" summary="xdx: Statement - Condensed Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250701__20250930_z4bfPEirwvjg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240701__20240930_zS7VoOhDUwjh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20250930_zjsG4MH4fU4e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240930_zeYf3WFFtabe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzBPC_zyIGwuwdhQ46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-weight: bold">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-07-012025-09-30" id="Fact000156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-07-012024-09-30" id="Fact000157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">233,600</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-01-01to2025-09-30" id="Fact000158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-09-30" id="Fact000159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfGoodsAndServicesSold_msCzBPC_zCGkkhT6D8af" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cost of goods sold</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-07-012025-09-30" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,570</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-07-012024-09-30" id="Fact000162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,243</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-01to2025-09-30" id="Fact000163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,208</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-01-012024-09-30" id="Fact000164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,733</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_iT_mtCzBPC_maCzXmN_zHObiC9sQtn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-07-012025-09-30" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-07-012024-09-30" id="Fact000167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-09-30" id="Fact000168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,892</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-012024-09-30" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">332,967</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zmIV6UO9nmzg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzLQe_zHlTqdKDtxBj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30" id="Fact000176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,594,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,453,363</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,467,532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,004,794</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzLQe_zl2ea65VUgAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-07-012025-09-30" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,115,491</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30" id="Fact000182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,048,987</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,672,192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-09-30" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,193,225</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_i01T_mtCzLQe_msCzXmN_zCgweGwZDXEl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-07-012025-09-30" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,710,241</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-07-012024-09-30" id="Fact000187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,502,350</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-09-30" id="Fact000188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,139,724</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-09-30" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,198,019</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_mtCzXmN_maCzMPz_z6TtKakl8CA5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Loss From Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-07-012025-09-30" id="Fact000191" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,709,011</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000192" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,286,993</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000193" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,821,832</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000194" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,865,052</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zIS1Z35eW8h1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other (Expense) Income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestIncomeExpenseNet_i01_maCzrQV_zz8cWzahusF9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2025-07-012025-09-30" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,740</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-07-012024-09-30" id="Fact000202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,547</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2025-01-01to2025-09-30" id="Fact000203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,621</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-012024-09-30" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">497,089</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--GrantIncome_i01_pp0d_maCzrQV_zCrhiZnk43Ui" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Grant income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncomeExpense_i01_maCzrQV_z8AMff1902Ba" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-07-012025-09-30" id="Fact000211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">930</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-07-012024-09-30" id="Fact000212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,336</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-09-30" id="Fact000214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,498</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--GainLossOnExchangeOfWarrants_i01_maCzrQV_zYsfegf33av1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on exchange of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0216">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2024-01-012024-09-30" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,698</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maCzrQV_zDXrt3C8Ovji" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-07-012025-09-30" id="Fact000221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">612,064</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-07-012024-09-30" id="Fact000222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,036,464</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-01-01to2025-09-30" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552,536</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-09-30" id="Fact000224" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">837,466</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzrQV_maCzMPz_zshsRKYHUx58" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Other Income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-07-012025-09-30" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">670,734</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-07-012024-09-30" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,195,577</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">787,493</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-09-30" id="Fact000229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,521,819</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_mtCzMPz_zVPf2Dv2Xp49" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30" id="Fact000231" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,038,277</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000232" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,091,416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000233" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,034,339</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000234" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,343,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20250701__20250930_z2O98UQJC1z" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20250701__20250930_zcuIqRr7ckT6" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-07-012025-09-30" id="Fact000236" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-07-012025-09-30" id="Fact000238" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20240701__20240930_zYGfVbCnF9Td" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pid_c20240701__20240930_zcuio1KvHkRc" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012024-09-30" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012024-09-30" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250930_zRgJulHjAY69" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250930_zt94qFfPkbQ3" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-09-30" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-09-30" id="Fact000246" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.26</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240930_ztLHeEnVkdD3" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20240930_zkk5Cgt6fhX9" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-09-30" id="Fact000248" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-09-30" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.96</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Weighted Average Common Shares Outstanding - Basic and
    Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250701__20250930_zYaUWWwq9s7" title="Weighted Average Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250701__20250930_zV7BJGlmVDtg" title="Weighted Average Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-07-012025-09-30" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-07-012025-09-30" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,116,172</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_z2tD1Fo8DkCh" title="Weighted Average Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_zwHfhtH6OZAi" title="Weighted Average Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,121,499</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250930_z3PRt5Gmnbuj" title="Weighted Average Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250930_zRWK5VXRQCw6" title="Weighted Average Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-09-30" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-09-30" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,742,085</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zTUw1M7Rc1W8" title="Weighted Average Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zyaS3gLAQujg" title="Weighted Average Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-09-30" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-09-30" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,643,437</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Y-005"></span>BIORESTORATIVE THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_114_za8PzrBtN78l" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesBConvertiblePreferredStockMember_zMtWinKybcVc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zY2OT4V4WLtb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zzVhzWbUGPx3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z4UBzsfE84hc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_z3bTwxjxbOn6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Series B Convertible</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="color: red; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: red; font-weight: bold">&#160;</td><td style="color: red; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_432_c20250101__20250331_eus-gaap--StockholdersEquity_iS_zmDCJpla4YW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold">Balance - January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zmBpuKBJapq8" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjOWEEH2N97j" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000276" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,195,434</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000271" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,678,715</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,531,393</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_z3y5AnQBqoej" style="vertical-align: bottom; background-color: White">
    <td>Exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb5QuiHkQDV9" title="Exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000284" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,249</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,408</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-03-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,411</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zJLXDtH8dpw3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance and sale of common stock, net of issuance costs <span id="xdx_F41_zYnFf1WEA9r9">[1]</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fWzFd_zFPUcBLVMG44" title="Issuance and sale of common stock, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000292" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">492,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">901,561</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31" id="Fact000290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">901,610</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueAbeyanceShares_zfWRKTd2kR64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued in connection with abeyance shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesAbeyanceShares_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zf739LlDiMv5" title="Common stock issued in connection with abeyance shares, shares" style="text-align: right"><ix:nonFraction name="BRTX:StockIssuedDuringPeriodSharesAbeyanceShares" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000300" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueAbeyanceShares" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueAbeyanceShares" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000296" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodSharebasedCompensationAbstract_iB_zrp3egEQ6NF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i01_zhta2exoLJj7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted share units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_i01_zsEt3YUjoTX5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted share units, shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_i01_zHMQd6L3gie5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,009,126</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-012025-03-31" id="Fact000324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,009,126</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_z0hcYubbvWx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,339,799</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31" id="Fact000330" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,339,799</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43D_c20250401__20250630_eus-gaap--StockholdersEquity_iS_zdu5Nyu37cwf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance - March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zuMhYpyyEt6k" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS0lM0QoHWsb" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,504,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,148,523</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000335" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">161,018,514</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,144,741</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zpe8KhM4Dmaa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance and sale of common stock, net of issuance costs <span id="xdx_F45_z7YEtU4kM0i7">[2]</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fWzJd_zQdBzd54KMci" title="Issuance and sale of common stock, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">473,337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">888,091</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">888,138</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodSharebasedCompensationAbstract_iB_zC3lSebjOaS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_i01_zisNuvMMx406" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,708</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-04-012025-06-30" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,708</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zt0usQu111wb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,656,263</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30" id="Fact000366" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,656,263</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43E_c20250701__20250930_eus-gaap--StockholdersEquity_iS_zu2FmiCjJPc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance - June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zzMlFeY69ZN4" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000374" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXVvPPPxlr7d" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000376" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,978,117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,505,322</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">163,674,777</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,845,324</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodSharebasedCompensationAbstract_iB_zmBqjH9Dhevd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_i01_z7EtymrKyNRh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,932</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-07-012025-09-30" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,932</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_z9Kp2HvOcK1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="Fact000393" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,038,277</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30" id="Fact000394" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,038,277</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43E_c20250701__20250930_eus-gaap--StockholdersEquity_iE_zZmfZR4SuLWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zUECLr99QbL1" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjJL4yZMIP85" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000404" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,978,117</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">797</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,905,254</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember" id="Fact000399" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">166,713,054</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,206,979</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Series B Convertible</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; color: red; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: red; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; color: red; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Paid-In</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_436_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zljPJe2Q9zq2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold">Balance - January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zzL34YfxjFca" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000412" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJAcNgXKKYOk" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000414" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,706,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">471</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,689,256</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000409" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">146,699,334</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,004,375</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueOther_zkFHrJ8CKJu5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued in connection with warrant exchange <span id="xdx_F4D_zS0XFfvQkRw3">[3]</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fWzNd_zHjChsqpbZoa" title="Common stock issued in connection with warrant exchange, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000422" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000418" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,742,043</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-03-31" id="Fact000420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,742,243</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_znVAT1g4YzWc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Return and cancellation of shares in lieu of payroll tax withholding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0iG0IeQzrp" title="Return and cancellation of shares in lieu of payroll tax withholding, shares" style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000430" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">34,825</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000425" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,406</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-03-31" id="Fact000428" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,410</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodSharebasedCompensationAbstract_iB_zswqd4KxPFLi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i01_zwQahVGETeUd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Restricted share units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_i01_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8TtzNhK4gHe" title="Restricted share units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000444" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">985,028</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31" id="Fact000442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">985,038</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_i01_zX1b1EN4HDee" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000448" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,043,336</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-03-31" id="Fact000450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,043,336</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zv0H90OzWjrb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000455" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,223,255</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000456" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,223,255</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20240401__20240630_eus-gaap--StockholdersEquity_iS_z53Rj8dAHptf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance - March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zvdH1VI42Nh4" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000464" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBvv4L8L2KYj" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000466" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,769,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">677</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,411,257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000461" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">148,922,589</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,503,327</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueAbeyanceShares_zsWPeCB1mdU" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued in connection with abeyance shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesAbeyanceShares_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYACq1ZfCCd3" title="Common stock issued in connection with abeyance shares, shares" style="text-align: right"><ix:nonFraction name="BRTX:StockIssuedDuringPeriodSharesAbeyanceShares" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000474" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueAbeyanceShares" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueAbeyanceShares" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000470" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodSharebasedCompensationAbstract_iB_zvR4GwBdYeKc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_i01_z4ZVus89FNF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">324,322</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-04-012024-06-30" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">324,322</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zlIAKytErkAc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000491" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,028,562</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000492" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,028,562</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20240701__20240930_eus-gaap--StockholdersEquity_iS_znN0yBeAiia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance - June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zHCaN1b5kRwd" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000494" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkyW5TbtXvY3" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000502" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,735,564</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000497" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">152,951,151</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,799,087</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20240701__20240930_eus-gaap--StockholdersEquity_iS_zNuBwrwZLfl2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z469DhVOxWv" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000510" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvRgcXacXV51" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000512" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,735,564</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000507" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">152,951,151</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,799,087</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodSharebasedCompensationAbstract_iB_zFCk1QdPjmj9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_i01_zSEsc1Z3eQM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-07-012024-09-30" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,245</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zUkKmWYpwbf7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0528">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000529" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,091,416</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000530" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,091,416</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20240701__20240930_eus-gaap--StockholdersEquity_iE_zDb8fQh677pf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance -September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zEbgagRsBmab" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000538" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000532" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjBohLzZhkue" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000540" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,019,809</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000535" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">154,042,567</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000536" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,991,916</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20240701__20240930_eus-gaap--StockholdersEquity_iE_zNRiFOk2niP2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zRD2SkuUThG3" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000548" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJABU3lAwto9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000550" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,019,809</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000545" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">154,042,567</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,991,916</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F01_zlGh76KLBJh8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[1]</span></td><td style="text-align: justify"><span id="xdx_F1E_zczVugKCZU58" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000551" xml:lang="en-US">Represents the
gross proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zPkGpeUXA026" title="Gross proceeds" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-012025-03-31_custom_ATMSalesMember" id="Fact000553" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,083,915</ix:nonFraction></span>, less issuance costs of $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_z11HcIisOgnd" title="Issuance costs" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-01-012025-03-31_custom_ATMSalesMember" id="Fact000555" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,305</ix:nonFraction></span>, resulting in net proceeds of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zlB0kglfAiyl" title="Net proceeds" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_custom_ATMSalesMember" id="Fact000557" format="ixt:numdotdecimal" decimals="0" unitRef="USD">901,610</ix:nonFraction></span>. See Note 4 - Stockholders&#8217;
Equity - ATM Sales for additional details.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F04_zgILqHy7uD23" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[2]</span></td><td style="text-align: justify"><span id="xdx_F19_zUugyRbomofa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000558" xml:lang="en-US">Represents the
gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zKw9V4fZzg5l" title="Gross proceeds" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-04-012025-06-30_custom_ATMSalesMember" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">927,335</ix:nonFraction></span>, less issuance costs of $<span id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxsQLuhgdqDh" title="Issuance costs" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-04-012025-06-30_custom_ATMSalesMember" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,197</ix:nonFraction></span>, resulting in net proceeds of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxHhFmIh8c7k" title="Net proceeds" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30_custom_ATMSalesMember" id="Fact000564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">888,138</ix:nonFraction></span>. See Note 4 - Stockholders&#8217; Equity
- ATM Sales for additional details.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F09_zJK05euMvrI" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[3]</span></td><td style="text-align: justify"><span id="xdx_F18_zDWIskLVZpW6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000565" xml:lang="en-US">Represents the
aggregate fair value of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHaF4Odvuz81" title="Aggregate fair value of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span> shares of common stock, which includes <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI9x89Qv0BMb" title="Shares issued" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000569" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> shares that were issued at the time of the warrant
exchange and <span id="xdx_907_ecustom--SharesHeldInAbeyance_iI_pid_c20240331_z1PxY0VQzHHb" title="Shares held in abeyance" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="BRTX:SharesHeldInAbeyance" contextRef="AsOf2024-03-31" id="Fact000571" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,351,580</ix:nonFraction></span> shares that were held in abeyance at the time of the warrant exchange. See Note 4 - Stockholders&#8217; Equity
- Warrant Exercise and Issuance and Note 5 - Fair Value Measurement for additional details.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Y-006"></span>BIORESTORATIVE THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_112_z8Vwnr3fQRzd" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20250101__20250930_z9hN0rtbNh6k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20240930_zG8wATBwgJ5g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z4l0vhXBMKq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maCz8aK_zwjVIutZSp68" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000576" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,034,339</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000577" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,343,233</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zy3qDhfTlvZd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_i02_maCz8aK_zEtyyuXE7ja" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2025-01-01to2025-09-30" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,149</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-012024-09-30" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,687</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestAndDividendIncomeOperating_i02N_di_msCz8aK_z5xCqZIdx4o9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Dividend and interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2025-01-01to2025-09-30" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,878</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2024-01-012024-09-30" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">492,476</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_i02_maCz8aK_zuJSPM8Sezl2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-09-30" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,877,766</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,636,941</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--NoncashLeaseExpense_i02_maCz8aK_zL3LgznjpBzl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:NoncashLeaseExpense" contextRef="From2024-01-012024-09-30" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--GainLossOnExchangeOfWarrants_i02N_di_msCz8aK_ziE8W6W9QzRh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain on exchange of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0594">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2024-01-012024-09-30" id="Fact000595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,698</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_msCz8aK_zMR9RAghxWs1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-01-01to2025-09-30" id="Fact000597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552,536</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-09-30" id="Fact000598" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">837,466</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zqwhvflTPk09" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msCz8aK_z1g45OvOSpMe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2025-01-01to2025-09-30" id="Fact000603" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">175,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-012024-09-30" id="Fact000604" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,700</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCz8aK_z64Qsu5KxUol" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2025-01-01to2025-09-30" id="Fact000606" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,993</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-09-30" id="Fact000607" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCz8aK_zAb7asJpQPP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2025-01-01to2025-09-30" id="Fact000609" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,070</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-012024-09-30" id="Fact000610" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,990</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i03_maCz8aK_zWmDeOkAQRaa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2025-01-01to2025-09-30" id="Fact000612" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">137,015</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2024-01-012024-09-30" id="Fact000613" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,449</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maCz8aK_ztmJ9dFhDS4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-09-30" id="Fact000616" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">119,903</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCz8aK_maCzcfF_z9fa82P0v6gk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used In Operating Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000618" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,373,790</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-09-30" id="Fact000619" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,882,501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zftJkDGmQOoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_maCzZiy_zpnWtv3TVd6b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2025-01-01to2025-09-30" id="Fact000624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,212,343</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2024-01-012024-09-30" id="Fact000625" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,370,243</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_di_msCzZiy_zUKNfLF7p0Ld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Purchase of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2025-01-01to2025-09-30" id="Fact000627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,679,147</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2024-01-012024-09-30" id="Fact000628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,294,566</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzZiy_zXfIpDSw5qq4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; padding-bottom: 1pt">Purchases of equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2025-01-01to2025-09-30" id="Fact000630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-012024-09-30" id="Fact000631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,755</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzZiy_maCzcfF_zd6CqJ8Z3El6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By (Used In) Investing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,496,796</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-09-30" id="Fact000634" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,018,078</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z1JEujtR0v33" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzQP0_zfnftVxehpA4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Proceeds from issuance of common stock in at-the-market offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-01to2025-09-30" id="Fact000639" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,011,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msCzQP0_zTAzPvhrc4Sj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Payment of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-01-01to2025-09-30" id="Fact000642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,805</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzQP0_zr0pZqfUgOX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt">Exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2025-01-01to2025-09-30" id="Fact000645" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_pp0d_maCzQP0_znryJk4NZf78" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Net proceeds from issuance of common stock in direct-offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ProceedsFromExchangeAndIssuanceOfWarrantsNet1_i01_maCzQP0_zQBVe2TIqQI5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Proceeds from exchange and issuance of warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1" contextRef="From2024-01-012024-09-30" id="Fact000652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,528,027</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PaymentsForProceedsFromDeferredOfferingCosts_i01N_di_msCzQP0_zgsY1hePoiuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Deferred offering costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BRTX:PaymentsForProceedsFromDeferredOfferingCosts" contextRef="From2025-01-01to2025-09-30" id="Fact000654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,308</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BRTX:PaymentsForProceedsFromDeferredOfferingCosts" contextRef="From2024-01-012024-09-30" id="Fact000655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,381</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzQP0_maCzcfF_zchm0ZHmdAjd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By Financing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,931,548</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-09-30" id="Fact000658" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,505,646</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzcfF_zTVunPNS59F3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left">Net Increase In Cash and Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-09-30" id="Fact000660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,554</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-09-30" id="Fact000661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605,067</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zc7HNdSiGN7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents - Beginning of the Period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,890</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000664" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,377</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zkZRCB5rxPNk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents - End of the Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2025-09-30" id="Fact000666" format="ixt:numdotdecimal" decimals="0" unitRef="USD">602,444</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-09-30" id="Fact000667" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,489,444</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z46FYoNRRXC5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental Disclosures of Cash Flow Information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SupplementalCashFlowInformationRelatedText_i01B_zoltZGPEZZC" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash paid during the period for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestPaidNet_i02_zvuCxfzdr5G5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0675">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaidNet_i02_z6br9I3l1fN7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0679">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zhScHCuf0rad" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_i01_zR4g7TesPZd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Return and cancellation of shares in lieu of payroll tax withholding</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-09-30" id="Fact000685" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,410</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IssuanceOfCommonStockHeldInAbeyance_i01_z55EN5JdgX95" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Issuance of common stock held in abeyance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:IssuanceOfCommonStockHeldInAbeyance" contextRef="From2025-01-01to2025-09-30" id="Fact000687" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:IssuanceOfCommonStockHeldInAbeyance" contextRef="From2024-01-012024-09-30" id="Fact000688" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ReclassificationOfDeferredOfferingCosts_i01_zGANuhFXH6K4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Reclassification of deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:ReclassificationOfDeferredOfferingCosts" contextRef="From2025-01-01to2025-09-30" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredOfferingCostsIncludedInAccountsPayable_i01_z1Ymua1Nxhv2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Deferred offering costs included in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:DeferredOfferingCostsIncludedInAccountsPayable" contextRef="From2025-01-01to2025-09-30" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,758</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="xdx_047_c20250101__20250930_zlFCEx2uFkCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Y-007"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000696" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zsU4hcvrI9i8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
1 &#8211; <span id="xdx_822_zOFIWkF7PVi9">BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#8220;Stem Pearls&#8221;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#8220;BRT&#8221; or the &#8220;Company&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Business
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#8217;s
website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated
by reference into this Quarterly Report. BRT is currently developing a Disc/Spine Program referred to as &#8220;brtxDISC&#8221;. Its
lead cell therapy candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal
stem cells collected from the patient&#8217;s bone marrow. The product is intended to be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect
to a platform technology utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic
disorders and has labeled this initiative its ThermoStem Program. In addition, in continuation of BRT&#8217;s mission of developing and
commercializing cell-based biologics, it is seeking to develop a biologics-based cosmetic products business. Pursuant to such business,
BRT would formulate, manufacture and sell products designed for cosmetic and aesthetic uses. Further, BRT has licensed a patented curved
needle device that is a needle system designed to deliver cells and/or other therapeutic products or material to the spine and discs
or other potential sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form
10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for
complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring
items) that are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company
as of September 30, 2025 and for the three and nine months then ended. The results of operations for the three and nine months ended
September 30, 2025 are not necessarily indicative of the operating results for the full year ending December 31, 2025 or any other period.
The December 31, 2024 consolidated balance sheet data were derived from audited financial statements but do not include all disclosures
required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and related disclosures of the Company as of December 31, 2024 and for the year then ended, which were filed with
the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 28, 2025 (the &#8220;Form 10-K&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying unaudited condensed consolidated financial statements have been prepared on the basis that the Company will continue as
a going concern, which contemplates realization of assets and satisfying liabilities in the normal course of business. For the nine months
ended September 30, 2025, the Company had a net loss of $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250930_zOfSbFUsKVRj" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000698" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">11.0</ix:nonFraction></span> million, and negative cash flows from operations of $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250930_zLdueRSXo8hc" title="Cash flows from operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000700" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">8.4</ix:nonFraction></span> million, and as
of September 30, 2025, the Company had working capital of $<span id="xdx_90D_ecustom--WorkingCapital_iI_pn5n6_c20250930_zFNA1zhTFMo" title="Working capital"><ix:nonFraction name="BRTX:WorkingCapital" contextRef="AsOf2025-09-30" id="Fact000702" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million. The Company anticipates that it will continue to incur net losses
and negative cash flows from operations as it executes its development plans during 2025 and beyond, as well as other potential strategic
and business development initiatives. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going
concern for at least twelve months after the issuance date of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable
securities and additional infusions of cash from equity and debt financing. During the nine months ended September 30, 2025, the Company
sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdCaEuIrsY41" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">965,424</ix:nonFraction></span> shares of its common stock under its at-the-market offering agreement (the &#8220;2024 ATM&#8221;) with Rodman &amp; Renshaw
LLC (&#8220;Rodman&#8221;) and raised approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPlQGqAjsPsd" title="Gross proceeds from sale of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember" id="Fact000706" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million of gross proceeds. On October 8, 2025, the Company closed on the sale
of an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251008__20251008__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOOexdVmT2li" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-10-082025-10-08_us-gaap_SubsequentEventMember" id="Fact000708" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">678,125</ix:nonFraction></span> shares of its common stock for aggregate gross proceeds of approximately $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjAihl2MxHXb" title="Gross proceeds from sale of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000710" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million. Concurrently, the Company
issued to the investors warrants to purchase an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251008__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwRgmBQVTSx4" title="Warrants purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-10-08_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact000712" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">508,592</ix:nonFraction></span> shares of its common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251008__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWG5Cpl1Q6c5" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-10-08_us-gaap_SubsequentEventMember" id="Fact000714" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.75</ix:nonFraction></span> per share.
See Note 6 &#8211; Subsequent Events for additional details. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable
operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its
development, marketing and promotional activities, which would have a material adverse effect on the Company&#8217;s business, financial
condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate
continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of
business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not
necessarily purport to represent realizable or settlement values. The accompanying unaudited condensed consolidated financial statements
do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000716" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zuAGmzPkV0Bb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
2 &#8211; <span id="xdx_82C_zl0oSPJPiYw">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000718" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zuoYoou5Mad5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reclassifications</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
prior period statements of operations amounts have been reclassified to conform to the Company&#8217;s fiscal 2025 presentation. These
reclassifications have no impact on the Company&#8217;s previously reported net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000720" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zWKRFvYaCgp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Cash
and Cash Equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#8220;FDIC&#8221;) coverage of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20250930_zJD8tEm9PdDb" title="FDIC insured limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-09-30" id="Fact000722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_c20250930_z4MdKwMJTX04" title="Cash in excess of FDIC limit"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2025-09-30" id="Fact000724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,180</ix:nonFraction></span> and
$<span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zox3igVmFcxj" title="Cash in excess of FDIC limit"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact000726" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,801</ix:nonFraction></span> as of September 30, 2025 and December 31, 2024, respectively. As of September 30, 2025, the Company has not experienced losses
on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000728" name="us-gaap:MarketableSecuritiesPolicy"><p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zA8EOTyYL9Ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Investments
Held in Marketable Securities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2025 and December 31, 2024, investments held in marketable securities consists of U.S. Treasury securities held in a
trust account. The Company&#8217;s investments held in the trust account are presented on the unaudited condensed consolidated balance
sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities
are included in interest income in the accompanying unaudited condensed consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000730" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zOKc1nRk6qEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Customer
and Revenue Concentrations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s contract service revenue is derived from one customer. Additionally, all of the Company&#8217;s product sales
revenue is derived from one customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000732" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z0Iff1vBFCL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts
Receivable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of <span style="background-color: white">September
30, 2025 </span>and December 31, 2024, no allowances for credit losses were determined to be necessary. Management estimates the allowance
for credit losses based on existing economic conditions, the financial conditions of the customers, and the amount and age of past due
accounts. Receivables are considered past due if full payment is not received by the contractual due date. Past due accounts are generally
written off against the allowance for credit losses only after all collection attempts have been exhausted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000734" name="us-gaap:DeferredChargesPolicyTextBlock"><p id="xdx_848_eus-gaap--DeferredChargesPolicyTextBlock_zPTZ9bBDS0tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
Contract Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs relate
directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying performance obligations
in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as cost of revenues in the period
when the related revenue is recognized. Deferred contract costs consist of consumables and labor costs and are included in prepaid and
other current assets in the unaudited condensed consolidated balance sheets. The Company had $<span id="xdx_902_eus-gaap--DeferredCosts_iI_c20250930_ztAqpn7wZG9" title="Deferred contract costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2025-09-30" id="Fact000736" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,491</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zlvqQHgH5kek" title="Deferred contract costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31" id="Fact000738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,250</ix:nonFraction></span> deferred contract costs
as of <span style="background-color: white">September 30, 2025 </span>and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000740" name="BRTX:DeferredOfferingCostsPolicyTextBlock"><p id="xdx_842_ecustom--DeferredOfferingCostsPolicyTextBlock_zUPPJ97vXR12" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
Offering Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs, which primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized
as non-current assets on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the
offering proceeds. If the completion of a contemplated financing was no longer probable, the related deferred offering costs would be
charged to general and administrative expense in the unaudited condensed consolidated financial statements. The Company had $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20250930_z4s2RZanSigj" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2025-09-30" id="Fact000742" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,066</ix:nonFraction></span> and
$<span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20241231_zxOLA0MPGa7g" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-12-31" id="Fact000744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,697</ix:nonFraction></span> of deferred offering costs as of <span style="background-color: white">September 30, 2025 </span>and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000746" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zZv6KZulSXol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
Financial Instruments </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated
statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option
pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000748" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zkANa1kvlmrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of <span style="background-color: white">September 30, 2025 </span>and
December 31, 2024, the carrying amount of cash and cash equivalents, investments held in marketable securities, accounts receivable,
and accounts payable approximate their fair value due to the relatively short period of time between their origination and their expected
realization or payment. The warrant liabilities are measured at fair value (see Note 5 &#8211; Fair Value Measurement for additional
details).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000750" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zDWt9x0oUJT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, &#8220;Revenue from Contracts
with Customers&#8221; (&#8220;ASC 606&#8221;). The core principle of ASC 606 requires that an entity recognize revenue to depict the
transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled
in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible
more judgment and estimates may be required within the revenue recognition process, including identifying performance obligations in
the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price
to each separate performance obligation. The Company recognizes revenue primarily from the following different types of contracts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    sales</b> - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty
    revenue</b> - Revenue is recognized as a usage-based royalty from customers&#8217; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#8217;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    reason for the bill-and-hold arrangement is substantive </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    customer has requested the product be warehoused</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product has been identified as separately belonging to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product is currently ready for physical transfer to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company does not have the ability to use the product or direct it to another customer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000752" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zUp6hfR82OB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s revenue recognized in its unaudited condensed consolidated statements of operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_z0f5J2lLd7qj" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250701__20250930_zmrJbKyBvxUd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zDeGk3t9GU94" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250930_zqyeKJkPHFF6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20240930_z6BY4V2rHPqk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zayVoAdXqGSe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-07-012024-09-30_us-gaap_ProductMember" id="Fact000755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-01-012025-09-30_us-gaap_ProductMember" id="Fact000756" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-09-30_us-gaap_ProductMember" id="Fact000757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zSCqOCQLgYXg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-07-012025-09-30_us-gaap_RoyaltyMember" id="Fact000759" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-07-012024-09-30_us-gaap_RoyaltyMember" id="Fact000760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-01-012025-09-30_us-gaap_RoyaltyMember" id="Fact000761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,100</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-09-30_us-gaap_RoyaltyMember" id="Fact000762" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,700</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zuuQYkToU9Ka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-07-012025-09-30" id="Fact000764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-07-012024-09-30" id="Fact000765" format="ixt:numdotdecimal" decimals="0" unitRef="USD">233,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-01-01to2025-09-30" id="Fact000766" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-09-30" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,700</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zjMjD1SO5q28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000769" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z0O1dsrwFqPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss Per Common Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. For the three and nine months ended <span style="background-color: white">September</span>
30, 2025, the Company had <span id="xdx_903_ecustom--SharesHeldInAbeyance_iI_pid_c20250930_z56gNeuQxRLa" title="Shares held in abeyance"><ix:nonFraction name="BRTX:SharesHeldInAbeyance" contextRef="AsOf2025-09-30" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,138,055</ix:nonFraction></span> shares held in abeyance included in basic loss per share given that they are issuable for no additional
consideration. For the three and nine months ended <span style="background-color: white">September</span> 30, 2024, the Company had <span id="xdx_90B_ecustom--SharesHeldInAbeyance_iI_pid_c20240930_zrGTXIJeWwD5" title="Shares held in abeyance"><ix:nonFraction name="BRTX:SharesHeldInAbeyance" contextRef="AsOf2024-09-30" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,201,580</ix:nonFraction></span>
shares held in abeyance included in basic loss per share given that they are issuable for no additional consideration (see Note 4 &#8211;
Stockholders&#8217; Equity for additional details). The dilutive effect, if any, of stock options and warrants are calculated using the
treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning of the period or at the
time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect
to losses, options, warrants, restricted stock units (&#8220;RSUs&#8221;) and convertible preferred stock have been excluded from the
Company&#8217;s computation of diluted net loss per common share for the three and nine months ended <span style="background-color: white">September
30, 2025 </span>and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000775" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zlziMoWXAXQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zOfUfoHaWSgi" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three and Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z0ddViGBv088" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zbwOLXMER4jb" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-07-012025-09-30_us-gaap_EmployeeStockOptionMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,262,973</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zYLGQoxDHrqk" title="Antidilutive shares"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zGzgyZjSdSIg" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,401,608</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOdb46xTIhE6" title="Antidilutive shares"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zMTo0rnFgyg8" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-07-012025-09-30_us-gaap_WarrantMember" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,384</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z7e261Idjqe2" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2gQOA9BOJdi" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-012024-09-30_us-gaap_WarrantMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,952,504</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zoAdP24LL9se" title="Antidilutive shares"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zxbicpBg5Pw7" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-07-012025-09-30_us-gaap_ConvertiblePreferredStockMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-09-30_us-gaap_ConvertiblePreferredStockMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBhtwPFuQYH2" title="Antidilutive shares"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjFYUbw8vdZ1" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-012024-09-30_us-gaap_ConvertiblePreferredStockMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_us-gaap_ConvertiblePreferredStockMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930_zw7VAXrfvgbh" title="Antidilutive shares"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zLSC5ZNyZcJk" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-07-012025-09-30" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-09-30" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,612,515</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930_zU0LwLcMz8y8" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zZuTFrCR4u39" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-012024-09-30" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,752,270</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zJWezSIb5gNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000809" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkl4bVbUTfu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segment
Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20250101__20250930_z6uvo58Te011" title="Number of operating segments"><span id="xdx_90F_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20250101__20250930_zVqE0Gyb38X7" title="Number of reporting segments"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2025-01-01to2025-09-30" id="Fact000811" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-01-01to2025-09-30" id="Fact000813" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">one</ix:nonFraction></ix:nonFraction></span></span> operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#8217;s Chief Executive Officer serves as
the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial performance.
The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated expense
data beyond what is included in the unaudited condensed consolidated statements of operations is not provided to the CODM. Since the
Company&#8217;s operations consist of a single reporting segment, the segment assets are presented on the accompanying unaudited condensed
consolidated balance sheets as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000815" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFqg54WqZt0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Issued Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09
should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of this
update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; (&#8220;ASU 2024-03&#8221;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000817" name="BRTX:TaxLawChangePolicyTextBlock"><p id="xdx_849_ecustom--TaxLawChangePolicyTextBlock_zJjlyrjJprU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
Law Change</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 4th, 2025, the President signed into law significant federal tax legislation, H.R.1 (the &#8220;Tax Reform Act of 2025&#8221;).
The legislation includes numerous changes to U.S. corporate income tax law, including but not limited to: permanent 100% bonus
depreciation for qualified property, immediate expensing of domestic research and experimental expenditures, modifications to the
limitation on business interest expense, increased Section 179 expensing limits, changes to the international tax regime, and
expanded limitations on the deductibility of executive compensation under IRC Section 162(m). Most provisions are effective for tax
years beginning after December 31, 2024, with certain transition rules and exceptions. </span>The Company does not expect the
enactment of the Tax Reform Act of 2025 to have a material impact on its  consolidated financial statements. </p>

</ix:nonNumeric><p id="xdx_857_zj3PHAK8EAmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000819" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_800_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zeyEgGadysl5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
3 - <span id="xdx_82D_zKZw4PePgXI9">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000821" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zIgMfJkz32R9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_z1vUJk1Sfkua" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20250930_zjbaifrt9Od1" style="font-weight: bold; text-align: center">September 30 ,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zzBgOOifDuWf" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALAOLzJ5Y_zQfcVLxZ3IUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">538,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">704,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_z5TEQmTk5Bmb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:AccruedGeneralAndAdministrativeExpenses" contextRef="AsOf2025-09-30" id="Fact000826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,595</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:AccruedGeneralAndAdministrativeExpenses" contextRef="AsOf2024-12-31" id="Fact000827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,485</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtALAOLzJ5Y_zKbjZiqer5me" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">607,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">744,485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zQLHNtTM2Af1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000832" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zHG5tvmySONa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
4 - <span id="xdx_821_zhU25ADtybPh">STOCKHOLDERS&#8217; EQUITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Exercise and Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2024, the Company entered into agreements with certain holders of its existing warrants exercisable for an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx5gSnUYYHZ" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember" id="Fact000834" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span>
shares of its Common Stock (collectively, the &#8220;Existing Warrants&#8221;), to exercise their warrants at a reduced exercise price
of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAtgLyiYvwt2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember" id="Fact000836" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.33</ix:nonFraction></span> per share, in exchange for the issuance of new warrants (the &#8220;New Warrants&#8221;) as described below (the &#8220;Warrant
Exercise and Issuance&#8221;). The aggregate gross proceeds from the exercise of the Existing Warrants and the payment of the New Warrants,
as described below, was approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGq6BKn2nqkc" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember" id="Fact000838" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.1</ix:nonFraction></span> million, before deducting cash issuance costs in the amount of $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZCTpSpST2xl" title="Cash issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,364</ix:nonFraction></span>. The reduction of
the exercise price of the Existing Warrants and the issuance of the New Warrants was structured as an at-market transaction under Nasdaq
rules. Of the <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZGqM0uZWQdb" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember" id="Fact000842" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span> shares of Common Stock underlying the Existing Warrants, <span id="xdx_904_ecustom--SharesHeldInAbeyance_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zDzEd4E6Vyw8" title="Shares held in abeyance"><ix:nonFraction name="BRTX:SharesHeldInAbeyance" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_AuctusFundLLCMember" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,201,580</ix:nonFraction></span> shares issuable to Auctus Fund, LLC (&#8220;Auctus&#8221;)
were held in abeyance as of December 31, 2024, due to Auctus&#8217; maximum beneficial ownership limitation <span style="background-color: white">(the
&#8220;Abeyance Shares&#8221;)</span>. On March 20, 2025, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20250320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zjDxgAVSTwd7" title="Warrants exercisable"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-202025-03-20_us-gaap_CommonStockMember_custom_AuctusFundLLCMember" id="Fact000846" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,525</ix:nonFraction></span> of these shares, reducing the remaining Abeyance
Shares to <span id="xdx_90A_ecustom--SharesHeldInAbeyance_iI_pid_c20250320_zdbB6qiEiMn4" title="Shares held in abeyance"><ix:nonFraction name="BRTX:SharesHeldInAbeyance" contextRef="AsOf2025-03-20" id="Fact000848" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,138,055</ix:nonFraction></span>. As of <span style="background-color: white">September</span> 30, 2025, the Company had issued an aggregate of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Pv2ppO2EI7" title="Shares issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000850" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,213,525</ix:nonFraction></span>
shares of Common Stock. Such Abeyance Shares have been fully paid for and are issuable upon notice from Auctus to the Company. See Note
6 &#8211; Subsequent Events &#8211; for additional details regarding shares issued to Auctus subsequent to September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 6pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of the Existing Warrants for cash and the payment of $<span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWpB6FU3W7G7" title="Warrants for cash and the payment"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact000852" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.125</ix:nonFraction></span> per share underlying the New Warrants,
the exercising holders received the New Warrants to purchase shares of Common Stock in a private placement pursuant to Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The New Warrants will be exercisable for a period of five
years into an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zhVPmr7uhBbe" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact000854" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,513,686</ix:nonFraction></span> shares of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zXqt8vRCbOyj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></span> per share. The securities offered in the private
placement have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company agreed to file
a resale registration statement with the SEC to register the resale of the shares of Common Stock underlying the New Warrants issued
in the private placement. Such resale registration statement was filed and was declared effective by the SEC on April 18, 2024. In connection
with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5, 2024, with
Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which the Company has paid Roth a cash fee of approximately $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240205__20240205__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zFmR4GeV6Rh6" title="Cash fee for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-02-052024-02-05_us-gaap_CommonStockMember_custom_RothCapitalPartnersLLCMember" id="Fact000858" format="ixt:numdotdecimal" decimals="0" unitRef="USD">528,000</ix:nonFraction></span> for
its services, in addition to reimbursement for certain expense. During the nine months ended <span style="background-color: white">September</span>
30, 2024, the Company incurred an aggregate of $<span id="xdx_90A_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zCgxSb4KVd5h" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,364</ix:nonFraction></span> of cash issuance costs related to the Warrant Exercise and Issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Prior
to the Warrant Exercise and Issuance, the Existing Warrants were classified as derivative liabilities. Additionally, the Company analyzed
the form of the New Warrants and determined that they should be classified as derivative liabilities</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
accordance with ASC 815-40, Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity. Under the New Warrants, the Company
does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the New Warrants and
not result in a change of control of the Company. As a result, such New Warrants do not meet the criteria for equity treatment. Additionally,
certain New Warrants contain adjustments to the settlement amount based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221;
option as defined under ASC 815-40 and, accordingly, such New Warrants are not considered indexed to the Company&#8217;s own stock and
are not eligible for an exception from derivative accounting. <span style="background-color: white">See Note 5 &#8211; Fair Value Measurement
for details regarding the valuation of warrants accounted for as derivative liabilities.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">See
Note 5 &#8211; Fair Value of Financial Instruments for details regarding the valuation of warrants accounted for as derivative liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000862" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zo19fZvsrdp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s warrant activity and related information follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zZ3PlS8QnNqe" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zULU5j9OkiMg" title="Number of Warrants Outstanding, Beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000864" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDQmWH9JHqqe" title="Weighted Average Exercise Price, Beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.22</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znMqdO0blV22" title="Number of Warrants, Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember20509593" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJvBG1DUXmO2" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember20509593" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy0i7C8bnsd7" title="Number of Warrants Outstanding, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,384</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKtxZKhWUYia" title="Weighted Average Exercise Price, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.21</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJq4qX3eMsTb" title="Weighted Average Remaining Life In Years, Outstanding"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember20509593" format="ixt-sec:duryear" id="Fact000876" name="BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.55</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRx5Q2Zfx1zh" title="Number of Warrants, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,384</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIJFLzpYIhEc" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.21</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7joyKclZvt3" title="Weighted Average Remaining Life In Years, Exercisable"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember20509593" format="ixt-sec:duryear" id="Fact000882" name="BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1">2.55</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_za5lKfk8sxSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2025, the Company granted options to purchase an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zGPLhmcTQmWj" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-02-142025-02-14_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,152,908</ix:nonFraction></span> shares of the Company&#8217;s common stock at an
exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlj9v5UYoXb2" title="Exercise price of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-02-142025-02-14_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></span> per share to employees, the Company&#8217;s board of directors and a member of the Company&#8217;s Scientific
Advisory Board. The options had an aggregate grant date fair value of $<span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWQIcTolxNzg" title="Grant date fair value of options granted"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2025-02-142025-02-14_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact000888" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,044,250</ix:nonFraction></span> and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zBVsBX5FSfXa" title="Vesting of options description"><ix:nonNumeric contextRef="From2025-02-142025-02-14_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact000890" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vest as follows: (i) options to purchase an aggregate
323,459 shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of 1,829,449 shares of common stock
vest to the extent of 50% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant.</ix:nonNumeric></span>
The Company is recognizing the grant date fair value of the options on a straight-line basis over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 5, 2025, the Company granted an option to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0ZuBXJ7t5ne" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-06-052025-06-05_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zimgpjmGrocl" title="Exercise price of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-06-052025-06-05_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.78</ix:nonFraction></span>
per share to an employee. The option had a grant date fair value of $<span id="xdx_90E_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNV5n0akZLDa" title="Grant date fair value of options granted"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2025-06-052025-06-05_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact000896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,250</ix:nonFraction></span> and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQzCyRduK3gk" title="Vesting of options description"><ix:nonNumeric contextRef="From2025-06-052025-06-05_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact000898" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vests to the extent of 50% immediately with the remainder
vesting quarterly over two years commencing one year from the date of grant.</ix:nonNumeric></span> The Company is recognizing the grant date fair value of
the option on a straight-line basis over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2025, the Company granted an option to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpoibAmWqss3" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock at an exercise price of
$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuL7CY8ZzLY8" title="Exercise price of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.62</ix:nonFraction></span> per share to an employee. See Note 6 &#8211; Subsequent Events for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000904" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znYuBL1ziLZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_z1wWVGt9vlj2" style="display: none">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z37XMit7f4ka" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" id="Fact000906" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.03</ix:nonFraction></span> - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxfdSV77vPHc" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.40</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zz2zKecFH9Ic" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.14</ix:nonFraction></span> - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zy4srh72s6Ag" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.30</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zw2WookFhCm4" title="Expected term (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000914" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.77</ix:nonNumeric></span> - <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziuM2v5u7cOj" title="Expected term (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000916" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.38</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjyJG6PA6aS9" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000918" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.77</ix:nonNumeric></span> - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zQR6mDHTPdJi" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000920" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.38</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zoRgnEW4J5qk" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">98.14</ix:nonFraction></span> - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zgMcQ5QsoGw9" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" id="Fact000924" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">99.22</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_ze1M3w366Qp5" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" id="Fact000926" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101</ix:nonFraction></span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziXN0JVmgKc5" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" id="Fact000928" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">102</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Expected dividends</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHhTEVNeZJ58" style="width: 18%; text-align: center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact000929" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction>%</td><td style="width: 1%; text-align: left"/><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaogLqcGvEN" title="Expected dividends" style="width: 18%; text-align: center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember20509859" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction>%</td><td style="width: 1%; text-align: left"/></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z4yJkz1L6Zk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_do_c20250701__20250930_zaJ7QgaILCP3" title="Weighted average grant date fair value of stock options granted"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_do_c20240701__20240930_zLmTZh77Jbza" title="Weighted average grant date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-07-012025-09-30" id="Fact000933" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-07-012024-09-30" id="Fact000935" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> stock options granted during the three months ended September 30, 2025 or 2024. Options granted during the nine months ended
<span style="background-color: white">September</span> 30, 2025 and 2024 had a weighted average grant date fair value per share of <span style="background-color: white">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250930_zxPzPvInIHY" title="Weighted average grant date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-01to2025-09-30" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.87</ix:nonFraction></span>
</span>and $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zWohCJHGjAC5" title="Weighted average grant date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-09-30" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction></span> per share, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000941" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWv2M3qYRMph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity during the nine months ended <span style="background-color: white">September 30, 2025 </span>is
presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zlBKQWNVMBRg" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding, January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhd1fbMc1OAf" title="Number of Options, Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000943" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,263,467</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyqcbmh3G9A4" title="Weighted Average Exercise Price, Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.63</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYJikieUBiU1" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact000947" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,177,908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Utpi7z1E8a" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #0D0D0D">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcjxWNpZEXC2" title="Number of Options, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,249</ix:nonFraction></td><td style="text-align: left">)</td><td style="color: #0D0D0D">&#160;</td>
    <td style="color: #0D0D0D; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4LZRf2tNRW8" title="Weighted Average Exercise Price, Exercised" style="color: #0D0D0D; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.45</ix:nonFraction></td><td style="color: #0D0D0D; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbFGtbkRLn" title="Number of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,153</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY5MaYv8AMn1" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.23</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMyvapoNh9d" title="Number of Options, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,262,973</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNC1OSsrXyf" title="Weighted Average Exercise Price, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.58</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlT9rvVz6pDg" title="Weighted Average Remaining Life in Years, Outstanding"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" format="ixt-sec:duryear" id="Fact000963" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.8</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4ggKcamAFA8" title="Intrinsic Value, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxCRQYm4YeMc" title="Number of Options, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,805,964</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1EzeOBaB595" title="Weighted Average Exercise Price Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCLZZ4ZLn9q8" title="Weighted Average Remaining Life in Years, Exercisable"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" format="ixt-sec:duryear" id="Fact000971" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.3</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zy6EeZ7DMJXi" title="Intrinsic Value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zcOQfjQkTMcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<ix:exclude><!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000975" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zSDcZLOPTYXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B2_zKoGZ1kN5cRa" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250701__20250930_zdcPCx4xRGV3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240701__20240930_zLNJc59cbcLh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250930_zsq10U8gkd72" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20240930_zLqIBApcfsX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrecognized at</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average Remaining Amortization</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"> Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJ3sW3wPgOJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact000977" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,398</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact000978" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,333</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact000979" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,308,322</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact000980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,314,298</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYpkGCwTTDmi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact000982" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,535</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact000983" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,912</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact000984" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,569,444</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact000985" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,322,643</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_ztRikAHkmre9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30" id="Fact000987" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30" id="Fact000988" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000989" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,877,766</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30" id="Fact000990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,636,941</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20250930_zQSnElFKLth" title="Unrecognized expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2025-09-30" id="Fact000992" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,878,612</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930_zyXAPbw3kbTa" title="Weighted average remaining amortization period (years)"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:duryear" id="Fact000994" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.76</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zgACj4pdDPxa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30" id="Fact000996" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30" id="Fact000997" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000998" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,877,766</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30" id="Fact000999" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,636,941</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20250930_z5a460ZK7FN7" title="Unrecognized expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2025-09-30" id="Fact001001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,878,612</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930_zjo2gjtyVdXi" title="Weighted average remaining amortization period (years)"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:duryear" id="Fact001003" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.76</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A2_zFjpcsrR5B6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001005" name="BRTX:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock_zsBI1ipxGnoh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents stock-based compensation by award type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span id="xdx_8B9_zvDA3KujAUgd" style="display: none">SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250701__20250930_z6ZTqHehz6Vi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240701__20240930_zn2OOoEhzk98" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20250930_zFXjSdEXksPb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_zTjmJ2NseNQ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV3WJPGewlZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30_us-gaap_EmployeeStockOptionMember20510484" id="Fact001007" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,932</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember20510484" id="Fact001008" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,245</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact001009" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,877,766</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember20509859" id="Fact001010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,651,903</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zd3IddrYGPx2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">RSUs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001015" format="ixt:numdotdecimal" decimals="0" unitRef="USD">985,038</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_z91a9z3GNKxg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30" id="Fact001017" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30" id="Fact001018" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-09-30" id="Fact001019" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,877,766</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30" id="Fact001020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,636,941</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zp3s2uAPl9o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ATM
Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025, there were <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_do_c20250701__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL1oEMYxf3bk" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember" id="Fact001022" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> sales of common stock under the 2024 ATM. During the nine months ended September
30, 2025, the Company sold <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztj50j89INd7" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember" id="Fact001024" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">965,424</ix:nonFraction></span> shares of its common stock under the 2024 ATM, generating gross proceeds of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0o9TgpNyNj4" title="Gross proceeds from shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember" id="Fact001026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,011,250</ix:nonFraction></span>. For the nine
months ended September 30, 2025, the total commissions and related legal and accounting fees incurred were $<span id="xdx_904_ecustom--PaymentsForCommissionsLegalAndAccountingFees_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcd44cifUHC4" title="Commissions, legal and accounting fees"><ix:nonFraction name="BRTX:PaymentsForCommissionsLegalAndAccountingFees" contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember" id="Fact001028" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,805</ix:nonFraction></span>, resulting in net
proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMoj4wiTQdof" title="Net proceeds from shares sold"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember" id="Fact001030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,938,445</ix:nonFraction></span>. During the nine months ended September 30, 2025, the Company reclassified previously capitalized deferred offering
costs of $<span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20250101__20250930_zHf4xVAtpgtl" title="Deferred offering costs reclassified to additional paid-in capital"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2025-01-01to2025-09-30" id="Fact001032" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,697</ix:nonFraction></span> to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Repurchase Program</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2025, the Company&#8217;s Board of Directors authorized a common stock repurchase program under which the Company may repurchase
up to $<span id="xdx_90F_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20250616__20250616__srt--TitleOfIndividualAxis__custom--BoardOfDirectorMember__srt--RangeAxis__srt--MinimumMember_zcltBrP2zzyl" title="Repurchase of common stock"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2025-06-162025-06-16_custom_BoardOfDirectorMember_srt_MinimumMember" id="Fact001034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> of its outstanding common stock through June 16, 2026. <span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfCommonStock_do_c20250930__20250930_zVnjpa6GnRNa" title="Repurchase of common stock"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2025-09-302025-09-30" id="Fact001036" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></span> repurchases have been made as of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Issuances</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025, there were <span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesAbeyanceShares_do_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKFJ7f2cOdH9" title="Abeyance shares issued"><ix:nonFraction name="BRTX:StockIssuedDuringPeriodSharesAbeyanceShares" contextRef="From2025-07-012025-09-30_custom_AuctusFundLLCMember_us-gaap_CommonStockMember" id="Fact001038" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> issuances of common stock by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2025, the Company issued <span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesAbeyanceShares_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8WVx7DEr5j2" title="Abeyance shares issued"><ix:nonFraction name="BRTX:StockIssuedDuringPeriodSharesAbeyanceShares" contextRef="From2025-01-012025-09-30_custom_AuctusFundLLCMember_us-gaap_CommonStockMember" id="Fact001040" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,525</ix:nonFraction></span> shares of common stock to Auctus Fund, LLC in partial satisfaction
of shares held in abeyance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2025, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztYvkBJs1qg4" title="Shares issued upon exercise of options"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,249</ix:nonFraction></span> shares of common stock related to the exercise of an option at an
exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU4nhYmNIsRh" title="Exercise price of options exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact001044" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.45</ix:nonFraction></span> per share, which resulted in gross cash proceeds to the Company of $<span id="xdx_903_eus-gaap--ProceedsFromStockOptionsExercised_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHs8DohRpmCl" title="Gross proceeds from exercise of options"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593" id="Fact001046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,411</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001048" name="us-gaap:FinancialInstrumentsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zWIei0oZrkef" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
5 &#8211; <span id="xdx_825_zVWiYOnlMsV5">FAIR VALUE MEASUREMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2025 and December 31, 2024, the Company estimated the aggregate fair value of warrants that are accounted for as warrant
liabilities to be $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJcqWDj8PgBd" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-09-302025-09-30_us-gaap_WarrantMember" id="Fact001050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,968,315</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20241231__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAEe4M7r7e25" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-12-312024-12-31_us-gaap_WarrantMember" id="Fact001052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></span>, respectively, using the Black-Scholes option price model (Level 3 inputs). The Company recognized
a gain on the change in fair value of these warrant liabilities of $<span id="xdx_901_eus-gaap--DerivativeGainLossOnDerivativeNet_c20250701__20250930_z30hwbndc2y6" title="Change in fair value of warrant liability"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-07-012025-09-30" id="Fact001054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">612,064</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--DerivativeGainLossOnDerivativeNet_c20250101__20250930_zvlwGBvcD9K3" title="Change in fair value of warrant liability"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-01-01to2025-09-30" id="Fact001056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552,536</ix:nonFraction></span> for the three and nine months ended September
30, 2025, respectively. The Company recognized a gain (loss) on the change in fair value of these warrant liabilities of $<span id="xdx_90E_eus-gaap--DerivativeGainLossOnDerivativeNet_c20240701__20240930_zYATYdoL83V1" title="Change in fair value of warrant liability"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-07-012024-09-30" id="Fact001058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,036,464</ix:nonFraction></span> and
<span id="xdx_90E_eus-gaap--DerivativeGainLossOnDerivativeNet_c20240101__20240930_zmWrjebF3sBf" title="Change in fair value of warrant liability">($<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-09-30" id="Fact001060" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">837,466</ix:nonFraction>)</span> for the three and nine months ended September 30, 2024, respectively. The following table shows the detail of the valuation
assumptions used as of September 30, 2025:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001062" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zYbR150SpqHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zcgeC8MqrZ5" style="display: none">SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zxEA6d76kmYb" title="Risk free interest rate, minimum"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001064" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.63</ix:nonFraction></span>%-<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2LyC3yTSKN2" title="Risk free interest rate, maximum"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.68</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zEjOyYzWXZL1" title="Expected term (years)"><ix:nonNumeric contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_us-gaap_WarrantMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001068" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.11</ix:nonNumeric></span> - <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zs74j345MWhg" title="Expected term (years)"><ix:nonNumeric contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_us-gaap_WarrantMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001070" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.36</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zChsDNjScRgl" title="Risk free interest rate, minimum"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001072" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">71</ix:nonFraction></span>% - <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zNNZYtdpL4bk" title="Risk free interest rate, maximum"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001074" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">95</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Expected dividends</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: center"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znlFqfExj7h4" title="Fair value measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_WarrantMember" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span>%</td><td style="width: 1%; text-align: left"/></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zRfP3IV2E5k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: left; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001078" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z0molxKWjZA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span id="xdx_8B7_z9xuaMvT1xX2" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the three months ended September 30, 2025 and three months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250701__20250930_zeCR0vBVgfgi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240701__20240930_zYoNyQCUs5b5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilitiesCurrent_iS_zxmARxdlRPSa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance, July 1,</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact001080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,580,379</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact001081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,491,969</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfWarrants_zmQMZLHyGDHg" style="display: none; vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Issuance of warrants</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ProceedsFromWarrantExercises_zdS9hwqjGvhf" style="display: none; vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Exercise of warrants</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zqccaL1gKsq8" style="vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-07-012025-09-30" id="Fact001089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">612,064</ix:nonFraction></td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">)</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-07-012024-09-30" id="Fact001090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,036,464</ix:nonFraction></td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DerivativeLiabilitiesCurrent_iE_zPCfqZ6CcHFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, September 30,</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact001092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,968,315</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact001093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,455,505</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the nine months ended September 30, 2025 and nine months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20250930_zyDniDIA96xf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20240930_z1eIEDR8hka7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DerivativesLiabilities_iS_zDuXqE4pQ9I1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance, January 1,</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="BRTX:DerivativesLiabilities" contextRef="AsOf2024-12-31" id="Fact001095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="BRTX:DerivativesLiabilities" contextRef="AsOf2023-12-31" id="Fact001096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,618,039</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zOrza3ZtG34b" style="vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-01-01to2025-09-30" id="Fact001098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552,536</ix:nonFraction></td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">)</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-09-30" id="Fact001099" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">837,466</ix:nonFraction></td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DerivativesLiabilities_iE_zf8kCHzACY72" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, September 30,</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:DerivativesLiabilities" contextRef="AsOf2025-09-30" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,968,315</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:DerivativesLiabilities" contextRef="AsOf2024-09-30" id="Fact001102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,455,505</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_ze9GaU9FQCCj" style="margin-top: 0; margin-bottom: 0">&#160;</p>




<ix:exclude><!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001104" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zJgEq6fVipC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities measured at fair value on a recurring basis are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BE_z9AJ9ruwatC" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%">Marketable securities as of September 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx0XRgOrIwVj" title="Marketable securities, fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member" id="Fact001106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,887,383</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXy6QSa4CiKj" title="Marketable securities, fair value" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAfGqdOs7p1c" title="Marketable securities, fair value" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250930_zDJYVBVmVbjk" title="Marketable securities, fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-09-30" id="Fact001112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,887,383</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsnvRgnScII4" title="Marketable securities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,184,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXWj3LcyLswf" title="Marketable securities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIV6QKf55UAg" title="Marketable securities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20241231_z2kNUxQuWnph" title="Marketable securities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31" id="Fact001120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,184,701</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant liabilities as of September 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zlbrjHmcywRe" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNRVZ9KTxIxe" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdIugE6kW3E7" title="Warrant liabilities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member" id="Fact001126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,968,315</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930_zRmBTjm57Jcc" title="Warrant liabilities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-09-30" id="Fact001128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,968,315</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrant liabilities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXF2LovcwaF1" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl1rAwhJDX96" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1132">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDK5hyhn8tm4" title="Warrant liabilities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231_zPIjIUPYLfFk" title="Warrant liabilities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31" id="Fact001136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zeUnMi7Tq9Q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001138" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_znPakqqd9Om6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
6 &#8211; <span id="xdx_821_z4TzsZfGHP7e">SUBSEQUENT EVENTS</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registered
Offering and Private Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2025, the Company entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with several investors
(the &#8220;Purchasers&#8221;) pursuant to which the Company agreed to sell and issue to the Purchasers an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251006__20251006__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlzNCmTpDIOh" title="Sold shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-10-062025-10-06_us-gaap_CommonStockMember_custom_SubscriptionAgreementsMember_us-gaap_SubsequentEventMember" id="Fact001140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">678,125</ix:nonFraction></span> shares
of the Company&#8217;s common stock in a registered direct offering at an offering price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQmPGfkniFB3" title="Offering price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-10-06_us-gaap_SubsequentEventMember_custom_SubscriptionAgreementsMember_us-gaap_CommonStockMember" id="Fact001142" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.60</ix:nonFraction></span> per share (the &#8220;Registered Offering&#8221;)
for aggregate gross proceeds of approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20251006__20251006__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zQJfYMcLg6A6" title="Gross proceeds from sale of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-10-062025-10-06_us-gaap_CommonStockMember_custom_SubscriptionAgreementsMember_us-gaap_SubsequentEventMember" id="Fact001144" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million. Pursuant to the Subscription Agreements, in a concurrent private placement
offering (the &#8220;Private Placement&#8221;), the Company agreed to issue to the Purchasers unregistered warrants to purchase up to
an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251006__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zrbksF93MJw3" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-10-06_us-gaap_SubsequentEventMember_custom_SubscriptionAgreementsMember_us-gaap_CommonStockMember" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">508,592</ix:nonFraction></span> shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPb5B4OeqpL6" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-10-06_us-gaap_SubsequentEventMember" id="Fact001148" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.75</ix:nonFraction></span> per share. The Registered Offering and
the Private Placement closed on October 8, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SaleOfStockDescriptionOfTransaction_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkCj8neueAD8" title="Description on sale of stock"><ix:nonNumeric contextRef="From2025-10-062025-10-06_us-gaap_SubsequentEventMember" id="Fact001150" name="us-gaap:SaleOfStockDescriptionOfTransaction">In
connection with the offering, the Company entered into an engagement letter, dated August 11, 2025, with Alere Financial Partners (a
division of Cova Capital Partners, LLC) (the &#8220;Placement Agent&#8221;), pursuant to which the Company agreed to pay the Placement
Agent a cash fee equal to 6% of the gross proceeds of the offering from investors introduced to the Company by the Placement Agent (the
&#8220;Placement Agent Investors&#8221;) (4% for other investors).</ix:nonNumeric></span> The Company has also agreed to reimburse the Placement Agent approximately
$<span id="xdx_908_ecustom--LegalFeesAndOtherExpenses_c20250811__20250811_z4Ue4YpUWl03" title="Legal fees and other expenses"><ix:nonFraction name="BRTX:LegalFeesAndOtherExpenses" contextRef="From2025-08-112025-08-11" id="Fact001152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,300</ix:nonFraction></span> for out-of-pocket expenses for legal fees and other expenses. In addition, the Company agreed to issue to the Placement Agent,
at the closing of the offering, a warrant exercisable commencing six months from the date of issuance until the five year anniversary
of the date of issuance to purchase up to 6% of the number of Shares sold in the Registered Offering to Placement Agent Investors (4%
for other investors), at a per share exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkv2vIYEvaBg" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-10-06_us-gaap_SubsequentEventMember" id="Fact001154" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.75</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Grants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2025, the Company granted an option to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zam1vFGvqj64" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock at an exercise price of
$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6s4OO6iNKok" title="Exercise price of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.62</ix:nonFraction></span> per share to an employee. The option <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zORSOjGXk9u9" title="Vesting of options description"><ix:nonNumeric contextRef="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember" id="Fact001160" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vests as follows: (i) 50% immediately, and (ii) the remainder quarterly over two years commencing
one year from the date of grant.</ix:nonNumeric></span> The Company will recognize the grant date fair value of the option on a straight-line basis over vesting
period.<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 27, 2025, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251027__20251027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zgQcx7pN8rN3" title="Number of shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-10-272025-10-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">220,000</ix:nonFraction></span> shares of common stock to Auctus Fund, LLC in partial satisfaction of shares held by abeyance.</span></p>

</ix:nonNumeric><p id="xdx_817_zJI44LgvgJTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aud_001"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of BioRestorative Therapies, Inc. (the &#8220;Company&#8221;) as of December
31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#8217; equity and cash flows for each of
the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024,
in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory
Paragraph &#8211; Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described
in Note 1, the Company has incurred significant losses and negative cash flows from operations, and needs to raise additional funds to
meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue
as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum LLP</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<span style="font-variant: small-caps">llp</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2020<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marlton,
New Jersey <b><br/>
</b>March 27, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_zTlmgg8rlL62" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zRnHsXd3yrQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zUEVmUdVKkyc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zDSsPwnj9rXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_ze0DUS58I7xh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_zIsVcp6tIK94" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact001170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,890</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact001171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,377</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--MarketableSecuritiesCurrent_i02I_zSfM6hVk6tl7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Investments held in marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-12-31" id="Fact001173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,184,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact001174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,181,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccountsReceivableNetCurrent_i02I_zYBOotSdRY2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="Fact001176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact001177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_zCvSPnljiWd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact001179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,230</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact001180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">305,231</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_zG9OiJ1e9hud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact001182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,144,221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact001183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,390,526</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredOfferingCost_i01I_zZHtJpRnTC9l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:DeferredOfferingCost" contextRef="AsOf2024-12-31" id="Fact001185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_i01I_zcTCtlHB3XFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact001188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,936</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zZYqEvXNowva" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1191">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_zzm75izBhAZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact001194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623,945</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact001195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">713,692</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_zngxqCEV6Vmj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact001197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,279,799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact001198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,611,720</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zt1rUKRiO51" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_z10K0Vup0Jy" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_zLV9TidhvRvk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact001206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">483,070</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact001207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,389</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_i02I_zguHfFRj0nn3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">744,485</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_zFbMpNtOf0b2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact001213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_i02I_z3ynHxm0Z8n4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,953</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i02TI_zSI52QEDHsK1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left">Total Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,748,406</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,607,345</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Liabilities_i01TI_zu7rqfshcSlf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact001221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,748,406</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact001222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,607,345</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CommitmentsAndContingencies_i01I_z4MrZ2KN0bCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1224">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockholdersEquityAbstract_i01B_zWYM1UKzKJ76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Preferred stock, $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zDNpUwygRo96" title="Preferred stock, par value"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zrIr3SmvVRNa" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact001230" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact001232" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zKdbU8aGSSt9" title="Preferred stock, shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zMzKIZylfd7k" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001236" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zoj4csIwMbfd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Series B Convertible Preferred Stock; <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zN8SuJv6KtX3" title="Preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zH6fgkv6TVDh" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact001241" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></ix:nonFraction></span></span> shares designated, <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zA825q7V8Fa" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zJxEfqM41Gha" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zKMET9bPze25" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zydQGuNWewM7" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact001247" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and
    outstanding at December 31, 2024 and 2023.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact001238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact001239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockValue_i02I_zJEQb0jj5mKk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Preferred
    stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="Fact001253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="Fact001254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--CommonStockValue_i02I_z27P8Tdmel24" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_zFm0V3LTdr23" title="Common stock, par value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zL7OOj1B52Je" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact001259" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact001261" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_z2d75Oj11Boi" title="Common stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zQ87Ire8gRQl" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20241231_zcbBZiwlpngb" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z5HONaabprKa" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001269" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20231231_zyLgarnuuFh2" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zK5FEWlcjvR" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact001271" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001273" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,706,917</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December
    31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact001256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact001257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">471</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_i02I_zgZXv50hh5W" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact001275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,195,434</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact001276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,689,256</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_zDwaHNq3HgP1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact001278" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,678,715</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact001279" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">146,699,334</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_zrNVCejLyIF9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact001281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,531,393</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact001282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,004,375</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_zIbITQeBGJE" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact001284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,279,799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact001285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,611,720</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_113_z5SAAYIHzMKl" summary="xdx: Statement - Condensed Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zWAXQb9ZXtph" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zSd3HTxBuaEf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zAXOLrirVB3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left">Revenues, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31" id="Fact001287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact001288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfGoodsAndServicesSold_zCIHruxpqTn9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-01-012024-12-31" id="Fact001290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,072</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GrossProfit_iT_z5mKbe4QfMoh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-012024-12-31" id="Fact001293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,928</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31" id="Fact001294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_zBj1zYDdC85k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_zeRDgHsxW3De" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact001299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,348,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact001300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,034,591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_i01_zpJECGZZTaA4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact001302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,579,413</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact001303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,331,983</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_i01T_zuiggmIKIeJe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31" id="Fact001305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,928,122</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact001306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,366,574</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_iT_zXWbLsoVLcz8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Loss From Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001308" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,555,194</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001309" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,220,774</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z0YwF9Li7o34" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other Income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestIncomeExpenseNet_i01_zwLJxGP5x38g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-012024-12-31" id="Fact001314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">616,077</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-12-31" id="Fact001315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552,293</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--GrantIncome_i01_zC4jPAs92Eql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Grant income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:GrantIncome" contextRef="From2023-01-012023-12-31" id="Fact001318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherNonoperatingIncomeExpense_i01_zRIDBK3lR2Di" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact001320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact001321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,664</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--GainLossOnExchangeOfWarrants_i01_zLl824sIrUjf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on exchange of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2024-01-012024-12-31" id="Fact001323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,698</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_zRGQV72xAoXg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-12-31" id="Fact001326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact001327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,997,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_i01T_zHS6pJyUSrcf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Other Income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact001329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,575,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact001330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,803,070</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_zKAssgOzOi7b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001332" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,979,381</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001333" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,417,704</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_zx7lZSohTgp9" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zLj6LcJouhig" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.16</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zPLGKuYYSvC4" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zZRmyr5CTU22" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact001339" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact001341" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.47</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Weighted Average Common Shares Outstanding - Basic and
    Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_za8Cmo1ZWCye" title="Weighted Average Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_zXS19XgulEe4" title="Weighted Average Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31" id="Fact001343" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31" id="Fact001345" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,763,932</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zMigcXFGyzpe" title="Weighted Average Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_z3lQfJevERSa" title="Weighted Average Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact001347" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,218,347</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_004"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED DECEMBER 31, 2024 AND 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_114_zzpGTYBV219c" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesBConvertiblePreferredStockMember_zCWtvGLnERYa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z11Oq97jYAJ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z1rfTKea0u64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zxnmAzKkmWI3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_zJtSgYde18Ea" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Series B Convertible</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_431_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zrYq7BMo5aF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; font-weight: bold">Balance - January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z6HzOyv4WxBi" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001357" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518,158</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,182</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znJLm3vMxCnb" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,677,775</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001352" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,556,418</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact001354" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">136,281,630</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact001355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,290,339</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodSharebasedCompensationAbstract_iB_z2DhzwOPs6l3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i01_zV7JzU6iTTq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Restricted share units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1367">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_i01_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zffQnoPFWndd" title="Restricted share units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001373" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,633,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31" id="Fact001371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,633,664</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_i01_z4BE4HMD7nNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1375">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,141,803</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1378">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact001379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,141,803</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_i01_zMrncSKXz0rk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1381">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD9oR1aXO9zh" title="Common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001387" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1384">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact001385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zlJhyCxMpRP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of Series B Convertible Preferred Stock into common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zZkB2halxbAc" title="Conversion of Series B Convertible Preferred Stock into common stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001395" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">120,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001389" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,200</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhuTJ0UAr6J5" title="Conversion of Series B Convertible Preferred Stock into common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001397" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1392">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1393">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zDiUd7SVTk71" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance and sale of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1399">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFGeLQJ8sOH9" title="Issuance and sale of common stock, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">817,860</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001401" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,348,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1402">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact001403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,348,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_z8xDBTopIfc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1407">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1409">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact001410" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,417,704</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001411" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,417,704</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zKAKi9vhRKk1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance - December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z5omHEyqboh6" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001419" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znofUx98zZZ" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001421" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,706,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">471</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,689,256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact001416" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">146,699,334</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact001417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,004,375</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zn3dL5AxdHd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zKjqErvyBoJk" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001429" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ3U6n8CBsLl" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001431" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,706,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">471</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,689,256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact001426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">146,699,334</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact001427" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,004,375</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueOther_zExUNccJBOji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued in connection with warrant exchange <span id="xdx_F4C_zO0cSBHnFjw3">[1]</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1433">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fWzFd_zwPXlgsagB8" title="Common stock issued in connection with warrant exchange, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001439" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,742,043</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1436">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31" id="Fact001437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,742,243</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_zFxlw1UkW3Zh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Return and cancellation of shares in lieu of payroll tax withholding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1441">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNHyvgeOVwid" title="Return and cancellation of shares in lieu of payroll tax withholding, shares" style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001447" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">34,825</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001442" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001443" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,406</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1444">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-12-31" id="Fact001445" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,410</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_zItgwfjgCFpc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued in connection with abeyance shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1449">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWcIRga4e3Tg" title="Common stock issued in connection with abeyance shares, shares" style="text-align: right"><ix:nonFraction name="BRTX:StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001455" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001451" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1452">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1453">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodSharebasedCompensationAbstract_iB_z1IfqdkKB1R" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i01_zyYrmdUCZFwc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Restricted share units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1463">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_i01_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZXBSFl6l1Dc" title="Restricted share units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001469" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">985,028</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1466">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31" id="Fact001467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">985,038</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_i01_zkfNBgnXCrd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1471">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1472">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827,528</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1474">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact001475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827,528</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zlC0xEuLjEf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1477">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1478">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1479">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact001480" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,979,381</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001481" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,979,381</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zkN8cQHR5G5l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zPq9ihANYwG7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001489" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRbgdjEOLUTi" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001491" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,195,434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact001486" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,678,715</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact001487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,531,393</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zrC65x1lKA65" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zHGxLKNXCn09" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001499" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztGDk9tm3rI7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001501" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001494" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,195,434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact001496" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,678,715</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact001497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,531,393</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F07_zxTxnGYXRYGl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[1]</span></td><td style="text-align: justify"><span id="xdx_F1A_zBpz89dKwW8k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001502" xml:lang="en-US">Represents the
aggregate fair value of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpPD4xdmm3mj" title="Aggregate fair value of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001504" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span> shares of common stock, which includes <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5nhgzoqroak" title="Warrants exercisable" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,150,000</ix:nonFraction></span> shares that have been issued and <span id="xdx_90E_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zQNmiOi5AQNa" title="Shares held in abeyance" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="BRTX:SharesHeldInAbeyance" contextRef="AsOf2024-12-31" id="Fact001508" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,201,580</ix:nonFraction></span> shares
held in abeyance. See Note 6 - Stockholders&#8217; Equity - Warrant Exercise and Issuance and Note 9 - Fair Value Measurement for additional
details.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_005"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_112_ziMkAVHcTAp1" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zHJEwn56X6L4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_z6h0uZN4ZNhi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zECibvoL6D8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_zmUPMJtnJlug" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001513" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,979,381</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001514" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,417,704</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zRw9CvelFmgf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DepreciationAndAmortization_i02_z0piTetiiVsk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-012024-12-31" id="Fact001519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact001520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,735</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestAndDividendIncomeOperating_i02N_di_z15eAeINU0k6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Dividend and interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2024-01-012024-12-31" id="Fact001522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623,801</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2023-01-012023-12-31" id="Fact001523" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,068</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_i02_z3b1AjU6Zdfd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact001525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,812,566</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact001526" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,782,967</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--NoncashLeaseExpense_i02_zEkVfCgZ0hF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:NoncashLeaseExpense" contextRef="From2024-01-012024-12-31" id="Fact001528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:NoncashLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact001529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--GainLossOnExchangeOfWarrants_i02N_di_zfrP1hwTHnUi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain on exchange of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2024-01-012024-12-31" id="Fact001531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,698</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1532">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_zfPWMNsTGuUk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-12-31" id="Fact001534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,188</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact001535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,997,780</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zVlOLHMTHrC3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_z0fGvENQrcN" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-012024-12-31" id="Fact001540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,100</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-12-31" id="Fact001541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_znNur52Lj3Bb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-12-31" id="Fact001543" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,591</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact001544" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,851</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_zeLqTxWhqw16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-012024-12-31" id="Fact001546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293,680</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact001547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,487</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i03_z8Ny9uxDO9Zi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2024-01-012024-12-31" id="Fact001549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,799</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2023-01-012023-12-31" id="Fact001550" format="ixt:numdotdecimal" decimals="0" unitRef="USD">581,616</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_z76CGT997BFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-12-31" id="Fact001552" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">162,317</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact001553" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">139,328</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_zPUjLZhYPaCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used In Operating Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact001555" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,230,346</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact001556" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,430,211</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zdUsCVewWmzg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_zenQZUfFm0sj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2024-01-012024-12-31" id="Fact001561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,508,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2023-01-012023-12-31" id="Fact001562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,964,373</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_di_zRGCI5Pcm0c9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Purchase of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2024-01-012024-12-31" id="Fact001564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,887,923</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2023-01-012023-12-31" id="Fact001565" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,541,287</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_zAKHsY21mae6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; padding-bottom: 1pt">Purchases of equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-012024-12-31" id="Fact001567" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,189</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact001568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,043</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_znv7vZokNGFa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By Investing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-12-31" id="Fact001570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">514,529</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact001571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,252,043</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zI41P0G7Wf8b" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_z4ZHICkTNNMh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net proceeds from issuance of common stock in at-the-market offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1576">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="Fact001577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,783</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_zNqDKJ9v13gh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Net proceeds from issuance of common stock in direct-offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1579">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-012023-12-31" id="Fact001580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,853,990</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ProceedsFromExchangeAndIssuanceOfWarrantsNet1_i01_zt1oa2qmmwSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Proceeds from exchange and issuance of warrants, net <span id="xdx_F4A_zTTsmaN2uOg1">[1]</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1" contextRef="From2024-01-012024-12-31" id="Fact001582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,528,027</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1583">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PaymentsForProceedsFromDeferredOfferingCosts_i01N_di_zegzwobwpPNg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Deferred offering costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BRTX:PaymentsForProceedsFromDeferredOfferingCosts" contextRef="From2024-01-012024-12-31" id="Fact001585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,697</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1586">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_ztuy5piC1Ewk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By Financing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact001588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,379,330</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact001589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,348,773</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zYlG8HG5DLV3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left">Net Decrease In Cash and Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact001591" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">336,487</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact001592" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">829,395</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_z0K5VwwO4aeh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents - Beginning of the Year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact001594" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,377</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact001595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,713,772</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zSj3hKr7vDic" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents - End of the Year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact001597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,890</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact001598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,377</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zHO7DehfCmfe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental Disclosures of Cash Flow Information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SupplementalCashFlowInformationRelatedText_i01B_zYrk6Tb1wuZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cash paid during the year for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPaidNet_i02_zCXUlgTr6pu" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1606">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1607">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxesPaidNet_i02_zvKeEpXwG0Yh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1609">-</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1610">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zO43AMsp65Td" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IssuanceOfCommonStockHeldInAbeyance_i01_z8R6wtTLdKg4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Issuance of common stock held in abeyance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:IssuanceOfCommonStockHeldInAbeyance" contextRef="From2024-01-012024-12-31" id="Fact001615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1616">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_i01_zAYEe9V9PIz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Return and cancellation of shares in lieu of payroll tax withholding</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-12-31" id="Fact001618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2023-01-012023-12-31" id="Fact001619" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F0F_zjqAxJSjdgh2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[1]</span></td><td style="text-align: justify"><span id="xdx_F17_zuzQmrhsdySd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001620" xml:lang="en-US">Includes gross
proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20240101__20241231_zSqmWfzB3Fwf" title="Proceeds from debt issuance costs"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="From2024-01-012024-12-31" id="Fact001622" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,123,391</ix:nonFraction></span>, less issuance costs of $<span id="xdx_908_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231_zFrZALfkTkQg" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-012024-12-31" id="Fact001624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,364</ix:nonFraction></span>.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_04E_c20240101__20241231_zVD3tJaw3d89" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_006"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001626" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zad1yrVgoFC6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
1 - <span>ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_823_zt5CeRGTE1T3" style="display: none">BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#8220;Stem Pearls&#8221;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#8220;BRT&#8221; or the &#8220;Company&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Going Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which
contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2024,
the Company had a net loss of $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zpyfxt7l3Ml4" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001628" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">9.0</ix:nonFraction></span> million, negative cash flows from operations of $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zbxaUj3RB9Eg" title="Cash flows from operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact001630" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">8.2</ix:nonFraction></span> million and working capital of $<span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_c20241231_z46fDtgeQMRg" title="Working capital"><ix:nonFraction name="BRTX:WorkingCapital" contextRef="AsOf2024-12-31" id="Fact001632" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.4</ix:nonFraction></span> million.
The Company anticipates that it will continue to incur net losses and negative cash flows from operations as it executes its development
plans for 2025 and beyond, as well as other potential strategic and business development initiatives. These conditions raise substantial
doubt about the Company&#8217;s ability to continue as a going concern for at least twelve months after the issuance date of these financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable
securities and additional infusions of cash from equity and debt financing. During the year ended December 31, 2024, the Company raised
net proceeds of approximately $<span id="xdx_903_ecustom--ProceedsFromWarrantExercisesNet_iI_pn5n6_c20240101__20241231_zN7GIeS7Bo81" title="Proceeds from warrant exercises, net"><ix:nonFraction name="BRTX:ProceedsFromWarrantExercisesNet" contextRef="From2024-01-012024-12-31" id="Fact001634" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.5</ix:nonFraction></span> million in connection with a warrant exercise program which is further discussed in Note 6 &#8211;
Stockholders&#8217; Equity. On November 6, 2024, the Company entered into an at-the-market offering agreement (the &#8220;2024 ATM&#8221;)
pursuant to which the Company has an ability to issue and sell shares of its common stock up to an aggregate offering price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241106__20241106_zicrnDnE8Hjb" title="Offering price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-11-062024-11-06" id="Fact001636" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,614,170</ix:nonFraction></span>.
Subsequent to December 31, 2024, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zD3UaD052txg" title="Sold shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact001638" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">492,000</ix:nonFraction></span> shares of its common stock under the 2024 ATM and raised approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z22hnIqNkwu3" title="Offering price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact001640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,084,000</ix:nonFraction></span>
of gross proceeds See Note 10 &#8211; Subsequent Events for additional details regarding sales of the Company&#8217;s common under the
2024 ATM subsequent to December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable
operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its
development, marketing and promotional activities, which would have a material adverse effect on the Company&#8217;s business, financial
condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;), which contemplate continuation of the Company as a going concern and the realization
of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented
in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying consolidated
financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#8217;s
website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated
by reference into this Annual Report. BRT is currently developing a Disc/Spine Program referred to as &#8220;brtxDISC&#8221;. Its lead
cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal stem cells collected
from the patient&#8217;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders
or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect to a platform technology
utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled
this initiative its ThermoStem Program. In addition, in continuation of BRT&#8217;s mission of developing and commercializing cell-based
biologics, it is seeking to develop a biologics-based cosmetic products business. Pursuant to such business, BRT would formulate, manufacture
and sell products designed for cosmetic and aesthetic uses. Further, BRT has licensed a patented curved needle device that is a needle
system designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 139; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001642" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKzKY88P6szc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
2 - <span id="xdx_828_zMyXsBBEEUzi">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001644" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zntv9Aiyyqwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zdk4PxG1qrLi">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#8217;s consolidated financial statements. Such consolidated
financial statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity
and objectivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001646" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zxDKCiAlpgg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z0fNjlbqN8zj">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany
accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001648" name="us-gaap:UseOfEstimates"><p id="xdx_842_eus-gaap--UseOfEstimates_zEU1sFsNaugc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z4poG7D1ldXh">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001650" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkkM4rTKhXL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z3GH9BVMoxqk">Segment
Reporting</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has one operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#8217;s Chief Executive Officer, serves
as the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial
performance. The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated
expense data beyond what is included in the consolidated statements of operations is not provided to the CODM. Since the Company&#8217;s
operations consist of a single reporting segment, the segment assets are presented on the accompanying consolidated balance sheet as
total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001652" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zutuEXoDmQC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zLcOVvLUxfTa">Revenue
Recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).
The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC
606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required
within the revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable
consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company
recognizes revenue primarily from the following different types of contracts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    sales</b> - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty
    revenue</b> - Revenue is recognized as a usage-based royalty from customers&#8217; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#8217;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    reason for the bill-and-hold arrangement is substantive</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    customer has requested the product be warehoused</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product has been identified as separately belonging to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product is currently ready for physical transfer to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company does not have the ability to use the product or direct it to another customer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s revenue recognized in its consolidated statements of operations:</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001654" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z7tV6GJV8wQe" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_us-gaap_ProductMember" id="Fact001656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_us-gaap_RoyaltyMember" id="Fact001659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_us-gaap_RoyaltyMember" id="Fact001660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31" id="Fact001662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact001663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zucK4GFra5g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001665" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z82RXuAQ9m83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zPY8JAe2pUG9">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#8220;FDIC&#8221;) coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zd4LGIJOhtt9" title="FDIC insured limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-12-31" id="Fact001667" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zkZR8JFpwxA1" title="FDIC amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact001669" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,801</ix:nonFraction></span> and
$<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zuUVXiGB8vo1" title="FDIC amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2023-12-31" id="Fact001671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,226</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001673" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrHslI4Q5v9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zMa1AmFIfaIk">Customer
and Revenue Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s royalty revenue is derived from one customer. Additionally, all of the Company&#8217;s product sales revenue is
derived from one customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001675" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z96cN1ak7Q7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zjqSBcHeCS88">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of December 31, 2024 and 2023, no allowances
for credit losses were determined to be necessary. Management estimates the allowance for credit losses based on existing economic conditions,
the financial conditions of the customers, and the amount and age of past due accounts. Receivables are considered past due if full payment
is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only
after all collection attempts have been exhausted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001677" name="BRTX:DeferredContractCostsPolicyTextBlock"><p id="xdx_841_ecustom--DeferredContractCostsPolicyTextBlock_zBfyPacgQe1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_z9v0S1hZqQUi">Deferred
Contract Costs</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs
relate directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying
performance obligations in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as
cost of revenues in the period when the related revenue is recognized. Deferred contract costs consist of consumables and labor
costs and are included within prepaid &amp; other current assets in the consolidated balance sheets. The Company had $<span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zZfVwr6cQXkb" title="Deferred contract costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31" id="Fact001679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,250</ix:nonFraction></span>
and $<span id="xdx_905_eus-gaap--DeferredCosts_iI_c20231231_zdJ4p8ov21Hk" title="Deferred contract costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31" id="Fact001681" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> </span>deferred contract
costs as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001683" name="BRTX:DeferredOfferingCostsPolicyTextBlock"><p id="xdx_844_ecustom--DeferredOfferingCostsPolicyTextBlock_zCSW2VIkUIsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_zv1g22C3EyB3">Deferred Offering Costs</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Deferred offering costs, which
primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized as non-current assets
on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the offering proceeds. If
the completion of a contemplated financing was no longer probable, the related deferred offering costs would be charged to general and
administrative expense in the consolidated financial statements. The Company had $<span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_c20241231_zRqgz5xgN36j" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-12-31" id="Fact001685" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,697</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20231231_zQ0rJYVdgKF6" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact001687" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> deferred offering costs as of December
31, 2024 and 2023, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001689" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrNWYT5nz4ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zheceqDJFsi8">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_z7kFHq54efw8" title="Property plant and equipment estimated useful lives" style="display: none"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001691" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>three to <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_z9lXBJdFqlhj" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember" format="ixt-sec:durwordsen" id="Fact001693" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">fifteen years</ix:nonNumeric></span>. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfnq9MSy6d45" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" id="Fact001695" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> years. Medical equipment costs
are capitalized and depreciated over <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZ4jRpsDJgA6" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MedicalEquipmentMember" format="ixt-sec:duryear" id="Fact001697" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years, while furniture and fixtures are depreciated over <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjMrGwd0Prad" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact001699" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span> years. Office equipment is depreciated
over a period of <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zFxufD0aVXDh" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001701" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> to <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcK9bTYPatcf" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001703" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years, and manufacturing equipment over <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRGoTgdUsUR5" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001705" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNoLqgQf3lLh" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001707" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001709" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zvYszRC8Li8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zEt2msSsRFC2">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records its intangible assets at cost in accordance with ASC 350, <i>Intangibles - Goodwill and Other</i>. Definite lived intangible
assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over
which the cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001711" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhNRS1Aqq6jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zFhYORrqYOJc">Impairment
of Long-Lived Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, the Company determined that
there was <span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20240101__20241231_zkUKhwWoBDvg" title="Impairment of long-lived assets"><span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20230101__20231231_zJwaUYA1d6li" title="Impairment of long-lived assets"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2024-01-012024-12-31" id="Fact001713" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2023-01-012023-12-31" id="Fact001715" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> impairment charge for its long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001717" name="BRTX:WarrantAndOptionValuationPolicyTextBlock"><p id="xdx_846_ecustom--WarrantAndOptionValuationPolicyTextBlock_zI9N9CDazI73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zUd3lVu9E2Sd">Warrant
and Option Valuation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221;
method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry blended with the Company&#8217;s historical
volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining
term consistent with the expected term of the instrument being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001719" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQ9biVqlTD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_86F_z6RhMrU5RzF3">Derivative
Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option pricing model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001721" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGbcb7LJWe47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zhJEhRPQrt7k">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of December 31, 2024 and 2023, the carrying amount of cash and cash equivalents,
investments held in marketable securities, accounts receivable, and accounts payable approximate their fair value due to the relatively
short period of time between their origination and their expected realization or payment. The warrant liabilities are measured at fair
value (see Note 9 &#8211; Fair Value Measurement for additional details).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company recognized aggregate dividend and interest income of $<span id="xdx_90C_eus-gaap--InterestAndDividendIncomeOperating_c20240101__20241231_zg5oD0W09dNe" title="Dividend and interest income"><ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2024-01-012024-12-31" id="Fact001723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623,801</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--InterestAndDividendIncomeOperating_c20230101__20231231_zU0r2WazoLE7" title="Dividend and interest income"><ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2023-01-012023-12-31" id="Fact001725" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,068</ix:nonFraction></span> respectively,
on its marketable securities, which was included within other income on its consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001727" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zV62cxfcykAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zSfIv1elO46k">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The Company has <span id="xdx_90D_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zLHCITQpABQj" title="Shares held in abeyance"><ix:nonFraction name="BRTX:SharesHeldInAbeyance" contextRef="AsOf2024-12-31" id="Fact001729" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,201,580</ix:nonFraction></span> shares held in abeyance included
in basic loss per share given that they are issuable for no additional consideration (see Note 6 &#8211; Stockholders&#8217; Equity for
additional details). The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding
convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant
to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants,
restricted stock units (&#8220;RSUs&#8221;) and convertible preferred stock have been excluded from the Company&#8217;s computation of
diluted net loss per common share for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001731" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1GIc8cffMY8" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" title="Total" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001733" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,263,467</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" title="Total" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001735" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,466,892</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" title="Total potentially dilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact001737" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" title="Total potentially dilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001739" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,019</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" title="Unvested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1741">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" title="Unvested" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" title="Convertible notes" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact001745" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" title="Convertible notes" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact001747" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" title="Anti-dilutive securities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31" id="Fact001749" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,613,259</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" title="Anti-dilutive securities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact001751" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,753,896</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zh9UmzbEuc23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001753" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4rqRiibYMW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zXmhvArh15nb">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be
provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified
warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction
of amounts previously expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001755" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zyorW7NGWskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zwBN5Q5WlHH">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes ASC 740, &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#8220;more likely-than-not&#8221;
that a deferred tax asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001757" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zUyYKWUBRBq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zvsoDK4W79Yj">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets and operating lease liabilities in our consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value
of lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement
date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company&#8217;s lease terms
may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for
lease payments is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001759" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXTkrjpty3U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zpKTHgzD4l67">Recently
Adopted Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
&#8220;Improvements to Reportable Segments Disclosures (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;), which updates reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis.
The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after
December 15, 2024, with early adoption permitted. The adoption of this accounting standard on a retrospective basis did not have a material
impact on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001761" name="BRTX:RecentlyIssuedAccountingPronouncementsPolicyTextBlock"><p id="xdx_845_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zmtEdleuNQYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zNfZlr2uXiec">Recently
Issued Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; (&#8220;ASU 2024-03&#8221;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.</span></p>

</ix:nonNumeric><p id="xdx_850_zSD8QCfCQlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001763" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zEvV1FTo67xk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
3 - <span id="xdx_829_zsg9IrEIAfo9">PROPERTY AND EQUIPMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001765" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2ZdwaDNWsb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zRiW19Duyqmj" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zcvb0j2Mshvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zCrUODQYb0Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zLOXDxjVNdhb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_MedicalEquipmentMember" id="Fact001767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,133</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_MedicalEquipmentMember" id="Fact001768" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,133</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zHKi6c2fM66c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact001770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact001771" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,486</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zTPXuLfpmrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_ComputerSoftwareAndEquipmentMember" id="Fact001773" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ComputerSoftwareAndEquipmentMember" id="Fact001774" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdSPeVh24a7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember" id="Fact001776" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember" id="Fact001777" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,779</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zHLEEhyimZOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manufacturing equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember" id="Fact001779" format="ixt:numdotdecimal" decimals="0" unitRef="USD">501,421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ManufacturingEquipmentMember" id="Fact001780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">395,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb0uKt79Uwyg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact001782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,048</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact001783" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,048</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzKiZ_z4su14VN8qy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    plant and equipment gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact001785" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,474,072</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact001786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,367,883</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKiZ_zeJSxm1HRBa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001788" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,111,136</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact001789" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,011,828</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKiZ_zPMObeOSxMXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact001791" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,936</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001792" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,055</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zZiYqaFLPewe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
depreciation expense for the years ended December 31, 2024 and 2023 was $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zvtQEHghKRO7" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31" id="Fact001794" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,309</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zi5SeumhaRl8" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact001796" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,989</ix:nonFraction></span>, respectively. Depreciation expense is reflected
in general and administrative expenses and research and development expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001798" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--IntangibleAssetsDisclosureTextBlock_z7XcTOpi2I3c" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
4 - <span id="xdx_82E_z8jFnJ0P8vsc">INTANGIBLE ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a license agreement with the SCTC (as amended) (the &#8220;SCTC Agreement&#8221;). Pursuant to the SCTC Agreement,
the Company obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from the SCTC
to utilize or sublicense a certain method for culturing cells and a worldwide, exclusive, royalty-bearing license from the SCTC to utilize
or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine
(and other parts of the body).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, the Company received authorization from the Food and Drug Administration (the &#8220;FDA&#8221;) to proceed with a Phase
2 clinical trial. In February 2022, the Company announced that the United States Patent and Trademark Office issued a notice of allowance
for a patent application relating to the Company&#8217;s BRTX-100 clinical program. This patent was issued in March 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 145; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001800" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdsSzvPsMxw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zovX5FmRjKn8" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zMa8DpLEhmyh" title="Finite Lived Intangible Assets, Gross, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_custom_PatentsAndTrademarksMember" id="Fact001802" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgkIpLlGFbo2" title="Finite Lived Intangible Assets, gross, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_LicenseMember" id="Fact001804" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593,530</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zqY3dA0k41Sl" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember" id="Fact001806" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">793,768</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20230101__20231231_z6h1cAws7Od" title="Finite Lived Intangible Assets, Net, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" id="Fact001808" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">803,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zDUNrjLtHqbj" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember" id="Fact001810" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231_zRrGfdmJ09Eb" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact001812" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zTRGfffLeNbf" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_custom_PatentsAndTrademarksMember" id="Fact001814" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBVozX7VDJlj" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_LicenseMember" id="Fact001816" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXRYXWxN8sRe" title="Beginning Balance" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_custom_AccumulatedAmortizationMember" id="Fact001818" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">883,514</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20240101__20241231_zqwLjk2xJY0j" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact001820" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">713,692</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zytthitOTw2k" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember" id="Fact001822" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231_zAM5NMN8yS06" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31" id="Fact001824" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zQuRKUBmR8mh" title="Finite Lived Intangible Assets, Gross, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_custom_PatentsAndTrademarksMember" id="Fact001826" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zoYjoWDb33X3" title="Finite Lived Intangible Assets, Gross, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_us-gaap_LicenseMember" id="Fact001828" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593,530</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztG665tY4AIa" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_custom_AccumulatedAmortizationMember" id="Fact001830" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">973,261</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_pp0p0_c20240101__20241231_zjzg3CCnlNxd" title="Finite Lived Intangible Assets, Net, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact001832" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">623,945</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period at December 31, 2024 (in years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zFTAQg0U6qf8" title="Finite Lived Intangible Assets, weighted average amortization period">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zWn6aGIbVlz8" title="Finite Lived Intangible Assets, weighted average amortization period"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LicenseMember" format="ixt-sec:duryear" id="Fact001836" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">10.3</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zQnJWoLGRUxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001838" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zyr8t0Ym6OWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zIE3bG4EPzp9" style="display: none">SCHEDULE OF FINITE LIVED
INTANGIBLE ASSETS AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zAQRVTNxCnRa" title="Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_PatentsAndTrademarkMember" id="Fact001840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zTV1EfXZQxkj" title="Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_LicenseMember" id="Fact001842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">790,092</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuMtebEZOmgf" title="Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember" id="Fact001844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">793,768</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zY8aapJwfbif" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1846">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgEjKj6jTWI5" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31_us-gaap_LicenseMember" id="Fact001848" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2rXVJBGP7il" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember" id="Fact001850" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zgRAH3stiYi7" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_custom_PatentsAndTrademarkMember" id="Fact001852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDe9KaWcOYI7" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_LicenseMember" id="Fact001854" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,838</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXVvp6oFTRTa" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_custom_AccumulatedAmortizationMember" id="Fact001856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">883,514</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zuHhehAQNkik" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1858">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6qgnUqvdCNe" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_us-gaap_LicenseMember" id="Fact001860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zygSxwRoDT8e" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember" id="Fact001862" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zpDaKpFlcUXl" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_custom_PatentsAndTrademarkMember" id="Fact001864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_ziQYvOYoF2Vh" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_LicenseMember" id="Fact001866" format="ixt:numdotdecimal" decimals="0" unitRef="USD">969,585</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z21atXqH7Mrd" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_custom_AccumulatedAmortizationMember" id="Fact001868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">973,261</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zXJeZ8EsBx54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001870" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zO5E84hy3qC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the next five years is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zDxhPMghSJb7" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">For the Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zLqGmLhSvkA" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz89Q_z1vNDKxW98G5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz89Q_za7zLx3utHS9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-12-31" id="Fact001874" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz89Q_z9FWK80aZ1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-12-31" id="Fact001876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz89Q_zCZfaJK7po9f" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2024-12-31" id="Fact001878" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz89Q_zlr2Quf6AHf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2024-12-31" id="Fact001880" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz89Q_zivgdmaXPRBi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact001882" format="ixt:numdotdecimal" decimals="0" unitRef="USD">448,730</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zRFY1LD10kBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001884" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zcCzM4pARQo3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
5 - <span id="xdx_820_zMsUx2ILh5Tl">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001886" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7ve0gvNg4Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z3T5qunqNukl" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zEWk23Yc0nC" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zeM88DjmnpU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALAOLzJ5Y_zfKjliCICsKd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accrued bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001888" format="ixt:numdotdecimal" decimals="0" unitRef="USD">704,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001889" format="ixt:numdotdecimal" decimals="0" unitRef="USD">638,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zWjZXZQ1wT92" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:AccruedGeneralAndAdministrativeExpenses" contextRef="AsOf2024-12-31" id="Fact001891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,485</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:AccruedGeneralAndAdministrativeExpenses" contextRef="AsOf2023-12-31" id="Fact001892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,686</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtALAOLzJ5Y_zh0kRlaqDaTb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">744,485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,686</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_ziyjOByjOsNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001897" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJPEBtlN7YIk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6 - <span id="xdx_82B_zUgzUG841pcg">STOCKHOLDERS&#8217; EQUITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2021, in connection with the Company&#8217;s public offering, the Company&#8217;s Board of Directors adopted a resolution
allowing for the designation and issuance of <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAv4O5ACYYm2" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" id="Fact001899" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of the Company&#8217;s Preferred Stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQNlJEUEDcQa" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" id="Fact001901" decimals="INF" unitRef="USDPShares">.01</ix:nonFraction></span> par value per share, designated
as Series A Preferred Stock (&#8220;Series A&#8221;). The Series A had a liquidation preference of $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3hczMMtKpU8" title="Preferred stock, liquidation preference"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" id="Fact001903" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. On September 8,
2022, the Company issued <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zo0GcvUNCdN2" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember" id="Fact001905" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of Series B Preferred Stock (&#8220;Series B&#8221;) to Auctus Fund, LLC (&#8220;Auctus&#8221;)
in exchange for an equal number of shares of the Company&#8217;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#8217;s Board
of Directors cancelled the Series A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
B Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 8, 2022, the Company issued <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYC3O1qRrCy6" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember" id="Fact001907" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of Series B to Auctus in exchange for an equal number of shares of the Company&#8217;s
outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is <span id="xdx_90D_eus-gaap--PreferredStockVotingRights_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKAmHWfyKJBh" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember" id="Fact001909" name="us-gaap:PreferredStockVotingRights">9.99</ix:nonNumeric></span>% of the then outstanding Common Stock of the Company instead of <span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuT87XMZHkJ6" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember" id="Fact001911" name="us-gaap:PreferredStockVotingRights">4.99</ix:nonNumeric></span>% as
provided for the Series A. The Company is required, at all times, to reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to
redemption by the Company or any Series B holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Voting
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7GqZ3KTuVV4" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001913" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the then outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional
Conversion - <span id="xdx_902_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zL2VXQ8WU4De" title="Preferred stock conversion term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001915" name="us-gaap:ConvertiblePreferredStockTermsOfConversion">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock;</ix:nonNumeric></span> provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znCDeplQWuW5" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001917" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the outstanding
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automatic
Conversion - From time to time, in the event that an event occurs which has the effect of reducing a Series B holder&#8217;s beneficial
ownership of shares of Common Stock to less than <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zphxO48CaFTi" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember" id="Fact001919" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.5</ix:nonFraction></span>% of the then publicly disclosed outstanding shares of Common Stock, then, within
five business days, the Series B holder is required to provide notice to the Company to such effect, which notice shall state the number
of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard thereto, including
the number of derivative securities compromising a portion of such beneficial share amount. Such notice shall have the effect of a notice
of conversion with respect to the conversion of such number of shares of Series B as would increase the Series B holder&#8217;s beneficial
ownership of Common Stock to <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zf50yJldC0Qg" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember" id="Fact001921" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the then publicly disclosed outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 25, 2022, Auctus converted <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_z5AXhJwz8bFi" title="Debt conversion, converted instrument, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember" id="Fact001923" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of Series B into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zlLsZqLS1tRe" title="Debt conversion, converted instrument, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember" id="Fact001925" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of Common Stock. The number of shares of Series B remaining
outstanding after this conversion was <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLoD9gwPh8vg" title="Conversion of stock shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember" id="Fact001927" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518,158</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2023, Auctus converted <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zFD1ODMs5Buk" title="Number of shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact001929" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> shares of Series B into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUB0LKFisLvh" title="Number of shares issued in conversion"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_us-gaap_CommonStockMember" id="Fact001931" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> shares of Common Stock. As of December 31, 2024, the number of
shares of Series B remaining outstanding after giving effect to such conversion was <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zveV0mvbGEcl" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact001933" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Stock Incentive Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company&#8217;s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &#8220;2021
Plan&#8221;). The 2021 Plan was approved by the Company&#8217;s stockholders on August 17, 2021. Pursuant to the 2021 Plan, a total of
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210318__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember_zQB2Po9BLkKg" title="Number of shares of common stock authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember" id="Fact001935" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,175,000</ix:nonFraction></span> shares of common stock were initially authorized to be issued pursuant to the grant of stock options, restricted stock units,
restricted stock, stock appreciation rights and other incentive awards. On December 10, 2021, the Company&#8217;s Board of Directors
approved an amendment to increase the number of shares of Common Stock authorized to be issued from <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zVPMbYgrWnQ2" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember" id="Fact001937" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,175,000</ix:nonFraction></span> to <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zncC5eiUPWt1" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember" id="Fact001939" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span>. Such amendment
was approved by the Company&#8217;s stockholders on November 3, 2022. On July 13, 2023, the Company&#8217;s Board of Directors approved
an amendment to the 2021 Plan to increase the number of shares of Common Stock authorized to be issued from <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zo1X1po4yASk" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember" id="Fact001941" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span> to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zVCTDa6pQi4" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember" id="Fact001943" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,850,000</ix:nonFraction></span>. Such
amendment was approved by the Company&#8217;s stockholders on September 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 23, 2024, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s 2021 Plan to increase the number of
shares of common stock authorized to be issued under the 2021 Plan from <span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240722__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zVT1EXT7QkA9" title="Common stock authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-07-22_custom_TwoThousandAndTwentyOneStockIncentivePlanMember" id="Fact001945" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,850,000</ix:nonFraction></span> to <span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240723__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_z0fNr8c0ddHb" title="Common stock authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-07-23_custom_TwoThousandAndTwentyOneStockIncentivePlanMember" id="Fact001947" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,850,000</ix:nonFraction></span>. Such amendment was approved by the Company&#8217;s
stockholders on September 19, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensatory
Common Stock Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231_ztpy3rsk930e" title="Vested common stock, shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-01-012023-12-31" id="Fact001949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,442</ix:nonFraction></span> shares of immediately vested common stock with a value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231_zKuKeGD0i2fd" title="Aggregate common stock services rendered"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-12-31" id="Fact001951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></span> to a consultant
for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;)
under which the Company had the ability to issue and sell shares of its Common Stock, from time to time, through JonesTrading, up to
an aggregate offering price of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--DemandSalesAgreementMember_z2vE6NAiKWPj"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_DemandSalesAgreementMember" id="Fact001952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,109,000</ix:nonFraction></span> in what is commonly referred to as an &#8220;at-the-market&#8221; (&#8220;ATM&#8221;)
program. During the year ended December 31, 2023, the Company sold <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zXplo7pD9iOk" title="Sold shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember" id="Fact001954" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">132,827</ix:nonFraction></span> shares of its Common Stock at a weighted average price of
$<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zpEUTC3wNX2l" title="Weighted average price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember" id="Fact001956" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.68</ix:nonFraction></span> per share and raised $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zunGcHy30dsd"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember" id="Fact001957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,782</ix:nonFraction></span> in net proceeds under the JonesTrading ATM program. In November 2024, in connection with the ATM
program with Rodman &amp; Renshaw LLC (&#8220;Rodman&#8221;) discussed below, the Company terminated the Capital on Demand Sales Agreement
with JonesTrading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2023, the Company sold an aggregate of 	<span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713_zGeXKDbsQOZf" title="Sale of aggregate shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-122023-07-13" id="Fact001959" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">685,033</ix:nonFraction></span> shares of Common Stock to several institutional buyers and accredited investors
in a registered direct offering at an offering price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230713_zcVAT4OtM4yi" title="Offering price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-07-13" id="Fact001961" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.03</ix:nonFraction></span> per share. The offering closed on July 13, 2023 with net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230712__20230713_zP7zaht68Fhf" title="Net proceeds offering price"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-07-122023-07-13" id="Fact001963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,853,990</ix:nonFraction></span>.
The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy
candidate, BRTX-100, pre-clinical research and development with respect to its metabolic ThermoStem Program and for general corporate
purposes and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the Company entered into an At The Market Offering Agreement with Rodman, under which the Company currently has the ability
to issue and sell shares of its Common Stock, from time to time, through Rodman, up to an aggregate offering price of approximately $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zH6H9vwuMDQa" title="Sold value of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_ATMProgramMember" id="Fact001965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,614,000</ix:nonFraction></span>
in an ATM program. See Note 10 - Subsequent Events &#8211; Common Stock Sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Exercise and Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2024, the Company entered into agreements with certain holders of its existing warrants exercisable for an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJLLRuKcXiXh" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember" id="Fact001967" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span>
shares of its Common Stock (collectively, the &#8220;Existing Warrants&#8221;), to exercise their warrants at a reduced exercise price
of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWIprX6rqLng" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember" id="Fact001969" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.33</ix:nonFraction></span> per share, in exchange for the issuance of new warrants (the &#8220;New Warrants&#8221;) as described below (the &#8220;Warrant
Exercise and Issuance&#8221;). The aggregate gross proceeds from the exercise of the Existing Warrants and the payment of the New Warrants,
as described below, was approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLxbdAHUuGN7" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember" id="Fact001971" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.1</ix:nonFraction></span> million, before deducting cash issuance costs in the amount of $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAFNeSFqflDl" title="Cash issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember" id="Fact001973" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,364</ix:nonFraction></span>. The reduction of
the exercise price of the Existing Warrants and the issuance of the New Warrants was structured as an at-market transaction under Nasdaq
rules. Of the <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzsKaWfvjyT2" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember" id="Fact001975" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span> shares of Common Stock issuable upon the exercise of the Existing Warrants, through December 31, 2024, the Company
had issued an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z68Q6vqjUh11" title="Warrants exercisable"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember" id="Fact001977" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,150,000</ix:nonFraction></span> shares of Common Stock. The remaining <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zvVWO1PSwBY4" title="Warrants exercisable"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember_custom_AuctusFundLLCMember" id="Fact001979" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,201,580</ix:nonFraction></span> shares of Common Stock, which are issuable to Auctus
Fund, LLC (&#8220;Auctus&#8221;), are being held in abeyance due to Auctus&#8217; maximum beneficial ownership limitation (the &#8220;Abeyance
Shares&#8221;). Such Abeyance Shares have been fully paid for and are issuable upon notice from Auctus to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of the Existing Warrants for cash and the payment of $<span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zBxG29Eh8Uv" title="Warrants for cash and the payment"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact001981" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.125</ix:nonFraction></span> per share underlying the New Warrants,
the exercising holders received the New Warrants to purchase shares of Common Stock in a private placement pursuant to Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The New Warrants will be exercisable for a period of five
years into an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNlyN1DFbIFj" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact001983" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,513,686</ix:nonFraction></span> shares of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRsdklXiIqW9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact001985" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></span> per share. The securities offered in the private
placement have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company agreed to file
a resale registration statement with the SEC to register the resale of the shares of Common Stock underlying the New Warrants issued
in the private placement. Such resale registration statement was filed and was declared effective by the SEC on April 18, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5,
2024, with Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which the Company has paid Roth a cash fee of approximately $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240205__20240205__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zzl7n2lB0Vtl" title="Cash fee for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-02-052024-02-05_us-gaap_CommonStockMember_custom_RothCapitalPartnersLLCMember" id="Fact001987" format="ixt:numdotdecimal" decimals="0" unitRef="USD">528,000</ix:nonFraction></span>
for its services, in addition to reimbursement for certain expense. During the year ended December 31, 2024, the Company incurred an
aggregate of $<span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zT0D139u7t1a" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember" id="Fact001989" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,364</ix:nonFraction></span> of cash issuance costs related to the Warrant Exercise and Issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Warrant Exercise and Issuance, the Existing Warrants were classified as derivative liabilities. Additionally, the Company analyzed
the form of the New Warrants and determined that they should be classified as derivative liabilities in accordance with ASC 815-40, Derivatives
and Hedging &#8212; Contracts in Entity&#8217;s Own Equity. Under the New Warrants, the Company does not control the occurrence of events,
such as a tender offer or exchange, that may trigger cash settlement of the New Warrants and not result in a change of control of the
Company. As a result, such New Warrants do not meet the criteria for equity treatment. Additionally, certain New Warrants contain adjustments
to the settlement amount based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined
under ASC 815-40 and, accordingly, such New Warrants are not considered indexed to the Company&#8217;s own stock and are not eligible
for an exception from derivative accounting. See Note 9&#8211; Fair Value Measurement for details regarding the valuation of the Existing
Warrants and New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the Warrant Exercise and Issuance to be an exchange by investors of Existing Warrants with an aggregate fair value
of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zwsYJKgpvCMb" title="Fair value of adjustment"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember" id="Fact001991" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,115,334</ix:nonFraction></span> along with aggregate cash consideration of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zfFm1YZsZXZc" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember" id="Fact001993" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,123,392</ix:nonFraction></span> (consisting of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zCSVqe8YkOf2" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31_custom_ExistingWarrantMember" id="Fact001995" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,809,181</ix:nonFraction></span> paid to exercise the Existing Warrants
and $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zbHEcEn03OHl" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember" id="Fact001997" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,211</ix:nonFraction></span> paid for the New Warrants) for an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zF7lId3Nr2Q7" title="Stock issued during period shares new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember" id="Fact001999" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span> shares of common stock with an aggregate fair value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zefA77ZQfLn9" title="Stock issued during period value new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember" id="Fact002001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,742,244</ix:nonFraction></span>,
New Warrants with an aggregate fair value of $<span id="xdx_909_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zk6OWlB7V2rb" title="Stock issued during period value warrants"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember" id="Fact002003" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,189,420</ix:nonFraction></span> and aggregate cash issuance costs of $<span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zWjJHU1kOYy9" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember" id="Fact002005" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,364</ix:nonFraction></span> and, accordingly, the Company recorded
a gain on exchange of warrants of $<span id="xdx_907_ecustom--GainLossOnExchangeOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zoVcOH6TDVVd" title="Gain on exchange of warrants"><ix:nonFraction name="BRTX:GainLossOnExchangeOfWarrants" contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember" id="Fact002007" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,698</ix:nonFraction></span> during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Activity Summary</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002009" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zSZin8yUZKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the warrant activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zGJJPKtZyAE5" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znAqvvT4Qbx9" title="Number of Warrants, Outstanding Beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact002011" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,019</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z87TDq6moIv1" title="Weighted Average Exercise Price,  Outstanding beginning balance" style="width: 14%; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact002013" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.57</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdjrTKuhx9z6" title="Number of Warrants, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640" id="Fact002015" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">2,513,686</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjdzOfyxLbwc" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640" id="Fact002017" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzgG1cCZ4vr1" title="Number of Warrants, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640" id="Fact002019" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zki4H944FIMe" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640" id="Fact002021" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOsoduSVUaRk" title="Number of Warrants, Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640" id="Fact002023" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,491</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrBkx7PzwuQk" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640" id="Fact002025" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,770</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfvfXo0Eesnl" title="Number of Warrants, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact002027" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsOAZv5WGZd9" title="Weighted Average Exercise Price, Outstanding ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact002029" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.22</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZ3LPAMieATi" title="Weighted Average Remaining Life In Years, Outstanding"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640" format="ixt-sec:duryear" id="Fact002031" name="BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.30</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSXFmGrNy028" title="Number of Warrants, Exercisable Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact002033" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlHDUWyygGWc" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact002035" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.22</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4jobdqNbrP3" title="Weighted Average Remaining Life In Years, Exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640" format="ixt-sec:duryear" id="Fact002037" name="BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1">3.30</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zXSUQ9QnVqc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average estimated fair value of the warrants granted during the year ended December 31, 2024 was $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDO6RUoak3l1" title="Weighted average estimated fair value of warrants granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509234" id="Fact002039" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.87</ix:nonFraction> </span>per warrant. See Note
9 &#8211; Fair Value Measurement &#8211; for details regarding the fair value estimates of the Warrants that are classified as derivative
liabilities. The Company did not issue any warrants during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002041" name="BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zpOFtra6fg6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock warrants at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zJhgTLHPR6Ie" style="display: none">SCHEDULE
OF STOCK WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBIP5ZD4QC56" title="Warrants outstanding, exercise price" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" id="Fact002043" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl2Jku2lXkle" title="Warrants outstanding, number of warrants" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" id="Fact002045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,513,686</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zU6Nhvq6d4e2" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" format="ixt-sec:duryear" id="Fact002047" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.1</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zC60jbXs1afd" title="Warrants exercisable, exercisable number of warrants" style="width: 21%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" id="Fact002049" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,513,686</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z17wx76SisWa" title="Warrants outstanding, exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" id="Fact002051" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUseg3QpPL84" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" id="Fact002053" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyTCTVYqM8Mh" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" format="ixt-sec:duryear" id="Fact002055" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zwoRloxfJKD9" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" id="Fact002057" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuBvZFdF9pE2" title="Warrants outstanding, exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" id="Fact002059" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWunI15vUYcb" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" id="Fact002061" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,150,358</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOE3aHbPJii4" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" format="ixt-sec:duryear" id="Fact002063" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCyYxBCsyVJe" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" id="Fact002065" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,150,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zroKiGu0kyKh" title="Warrants outstanding, exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" id="Fact002067" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvBqal267Qf4" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" id="Fact002069" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">235,970</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zsRzI4SStm05" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" format="ixt-sec:duryear" id="Fact002071" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zjlWnxsI3Tue" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" id="Fact002073" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">235,970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcUo7cIEyFd6" title="Warrants outstanding, exercise price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" id="Fact002075" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4H9FGqoOWtj" title="Warrants outstanding, number of warrants" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" id="Fact002077" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlijR7PFbo2l" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" format="ixt-sec:duryear" id="Fact002079" name="us-gaap:WarrantsAndRightsOutstandingTerm">0.0</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJksqF3ibGo6" title="Warrants exercisable, exercisable number of warrants" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" id="Fact002081" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zMTGD0WHNxH" title="Warrants outstanding, number of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31" id="Fact002083" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zfJ2T3TGfPA7" title="Warrants exercisable, exercisable number of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31" id="Fact002085" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_za7feX7DXOtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002087" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfNfCP9eNvD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the option activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zrN9b2GV9bbk" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTvM4oSXln82" title="Number of Options, Outstanding beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact002089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,466,892</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zoDROm8SpfK" title="Weighted Average Exercise Price, Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact002091" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z1Abs0lPnAC2" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31" id="Fact002093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,934,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zf56QyHtDan2" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31" id="Fact002095" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zBqFaBP2hRrg" title="Number of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2097">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zQdf2naQfNwc" title="Number of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31" id="Fact002099" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">138,141</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zPDXmZhZIG01" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31" id="Fact002101" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.76</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zcyRTNE1DYVe" title="Number of Options, Outstanding ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact002103" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,263,467</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z6AUvmyFe4hl" title="Weighted Average Exercise Price, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact002105" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.63</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zTVIyvLVQU9e" title="Weighted Average Remaining Life in Years Outstanding Ending"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact002107" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.5</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_z0jhmSrRb99" title="Intrinsic Value, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2109">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z6OaUmtzPBzj" title="Number of Options, Exercisable Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact002111" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,499,132</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zLxmZKqE199h" title="Weighted Average Exercise Price Exercisable Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact002113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.95</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zv88ELOpOHR9" title="Weighted Average Remaining Life in Years Exercisable Ending"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact002115" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.1</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231_z0nAmGqFN17c" title="Intrinsic Value, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2117">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zoAlkje3gnuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of the stock options granted during the years ended December 31, 2024 and 2023 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zHbmqifX8bie" title="Weighted average grant date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31" id="Fact002119" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.45</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zRFePEuvUmbe" title="Weighted average grant date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31" id="Fact002121" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002123" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRtaMfXkznRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock options at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_ztcIUlTEysz5" style="display: none">SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeGpMtvcx146" title="Options Outstanding, Exercise Price" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_RangeOneMember" id="Fact002125" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFR9VoHQVghd" title="Options Outstanding, Outstanding Number of Options" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeOneMember" id="Fact002127" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,825,067</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBesCUmhfgB8" title="Options Exercisable Weighted Average Remaining Life In Years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact002129" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">8.1</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOElztZCIEXk" title="Options Exercisable, Exercisable Number of Options" style="width: 21%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeOneMember" id="Fact002131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,138,579</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zlN1nxbD5Qm7" title="Options Outstanding, Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_RangeTwoMember" id="Fact002133" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z5su5TfUL9I1" title="Options Outstanding, Outstanding Number of Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeTwoMember" id="Fact002135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">626,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmxifRgIyVvh" title="Options Exercisable Weighted Average Remaining Life In Years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact002137" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">6.7</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrvHndT1tcGc" title="Options Exercisable, Exercisable Number of Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeTwoMember" id="Fact002139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">548,368</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGAMtsYhR5eh" title="Options Outstanding, Exercise Price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_RangeThreeMember" id="Fact002141" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoR8Y98253Y8" title="Options Outstanding, Outstanding Number of Options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeThreeMember" id="Fact002143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">812,185</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1xz1zj7zjja" title="Options Exercisable Weighted Average Remaining Life In Years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact002145" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.9</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIZKhcRWSsw5" title="Options Exercisable, Exercisable Number of Options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeThreeMember" id="Fact002147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">812,185</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231_zbocWCIXa5Vc" title="Options Outstanding, Outstanding Number of Options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact002149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,263,467</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_ziXBWM6T6LZ" title="Options Exercisable, Exercisable Number of Options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact002151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,499,132</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zrKbEgsvNC01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 150; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002153" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzhvGPbrfrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zZxbFDb2dxqf" style="display: none">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zGOcrqNV9u6b" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember" id="Fact002155" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.14</ix:nonFraction></span> -<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zlS2vh9EUFd4" title="Risk free interest rate"> <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember" id="Fact002157" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.30</ix:nonFraction></span>%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoHTrUNaM9yc" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" id="Fact002159" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.22</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z1KylLmbD0Dj" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact002161" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.77</ix:nonNumeric></span> - <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zar0bL5bcuah" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact002163" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.38</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx5RjK2kIGab" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact002165" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zWWPgchvXA8e" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember" id="Fact002167" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101</ix:nonFraction></span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_znbbAp1dPtUe" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember" id="Fact002169" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">102</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEkATAdzvs76" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" id="Fact002171" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">175.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zauNMGbqKima" title="Expected dividends" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember" id="Fact002173" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0OQS4xjFub7" title="Expected dividends" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" id="Fact002175" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zjeFEbC9TUoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the 2021 Plan, the Company may grant restricted stock units (&#8220;RSUs&#8221;) to employees, consultants or non-employee directors
(&#8220;Eligible Recipients&#8221;). The number, terms and conditions of the RSUs that are granted to Eligible Recipients are determined
on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Recipient one
unrestricted, fully transferable share of the Company&#8217;s common stock (or the fair market value of one such share in cash) for each
vested and nonforfeitable RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002177" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zbjCRCDfsw47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the unvested RSUs as of December 31, 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z7qX6TjqzmYg" style="display: none">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Non-vested at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z54caD9t4qNf" title="Number of shares outstanding beginning" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002179" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7rNzZRrwG7c" title="Number of shares granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2181">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6DHLnyY2Zc" title="Number of shares forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20515187" id="Fact002183" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVJwCiRoFDV8" title="Number of shares forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2185">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z984AZuQj4Zh" title="Number of shares outstanding ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2187">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zHAVwHeWUTFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002189" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zKMX8JsmytWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNmDZQdJkQIj" style="display: none">SCHEDULE OF STOCK OPTION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unrecognized at December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Weighted Average Remaining
    Amortization Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8mg1PWdtnvh" title="Stock-based compensation expense" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact002191" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,812,566</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0lPbAx67Oo4" title="Stock-based compensation expense" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact002193" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,782,967</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAfZqmoXHmha" title="Unrecognized expense" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact002195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">774,470</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbb2sY1Dla3" title="Weighted average remaining amortization period (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact002197" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.95</ix:nonNumeric></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231_zbrAVj7QZ22e" title="Stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31" id="Fact002199" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,812,566</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231_zf5gaaCKHH4l" title="Stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact002201" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,782,967</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231_zZzUIJJBw2k1" title="Unrecognized expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2024-12-31" id="Fact002203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">774,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zOzUVTj3znM8" title="Weighted average remaining amortization period (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact002205" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.95</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zFWRUvqoB1Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002207" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zVozmWE0SJyc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
7 - <span id="xdx_826_zR22wSIZcwLf">INCOME TAXES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company identified its federal and New York tax returns as its &#8220;major&#8221; tax jurisdictions. The Company is no longer subject
to income tax income examinations by these tax authorities for taxable years ended December 31, 2020, and prior. The Company reviewed
the prior New York state income tax filings and concluded that the prior year return will be amended to change the apportionment from
zero to <span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20240101__20241231_zUkrmcjJv7h4" title="Prior year income taxes, percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact002209" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>%. The Company believes its income tax filing positions and deductions will be sustained on audit, and it does not anticipate
any adjustments that would result in a material change to its financial position. Therefore, no liabilities for uncertain tax positions
have been recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company had approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zePnVp7cedXh" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact002211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,200,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zRa5IkvBOzVf" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact002213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,800,000</ix:nonFraction></span>, respectively, of federal and state net operating losses
that may be available to offset future taxable income. As a result of the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;),
certain future carryforwards do not expire. At December 31, 2024, approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_c20241231__srt--StatementScenarioAxis__custom--ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_zDqomiSyERfd" title="Operating loss carry-forwards subject to expiration"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="AsOf2024-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" id="Fact002215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,800,000</ix:nonFraction></span> of federal net operating losses will expire
from 2030 to 2038 and approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_c20241231_zXc6BzRqcNMd" title="Operating loss carry-forwards not subject to expiration"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" contextRef="AsOf2024-12-31" id="Fact002217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,400,000</ix:nonFraction></span> have no expiration but are subject to a utilization limit equal to 80% of current taxable
income. <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_z84EZ3UauGO9" title="Net operating loss description"><ix:nonNumeric contextRef="From2024-01-012024-12-31" id="Fact002219" name="us-gaap:LesseeOperatingLeaseDescription">The state net operating losses have a 20 year carryforward period and will begin to expire beginning 2035.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 151; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zywpKWkgXOba" title="Income tax examination, description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SectionThreeHundredAndEightyTwoMember" id="Fact002221" name="us-gaap:IncomeTaxExaminationDescription">In
accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#8217;s net operating loss carryforwards are subject
to annual limitations due to several greater than 50% ownership changes.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not performed a formal analysis for the year ended December 31, 2024, but it believes its ability to use such net operating
losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections
382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit
use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred
over the three-year period ended December 31, 2024. For the period ended December 31, 2024, the Company has recorded a full valuation
allowance against the gross deferred tax asset balance as management believes that it is more likely than not that the results of operations
will not generate sufficient taxable income to realize any of the deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this filing, the Company has not filed its 2024 federal and state corporate income tax returns. The Company expects to
file these documents as soon as practicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002223" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOmgaPOBaQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zZUwWPmupGV3" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zL9QFC7L3Yig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zhbF1s19zvl7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zEjIVolmYEU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzcBK_zW8G8vTtyQJk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact002228" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,004,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact002229" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,311,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGzcBK_zFIFQbADeNHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact002231" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,695,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact002232" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,788,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTAGzcBK_zdxqp5f1BD88" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact002234" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,694,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact002235" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,676,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGzcBK_zOXQBzh1v0Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2024-12-31" id="Fact002237" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">330,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31" id="Fact002238" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">330,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsRightOfUseAsset_i01I_maDTAGzcBK_zZJt7OwUWjwa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2240">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:DeferredTaxAssetsRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact002241" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcBK_zwScf9aTi8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact002243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact002244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGzcBK_maDTALNz6jW_zRxljnsv5rrj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact002246" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,724,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact002247" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,134,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zlws6xNcz8z3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred Tax Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxLiabilitiesDepreciation_i01NI_pp0p0_di_maDITLz8iB_zvhfLWJlS6a1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:DeferredTaxLiabilitiesDepreciation" contextRef="AsOf2024-12-31" id="Fact002252" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">153,200</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:DeferredTaxLiabilitiesDepreciation" contextRef="AsOf2023-12-31" id="Fact002253" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">122,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_maDITLz8iB_zMvdEk1EX2Mf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2024-12-31" id="Fact002255" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,700</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2023-12-31" id="Fact002256" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_i01NI_pp0p0_di_maDITLz8iB_z5JN7o7R2Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2258">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2023-12-31" id="Fact002259" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLz8iB_z626f9pOcRZd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2024-12-31" id="Fact002261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2023-12-31" id="Fact002262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pp0p0_di_mtDITLz8iB_msDTALNz6jW_z5ov3kRZfdYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact002264" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">289,900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="Fact002265" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNz6jW_zDuuMmzJjzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Deferred Tax Asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="Fact002267" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,434,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="Fact002268" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,840,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8Hs2v6wALU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact002270" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,434,100</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact002271" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,840,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_z8GkK0NwV2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred Tax Asset, Net of Valuation Allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2273">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2274">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Change in valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20240101__20241231_zmS2WbGfj5n6" title="Change in valuation allowance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-01-012024-12-31" id="Fact002276" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,405,900</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"/><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20230101__20231231_zc9ckzJO7A9f" title="Change in valuation allowance" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-012023-12-31" id="Fact002278" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,064,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zgRHuIkbL9D3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 152; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002280" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zltwcQOflIb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision (benefit) as of December 31, 2024 and 2023 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zewWuR64PcD5" style="display: none">SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zRwhUVQspGih" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zxkSMrPCvzR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlI2aJg7XIZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maDFSALzNuk_zO5ShPfW6jN4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2286">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zk51qR840bie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%">Deferred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact002288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,567,000</ix:nonFraction></td><td style="width: 1%; text-align: left"/><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002289" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,090,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zTDgkAmF6Uzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State &amp; Local:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maDFSALzNuk_z2FcUaberu53" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2294">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2295">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zRDQK8KB7bX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Deferred</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact002297" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,161,100</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002298" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">974,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBz5Bf_mtDFSALzNuk_zPjhdL5jZTtd" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact002300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,405,900</ix:nonFraction></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002301" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,064,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ChangeInValuationAllowance_i01N_di_msITEBz5Bf_zhzlgQSBeSpj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BRTX:ChangeInValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact002303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,405,900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:ChangeInValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact002304" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,064,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz5Bf_zTflNXI3Iww2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2306">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2307">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zE62j2LkqvZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002309" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbnotrZxBuda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zkPZz0PDfa4f" style="display: none">SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zIN1SWuTCKCd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zYoEk77mdqyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR_zoD8GqfTv0Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact002311" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact002312" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR_zBasGeNwUdq5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact002314" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact002315" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.7</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR_ztCkHqhYvo49" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2024-01-012024-12-31" id="Fact002317" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2023-01-012023-12-31" id="Fact002318" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_maETR_zeaqqe9LYYr1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax return to provision adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" contextRef="From2024-01-012024-12-31" id="Fact002320" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.4</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" contextRef="From2023-01-012023-12-31" id="Fact002321" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR_zu0T4TNCIfFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in federal valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact002323" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39.7</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact002324" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">29.7</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_pid_dp_uPure_maETR_z06HeVNrY5Z7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Adjustment for stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">-<ix:nonFraction name="BRTX:EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact002326" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">62.1</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2327">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR_z9fAJvH2U32l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-012024-12-31" id="Fact002329" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="Fact002330" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zWRkjNmqbrWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002332" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zgcg9trQLw4b" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
8 &#8211; <span id="xdx_82A_zZqO5mhrGS0j">LEASES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a lease for <span id="xdx_90B_eus-gaap--AreaOfLand_iI_usqft_c20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zh4cxmaJnd2j" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2024-12-31_custom_MelvilleLeaseMember" id="Fact002334" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">6,800</ix:nonFraction></span> square feet of space located in Melville, New York (the &#8220;Melville Lease&#8221;) with respect
to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zmpZ4l7IQSC6" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MinimumMember" id="Fact002336" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132,600</ix:nonFraction></span> and
$<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zOjbIvPdVbN8" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MaximumMember" id="Fact002338" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,260</ix:nonFraction></span>. In June 2019, <span id="xdx_908_eus-gaap--LessorOperatingLeaseOptionToExtend_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_z4SYxbAeZm8h" title="Lease extension description"><ix:nonNumeric contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember" id="Fact002340" name="us-gaap:LessorOperatingLeaseOptionToExtend">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zIdUhKaj4omk" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember" id="Fact002342" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">153,748</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zAvMxkpiKrlg" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember" id="Fact002344" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,060</ix:nonFraction></span>.</ix:nonNumeric></span> The lease
expired on December 31, 2024 and the Company is currently leasing the premises on a month-to-month basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zrQlabrxcXu" title="Weighted average incremental borrowing rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact002346" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 153; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002348" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zfhOXOmxfDS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8BA_zYd7fINKNxyl" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zAim7KPlS8Vd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_zJY5zkeqo6Qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease Costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzEnl_zdxX3SOKOhwd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-012024-12-31" id="Fact002350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,060</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact002351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,028</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zNJI74DdZmgh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-012024-12-31" id="Fact002353" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,060</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-12-31" id="Fact002354" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">168,028</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zaVUvxrI8Xgk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease - operating cash flows (fixed payments)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-012024-12-31" id="Fact002356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,060</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact002357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OperatingLeaseLiabilityReduction_zlA1fMwWsVF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease - operating cash flows (liability reduction)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:OperatingLeaseLiabilityReduction" contextRef="From2024-01-012024-12-31" id="Fact002359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:OperatingLeaseLiabilityReduction" contextRef="From2023-01-012023-12-31" id="Fact002360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,328</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current leases - right of use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20241231_zlGR7yPRwte5" title="Non-current leases - right of use assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_z3Cs3WdUJgzk" title="Non-current leases - right of use assets" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact002364" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">151,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20241231_zait734oCTT3" title="Current liabilities - operating lease liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_z5SMTMDgFzqf" title="Current liabilities - operating lease liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact002368" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zXJzCNst9qGg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23OperatingLeaseLiabilityCurrent"><span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zRFYux9HxGJ8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23OperatingLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl2369"><span style="-sec-ix-hidden: xdx2ixbrl2370">Non-current liabilities - operating lease liabilities</span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20241231_zqhxJYXaknKk" title="Non-current liabilities - operating lease liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2372">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_zSdrEeHsTO37" title="Non-current liabilities - operating lease liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2374">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zHFgvhk3iHe6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no future minimum payments under non-cancelable leases following the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002376" name="us-gaap:FinancialInstrumentsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zltmBzWqEc73" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
9 &#8211; <span id="xdx_822_zkzDTDJn5Zsa">FAIR VALUE MEASUREMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the Warrants as liabilities in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging &#8212;
Contracts in Entity&#8217;s Own Equity. For certain Warrants, the Company does not control the occurrence of events, such as a tender
offer or exchange, that may trigger cash settlement of the Warrants and not result in a change of control of the Company. As a result,
such Warrants do not meet the criteria for equity treatment and the Warrants must be recorded as a derivative liability. Additionally,
certain other Warrants contain adjustments to the settlement amount based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221;
option as defined under ASC 815-40 and, accordingly, such Warrants are not considered indexed to the Company&#8217;s own stock and are
not eligible for an exception from derivative accounting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2024, in connection with the Warrant Exercise and Issuance, the Company estimated the aggregate fair value of the Existing
Warrants (see Note 6- Stockholders&#8217; Equity for details) to be $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20240208__20240208__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_ziBScYzZ13xb" title="Fair value of adjustment"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-02-082024-02-08_custom_ExistingWarrantMember_custom_BlackScholesOptionMember" id="Fact002378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,115,334</ix:nonFraction></span> using the Black-Scholes option pricing model (Level 3
inputs). The following table shows the detail of the valuation assumptions used:</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" continuedAt="ConU002385-01" escape="true" id="Fact002385" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-ZMNRFLS_zGWiyj8eGB08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zy4Lx3EQdX9j" style="display: none">SCHEDULE
OF FAIR VALUE VALUATION ASSUMPTIONS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_z3vjeUokVdy1" title="Risk free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember" id="Fact002387" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.20</ix:nonFraction></span> - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zsQwgnRfo9ne" title="Risk free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember" id="Fact002389" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.28</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zqcGcNRJo4Xb" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_ExistingWarrantMember" format="ixt-sec:duryear" id="Fact002391" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.75</ix:nonNumeric></span> - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zMr7mo2LgO82" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_ExistingWarrantMember" format="ixt-sec:duryear" id="Fact002393" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.76</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zT7MOzpWsO63" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_custom_ExistingWarrantMember" id="Fact002395" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">102</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zByUcEfDP6Vl" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ExistingWarrantMember" id="Fact002397" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zWTVHDTVNATa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2024, the Company estimated the aggregate issuance date fair value of the warrant liability related to the New Warrants (see
Note 4 - Stockholders&#8217; Equity for details) as $<span id="xdx_909_eus-gaap--DerivativeLiabilities_iI_c20240208_zaZ4oNIOeEXf" title="Derivative liabilities"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-02-08" id="Fact002399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,189,420</ix:nonFraction></span> using the Black-Scholes option pricing model (Level 3 inputs). The following
table shows the detail of the valuation assumptions used:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_zFEXuwxSsfh3"><ix:continuation continuedAt="ConU002385-02" id="ConU002385-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C07_gL3FVAALMORAN-ZMNRFLS_z9jIJ08bBYOb"><ix:continuation continuedAt="ConU002385-03" id="ConU002385-02"><table cellpadding="0" cellspacing="0" id="xdx_300_zBSJWV5SGvha" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zD3oN4V56Q5b" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member" id="Fact002401" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.12</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8SRKjJEIcZ3" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member" format="ixt-sec:duryear" id="Fact002403" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0OvHJjsBvog" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member" id="Fact002405" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmGV2nd8un74" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_FairValueInputsLevel3Member" id="Fact002407" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C04_gL3FVAALMORAN-ZMNRFLS_zRoWvOb3mFlc"><ix:continuation continuedAt="ConU002385-04" id="ConU002385-03">&#160;</ix:continuation></span></span></p>


<ix:exclude><!-- Field: Page; Sequence: 154; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2024 and 2023, the Company estimated the aggregate fair value of the warrants classified as derivative liabilities to purchase
an aggregate of <span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zLLHtFGQXIk2" title="Fair value of adjustment"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_custom_BlackScholesOptionMember" id="Fact002409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,900,014</ix:nonFraction></span> and <span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_z5RerJc1v6T2" title="Fair value of adjustment"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_BlackScholesOptionMember" id="Fact002411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,737,908</ix:nonFraction></span> shares of common stock, respectively, to be $<span id="xdx_907_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zC0D4h0jC5k6" title="Fair value of derivative liabilitiy"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2024-12-31_custom_BlackScholesOptionMember" id="Fact002413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zSAOIQsG5Qm9" title="Fair value of derivative liabilitiy"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2023-12-31_custom_BlackScholesOptionMember" id="Fact002415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,953</ix:nonFraction></span>, respectively, using the
Black-Scholes option pricing model (Level 3 inputs) using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_z6Jk0lFnAFsd"><ix:continuation continuedAt="ConU002385-05" id="ConU002385-04"><table cellpadding="0" cellspacing="0" id="xdx_307_zKLVcIhIzVE2" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv7eKFqVeiu7" title="Risk free interest rate, Minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact002417" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.12</ix:nonFraction>%</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBHAeic1Mmv" title="Risk free interest rate, Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact002419" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.34</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvyycNHmduL7" title="Risk free interest rate, Minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact002421" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.04</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zA8LVCxdYpp9" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact002423" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">1.86</ix:nonNumeric></span> - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMhtVWrrmuYj" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact002425" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.11</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z570pw5hpvj8" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact002427" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.86</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCRrHeM4Aqyi" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" id="Fact002429" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">97</ix:nonFraction></span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zQRlaizdtMj2" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" id="Fact002431" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">110</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmLHGhk0izj8" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact002433" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">87.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1AoHDe9wf58" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact002435" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4BAeX5Y6SXd" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact002437" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_C01_gL3FVAALMORAN-ZMNRFLS_zQgLe4Ufswxb"><ix:continuation id="ConU002385-05">&#160;</ix:continuation></span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002439" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMC0qycoxwah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zKAQQdINnHu1" style="display: none">SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance, January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_c20230101__20231231_zq0KZ6eETEId" title="Balance, January 1, 2023" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-12-31" id="Fact002441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,541,733</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20230101__20231231_zzNM3R7N5ZQa" title="Change in fair value of derivative liability" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact002443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,997,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_c20240101__20241231_z9mQLh7c0ln7" title="Balance, January 1, 2024" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31" id="Fact002445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,953</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231_zKGDn9WG9Bhf" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31" id="Fact002447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,189,420</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_iN_di_c20240101__20241231_zF9LX4FrXUh9" title="Exercise of warrants">(<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-12-31" id="Fact002449" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,115,334</ix:nonFraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20240101__20241231_zpDBZORmgt8b" title="Change in fair value of derivative liability" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-12-31" id="Fact002451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iE_c20240101__20241231_zNGCeauSjfRl" title="Balance, december 30, 2024" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31" id="Fact002453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z3mL6NzRpPKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities measured at fair value on a recurring basis are as follows:</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002455" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6tGfwS6kgK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z5r5D5GaLK3d" style="display: none"><span>SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%">Marketable securities as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4WzJJjC4wS1" title="Marketable securities, fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact002457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,184,701</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxeusrZDKjP6" title="Marketable securities, fair value" style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2459">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2rpFzeBYrv1" title="Marketable securities, fair value" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2461">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_c20241231_zmKh1dwd0rfe" title="Marketable securities" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-12-31" id="Fact002463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,184,701</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zC3pfJMA2Vod" title="Marketable securities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact002465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,181,618</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFxBE74S8NCj" title="Marketable securities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2467">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUaeaX3Cxbrj" title="Marketable securities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2469">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zkPmSxUWuL6e" title="Marketable securities" style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact002471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,181,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant liabilities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaDiGqMl6dni" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2473">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZUD9addK6D7" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2475">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlzurmG7ynm" title="Warrant liabilities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact002477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_ziSFoXIxNsge" title="Warrant liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact002479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrant liabilities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRXvDdOz7IR8" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2481">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWQ1XwDflpwh" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2483">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzV5BGldJR4" title="Warrant liabilities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact002485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,953</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231_zyQUQAE5wWT5" title="Warrant liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact002487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,953</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zHZFVjyZEVW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact002489" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zQwk95xqwdn2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
10 - <span id="xdx_827_z8pGpu2YREya">SUBSEQUENT EVENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to the year ended December 31, 2024, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKg7Zk2AAER1" title="Sold shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact002491" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">492,000</ix:nonFraction></span> shares of its common stock under the Rodman ATM program with a weighted-average
gross price of approximately $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFw7mnG04Qni" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact002493" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.20</ix:nonFraction></span> per share and raised approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zus5kgmQYQ7" title="Gross proceeds"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact002495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,084,000</ix:nonFraction></span> of gross proceeds. The total commissions and related
legal and accounting fees were approximately $<span id="xdx_904_eus-gaap--PaymentsForLegalSettlements_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuIqcQVJa93f" title="Legal settlements paid"><ix:nonFraction name="us-gaap:PaymentsForLegalSettlements" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact002497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,000</ix:nonFraction></span> and the Company received net proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zfCSxkZoeUo1" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember" id="Fact002499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">906,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Grants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2024, the Company granted options to purchase an aggregate <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9OxoGbvnv17" title="Grant options shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact002501" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,152,908</ix:nonFraction></span> shares of the Company&#8217;s common stock at an
exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8mtyATWWQi7" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact002503" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></span> per share to employees, the Company&#8217;s board of directors and a member of the Company&#8217;s scientific
advisory board. The options had an aggregate grant date fair value of $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP0528XPAvEi" title="Grant options shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact002505" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">4,044,250</ix:nonFraction></span> and vest as follows: (i) options to purchase an aggregate
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zA3ysS42tju2" title="Options to purchase shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact002507" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">323,459</ix:nonFraction></span> shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoMpjuVT8AZf" title="Purchase of common shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact002509" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,829,449</ix:nonFraction></span> shares of common stock
vest <span id="xdx_908_ecustom--CommonStockVestRemainderPercentage_iI_pid_dp_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSBDnzWykyNg" title="Purchase of common shares"><ix:nonFraction name="BRTX:CommonStockVestRemainderPercentage" contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact002511" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant. The Company will
recognize the grant date fair value of the options proportionate to the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common Stock Issuance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to the year ended December 31, 2024, the
Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zn754CUGeFkd" title="Number of shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember" id="Fact002513" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,525</ix:nonFraction></span> shares of common stock to Auctus Fund, LLC in partial satisfaction of shares held by abeyance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><p id="xdx_814_zwydxQb5pRWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_006.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; background-color: white"><b>Up to 9,708,738
Units, each consisting of:</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; background-color: white"><b>One Share
of Common Stock or One Pre-Funded Warrant to Purchase One</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; background-color: white"><b>Share of
Common Stock and One Common Stock Warrant to Purchase up to</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; background-color: white"><b>One Share
of Common Stock</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Up
to 9,708,738</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b> Shares of Common Stock or
Shares of Common Stock Underlying Pre-Funded Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b></b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; background-color: white"><b>Up 9,708,738
Shares of Common Stock Underlying</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; background-color: white"><b>Common
Stock Warrants</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>&#160;</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Prospectus</b></span><b>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Rodman
&amp; Renshaw LLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8195;</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#8195;&#8195;,
2026</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 156 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    13.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
    Expenses of Issuance and Distribution</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the estimated costs and expenses payable by us in connection with the sale of the securities being registered.
All amounts shown are estimates except for the SEC registration fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">SEC registration fee</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><p style="margin: 0">2,858.67</p></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FINRA filing fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">2,981.25</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">190,000.00</p></td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">55,000.00</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Miscellaneous fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">17,160.08</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">268,000.00</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: lime"></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    14.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
    of Directors and Officers</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
78.7502(1) of the NRS provides that a corporation may, and the Registrant&#8217;s Amended and Restated Articles of Incorporation (&#8220;Articles&#8221;)
and By-Laws provide that the Registrant shall, indemnify any person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (an &#8220;Action&#8221;),
by reason of the fact that he is or was a director, officer, employee or agent of the corporation or is or was serving at the request
of the corporation in such capacity in another corporation, partnership, joint venture, trust or other enterprise (the &#8220;Indemnified
Party&#8221;), against expenses (including attorney&#8217;s fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to
be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable
cause to believe his conduct was unlawful; provided, however, no indemnification shall be made in respect of any Actions by or in the
right of the corporation if the Indemnified Party shall have been adjudged by a court of competent jurisdiction, after exhaustion of
any appeals, to be liable to the corporation, unless and only to the extent that the court shall determine that, despite the adjudication
of liability but in view of all circumstances, such person is fairly and reasonably entitled to indemnity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the NRS, the directors have a fiduciary duty to the Registrant that is not eliminated by this provision of the Articles and, in appropriate
circumstances, equitable remedies such as injunctive or other forms of non-monetary relief will remain available. In addition, each director
will continue to be subject to liability under the NRS for breach of the director&#8217;s duty of loyalty to the Registrant for acts
or omissions which are found by a court of competent jurisdiction to not be in good faith or involve intentional misconduct, for knowing
violations of law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock
repurchases or redemptions that are prohibited by the NRS. This provision also does not affect the directors&#8217; responsibilities
under any other laws, such as the federal securities laws or state or federal environmental laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 157; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Section 78.7502(3) of the NRS provides that determination of an Indemnified Party&#8217;s eligibility for indemnification by the Registrant
shall be made on a case-by-case basis by: (i) the stockholders; (ii) the board of directors by a majority vote of a quorum consisting
of directors who were not parties to the Action; (iii) independent legal counsel&#8217;s written opinion if: (1) a majority vote of a
quorum consisting of directors who were not parties to the Action so orders; or (2) a quorum consisting of directors who were not parties
to the Action cannot be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
Section 78.752(1) of the NRS empowers a corporation to purchase and maintain insurance or make other financial arrangements with respect
to liability arising out of the actions or omissions of directors, officers, employees or agents in their capacity or status as such,
whether or not the corporation has the authority to indemnify him against such liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registrant&#8217;s Articles provide that, to the fullest extent permitted by the NRS, no director or officer shall be personally liable
to the Registrant or to its stockholders for monetary damages for breach of fiduciary duty as a director or an officer, except to the
extent that such exemption from liability or limitation thereof is not permitted under the NRS currently in effect or as the same may
be amended. If the NRS is amended to further eliminate or limit or authorize corporate action to further eliminate or limit the liability
of directors or officers, the liability of directors and officers of the Registrant shall be eliminated or limited to the fullest extent
permitted by the NRS, as so amended from time to time. No repeal or modification of this provision of the Articles will apply to or have
any effect on the liability or alleged liability of any director or officer of the Registrant for or with respect to any acts or omissions
of such directors or officers occurring prior to such repeal or modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registrant&#8217;s Bylaws provide that the Registrant will indemnify and hold harmless any person who was or is a party or is threatened
to be made a party to any threatened, pending or completed Action in such manner, under such circumstances and to the fullest extent
permitted by the Articles and the NRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons
under the provisions discussed above or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 1.3pt; padding-right: 1.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
    Sales of Unregistered Securities. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Date Issued</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Term <br/>(Years)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Purchaser(s)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Consideration(1)</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; text-align: right">2/6/24</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,513,686</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">314,211 (3</span></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">10/8/25</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">508,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">361,409 (4</span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">10/8/25</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,761 (6</span></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            value of the non-cash consideration was estimated to be the fair value of our restricted
                                            common stock. Since our shares are thinly traded in the open market, the fair value of our
                                            equity instruments was estimated by management based on observations of the cash sales prices
                                            of both restricted shares and freely tradable shares.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accredited
                                            investor.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            warrants were issued pursuant to a private placement of securities at a price of $0.125 per
                                            warrant. The fair value of the warrants was $2,189,420 as of February 8, 2024, the date of
                                            issuance.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            warrants were issued pursuant to a private placement concurrently with the sale of an aggregate
                                            of 678,125 shares of common stock in a registered direct offering for aggregate gross proceeds
                                            of approximately $1.1 million.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
                                            Agent.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
                                            as compensation to the placement agent in connection with the sale of common stock and warrants.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 158 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.75in"><b>Item</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.</b></span></td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"><b>Exhibits.</b></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_3.htm" style="-sec-extract: exhibit">Amended and Restated Articles of Incorporation, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.3</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_4.htm" style="-sec-extract: exhibit">Certificate of Designations of Series B Preferred Stock, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.4</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_5.htm" style="-sec-extract: exhibit">Bylaws, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.5</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224043839/ex4-1.htm" style="-sec-extract: exhibit">Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, incorporated by reference to the registrant&#8217;s Amendment No. 2 to Annual Report on Form 10-K/A for the year ended December 31, 2023, wherein such document is identified as Exhibit 4.1</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-2.htm">Form of Common Stock Warrant*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-3.htm">Form of Pre-Funded Warrant*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-4.htm">Form of Placement Agent Warrant*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Certilman Balin Adler &amp; Hyman, LLP*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420412021914/v308966_ex10-44.htm" style="-sec-extract: exhibit">License Agreement, dated as of January 27, 2012, between Regenerative Sciences, LLC and BioRestorative Therapies, Inc. (&#8220;License Agreement&#8221;), incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, wherein such document is identified as Exhibit 10.44</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420412021914/v308966_ex10-45.htm" style="-sec-extract: exhibit">Amendment to License Agreement, dated March 21, 2012, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, wherein such document is identified as Exhibit 10.45</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420416091575/v434828_ex10-20.htm" style="-sec-extract: exhibit">Amendment to License Agreement, dated November 30, 2015, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2015, wherein such document is identified as Exhibit 10.20</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-4.htm" style="-sec-extract: exhibit">Letter agreement, dated November 21, 2022, by and among BioRestorative Therapies, Inc., Regenerative Sciences, LLC and Regenexx, LLC with regard to License Agreement, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.4</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177114000054/ex99_1.htm" style="-sec-extract: exhibit">Lease, dated as of August 25, 2014, between BioRestorative Therapies, Inc. and 50 Republic Road, LLC, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated August 25, 2014, wherein such document is identified as Exhibit 99.1</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 159 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315221006285/ex10-37.htm" style="-sec-extract: exhibit">Lease Amendment, dated as of June 4, 2019, between 50 Republic Road, LLC and BioRestorative Therapies, Inc., incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, wherein such document is identified as Exhibit 10.37</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-7.htm" style="-sec-extract: exhibit">BioRestorative Therapies, Inc. 2021 Stock Incentive Plan, as amended, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, wherein such document is identified as Exhibit 10.7</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_2.htm" style="-sec-extract: exhibit">Executive Employment Agreement, dated as of March 18, 2021, by and between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.2</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_3.htm" style="-sec-extract: exhibit">Executive Employment Agreement, dated as of March 18, 2021, by and between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.3</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_4.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of March 18, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.4</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_5.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of March 18, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.5</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-12.htm" style="-sec-extract: exhibit">Executive Employment Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Robert Kristal, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.12</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/ex99_1.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated November 4, 2021, wherein such document is identified as Exhibit 99.1</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/ex99_2.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated November 4, wherein such document is identified as Exhibit 99.2</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-15.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.15</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-16.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.16</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 160 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-17.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.17</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-18.htm" style="-sec-extract: exhibit">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.18</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-19.htm" style="-sec-extract: exhibit">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.19</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-20.htm" style="-sec-extract: exhibit">Common Stock Purchase Warrant, dated November 9, 2021, issued by BioRestorative Therapies, Inc. pursuant to public offering, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.20</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-21.htm" style="-sec-extract: exhibit">Common Stock Purchase Warrant, dated November 9, 2021, issued by BioRestorative Therapies, Inc. to Auctus Fund, LLC, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.21</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-22.htm" style="-sec-extract: exhibit">Amendment No. 2 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.22</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-23.htm" style="-sec-extract: exhibit">Amendment No. 2 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.23</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-24.htm" style="-sec-extract: exhibit">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.24</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-25.htm" style="-sec-extract: exhibit">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.25</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-26.htm" style="-sec-extract: exhibit">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.26</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-28.htm" style="-sec-extract: exhibit">Incentive Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.28</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-29.htm" style="-sec-extract: exhibit">Incentive Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.29</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 161 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-30.htm" style="-sec-extract: exhibit">Incentive Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Robert Kristal, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.30</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-32.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.32</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-33.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.33</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-34.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.34</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177124000033/ex10_3.htm" style="-sec-extract: exhibit">Form of Warrant, dated February 8, 2024 (issued to warrantholders other than Auctus Fund, LLC), incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated February 6, 2024, wherein such document is identified as Exhibit 10.3</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177124000033/ex10_4.htm" style="-sec-extract: exhibit">Warrant, dated February 8, 2024 (issued to Auctus Fund, LLC), incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated February 6, 2024, wherein such document is identified as Exhibit 10.4</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-36.htm" style="-sec-extract: exhibit">Incentive Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.36</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-37.htm" style="-sec-extract: exhibit">Incentive Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.37</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-38.htm" style="-sec-extract: exhibit">Incentive Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and Robert Kristal, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.38</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-40.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.40</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-41.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.41</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-42.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.42</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 162 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177124000188/ex1_1.htm" style="-sec-extract: exhibit">At the Market Offering Agreement, dated as of November 6, 2024, by and between BioRestorative Therapies, Inc. and Rodman &amp; Renshaw, LLC, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated November 1, 2024, wherein such document is identified as Exhibit 1.1</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000164117225001011/ex10-40.htm" style="-sec-extract: exhibit">Incentive Stock Option Award Agreement, dated as of February 14, 2025, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, wherein such document is identified as Exhibit 10.40</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000164117225001011/ex10-41.htm" style="-sec-extract: exhibit">Incentive Stock Option Award Agreement, dated as of February 14, 2025, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, wherein such document is identified as Exhibit 10.41</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000164117225001011/ex10-42.htm" style="-sec-extract: exhibit">Incentive Stock Option Award Agreement, dated as of February 14, 2025, between BioRestorative Therapies, Inc. and Robert Kristal, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, wherein such document is identified as Exhibit 10.42</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000164117225001011/ex10-43.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of February 14, 2025, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, wherein such document is identified as Exhibit 10.43</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000164117225001011/ex10-44.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of February 14, 2025 between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, wherein such document is identified as Exhibit 10.44</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000164117225001011/ex10-45.htm" style="-sec-extract: exhibit">Non-Qualified Stock Option Award Agreement, dated as of February 14, 2025, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, wherein such document is identified as Exhibit 10.45</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315225017446/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant, dated October 8, 2025, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated October 6, 2025, wherein such document is identified as Exhibit 4.1</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315225024081/ex10-49.htm" style="-sec-extract: exhibit">Amendment, dated October 15, 2025, to Common Stock Purchase Warrant, dated October 8, 2025, issued to Auctus Fund, LLC, incorporated by reference to the registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on November 18, 2025, wherein such document is identified as Exhibit 10.49</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-50.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315219004292/ex21.htm" style="-sec-extract: exhibit">Subsidiaries, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, wherein such document is identified as Exhibit 21</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Marcum LLP*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Certilman Balin Adler &amp; Hyman, LLP (included in the opinion of Certilman Balin Adler &amp; Hyman, LLP filed as Exhibit 5)*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Y-001">Power of Attorney (included on signature page of the Registration Statement)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document *</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Schema Document *</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Calculation Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Definition Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Label Linkbase Documents*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Presentation Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex107.htm">Filing Fee Table*</a></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Filed
herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 163 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="padding-left: 10pt; text-indent: -10pt; width: 0.75in"><b>Item</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.</b></span></td>
  <td style="padding-left: 10pt; text-indent: -10pt"><b>Undertakings.</b></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred
or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned Registrant hereby undertakes that:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)&#8195;For
purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of
this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule
424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was
declared effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)&#8195;
For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates
in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 49.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 164 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in Melville, New York, on February 9, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
    THERAPIES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lance Alstodt</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Chairman of the Board</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Y-001"></span>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lance Alstodt as his true and lawful
attorney-in-fact with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities,
to sign any and all amendments, including post-effective amendments to this registration statement, and any registration statement and
amendments thereto for the same offering pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and to file the same, with
exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming
all that said attorneys-in-fact or their substitutes, each acting alone, may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><i>/<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s/ </span>Lance
    Alstodt</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Chairman of the Board (Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    9, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><i>/s/<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Francisco Silva</span></i></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President, Research and Development, Secretary and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">February
    9, 2026</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><i>/s/<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Robert E. Kristal</span></i></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer and Principal Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">February
    9, 2026</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E. Kristal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><i>/s/<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Nickolay Kukekov</span></i></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">February
    9, 2026</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><i>/s/<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Patrick F. Williams</span></i></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">February
    9, 2026</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><i>/s/<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    David Rosa</span></i></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">February
    9, 2026</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 165; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex4-2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BioRestorative
Therapies, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
  Shares: _______</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
  Exercise Date: [______], 2026</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the
&ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York
City time) on [_____], 2031<SUP>1</SUP> (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase
from BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment
hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant
shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 25%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP>
Insert the date that is the five year anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, insert
the immediately following Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the securities purchase agreement, dated as of [______], 2026, by and among the Company and each of the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1 (File No. 333-[______]).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Transhare Corporation, the current transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants, issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise within one (1) Business Day of the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $[_____], subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in
whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=
                                            as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
                                            Notice of Exercise if such Notice of Exercise is (1) delivered pursuant to Section 2(a) hereof
                                            on a day that is not a Trading Day or (2) delivered pursuant to Section 2(a) hereof on a
                                            Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule
                                            600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day,
                                            (ii) the highest Bid Price of the Common Stock on the principal Trading Market as reported
                                            by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) within two (2) hours of the time of the
                                            Holder&rsquo;s delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such
                                            Notice of Exercise is delivered during &ldquo;regular trading hours,&rdquo; or within two
                                            (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii)
                                            the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
                                            is a Trading Day and such Notice of Exercise is delivered pursuant to Section 2(a) hereof
                                            after two (2) hours following the close of &ldquo;regular trading hours&rdquo; on such Trading
                                            Day;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
                                                                 <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=
                                            the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
                                                                 <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
                                                                 <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=
                                            the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
                                            with the terms of this Warrant if such exercise were by means of a cash exercise rather than
                                            a cashless exercise.</FONT></TD></TR>
                                                                 </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mechanics
                                            of Exercise</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
                                            of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased
                                            hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account
                                            of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
                                            through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the
                                            Company is then a participant in such system and either (A) there is an effective registration
                                            statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares
                                            by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by
                                            physical delivery of a certificate or by book entry, registered in the Company&rsquo;s share
                                            register in the name of the Holder or its designee, for the number of Warrant Shares to which
                                            the Holder is entitled pursuant to such exercise to the address specified by the Holder in
                                            the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the
                                            delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising
                                            the Standard Settlement Period after the delivery to the Company of the Notice of Exercise,
                                            all subject to receipt of any cash required from the Holder unless this Warrant is exercised
                                            pursuant to Section 2(c) (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
                                            Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes
                                            to have become the holder of record of the Warrant Shares with respect to which this Warrant
                                            has been exercised, irrespective of the date of delivery of the Warrant Shares, provided
                                            that payment of the aggregate Exercise Price (other than in the case of a cashless exercise)
                                            is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading
                                            Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.
                                            If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to
                                            a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder,
                                            in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
                                            to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
                                            of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading
                                            Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share
                                            Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The
                                            Company agrees to maintain a transfer agent that is a participant in the FAST program so
                                            long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard
                                            Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
                                            of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common
                                            Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the
                                            foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m.
                                            (New York City time) on the Initial Exercise Date, which may be delivered at any time after
                                            the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant
                                            Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise
                                            Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes
                                            hereunder, provided that payment of the aggregate Exercise Price (other than in the case
                                            of a cashless exercise) is received by such Warrant Share Delivery Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely
due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker
to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
&ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares
of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent
periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C)
a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon
the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving
effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution
Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo; shall be [4.99/9.99]% of the number of shares of Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease
the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the
Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The
limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all of the
record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the
Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record
is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to all of the holders of shares of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of cash (other than ordinary cash dividends), stock or other
securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other
similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each such case,
the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if
the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record
is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock
as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the voting
power of the equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires greater than 50% of the voting power of the equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,
in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the
date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder
an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date
of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within
the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive
from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value
of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration
in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function
on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to 100%, (C) the underlying price per share used in such calculation shall be the VWAP immediately preceding the public
announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if
earlier), (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental
Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer
of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election
and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction
in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the
Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by
a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares
of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon
exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and
with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under
this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this
Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the
Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally
with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall
assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect
as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the
avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the
Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction
occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice (unless such information is filed with the Commission, in which case a notice shall not be required)
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock
of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect
therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To
the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company
or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board
of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new
Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event, including if the Company
is for any reason unable to issue and deliver Warrant Shares upon exercise of this Warrant as required pursuant to the terms hereof,
shall the Company be required to net cash settle an exercise of this Warrant or cash settle in any other form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 40 Marcus Drive, Suite One, Melville, New York 11747, Attention: CEO, email address: lalstodt@biorestorative.com,
or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or
other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or
sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. Other than Section 2(e) above and this Section 5(l), which may not be amended, modified or waived, this Warrant may
be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the
other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BioRestorative
  Therapies, Inc.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
  Alstodt</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
  Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
BioRestorative Therapies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;]
in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: ______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: _________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
_____________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
                                            Print)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: _______________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: _______________________ </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>3
<FILENAME>ex4-3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PREFUNDED
COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BioRestorative
Therapies, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares: _______</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Exercise Date: [______], 2026</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the
&ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) until this Warrant is exercised in full
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from BioRestorative Therapies, Inc., a
Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the securities purchase agreement, dated as of [______], 2026, by and among the Company and each of the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1 (File No. 333-[______]).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Transhare Corporation, the current transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Prefunded Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise within one (1) Business Day of the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share,
was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the
nominal exercise price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise
of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise
price under any circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant
shall be $0.0001, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo;
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
  =</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
  applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise
  is (1) delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) delivered pursuant to Section 2(a) hereof
  on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated
  under the federal securities laws) on such Trading Day, (ii) the highest Bid Price of the Common Stock on the principal Trading Market
  as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) within two (2) hours of the time of the Holder&rsquo;s delivery of the Notice
  of Exercise pursuant to Section 2(a) hereof if such Notice of Exercise is delivered during &ldquo;regular trading hours,&rdquo; or
  within two (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii) the VWAP on the date of the
  applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is delivered pursuant
  to Section 2(a) hereof after two (2) hours following the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
  =</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
  Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
  =</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
  number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
  exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a
certificate or by book entry, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number
of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise
by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number
of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise, all subject to
receipt of any cash required from the Holder unless this Warrant is exercised pursuant to Section 2(c) (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of
delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise)
is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period
following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not
as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery
Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m.
(New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement,
the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise
Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely
due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker
to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
&ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares
of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent
periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C)
a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon
the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving
effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution
Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo; shall be [4.99/9.99]% of the number of shares of Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease
the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the
Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The
limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all of the
record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the
Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record
is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to all of the holders of shares of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the voting
power of the equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires greater than 50% of the voting power of the equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor
entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in
writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior
to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead
to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor
Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity
or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents
with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the
Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless
of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a
Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice (unless such information is filed with the Commission, in which case a notice shall not be required)
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock
of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect
therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To
the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company
or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board
of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new
Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 40 Marcus Drive, Suite One, Melville, New York 11747, Attention: CEO, email address: <U>lalstodt@biorestorative.com</U>,
or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or
other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or
sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. Other than Section 2(e) above and this Section 5(l), which may not be amended, modified or waived, this Warrant may
be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the
other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BioRestorative
                    Therapies, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
BioRestorative Therapies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;&nbsp;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: ______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: _________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
_____________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
                                            Print)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:_____________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:</FONT>______________________</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>4
<FILENAME>ex4-4.htm
<DESCRIPTION>EX-4.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENT COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BioRestorative
Therapies, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: _______</FONT></TD>
    <TD STYLE="text-align: right; padding-left: -10pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: [______], 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or
its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00
p.m. (New York City time) on [_____], 2031<SUP>1</SUP> (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for
and purchase from BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject
to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under
this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement
Agreement, by and between the Company and Rodman &amp; Renshaw, LLC, dated February 4, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP>
Insert the date that is the five year anniversary of commencement of sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the securities purchase agreement, dated as of [______], 2026, by and among the Company and each of the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1 (File No. 333-[______]).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Transhare Corporation, the current transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants, issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise within one (1) Business Day of the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $[_____]<SUP>2</SUP>, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in
whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
    Exercise is (1) delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) delivered pursuant to Section
    2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
    NMS promulgated under the federal securities laws) on such Trading Day, (ii) the highest Bid Price of the Common Stock on the principal
    Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) within two (2) hours of the time of the Holder&rsquo;s
    delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such Notice of Exercise is delivered during &ldquo;regular
    trading hours,&rdquo; or within two (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii) the
    VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
    Exercise is delivered pursuant to Section 2(a) hereof after two (2) hours following the close of &ldquo;regular trading hours&rdquo;
    on such Trading Day;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP>
125% of public offering price</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mechanics
                                            of Exercise</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
                                            of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased
                                            hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account
                                            of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
                                            through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the
                                            Company is then a participant in such system and either (A) there is an effective registration
                                            statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares
                                            by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by
                                            physical delivery of a certificate or by book entry, registered in the Company&rsquo;s share
                                            register in the name of the Holder or its designee, for the number of Warrant Shares to which
                                            the Holder is entitled pursuant to such exercise to the address specified by the Holder in
                                            the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the
                                            delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising
                                            the Standard Settlement Period after the delivery to the Company of the Notice of Exercise,
                                            all subject to receipt of any cash required from the Holder unless this Warrant is exercised
                                            pursuant to Section 2(c) (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
                                            Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes
                                            to have become the holder of record of the Warrant Shares with respect to which this Warrant
                                            has been exercised, irrespective of the date of delivery of the Warrant Shares, provided
                                            that payment of the aggregate Exercise Price (other than in the case of a cashless exercise)
                                            is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading
                                            Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.
                                            If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to
                                            a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder,
                                            in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
                                            to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
                                            of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading
                                            Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share
                                            Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The
                                            Company agrees to maintain a transfer agent that is a participant in the FAST program so
                                            long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard
                                            Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
                                            of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common
                                            Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the
                                            foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m.
                                            (New York City time) on the Initial Exercise Date, which may be delivered at any time after
                                            the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant
                                            Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise
                                            Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes
                                            hereunder, provided that payment of the aggregate Exercise Price (other than in the case
                                            of a cashless exercise) is received by such Warrant Share Delivery Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, (other than any such failure that is solely
due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker
to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
&ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares
of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent
periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C)
a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon
the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving
effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution
Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo; shall be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the
Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the
Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The
limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all of the
record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the
Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record
is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to all of the holders of shares of Common Stock, by way of return
of capital or otherwise, other than cash (including, without limitation, any distribution of stock or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the voting
power of the equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires greater than 50% of the voting power of the equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,
in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the
date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder
an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date
of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within
the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive
from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value
of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration
in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function
on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to 100%, (C) the underlying price per share used in such calculation shall be the VWAP immediately preceding the public
announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if
earlier), (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental
Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer
of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election
and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction
in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the
Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by
a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares
of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon
exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and
with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under
this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this
Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the
Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally
with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall
assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect
as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the
avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the
Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction
occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice (unless such information is filed with the Commission, in which case a notice shall not be required)
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock
of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect
therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To
the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company
or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board
of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws, this Pursuant to FINRA Rule 5110(e), neither this
Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred, assigned, pledged or hypothecated, or
be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition
of the securities by any person for a period of 180 days immediately following the date of commencement of sales of the offering pursuant
to which this Warrant is being issued, except the transfer of any security:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            operation of law or by reason of reorganization of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            any FINRA member firm participating in the offering and the officers, partners, registered
                                            persons or affiliates thereof, if all securities so transferred remain subject to the lock-up
                                            restriction in this Section 4(a) for the remainder of the time period;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the aggregate amount of securities of the Company held by the Holder or related person does
                                            not exceed 1% of the securities being offered;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            is beneficially owned on a pro-rata basis by all equity owners of an investment fund, <U>provided</U>
                                            that no participating member manages or otherwise directs investments by the fund, and participating
                                            members in the aggregate do not own more than 10% of the equity in the fund; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            exercise or conversion of any security, if all securities received remain subject to the
                                            lock-up restriction in this Section 4(a) for the remainder of the time period;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Company meets the registration requirements of Forms S-3, F-3 or F-10; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">back
                                            to the Company in a transaction exempt from registration with the Commission.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to compliance with applicable securities laws and the foregoing restriction, this Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new
Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event, including if the Company
is for any reason unable to deliver Warrant Shares upon exercise of this Warrants required pursuant to the terms hereof, shall the Company
be required to net cash settle an exercise of this Warrant or cash settle in any other form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, 40 Marcus Drive, Suite One, Melville, New York 11747, Attention: CEO, email address: <U>lalstodt@biorestorative.com</U>,
or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or
other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or
sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. Other than Section 2(e) above and this Section 5(l), which may not be amended, modified or waived, this Warrant may
be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the
other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BioRestorative
                    Therapies, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lance Alstodt</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
BioRestorative Therapies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;]
in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: ______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: _________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
_____________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone Number:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature:_____________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Address:______________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>ex5-1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FRED
S. SKOLNIK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PARTNER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECT
DIAL 516.296.7048</FONT></P>

<P STYLE="text-align: justify; margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fskolnik@certilmanbalin.com</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5in 0pt 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
9, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40
Marcus Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melville,
New York 11747</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Statement on Form S-1</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), in connection with the Registration
Statement on Form S-1 (the &ldquo;Registration Statement&rdquo;) filed by the Company with the Securities and Exchange Commission (the
&ldquo;Commission&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), relating to a proposed offer and sale
by the Company of up to 9,708,738 units (the &ldquo;Units&rdquo;), each Unit consisting of one share of common stock, par value $0.0001
per share (the &ldquo;Common Stock&rdquo;) (the &ldquo;Shares&rdquo;), or one pre-funded warrant to purchase one share of Common Stock
(the &ldquo;Pre-Funded Warrant&rdquo;) and one warrant to purchase one share of Common Stock (the &ldquo;Warrant&rdquo;). The shares
of Common Stock underlying the Pre-Funded Warrants and the Warrants are collectively referred to herein as the &ldquo;Warrant Shares&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this opinion, we have examined the following documents: (i) the Amended and Restated Articles of Incorporation and the
By-Laws of the Company, each as amended to date, (ii) the Registration Statement, (iii) the form of Pre-Funded Warrant, (iv) the form
of Warrant, and (iv) minutes of meetings and unanimous written consents of the Board of Directors of the Company and committees thereof.
We have also examined such other instruments and documents as we deemed relevant under the circumstance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this opinion, we have assumed (i) the authenticity of all documents submitted to us as original, (ii) the conformity to the
originals of all documents submitted as certified, photostatic or facsimile copies and the authenticity of the originals, (iii) the legal
capacity of natural persons, (iv) the due authorization, execution and delivery of all documents by all parties and the validity and
binding effect thereof and (v) the conformity to the proceedings of the Board of Directors and committees thereof of all minutes of such
proceedings. We have also assumed that the corporate records furnished to us by the Company include all corporate proceedings taken by
the Company to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing and subject to the limitations, qualifications, exceptions and assumptions set forth herein, it is our opinion that
(i) the Shares have been duly authorized and, when issued and delivered by the Company against payment therefor as described in the Registration
Statement, will be duly and validly issued, fully paid and non-assessable shares of Common Stock; (ii) the Pre-Funded Warrants have been
duly authorized and, when issued and delivered by the Company against payment therefor as described in the Registration Statement, will
be valid and binding obligations of the Company; (iii) the Warrants have been duly authorized and, when issued and delivered by the Company
against payment therefor as described in the Registration Statement, will be valid and binding obligations of the Company and (iv) the
Warrant Shares have been duly authorized and, when issued and delivered by the Company against payment therefor in accordance with the
terms of the Pre-Funded Warrants and the Warrants, will be duly and validly issued, fully paid and non-assessable shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the use of our opinion as herein set forth as an exhibit to the Registration Statement and to the use of our name therein
and in the related prospectus under the caption &ldquo;Legal Matters&rdquo;. In giving such consent, we do not hereby admit that we are
in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinion expressed herein is limited to the Nevada Revised Statutes, as currently in effect, and we express no opinion as to the effect
of the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is as of the date hereof, and we do not undertake, and hereby disclaim, any obligation to advise you of any changes in any of
the matters set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are rendering this opinion only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is for your exclusive use only and is to be utilized and relied upon only in connection with the matters expressly set forth
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTILMAN BALIN ADLER &amp; HYMAN, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Fred Skolnik</I></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fred
Skolnik, a Member of the Firm</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.50
<SEQUENCE>6
<FILENAME>ex10-50.htm
<DESCRIPTION>EX-10.50
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.50</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of February [____], 2026, between BioRestorative Therapies,
Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities
Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B><BR>
DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1st) Trading
Day following the date hereof (or the second (2<SUP>nd</SUP>) Trading Day following the date hereof if this Agreement is signed on a
day that is not a Trading Day or after 4:00 p.m. (New York City time) and before midnight (New York City time) on a Trading Day).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $ 0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Common Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Common Warrants shall be immediately exercisable and have a term of exercise equal to five (5) years
after the initial exercise date, in the form of <U>Exhibit A-1</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Certilman Balin Adler &amp; Hyman, LLP, with offices located at 90 Merrick Avenue, East Meadow, New York 11554.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company
pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of
Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered
to the Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder, warrants to the
Placement Agent in connection with the transactions pursuant to this Agreement and any securities upon exercise of warrants to the
Placement Agent and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and
outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to
increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities
(other than in connection with stock splits or combinations) or to extend the term of such securities, (c) securities issued
pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided
that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights
that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section
4.11(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself
or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company
and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in
which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is
investing in securities and (d) up to $[______] of Shares and Warrants issued to other purchasers pursuant to the Prospectus
concurrently with the Closing at the Per Unit Purchase Price, less the aggregate Subscription Amount pursuant to this
Agreement..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers
of the Company, in the form of <U>Exhibit B</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Unit Purchase Price</U>&rdquo; equals $[_____], subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement, provided that the purchase price per
Pre-Funded Warrant shall be the Per Unit Purchase Price minus $0.0001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means Rodman &amp; Renshaw LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in
accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire when exercised in
full, in the form of <U>Exhibit A-2</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means any preliminary prospectus included in the Registration Statement, as originally filed or as part of any
amendment thereto, or filed with the Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pricing
Prospectus</U>&rdquo; means (i) the Preliminary Prospectus relating to the Securities that was included in the Registration Statement
immediately prior to [___] [a.m./p.m.] (New York City time) on the date hereof and (ii) any free writing prospectus (as defined in the
Securities Act) identified on Schedule I hereto, taken together.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission File No. 333-[_______] which registers the sale of the
Shares, the Warrants and the Warrant Shares to the Purchasers, including all information, documents and exhibits filed with or incorporated
by reference into such registration statement, and includes any Rule 462(b) Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
462(b) Registration Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Securities,
which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated
by the Commission pursuant to the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and/or Pre-Funded Warrants and Common Warrants
purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription
Amount,&rdquo; in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise
price of the Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, the Pink Open Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Lock-Up Agreement, the Warrants, all exhibits and schedules thereto and hereto and any
other documents or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Transhare Corporation, the current transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Warrants and the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B><BR>
PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the
Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $[______] of Shares and Warrants. Each Purchaser&rsquo;s
Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery
Versus Payment&rdquo; settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares,
Pre-Funded Warrant and Common Warrant as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the
other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections
2.2 and 2.3, the Closing shall occur at the offices of EGS or such other location as the parties shall mutually agree take place remotely
by electronic transfer of the Closing documentation. Unless otherwise directed by the Placement Agent, settlement of the Shares shall
occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company shall issue the Shares
registered in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement
Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares
to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the
Company). Each Purchaser acknowledges that, concurrently with the Closing and pursuant to the Prospectus, the Company may sell up to
$[______] of Shares and Warrants to purchasers not party to this Agreement, less the aggregate Subscription Amount pursuant to this Agreement,
and will issue to such purchasers such shares of Common Stock and Common Warrants and/or Pre-Funded Warrants and Common Warrants in the
same form and at the same Per Unit Purchase Price. Notwithstanding anything herein to the contrary, if at any time on or after the time
of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing
(the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued
hereunder to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser shall, automatically
hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase,
such Pre-Settlement Shares at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such
Purchaser prior to the Company&rsquo;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that
the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to
whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such
decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such
sale, if any. Notwithstanding anything to the contrary herein and a Purchaser&rsquo;s Subscription Amount set forth on the signature
pages attached hereto, the number of Shares purchased by a Purchaser (and its Affiliates) hereunder shall not, when aggregated with all
other shares of Common Stock owned by such Purchaser (and its Affiliates) at such time, result in such Purchaser beneficially owning
(as determined in accordance with Section 13(d) of the Exchange Act) in excess of 9.9% of the then issued and outstanding Common Stock
outstanding at the Closing (the &ldquo;<U>Beneficial Ownership Maximum</U>&rdquo;), and such Purchaser&rsquo;s Subscription Amount, to
the extent it would otherwise exceed the Beneficial Ownership Maximum immediately prior to the Closing, shall be conditioned upon the
issuance of Shares at the Closing to the other Purchasers signatory hereto. To the extent that a Purchaser&rsquo;s beneficial ownership
of the Shares would otherwise be deemed to exceed the Beneficial Ownership Maximum, such Purchaser&rsquo;s Subscription Amount shall
automatically be reduced as necessary in order to comply with this paragraph. Notwithstanding the foregoing, with respect to any Notice(s)
of Exercise (as defined in the Pre-Funded Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which
may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Warrant Shares subject
to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date
(as defined in the Pre-Funded Warrants) for purposes hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in a form and substance reasonably acceptable
to the Placement Agent and the Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
subject to Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead
and executed by the Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an
expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal to
such Purchaser&rsquo;s Subscription Amount divided by the Per Unit Purchase Price (minus the number of shares of Common Stock issuable
upon exercise of such Purchaser&rsquo;s Pre-Funded Warrant, if applicable), registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
a Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum
of such Purchaser&rsquo;s Shares and Pre-Funded Warrant Shares on the date hereof, with an exercise price equal to $[_____], subject
to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
for each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser to purchase
up to a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to Pre-Funded
Warrant divided by the Per Unit Purchase Price minus $0.0001, with an exercise price equal to $0.0001, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
on the date hereof, the duly executed Lock-Up Agreements; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
the Pricing Prospectus and the Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount (less the aggregate exercise price of the Pre-Funded Warrants issuable to such Purchaser hereunder,
if applicable), which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects)
on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in
which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality,
in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B><BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall
be deemed a part hereof and shall qualify any representation made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company
owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and
all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and
free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus, (iii) notice(s) and application(s)
to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required
thereby, and (iv) such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed
by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the
maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the
Registration Statement in conformity with the requirements of the Securities Act, which became effective on February 11, 2026 (the &ldquo;<U>Effective
Date</U>&rdquo;), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this
Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness
of the Registration Statement or suspending or preventing the use of any Preliminary Prospectus or the Prospectus has been issued by
the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission.
The Company, if required by the rules and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule
424(b). At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the
Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements
of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein not misleading; and the Pricing Prospectus and the Prospectus and any
amendments or supplements thereto, at the time the Pricing Prospectus and the Prospectus or any amendment or supplement thereto was issued
and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and
will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule
3.1(g)</U> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as
of the date hereof. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act,
other than as set forth in its SEC Reports or pursuant to the exercise of employee stock options under the Company&rsquo;s stock option
plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant
to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under
the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate
in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities and as set
forth in the Preliminary Prospectus or on <U>Schedule 3.1(g)</U>, there are no outstanding options, warrants, scrip rights to subscribe
to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable
or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any
Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to
issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the
Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than
the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts
the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any
Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar
provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may
become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom
stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are
duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws,
and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the
Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital
stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. Except as set forth on <U>Schedule 3.1(h)</U>, the Company has filed all reports, schedules,
forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant
to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by
law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference
therein, together with the Pricing Prospectus and the Prospectus, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;)
on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply
in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto
as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted
accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise
specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries
as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has
had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock incentive plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no
event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with
respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed
made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth on <U>Schedule 3.1(j)</U>, (i)
adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii)
could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company
nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or
liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of
the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former
director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective business as described in the SEC Reports and which
the failure to so have could be reasonably expected to have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property
Rights</U>&rdquo;). Except as set forth in <U>Schedule 3.1(p)</U>, none of, and neither the Company nor any Subsidiary has received a
notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected
to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary
has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim
or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could
not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property
Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company
and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual
properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title to the Intellectual
Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all Intellectual
Property Rights that are necessary to conduct its business as described in the Pricing Prospectus and Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage of $1,500,000. Neither the Company nor any Subsidiary has any reason to
believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other
than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company
and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. Except as disclosed in the SEC Reports, the Company and the Subsidiaries are in
compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended that are effective as of the date hereof
and as of the Closing Date, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective
as of the date hereof and as of the Closing Date. Except as disclosed in the SEC Reports, the Company and the Subsidiaries maintain a
system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with
management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the SEC Reports, the
Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed
by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the
time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently
filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most
recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in
the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that
have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company
and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except as set forth in the Pricing Prospectus and the Prospectus, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities
Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which
the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance
requirements of such Trading Market. Except as set forth in <U>Schedule 3.1(w)</U>, the Company is, and has no reason to believe that
it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock
is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the
Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection
with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Pricing Prospectus and the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing
representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company
to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including
the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they
were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement
taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not
misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to
the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.1(aa)</U> sets forth as of the date hereof all outstanding
secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For
the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess
of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other
contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due
under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to
any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. The Company&rsquo;s accounting firm is set forth in the Pricing Prospectus and the Prospectus. To the knowledge and
belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall
express its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year
ending December 31, 2025. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been
asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. </FONT>The Company further understands and acknowledges that (y) one or more Purchasers
may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation,
during the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging
activities (if any) could reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time
that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute
a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement
of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any
Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
&ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of
any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and
Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders,
rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)
the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company
and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Compliance with Data Privacy Laws</U>. (i) The Company and the Subsidiaries are, and at all times during the last three (3) years
were, in compliance with all applicable state, federal and foreign data privacy and security laws and regulations, including, without
limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy
Laws</U>&rdquo;); (ii) the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to
ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii) the Company provides accurate notice
of its applicable Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws; and
(iv) applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating to its
subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy
Laws. &ldquo;<U>Personal Data</U>&rdquo; means (i) a natural person&rsquo;s name, street address, telephone number, email address, photograph,
social security number, bank information, or customer or account number; (ii) any information which would qualify as &ldquo;personally
identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR;
and (iv) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection
or analysis of any identifiable data related to an identified person&rsquo;s health or sexual orientation. (i) None of such disclosures
made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii) the
execution, delivery and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither
the Company nor the Subsidiaries (i) to the knowledge of the Company, has received written notice of any actual or potential liability
of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy
Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant
to any regulatory request or demand pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement by or with any
court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five (25%) percent or more of the total
equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its
Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject
to the BHCA and to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises any Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3),
(a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither
the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect
to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the
Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to
such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company, the Placement Agent or any other Person representing the Company setting
forth the material pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with
respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered
by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without
limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained
the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).
Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or
preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Warrant Shares</U>. The Shares and Warrants shall be issued free of legends. If all or any portion of a Warrant is exercised at a
time when there is an effective registration statement to cover the issuance or resale of the Warrant Shares or if the Warrant is exercised
via cashless exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any time following
the date hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of the Warrant Shares)
is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the Company shall immediately notify the
holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders
when the registration statement is effective again and available for the sale or resale of the Warrant Shares (it being understood and
agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in
compliance with applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement (including
the Registration Statement) registering the issuance or resale of the Warrant Shares effective during the term of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Furnishing of Information</U>. Until the earliest of the time that (i) no Purchaser owns Common Warrants or Pre-Funded Warrants
or (ii) the Common Warrants have expired, the Company covenants to timely file (or obtain extensions in respect thereof and file within
the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even
if the Company is not then subject to the reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the
rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including,
without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition,
effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any
of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that
each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each
Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and
neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior
consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect
to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required
by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication.
Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser
in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except
(a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to
the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of
their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade
on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. Except as set forth in the Pricing Prospectus and the Prospectus, the Company shall use the net proceeds from
the sale of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion
of the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in
violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or
any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such
Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws
or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct).
If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such
Purchaser Party shall promptly notify the Company in writing, and, the Company shall have the right to assume the defense thereof with
counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there
is, in the reasonable opinion of counsel a material conflict on any material issue between the position of the Company and the position
of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party
effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent,
but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations
made by a Purchaser Party in this Agreement or the other Transaction Documents. The indemnification required by this Section 4.8 shall
be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser
Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Listing of Common Stock</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation
of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply
to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and
Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other
Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is
necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible.
The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market
and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading
Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company
or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company
or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii)
file any registration statement or amendment or supplement thereto, other than (y) the Prospectus
or (z) filing a registration statement on Form S-8 in connection with any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until nine (9) months following the Closing Date, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a
combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other
price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset
at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events
directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been
issued and regardless of whether such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, after ninety (90) days
following the Closing Date, the entry into and/or issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with
the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction or a violation of paragraph (a) hereof. Any Purchaser
shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to
any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat
the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the
purchase, disposition or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included
in the Disclosure Schedules (other than as disclosed to its legal and other representatives). Notwithstanding the foregoing and notwithstanding
anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section
4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance
with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty
not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors,
employees, Affiliates, or agent, including, without limitation, the Placement Agent, after the issuance of the initial press release
as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby
separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge
of the investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set
forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Capital Changes</U>. Until ninety (90) days following the Closing Date, the Company shall not undertake a reverse or forward stock
split or reclassification of the Common Stock without the prior written consent of Purchasers who purchased a majority in interest of
the Shares and Pre-Funded Warrants based on the initial Subscription Amounts hereunder, other than a reverse stock split that is required,
in the good faith determination of the Board of Directors, to maintain the listing of the Common Stock on the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required
of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to
exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms,
conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16
<U>Lock-Up Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except
to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If
any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use commercially reasonable
efforts to seek specific performance of the terms of such Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Pricing Prospectus and the
Prospectus, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded
Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case
of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification
or waiver disproportionately and adversely impacts a Purchaser (or multiple Purchasers), the consent of such disproportionately impacted
Purchaser (or at least 50.1% in interest of such multiple Purchasers) shall also be required. No waiver of any default with respect to
any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any
subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party
to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the
other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with
this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations, warranties, and
covenants of the Company in this Agreement and the representations, warranties, and covenants of the Purchasers in this Agreement. This
Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the
benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section
5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall
be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
(including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic
Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method, such signature shall be deemed
to have been duly and validly delivered and shall create a valid and binding obligation of the party executing (or on whose behalf such
signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that, in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and
the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company
has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because
it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in
this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and
the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21
<B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BioRestorative Therapies, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 49%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Lance Alstodt</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">E-Mail: </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD><U>lalstodt@biorestorative.com</U></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2">With a copy to (which shall not constitute notice):</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2">Certilman
    Balin Adler &amp; Hyman, LLP</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Email: <U></U></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2">90
    Merrick Avenue, 9<SUP>th</SUP> Floor</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><U>fskolnik@certilmanbalin.com</U></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">East
    Meadow, New York 11554</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2">Attn:
    Fred Skolnik, Esq.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">BRTX</FONT> SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory: _________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Warrants to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrant Shares: ___________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Warrant Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: ____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to
purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the
Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)
the Closing shall occur on the first (1st) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated
by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any
agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be
an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or
the like or purchase price (as applicable) to such other party on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Free
Writing Prospectus</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 36; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>ex23-1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in this Registration Statement on Form S-1 of our report dated March 27, 2025, with respect to the financial
statements of BioRestorative Therapies, Inc, included in this Registration Statement. We also consent to the reference to us under the
heading &ldquo;Experts&rdquo; in such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <FONT STYLE="font-variant: small-caps">Marcum
  LLP</FONT></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marlton, New Jersey</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 9, 2026</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>8
<FILENAME>ex107.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ffd="http://xbrl.sec.gov/ffd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:BRTX="http://biorestorative.com/20260209">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_027_FFD%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_BRTX_biorestorative.com_20260209 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20260209_20260209 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001505497 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-02-09" id="Fact000003" name="dei:EntityCentralIndexKey">0001505497</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-02-09" id="xdx2ixbrl0009" name="ffd:FeeExhibitTp">EX-FILING FEES</ix:nonNumeric>
  <ix:nonFraction name="ffd:FeeRate" contextRef="From2026-02-092026-02-09_1" id="xdx2ixbrl0014" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="From2026-02-092026-02-09_1" id="xdx2ixbrl0018" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:MaxOfferingPricPerScty" contextRef="From2026-02-092026-02-09_1" id="xdx2ixbrl0019" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:FeeRate" contextRef="From2026-02-092026-02-09_3" id="xdx2ixbrl0028" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="From2026-02-092026-02-09_3" id="xdx2ixbrl0032" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:MaxOfferingPricPerScty" contextRef="From2026-02-092026-02-09_3" id="xdx2ixbrl0033" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:FeeRate" contextRef="From2026-02-092026-02-09_5" id="xdx2ixbrl0042" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="From2026-02-092026-02-09_5" id="xdx2ixbrl0046" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:MaxOfferingPricPerScty" contextRef="From2026-02-092026-02-09_5" id="xdx2ixbrl0047" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:FeeRate" contextRef="From2026-02-092026-02-09_7" id="xdx2ixbrl0056" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="From2026-02-092026-02-09_7" id="xdx2ixbrl0060" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ffd:MaxOfferingPricPerScty" contextRef="From2026-02-092026-02-09_7" id="xdx2ixbrl0061" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2026-02-092026-02-09_8" id="xdx2ixbrl0066" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric>
  <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="AsOf2026-02-09" id="xdx2ixbrl0079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-02-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-09</xbrli:startDate>
        <xbrli:endDate>2026-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-092026-02-09_1">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>1</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-09</xbrli:startDate>
        <xbrli:endDate>2026-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-092026-02-09_2">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>2</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-09</xbrli:startDate>
        <xbrli:endDate>2026-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-092026-02-09_3">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>3</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-09</xbrli:startDate>
        <xbrli:endDate>2026-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-092026-02-09_4">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>4</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-09</xbrli:startDate>
        <xbrli:endDate>2026-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-092026-02-09_5">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>5</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-09</xbrli:startDate>
        <xbrli:endDate>2026-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-092026-02-09_6">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>6</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-09</xbrli:startDate>
        <xbrli:endDate>2026-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-092026-02-09_7">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>7</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-09</xbrli:startDate>
        <xbrli:endDate>2026-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-092026-02-09_8">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>8</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-09</xbrli:startDate>
        <xbrli:endDate>2026-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90B_effd--FeeExhibitTp_dxL_c20260209__20260209_zzVNkMjVXxb" title="::XDX::EX-FILING FEES"><span style="-sec-ix-hidden: xdx2ixbrl0009">EXHIBIT
107</span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Calculation
of Filing Fee Tables</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<span id="xdx_905_effd--FormTp_c20260209__20260209_zqj1AEBoOj25"><span id="xdx_901_effd--SubmissnTp_c20260209__20260209_zOcBEVLbzsIj"><ix:nonNumeric contextRef="AsOf2026-02-09" id="Fact000010" name="ffd:FormTp"><ix:nonNumeric contextRef="AsOf2026-02-09" id="Fact000011" name="ffd:SubmissnTp">S-1</ix:nonNumeric></ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Form
Type)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityRegistrantName_c20260209__20260209_zMVhwRFxTnn4"><ix:nonNumeric contextRef="AsOf2026-02-09" id="Fact000012" name="dei:EntityRegistrantName">BIORESTORATIVE
THERAPIES, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
1: Newly Registered Securities and Carry Forward Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_101_zbTbbH5XMkQj" summary="xdx: Document - Offerings" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td id="xdx_48F_effd--OfferingSctyTitl_zWqWaE4KcHFc" style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_489_effd--FeeRate_pid_zg0thqrHzJ73" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_481_effd--FeeAmt_pid_d0_z75viclDcrhg" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Security <br/>Type</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Security<br/> Class <br/>Title</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Fee<br/> Calculation<br/> or Carry<br/> Forward<br/> Rule</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount<br/> Registered</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Proposed<br/> Maximum<br/> Offering<br/> Price Per<br/> Unit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Proposed <br/>Maximum <br/>Aggregate <br/>Offering <br/>Price(1)(2)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fee<br/> Rate</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount of<br/> Registration <br/>Fee(3)</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_41E_20260209__20260209__ffd--OfferingAxis__1_zLMRJIcJ1SCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; width: 6%; text-align: center">Fees to Be<br/> Paid</td><td style="width: 2%">&#160;</td>
    <td id="xdx_981_effd--OfferingSctyTp_c20260209__20260209__ffd--OfferingAxis__1_zWlz1mG7Bysg" style="vertical-align: top; width: 6%; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_1" id="Fact000016" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 26%; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_1" id="Fact000013" name="ffd:OfferingSctyTitl">Units, consisting of</ix:nonNumeric></td><td style="width: 2%">&#160;</td>
    <td id="xdx_983_effd--FeesOthrRuleFlg_dbT_c20260209__20260209__ffd--OfferingAxis__1_zId3DP2ISvb" style="vertical-align: top; width: 6%; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_1" format="ixt:booleantrue" id="Fact000017" name="ffd:FeesOthrRuleFlg">457(g)</ix:nonNumeric></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_effd--AmtSctiesRegd_pid_c20260209__20260209__ffd--OfferingAxis__1_zkodWpcEOi7i" style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0018">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_effd--MaxOfferingPricPerScty_pid_c20260209__20260209__ffd--OfferingAxis__1_zAXIWXISa3nc" style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0019">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span id="xdx_90B_effd--MaxAggtOfferingPric_pid_d0_c20260209__20260209__ffd--OfferingAxis__1_zF0XOL0Sufrd"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-02-092026-02-09_1" id="Fact000020" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USD">-</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0014">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-02-092026-02-09_1" id="Fact000015" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USD">-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20260209__20260209__ffd--OfferingAxis__2_zwQFaXodjKt2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td id="xdx_984_effd--OfferingSctyTp_c20260209__20260209__ffd--OfferingAxis__2_z7hqkVGzhQVa" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_2" id="Fact000024" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_2" id="Fact000021" name="ffd:OfferingSctyTitl">Common Stock, par value <br/>$0.0001 per share(2)</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_98A_effd--Rule457oFlg_dbT_c20260209__20260209__ffd--OfferingAxis__2_zAopGgoRTMl2" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_2" format="ixt:booleantrue" id="Fact000025" name="ffd:Rule457oFlg">457(o)</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_effd--MaxAggtOfferingPric_pid_c20260209__20260209__ffd--OfferingAxis__2_zHSucgP9zwDf"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-02-092026-02-09_2" id="Fact000026" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">10,000,000.14</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ffd:FeeRate" contextRef="From2026-02-092026-02-09_2" id="Fact000022" format="ixt:numdotdecimal" decimals="INF" unitRef="Ratio">0.00013810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-02-092026-02-09_2" id="Fact000023" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,381.00</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_415_20260209__20260209__ffd--OfferingAxis__3_zzqzXn4L9Zpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td id="xdx_984_effd--OfferingSctyTp_c20260209__20260209__ffd--OfferingAxis__3_zBI2Qp5Ptqyj" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_3" id="Fact000030" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_3" id="Fact000027" name="ffd:OfferingSctyTitl">Pre-Funded Warrants to purchase shares of Common Stock (4)</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_980_effd--FeesOthrRuleFlg_dbT_c20260209__20260209__ffd--OfferingAxis__3_zgIzwoASBg02" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_3" format="ixt:booleantrue" id="Fact000031" name="ffd:FeesOthrRuleFlg">457(g)</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_effd--AmtSctiesRegd_pid_c20260209__20260209__ffd--OfferingAxis__3_zHQllYW77C5g" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0032">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_effd--MaxOfferingPricPerScty_pid_c20260209__20260209__ffd--OfferingAxis__3_zLK1dX9qBuXh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0033">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_effd--MaxAggtOfferingPric_pid_d0_c20260209__20260209__ffd--OfferingAxis__3_zRw77B2S8rFg"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-02-092026-02-09_3" id="Fact000034" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USD">-</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0028">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-02-092026-02-09_3" id="Fact000029" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USD">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_417_20260209__20260209__ffd--OfferingAxis__4_zgPrbA21qRy8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td id="xdx_984_effd--OfferingSctyTp_c20260209__20260209__ffd--OfferingAxis__4_z2xJKzao3QX6" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_4" id="Fact000038" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_4" id="Fact000035" name="ffd:OfferingSctyTitl">Common Stock issuable upon exercise of the Pre-Funded Warrants</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_98B_effd--Rule457oFlg_dbT_c20260209__20260209__ffd--OfferingAxis__4_zcXSilur8Wcf" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_4" format="ixt:booleantrue" id="Fact000039" name="ffd:Rule457oFlg">457(o)</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
                                            Above</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt"><span id="xdx_90E_effd--MaxAggtOfferingPric_pid_d0_c20260209__20260209__ffd--OfferingAxis__4_zGNL6LxkxVhc"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-02-092026-02-09_4" id="Fact000040" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USD">-</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ffd:FeeRate" contextRef="From2026-02-092026-02-09_4" id="Fact000036" format="ixt:numdotdecimal" decimals="INF" unitRef="Ratio">0.00013810</ix:nonFraction></span>
                                            -</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-02-092026-02-09_4" id="Fact000037" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USD">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20260209__20260209__ffd--OfferingAxis__5_zHbmeFgOxJ61" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td id="xdx_984_effd--OfferingSctyTp_c20260209__20260209__ffd--OfferingAxis__5_zPm3ghW9T7le" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_5" id="Fact000044" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_5" id="Fact000041" name="ffd:OfferingSctyTitl">Warrants to purchase shares of Common Stock (4)</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_98B_effd--FeesOthrRuleFlg_dbT_c20260209__20260209__ffd--OfferingAxis__5_zAEI30h6FxGg" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_5" format="ixt:booleantrue" id="Fact000045" name="ffd:FeesOthrRuleFlg">457(g)</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_effd--AmtSctiesRegd_pid_c20260209__20260209__ffd--OfferingAxis__5_zX74mEC6Dofe" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0046">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_effd--MaxOfferingPricPerScty_pid_c20260209__20260209__ffd--OfferingAxis__5_zkEYN5raKRoh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0047">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_effd--MaxAggtOfferingPric_pid_d0_c20260209__20260209__ffd--OfferingAxis__5_zUfuu6gpVKCb"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-02-092026-02-09_5" id="Fact000048" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USD">-</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0042">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-02-092026-02-09_5" id="Fact000043" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USD">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20260209__20260209__ffd--OfferingAxis__6_zzkfFU74Z5P3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td id="xdx_986_effd--OfferingSctyTp_c20260209__20260209__ffd--OfferingAxis__6_zJu2Oht1Kbka" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_6" id="Fact000052" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_6" id="Fact000049" name="ffd:OfferingSctyTitl">Common Stock, par value <br/>$0.0001 per share, issuable upon exercise of Warrants</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_983_effd--Rule457oFlg_dbT_c20260209__20260209__ffd--OfferingAxis__6_zINhPg2K3Hld" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_6" format="ixt:booleantrue" id="Fact000053" name="ffd:Rule457oFlg">457(o)</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_90F_effd--MaxAggtOfferingPric_pid_c20260209__20260209__ffd--OfferingAxis__6_zR3G5JIEr2j2"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-02-092026-02-09_6" id="Fact000054" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">10,000,000.14</ix:nonFraction></span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ffd:FeeRate" contextRef="From2026-02-092026-02-09_6" id="Fact000050" format="ixt:numdotdecimal" decimals="INF" unitRef="Ratio">0.00013810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-02-092026-02-09_6" id="Fact000051" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,381.00</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_418_20260209__20260209__ffd--OfferingAxis__7_zURZVhGm6Q2j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td id="xdx_984_effd--OfferingSctyTp_c20260209__20260209__ffd--OfferingAxis__7_zigw6jG388eb" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_7" id="Fact000058" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_7" id="Fact000055" name="ffd:OfferingSctyTitl">Placement Agent Warrants (4)</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_985_effd--FeesOthrRuleFlg_dbT_c20260209__20260209__ffd--OfferingAxis__7_zDAOkiUaKnP6" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_7" format="ixt:booleantrue" id="Fact000059" name="ffd:FeesOthrRuleFlg">457(g)</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_effd--AmtSctiesRegd_pid_c20260209__20260209__ffd--OfferingAxis__7_z4GmooPzaPB7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0060">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_effd--MaxOfferingPricPerScty_pid_c20260209__20260209__ffd--OfferingAxis__7_zDAP98DzeOye" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0061">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_effd--MaxAggtOfferingPric_pid_d0_c20260209__20260209__ffd--OfferingAxis__7_zITcPNPkPB77"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-02-092026-02-09_7" id="Fact000062" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USD">-</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0056">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-02-092026-02-09_7" id="Fact000057" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USD">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20260209__20260209__ffd--OfferingAxis__8_zihoNbnIrmua" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td id="xdx_98D_effd--OfferingSctyTp_dxL_c20260209__20260209__ffd--OfferingAxis__8_zPpDb3uaAsWh" title="::XDX::Equity" style="vertical-align: top; text-align: center"><span style="-sec-ix-hidden: xdx2ixbrl0066">1</span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_8" id="Fact000063" name="ffd:OfferingSctyTitl">Common Stock, par value $0.0001 per share, issuable upon exercise of Placement Agent Warrants</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_985_effd--Rule457oFlg_dbT_c20260209__20260209__ffd--OfferingAxis__8_z4OyYNjgr5Ql" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2026-02-092026-02-09_8" format="ixt:booleantrue" id="Fact000067" name="ffd:Rule457oFlg">457(o)</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><p style="margin: 0"><span id="xdx_900_effd--MaxAggtOfferingPric_pid_c20260209__20260209__ffd--OfferingAxis__8_zgeJpk12fcYc"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-02-092026-02-09_8" id="Fact000068" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">875,000.00</ix:nonFraction></span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ffd:FeeRate" contextRef="From2026-02-092026-02-09_8" id="Fact000064" format="ixt:numdotdecimal" decimals="INF" unitRef="Ratio">0.00013810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-02-092026-02-09_8" id="Fact000065" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">120.83</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></td><td>&#160;</td>
    <td colspan="8" style="text-align: center">Total Offering Amounts</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p id="xdx_98D_effd--TtlOfferingAmt_pid_c20260209__20260209_zTNJvMzxZFd" style="margin: 0"><ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="AsOf2026-02-09" id="Fact000069" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">20,875,000.14</ix:nonFraction></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p id="xdx_986_effd--TtlFeeAmt_pid_c20260209__20260209_zSymKxqJQpy7" style="margin: 0"><ix:nonFraction name="ffd:TtlFeeAmt" contextRef="AsOf2026-02-09" id="Fact000070" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">2,882.83</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="8" style="text-align: center">Total <span id="xdx_90C_effd--PrevslyPdFlg_dbF_c20260209__20260209__ffd--OfferingAxis__1_zEaqkXMEmcB3"><span id="xdx_902_effd--PrevslyPdFlg_dbF_c20260209__20260209__ffd--OfferingAxis__2_zj9HfukwEGFi"><span id="xdx_90C_effd--PrevslyPdFlg_dbF_c20260209__20260209__ffd--OfferingAxis__3_zIYpQFjM9Vu8"><span id="xdx_905_effd--PrevslyPdFlg_dbF_c20260209__20260209__ffd--OfferingAxis__4_zwkLWFi30vgc"><span id="xdx_904_effd--PrevslyPdFlg_dbF_c20260209__20260209__ffd--OfferingAxis__5_zMHe5l7P8W39"><span id="xdx_90F_effd--PrevslyPdFlg_dbF_c20260209__20260209__ffd--OfferingAxis__6_z2b81Oyh00Ab"><span id="xdx_90A_effd--PrevslyPdFlg_dbF_c20260209__20260209__ffd--OfferingAxis__7_zFgRGzB9OFBj"><span id="xdx_906_effd--PrevslyPdFlg_dbF_c20260209__20260209__ffd--OfferingAxis__8_zMTlsgICQMG6"><ix:nonNumeric contextRef="From2026-02-092026-02-09_1" format="ixt:booleanfalse" id="Fact000071" name="ffd:PrevslyPdFlg"><ix:nonNumeric contextRef="From2026-02-092026-02-09_2" format="ixt:booleanfalse" id="Fact000072" name="ffd:PrevslyPdFlg"><ix:nonNumeric contextRef="From2026-02-092026-02-09_3" format="ixt:booleanfalse" id="Fact000073" name="ffd:PrevslyPdFlg"><ix:nonNumeric contextRef="From2026-02-092026-02-09_4" format="ixt:booleanfalse" id="Fact000074" name="ffd:PrevslyPdFlg"><ix:nonNumeric contextRef="From2026-02-092026-02-09_5" format="ixt:booleanfalse" id="Fact000075" name="ffd:PrevslyPdFlg"><ix:nonNumeric contextRef="From2026-02-092026-02-09_6" format="ixt:booleanfalse" id="Fact000076" name="ffd:PrevslyPdFlg"><ix:nonNumeric contextRef="From2026-02-092026-02-09_7" format="ixt:booleanfalse" id="Fact000077" name="ffd:PrevslyPdFlg"><ix:nonNumeric contextRef="From2026-02-092026-02-09_8" format="ixt:booleanfalse" id="Fact000078" name="ffd:PrevslyPdFlg">Fees Previously Paid</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span></span></span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_effd--TtlPrevslyPdAmt_pid_c20260209__20260209_zGWiVYAY8Ya1" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0079">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="8" style="text-align: center">Total Fee Offsets</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_effd--TtlOffsetAmt_pid_c20260209__20260209_zbH6OjJ160fg" style="text-align: right"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="AsOf2026-02-09" id="Fact000080" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="8" style="text-align: center">Net Fees Due</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><p id="xdx_984_effd--NetFeeAmt_pid_c20260209__20260209_zi0ypEcZEOs1" style="margin: 0"><ix:nonFraction name="ffd:NetFeeAmt" contextRef="AsOf2026-02-09" id="Fact000081" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">2,882.83</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_effd--OfferingNote_c20260209__20260209__ffd--OfferingAxis__1_gIFON-HCPQ_zg4aUL5zJ436"><span id="xdx_903_effd--OfferingNote_c20260209__20260209__ffd--OfferingAxis__2_gIFON-DYDU_zbMCur8HwARb"><span id="xdx_90E_effd--OfferingNote_c20260209__20260209__ffd--OfferingAxis__3_gIFON-GHQRUYJ_zsNMm9Jd4GE3"><span id="xdx_908_effd--OfferingNote_c20260209__20260209__ffd--OfferingAxis__4_gIFON-SKI_zbPUKE3Ok3A4"><span id="xdx_909_effd--OfferingNote_c20260209__20260209__ffd--OfferingAxis__5_gIFON-UEJ_zhAVtLHR4Ax5"><span id="xdx_907_effd--OfferingNote_c20260209__20260209__ffd--OfferingAxis__6_gIFON-XDHX_znJHoRmNEPLb"><span id="xdx_90F_effd--OfferingNote_c20260209__20260209__ffd--OfferingAxis__7_gIFON-EBFK_zGYJBalCEfEf"><span id="xdx_906_effd--OfferingNote_c20260209__20260209__ffd--OfferingAxis__8_gIFON-CBJI_zZp2ZvEXl6I6"><ix:nonNumeric contextRef="From2026-02-092026-02-09_1" continuedAt="ConU000084-01" escape="true" id="Fact000084" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-02-092026-02-09_2" continuedAt="ConU000087-01" escape="true" id="Fact000087" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-02-092026-02-09_3" continuedAt="ConU000091-01" escape="true" id="Fact000091" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-02-092026-02-09_4" continuedAt="ConU000094-01" escape="true" id="Fact000094" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-02-092026-02-09_5" continuedAt="ConU000098-01" escape="true" id="Fact000098" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-02-092026-02-09_6" continuedAt="ConU000101-01" escape="true" id="Fact000101" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-02-092026-02-09_7" continuedAt="ConU000105-01" escape="true" id="Fact000105" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-02-092026-02-09_8" continuedAt="ConU000108-01" escape="true" id="Fact000108" name="ffd:OfferingNote">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span></span></span></span></span></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C07_gIFON-HCPQ_zRIZ7BJDyy51"><ix:continuation continuedAt="ConU000084-02" id="ConU000084-01"><span id="xdx_C0F_gIFON-DYDU_zB3f64l95Zvf"><ix:continuation continuedAt="ConU000087-02" id="ConU000087-01"><span id="xdx_C0E_gIFON-GHQRUYJ_zf49cdNGa2I4"><ix:continuation continuedAt="ConU000091-02" id="ConU000091-01"><span id="xdx_C08_gIFON-SKI_zIhKc3G4tQfe"><ix:continuation continuedAt="ConU000094-02" id="ConU000094-01"><span id="xdx_C0B_gIFON-UEJ_zZfXxrlNQts7"><ix:continuation continuedAt="ConU000098-02" id="ConU000098-01"><span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"><ix:continuation continuedAt="ConU000101-02" id="ConU000101-01"><span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"><ix:continuation continuedAt="ConU000105-02" id="ConU000105-01"><span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc"><ix:continuation continuedAt="ConU000108-02" id="ConU000108-01">Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</ix:continuation></span></ix:continuation></span></ix:continuation></span></ix:continuation></span></ix:continuation></span></ix:continuation></span></ix:continuation></span></ix:continuation></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C09_gIFON-HCPQ_zEXwMOuHXLnb"><ix:continuation id="ConU000084-02"><span id="xdx_C0E_gIFON-DYDU_zpg86F7pLEj8"><ix:continuation id="ConU000087-02"><span id="xdx_C02_gIFON-GHQRUYJ_zQSy3JjIeSN4"><ix:continuation continuedAt="ConU000091-03" id="ConU000091-02"><span id="xdx_C04_gIFON-SKI_zqVRBVBoDev9"><ix:continuation id="ConU000094-02"><span id="xdx_C03_gIFON-UEJ_zjgS3N808BA5"><ix:continuation continuedAt="ConU000098-03" id="ConU000098-02"><span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"><ix:continuation id="ConU000101-02"><span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"><ix:continuation continuedAt="ConU000105-03" id="ConU000105-02"><span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6"><ix:continuation id="ConU000108-02">Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.</ix:continuation></span></ix:continuation></span></ix:continuation></span></ix:continuation></span></ix:continuation></span></ix:continuation></span></ix:continuation></span></ix:continuation></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0D_gIFON-GHQRUYJ_zeFkC4l8k6rg"><ix:continuation id="ConU000091-03"><span id="xdx_C04_gIFON-UEJ_zuQ987MkBvlb"><ix:continuation id="ConU000098-03"><span id="xdx_C05_gIFON-EBFK_zHHgbUJ57zx2"><ix:continuation id="ConU000105-03">No
    separate registration fee required pursuant to Rule 457(g) under the Securities Act,</ix:continuation></span></ix:continuation></span></ix:continuation></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_900_effd--OffsetTableNa_c20260209__20260209_zDlhYqf4ghBa"><span id="xdx_906_effd--CombinedProspectusTableNa_c20260209__20260209_z1WG7szryWWd"><ix:nonNumeric contextRef="AsOf2026-02-09" id="Fact000109" name="ffd:OffsetTableNa"><ix:nonNumeric contextRef="AsOf2026-02-09" id="Fact000110" name="ffd:CombinedProspectusTableNa">N/A</ix:nonNumeric></ix:nonNumeric></span></span></span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OmoV8cK7EovIIkSi2yXHWNIdmd3+Hqm3bFWiYWCYOeebI8RMbGitW2Q4r8oCKuz6VjmEEhtkNBf0jmy7S8HPEq/aOlbGjesPzMgz6JlkHit/H50PbbFOQUYLmSyiBGSchjEs9yIY9IxMo2s0TqsWlKnhyNSzRqf4PX2o1IsMde8x6YRsNZkUwrmc5A9EMozgQA/1JL5ZKIpMBLOxArFhuvfelb8cmoGEvMXOx9mJ/nfwBcL6Sk0= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>forms-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'Y X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME2JU(IR4QE&:;A*,U&4H2<)1DE.#M.#<922G!Z3@VI1>DHQ>@4445!04444
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MB#QU\+OA-X;^''@7Q1?V=[\.%UK2]#\0^)_&UWI^B7OB#4&MK"..QTUM0O\
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M/2;WQMX*\0V)NK*_DTKQ!IUMJFG7PU+1M9U2SO #]\*^/OV"/VK7_;=_9/\
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M43H3CB:52JJ483J3<FE#&T^:"^KP=1P_;'QO^UI^RO\ #/X@6/PG^(_[2WP
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M$>F:O+!?,0EE,EF8[MR$MVD8@'\^_%VBZ9X5_P""RG[-&@>#= TC1])\.?\
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MC?$#XIZI!K&M7VNW+^+_ (F>([OQ5XKN8;N_DDF@L;G6+VXFM-/0_9[&)A!
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M_=A)/NI*7Y.+ZO1KS"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 5I+E4/L"0<]<@D8(QTSSQS@9]10D^[T(]NO.3
M@#N0.<=<8) )Q6?J\$HA:ZMUW21*6EB ),D8'+*H^])&!D#&YT!49944\[9:
MPCE<L"OH#P,@G( XZ].Q7'L* .[Z]**I6UP) N&!4CKG.#R<=!@^OKR3MZ&[
M0 4444 %%!Z'/I7X-_"2XD^,G[/'Q!_;S^-'[?'Q;_9D^*_A3X^?'/P_JVJZ
MM\9XO#/[,G[*=O\ "3]HOQ?\'-(_9F^('[-VM:GX9^ _CZVMK+P]HW@SXC>*
M?BSH.J_'3QUXT\5:OXD^%OQ8^'::Q\+;+P6*[>BT7+=Z:<TU"*2W;<GTV2UU
ME!2'HKW75)=7:+F_1)+=Z7=NDG']Y**_%5OVZOVIOM:?M"C5/V5A^R^__!2D
M?\$\U_9Y?PE\15_:4;'[:3?\$_V^)Z_M!_\ "X#\/3XL3XGH_P"T3_PI0?LP
M?\D$5O#+?%$>(0?':_EC^S-^WM^U!\)_A[^S;!X9\2>+OB[\4/VD/V#_ /@B
M#X#\/ZS\4[?XF?M#Z)X*\?\ Q/\ @K_P4D^-7Q@^,5]\(=.^)_PZ\1?%#Q]\
M2?#_ .SW#X-NK73/BG\.-<\:>-]2^'^I^*O&E_8>%(='OG%.<>:.JLG;6]FH
MR6C2M[LX.V]I:I6LU)\K5]KM7Z:*5[=79QDGI9-;]OZ^**_"3X+_ +<W[=GQ
M\^(_A#]E?3+?]GSX,_'"*\_:N\1^*OCE\3/@#\1]=\&>+? /[.D/[&SZ1I.C
M?LBZ-^UCH'C_ .$'Q%\0:E^VMH6C>+='\=_M2>,+GPU:?!'7O%>F:%K/AWXX
M^![SP'\Q?&O]I#]L#Q!'^V?XO\;?&K]EOXB?"/PW_P $ZO\ @GA\2[SX8?L_
M:G^T+JGPMOOB+\5/VA/VPOASXH\5?!?]IWX:_M(?!KQK8:;JOBSX0ZIJ_BK6
MM+\(Z7JOBGP1'\+/A-/-I=S\)_%OC_XSEFW!;<\HQB_\<H0B[6V<I.*NXOF5
MOA?.%_B_NIMW\HRDUI>[Y8N3_NZJ[]T_IXHK\5[/]N?]JIKC1?VAKR__ &84
M_9C\0_\ !1W5_P#@G_8_LYMX(^(]E^TXD>G_ +9/B/\ 8-A^)^G_ !ZF^,4_
M@#Q%XKA^(GAZ;]HOQ%\&(_V8]&&A? "+Q'H8^)M]KWA*3QKKV#^Q9^V[^V]\
M1;+_ ()L_$S]I"\_97UWX;?\%'OAKK]]I/@?X(_";XM?#OQK\$_'5A\!M7_:
M*\+ZS?\ C[QW\>_BOH?Q.\*>(_!O@3QIH?B+PM!\/OAUJ_@_Q-KWA--+\7>-
MM+T#6]1\1):I-/=1:O=?''FBM8JSE'6SLU]KE>@WI>ZVYK[?8?+)W3::4M-&
M[]+]/W%P..!P,#CH#C('H#@<>P]*4 #@# ]!7X-_M:?M_P#[8_PZ^%/_  4$
M_:8^#.O?LD>$/AA^PM\5KWX&)\&_C]\,?B=JOQ#^)?BJR\&?!O6/^$MU'XO>
M%OVA? FA> ;KQ1K'QJTB[^#WP?7X,>+-1^*OA^P\$0GXG^$;KXXZ?J?PKVO#
MW[<'[;T%\GQT\67'[+NJ_LTQ?\%.?B=^P-)\&_"GPC^+6E_'F^\$VG[7'CC]
MD7X>?%>U^-.I_'O7? D7C31_&=GX0USQ5\//^%$7&C>,?#>G>)KG1?&?@W6/
M$^C:#X0:5X.HK<BY;R[<Z4HWMS7YE)6MS--VDHRNA/1\MFW[VB7\KDI6OR[.
M,M[)I7BVK-_N5@#H,45_/I\,_P!J']L+XW^-O^"*WQM^)/Q5_9VT;X1_MR?%
MKQ1\9="^!7P9T/XG>!/B?X-\#^(/^"9W[9'Q9\.?"WXC^+-;^,_CGPS^U+X6
M\&7>K^!YOB'XPM/AA\"=)\+_ !D\%> M=T_P!=GQ1HL'@+M/CYXT\?\ PW_;
M0\<?&'XG?%;XZZY\"O"/[27[&WPG\ ^*/V5_VE_!TWA#]EJY^*P^!/@F_P#V
M=/VU/V)M=O?#6D>+K/\ :!^(OQ9LO$[?&B/P_P#M!?'/0?AA\>/A[J7@#2?@
M/H?PWT?XC:DK2]I*GROGC)P:[2NERM[7YG9VDXWLE*3E'F&TH\UTHJ/-=Z:+
MFNUI?2,)2LDVHINR2ER?NL !@  !1@  # Z8'H, # ]*6OYT/V:/VC?VO/A[
M\&O@)>_$SXD?#?XL?!O]J']JC_@H9^SEH7A?5?"/QAA_: ^'EQ\/W_X*$_&C
MP?XOUW]I.[_:+U*U\;Z)%9?LRKX"MO OA_X/?#34O!7A?Q;X>L_"GQ#+_#&*
M?QSQ/[-/[>O[:7BO]G#XN>)_AQXO_8B^&7P\_81_82_8R^/&K>"/BMX5_:$^
M)OCCX@Z-\1OV!_ W[1>N^'_%?Q5\4?M7VWB7X/>"[75],\8>%_"W[0GQ!M?V
MD/$^OVTNK:CXR\-^)/$7P?\ $VK?&,ULY6:C&,92;3]WFIQJN\4G)\L))MQ4
MF[:1;:B5;6VEVVDE;WO?E35GHM91:][DMNVDFS^F0*HSA0,]< #/)//KR2>>
MY)[FEK\"=2_;^_;IU[PQ\;/C]X$3]F?0/A3\/_VROV8OV1?!?P%^)OP0^+MG
M\7+^7]K.+]C7PKX7\9?$GXS:/^T5_8/A#6OA7\0OVO+>^\9^!='^ .O#Q)X<
M^&NJ>&K+Q%X;USQA:^(_!A\3O^"A/[:_P8^).N_LE>)M/^#GQ-^/][^T1\-/
MAYX-^.7P7_9?^+>K^!8/AK\0/V2OC;^T[*VI?LF7O[4][XU\0_%&RU+]G3Q_
MX$L;#2OVJ])\/7'A+Q!9?%R;=-\/?$/PQ\44X2BVG%Q<;IIV3O'E<EHVGRJ2
MDVG:U[-O1PI1:NI*2Y8RNKO23:B[-)W<DXVLW?=6O)?OM17X,_!/]MK_ (*"
M?M(?$[X5? 3PY>_LP_ KQS=^"OVW_$7Q"^(/Q&_9S^)'Q+T[Q9-^RO\ '[]F
MKX4>"[_PO\%O"W[:/@;7O@S-XOT?X\:K'\2OAK\0_BSX\\8_#CQ]X(U?PS#K
M&KZ:;'Q#?]1_P3Y_:?\ VJ/VMOVH!\4O$/C_ .''AGX%^-O^":7_  3J_:"U
MG]GNV^&WC36+_P ,?$#XY>)?VZ-#\4O\/_B=<?&JTT72;@^-_A1/<^(_$FL?
M"#6;KQ]\-;#X5>#5T7P-XA^'VN>-O'J<6K7LKI2U>O*W**DDKZ.<7!=5+1QB
MKR3;2Z]>72[]Y*,G&]MU&2D^BCUO[I^WU%?BCK/[<W[6*)XE_:'T;4OV8$_9
MN\._\%$M-_X)_G]GBY^'WQ(U?]I:2?4?VPO#_P"P?_PM/4_C;:?&W2_ ND^(
MC\2_$$7[1/A_X(K^SC?/XG_9^/A[0/\ A:VC>(?&<?CGPU[!_P $<+?XHWG[
M$7A[QY\8_B'I/Q2^(/Q9^*OQM^(VO>,M.\/>.O#]]J-U?_$SQ!X?EBUU/'OQ
MA^,UY>75G<>&[BWT&/P[J_A+P9X9\#)X1\">&O FCV7A(ZCK*ZORC&3[^^TH
MJWHU)MV5FDKN]F]%%[\TI1_\ BW)[+9IQMNVF_ALY?J=1110 4444 %%%<GX
MI\11Z-#%:0.IU._RMN@PQMX 0DMXZ\@!"=D ?B6<Y"O'#.% -B34HQ=-;QD-
MY61*<C!?&616_O1@8?&0'.QL,K"M)'5QN4Y'Y\X!Z]\9Q]:\]T)9'1"Y8E@=
MSG))+>9EB3R3R"2>3[FN\MU(4'/ 7'3&2<-G&<#&<>YSGI0!8HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *\>\86,OAZ[34[=<:5>R[) N=ME>.&/ED X6WN
M2"T!'RQS!X,QJULC>PU4O["TU2RN=/OH5GM+N%X9XFR-R..JL,-'(C8>*5"L
MD4JI)&RNBL #SK0?$$<H0&0'J ,Y!R.F#ZGT_$Y)!]%M9UE08(Q@8.1U/0 <
M=>2/?('  'RGJ)U#P-XBDT/497>,XN=-O2 J:AI[N5BF_A47$)!@O8ACRKA2
MR V\UM++[3X8\117D2 ,NXC!Y[' !ZY./3 "Y!R>: /3J^;IOVQ?V4+;XU2_
MLXW7[2'P2LOCY%K=IX8_X4]?_$OPE8_$2;Q1?^&K#QG8^%K3PK>:K!JU[XHO
M/!^IV/BRV\.6=M/K<_AJ<:[%8OI:272?1<,JR*N.NT$Y[YXS_D#KZYQ^,'@C
M]B/XK?%3]H?]NKQ!X_\ B9\2_AM\%M1_X*/_  ._:5\ _"*V\%?#R/P;\;O$
M'[/W[,7[ OBWX5_$+5_&^K^%-3^)DO@#0_VAO@K9IKVA^ /%O@R37]5^$DOA
MN?7+?0[WQ?I/B%-V;NI-*$Y6BDY-QY;12;6LN9J*ZNRTBY3B[73=TGS123=E
M[S:;?6T;)M]%=ZNRE^S=[>V>G6=WJ&HW=M8:?86UQ>7]]>SQ6MG96=K$\]U=
MW=U.\<%O;6T"/-/<32)%#$CR2.J*Q'P[IWP>_P"">?QG_:.T?XS:;^S]^SU\
M4/VAK[X?_"O]HOPQ^TI;?L_>'?%]UX@\)7K7?AOX.?$GPI^TVG@:_P#"/BCQ
M)IFF^%&A\#RZ!\1=3\=^%O!0TC5=-M=)\&^(=&OM4_"WX8_LM>+_ !=IW[ _
MP[OOV2?VR-"_:'L'^.G@K_@J)\4/BQK7Q!?X1?%?XE>-_P#@G)^V7\,O$/B7
MXF^-=:^(VJ>"/VFM*^)WQX\4V=_\%/B]X"M_''@KX+>"_$UE\,I-:^!]WX\\
M+?"F_P"+TW]F/]L"U_9/\ >!OV>O@]\;?@UH7A+]@#_@FC\/_C+\.M2^'_Q'
MT.ZU;Q5\(?VK_B_JO[>7@;2OAUHGQ?\ V?\ Q#\2]?U[PU)'XB\;:+\-OC'X
M3U#]H_X-W,_@OX<>./%EG\0/#&DZVX)2G*+TY;*,K6C*\9MRC)\ON)J"3?*V
MG=Q3=H*2M&+3O=2<EI=6E!*+2<O>:<W:S6BM*R;E_38/V1_V6!\=O^&H1^SC
M\#A^TB&:4?'@?"SP3_PMP73^%?\ A WU$>/_ .Q?^$G&K/X$ \"OK(U(:HW@
ME1X2:\/AY1IP\S\>_!/_ ()\^%?"/B;X/_$SX7?LE>'?!6I? 70;OQ7\,_&?
MA3X3:5HEW^S/^R)K-IJOA?4M5\(:S9P02?!O]F/Q)X_TW5/#^JRZ?_PB7P:\
M0^,=*U#3+GP[JFNV$US^+'P!_8O^+GCSQC^SQX>^)_A_XD>*OV0M>_;!^-WB
MZ_\ @_#^SS\8_P!CKX'>%OA=;?L6>(?"T-HO[.GQ0_:G_:&^+'@W]GSXE_'@
M:??V_P &_BW<?"WP_J'Q4TGQ'XJTWX&6W@[XA6GB7QQT?P0_8<L8?VF?V=)_
MVE?V9?'WQ*^%UE\/_P#@L3^Q;H.K?$/PWXZ^,L'AGX/Z_P#\%!H=5_8W\"_$
M;5]?O?%.M:9\%]7_ &,5^(WACX;>*O&TTO@M_A]J=KX%U37(IO$/A32=7$KJ
M.J2?,DG=VY4[7C[MFY<MK+5/22^)*Z3=U)O1>ZDKZQOJ[W27-O=W5U&2NG^S
M/_#&'[#'Q&^!?P^^$I_9=_9K\6_L\:%-+X]^&7P_?X0?#[4?AMHM]XQAU34]
M1\8^$O#[Z"^D:9JOC.W\6>(+CQ#KVG6\&H^*[?Q7XB77;K48O$6L+>^%?$*^
M_P""0ME\;_#'P0^**?L#Z;^T!X2\'> OV8?!_P ./&FG? _3?B'X;\!>+1H>
MK_"S]G;0M&U>UM]3TGPOXB?6/#E]\.?A#9QP:9J=UK&C2>%?#LUUJ=G]H^2O
MAO\ "?XD^&O^"L/B#QS#\,/V@O$MCXH^,_Q/U?Q3\0_B+X.^(_@I/A[\(]1_
M9METSP[J7AS]ISP/\;O$/[.7[1_[)NI?$?0O"'A#X8_L-^,_A-X2^/?P?^+_
M (OU7]H?4[6.R^&\_B+Q-\Y?M<?!/X_^*?VC/^"@GA3PSHW[8_B*U^-G[2W[
M&_Q!^%_[/GA3X(>!+W]B_P#:=T3X>_!G]D33?%%Y\=/VD]<^$,?C+X3^'K'Q
M!\+/$WA3QW>>$?VIOAKJ&B:%X/@U+0OA9\3M9O+GP-\3G!*4H*_(I-.[WB^:
MG!-VY=5&<O>5E:F[.,%)0'I&6S:5K+9W4VU:[=FXKW=;\ZO>33E^]L/[(W[*
MUM\=?^&H(/V;_@9#^T@7NI1\>(_A7X(3XN+=WWAC_A![[45^(*Z(/%":M?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)0O+E;NNKTLKQMNVU[_/ML[^SY79WBYV2DHFYXA_X*5?LL>!9M%T_P")-_\
M%SX>:Z?AW\-OB=\4-,UG]GCXY^(-*_9C\._%+3GU308_VN/B1\._ 'C;X/\
M[,.H:39PWE_XQC^,OQ%\)6?A'P[87WCG7+ZT^'UL_BRN5_9\_;WU/XW_ +0N
MC? V[^%EAX9@U:Y_X*9P+XDM_&-QK,T,?_!/C]L?X)?LJZ9(=+E\,:7&S_%:
MS^+TGCF]B&H >"KK0H_#L$OBB+4&UNT^5/C/_P $9Y_B7\4?B/XPL?CKX2\1
MZ)^T'X0^%7AW]H?7/V@O@7)\6_C-XB\1> /A)X5^ 7BWXB>!M:\%?%7X+_L]
MZ3KWQ8^$'@;PKI_B+PG\1/V8OBC\*](^(-OJOC.V\!ZIX-UK4/A+/]9?L_\
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MJWQ#MO@5K \8:)!X-^->I>%[+X7_ !#OGOM-^'_BKQ/J.EZC:VT7PG_X)H?
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M#Q]9:IX4U7P5XQ\%Z7XFL/$.G2:1=Z1!<2QFO*/!O_!/;XFWO[2?@/\ :_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<VH:C?W9\ZYO+V[E:XNKNXE/WYIYI'ED; RS'  P!]V>%M AT^WA18P  O\
M".<+DDYXP#@X)/IS@U\X>X;^C:8EG @"@84#D=N.!R>V1CH,YZUT%-50@PHP
M,D_B:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !2$X_I[GTI:_(;_@KC^UM)\%?A!:_!3P1J[67Q-^-ME?6NH7=C.L6H>%/A
M;"S67B754E1S/8:CXMN'_P"$0T&<Q1.UD_B_5=+OK75O#=LU?3<'<*YGQMQ-
ME'"^40OC,UQ4:+K2A.='!86FO;8[,,2H+F6&P&#A6Q-6SBYN-&A"2JXFD>%Q
M-Q!@>%LBS+/LQ;^K9?AW45*+2JXK$3?L\+@Z/-HZV+Q$Z5&%TU!.K5DN2A._
MYA_\%1?VX#^T1X^;X-_#/6(YO@I\,=;F-UJ^E77F6OQ+\?V DM+CQ!%?02>7
M>>$O"KFZTSP>]H19:O?R:IXL6XU6RF\(76F^S?L1_M02^/M%7PQXFU MX^\*
M6T(U"65U63Q+HBO':VOB6-2 7O8Y'AL?$BH&5-1DM=2 AAUJ"UMOPR58U4*H
M4*%"J  H55  55& H &  !@<=JZGP;XQ\0^ /%.B>,O"U\;/6M"O%NK21]\E
MO<(5:*[T^^B5XVN--U.U>:PU"W$D;RVL\@BEBF$4L?\ HGQ;X#\-9OX9X/@?
M):%'!YAP]0J8OAW-ZRA'$5,[J4HRQ]?-:M*$IU*'$56FZ>:)*<,+?+J^%IJ.
M34:=;^*N'/%W/<MXZQ/%>:5:N+P><U*>&SO+:4I.E'*X3DL)2R^E.2C"MDL)
M\^7M\CK?[;2Q$[YG5G3_ +5_AMXVCO8(8S,"=J;2S G@#@9_'J#QD"OHZRND
MGB# @D^^<9QQGZGCIQQR02?Q@_9@_:!T7XF>$]%\5Z'<-"ESBUU32Y;A9+O0
M=<MHX3J.C7K*(RTELTL<UM<&*%=0TVXL=3BBCAO8T7]2_!'BF*_MH29%+%5R
M-V3GU'N3CKQD9SQ7^:68Y=CLHS#&Y5F>%K8',<NQ5?!8[!XB')7PV*P]25.M
M1J1NU>,HW4HRG3J4YTJU*I5HUJ-6K_=&"QN$S'!X7,,!B*6*P6-P]+%83$T9
M<U*OAZ\%4I5(.R=I1EK&2C.$XU*=2%.K2JTX>Q45'%()$5@0<C/!KQ_X]_M!
M?!S]F+X::W\7OCKX]T3X=^ -!\N*ZUK6'N)9K[4;A97LM"\/Z/I\%YK7B;Q+
MJ8@F72?#?A[3]2UO5'BE6RL9O*E*9X3"8K'XK#X+ X;$8W&8NM3P^%PF$H5<
M3BL3B*LE"E0P^'H4ZM:M5J3:C"G3IRE)WLDE*4-JM6E0I5*]>K3HT:,)5:M:
MK.%.E2IP3E.I4J3E"$(1BFY2E))):O9/V0G'K^ )_EFOQJ_;<_X+9_LJ_LF7
M6M^ O!-RW[1GQPTB:YT^]\"_#[6;2V\'^$M6M9O(GL?B+\3_ +-JFC:'>VTT
M=Y:WWAWPOI_C7QCI6I6R67B'PYH4%U%J"_SI?\%"O^"WWQY_:ZEUOX:? Z3Q
M#^SW^SI=&^T^XL=-U/[#\7OBCI-QNA<?$/Q/HE[-'X7\/ZA:*(+CX=^"=1>T
MN;>[U33O%WBWQOI&HQ:5IOXJV/DP1I%&B1QQHB11Q(J1HB<HJ*NU$50"H48
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M\,*PH%48X&>G4>^!U[_2JUA:);1!0!G@<8ZKU/3U'TR">A%7Z_EP_?@HHHH
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M1CJE^[Q4I127*F]_\YC3-9MKA%V2*3P0>N,CV+' QD'D9)X[#L[699!D,#D
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MR21_:XZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT[3K/^9?&[QRP_ M&?#_  _*AC.*\31NU/EJX;),/6B_9XS'4U*U7%58/VF
MR^4H*<5'&8SDPBI4L;^V>%WA35XJJQS?-XU<-P]AZEDX7IU\TK4VG+#X6;7-
M3H4Y)1Q6,BI<C?U?#.6)<ZF$^:/V#_\ @FI^S#_P3Y\)W6G?!KPE'J/Q$\1V
MC6_Q ^-'BB.+4?B-XR66\CU Z,NIN&7PQX%T^X@M$T7P'X=^QZ';IIUEJFLC
MQ!XNEU?Q3JOZ!445_GKFV;YIGN88K-LYQ^+S/,L;4=7$XW&UIUZ]63T2<IMJ
M%.G&T*-&E&E0H4HQI4*-*G%1/[*PF#PN P]+"8*A2PV&H04*5&C!0A%))7TN
MY3E9.=2<IU*DKSJ5)SDY,HHHKSCI"BBB@ HHHH **** "N8\9>"_"/Q$\+ZY
MX)\>>&-!\9^$/$MC)IOB#POXHTJRUS0-9L)&5VM=2TK48;BRNX1)''*JS0MY
M<T<<T966-'7IZ*J$YTYPJ4YSIU*<XU*=2G.=.I3J0DI0J4ZE.<*E.<)1C*$X
M3A.$HQE&4914E,X0J1E"I&,X3C*$X3C&<)PDG&4)PG&4)QE%N,HRC*,HMJ46
MFT_XH?\ @L'_ ,$2OB5\([/4OVC_ -D@^(/B1\"?#%K?WWC'X$%;_7?B!\']
M-<O>:AXM\%7;R7NJ_$OP)!%''#KMC??:?B%X.T_3['4I+KQSH,FNZGX._%/]
MC_\ ;X_:;_8WUFUUS]GKXGWFE>';F[CU/6?AGKR-XK^#_C R.D\KZSX'N[I+
M&UN]058XY_%/A&[\,>-?LI:"R\56D,L@?_4*K^.#_@N-_P $;;;P''XP_;E_
M9%\)BT\*QMJ/BG]I/X,>&[$+9^'HF,E[K7QN^'^CV<8%EHT!,^H_%?PU81+8
MZ9 ;GXB:=;V=E;^,-_\ :7@SXZ8/B##TO#7Q6HX#.L!F+IX/+<TSG#X?%8;&
M5)-0P^79Y#$4W1>*E*:AEN=1>&Q+Q$X4,5BJ&+JX;,:OXMQ=P%+*4\_X/53+
M9X13K8C!Y?*I0G0C=U*F(P'LIIJDGS5,3@FJM+D4JE*E.E">&A^H/_!/S_@N
MQ^S?^U5/H7PR^-%M8_LU?';4WL],TZP\1:Y'<_"7XA:O*BVZ0^!?B!?Q6$>B
MZUJMXB"Q\">.8],U2:^U/3_#WA/7_B%J*W%R/W>SG^5?Y*MC)#?6S!Q%-%<)
MM9'"R12)(NUE8',;I(,94Y0AB"" 0/W^_P"":W_!;KXO_LERZ#\(_P!HFZ\3
M?'+]F^"*UTC2KRXNFU?XL?!JPB*16C>%=4U&=9_&_@?3+<?9&\ >(+T:EHFF
M):1^!-?T[3M#M? NN>AXJ_14I.AB.(O"J52I&,:F(Q/!F+Q#K5)15Y2_U<S'
M$34ZD_B<,GS2LZDDE2P&9SG[/#3Y^%?%9J=/+N*N6+;5.GG-*FHQ3NHQ_M'#
MTHN,8OKC,-!16KKX514JJ_NLHKSSX4?%CX<?'+X>>%?BO\)/&6A^/_AYXUTQ
M-6\-^*O#MU]JTW4+;S9;:YA<.L=UI^J:9?6]UI6N:)J=O9ZUH&LV5_HNMZ?I
M^K6-Y90>AU_$%>A7PM>MAL31K8;$X>K4H8C#XBE4H5Z%>C.5*M1KT:T*=6E6
MI5(3IU*=2G"<)PE&44TT?N%.I3JPA5I5(5:52$:E.I3G&I3J0G%2A.$X2E"<
M)QE&491E*,HM--IIA1116184444 %%!X!/I7Y[?$+_@K'_P31^$GQ1\0_!7X
MJ?MR?LT_#?XI>$?$ \+>*_!OCOXJ>&?">I^&->(@9K#Q%)KMY8V6B&%+F&2Y
MN=2N[:SM8G\VYN(HU=U5U=*ZN[M*^KM:]EUM=7[75]PL[-V=E:[MHKWM=[*]
MG:]KV=KV=OT)HJEINI:=K&G6&KZ1?V6JZ3JME:ZEIFIZ;=07VG:EIU]!'=65
M_87MK)+;7EE>6TL5Q:W5O+)!<021RQ2/&ZL;M, HJM>WEOI]G=W]Y(8K2QMI
M[RZE$<DICM[:)YIY!%"DDTA2)&81Q1O(^-J(S$*?G;]DW]KS]GC]N7X)Z!^T
M5^RU\0C\4/@YXHU/Q#H^A>,?^$2\<^"?M^H^%=8NM U^W'A_XB^&?"/BFV%A
MJUE=6GG7>B6]O=&(SV4MQ;,DS&][=$F_)-\J;[)R]U-[O3<.WFVEYM*[2\TM
M7Y:GTE117,^-?&GA+X;^#?%OQ$\?^)-&\&^!/ 7AC7O&GC7Q?XCU"VTGP]X5
M\)>%M*N]<\2>)->U6\DBM-,T;0]&L;W4]4U"ZECMK.QM9[F>1(HV8&P'345^
M;?QK_P""K'[)7P;TW]BOQ'8ZQXT^.'@C]O?XZZ-\ /@)\1?V=_"H^+/P^N/%
M>LZC+I":UXF\6Z1JEMI-CX<M-4AN+)[?1)_$/C+4C8:[=^'O"&M:=X4\67FA
M_I)1KJ[.RDXNZM[R46UK;5*47MM):ZV#MYI27FFVDUY7BU\F%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?R$?\%\E^%6B?\%9/^",'C;_ (*":5I&
MK?\ !+K3-2^.FD>.#XWT74==^#6G_M$:AX8U"?P/_P +BL=/M[C2YM O?$%O
M\']073_'$=QX4U7P=X:^)S:OI^H>"--^(]N>)^-GB'_@A+XGM/\ @L,W_!-'
MX=^&[G]J70_^"2'[9L7QB^*W[)MMXOT7]D&'X=ZE\ -;,GAZZ3P/XETS]F;7
M=<UC6K7PAJ#77@OP9J]WJOBRPNM2DUJX\3Z!XTFTO^N[XG_"?X6_&[P3K'PU
M^,_PU\ ?%WX<^(1:#7_ 'Q/\'>'?'W@G7187EOJ-B-8\*^*]-U;0M3%EJ%K;
M7UI]ML)_LUY;P7,.R>*.1?,OA]^Q[^R7\)?AKXZ^#/PJ_9@_9Z^&?PA^*-CJ
MVF?$WX6^ /@Q\.?!WP\^(VG:_HDGAG7K'Q[X-\/>&].\/>,+77/#DLOA_68/
M$.GZC'JFBRR:7?+/8R/ RBN6_:]26FC;J):-M.R3712;C:.BU"?O6V^&G'75
M)4W>Z5]7)=[6E>7O;/\ S]OV?_V@OC]X&U#_ ()Z_"[P+\=OC1X(^&<O_!M9
M^UK\4I?AWX-^*OCWPKX%D^)WA[0O^"@C^'_B,_A+0/$&GZ _CW09M!T"XT7Q
M@;#_ (2+2KGP_H-S8:E;W&B:7)::/@C6?VL_V</^";'_  1G_P""MFB?\%%/
MV]OB%\<?CI^W-X._9^^)7PC^*O[0WB#QI^SGK'PHUCXF_M#I=^%A\/KZW75;
M^VU32O@MI-GXC?Q7XJ\4OJU_K^KZU8G1+O3O"L?A_P#O9@_83_8DM;CP]>6O
M['O[+UM=^$?A7KOP+\*75O\  /X5P7'AGX)^*(?%EMXF^$'AZ:+PJLFC?##Q
M%;^//'$&N^ M.:V\+:O%XP\3QZAI5PNNZF+K6NOV,?V/[[X4^ O@3>_LK?LY
MW?P1^%?BQ/'OPP^#US\$_AM/\+OASXXCO/$6H1^,O O@&7PVWA7PEXIBO_%_
MBR^B\0:!I5AJL5YXFU^YCNUFU>_>XV4X>U524')*<)-<R5XK$NM.#T<7S4FZ
M2<D[:_8;1DH-4E33C&T.1M+=_5HT5.^DD_:)U6D]79WYUS'\"W[4?[??[<'P
MTB_X+=Z7X5_:[_:+\!>"8?\ @M3\"?V:]>^*=GXU^*'C;4OV3?V6_%_B']M/
M5?%NI_!QH]=N[GX,:7'KW@?X=^'S)X#;PX;ZS.F>!],D@NM5T..#W7]I3]HF
MW_83_9(_X*D>#_\ @E[_ ,%O/VE/V[T\(_";X%2ZCX=\5W?B/X[:O^R9H7Q,
M^+7P>\&>*?B]\*_V^]"L8O@EJ&M^*=/^(OBCP8O@;X-P>'_&_A75/%TWCFRO
M;#QY^SYXJ\3VW]OUM^Q]^R79VOQNL;7]F#]GJ"Q_:8U"35OVC[*+X,?#E;/X
M_P"JRW^L:K-J7QJM!X;^S_%*_EU/Q#K^H2WGCB/7+B2]UO5KII#/J%T\L7PL
M_8X_9)^!OP^\;_";X,_LP_L__"OX7_$RVU&S^)7P]^'_ ,'OA_X3\&?$6SU?
M2KC0=5M?'OAO1/#]GI/C.VU'0;JYT*]@\26FIQ7&B32:1*C:<QMJR7\.,&K2
M5.$'-/63C!1:=U;D<ES:)5/>E[RDE(U6E24]TZLYJ+M:*G*ZY;6?,HZ6;<-%
M[KC>+_B&^ WC[P)\'O\ @JU_P1-^"G['W_!9[]J;_@H#\)?C#9^.OB/\?O /
MCC]HS5/B'X;\)>+O$GPYDU""#7[#P]<:?%X:LO'&I:1?ZLW[-_Q5_P"$B\>?
M!S6/"U[J_B6?^TOB')=7OZ(?\&O^B>#?$W_! 'XQ^&_B-J'BW2/A]X@\=_M>
M:)X[U7P#8:UJOCK3/!NJ^!=$L/$^H>"M+\-Z)XF\1:EXMLM$N+ZY\.6&@^&_
M$&M7FL16=OI>B:K?206%Q_1U\._^">_[!GPBU7P9KWPK_8K_ &4?AQK_ ,.?
M$GB#QC\/M?\ !'[/?PG\,:[X'\6^++#2])\3>)O".LZ-X3L]2\.Z]KVD:'H>
MCZKJVD75I?7NCZ)HVDSSOIVE6%M;^S_!KX"_ []G/P>WP]_9]^#?PL^!G@%M
M6O=>;P1\'_ 'A3X:^$3KFI16L.I:R?#?@W2=&T<ZMJ$5C91WVH_8_M=VEI;+
M/-((8]NCFG1J4N1+G]KKHTHU*L*D862C)PIQBZ<4W?E>ZU(46JE.:E?V?+=[
M2E*-*4'.^J4YR?M&[-<W1G^='^PEXJ_9G_93_:$_X)/_  =T?Q)_P3=_X*P_
MLU>./VSH_"'[+?QM^&OACXA?LW?\%&_V9/B/XI^.'@PV'Q%^.?PLOIM$\86G
M@O1?B)<1^,/"VA?&31?B0?$OA7P\MEX>\<^%_ 5QX-AU?Q/]NK5OB?\ M!_\
M$SOBY\7OCE^TA^TGXO3X#_\ !QS\>O@7HUMX@^,WBWQ%X-\-?"?QG\'_  ?J
M-G?7MIXID\0_V?/\';CP$]I\%;VVN].T;X=Q_$[XG6]CI5U)XZN!%_H[> _V
M%?V)_A9\6KWX]_#+]D+]F/X>?'#4;S7=2O/C!X(^!'PO\+?$V;4O%,>HP^*M
M1_X3C1/"]EXDCU#Q5%J^J1^*+Z+4H[OQ&E_=KK4U\)G!VX/V.?V1K;X;_$7X
M.0?LM_LZQ_"+XO\ BZY^('Q9^%@^"GPV/PY^)_CN\N]%U"[\:_$/P0WAH^&O
M&GBRZU#PWX>O[GQ%XDTS4M7GO="T>[EO&N--LY(<E=3C-I2Y86497Y5/ZQA:
MO-[KC?W*%2FY64VJJUM%LM[65XWG>5K7<70Q5)QU3M[V(IS4;N"=';WK'\$W
M[>O[07Q9E_;RO/V1[7]NOXUWW[$G[-7[#WPD\=?LB?&*Y_X*P>%OV,[G]I^V
MUKPGX0U+6?VK=<_:6N_A3\5/"/[7WQ,L?B!JWQ \*Z-X;\%>'['5M6D^'U\W
M@A(D\/>/]+\0?UX_\$*/BG^T#\8_^"7W[-OC7]I7XM>'OC[\1S;>//#-O\<?
M#NKZEKT7Q4\'>"OB)XH\(^$?$NKZSK/AOPIJVM>(;32=%C\,:UXEU;2IM8\8
MWGA]_&.M:QK^L:_?ZU?_ %YX]_X)^_L(_%/PM\-/ WQ+_8O_ &5?'_@OX,:7
M+H7PB\)>,?V?_A5XC\-?"_0+B6SFNO#O@#1-6\*7>F^$?#M]+IVGMJ&@:%;6
M.CZA]ALUO;*=;:%4^I=!T'0_"NAZ-X8\,:-I7ASPUX<TG3M!\/>'M!TZST?0
M]!T/1[.'3])T;1M)T^&VL-+TK2["WM['3M.L;>"SLK."&VMH8H8D1;YM)+?F
M:=].DI2YK6TDU)0?+:/+&UK<JBFKN+VLM4MO@C&R>CY4XN2NKWD]W>4M:BBO
MBC_@HW^V-H7_  3_ /V'?VE/VP->TZ#6A\%/AQ>:SX:T"[^TK8>)?B+X@U'3
MO!7PK\+ZI/9$7=EH_B?XE^)?">@:QJ5L'GTO3-1N]1BBF>U6)Y&?,'_!3_\
MX+;?L+?\$H-)TFQ_:#\8ZWXN^,?BG2SK7@[]GCX1V6E^*/BUJ^AF]CTU/%.M
MV6I:SH7ASP%X/>\:X6SU[QQX@T)O$J:/XD@\!Z?XQU7PUK6E6G\HWQ8_X/;]
M1\9^&O'_ (,\(_\ !.K^P-.\4>$_&GA31_$VH_M7F;7]-N->TG4=(T/Q2VF6
MG[.JV$$^EM=6^J7?A]-1O4GFA:Q@\10H5OZ_B.^.OQS^+7[3'Q@^(?Q\^.WC
MG6OB3\7/BKXFO_%OCKQIK\D)O]8UB_*J%AM;.&UTS1]'TRSBM='\.^&]$LM.
M\/>%_#^GZ7X=\.:7I>A:7I^GVW]'=M_P;1Z#H'PP^ /Q&^.7_!7'_@GK^S/>
M_M$?!CX??&[P3X%^/GCNS^&7BZ?PMX^\.:7KT+66F^,/$VA3:Y!I4^I-HUWJ
MNE0S:?)J-I-&LD<F8DUHU9X>M1Q%)Q56A6HUZ;G"%2"J4*M*O3<Z=2,Z=2*J
M4:;E3J0G3J14J=2,J=2<914IQJTZE*=^2K3J4I\LI0ER5:<Z4^6<'&<)<E2?
M+.$HSA+EG"491BU1_9R_;]^"7Q\U#3_!]J^I?#WX@72PV^G>$?%TEH;;7;C&
MP67A7Q-:.NGZS>_ZN.'3=0M- UF_FD$6DZ3J CF9/N1+Q<GG&,<9P1ZXQP#]
M1@\\]17\:?Q)\)P_#/XG^/\ P+I7B_0?&T'P_P#'GBKPEIOC[P9?QWWACQ;#
MX5\07^CV?B_PIJEK--%=Z%KR6$>M:%J%M<2I/I]W:W,,[JRR'^D7]AK]H'5/
MCY\"]+U?Q3=&]\=>#-3G\$^,+^5PT^MS6%K:7NB^)KA3),YN=9T6]MX=3N9'
M#:AXBTO7;Y8H89X84_T/\!/'?,/$'&XCA3BREA(\14<%6S#+\TP5%86CG&&P
MKI_7:.)P<93HX?,<+3K4\5&IA91P^-PSKMX>AB<.U6_D;Q3\*L'PKAJ6>9!+
M$/**F(IX3&8'$5'7GE]6LI+#5*->485*N#K3IRH.%>]7#UO8J-6K1JKV?W=]
ML"J&W9QT''0C') P>3C! QR3T-6O!G@_QS\9?B)X*^#_ ,+=&F\2?$/XC:_:
M>&?"NC1-)'%/J%TLL]Q>ZC<Q0SG3M"T33;:_\0>)-8>&6WT3P[I>J:Q=K]EL
M)B//K_5$@@<Y!(!.0?;.>IP>^,+T.*_IY_X(%?L<QZ+X,\0?MM^/=,$GB3XC
M#6/ OP0@OHE=]$^&^DZI]A\7>,[:-Y"UMJ7CSQ1I4^AZ?--9Q75OX1\*)J&D
MW\VB^/[R*7]0\7./\/X>\(YAG4N2KCYI8')\)-Z8K-<5"I'#0G&,HS>'H*-3
M&XQQ::PN&E!2C/$TVOA. ^#JO%G$&$RY*4,+%_6,QKQ5G0P-%P=:47:4?:UF
MXX?#\VCK5E*TE1E%_LG^Q9^R-X!_8M^!7AWX.^"F75=25O\ A(/B'XXGLX[/
M4_B%\0M1M;6+7O%-[ CS/9V9%K;:3X;T=[J]/A_PMIFC:(;[4);&;4+OZSHH
MK_*C,<QQN;8_&9IF6)JXS,,PQ-;%XS%5I<U2OB*\W4J5)/1)7:C"$%&G2I0I
M4J4(4J5.$?[NP>#PN7X3#8'!4*>&PF$HT\/AZ%*/+3I4J45&$(K=Z)N4I.4Y
MSE.I.4IU)RD4445Q'2%%%% !1110 4444 %%%% !1110 4C*&4JP!5@0P(!!
M!X((((((X(((()!I:* /X _^"UO_  33@_87^.-C\6_A!H?V']EKX^Z[J+^'
M-+T^S-OI7P=^*<D-[K>M_"B%8E:TL_"VN:?:ZEXN^%=M ;9+'2+'Q5X,M=+L
MM+\!Z7?:W^0=D@G52 #T((Y QD@CDG(S@YY!7'&<K_IV?M:?LR_#_P#;"_9X
M^)_[.WQ)BV>'_B+X>FL++6X;<7.I>#?%=C)'J?@WQWHD336ZR:UX+\3V>E>(
M]/MIIUL=1ET\Z7JL=SI-]?VD_P#FE>-/AIXX^"OQ+\??!GXF:6-&^(7PM\7:
MWX&\8:=&TTEHNM:#>RV4UYI4\\4$FH:!J\*PZSX=U7RHX=8\/W^F:M;KY%Y"
MQ_TG^C5XK5N,.'ZG#N=XF5?B'AN%"C.O6J<U?-,HG^YP./J2FW*KB:$H1RW'
MU&Y3G4IX/%5)2J8JM4J?S#XI<+0R/,(9E@J2IY;F<JDHP@K0PN,C[^(P\4DE
M"E4C+ZSAXJRC%UZ44HTH1C]Q_P#!/7_@H?\ &;_@G[\1CJWA.6[\9?!SQ5JE
MM<_%3X*WU^8-&\2*(H+)_%7A6:Y+V_A7XDV%A;P6]IKT"+9^(;&RL= \6PWN
MGV6B7F@?WU? /]I#X/?M+?!SP]\=OA-XOL=:^'FO:=<7DNH7CQ:;>>&[O38]
MVOZ%XNLKB7=X=U[PU,LMOKNGWSJ+-HOM44UQIT]I>W'^9?';!AG;R3ZDG\"/
MF(Z9 R>AP.K?&_[;'[<?QX^ WPA\:?LB_![XH^*? _@3]J'0+#4_V@?#>BW2
M6UIXM\&:)JLMEX>T7SWAFO-(7Q)=Z;JVG>,I] N=%OO%'A'2[7P;XDN-9\'Z
MK?:)-Y'TI/#7A;&\,X[Q'ISH9+Q'E<\#0Q%6E12H\41Q>)HX+#8+&4Z,8WS:
MDG*>"S-Q<Y8;!U\'F,JU"&$KX7H\)>+,VIYO0X8<9X[+,7'$5:<93O/*O84I
MUZN(I3FW_L<WRQK871*K6IU<,H5)5J=7^R7]O+_@\(_81_9C\:ZY\,_V7_AM
MXN_;B\5>%]5DTK7?&7A;QCI7PK^ <US97]WIVK6OA+XJW_A[Q[KOCJ2PFLGE
MMM=\,?#6^^'7B.PN=/U+PGX_UW3[HW4/PK\*O^#XGP/J'BS3+'XX?\$\O%?A
M/P+<7K_VSXI^%7[0VD?$+Q9I.G-(/+.F> O%WPI^&.C^(;V.(D.+OXD>&()Y
M%!5K=9,1_P 'W[.WP#^)G[4WQT^$_P"SI\&]$'B'XG_&?QUX>^'W@O3)96MK
M)M8\0W\5E'?:O?+%.-+T#1X7FUCQ%K,L3VVC:%8:AJMT!;6<I']!?[8G_!LW
M\4/V:OV8_P!H#X^?"K]MK]F']J_QK^QQ::;=_MB? CX3W5[#XV^"JSP6]WK2
M1W#:IK$VH3^&]*EO?$^H67CO0_A7J=WX3\/>)[W2K"]U[2!X9NO\[S^EC_2T
M_88_X*$_LE?\%'/A!#\:/V2_BOI7Q$\.VS6-EXO\.S07&A?$'X:^(+V"67_A
M&/B+X)U1(-:\-:JKVU]%8WCPW/ASQ-%87.K>#=>\1Z ;?5Y_M.O\3'_@DW_P
M4<^)G_!+[]M+X7?M(^"M0U*X\#+J^G>$_CYX!M7FEL_B9\$=:U.S3QOX=DT\
M7^G6T_B/3;&,^)OA]?WEQ]FT7QYHOA_4;V&_TJ/4])U'_:_TK5--US3--UO1
MK^TU71]8L+/5-*U.PN(KNPU'3=0MX[NQO[*ZA9X;FTO+6:*XMKB)WBFAD22-
MF1@2 7Z_SS]:_8__ &M_VW/^"EW_  <5_ 7]EWX$?\$__B?:_$+XB?![X??$
M3XG_ +;.D^)=1\5?L_1^.O!?Q;TKPQX]_9VO?#'AOQ-?Z!XTMO(\1Z_<Z_%I
M]U=Z%XH\(?#;7++2]9DTM[!_]#"O*_!'P,^"GPR\:?$SXC_#CX0_#'P!\0OC
M1J.D:O\ &'QUX+\!^%_"_C#XKZMX?&JKH.J?$CQ+HFEV6L^.-1T1-=UM-(O?
M$U[J=SIR:OJ:6<L*WUR)(E#FG&3VC"I%K77G]G;5-6MR=U^9:FXPE%;RE2DG
MH[>S=2ZLT]U4T[6UZ'\5OP__ &(OVH-1_P""MWPW_P""27A__@I-^UC\%_@Q
M^S/_ ,$?_@%J?Q+O_@UX[\2:*GQ2?X<>._ACX:US1?!VBWVOOH_PIL/%'B;7
M-%W:WI6G:GXB7X6>'+CX4ZI=ZKHOBKQ!=7'YM?&#]L3XE?$3X1_\%1_V[/CU
M_P %;/VG?V5O^"G7[+/[;GB7X<?LQ_L&^#_VAK+P3\.]%\!>$O'WPU\-6O@O
M3?V:FL$U3XA^'[:";X@^!/%]QH,D6EPS^ )?'7QUM_&K:]XG;Q3_ */-G\#O
M@MI_Q>U3]H*P^$7PRLOCSKG@Y/AWK7QKM? GA>W^+.K^ (K[3M4B\#ZG\18M
M+3Q=?>$(M2T?2=0C\-W6KRZ,E]IFGW:V8GL[>2/ROQI^PW^Q;\2/C%IW[0WQ
M"_9'_9I\<_'K2=0T'5M.^-'B[X&_#/Q%\4K75_"D>F1>$]6C\>:OX9N_$QU7
MPG%HVE1^%=3DU-[[PVFGVB:)<6"P1A:7.TN:5WS5I.244U*I6]HI1NMXTU&D
MDWR\JNE>[E"Y4YM15FJ48Q;?P4Z7)*$FFKJ55RJW24KOE;:V_AXO_P!J/XA?
MM6_MQ?M9:_\ \%.O^"JG[1/_  2:^(O[+?[$'[)/Q6_9U^ 7PS^*MK\%_!)^
M*7CW]EOPE\5/C#%>?#W7+*YT_P",>LV?C[Q5N\0_ E;6^^.'Q:T7QY_PK'3/
M$1\*_#./P[IG@'_!/+]J+5?V7/V>?^#93Q'XE^/7B7X#_LY^(_VM?^"E.D_M
M :J_Q"\0^ ?@_K-@WQ/^$]CX*C^-$UGJ>G>$KWP]I>J:OJ=Q:WOCSS-!\.65
MQK^M7=SIVDP:W?0_Z#WQ4_8[_9+^.?Q#\&_%SXU_LQ?L_P#Q=^*GP[ATZW\"
M?$CXF_![X?\ CKQSX0MM&U6\U[1K;P[XJ\3>']3UO2;71=?U"^U_1K:RO88-
M)UZ[N-:TZ.VU25[LX&H_L(_L1ZO\&-*_9QU3]C[]F&__ &?-!\2R^,]!^!UU
M\!_A?-\)-!\8S_VH)O%NB?#M_"Y\)Z1XGF&N:V)?$&G:3;:M(-8U4-=D:C>"
M;6G4=.4I*,;OE2CO#W<15K7:LG?DJ1A9>ZO90:5MHE'FY5=JS;ONU>A3I<JN
MW>*E!SO*\W[27-)O5_PK?MC?\%2OVE+8_P#!QY\9?V(_VJ?'GQ ^&6B_%[_@
MGQ\+?AI\5_A[\5/$GB[P;\"?A7\18?BAX,^+?CS]GS4X=8OO#7@H^*_'_AO0
M?AM;?$/X?I:H]SXQM/%7@G78=>C\)>*;+Z7\2_#O]EE_@C_P5&_9@_9'_P""
M]G[7W[<.@>)_^"6_Q;^/OB']F^^\4>,/C_JNE:_\'M/TSXFP_$'0_P!KWPQI
M<GPO\!:%\0-9MK+X+_'+X!6FEVOB/XA> ?BSX@\!>/6N_$'_  A&H^$?[*_!
M?[&7[('PVTSXAZ)\._V5?V</ 6B_%SP?HWP\^*VB^#/@A\,_"^D?$WP!X<\/
M7/A+P_X&^(&EZ)X8LK'QCX/T/PK>7GAG2/#/B&WU'1=-T"[N='L[*'3[B6W?
M0^ _[)7[+'[+5GXGT_\ 9H_9O^!7[/UEXVN+&Z\96WP8^$_@7X9Q^+9M*.IG
M2&\3#P;H6CG75T9=9U:+1H]4-U'I%OJ5[;::EK;W,L39))04%=VI\G,VFVU"
MK%<VEG'FJ1J2T<G*%KVY7'1-J<JEE>59U7%72LY4'9:V34:,H*RC&TV_BYK_
M ,"'[%WQ#U+X)?L.?\&\-K^SE^VO\=?$$_QW_P""NWP;\+_M/_#/1_VDM0U3
MP]\-(-3^)'A#0=1_9KO?!'@F\T0^#?A=XB\,VEI\0+WX0?$"#68]8OO'.L>*
MB+K2/$]LI\%^)7[:/Q<\7_LS?M[?\%$OC=_P5@_:?_9J_P""M/P _;BO?A_\
M%_\ @GYX;_:%LO!?PX\)^"_#/Q"^%&B7GP\L_P!E'5[*ZUGQ9X.\+V-]\2=,
M\67(DD\%:G/X F@^+FD>+==U+QA<>+O]#3PU^P!^PCX+A\,6_@[]BS]D_P )
M6_@GXF:?\:?!EMX8_9W^$6@6WA'XQ:2FF1Z7\5_#%OI/A"S@T#XDZ='HND)8
M^.-*CM/$UJFF6"P:F@M( FGXC_8;_8M\8?&JS_:1\6?LD?LT^)_VA-/U71->
MLOCAK_P-^&>L?%BV\0>&4TR+PQX@C^(&H>&;CQ0/$'AF'1M)M_#>NG4SJV@V
M^G6=OI%Y9PP1HH]:E2>RGLE=.G_ ^#7E?\*<5SW]RHV_>NV:*$(\J;CNW_R\
MUKZ3TT3]K&;Y;/GIJWNI6_CN\(?#?]K#_@IS_P %8O\ @H]\'OCK^VC^W3^Q
MGIO@']AK]BGX\ZI\!OV;/CAXM^&WAWP-^T!XR_8\_9NU[Q'X4U+PQK<^O6UC
MX(\*>/?%'C6^\3> ](MO#VJ^+/$\ECJVK^*[34]%\Z]_>K_@W!_:2^-/[57_
M  2%_9F^*7[0/C[Q#\5/BA!?_%GP-J_Q%\8:A-K'C'Q9I7@3XL>,?#GA:]\6
M:Y<EKWQ!K]AX8L])T.]\1:I+=:[X@_LJ/6O$>HZMXAOM4U:]_7#2_P!G[X$:
M'\3_ !_\;=%^"WPHTCXR_%?1--\-?%'XM:7\/?"=A\2_B/X=T;3M+T?1] \=
M^.K328O$_B[1=*TG0]%TO3=+U_5+^QL=.TG3;*U@BMK*VBCT?A'\%_@]\ /
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M1\1>%-%UKQ1^S-\&_C-X_P#$'A+PUXB\::)'X&\0>'O GAOQC9>)Y_A_K_\
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M 7'B#XI?$K7/B5X>\!^#)=>^('[4?QA\?_&#X>^#OV9?'=AX^^%/ASX/^/\
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MKFK^*IOCW\3?C_X9\#?$/XF_$WQ%JFO:OXWG\ >%_#FM1S^#QKOA[7-_5?\
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M-X(^.WA3XP_%O]I&U\%>/[?2_P!ESPA^S+X%^(&I?$+X:?";P=\/M;U+5O\
MA9WQ?\!?%.U_JCQQC_/^?Z\T8[\_F?Y9Q3DVU)12@I>UO;7E=1R<7!-OE=%R
M7(Y.;DE:3:21,5RN+;<W'V>LK7ER**ESV2O[3E]Y1Y$FVXQ5[K^2#X5?%37K
M7QE\9_%?CKX_ZGK_ ,>?C/\ M'_\&_\ \5+?X&_$C_A3>N:=XI^%WQ;\??\
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M-YX5^VW^P1^U1_P4Z_;/G\&_&S3->^ G[!7P+^&_C:W^$'B;3O%7PX\2:_\
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M1:6&B:I9^'/"%I>>))!I'[?V/[:/[/\ XFT;]IR^^&?BRZ^,?B+]D.S\7?\
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M?H4=GJOBK0;W3=1LO#WB*\\(G5]-\._%N*^\/>'_  IXJTBVT+Q3/KGA\?T
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M&<WA?XE>(_$G@YU\*:])IE_JMUJVBZC'!X9'B 0P_P!H-97-M<CM5&/ER1R
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M (-_$/PROB+X57.L:O\ J'112_X';LD]DET_S;=VZ_X/]?U]R"BBB@ HHHH
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M*W\H>(>2O*>,,;*,.7#9I.&:X>2ORMXF5\5%=+TL;3K\R3=E7BVES(_TG_\
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MOVS-<\%WEY^T7\-_ 4_PR\&^.D\8^-K2RTKP3<CQN)](E\%67B*W\":I(_\
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M)\*>)-9T+Q[XUTCQEH\B7OB"^TF3Q;X.N_V.^#G_  3/_8?^ FG?&W0_A=\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.I/FC"C3<JU6<*4)SC]R:Y\9OF<1W'!R55#DG&<D =2>N >Y'I7R?\3?VO\
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M,L=4HXBO0]GC*5"DL/A(*AC\/+#8RG%SHUY)1Q$Z:FI25*]V_P"1;QS^P_\
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M[ET*PUKP'?3++B?PU?R3Z;YK*RJTNB:VNIV<< !'^C:3)HR'8-CQL6+?K/\
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M<:E?2VFEV=Y>V_Y8^-/^"H2-?3V_P_\ A+')I<<K"WU+QKK[K?7L/&V270M
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MGM'/7!%Q"/\ @:!)?4Y-NHP.N<@*^CQ9.U0/0]",$\$9[<YZ<XSCI0FE*F,
M$=1A3D]2,GD#D\\\\X)H Z"*XAG :*1'!&< \@'U4X8?B!4U4K. 1!B!SPO7
M/^T?Y@'/)VY// NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&[K@,/4U:FNHY$+HZNK $,K!P?E/(93AO48.,X8'G:<2XF!ZGI@=<\],<8!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+)%D\:?M-?M#:VH!,B>$]-^%?A%W94).R36_!OCU(@3G:7CN-H(!#8K4O?\
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M)^W1^W]^WK_P64_9&_X)$?\ "?\ @W]EJP\(?M0_\%"/$'P/UCX/Z-J'Q_\
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MYH27,GS=4Y\T5K9ITYJ>SC&-7VLHZVY>><X-MVE%I-.+/Y+_ -J3_@CUX/\
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M%'X[\*VMOXJUG0?#_AC1/!MW<>%Y_P!*_B!_P53_ &&O!_PK_:1^*'AGX]>
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M:^'?PGTT>,M.3Q%X\^(_AGQ/X2\&>*?AOX?\+2NGB6Z^(WA/Q+XZ\*Z9XM\
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MIQBO=;C96E%<TKELHZ?NZ?*M=8TU"2LNMW&#5[WMY-VWO@G^P1\1OAA\,_\
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M?%CQ9X<\>']K&TT[5?'?BGXI3>*/B#XMTGQ-XMG\%_#/2+OPUX+T'S'X;?\
M!./]LCX<>&OA!\>O$/QB^#_QZ_;P^$_[2VB_%SQ->^/]1\?>%/A!\=_AMX#_
M &1/%G[ G@WP=K'Q L_"'CGQ[\)/&>L?"'Q+K?[3>L>*-'^&OQ+T#PA^TW\5
M?CMX0\.^$M8^''Q&N_$</[O44KO36UDDDDK:2E*]GS).\Y*^K<6XMO1Q;UW[
MWOU^%1M?>UHQ=KVYHJ22>_XA^ ?V#OVO/#'Q;L?VC=?N/V8;_P"(UQ_P4_\
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MFW:VR_NI*[204444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<?&WP;K%Y\</&G[1WA37/ _[0GQE\-:M\)OB_P#%"Z\;:C\7=>^$-U9^,B/
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MDI.+:79-QBVK6]U::(/\^;YV:OZVE+7^\^[N4444 %%%% %.] ,+ ]-C^O\
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MN[---N]V[QB[MMWBG=M)K\^?!'_!+W]CKP1X1^)G@@^#_B3X[T/XI_#GP?\
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M]<YKLJYKP?'Y7AO2X^/ECG''_7U.?Z\^_3BNEH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (Y1E#Z\ 9Z9/R\^O!/%<=JUOYBDC
M!&#DD@]MO7'!X(!.0Q)./3M&&Y2/4<?7L?P/-9-S:EQP&Z\@9X.1CV( R W0
M[0,]* $T"/R=(LH_[J2_K/*?;U_QR>:V*JV<9BMHXR,;=_!&#@R,1Q]#5J@
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MZ/\ A"- ]==_\*WQ9_\ +NNMHH Y+_A"- ]==_\ "M\6?_+NC_A"- ]==_\
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M&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\
MEW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@
M>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW
M1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;X
ML_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_
MPA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+
M/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_
M^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4
M <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\
MA6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@
M>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW
M76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA&@>N
MN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_
MPA&@>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+
M/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA
M&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\
MEW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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:P^=,7D\J*./=L10+5%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>forms-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-1_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '2 X0# 2(  A$! Q$!_\0
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M%=%%^S+>6W@.Y\-^-/C!XL>Z@M4@L]=M[_R452!LDE4QAV;=C?M(+ '[PQD
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M&$DC8!=HTD"D$X)49]/&Q^Q!_P (MX[N_$Z_M ^*++0-6D/V#3+W5I)YI&+
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M^C6P\V\O?-!$$.Y!Y<4F QVDD@CG&10!]+/;PR-&LT;2;$.QRI R#G'(P">
M 1V!]ZF4HJ&.+"  @Y//RG ''?D\]QGGJ1^:WP+_ &R-4\?6&OZOK5B]A>:=
M)<,G@NZDBAUB18V8H8[EV6!050D<E<$$LQ&:NZO_ ,%*?@5IGA72=?\ LFMZ
MIJU]J=WI.H^&-.4S:AHUU:3K!()Y4W17$;N^X-"V-D;9P"* /T>+%8R&;<W4
M\\[>I&>1D@$  GK[$TP284R8VA S'..0ORD#MR6P.>HKX1D_X* _ K3_ !K+
MX0U>75]*T:QTFQN[_P <WUI<+X?L]<U2S6_LO#!9(I'DU.:%]B^67B\S:'
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MXAU_2;D:UHGAO2+=Y=-\<ZE;21Z-XAG42,+.QC""6.4[>?,P 7" #!VTX/\
M@HQ\"KBPTV2VM_$$^JZOXD'AK2M$CM)C/?2&5474(;G#0FV()8@L6&0"<E5
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M^?;IO\P AOE;!V[: /O&=KDLGDOD94L.AQN!( )[8/ID'OP:F:12V5QR>,=
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M]::<L%W6R':XD0G&%D''F9SG.,<] 1D@FDJLWM2E_P" O\MPUWL[?UTO<_)
M_ K]H_1YX_$NF^)[[[?XI\06]UXC@\^<FU5K)HI$88V@"1QG<JAN",8P=:'X
M-?M"R>([Z6;5;J?Q'%9RQZ#>W,TXM(H]AQ]X!5E5N@52"1@GK7ZL_-\X,"$2
M-NEVE2';C!)R,-D<]3C'(I6:1B&:)&92"I!!8,.A!R"%]@<4_:5/^?,O_ 0/
MS0'P[^/6L^$+;0M&U/4+#Q/:7K?\);?7CW"">$N0&TYMN"A!!=@1A00 1P*6
MN_"?]IJQU?PWI6D^)KF]\.K/!/JQ6XF(Q]Z0,1Q\V2.<E1P>F:_3YGDZF(98
M'=\R]",$=B<@]S@'D"HU=T!5(552<X4@9)&"2,\D_7^=+VE3_GS+_P !8:]G
M]Q'H,$]IHVF6MU*)KFWL;6*>09^:5(E5R2>IW!@3U.,D#-:]9PEE486,#N0&
M &2<D\'O_GV=Y\W]P_\ ?8_QH<ZO_/J7_@+_ ,PL^S^Y_P"1?HJAY\W]PY_W
MQ_//]*//F[H?^^P?ZBESU?\ GU+_ ,!?^8:]G]S_ ,B_15 33'_EF?P?/]:7
MS9O[GX;QN_[YS_7IS1SU?^?4O_ 7_F'W_<7J*H^;-_< _P!YP#^63Q1YTQZ*
M/Q<#\N31[2K_ ,^I:^3_ ,P+U%9Y>3/^O"$\[6.0,]LD@$=0#WQQ2-+*J@B5
M'.<#W)/J"1QG\OI2]K/_ )]R_P# 9#2;V- Y[8]\T<Y]L?KFLMY9MNY\%0">
M,YP#Z8/4].AX].0"<3QC8)!$,D/Y@4L ><YY!R<#V&.>VE*;FVI+E]59^>C=
MU]PY0<(\[ZNUKIV>W1NW?J:M&1Z^_P"'K62VYT*('7( ,@FY7&>"%(&3ST(S
MWS2&>3SDCV.(E^1I/,&UEP%W')P3QGECG..G79J/\WX,CW_Y/N:9\[?M?_\
M)$/$?_7QIOZ7//Y5Z)\*%W?#'PBI)7=X:T]21PP!,@.WD?-C.WD'..<UY?\
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MCQ#X,73/$W@#Q!XE2TO+/5[E)8]$TE%,KMIN6'EL(P5CV;F*C 4@5] ^,O\
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M:;<7]V;J34#(6)5U:0@R#:55  >./MKX/^/D^(W@;2?%4MC%IVJZK;M=7&F
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MDTCXP_#/7+2RFT_Q9ILNGZLDKZ-.DD@345@<QW'V=2FXB-_W;EE4 AB,KDT
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M^V+\&_@I\/-/^)5[XETOQ&GB1[:/P1IED[W,NKB\/EPS010(S1(\F%1KD19
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M/ J&;]HOX+V.I:-INH>.M#LG\2*&T"*>Y=)M04(#_J\;X %&"+E82<8&2<D
M]P+73<QE%3L,K_5A^>.>M%?*/B7]L[]FGPWK%YHNJ?%+1+:_L7\FY@6WU>Y$
M4JDAD\ZUM9H&((.=DC#W/4E 'CG[7/[9WA7]GG3_ !-X.T;1=9^(/Q7'AJ;Q
M$ND:'&';2D)DMUNKL(/,6.,Q.[.%QC[Q7)(^<_A'_P %'O#>C^!O"/BSXO37
M]SX@\6:;INGZ)I%K &&GZI?ZHUK;1:HP8""&-_+621P5 4Y&017LG[3'[$?C
M/XM?%;4?B_\ "CXAVW@[Q#XH\'#P-X@BU"#S(9=(EFD>>2V1UWK?K#-* P7
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MM=W9_P#!/&PMOV2IOV7=<\7W'BO5-5\91>-O$NO?9##'=Z@=5MM7*0*ZB*)
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MZ5!I^LZSX4UKP+KEI:&2XL=2\.6L=O:/JLL+%+F*1%D:5H6!W[2N!P:?PO\
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MO[9\'P9^,?@'PA/87&I?#[QKX3_MJ37HHF)TNWC@5H[JR?8T8D*'+JYSAB4
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M;JYF\G#'YY6*(JE6P>OVQ^U+^WUJWP/_ &I/!/PO\"ZEIOC+0=4U"WT;QEX
M\G?J&B22Z$]\DL<CDEF$X7.US\S_ 'L=/N2V_8Q_9OL_B':_&C3/AEX>O/%K
MW2:^VNVS6[0'5$8O]MM N82]U(YE+(,N&QNXP/,OCE\(OV0O!?CW1?CI\8_#
M6D:!X_\ $WC+3+?0=2CD@;4]3U VR6=K$Z';N61$_>C&<, 1AB* /@#XB?\
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M\0_"+PYJ&N>-]>NI(+/2?&<]A$3:VOAZ6<^5?SR^64%M9[G+' 4,_'9>&_\
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MXR\7_L\:%K$6KZ#:_%#Q!X"M[RYFL[F&.$>)Y+".98[B8$K!B1F5BX!!R-M
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M-]Y"#E5&.BU?_@HG_P (E;_$BR\5>&U^U^%M1L+7P7);*I3Q-_:ZSO9:Q,P
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M=&"2'3E)R4<K*C[0.RMN K>^*_[;?BSP3\0/'6@Z#X5T)_!N@ZY<>&9]2%[
MNNSS2:0TT-Q;6Q!<Q?;V4'#%!\S=6)(!V'B[_@GQX#\2W\.NZ;X@GMO%&B6%
MM;Z7=12/)'"\-R+DEK0 J=I6,9V$G!ZBLSQ+_P $^=/^)GQ&TSQYXY^)NK:]
MJ6F6O]G7L-G/Y45O9K$8X4C0HB!V;((5%;"@$< UY)\*/C+\9?"?[%WQ4^.W
MB:ZGUOXCZKJ]_I^BVMN\DJ>';&ZOKE;&XE!"^7Y%L\#.XQMV8 /;P3P[\?O'
M&O67AWX*+\8+OPSKSZ+-\3/&/Q(^UNFG26P22YA\,QW9D13,\D'D+$)(R"Y.
MTAL$ _0#7_V"_!=YH5QINCZUJWA>\MI-)73=9A:.61Y["[2199P(F)WL "'!
M# X*CY<:G[0_[(UI^T1X;^'_ ( \0_$'7])M?AW;O!X@6TN$7_A(H]1@CMH+
MNY"(=IE*.50! %<\*5^7\_;C]JC]HG0;[0_B#JNK:C<>!->TS4/"-KX;9G;_
M $FV@EAA\:>65PL9:,W E+< (VXG&?OJ;]HGPEH?[+>D?%,>+([_ %C;::.=
M=E*-<Z_XML Y6PNG+DR6KW!,2;AM9%XV[\4 =A\)?V7(_A#\39/'?A?Q=J8T
M6+P=IGA#4]"G19(K]M)MY;:SO'98]WFPET<$R9PN-KDD'RK7?V--=7XF>.?C
MSI?B^0_$&]ME'AT&4K):VS)$@#)@&-=A8?,0,*<C!('D'P7_ &V?C/\ &GX\
M?"'P[I6CZ5I'A#6K'Q&GQ*MG:-$M[S2S(D$^GLRG>DF4#,6W,XVY.,CH/VC?
M'_Q#^$W[8'P4-IXT34/AU\2M8CT74O#UK<B2\A9FD0++"I/[HR1<L!AE;!^7
MB@#Z9^*WP7\;?&'X2^'_ (?>(_%Z6%S-IBS>-KED:Y-];R+#O2U*1L0^=X8I
M@(>21D ^#7?_  34\$)>>%IO#OB.Y@T[2;,2ZFLKRROK5];*);55*$O$D<L<
M+'E2@& #C%=7\6?VW'^#WQ/\3?"S6_"1F\2P6KZW\/[2U0//K_A>V0_VC.R9
M60B)C$CG:X#D@N,8;Q/X>_\ !1G7OB)H'CG67\)V_@[1](L[V7PK?7DL=M;:
MAK5@DKRZ=<3.0BKN"J,YPQ);(8$ 'V%I/P6U7QM\+[WX??'[=XGT^YNI+32=
M2M+D0SZ7IT'F1:=$ "AW1(D"Y<'Y5&X[FS7S;-_P3 ^&]EI<>CZ%XLUF&,Z[
M=:I>0Z\TUY;27<L:K&;5B"D+*H\M' (8+&<97-<9X9_X*"?$SQ[I/@:X\'?#
M33M4NY]#UO5_%!GU&V$)FTR6Y4O"Q1@%S )%[%5X^Z,>^>$/VN[W7OV7-0^/
M/V6RU'Q.TT^BKX:-] UAIWB.":XB2"\E&8H K0*79EVD?+NR* .V^$WP+^(?
M@?2O$O@;Q3XH>_\ AC?Z%-HUIIMS+YVHQ/>0R6Y=)=I*VJ^8&"%@P577:K8%
M>!Z9_P $W?A[I#:S<ZIX_P!2F\0WEY977@*>&2<6WA75],FDN;"Y@A13&S12
ME0<*V!GJ2<\/;?\ !0OXAMIESX*U+P1H$/QUU'2VU;2I5U*WE\#)HT!EG99[
MPJT+W)A1P8N6+!@HW'(Z*3]O'7KF#P59OH6B:9:^*_#&N&?QK<B(Z5I_CW3;
M5G33[&-_O6TUR'52O/R[PO8@'T5X5_8=^'EWICW?Q7GF^(_CNYO+F?7/%EP&
MBEU"XD*EMRXB^X^_^'C=MR=M%8_[,_QL^+/Q,^%>G^)OB?;VJ>*CJ>I:=-)X
M7F$.E75E9-$+.\2-%"K-<+([S #@X!R1FB@!?V^?B#K'PS_9SU2/0_#6NZ[K
M.O/<:%9S>&[N2+4-%FEA:.+56FA21YEB>16,:A=^PJ"<%:_+CP;\0/C+X3_X
M)/\ QM\5^/O%WC'1M=T?QE+9VGBA8;J/Q7;^'Y]3MTDF@?/GR,$NA!&0HW+'
MSG)4_P!"%[9Z7-:;+VSLM06Z7%OI6L1Q2'[2H"_*LQ< L0 S$+@ 8()KCO&W
MPE\'_$KP-=_#WQ5HNFP>$M5EA.I:#8P0K9W%Q',DV+E(R$="5VDMEC@<YP!R
MTL0IO>]_ZT_KT _FGT'5/C;=^%]'U'X':S\3_&/P=U?X:>&=0\=:UX@%[<ZQ
M?ZI>[7OGL6:-)(&1Q)P0Y#%?F)(%86G:)\6/!^D:UHGC2U^*/@+X7S:=>>)O
MA]?>$H+_ .V7'CJ6(3:9)K<<,;////?+$6#@;<;>K"OZD-$\#Z!X3\/6G@_P
MCH>E^'M#TRSM=-M;1;*".UN+:P0&**1#P\> "NX]\AB ,VY]'T=X([:]TW2[
MG3897O[YM3T^&2TB\G#V_P!D20$!%9<H44QDC&,=>K?8#\+?V+?!'Q TC]NN
MV^)/QU@\=Q>,/%7P3T.+PUJ=_<73^']:LX=(B6[NKZ*2-8H-1M%C"K%*PE>0
MG&XG->#_ !N\&_%+7->_:K^#>LR?$KXA^%M=\0IXLT;XDZ1)?V@\(6IN9[@Z
M9:V$:OYZK&RQAXVRWELPVG ']*ZZ=9W5PFKQ6ECJ$440%G<36T7G6D"\?9K"
M89=(2NS=&N(R%(^7<<+/X7TUTU-K*UT_3)?$%LD=^BV4+-=D*P*2@KSN5B-N
M00W."<X /YL-;^,7Q@^%^GWWP^\*V_QCUJV\3:?X1T[]GBYCT75I_P"U;JRT
MN*#66U65(@L*"]C8^:X''<YKRCQSH/Q5^,MU\*/#?QELOBAJ?QZT7XMZ89=$
MN]*U&#PUX3TYM,D\O7+F_=#;R06X\N0IN&W8&)!6OZD%'A&.]TY'LM)L[G3'
MCTK23?06T<UA<E7&_2H75C;L[MD[<,QVG/%79O">CR+>2'3;&[U>\M[A;G6;
M@0O?,94DMF9Y&7S,);.RQ,H R$/!Z@'XB?L7>*?VA/B7\?\ XU>#/$OBK4]4
M\)_LGZ)>^%])\0VLSW-GXV\:3P7ALO+82&-4MTA$+!<X(8*0(CCY?T#Q%^U!
MHGB75+WPA<^/+G]I3Q1JWC/2O'V@:A;7USX8T7P7#974NE_8&($4DQ+-+'()
M7 <*I"LF3_0S\*?@?X,^">@ZAH_PXM1I4NOZ_=>+-=N+C$VH:]>7+R-.UY,^
MYYBLDDC1*V JN5SM8Y]%L]&T43IJNF:?I5IJUV72;4'LX/[4^S$D3P7$J@2;
MF!="Q(&Q@0,Y% 'X6_L8^$_CO\./VC/@//K&L>.O%FE?$KPIXFU'XFW.MF[A
MTG0-72UGGBM(HILJP2X!1,C_ &0W!KE_&?Q4^+GP-^/O[4MMJWA#X@_'#PAX
MI@TV#P-#I,6H:1:>%9M6N;F"]G4A)DNT@!4L$V$K$"3\XK]_KRRT_2X8=3,=
MNMAI,"FU6SMHQ=1FX^24AU4,J%RQ9<X.\_+\O*V^GZ3-''=V]KI4D5T8WO9;
MW3X'FE5\_9]Y9,L48-CKACN&.* /Y0OA[\-/VC/B[KOPRU;QIX>\7^+=;^&>
MK?$/7OAMH^LV5Y%I^C7*))<:7>7DLX\MCIKDF!LJTCKM0KD&MNU\"?M)_&GX
M)_'KQ'\2/&?CS7;>"]O+/QGX$TQKRTU&6\AOHX[*]T2[ =XTLN0$C1BX++@D
M$5_5?_9ME9M+'I&G65E-@H)(["*,2>8<W.R3:-B2#(?;@';D^M8.GZ-X:66X
MM;#2/#]J8YFN-6M=,@M':\DP0QU"")5,X=CO82AF+@-G@Y /YV($^+.A?M%?
ML]?LC^ _&7C'4/AC\2_ 'A3QQXMU5WNY;_X:Q:):68.CZF?D:\GO029Y7";)
M() VU@P'HO[=7Q-^/\G[3'PG\.?!KPIX]TK4/A=XDTC3E\2(;V?3?%/A.+37
M%]J,ELJK'&'N0ZN=Y&6.2Q.:_9[0/@1\-O#OQ+\0?%O1=/N8O%M_I4VD7$\_
M[S[';W!9UCM8V+"&-,DHH5MJD@8'3M_$>I>!-"UC0;WQ9-IL'B;4;)]+TR::
M-3<3Q,W&UB"W#L!N..21N"\4 ?S:>(=._:Z\):!XQ_:0\$ZK\1[_ .,NL_%%
MO#0^'U_;W]SIM_X=FL9V;4K-"%%M$D\<0V@LJ!B%&Y3GM/V3O#>MZK_P4!^"
M?CW4]+^(NM>-[KX77?\ PN/7O$5EJ \.^'_&DIEE.D:89D6&!(U)CW>9(0<8
M;;P?Z0+6RM9$A=M/L7N;+]XBK%&5<."!<<A<S>4P(8D-EB<\UG6'AO3=.N;Y
M]+AT^S74;@WEUJ5K9Q)<FXW M&UPH&X[NAZG)P1C% '\V.M:-^V;\1OVA/VD
M="\1^)/%'ABUANO$L?A:S"W5]_;/@V6R=)M(TM@X2T$MH719%7"DXPQ^1OG3
MP9^PC9^$?^$.\;>!?"?Q"L=8L;:[U:STS63=ZC)IGB(EYIM3CA>&-FC>Y!(4
M<_O,9"ONK^N-M&TEM0?6IM#M'U@(+5M66%3>/%*HB#X W-&R$*X('!;<N,T/
MH^G+<-]EM8(]5BLWAM=0%H@LXSM'RL@4Q;BHPXV=1CKB@#^?KX _$_X@:+XJ
M\<>._P!IZ'XD:O\ &'PKX&U1?ASX1MK'4$TS4H+6RE>UDAE\MDCNKV10DJJ2
MT3'/5?E^5_#GQ2_:]EB\>P1Z3X\LO@IXA\3Z)K?B_3EM-0_M3P?X;U*<2^)8
MH9\%KF>1"FQU0LKY.",U_4ZWA[3KS4+75=1TC1KB^TVQ^SV]U=:= ;J\=D;[
M6BR&/_4C&$4$C)R<@G%V#0-#LQJ=M:Z'ITO]L1!M1LOL, M)G*!4ANE*^6R$
M#E<%<G[HQF@#^=?X^>*_B5\*_B9\"_AS^RYX[\3:[X*_:<T.QT/48=7N9I=6
M\!DFW\O69(B$E<I C@0L1DYPRJF!_1-X2\/Q^&?#VD^&Y;N?5)=)TG3+6^O;
MHLSW-[:V<$,UZ"3\IN)$:4J#QDKDXKR*W_9X^$)^)^E?%230HIO%&AV[Q:7Y
M"-_9FA2.0S_9X4410E.40A>%#'C.!] 6,<P@1KJ2*:=GDD:6(8$B%LQY P3@
M=CDC:!@#((!<,1D9"!M0 )+&0&5P1\P8GKP>O4GG/K1M],DAN9II+CSD)(M(
MFC.+7)SE6R,_[V/Y'.CDK\PX/U4@XYP0">H'7 (]>U6: ,JZTY+NV:WN ',D
ML,DDB($,C1/O0L,\A2%!.>Y^M32VT[121QS^6S2)A]F?W04*R\=-P!7/&.IS
MFKQ(')HR,\D8(XYY/K^'3\_I0!36R1"2CLHVD*N3M5B22P&<9R>OH .W+$LY
M8XY2+AWG8-LED!?RV;^)5SSMP,#'(&!UYT** *$-L\1B!D#!5_>YCYDES_K!
MR0OH!P!UY.<2PVWDL2&R"2V#DG) !Y)Z' ..0.W8BU10 PC<RMTV[N",$Y&/
MZ?B*?110!\N_MB?\D+\1_P#7YI?_ *4UZW\)?^2?^&O^P9:_^BEKR3]L3_DA
M?B/_ *_-+_\ 2FO6_A+_ ,D_\-?]@RU_]%+0!Z/56[($3DJ) $)*9 )P001_
M%D .1CWS5JJ%ZG,,HW%D+*$!P&WC!W9(4@8'4CT!&30!PWC+POX?^(/AW5/!
M?B>T:[\.:U8,+T96$6\88L0TC@KG<3@X('&0017B'A+]EOX%>"M/=O#W@RPA
M@_M.TNHM2C@CFOM1>&&2+RGD"@E&+GYL_,5+#[QJW^V!?^,[']G/XN7?@#44
MTCQ)I7AB2YL[E%&^/:8BQ5ER0=I<_*&/0CN:_-&Q_:$_:5T7P7X"U'P_=VVN
MZ#X5^%1\2>(IQ&&:74[:.U$OFN0K,XFE=<D X)!&<F@#]$-6_8Q_9\U[5-'U
M.\\%FUGT2\.N#^S"NGP37K3&Z07R*A^TC?\ ,8^"Y#,>Y'K.K_#/P=XD\1^#
MO&>N:)%>:CX+93X6C*+(FBW-OOBAO([7;\K" B+((*84@[EP?QUUC]MWXZZ1
M\$KKX@>)K\Z9K?B#5[&^\(6MKIOVN:]+2QH-/^RQJSI&\;X8D)RQP>F+/A7]
MH_\ :)N/$'QH\;ZAX]DTZ[U/PKH*^ _"5QX?4Q1:A<-9QSR1Q&%D5OWK.?GY
M +'.,@ _4/PY^R_\(=%^,?B+XZ:#INI6WQ!\1.UYK.H7DK+%=/(@5/)+QJ8E
MWJFU06&P8W< UOW/P7^&VJ7VI^(M1T"^N]8OM0M[_6W(DQ-J%I-]I%PNY-TN
MR1/DP&^4# P1G\L/"W[3_P"UMI7B%=>^(-O'JWA[1M4O=)CTVQLHX+O5!%HW
MVNVN6MX\;$$R8;)4$MG<1N!Y_2_VM/VO/$GABXN+-K&$^.-8M+#0%CMD^T>'
M6GU 6\L5Z1DJS12(%#*,,I()4YH _3WQ-^RI\&/'.HV6KWOAN:'6-/U:?7K/
M48<64FK-=A?M]G=QE<W@>!3&SY&T#< -N1TFI?!WX+Z;IMW+J.F:;H>ASPK9
M7UM?/!:6T]LB@"TBCFP/,@4,H9<EB=P!#5^9GA+XQ?&^[_:3^#,?Q#\=OI/@
M?PEJ/BO1/%%M#"8X;Z^L=*EE43XC^8^8RG@[3QEL<#V7_@I#J6N>-/ ?P5M/
MAV^J7,?B[XC6MA-)I1FC>739I)%:5]@8,C!=^2P7@#.,4 ?7_A7]G3X*:%IX
MM/#GAB6\BU&PO(+2ZNKY))KC1M14I?0VEX8PL5IM*CR0 -N#@[,U8T[]G_X2
M:!XRTCXAV.@7D>O:);KHFAWDETI2VF9&@AM(T$8>10K8608"JAR#T'PGXL_:
MR\7? /69OA%K-HU_K^B3>'='\*6D<32WDMGJ$;Q7'F>6#&Q!49#R<L2,H *\
M=?\ :Y_:Q\'Z59^*?$4VG:SHWBW2?&4]EIT>DPF7P7/INHO::?J-ZJ*2K16^
MZ3><GE&''- 'W[X._8@^%GA;XH^/OC%XGL)/&GBOX@ZN+B_T_49HI-'T'3GA
MD\QH+)@1/=J7!6X!W*I*IPW&_P"&/V0?@'I_AS7D\-Z#J5WIOBZ2=M3FU"=K
MNYDMEF<MI^G-)&ALH&=G5=@<*F4&<''YY?%+XD?%J.3X#^(](^-::]I>KZ4^
MJ^)=:TJ(QZ>]S.L4TN@7*I&";A7=X5.T[%!VDC)#W_:U^+C:IH]W%/>>$CHE
MG<GPSX&N;5A<^-I(99)$N;=,%9A,X&U<[B'Y7!S0!^F_A3]FKX0^#]>M?%/A
MOPA'!>PZ6FB26E]('TRSC1MT<[V[HOFR+)R1OPQ/ Q@DUK]GSX-0>.XOB%K:
M:;I?C.^>)K>Z-[%I]A=3VA\RR:TTZ0@220RHC-MD=F5,X(YK\[-!_:Y_:/T#
M48/'OQ)@N+?PAXGTJ]2;PW!X>43^'[F-)4AN)]D9:--R(X*G^Z< $YY#X*_'
MGX@?M!_$+X4VOC>74=6\.:;\5]::RUV'1S!:S:7L8VNFS2*H1C&@5',F?+(+
M$YX(!^HLO[-GPJN/$NL^.-1T-XO%?CN![/Q//9D?8M6,R-#)>>0L;);3/'@K
M,2=@";@0M<QIG[&OP$\+:!XC\/6'A+[)H.J^3<:I*)!'J-P0_F22_:MJLRQM
MDL2% Y&",Y^.?B-^T=\</#WC/]HK7-6\3MX<^&G@9AH?@UH?#ZS,EV5"1NK*
MCR.P=T!8GDC(X8@>$Z)^T'\</&?BSX2^*_$'BS4;#P3K7A_Q3I$E@UN]L_B;
M4-.M)E@N_)0%T,SH3&&VD\ 9Y- 'ZSZ+^S]\%K:PTBRTSPBXAT73[NPTC4,%
M%N[75 $G26=8QN,V"%9L @D@G<*R7_9@^%FF>+]/UW2=)N-%O51)M6D13]BN
MQ;J1;/-<;4C#01[EVY]#CG)_-CP3^TY^TG<&X^($JM;?#3P--J&C3>$)[;9J
M.I")_+AU)>&DVVVS=(5.=I+,QP,>I?L6?M%_%_XX^*/C)K/C?Q=I5_\ #:ST
MO43X>\(Q"(:[!<P6LDA48 N-I?RPJAL$J1TS0!]\7W[.GP7\4V^F&3PQ#J%I
M86>J:?:SVSQ1PI%?W1GO2CB/DR7+-(VT\2 9.Y33_"_P=^&OPQ\/W7ARVN+K
M3M/\2W$EF;;4KT-.T;B1?LNFRL 8Y06!7;D].F*_*V']HC]IG4=#MI_!-I)H
M6B> YO$UQ-H]W&%O?$=E!K,BQ+&9 9&/EL,J2KX5F4]"?(_B#^TW\8_B%\2?
M OC.]U%X[GP/XBM)X/A=:H\=U>7?]G%Q'<1(JDAI$5VW,%8DLS*<X /U^T+]
MDWX%:-->C4/!<6K:KJ6I2ZNVI7D'VF]O8) B1V]U=,&+(2/F1B"!EN!S7,?&
M[]D/X7?$GP-/X-TB"#P[JNDE;VQ(A%XFGQ.7 ABMPH'ER[]HP2H&[<=P K\Y
M)OVT?VL?#7P4\7_%0V=IX@URWUV1-.\+1VR-J&F)+<) ;*6,)O+0PS&<JI*G
M9G&2!7Z5^"/BCXBN/V3;?XQ2ZC;0>-;SP7=>)M3N[FT\^*SU#9,1I4RNGWK9
MD4[&7'RYY#"@#%^#/[(7@[X<^%/[.^(;0^--7OK:YTZPGO8=EOIFD3QLBZ-!
M:L"!);JP>)\YE953[RX;U_1/@G\/?#_P^U;X;#0M3/@C7%NHI=!E1IXIHKD#
M#16H3-H$9006)Q\IP #G\;?"'[<OQSO]&U'5H_$%OX[\"ZQ::8?%?BC3]+0K
M\/-<U*^DMIE9D1#$+9-[.$23:8NB$ UZM;?M5?'JT\'^$9;WQ#')X/'Q$U/0
MI/'"VP>^\1:.C1&W-M$J"0J#+Y(=44J1D@C! !^@EG^QQ\!]!\%/\.]-\.26
M'A;4=2M+^]TWS8Y SPR&:0RA4(@(=FVEF_=C=P0#5VU_9)^#4]AJ\&L^%UO9
M&MWL+29Y!>-;:>@,5B89%C(DN$10!D;EQT[U\$_ #XJ_&;5?!W[1\PU?4/%5
MYJE]KT6AM<"1-0\&:5$LD=MJ%RC+E8WB9I(@?,8'82O&*\_\"?&?]J#1/ OP
M[\&^"O%</C'4O#FG>+?&'BC6KA!-)?0:7)%+::?,\B L$42+L!"L&/R]P ?J
M'<?LR_#&_P##7@_PAKUOJ>IZ7X-DFU73A-,)6B)8.D:$(1"R\8 P5P,@#!J/
M0OV4_@CI=YK.J+X2;S[K4HKZVNKT#SA*8=J21[X@9-K2!<C)QSG:"1^<?@?]
ML;XQS_"_XC^+O%LR6^DI-)'9:O!;EVBU*0QS26B<;TV3N8T VH0%7IG'F7PH
M_:G^/.N^/1\1=6\8W<6C0_#W5;;P_P"'-0T\FPU'5C=Q1VMUY+(R/-'&1M9N
M0H;'WJ /V/NOV=?AAJ&F0Z?J7A&RFLKB6<ZO#((U:59E8)/DIEB,L2J],$8&
M#C)T#]G7X:>#K2U6STE1'IES=06""W6Y@TQ-1C>"6UC@"!A')#.R%P3D.QY)
MP?RST_\ :*_;1\,VTOB_Q/JEKK^E>$](D\26NDVNE1&;Q!#>7ACCM654!D:)
M' "978"0,AN-7P[^U]^U1XMM/&GBO3TT.WRUKI47A&2!%U'2GNC"JW4]NRAD
MEB\S)968A &ZEJ /U'T/]FCX4:%XWLO'>C^&8=&UW1=,@TRTN+/%L6BCD%P9
M%N-N&,K.Q>/. 6QQ@@7=5^ OP[UQKJ75]"CEMFUS4M>U73Q$&BU"YU!-KO.=
MH *[&+' !4<C'%?D3??&?]I&\\6_"#3/&OCN\\.Z%9?$8Q:[J%O;[DU.&X16
MATQPJ-YB9;8/E.T@#"@G'U?\9?COX\7]IR_^&*^,)_AWX"7P2DPOK_2PW]LW
MDEN=QM9C'*6,C/M7!!Y8+@@8 /H#PY^R3^SSH-Q-X@TG0+349KZ_GDTR^66&
MZ;3+ABPN+=9XPP1(>048YC(VX!P:]$OOV>_@]>1I'JG@RPU>#R3<$R1QW)GF
M&2"F5/S#?PH8Y*_*" <?D/\  KXV?''X)V.J1>)]<U36/ WB77/'DWA^'4-&
M%Q?!K0-*M_%*P\U;>4IF(90#Y@H[$\%?M<_M,?%?0!;>#=7.CV^A7NLZG'JE
M[H44*WL6GSD"TEEE3>(BCE=Y 52"RD]* /UC\*?LT_"_PI'I%G965V\EEK;>
M(=*WP[CI<DCB1((V"YM_*Y^8\@D@  &J'B/]DSX(:_<6;:AHNH65]9ZI)K8U
M?3KPZ?=S:B\_G>=-J"Q;IOWC; F#P=N020/RGT_]M[]HWQ5\7H--TV:QTC3?
M"_AYKKQ9IUPL:RZ\\,4CRR:<K!FPXR(TB4$GE1M85]8?L>?'3XW_ !G\2?$D
M^,KG2Y/AY/;:FNBV\P2+5M#U2WMYC"'!5)A \D:R?>*!FR/0 'V1XZ^!'@#X
MAW&@Z[XIT-QXF\$?9X] UJV59]66QMC&EN[O@O=-((8XW92O+L>N:S->_9F^
M#&NZAXJUF_\ !\%SK/C_ $R+3==OXUC2>.%$*;EE"9@8J=[HQ+C;\QYQ7YD6
M7[7GQ8UYC\*-:U]_"?B72OB%?Z3<?%(1$Z'8>&;>[N%M;6[D*F$NT<,41RA=
MG9?FS3/$_P"V=\=M%\8ZF^FZ^+]_!%_<Z1I_@M= C-]\2-EED:AIB!4WQ$@2
MH4D3Y2N%8&@#],/"_P"RO\"/!6CKH&E>!+2>P%K-#<:E<)'-M:7.Z3_5@/(=
M^S?C !)'2N1N?V&/V9KC1M1T^7P)'_9^LRV\MW-L"S-)%*\A?S"A98W#XPRE
M<<C=S7YR^(?VK?VL?#?A#X;:I=[KUOB;KR26<,FDK;0^%KBXNI8QI6L2JBE%
MMU XER!\V>F3]5?!3]H'XMZA^T^OPB^+-S;:A>7/@Z+6=,M]!B5M%7SHHI-U
MW-#'Y2LN]1EE&,.>< 4 ?4.G?LM_ K0M:M-2T7P-:1&VT(Z+.&@$MA+IT<+1
MVIN(F"K<<G/<,O0#OA1_L<_ "Z\3W7CR;P1"NJ2Z5-IQMK%1:Z.MHJE%E73M
MA1K@A<QR'F(Y8 D"OS\_X:O_ &I->^(WQ6>VL+/1-&^&6JZ_IX\/^4 ^L:=8
M([:>]N3\T@F!PKAMI(4#!R3R_P /OVX?C]\6=;\$:3XT@C^#MI_:FIBX;48/
M)&ORV33+I6F1D1R_/J0"HIXPK9&0!0!^NGAKX3_#[PEXAT_Q'X>T&YTW73IB
MZ3;ZE-&98K6 J5B@*B,#]XL9(P>!C)^6G^+_ (,> O&]YJ.J^*?#TG]J:MI<
M^B:A/:2B&6^LG9_,>:Z"D(L@!8(^2JY0'&<_E'X1_;&_:GUB^^,6MV6D6NO2
M>"[3Q$B^#8K91?:9'IUQ+!8:D8P3MC,*;S\S '><!, \/+^UE^TGJ'PGTE/$
MVJ02>%?B+<3V<OB_2DW:OX=FGA<SV<^$\^!K>4A!D?*W",1F@#]+M&_9,_9Y
MBTI?"WAOPP88[+5/^$GEOK0K\][;L]N\<DJ1@71,;-&5!)8MTX.>YA_9^^#?
MA^9HK+11I2>*K9_#\NEI-%;PW,+(9!)-:!,W#>:YF8,#\S$D@\5^-OP/_:B_
M:/T.V^'_ ,,]!F2_T>R?6=6M?%.N09U+QA$FJW8%A"\P+3G#90-M;:JG(3<&
M]LT/XS?$GXD?M;?!M?$OB7^RO)\<7&DOX3B#QPS206,<A+1IA2J;#EB_/S9.
M.H![CX*_X)^Z-\.?B3XJ\4_\+)_L;0?$DCQZEHXEBMXKVWNG*?90SE5C+(WE
MJC*#G!4,6-?9^B? 3X:^&O ^J?#CPWIYT[PIKK,=0L#*KMJYNV+3W"@H%*2-
M(S,X4@98<?-7Y*?$;4/C3KWC;XZ^$Y_'5XU[_P )Y#)X4T2*U:YETI7N88[>
M>60H +,, 3&&* >Y($7B/]K;]K'PG:Z/\-M3GL!XCT.^%B?&J:'";&>S@M@J
MV,SK$%^UR1M%$IVA@P+,2<9 /U1\/_LR_!G0;>_MO"_A&SMI$AL=+N88PBPZ
MC9V4C;4OHPN+E%\QBZD\;LAAP153]ECX!^$O%6I^-X_#,.B+?6T4%W80.(-$
MDNI\AIK.Q";8IW8@RRJS,[  GY>/F[]HWXL?M">%/A[\!9_AA>VMMXM\9Z)J
MM]XD$NGPN2;?3+.[\Q\HP&&F=5&1D#."3BODS_AJ7]IFSL-*T_XF0IXEL_$8
M-UIU]868A31)]+),YNQ$J@^:4!4D,%W H>,4 ?J3I'[+7P'\+ZII7B?3?"MG
MI[6<&L26]U=)$P9]=D,UQ+*9 24D,C':P.2W*@')J?\ #*GP6&A:QX7B\,_\
M4IXINY=>66U14N='U/#+/<Z?<*A\K[465T94<X"A05(-?FW=?M#?M'V]H-4\
M8VKZAX,\08T_PY;6<3>:"K%8\K'AMR^4PR0<88C&<AFN?M%?MC7[>'O^$5U6
M+2]._M*TTE-/G\/P-(]K",;79EY;RXVR[$%B<' &2 ?J1X<_9U^#7A+P$?AI
MHWA""7P=JM^;R^BOW^UWUQ=X#G5KN:1%8^6R)&9)5  SW )2R^#/P3BE\/\
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MO'NL^-]:UR#XR26NA7<2V]AIUM=Q(T< 0*Z2KY^Q0.<>6 1NR* /LD:KI5A
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MWPK\?_ACJ7BGXP^(;?4?BGIZ^!KN32O $B3W,4UY]@E5;>ZMM[X61D"NH4,
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MQ(Q(F9P&7!^[EJ>N^+_V>O#\O@GQ??W'P^T:;Q?;0)\+]<DTW39KS54D5?\
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M &EKWXC>$M U/QWX['AN'0])U+2[PQSK?7.J1RVU[>6NLKO*1VXA)@C.<D@
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M1F#/-;/LW0R,0IWJ0P(!W8R*=J?@CPS=:9<Z"WA[1GT6^=9=7MAIMH8;R9%
M2YNH_)VSW0PNV60;P!@,, 'O4A"D_NE!8_,^02>.OUZ8XQD'/:AHGY5,;&/S
M$]>0<D8QSDD>F,>F" >=:9X6\*:=&EI8^%M+DBCB%M&S:=;$+ N2L"_N\"%0
M 5C& N!RW6FS_#KP'-K(U*[\&^'SJ,]G]FDO$TBT%Q-:_,!!+<>5YKQX;8\;
M'#CDG.0/21&R_*NU5Z[@,$'H0,=1@#GJ2<\8Q49@<,I5RQ#<ECRH_P!GV.>0
M??J<4 <18^!O!=C'';6?AS3;2*VF\^V@@L;>&&WG4[A-#%'&J1/D %D(&,\#
M/'8A2KC/4E ",D%1MSCZ#@G R!]:L/'*9PZL!'C#?WN!P>^3G ^GH>:>Z$M\
MH4 ]3W!).2/P],9H E!! (X! (_'FBA1M4#.<#_/X#H** /A?_AC"/\ Z*/X
MM_\ !C<'^<I% _8QB'!^(_BM<]_[0G_EYM?=--9%8C<,XSC\: /AK_AC*$?\
MU*\5G'/-_<=OI+31^QK#SCXG^*A[?;;CC\I.]?<WEI_=%)Y49))123[#_//>
M@#X9/[&D8Y7XH>*P?:^N%//7D/GIV/7H:D3]CW81_P 72\7#&0?^)C/P"<DC
M+YSCGGW'2ON+RHO[B_E1Y,7]Q?RH ^)3^Q]&Q)/Q0\5L<#):]G9CC.,_O !@
M=./6F-^QZFT[?B9XJ9NRB\G7<?3/F?Y(K[>"* !M7 SC@=R3Z4X*HZ*!] !_
M*@#X@7]C> Q[F^(_BP, <'[?<$@ \G/G'@\]1G''O5<_L<(W+?$OQ6IY ']H
M7'3)YYD/4[O88QUS7W132BL<D GIS0!\,_\ #&\2D$?$[Q4>?^?ZX _5SG-6
M?^&/8R.?B=XIR>O^F7'7Z^:*^W/+3KM''3BEV)_=7_OD?X4 ?#K_ +'4;D _
M$WQ5@'@_;K@>YR/,.>_&>:8?V-XNG_"S?%/X7EQD?G*/\BON4HA&"JX'3@4G
MEI_=% 'Q G['$,7)^(_BL G@_P!H7&"<GMYIZC/&",=^U-/[&T)<2?\ "R?%
M2DXPQO[@@\   >:<# [XZU]QD C! (]" 136C1@ 1PN< < 9H ^()OV/'DC*
M#XC^*5&TJ&-_-T.!P1+GH,]#CD D&JZ?L8@(BGXE^+G('WO[1GYY]Y,^GXFO
MN=D5U*$#;@ >V/\ (_6E5%10J@ *,#V'I0!\.)^QH P_XN7XO7@C<-1N..O8
M2C/7'XTT_L<Y9?\ BZ/BX'@8.HW/ .>PEYZD]L^M?<],$:#MWR,\X]A[>U '
MQ#)^QTDD?D/\2/%AV=93?SJ3NZ?\MB>W!.>I[YJ.#]C:*V1T3XC^+9/,!0,=
M0F)4L!TS+^!/U/?-?<A 8$'H:15"# Z9S_G\J /AG_AC)?\ HI/B[_P8S_\
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MPMX_,0-@Y5MF1DX/''UQ6J\$+[ \:L(V#("/NL.,@=!T%*L$2L[JBJTC!I&
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MLY(]QBNA,,9C:/:-C9XYP,C'8@X XZ]*:+>($X4 %2N.2<''KG&,'CITXZT
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M5LY4CN[55"WIB3S'X_>J6*]P1USQD@=36X(8PI 1.<\E0>OX4HAC!R$4<8X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4LF=C8&3C@>OM]/7VZ4 .#*>01^=&1ZC\Q5 ^;W7GW0?X^E'[S^[_P".+_\
M%4 7\CU'YBC(]1^8JA^\_N_^.+_\502X'W>?3R\=\=>GY9H OY'J/S%&1ZC\
MQ6>688)  /3* 9/7'7Z\]/PI0S@'*J1Z[< >^2/<8Z@T"NMKFA15?='W;![\
MKC/^>F>M/1D)^4Y]#G.>1_7CCCCKUIM-=_FFA<\-E)7O;^M62T444B@HHHH
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M98UW9<#9G?S]W"EB3Z8 /\NM-6Y@=VC26-W159U5U+(K E689RJD \GCC'7
MH 1\LQ!Z#@?BH)/UYX_'UK,^RHS+DRC+#@;LCMC.1P#^.03@@U?>6,?.74([
M*J,2-K,0H"@C/+'H,<]N:<)($9-TPWLVQ077YI"I.U5SRV,X [8ZYH I?9(_
M6;_OIO\ &C[)'ZS?]]-_C6D98U)5G4,%W;20&V\\XSG@@@^_'<4&6->KJ,>X
M[=>G?CIUH S?LD?K-_WTW^-'V2/UF_[Z;_&M$3PE2XE0H#C<&!7@9)R#C [G
MH,'/2CSHB P==K $-G@AB O/^T2,#KWZ4 9WV2/UF_[Z;_&C[)'ZS?\ ?3?X
MUHF>)95A:11,ZEDB+#>RCJ0N<D#N>@QZ<TBW,#E0DL;%RX3#J=Q3[X7!Y*X^
M;'3O0!G_ &2/UF_[Z;_&C[)'ZS?]]-_C6H74$ D!CR%)&<#'.!GU'YBFF6,
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MO?UHHHK7\34**** "BBB@ HHHH **** "BBB@ HHJ.1F1<J 6.0 >YP2!^)
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M0T2\\0_#GQ7XL7Q/'J7D0:?J-[?&&333O\Z[+-*Q$D:#<L6&)^Z0"PJ'X?\
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M:_!C7/@5\:? ?PW^&VHZ[JWCOQ5I.K0WMYXATVSU+4GO[36=264:(MWME++
MDY@64$A8QP!D$FZ/"_[8?@UHO KZ5XN\1:WXDC\+^(+7Q%#>WS6GAO0+%GGU
M#13.&8-*ENT<<H;#;E9V&[(H _<R+4;"^DN8M+O])NIX%;[7!#=QW$MK-$$(
M18D;*B/YMW3'8CY<>0_&']H+X7?!BUTZZ^(VMW6E0:K)%9:9<6T+N+J^;Y4@
M7RQPSNK9#?*/;BOQQ_9>N/C'KGQ*C\=^#]+^(=E:>%_&'C.V\:#Q$;LZ3K#+
M<1BSMH!,YCE@='^69D("D;5Y.?TI_:O^&NH?%?X;_#^>#P9IGBK4+#Q9I>IO
MI]Y$%^Q><9WFV 1L3]EFP!E%##86/!) /J'PKXP\.^+]&TS7_#UU;RPZC8I=
M-:7=^MO<0:6RAI+V:V+?NV^97#L%^]U(+8Z!K^T%S%;-/IYN+B)SH\2:FK?;
MK-05EN!\V'9"&&4+8*\%0,#\/?&OP!_:&T;P1\5/'=E?^)4\2Z[XMTC3-.TS
M3[R[LH-)\(0PR1W&GV-I;2B..$_)O:.-.4C!4D[EYWQE\)OVF+#1OAEX)\'6
MOBK7M0G\CQ#<>/;G7-5MM4\,VKE8;CPO;VJN4N+2<%Y3<2R[]S8V]00#]T-
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M_2]9_8G^)WB.^UC5)]3N-3M/">H&Y@A=R]I$C+IORILP-IP000>, \T_CO\
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M=P(QZC=UQC:<=3E%&1K>L:;X>L;_ %C5=0ATW2-(MGNKYG\M81"L?F-YTC9
M4#.?7.!D$U\SZ7^UG^SWKC6QTWXB:8C:OJKZ1(EH8EB6[!<(+E51@>(R#(25
M8YR3ELW_ -L3P_XI\5?L[_$KPUX.M)I=<U[0)8(%A=EGWD1G*,F9%.U".A.2
M<@Y!K\NOV1/V6]0\20V\OCCP0G@RP\(QV&GSZG,DYEUG7I+(HMXJ.6SB5R9)
ML+\X;&"V* /U;T[]HWX':E<:CI^G>--%N[G05=DV/';X,<ABE:V8*AEEW;@5
MB+-C:<<@FWXN^/OPE\*:-<:]XA\;:-<Z=IT]O:SQ17)CU"":Y$;1M(@!F<*L
MGS[4&,YST)_-?3?^"?OQ(O RZUX@TO2+KP;J6L7W@^XM)GB;Q'K-W=276E1W
MK+&?M%NL2(LD=P70*S*4YY\\\;?LI?M(6T?@BYU[3;'QAXT\9:]+8ZB;=E.G
M^'K%XFM8+Z[MXMMN_E)MF#.CD  X4C( /U[\4?$+X06_@[2/B7XDU[P_+X*M
MX(]5\/\ B'59DN[:"\N8U$:P><&_T@8_U0 E3:V1P*PM'_:/^$.K:C966F^-
M]%N=8U333>_O[Z-+>XL8$9W:W.\+#(D>6*85@%Y484U\UWO[&]QJ_P  _ 7P
M@UCQ+<ZC<>%/%<>N>+,.WV.^N)?.D>"W P#:P^:L:1* BE<XP.?(-&_X)Z6U
MIXW^)-K>RQVMIJL&HZEX4UA=0NP=(^VVKV^WY)1Y4/0^6N$#*?EX. #[=L_V
MFO@;#HEUXFL_&-A>:/I>K2V#7%Y<2QW]O?7LJQ7R68N<-/ I=B# &78I(/!(
MV-'^/W@C4/$0T@^.M M[&ZB^V:/>27L4CW<+X9+>3+\/&-RE3@X88YZ?G9K7
M[$?Q0\;>'/A;I_BB72I5^%6IS0:.NGD6 \8Z0\S['U-+;RA>3!)#)YUT'F(!
M)8@#/<^,?^"?7B#7/"&O1^#O$*>!?'EUJFF7VA:FUS)/;65E$7^U6,:R%PI0
M; X5=KIM Y!H ^Y7_:!^"]OK=CI-QXU\.0ZIJ,_V22UGOH3:F<,=C!9'$<4A
M.X N1GIC(Q7G^A_M3?#KQM\:-.^#/P_UK_A(M>FT+7KS4=0LXV@TW39-.FE5
MESY0@G"[0F8Y&!R,9;@_'%S_ ,$];B'Q[&VI75YXK\.ZYX>AT_Q#K)NY[>73
M?%8@91K%NZ21R1103L)3Y)1#NR%*EL=]^SC^R#\0_A/\;]-\;>,]>T>[\(>$
M/#>O:'X:-C$D-Y<Q:C)*5N;Z>&-;BZ99) V;B24MM4LI/0 ZGXD?MJ^%/A'\
M6-3\&_&'X8ZC;ZKH6BW.J>#?$UE8/>C7;6TRLLT2)%/)'\ZQ*&0[5Y;(^45Z
ME\'?VJ-(^)O@7P_\1_&)MOA;I/BL77]@OK4T$$\\%O<21)O>Y?S+=F"G*2^6
M2648.=M>'Z%\ _VBX/VD?BK\6_','A+X@^'O$5K+IGP[CU"*&Z3PSH$D4D;6
M/V29#!&\K&)V/EAA@?,!OKQ?7_\ @G!X_P#B=\-_'G@77?&,_AA/$NN+JVGP
M6-_<1QZ>D5Y%=&#3O+=?L,+,HWQVQC0@#UP0#[&O_P!L'PII/Q?F^%5]::LV
MF?\ "'R^,;+Q];VK+9ZU%:([+;M*D)AEA<H40JQWJ  V *\:U'_@HGH=H=16
MX^'^LZ)I]U9&\TC6V@D6VU2&*9XI'M56$K(TJ#<[1[BH)YXJGKO[)_QKU7QW
M\(;>#7-'L?!_@_X;R> ];NS'%)/+9)9-$MQ-)M,LDCR  R!RY+'YNE:'P6_8
MY\8V'C-?^%R:MI?BCP!X$L-1T7X=VD:1_OH[AY"+B=556GQ$V$\WS",8&&YH
M ]9\1?MF^ _ 4GP:E\9W*Z3:?%ZWD?2=0>R,LD%I&H9/,,<+>6D99CF0*JX)
M<CBO8;S]H[X-6/B+2]*NOB#IZW7BJV1=*DCDBFM,*-XFDFC#00EB&5A(R$?-
MT(X^8?VD/V8/%/Q(O/A+=?"F/0UTGP18:GH6IV5]%#<&VAOH#"QA6Y65H6C4
M@J\6W!Y!X 'SLG_!.CQWH%H_@?P_XDMKWP5XB47?B+7;BY>YU_1-5F):XLM+
MGF+36]JC'"+"Z+L($>TB@#]+=*_:/^#'B/5->T73?B#8O?\ @Q7GUMQ-"L<T
M-N6#N)')2=00V#&)% )/R]]?P_\ &SX8^.O".L^.?!_BO3+_ $;PQ+*^KWUJ
MT*K9^7_K3<%0!'A6SN<X(W$G R/SJOO^"<.J2>%;7PO9>*X=#NK2(VL'B."Z
MF6;5K695\ZSU>7*RS3W PH+E_F+'G ->W?"S]E ^!/V=?BW\);32DT;6_'%A
M<Z&;XW<H74?/A6(7:$R#RY&!=MR -N&[('4 ]PTW]K+]GG7=<TO0=+^).F7>
MM:E>1Z?:6%L4D&H7MRCOAUV["(BK*'; WJ <D\]'=?M _"JSF\:Z%>^/-.TS
M6_ 427&MQW9B@FTVWDRHFBCQAU(;RCMW;F(P"-U?"]M_P3SETJTM$T*ZT[1/
M$NEZ9IR:-K7FL[0WUK;*LDCOG/F-,KEI#\V=RG/?A?#7_!/3XQ:MXC\7:[\2
M?&NG:GJ.M0VEF[)(T::C96]Y%,L<QA$?F.8XB"6!8AU!YS0!^A%M^TS\#C?R
MZ);>/-*)L]&?5#%/Y9CNRRO.LBQONQ(QRZ@#YMRA<ELU>\,?M"?"'Q)I=MKM
MK\3?#D5CIDU[/J=MJ-Y';7EN4#QA?LKLDD<.58QDIRH. ":^1O'/[#*:GJGQ
M$\2>&HK"S\1ZI#I%IX2@,TBI:7FF6UJWG/'NV+;L\0\Q=NW#L",$D>,:[_P3
M<^(/B_PM=:SJWBJRTCXA>(M3?_A+7TZXEM["31([;R8(K2WMMENDPVJ6,<88
MMDN3DY /U8\*_$CP+XT@N#X8\6Z)XHF2,:HK"[A\NS@N7>-IHGE8(/*7>0$S
M@ Y8 C/SQ9_MC_!Z\^+>J?!W1]<@&JZ9I.H:CX@U2]D9;=H["W>:X6TN9%6V
M)V H/+E))" CY:\._9\_8*O?AAX+U[PUX[\>2:UK.HP7EKX$NK&\N[632X9X
M90OVQ[<Q-/Y9>+<D^\#80OS!@/"T_P""<OQ<\46[0^)_$VEZ2?#CZVNES6K>
M5J/B07<3&&&XOX1]IECD+B-O.E*!ER,#&0#])+G]I[X+V/A?3==TSQYIEY_:
MWF6.A:*;O?>W5];&:.7=$I,WE*R@LS$(=XPQ[7?"7QK\)Z[8W=SX@\0^'/#N
MJZ%>6CZA';7T42)8W2DE[M=YRNU2"S J<D%>2*^/OAG^PK%I(T3Q)JFF1Z-K
MVE>$M:T.6S:XDNX9;N\C6*UU%(9VEBCDRBOYL,:2##,6[GA[C_@GKXK;Q3\-
MM2@^(,MII5G+>O\ &6W:ZD8ZAI,AS8VT"L3\_DB0+M5=@8;N1F@#[U_X7W^S
M[K^K:@@\;>&9-0T&.2Y35[IK.>W*Q!I)!9>82KL$W!#&JR%E8J=P /EO@;]M
M/P7\3/ 7QK^*/A2RN-0\*?!:2]TN_N[."7[?KU[9*SRVEDLD(D2"5(_-01@X
M9T9<D K\C>%O^"=>J:;HGQ#T>.9+/5[?6;_4OAYXGN+Z=H[VSO91/865S&[E
M'818B970 -D\#)/L_P "/V2/'?P]^$'Q:^'_ (BUC2M)U/XK7UNY^P10B#[=
MY(B>[>.)%1!+"K!\*22XW'*\ %ZR_P""B_PON_V</A_^T1IF@>(D\.^/?$S>
M$[+PM)$_]K6E^DT<<MS-%Y:W2QAY%(=XPC<<#DG3\!_MZ> _$R?%KQ3'I%]H
M_@#X96-G;SW=Z@BO]1\4W_E((K2UD6.[G\QKF*V5[>)P,OU(9*^=M-_X)H^,
M[*X\2:9%\18+?PE:BWO/ %C^Y^QV6LQNLEW<&R\L0HTVP@-Y8)^;<P!S5+Q5
M^PAXX^)OCNWUW5]>TKX:7?AO2H+#PX-%,Z6WQ$NM)47$>L>(],57T^2YDN(%
M1WEMVE$04# !V@'V7\.OVJ;;7/#$/B;XQ^&+GX=V.H:U]@\$S:C&\2>)(+AV
M6SNA#<JCLQS',"HP&PVT<U]BZ?<7%S:6$J222B5]LEQM7;) P5E=E'RLBJ1R
M!LV$D8!^7\T?'O[.O[17QI^#V@>!_B%=^%1XL\,:[I^K>#O%&CJ]O)I5MI\I
MA5KB%$BMV,]JB(5*$Y.X*#G'V]\)]/\ B/H6@S6'CW5(M8N]'@2TB\D(&FA2
M,1;SL5<G"YW9YY .<4 ?/VI?M=3GXN^*? 7P_P#AWJ7C73?!J,_C7Q=IZL]C
M8K&'+VH:%1$L]J#YCIR^&;C;S6[X-_:M\ >(?#'B'Q)KWB+_ (1K0M(U"18[
MJY,:2QO%,5EMOF_>@ [P,+E=H.,$9\<TC]FWXN?"WXJ_$&Y^%FKQ6/PZ^,'F
MWVKVMYMN;FSU6]@=+Z;SIDDEC1]VU45U&&(VD9K@=._X)X:Q#JC'6/%/]I:2
MVKB]O=/$[&WNS(6>2)H05B;+G#_*#C&<X- 'V!/^U+\+I[RWU>U\8:1-X C\
M-W]YJ>IRWI5Y'RS%8@S RR!,82,-*2V IR =VZ_:+^$O]F^#+^?Q##8Z)XA$
MNI^'+F93%;ZA;V44_P#H\QNXU59I)$VQCDMO!4X.:_/#Q%_P3A\;WDEQ<6VO
MV<VG:/K8UCP_X9ANGA011S^=%;SQKL6> I&B-'/O5CG ZYV_BG^Q=\>_C%>_
M#(>*O%FF:/X7\,3PQQZ%I,<%H]B\,,D4.Y+:- $9<,X&X2$[F()S0!]Q?"S]
MI31_B-\/_%7Q%U5)/!?AOPOKU_H]O>7FR.+5(;)YXUEMUFV%UF,(,83)<8V=
M\;_AK]H#X6^.M+M=7T/XA:= ;B6?2[BUN2BLT\222.9;281R@&+)$C1[2I)!
MZU\Q7_['?C*[_9_U_P"$I\8"#Q(VOIJWA^[B?RK416YEDBCE5/D=G81A]X=3
MAP5^;CPB3]@CXN1Z0WCB+Q+IEO\ $B[98;VSMY6M].@@\A;1)OLD.VU20JK%
MV5-Y9LG/8 ^Y&_:]^ \?CV7X377BS39?$%AX4'B@21Q1FS>VR T,$@C$$-P1
M@[2ZR$GHV&K1U#]I[X+V&G^'=3?QE::5)XD6&T@L6A;[;Y&XD2M&$$L4+HID
M$LJJFT]1G:/S]A_X)W?%*PL;Z>+7]'O/$NNV5H-1U F)KF V=Q]K6VCNP#,D
M1?$;1*VQ@Q7&PDUW'BW]CGXRZWJ6G^*TOM".MW?A6W\!:I9K' (;/3HH/LDF
MH6\14I#<F,&07,:K,"&RP.,@'V!KO[4G[//@V^G\.ZM\4='DDE@34-JZD\K1
MM.?DA)A+(&8C.PG=R!G.%/2W_P"TM\"M(M?"<U_\0- '_"6*UKHDL5_%<2;)
M=Z@2(6=HN5*LLNT@8R 3FO@+PY_P3<;P]9R)JVJV6IS?:='"7%Q,UU(PT^<2
M,#+*7?:22K#/(Z@XS67I?_!.#5/#WQ*T3Q9J!@\7>%(]6O\ 4+C0&OYB;9;U
M@R30(9-L,=N0I"0%,9("@<4 ?IMX:^+?PY\6ZYJ6B>%M>M=>G\)6[7&J_8-@
MM;2-1N,TFQ55P%!('(.&R,<53C^-_P )KK4+;31\0=#N+B]TZ^U2*]AN88G6
M"QN7@EBF9#@/%*K+Y3E7//&,8^;O@O\ LR^+_A7\??&_C>#4K+3?A-XGT2XT
M^'P^9?,N1/,'53([EI'\L,"-TC9(;.X\5\CZK_P3/\?'XD7OBS2OB5]FT'5_
M&#ZG::"MW)FVT6>1Y+J(9&5A<_.T8(7<22K9S0!^H%G^T5\%[N_\0Z-:_$+0
MM1U'PG$+GQ-';SP[A$\*RP[\$*Y$;#(!)!4C!!&.2T;]I;X,Z['HT.G>.M+U
MO4/$VIR6]C]HEMEFTT),(WCC20"18T. I "-C[Q^8GXO\%_L 7OAS4_B;'<!
MKC4?$]_ MAJKW4V#8>6GFRR[77>HP8P,-TP!@@54U?\ X)UR6WQ9\$>*],:.
MXT31M'M(=2%M?7$,*W<5Y!*Y\J*2./+LK@N>2N[+$8R ?4/Q5_:S\._#_P"/
M'@WX/&2+[;KVCQ^(I_$+D1V5KH+&:-;9F=%B+B2*2=-K,<.A4%BQ+/B3^VQ\
M-O#.E:)KG@R_@\8VDFIZUINK6-A$8YDETJTEG9GA6,2F-)(@-P0H^05.#D\1
M^TO^QCJ7QU\<V/C33M4M_#+>#/"MKHVB00DI-?R64DEPDCS*A9XV1A%B1L%<
M Y;);P_PU^PA\2=1\SQAK/B2TM-6M+"\T^SLDABCMF0PFW-RUO%$L3S,JJ7E
M91+(QSR!@@'VWH7[67P@O-%\"W6O^(],\*7OC;3[2^@L'6-D@FN%&U)G"$6Q
M^89,PC8E20N0:[Q_C5\-+J\M-)B^(^APZ[=->3:?(\]L6N+"P"O?>1N<@A8]
M^\C)!SQC%?FQ%^P%\1=,U"TT[_A(+;Q!X<\3CP]+K<LF))-(&G7#2W"V3L-]
MIE9#O6U9,C(4?+@<S-_P3-^(,?Q&N_$NE?$>8:!I]_-!X38WDSOIMKK(V:P)
M!O)=&$A"B8OC:0,#% 'ZAZ7^T7\'M?U_4-%TOXAZ?-J/AK3Y-1U0)-;B.2SM
MQNGR2VUF!.-J9?)VJ"2H/FGPP_:S^&WQA\<?$;3O"6L/'HOPULP^IW[6YMX1
M<LDCR3LDD2^9Q&V'3<NS(+-D&OD'P9_P3OUGPQ?>-_#TVLRZBM]:/J6E>*UG
MF21K^7R[C[,[%XW>+SPR/#)N0@#]V5%>H?LZ_LM?$/PC%\9[GQS_ &/;7'Q!
MT!?#^DM91PVN]K:VEMX9YEA6,-*Y<$N5SD\YY) /KW5/C_\ "W1=*L]3U;QG
M;3:1JVG3ZDFH;[=DMX;1B)$9!N<-D,<!<G&5!R*\F\6?$W]GJ+X7:I^U'INF
M:-XZL/"EA/=6VH6EJLNJ+?VS/&J.GD--%*6@;:IC!(&1G@K^;?Q"_8J_:!\)
M>$Y-22_37YHKMM"T31()WF\B*[OHY/MLL'S1F)4/SY7DJ01W/VW\'_V2_$>A
M? /XA_#GQ;JMO;^(?B==6>J"&-(_L&GLMF@DCCMU1H(0LCOYJJJ@R*6.2: /
M2/@]^V+\,_B1X6\$>(?$.MZ1X<\2?$6Q>ZT?PQ.Y%U!I2RLD=UJOF#;;2JAW
M$.\05<\8S7L>@_%GP!XZMO%=CX.\30^*H/!EGJ<NNQ:;_I"ZBUM:/-)IYN%!
M#!"XCV0EBV0HSEA7YCZA_P $X/B-8,OA72O%]M-H>L:,EI>^(D/DSZ*QD<-!
M92!$N+:,9X\AE3Y0>:^]?V</@;_PS;\*M0\#V)M[WQ!)<:G<Z=JSJ)Y-7O;B
MU/D?:)I"SRH)0A83DH<D8."M &5^S[^T!X;^+OPU\0^+4T&3X<:-X)\2:KI%
MUIEM;FT^W'2I)4:20-%&RM(Z;W#!B2[,[#((])U'X]?"32K9-9U7QSHWA:#[
M&NH2)=RVAOIH9P64D@E_*D11Y63AL'9SG'@7[+OP2^*'P_T'XS>&_C?=6>H^
M'_B3XEU/Q!8QV,4*?8)/$$LJW4"^3''Y1ACD1D" *CH25&>?@7P3^P=\2/&W
M@OXGR^,[Z^_X2;0_BN\/@ZUFNYVBUGP!I-^KZ1:J'D"'-LS(Y VOG!S@"@#]
M:IOV@?@_!)X9N$\;V=U;^+6>QTB]EE7[#)?7!98VF+8BY/+JQP<Y!Z5L>$OC
M!\/_ !I?^)]"\*^++3Q'J/@Z"67Q&T.&%@MN2)ULYT!CC1&!"JC84!3Q@&OS
M2\??\$^?B9XTM/!.DZ/K*^&?"UA<C4[O0DN=L]EJB,62=9U/F(H8!A&KJJ[F
MXQC/UK\'_P!EG4?@W\'O'G@SPIKL;^._%MO<I<ZO.HDD:65&5V%U*CR$$DX!
M<J0,D$XH ]1@_:?^!L'A;4/$_P#PGMOI%AIVI_V3>F[E22Y?4=P41%&W2NSE
MCP![XP":Y7XP?MF?!'X2_#M?B/=^)[+78M2L[.'3=-T_$SSK?7T%HK2V\"R2
MQYGEW.9 !@'<,*37Q/\ "C_@G)XX\+P7]UX]U^U\2M<^*_[=?399M\*YA,0F
M\H8C=8]P;8PP2N['.3SOB3_@F[\2X1KNE^&=<TS4+#Q1;)!'?ZA)]J@T.(:P
MNI/#!;SM)#$4C0Q!HP""%"YSR ?I=J7Q[\/Z/IW@'6_$%U%X6T'Q1I<.O&^O
M?(A@:WN[*"ZB0Q@H6PLR\F,ODCC=C'&7GQ?_ &7O$]E:?$F^UGPMK&IZ?>6^
MGC5HX8YKSS6G6&(O!M>658Y"C B/EE!'>O)?CA^Q_P"(?BK;?"?3$UIS:^!_
M"VG:;>;;F5;>6XLK6V@D;RU98Y%9X795P<H<<C:#Y+XG_8!\9Z9K'@?QQX!U
M[2+75O!3VVH76EZGYATO48[:59/+:PBWV]Q*QBSF>+&6&3G  !]D^ /VHO G
MCSQ#XLT.[OK'P]8^%KF*WLK[44")XB 6(QS6]O/'N5K5CN5%CW*P5@5ZUS?Q
MX_:]^%7P/\,:5J0\46-[KFK^(+"PC\/>:\]]?IJ\YBEN (UD:UMF(WQ%F6,K
MC&6'/S5XU_8N^+^NW;_$7PEXH\(6?CC5+B[U*^M"+J&QCDU.V%N$2U6-8(Q&
MZQL 0 IR3CFO/_$/_!/?XO"W>)/$OA_Q-/XSC\-1>-M0U%A<2^'IM+PUZVA^
M>"UI%$2WEO#M8@%CAC@ 'Z'Z-\??@GI.I:GX6L_%'A[0+_P]X<B\7ZKH=G-;
MGS[34H'N3YDB?NIKA(XF#Q!I)%(.X(2!7.? K]K'P+\??%OQ!T#PC/\ 9-*^
M'2VSZEJ5PC6\/^D1B<3/)<I'$L2^9Y@DX4DCG'-?#_AW_@FUJ^B#Q=X437I+
M]9(XKS0?&M_>7#ZGON5R=.$S.9+BS#)Y9CF=D1"54*,9];_9^_8_^('A#1?V
M@=/\=>)+,'XK^&8?!^CSZ5'#8O:_9+2.QCN1)9QPD2_N!F4_O"[.V\Y#, ?8
M&F_M(?!/Q)KD_AFR\?Z3?W2W+:5>6KRVQA-VO(?))0@%"2RG:PY'.!5G5OC]
M\)M)N]/T:?Q)927NN17S:?;QF-%G2P@GD>WBN57R]Q\C<(T9F&X$8.0/S-T+
M_@G-XET7X->,O!FG7<UM\4K'5[1/#GCL7TH6]TAR#<%I"2'F09!D93)EN#AC
M6GXP_P""?OQ>OM2^%-G9_$F.X\&^#+:"]N<.%U#_ (2-XQ%=NUT%^T20$;B4
M#F,EF!7K0!]T?##]J'P#X\\)7WB2^\167A^VTK4+B!A+<$3R:;%J+:=&Q,F&
MPTZJH;'*GY2>*TO%'[2_PB\./XOFO/&5G!=^ ]-_X2'4-(DF7&HZ1<1Y2XMT
MDW23++&#A(0[= %+$9^"/&?_  3Z^*/G:II7@WQ_#%I&KZ5I^CWNTK$JS0:C
M!JCN%$8\MM\;9? =U('S;E#5-4_X)V_%GQE\1[WQ1XT\7Z?>6^D:5:6F@2QR
M"&*^%I!$L%G>P0HJW41DA3Y+D2*0Q!)&X  ^WO W[6GPL\4>';OX@+KVGZ/\
M/VT?^THD=%M[E982S3O';/'%.[NJ,0J0DL5& .&'6:A^U1\ K/PQX;\57_Q)
MTR'3/&#QQ:'(54Z@&D=T0S0%/M-L@:(Y,R(!]\$ @U\ :G^P7\5M>TI_$=UJ
M^F67B;19 FDZ':%;?39[6T8E!)IT(%G(6SEEDC*NK$%6YJ_H?_!.OQ!=R>*/
M&?C#7[>3Q!XB\'76F0:0F!8Z?=F"-=]C8 "VLY@8E"20Q1L-V<J3F@#]:](U
M,7FFV=[I4T6LZ?>0)=6FHK(&6XAF4,C*Z_*ZE<%64D$$8-%>>?"K2C\-?AEX
M!\$7U\TMYX>\)Z-I]Q(X\QWE@M41F:1]Q=B5R6S@DY&1R2@#U&6X2%MES-Y8
M(3Y]V5$QQB%>?F9LY[ # YS38)[6XBDD5))FCD\EXV&URRC<^W^]P-W;N:_)
M+Q__ ,%._AE\)OVL/BE^S1\7K"X\+>"?AK\.+/X@GXG7+.)KB[FOY[86ZAF1
M7/F0JF-AW$( N" >)^-7_!;/]DSX6_"CP]\2_ =_KOQ6NO$7CS0_ \>DZ-:7
M%SJ5C<:OJ$-A]ONK>WCEE6V02>:\K!8EC&\Y! K'ZM4>R=_5E<U-]+>ED?M"
M\NG!!(8\Q,53<H8GS&P%39][!.5W8QD<9)XM17,!7$:D;&\O:7"'Y<%R,XXC
M4Y8]/0X!K\\YO^"C'[(<GQ,L/AE'\7-+LO&7B31+:^U*>>Z5-'\-2PPVUY-I
M-])*R1PZG$)S');N2T3HX^;::YOPQ_P53_8@\>>-]>\!>'_C%I4VK>%K75#/
M?ZC!/#INL3:=&QU>UTF=S'%=7$"*=S0,Y!(RO&0OJM;L_O81BJEU%-I;W=]O
MP_$_2\7UMNF1FDC>%E$@.YL*Y.QPRY5E<#(QSC/H331>Q@7&Y90;<KD.5!E#
M_<9%Y)#=@>67! R<#\Y=0_X*G_L1Z3K7A+P7-\6M/&O>+C:V4%K:V\Y?1H)_
M,%DVJSLK1VKS;0+82-F164X7!!\$_:>_X+0?L?\ [-EIKMI;^(M7^)_B7PKK
M>BZ+K*>'+*ZU"'2KW6MQTT7OV:*4JK1HY4F-<%?]HT?5:W9_>QN@^WX?JM%_
M3L?LE%J-M.&$*F2&)29Y0,+"P_Y9LIP2Q/' ]3DC-/ENT2)9;2V>]<2A62%A
M')$A(!D.\@%5&<]"<X QDU^;6B?\%/OV0]6O_ASX=O/B);6'BCX@Z;#K*Z9(
MP@DL+R:REO+>RU&V<I(CN48JC*&.T 9W5X'^RC_P6"_9^^.GBOXD^"_B%J;?
M"CQ+X+\7Z]X?T?5M?5]/T7Q=IVF7%V ;![A8XYB;> L5A(+87 XR18:LMG+[
MW_F1[L&T[)KR3_.Q^TPNE9)66-V2( EU<%2."Q!QGY,\\\X..*B?4;1%B?S&
M99V18=NYMY<* 003@;MR\X.1CTS^83?\%:OV$K;2I?$-G\4;N?PKHFOW'AB]
MU[3]'O[G0&O5E:&=9+^)&MU5)5(^:8-M."#2_!/_ (*'>%_CS^TQXV^!WP[L
M8M:^'OA7X8VWQ,M?'^AS"W5]$FDF'V7R969_M!>!N1MR\H4#<A)?U>OU<K=[
MO]64W&VB5^KLOGIJ?J!]K"[T9&68'B'<"[)@9<<D#K]W.>1R>M1"ZB9U1+=V
M!4%V)"*F1D9+=21GA<\@XR*_FITK_@NO\2[;XF_$+Q!J_P"RIXDF_8Y^'OQ>
M/PGU/XZ)>+(\.M7%^FG)<W3[/)2**<3LQ:),B(#Y1C'W#;_\%8/V>-,U#Q%;
M?$/QG8V=A-XHM])^'M[:3QK_ &JUXRI:I-(DNULN\*OP P8@*<XH>'KZM.7W
MN_YV(LGK9:^2/UW%VOEEH0A*L5,6#YDA!.T;<':<C"Y.#GJ!0+JWF**R!V;(
M" 8.5_UO<%1#C]X<'# CKG'Y[^//^"B7[+_@CXD^#/ASJ7CF]U+QE\0K335F
M7PO%+J%AX5BU G[!<:^UJDL>GM<C:\)N&&[<"K9.*^:O^"EW_!3[Q+^P]XS^
M"?PY\ ^!-%\8ZI\8]"U75-+\2>([U;'3+<:=&T@$]S+-!#OO$7<BDYD=R I/
M(UBFDE)W:W]022V1^SJ2K(Q")"R%@L4GF +*N=K%,]=F""HR<X4#/2O#J-E-
M-=1[&)M>1A7S(@)!D0=U3:0V>,@]A7XM?L^?\%DOV>O'7[-?AKX^?&SR_A5K
M4WC"[\#P^#+@O!>7FI6MVME?ZK:6\FTW&G27!W1W*;HC&592RLV/H#QU_P %
M1OV+/"'B#PQH]Y\98[O4/%,FG2: ="@>XMK>#4VA15UZ2!7%M9K/,%N)9]D4
M8W*7)P:8S]+&O;%%1V#>6XRC@$J>.<X&5P>#G&.O3%3+)&P0^00&+;\LN8T4
M'#N Q"@XW$=005P>,_GK\1O^"B_[,?@OXC+\'-:^(EIIWQ#O_#\NM>$HX9!+
MH'B.0V U2VMDN@WD"2>/8"I<OL+#G//F/PU_X*?_ +/GB(?#WPS\2/%5KX5^
M+/Q4U(:?H_A/1V^UK=))?IIL)S&TI$<JE"[$[07+;CP2 ?JNEQ9RI')"1+'*
M9/+=/F$GE;MP0C R2/ESU/&.>6_:+9+875Q&]O'C)W DCD@#:,G)QT&>2 ,G
M@?CIXP_X*N_"7X1_MM^./V3OBCI]SX-\-^"?!ND^)K+Q8EK,+)I=38"(7MT,
MP0K<L\2('<2.S$?-DK7T_H'_  4&_95UEM.;0OBK9:YK?BO68]%T;PS]H62Z
M:XDDVH8[<8 4J X4N)6#@B(H0U 'W*=0LTC$TD3I"YC6%WP/.:4D1@#(*;C@
M9; Z 9)-6Q+;[Q"RJEP5W"(GYF0=7Z\(<CGMQWSC\:_^"@__  5&\)?L&_&W
M]F3X,:MX>F\97G[0/C*VT;QIJJES%\-- FNK2#3-5O=@1;2.X$\[Q-/MCD-J
M7WY88X3XT_\ !8.Q^%?QL\9?".S^&SZO-HGB/X=Z-H'BLI(^GWFC^.H8+E=2
MFD3:KVEO"[,7!"G<N)05!(!^Y2W-H[(8QNA=S&)@"5,P?:8SC!'0X.#Z\TC7
MNG(NYG'WBGR_,-V<8# 8_P #P><9_.?1O^"F7[(>K>,=8^':_%S0=-U[2=#2
M^O-?N8)H_!L&HQQ[]1TFUU*1A:S:C!*)8Q#',TFY>1@XK$\$?\%5/V(?%6G^
M-+30?C%:6<?@2SO+K5QK>GW-H;QK9MUS-HSW'EB]M7D5@DT)9 >=Q  (!^FA
MNK4+'B(M+("R19P=HQDLV0 !R<''Y#(5KJSV,Z8<QG$D9;:Z <L=A^9MH_N9
M'&,^OYBS_P#!6;]AQ?AU>>/F^*MM+HZ:FU@=,@MICJT[PQAR]K"NZ7RCL$@(
MZCGD$L-76/\ @IG^Q+:?#[X=_%F?XJV,^D>.KB*UTJWL[V-M;M78[2;_ $U&
M^T1F)L*VY,$@J6!R* /TB@O;&Z"F)7:-V9$<HZ!G4'>F&PP*C#$X*D8 Y!%3
M&:UWF-%W.I(=,A67ME5/+X]!GI7Y56__  4O^#=KK'Q7U+Q1\0-,L?A;X!\*
MV'B?3=6LF1]?\0->3RA],TNT5FGNKR% &>.")I,.?D   ^Q_@#^T1\-OVD_A
MOI/Q.^%\FJ:UX7O/,1;W5K>>QUFU,;LKO+87"1W&T%=RNT?S ACQC(!]*HL#
M[2JL0X#*Q& 05W#KR..Q&?4436J.A4# /WL$ABO< CIGIT.0:9:NKQ6SH[21
MM$K++(-CN A7<ZG&)&X8KM7&3QQBKU &;+9"8?9WVK;)M:,(7$BLO()/ /.#
M@<'.*\9^+'P4\$_&&Q?2_%=HL-]:@?V?KUDJIJEJJH ABN<JZLIVO@2#+ '(
MZ5[N3@CZ'G\5JA)'')(0R$-\OS@8S@<$=20,GG.,X.,&M*?Q)W:MK=6\^YSX
ME7@EW=_^!^!^77B3]E']I:RMT\)^#_CX]MX*@NB]E;7C7;7<=N/N0W4PW/Y:
M[5.$?#8.X8&:U?@W_P $_/"_ACQU#\4?C#K=Y\6/&5J";0:DTU]I-JZG$310
MW<TPV1[(BHV +CY0 *_3+RFC4Q[%D4@@DX. P)]R,9)R>3CN,8D4A$ *@$ <
M[5S@ <'U.0>G3@DUO+%3G!TOB2T5G9[=TKV\OF%*G9)\J_'7[D_G^>Y\K?M5
M1K%\!O$D<<(@MHKO2[>WM0BQQ00QW"JD4"J %A15 4  #CCO7L7PD39\/?#D
M:<,UC;'<?3RT?.1CG;^.>3@FO+/VNVW? KQ&=H7_ $S3>G3_ (^_H/\ )KUC
MX3?\B'X9_P"P?;_^DL=<ANE96/3*I7:/(RJCM&3'(!(/NJS#:A;U'+<9Z9]<
MU=JG<S^2T:NH,+DI(Q&0 V I)XVY.X 8.[&01@T#//\ QOXUT+P!X<O?&7B3
M4XK?0="M)?[1:<+B<D  1^80A)9U7#$$J< $G(_-;XR_\%&].T70-!L/@KX9
MEO\ XF:KXVT7PQ-X"U.S GDTG6LRP>(HU@B<2PK;)YT;[,%6#AR""/T+^+7P
MXT+XN^ _$_PPUY);;3]<LV2.X5BN6W*\4B-T^22-"0.<8& >3\8^"_\ @G_X
M4\/ZCH_B#4_&NKZK\2]"UK2K^SUZ*)%LH=&T>(VUCI9+P,"T5HJPL[.64H%"
MX;< #U7XM?M6^#/@=-X#\/>+M(U?7]9UNPM-3UVYTT!H/",T\<7VB^O4*&01
M022SJNW=M6'[NX[:R/&'[;OPJT&?3]%T74I!;>(O#B:EHGC2Z1Y=,2ZN;DVX
MM;A3F;S0V$XR%QA<=3P/[0?[)OCCXX?M ^#_ !=:ZY=>'OAZ_AXZ'XS$,\*W
M&KHKJ66&(J2N_9*RD*I!8.#@@5C3?\$WOA_J/B33M43XC^+)/"6GZ=]@TK19
MI(]B7L,[S?=\@919OFV@@D9/6@#TC1?VY/A,_C;PK\-KJZU*[UF_N4T6[\36
M4(B\,R:K+")A&XF'G%MK(0'^[DC=G%?0_P 7OBGX.^"GA23QKX]F@2RD2/28
MH0=\VL7APUE'9 ,"T<TCHCHW0/P.<'Y8U?\ 8=\-1^&M9T'3=>D/B9=63Q5H
MFLS0AI[?5TB,$$'GK'M;Y$0E58$,HY RU>A^*?V;M6^+_P #='^&_P 6=:N+
MGQ#HU_::M9Z[82AKNQNK:17MU=2)#UCBWEQC!X4=* /E[X6_\%#(O$5EXV\2
M^.;!?#EGH&OZIINC^'9+>=]4O-&TE$EE?2%1%VS26Y+!RK<X)X!4_2?C?]L_
MX8>$O!/@SQ[XBAU(:%XKMX9/#<EN3E)]11C96U^&"M]KMU3%V-I48) R<'R3
M1/\ @GKX<T-=3NY_'NN:UXXOGU9K*"9X/[*A@U&V%G,#&8E0S10'S&9CN5@2
M<@&L?6O^";_ACQGHWA31]6^*OBR?P_X:G2]OM%N2H"7<!D:8:?F +L5B538&
M4G:030 _X2_\%!++QC9Z[HGCFWF\*:W;WNI?\(IJZQ;/#VNVMFY6"TN"R([2
MW8(57"L1M.2.#5W7?VX;WP;9_$CQ1XATO1Y].\'2^'K2P\+QAFU'Q+#JMI#)
M,FB$KY899)=Y5U88#Y8GI/X=_P"">?@NPU-[O6O'^N:IX(B=V\/Z.8L:A:7M
MTX6*:Z(A+")2-S+L!QU<=1Z5J?[#/@#68)++5=;O+N\EFMKJVN)58HBV"F.#
MSSL 8(45E+'[ISR2* )/!'[<WPAU;P3H'B'QG9ZA\.]4\363ZEI?AK6'\R^U
M(><(HK:S6,H7==Z[P$V*P;!) 6O0/B;^U/X+^%VO?#S3/$FG:G#;_$*2.#2]
M82:*.UTN*:+S1)?P2,)610RHQ3JS;U/.T?*OCK]A2^UWXL_LT^)'U*#5-&^%
MFI7!UNUVC['/IWVD7""?: C[<* 22V-W3) ]?^.7[$>C?'_XNZ+\1_$WC74;
M31O"J1'1O#MB/+L8S;?(&C11Y8( 4$H-IP#C/% %C2/V[O@?J?C77?!NK3WV
MB:-I>G2C_A)-5MYETKQ)+"6E\C2G"KEWV,JAW 8<;@6!'._L]?MCV_QK\=?&
M&VGTV/PO\/?AII2:AH$FIP2_:$M(;AXWU&\*1 -!-%$TD3J[N ZY9FSGIO%/
M["WPX\2>'M/T6\U[68OLVYM.N;0P)*LH.06<1$L%!(VMVXSP"7?!G]CC1/A'
M;_$#[=XOUG6['QSH4_A?7+.01M)#IDBR+"\0C1298RR'DD J6SSB@#(\*?MZ
M? S6O$5[I$%CKF@&ZO8[:SFNE"V7B4W,XM[2^TS80$@GF+8;I@*" K$UW_B;
M]K7X5>$+#5-4O;>]6'1]2M]/FDM;N)+AKZ<J$!#-L,1?B1"<@=<C(/QEIG_!
M.;Q$_P 3I4N_%%[#\,3X8&D>&KA'B&IZ3=V+3SZ?<Y$>1)YD@Q(4 8A>ZAJ[
MW4?^":&C:IX1A\.:G\3-7O6N-8L[_5KR:4M-/>03>:X9@F"X&%8L1DGD#F@#
M4T/]MW4-:T[QWXGU?3M&&EZ+;:I=^&-"M'(OM472]WEW%PSA5,[  Q%-RH['
M!PW/?^ OVZ?AM\0?"-MX@U[0M?\ "GB33M7T'3H/#6KLGVS7I]46,)<Z5Y81
M7A#.2[.H*L"NYLY-.Q_8.^&^BV^T^(]3F2PTC4=(AACC=O-N=0C"1S2*L>"J
ML,R'&#MST(KS/4OV#?$%U\3_ -G;7;;Q/:Q>'?A&-3U#Q?GRXWU6>2X:YT,3
MAMH8VD0C7+#/!(P,D 'U/\0OVKOA9\._%%GX9U&.\U+5+WPY-XLU!(F4#0+&
M(Q*MI=*2'2XD,I(QA<KDDE@*^?\ X/?M9>)OBKK?[1?BVZT9-.^'OPNT_P"Q
M^%4E9S/J^KW-K/=6<L;IE8[?9"%E$K';Y@P"5)KT;XZ?L?>&_CAX\MOB3I>O
M7'@RZ;2)= \3*D99->T^.>,P;%"E0K+#&H<95MO/7%>@^!/V=/"OP^\$^/?!
MD;/9Z%\1?L<%X\$9EN!<06AMH;@A0?*\R/+L6485L<#F@#X2\3_\% /&.F?!
M3PUXBBTFR_X65J/BO^R_$7E','AKPX;B%'U*]0@N5%H[L2JD_*>217VE\"_V
ML_A?\7?$ECX$T"]U"?Q#IVCP:D-2C5Y=&U@30Q).XD4Y 2>8H%D8@%,_>( \
MLL?^"?7P^M-.O]-?Q)>:C+K4S?V[/-&9(FTYP088B$V(RQ94'@Y(8D\"NI^$
M/['>F?!4ZU'\/_%$.G6T\[3:?>SP"2]M;61<FW6=5W*NX;L<L>IZ'(!]P)82
ME;@RO']KEF+QN>1'C:0D1.3&I&5?&-Q// Q39K 3&%V"RRJ8]OG%]L!!!9K?
MG@]U P,@$@#@97AJSFTG2[*PO=6DU?46*F2_F5E60K\S[=QY+8PHRI;J#Q@=
M=&G( '.!EAS@$YZD\X'3CMW!H S;FTN3&GV.X F6=!(]QNVO;-DRPA02=X4@
M1'("L ">M)<Z7%+)/+%L1KA4\\/EDN'B)$*S#E2!D$_+\HR1QDG<$:=QGW//
M^?\ )/-'EI_=% &"UNTD<,5PD,B0W$4T: L$B$892(S][Y3]P<8&/O#I!#IT
MK2D!DG2022337.]KB.4N2@@*DXC'&<," %R2.*Z$&(@$@*?0YZ=OT_+IVIZ^
M7GY,9QV]./\ ZU &2VDI.D1G""2(Y41[@BE22"N>07/WSW!QC(J"6U=T=))'
M2<RB0S1*I:! "-ML6SM^4\KG:69_D)S70Y&<9&?3O41\K)SMSDYZYSGG]: ,
M9+68O"B7$JQP0M%&N1F=R#M>Y Q@ Y("8Y/TQ82RE6:"=G7=Y)CO!\VV;;P"
M.I'J.N0>>>:T1Y0( P#D8'(YZC_ZU2T 8T=E>+!-&\\;%B#;,5),();@9[_-
MP>,>Y%/AL!"$RRR1X+RENK3=FYR0,XZ$=P<\5K4A (P1D'M0!A"V E>ZDBA6
M\7 AEB+C,08;$D'=AEMV!Q@Y'6K0LT$DUS"J?:7PQ\PLT328*AR.HQ@8VX/'
MT-6)(SN(!497OQQN; !) S@X_"K*@*N3C)Y8^W)'/L#B@#->SFF53*L'G!1B
M5 =Z,&R=I8!@IP. PR,CZ4I]-,LET\;*OVN*.+)=\@J^]RW)(#?, 1QDCTS7
M1=>E,\M/[HH QDL8K96^S@(S,CJXDD+ @_,"0P."2,J2.6)-1"S5+@W*8^>2
M4S!F<[XI0<*%R1E0<]/O;<<\#;>)6QM"\,<\\< CD \D'CU'I3/LX_V![@'(
M]QSUH STTFV)(,$+P$*4#EF;)&6)[9).>_.>F:3^SI$BEV2+#*),0R19R(,X
M6)MQ((((!)7.=Q[UL*-H XP% X]1U_#IC\:4@$8(R#VH P9K#S($B:*VF(8$
MB8R%0%)9MJ\J".V!P>!33I<)ECE2%4>*'[.IC9]BPL"2L9."6W$[<].<^AWO
M+3^Z*3<PX$9P.!@C&!T_3\J ,9[2;S8IXI7'E1^2(Y#\DD!X99".5(X*@9[\
MG%21V,<,<MM;J$MYY7:96)+;7C^;9D$C+')QC!)Y&<5J[B>#&V#P<XQ@\']*
M7RT_NB@#&6Q82',A\M+<6\2 D -DL"<$#&" 3CMC@8JQ''(%B:0IF$-L5,K&
M20  PX^7.<YZDD\$9K1\M/[HH\M/[H'N.H^E '-16=S$DYAG$<MU(WFKN;R%
M0J<"($D JK$8& <8S@9J5+*6/R[>W^SK8Q(-T+%MTCNV69TQ@'.<8(P3C&#F
MMKR,= I[=P3]3D_6GI"HSD#G''7&,]_?.?Q/X@&6UG("B0S>5;1@,D(SAF&2
M=[') )(Z<@<CD<K+I\$T<*S1AVMI#+;_ #,%5\Y&X*5RN<8X) 7.>6K6*1CJ
MJCZT>6G]T4 9-O;WCLTEX+-YBY&8D+(+?^ ?.& <L QQR>2#CBECLKA/WLLJ
M7$VV1"\@.%1B?E7'*]LE<<<=*UPJKG  SUQ2T 8IL IBC25UA@+@P$DPS(Q)
MQ,W#%LL"%_A& #P"(Q9/"YE$OG*J?NTFRQMF!))MFPQ3+$J,X)&!G .=PHI.
M2H)/>FE8AU"C% '+QV=U"]YLN6N(+UM[Q7;&00L3^]\D98@;?]6,Y!Z9(K22
MSBW6XB B6WBEC!'RRAFRBR +\A*C)!;YLX/L-3,789 QR =H^IZ"G!(V&0HQ
MS^AQ0!B16%Q!')$EY-,+AQ)++<,6ER0 5# X"] H X P.U7EM9DEB*^0%0!6
MD"L)F7.2,C YYSG.3W .!>\M/[HI] &3/IBS3,Q;Y)@?.8LQD("X"+V",?O
M8.,X.3FJD>ESL$25X8X;<?NX;?S41R&8;I6X9OE R.<G!&,9/0D@#)( ]3P*
M* ,C[)-%;SQ6LB"1SB)W#GRTP5QSN/)./O8"GZFA;=[6*,G,TQ3RW)YB8C&X
MLN.!GA>"3SDX QKTUG51GD\X.T;B#Z8&3]: ,*!)(KB6X,>UI#L(A4!?+!!C
M4@@892&)P#C/!YX;+8BXE9I8$\J>W,4C[G68Y!#. OR^8<$@G#>AYK:\P?\
M/,_D/\*>';'^K;VZ=.U '/"PF2.UCD9)#9.HAFR_G&'!4*_]Y\9 +,<,21@=
M76EI)9V[6JO',@FFN$>9F\Q99)6D3AL\(",\]<\BMY@9!M*D#EN3U*] <>N>
M.>V><$5'Y&?X4'UR<_EB@#*%E>&2,I>-]D(8W,.6+%\980R9^X3VX.23DC.)
MA92)CRE@3+$O&-YB,6,;B.,38P<XY8L3G(-:J+L4+D8&>>A))R._IG/4^]/H
M RS8!'(B5%@EE,\X!;S#)MQE/8C@9Y &,>JM9F=/*G"NL+>9;C<X8%2&3S6S
MR5Z=".>,8K3HH R19.95O9A&UY&/+4J6$9B!.00#C=MW#)W8^N,48;3S+E;V
M9WDFCED=$R=@@F&U4QT9UQEOE&0._2NC;.#CK@^U5([<KD$ $G&[.>,8SCUY
M( [#% %4:=%,3)?6]M-,6(#JLF!$.(U[8*CL,@=CBBM:B@#^=G]L[_@F9X!_
M:/\ VM?&/Q&D_:,\*:?\1O'GAO1-)TGX.ZI>0I-)HNCZJE_>2:C8*3<2VGDQ
MRM,=N,*6!SACP-I_P2<\">+)?BG>?L[_ !P^&NL>,(=<\-/)I>B6\6H^%_"6
MH:)>67]KVGV:,7%O97IBMW!9F#;G"A4D.!\%?\%0_A=^T58_\%4O$W[3?P+\
M.?$#Q'J'PO\ A':V,MCX=AU*71M5@U^]ET:0PI;&2W:[AAG<2MLW*B^8IP3G
MXV^$EI^W-^Q9\*_CMX?^%>C>//"MG\5_&_\ PE7Q;\3ZG'J=YKGA-M5GAO9A
MH<+ S2IF8)LB9%P"@([.[[O[W_F%EV7W+_(_:G3O^"#UW!\9/'WBW4_'ECK?
M@WXDVMUK>K7UT)Q>:=XQUBW6*XN=)("/%:)/)(X1!Y(C*!1D8KIOBI_P09T/
MQW^Q]X%_9W\+>--+\"?%GP5\5X_&,GQCT.SN+3Q/>>&-0O[:;5=';4 &>YMK
MBU26.="I+*Q4,I//YY_&O]H?_@HEX$^"W[,OC74OB!\0+G1Y_$%I(D.DZ3JO
MV[Q5X,,<36L^M6$>7M)I0094GR(LAL@*#6IX$_;$_P""GOQ!_:F\/:GKVG^,
M?"D=C&Z>#OA9;6&HW>D^*/!Z*YL]>U#4E1+>&ZD7S)3;2QLVY"&8F1L%WW?W
MO_,$[;:>FGY6/OCQ;_P0HT]OVA_#/Q'\(>,H+CP9?>%_">A>+;#4;>XD">)?
M ]DMI::VD3 R*-0N(0\YB8*[,=V017<>(/\ @D'\.O!'P _:F\+>/?B9X.\.
M^*OVA/%_A[Q#IGQ3U.!;0>&[_P /_:(])TRR:\W")KI9MJQ11L[$'J<BOR\N
M?CU_P6 ^'1M_C;X=USQI\0=:\>^-?BIX4O\ X,WFBZI%IWA71[.^>#3-3L9)
M0T+SPV\8G298B\;;"#\U<KX^UKXZ_M&_LF>(?",?C?X[_$?QOXE\>Z/=^,O"
M^MZ;KUM-\,-;TYY([H:%)-(S7-G#<O)\\2QI*L(/WB&!=]W][_S'=]W][_S/
MT \+?\$+?%>@_%_PG\7=>^)GA[Q:;C1M*C\5HMA.S6UGIEA_9UOJN@PH@$=Z
MT,YNFDB5@[$81RI CT[_ ((+>-[SX@ZMX<\0_%/3M5^#=K=:OXM\(>(7M6B\
M76VM:PMUY6FR21QQ7"V\'VPJYD:1#'%DEB4KX0\;_M8?M_\ [$GPR\6^+?'/
MQ0\0>([3X$_\(?X2\-7GB&>]27Q@GBF*RM(-)2&Y+_;KVP-[&%B&]U90%(P"
M>@^(_C#_ (*PW-YJNK>'/BK\1]%?2O"OA/X@:)HT%EK#:=JL'C6VTS4Y/L6Q
MRDZZ?::NZ, BE3!Y8P54 N^[^]_YBWWU]=?S/T"^(O\ P1+\?7_[/OP4_9Y^
M&'Q!\)^#O"7A4:Q<?%&%],_?^,+[4YY#!J%]<RQRRS7ZQR.ZNMPA+NQ8945[
ME^P/_P $U]!_8E^,,S:A\;](\5^*O''P7'P]U'P1(XA\21:0EW>3Q^((TE(F
M:R1YA"'\O!$8 =R"%_(GQ9^T_P#\%"OA+\.OBM\%O'6L_%'Q7J^N^-+36/A]
M\9;+2M6DNHKF;0?MLNAW\/,UGI\5W.T*R/(T3",MM++Q[5_P3-\1?M-?&+]N
M+X0?%;]H;PYX[EUB;X/W?@75]?O[?4+;3XA81ZA/:DRS (\<A=-TS ,'8(I)
M!R7?=_>_\P)1_P $P)M ^,WQ#^!?BW_@H/\ #1?V7O'_ ,9+KXP>(?@=97EE
M'K::S<7Z7L7AR_E*&8W'FO,(XX[Q)!Y@.%;@>V?%K_@A!J?BO2/'#_#3Q[H]
MMIVN^(KC6O!>G^(K6ZO+_P /Z;.P:QO]*E!W6T\(*S0-(78L$8C*@U^!/QK^
M%?C=_P!L;]J^\MO _P 4;[QSHO[36F:EX#M=.TS5I[74;*/7+=UMEU:-FBBL
MY4<B4B/;R%*<D#]%]5_:[_X*7Z-\;M?&GP^/;3XN^'],U&(? A]*U._\.6O@
M9+.)-%U*'Q$I%K+?LD;-);BW\Q<\GY^2[[O[W_F!^A7A/_@C-\<?A%\0/!WB
M?X=_%#0-?M?$]EX0MOCM?^-(SJ>J:TOA3<UD/#,MQ&SZ9P$\_P DQ^8%(! -
M?8O[;_\ P3*\'_ME?%W]FKQ[X\UR&[^'7P7TJ[\-:SX89IUDOY;N.6'[5%<Q
M&-HELV##)E"IQ]X?,OX?>#?CY_P53^%[:-\4O[5\;_$;4?C1X(^(A'PAUVRU
M0V/@W7=&LI&T(V5[/YD6GI<R@,76-<[0  I(K[8_X([_ !?_ &U/B%K_ ,97
M_:"\1ZWXD^'Z^"-4O=4\+:UI=W97O@_QK)"@NM/TB_NMR7\$,[W%O'=0A0ZN
M77 )!0'B?B__ ((S_"N_T2^UCPU^UQ\/_$,'P9^*$FH>.+?6M7@O/"'@?P;>
M7_VNWT:98W^SPZE;V:B"X:1B[R0CY]P(KF)?^"0WQP^*/[17BZR^#VH^ XOV
M3_'WA/2],D^,$-RM](+-#%>7G_"&H&>>%Y9XU*3VP) <GS0K,!^0H_9G_:ST
MSP9^UM\#? _A+XK0_"G]K#XA>+M;US5[V?6+C5K6VL]9NPK6=P6\R.W>*3S+
M=8W 8%& *E:^[_$WQ^_:Z^!_P&_9-^"GP+T_XP>%K_X/Z+;:=?QSVFJG3O&>
ME6=Y%#=PZJX)42N(FV&5Y#M8$%1A0 ?=_B+_ (-_OB+XG^*6D:A>?'.6X\#>
M%=1MKGPOK%[+.WB06<6AG3_L(D3,ZVSRDD([CY4C?'RH]?8_[+/_  1ST[X#
M?'3X??%OQEK6B?$2T^''A9K+0[+4;6:YO+?6C?//'<PF0K&9X (YXY61DW!0
MP8* /RB\0?&#_@I[\0?A9\:?C\OQ \:^%M0L/&_A/P!\/_ L&GZIY&GZ7J4=
MI!J&M+$C*B-#.)7^2,@_-D@4?&#XO?\ !3/X0?'?PQ\$=>^*7Q3UWQG=^'O"
M-S\,;G1=-UJ7P_XQ@URXLXKV^U_5(G,&DW%HL[0O%<AG_<N<+Y;"@#](OVR_
M^"/OQ7_:!_:F\;?&?PO\3?#D?@OXV:-X=\)?$C0=7TLG5-"T?0+Z*\M[OP]>
MF/?!='RE"M"0.<."J@-\P?LP?\$\[CX8_P#!3#QQ^T7\4])C^'W[(_[,'PYT
MOP/X%O?%.I_9-$\8^/K1+6VN_&U];W#$7EV\D,UR)ANBP"&0=_DCXI_MV?\
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MAI/Q7^#7[*TFK7VI:EXBTJV\8OXIE,K2R>&[:0171OIV):WN6$3!K:1B1N;
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MT!/^SUX:GU?Q5=^$/"?Q:TG59]7EMKVVF\<>')$ADNK'582^ZWC2900)FEX
M#)M8[@#^@Z&ZCU&".?34D:*1-T$D1 MKA)!E'8?QA@PP<[,$X[&L+4/$_A[2
M]1M] UGQ+H5E=ZD$M['2FECAOY]0)#A?ODD,"%53C/0'@9_+?]JS]IGXB?#S
MX^_#/X9_"E?$":='?Z)9:CI@TZX@T_RWGACF0WBMY3*$5B3MP0<$<5#^W?XC
M\&:K\3OA#\/K"P\3Z+\6=2N_#_B>Y\7:3;W!TO3["00K+;3W4,B 3 L9&1L
MJ Q&,F@#]3(/&/A62^G\/-K.GWOB.QN?]+TBWF5[BPE8[3 47[C1#)1<Y5R
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M< "OPS\3_M(?'_P_\.OA1H'A/Q/XE\:+X_M9=4\8^+[RQO+.\\+>()KN)O\
MA&U1C*\UK8N%MUE#1H0SA5 &1W.GZ3X]_P"&L? 5[XJ?Q#J;ZM_85_K M$N9
M],N4CTN%52216:-'DRQD+J2"K(02^5 /V5DUHZ=#'=ZQJ-MI*H@M5GOYTAMK
MZ<R!@;8/Q+(P^4!,G:5QD9K2NM0N(C.4M)K@"W@N0L+CS)$FD1"4 /R 9=CT
M8 9Y Q7X(?M<?$SXO>-_C%KFAW%[XITNP\!^*;34O!G@W2;.Z%GJL-G*KQF\
MNH76!1*T"H1(C#:6W#"D+VN@?M _M!>(IO&%KH>MZXWC#6='34=9L;VTN;>Q
M^'HLK=432;&Y>3;=[E@65'C$89W*LN&8$ _</SW$%Q\L^81O9%.;B)U4.B'!
MR=[$*0 200#P3BF-8N+9;)[U))/MREYE@A<M91D95IMN=FT9#,P &#G)R:_!
MB_\ VL/VH?&.K_#70?#-KXAT">-['1]3\476G7L5EXEUFVN%COHYFP%$)4';
M.Y<,H+?=49^J_P!M?XR?M-?"*Z^'0^&]O'K5Q\0M .C7BV=D\UO'KMM;*UPK
MO%Y@MU=Y@0^!G>V3@9H _4@R:J5MEC:.XCFD)DN44(R6S@^7M5@H+D %F*GI
MP 3DR23NK3V[+,L,9CC^T!\2J9>/-)/S!=PX.&P..AY_GZ\3?MH_M$7/PGT7
MQ'<V?BC0/$:>(;#P?8:59:7>%=1U70KJ.+59K@H4^SVCF1I(KAU9943*@A2*
M^N_V<OC]\5O$?[0UGX0^)@U6VC\5^#K>_AL([>:?28VBLUEDEGO=_DV\NX8
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MCW]KS6/AUXE\3-XLU:+6G\9_8["W2PNW,>A)9)/D2=8S#)YB&-5PQ16!P3D
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M+7@3X:>!O!=I/XB\)^&K^[\)Z;K7CP6=S/?1&&9@?.A1DE*SA DLADP-X)#
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M-:*W4HA\\&06J++</<3 PQQI]XK(D@5E$84DX^7!YP.O\^?P3^+W[4&C^*?
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M<$D[LCCC@[@00<8JO=K;W!MFDW3- ZW5K#;R! CQA<"1D8[P,@[7P"5;/'-
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M_P +_#[Q#X1M-?UWPZ/%D>IZK=:E>Z\NF:6]G>7MK=74SRVD-U<*)@L+H%7
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M?VCM _9A^+.B>('U'PWXNU&26;PO#<W!NI;OSGF:;3(FF=VB;)")("&W$$'
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MEB;PG+XML58ZG</+9R7UM;R;@S2?,98U*NHPX PIXP:X+P]\5?A/XQ\::_\
M#OPU/I&LZWX<LY1X@NHD@FMM/2-&+-*Z%E15?DY;"G 85^6=]^RC^T+I5UJO
MCCP=>Z\/'6KV[+XMN)M<N+FVU6SC&!#:V$S&"U9T50#"%.!DCDX[C]AKX&>-
MO!WB/X[:UXF\(ZCX5T[Q]X5N],OM0O=1FNM3U/76%PTKZ:TDDDT )$C%(2%!
MQ@X(P ?I,=?\!:0FE>'M/@\/75KXA:>UU.6QEMDMI20J2++)&"&#;B&7.1D
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M*AB^ULJ;]K, 4\P%<D =>!B0^'? 5KIVI:.R^%;OPY<W,D^IVTES9LVG;PI
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M$D\ID<A7GCCE_P!2G5U"%0"N N.#]V)#&%C5<XB7RQN.YL!0N&/<@=>HSZT
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M?M(Z_HTIL=(N)]2N=3<V^P01R.VYIMACD!;;ELJ3G)P: /HCP7H'Q_:S\;>
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MM@K65F!(P2!1&RQH@Q@8],@'W)XQ_:D^$?A3X7_$3XI6&OW?C3PK\'4DNO$
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MUK<?$[Q;XJU32=;\2ZKXQTCQ'IOA^:..72Y);2!%DOK:-BRBZ8J\H<?/YH#
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M>M(T:R/-:1YAA>175C'<$!2C,00<<G->H?LZ_LP^//#-C\;D^)-AI6GM\2O
M=QX6BL]/CCC_ +5,-I=0BXNU',CL)B290<[R. 2* /1K/]NSX':KK'P]TR]U
ME+/PQ\3;2Z;PUXPN";>VU76=.,AD2VDSN>)I(66/=Y> %   &?I4?%CX>3^+
M$\ CQWHL'BW5=/L+[3=.DNHVNM1M!"K2/;1Y_>@;UW#(.YCRV0*_.OPG^PGK
M^K^%/"'A7QWIFDQV_@^UUR'PM>0".--%CN_,^QR0*"!#.P?+.FUOF//.!C_#
M?]@?QGX*^./A_P >>(->O-=BT"2)K#5'N?-80LRLMH7\PG;L&" %#'/RKC
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ME:'>>*-1%UXAO=3>*6]$,<ZA1$6D4[A'@*#U9%)R-PH ^RK']K7X0:_XWO\
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M^1_PK;PB"0"/#>G(>>C$,NT^A!X(ZCJ>#0!ZS5>X5G"JKLA)(W+CCC.3D$]
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M_P""=FF>/?'?@?Q%J?Q!UYO#/AI;4?\ "%H=MC'>0V;01W.Q)%BVQ.0S#!Z
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M^(/^"=6AZ]XPN9CXVUFQ^&T>GSRV'@J!8UQK-Y:+!->%P$ /FF24X.[)&""
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MESJMD-,\<:E9>'DQ%JGAAH(2KP7#+)(3)@JZE@& ;D,BD@E15GQM^PEINO\
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MJ/LUO_SR3\J /CC_ (4=\;>?^+Q:ASZ-C^1'_P"OFD_X4;\;/^BQZC_WV?\
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M_P"^G_PH\D?\\X_^^G_PH ^//^%+?&W_ *++>_\ ?8_^*H_X4M\;?^BRWO\
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MQCZG-/484 ]@!^0H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0<T :U%11#Y%;/!4\=N23]<CI4M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4UG"XSGGI@9Z8_Q%5O.?T;'4G:,?S[=2<^V,TY
M)@V0PSGH"!DXYSCN.XQGH?;(!+YJ^C?]\FG@AAD=#^'3@_K4/F0J>5"GJ,J
M?J/\]J>)5/0,>G1<\'D'C/6@![$*,GH,=.>IQ3/-7T8?\!-(94P=P..^Y>.#
MCG/O_D&FB2'J /8A10!()$8X!Y],$=/J!2AE/ .>_P#+_$?G5>22%-C%B [<
M!?7&<_[/KP1G/>C]W%(F2096RH/KM;Y>N,X)/'&!0!:IAD56"'J>?P)P/U_J
M>U/JO-Y0.Z0C@  =^"Q_7M[T 2NX3&<\\#'/<#U]QTS3ZK%X)/FW#('!X)X)
M/'7!_(]#Z5+Y@(!VO@@$' P0>G?C/OC\^* )**8KABP (VXZX[Y]"?2GT 1F
M102,-P2. >W%.5PV<9XZY&.N?\#41EAR<A<Y.3A3SGU[YZ_SIK3*!A.!GL!T
M')XZ8SU]>G>@"S3#(JG!SGV!/;./RYJ#SGZ_-CUV#'/3^+OQ^>#S3EEC*KOY
M[_,%]>#UQG'X_2@"02*3CD9]0:<77!P1T[YQ^/'2H=\+_*N%)Z$ 9&.3@CV&
M..M1LT2=93P,C)&#UXZCN.?K0!860,VWG.!R!\I)!/![XVG/'\Z5W"$ YR2.
M@)ZYQT]<'UQWJ"*XB/RH2[GD[0"Q]\9/RKG&3P./6G23Q(0'Q@D!2<;23TY/
M'K@C.>U $GF+Z-_WR:<K!AD9X..1CT/]:BWQ=-HSTQM7OTYZ<Y&.>]2H5(.T
M;1GTQS@<XH =1110 4444I.R;[?\#_,"/S!DC))!...F#C&<_P#U^_>FF=0<
M=_R/]>G?GM^%1LP+,N1NRP&?<D#Z]!D"J]P62%C&4WA6.7)VA<?/CCTYXYQS
MTYK*C45Y.J]$Y:I6:U_%6^>AC)U:DE&C9.]OYKN]K6T6O>^EK%G[2I.U1N)R
M!CL1GKZ X_3W%59+@^8WELH. 2F?WG"C.1R/[OIVSZU\8?M/_MK_  1_91T:
MSU+XF:N;22[E1%5'42-EQOQOR<* 3@ +T! X%=5^SA^U?\*_VHO"UMXN^&=X
M]WI6H0,]I=2;?,<(!OR5X4J3G.X@@'(X&*6(P\YNE3E>:5]^FGFST(99F,*/
MMZ])\E[*27*KVZK6]^WS9]4":1=K2L4C/!#%<L<$X4=^,]\^E6_.BV@[A@]!
MC^A';^E9<:AXH_/<RRQL0O#?+\K##$<'&T9;.!4XDR,!$XXP<=AGH2.W3^M:
M'(WRSY9JRZ]2P+N-B@0,P=MH.WCJ1Z\<CN/P&>)$G5Y&C 8,O7(XQV.<]#QC
M _\ K>/?&[QU-\,O .I>*K:,.UI);1,%^ZIFF6/D=?XEYX' SCBNS\&ZW)XB
MT+1=?D1EDU/1[6\9#@8$Q;TP <+N/; (ZXH&=CYB?WA^M!D3L2?H"<?6HOW1
MY#8'7[Q&/PP1Q]:-\"_Q!L^I#8_/IG]<4 2>:O\ M#_@)_.I*@$L(/R@9/'R
M@ _TZG ^N*F!R,X(^HP?R-  Q"C)Z#'3GJ<4SS5]&_[Y-*[A ">F0/Y^OTJ+
MS8/1?^^5H G!R 1T(!_.EJ,2+M!"MC Z*<8]CTP/;\*/-7T;_ODT 245&95'
M7(/H1R. >?SIOGQY"E@"><$@<>O7TYQUZ"@!X=#@!ASP/?G'\Z?54(K2*\;<
M9&0">0#C'0C'!.,_3GI:H 8SJIP<YQG@9]?\#2>:OHW_ 'R:)'C7 ?!SSR >
MGU[\U'YL(Y4#/;  /IUH L @@$=",CZ&BCKTJ&67R\=>W/'?(Q^F<^V.] $U
M%4S<'D!N>> G?\S5CS4XYSD C'/7H.WZX]: '.X09.<9 X&?\_KWXI-YV;PI
M.2>!P=N3@X//0#/UJ)YH\ D,<,N,#OGC_/<=/9WGH0>&P!DDJ=N.AR>0/Q_Q
MP 1R!Y5.V-&4GC<<'(X]N#R0?0CM@U$MNH&YHXP<DY#<#MD9SSQSUJQ'(NT!
M0Q&>,8;J<YR.,<@@\Y!'O3F=2"'#*.I)X  YSD$@<@"@"MY</_/*'\S2B&,\
MB"(@=<?Y_P#U]JES#_ST_P#'S2&:*,XSG< <[LG'8<_H/?UXH @ M\X:W4'(
M'\..<<]3D<]1D8J7[.G_ #[Q5+OC?YL<CNXV]#ZGCU(]<'T.'":,C.]<>N3M
MZX^\0!UXH @^SI_S[Q4?9T_Y]XJF\^/C#!LY^Z0< #.>.QXQZY&*<),C(5B.
MQP,']<]>.E %7RHLD>3%QUZ_YQ1Y,7_/"+]?\*F:6+^(=,@;@.3WVYZX(P<=
M#UI/-@XX7DXZ+Z$]\9Z'@9/H* (3%$!GR8N/K3Q;QGD015)YD0/0!A_L@'I[
M<\C].M.\U!USZCCJ* (#!&.3!"!W]<>W^33?+@[10_G5DRHW'.T@AB> !CO]
M:9F'_GIS_OG\: (Q!&1D01$'O2_9T_Y]XJ5I=G R%QG[I8'DY.3@_P!/UH6?
M+ 9+<X(">O'7/;K^% "?9T_Y]XJ0PPK]Z&(>G/?CK5@R <E6 ]2/_KY_,4TO
M&V-Q*^A)QD=^?KV]LT 5_+A_YY0_F:40Q8'[B+\C4O[K#$,Q"C)(8D=^,] >
M.A/>CS8/1?\ OD4 1>5#R?)BX_#KZCKZ\=<TGE0G_EC#^=2MLD VE5"DG.0H
MR0<<C)R!G(QW%,\H'(# Y!Y\PD?R&<=2/04 +]G3_GA%2&",#)@B '>K <#Y
M0"Q4 ':!@<>Y'^12&2,@JQ*^N>,$'IGUR* *WEP_\\H?S-'EP_\ /*'\S4V8
M>SD\@?>/4]/\^QH/E \N1Z98C/T]: (?+A_YY0_F:/+A_P">4/YFI_W(ZN1_
MP(TG[G_GI_X_0!&((V&1!$1TI?LZ?\^\53J54$*'(SR<,>>!Z?3VI?,!.-KY
MXSQTSTSS_G!S0!7^SI_S[Q4QHHTZV\9^@)[9ZY[=^_Y&KU5IWPT:X)W[AGL,
MX )X/OV_/I0!&(8S@_9X^>F>/YGD]CCOZY%'D)_S[)^7_P!>FW+R*F]I4B &
M<MP< @@\_*N,\Y.??@8DCNHRJC>')7.X$8([GC@#/ YY]: ()(H>/W00$@#
M)YQT8<8!.>?;KZ30Q1-R%X3 &>,\'GJ<C!XY]0<XJPVPC+!2.V>_'3\\^WK3
M3*B#@849&>V0<'&,Y]<T 2@   = ,4M,#@H' )! ( Y."<9_+FHGF*@G  R
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MP3TOP+_X*7_"GXQ:3=ZAKL-[\/9UM]?N_#J:W$;2Q\3P^&;?[3J,=A-<JGG
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M_!JZ\8:A9W7B2Q>PU;Q.@83:AHMQ\MW;P31C"S-$=J'(*OP#O.!\[)_P3Z\
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MZY>^!==\/ZTUSI^O:9M.JVNG/!':7]CJ+-YJEKN 3%C\V3.<,#N%6](_8/\
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M:>&6QM8H(ETXHR_9V0CG<RX; V@$%F(4<],:KWMNTLZ^8";,"2YW!E,:G;R
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M0 ?GKXG_ &\/%=RKV'Q+\(OX6M9+N"]T2VT25YY+EK=0ICN[B$8*2-S@L H
M'/.WNM'_ &T?&&H_#3Q?\5KR/P=X.T+P_:BVT#0WNHCJNO2P<LDH+ J\\49
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M%\(;KPWK_A*VT&WA_P"$@BF%P\0P%DE\P!HB2<%6)P.N,'.<X\&_9L_8CB^
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MK:.\L(;Z[@^QM/;^863>K+D!>!R1DC H^#O^";7[._A7QA>>+M4M]>\175Q
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MBC2? [WSIH=GJ9D"+J:VY8Q&>%PT@=8E/S#:Q)KWWQ]^SS\,_BYXRF\9^)]
MFA\16'AV[\,ZAJ,T(!O-*O(6B6&*5B2ZH@<$\@G!/!H _)G1/^"J?Q+\(^%M
M:U[XM?#:UTRQ\4:)!JOPK&E)'<3Q7.IHWG+J"0DD)#(IVL^0H7*[B<MJ6?\
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M@# RI' Z5I;1NW8Y/?)]ATZ=A5:U9WC5I $D;YF3C<N %*D^@('/<C'05:H
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MSXO[U %'^S\DY"D=L]O7ICVZY]L=*8^G,"-A Y&2/3GCD?3KGH*U=Z'^-?\
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M@$XQ\RDY(R"3D8QD8]S["75?,+.0 QW-D[@>@W' !&>1C&>.*O></3_QY?\
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M))-/DA2REDV1AFM%*1,9'=4(\LL S8!+GKG% 'XR_%__ (*7_%BW^%G@G4/
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M8D,#P>F??C&.>IY[UPOAVT;3-,\.17VI)?3:9HEII%RR$,7NH(HX7<@="=C
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MIXZ^/>F?M0W7CT^+;W2-9GU?P//IS6$EA!J,\!AFM-4DAB<F-%Q^[++*-Q+
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M;BSMP;A'\E8)6BE4&X+.5:.0"3)*A0"*T]0'PG\4VUSX>UJ'P;J(\6PQ7_\
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M"[><$9%:-]H4%X+--1M+*[BCE286\\22PVCQY,8LHI T896&X;@6!52K @4
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M%2?MW^$K/3M/^)>JQ1-H&J^#=5\21^&[%TN+U[W2YEMXK<!EW+.,@#:N<KL
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M8?\ #&O?#\Z1X/U"?0?$36^JZ%:^(;E@)[+2->OQ=W[;XE'S<#RR"!AN>HP
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M4^(O"WA"TT/4K+4;Z\GL-<U9HTBL_"^K):237-J2H D$)W @<$IG@D&N/O\
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M%!' (K:;_P %*?@L;#Q9<1Z%JVG:9HNIQ:=X1<Q*P\<WZ1R,;:&8H K"01Q
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MO%/@OXL_$OPE\4O!GP3UCQQ\-O#]KX?M;R]MM;UB[2QDBU)# DL<DT<\Z_.
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MK]-+;]D']G.PTV^TK3OAOX>MEUY;DJ([(*UM)=EI+BXC< 21O*S,S%&4$\
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M"VM=#N4O?#<S6T;OH-Q;OYXEM9V7S\[B1MEE< #A1MP #\8?BCX\_:H\4_%
M^(T\6R>$_#D7CVTTVZT.UN$C>2.66,M"(D1"<D$!>,ABH( X^RO"?[57C"\\
M2:3\(_!2VVF7KW'BW^T]6\7-'#;7;:3;1-(;26YX:2,$NRQ\_P!\'?S]]?\
M"C/A6[[]2\+Z;K%]]MBU,WEW;%Y6U-.8KUL\&=&("MUX8<\XR/$O[._PC\4W
MNG7&K>";.YU'2;F]O['4(H1#+;RZH4.H-$\2HY:\$>)RY8NJ@<CB@#\T(/V_
M/$_A?7]$\!Z!X5/B/5[S6]03Q;<7ZA].NK*R8_:%TN5\PO(, Q;"V0  !NR-
MFY_;F_:$OK'Q+J.F>!-+TN*YCU.R\(7%X+>..V\F4QPEG< ,R!4Y<D$@\ <#
M]%)_V8O@I/\ V)-:>!=.LYO#=RUW83);H&BD?+7&YRH=S< D298[S@X)4&ND
MU7X'?"W5=-&G7/@_29K&-Y;B*U-K^Z229BTK+L (+G.X=N<9YR ?$>E_M*?%
M7PI^Q[X-^(GC>/2+CXM>*=2N="TG5+!X)-)LKV>Y2.V?5YT @0D2,7\W8JC&
M& ''BFL_\% _C-96]MX%\.^"],\3>/O#L46I_$37$6&70Y+!]MP_]DS*&@>X
MB@8'"X(92P4!6K]-E^ 7PNN_ 5[\,)_".EOX0O+TW\6B20.UA#=$)NGB5R6A
MD=E)+(1N;#8! JMX<_9M^#_ANP;1-.\$:';HT;023160:1H&4AHI)V#221L"
M%9'<@\9Z8H ^7_BO^UAK_A[X+?#OQ)X,TFWC^('Q6T\KI.HZHL*:&TR1;+AK
MV:0^0&6YD#(#AE5"N,G!^$8_CG\:K_X4:9X6L/$5Q'\3=1^(<^G^(];MI8VT
MQ+&ZV(MG82H)$\N$N754VG'#+@@G]GO$OP*^&OC+PGI7P]UCPOI=WX9T!S)H
M>EW%OFVTMR6)>Q 7?&W+?.&!P=O0"ET3]GSX4>'M'L/#VF^!?#[0:==_;H6>
MT#&"Y*A?M,;LA?S<KC)8GCJ,# !^2?P4^.7Q+^ GQ-\0R_%O5FUK2;[3[_2X
M-3NYP\=NFFV@N;27>V H>0$9Q\PX/ Y]\@_;<\0^(O&-EX9UE-.\/>!/$O@?
M4=3TWQ!9/$)[ZY6U!40R!R6F=2N53[I/  Q7V_XQ_9W^#_BRUDM?$O@S2[^"
M5'62)K8L#N78RDJH+!ERK $?(.<@D#('[+/P(6#P_&/A_H4EGX;M1!H\;VNX
M:?"55'C@W<J'0?,K$X&." , 'YZ^$OV^/%K2Z/+X=\-VB>!_!5_#H'B32=5"
M)XD\22ZHQ2UU2SA=_.DBM\;BZD A6P0 :];^$?[7_P 4/%OQDL='\4^$+6R^
M%?B&]O;+1+R.)1J4%]&76-I=BAS&#&VX,2=I5@>I/UG/^S3\$KGQ;:>+?^%?
MZ"VJ6-KY%O=I:*LB(N5@PD:B%O+W\.ZE@H//4GMK+X4> --O+?4-/\,V5G>V
M4KS6EW!;*);663=ODA^0HK/N8$@#@E<XXH _&>P_:N^*_P ,?VAOVDM$^('C
M>ZO?!OBM-7\+_!"UAM_/AT+Q+,UX+&*)Q&P>8D197?*054X!(-?/.N_'W]J2
M'X4?!_0(OB3J>O\ C?4+;5M5\4SQ6I5M/-OXB(@2YE6!!"!8QNIWD>A'R\_O
MS>_L_?"#4[R"YU+P#H5Y/9ZN/$=K/=:?'-)!KY=F.K1,R$BY/F,0V=H!. ,+
MC9M/@;\)[..[DA\":$C7D<D5VRZ?&#<0RES*K,8R5$A=BVPJ<L>AH ^+/V,?
MC/XH\<^+_B5?^/O%,5W9P:?IFG:9%<3QA#>QQ6D$Q3!'SLZ.2 V>< < 5^F4
M22SF7>BH(W"PE,%9(6571\ EL$C.6Y)8^IKQ/1?V??A7H$TEQX>\(Z7H:SSK
M=SQ6%N\*S7 .Y9G"\&1#T)'!&5]O<=,1(X"B/))L8*3("" HPJC/8+@ 9.!0
M "T;=G@C/0YQCTZ#''3G&<#D59,!ST0_4MG_ #_^NK-% %;R6'0(/Q:BK-%
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M;R\$[-QP20/^F@ P?8'&!D#(+/\ AE3X@L'C7XV^*O+DV'&XX1U.0^=V<':
M.<]^@((!R&M?"/\ :;T=M6\01>.5O+]FM[:U&[S(HK9I%21H8O,_=2!0O[Q
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M_P#AE?XHMR?CEXAZ>K?T./\ /UH'[*?Q(V+O^-_B,O@;L,_7'LW3&.I)YZ]
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M?Q&_Z+=XE_.7_P"+H_X93^(W_1;O$OYR_P#Q= 'W1YC^D7_?S_ZU'F/Z1?\
M?S_ZU?"__#*?Q&_Z+=XE_.7_ .+H_P"&4_B-_P!%N\2_G+_\70!Z9^UR99O@
MEXFB\F*4M)I[0J+C8YE2XR"%QEE #%L#D#@UZ9\)+B9OA[X5:5!;9T&Q+G)<
MFX((; ]P$4#/ ([DBOEO4OV1?%&KVMMI6O\ Q2U[7;.6ZCEN$FE956*-B0I4
MGD+NSCDD@#DC%?9OA[P[9>&]'TWP[ \\T&GVL<*SR G<8MK(6." 3M+'@\X!
MYY(!UHSCGVY]>!SCMSGBEI  !Q[<^O &?R I: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M K8'H/R%21]6^B_S:BB@"6JQ RW ^\W;_:-%% #T^_\ \!/\UJ:BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *;?\?B_]<Q_Z$:FE[?[K_\ LM%% $U%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>forms-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *B Z4# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !11368*,L0![T +152748(L
MX.X^U4)=8=ON+MH VNG6F-+&O5P*YU[V=^KFH3(YZL: .A:_MP<;LU&=4@'3
M)K HH W/[5A]#BC^U8?0UB!2>@-/6"0]%- &TFI0/ZBGB]@;^,#ZUBBTF(SL
M-.%E/Z&@#<$T;='!I00>AK%6RN ,\BG+%=Q],TQ&SFDSS68LMVO4<5+'>.3\
MZ8Q0!/J5XEG9F5CC%>=76H?:-7$N[;;RG;O!XKL=>N?,TYS&F\@<J:\XNW@@
MB!F1H+=WR">QKCKRUL>Q@()ILW+R.:]WVL[!$A8/!(G4U%%(;C456W=(;H+M
M9G/4>M8$6MSG4TMK>%[E!\IF7D+[UL'3(?,EN[MVFE PFPX..]87N=SARJS$
MM;J6V@F"RB:9)3YS,>2M3^3"\+SK=/Y,K<*A^[58VL=FOG6VE/,I&6W,=Q_"
MHH['4IM-D\I(K6-GW(I/(-*S'IZ'4Z'>M:3F!8]L*]#Z_6NTC/F*&'0UY*FJ
M_P!G[;.]DQ>N?O#I7I>B7#7&GHS>E=5&5]#RL;3Y6I%]^M-S2,?FI,UU'FC\
MTM,!I<T /S2YIE+F@!U+3:6@!U%)2T@"BBB@8M%)2T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E7QG\0:YH=OI9T.X,4T
MDARH&=_M534OBK)/\/(GT_GQ%*IB: ?>1E'S$BK?Q;60ZWX6*1.X%X,[5SCG
MO6Q-\.=&TS6M7\2P1DW$MK)MCQ\JL5.2!0!Q6@>*-2O?@_=ZEJ^L303)=!/M
M$:;F7GIBO0KOQMIGAO2=+2[EGN[FYB4Q)&F9)..N*\?TN&<_ /5$\B7S#?@A
M2O/WO2M?QO=_V9J_A*^@D>WOH;52L@C\SC'3;0!VUA\4H+]M5NQ82Q:7ID9:
MXDD&) ?3;5[2OBCX>U:UN+N%KA+6"+S'FDCPOT!]:\YLY=,F\$>,Y8=1DO-;
MO82]Q&T7ED<]EK:>2ZT;X$6DVFZ5'-<&)0\;19P#U)'>@#J-*^*N@ZIJ-M9^
M5=V_VHX@DGBVI)]#5>SU:-/B5J\3ZM<2"VMO,:S,?R( .H/>O*;VZ74=3\(O
M!/<W;K.AE @*)"?05V\,<H^+7BI_*DVG3CAMO!.WM0!K_P#"[?"[6OVE([UX
ME?9(RPDB/W-=/JGC;1=)T&WUB:<O;W(!@$8RTF>P%>4>%+%/^%%ZZ6LL3NTN
M<Q_,W-9NOZ1?3?#SP+J 2<6EH@\_8I+1\]<4 >Q>'?'VD>([J6TB6>UNHUWF
M&Y38Q7U%9<WQ;\/17TL"I=RPQ2>5)<QQ9C5O<UQ/A6+3=2^($5[8RWVH216Q
M#W$D91<8^[7,ZL;;3Y+^Z\/_ &NSOVNOGTF:(NDASU% 'TK!/'<V\<\3;HY%
M#*?4&L;QC>3Z?X2U*[M7V310LR-Z'%83>.X_#\'AVQU>S>*ZU&-5Q&ORHWI6
MOX[5G\$:JJ*68V[8 ')XH \J\.67C[6?!Z>);+Q.6G 9Q:NGRD#WKN?!/Q%A
MUGP7<:OK&VVDL&,=T>VX=Q7 ^"_B7I?A[X=II'V2]FU4*RK L)P2>G-0+X(U
MV/X-ZB[P.MW=W/VIK<?>V$],4 >G:/\ %'0]7U."Q$=U;/<'$#W$>U9/H:35
M?BEH6DZ[=Z--'=27MLNYHXHMV[Z5Y-9Q:7JMWX>MDN-0O;V&1<0^44$!'O6R
MNN:?X>^.&LW.J0/+"+<+YB1[RAQZ4 >E6/Q%T/4/#%WKL+R_9[3_ %\;+AT/
MN*CT7XE:#KMM<75NTZ6MO'YCSRIM3'IGUKRG2;:YN_#'CO6HK66&QO6S;H4P
M7'KBNFN="N+_ . ,=GIMKLN6@5V15PS8ZT =/IOQ6T'4=1@M?+N[=;AML,\T
M6V.0^QJWK_Q%T?0-4_LUTN+J[";WCMTW%5]37BMO#IFI6&@:>\^HW5[!(H^R
MB$J(&!YYKI?&]KIB^+&ED>]TG4XK8;+J-2Z3X'W30!Z>?'6AKX6/B%[@I9#@
M[AAMWICUJIH/Q%TCQ!J2Z?'%=6T\B;XQ<1[0Z^HKSZRGN-3^#MR?$FBO-$)\
M(($V,5_YZ8JEX-N;RS\=:99Z//+JNF-"=\EQ#A[;C[NXT =WX+UNV6\\2W%Q
MK,US#:S?O!,FU80.P]:DLOB_X:O-1CM?]*BCE?9'<R18C<^QK@+'2;_5?#_Q
M L[..03O<952,;Q[53U76[#7OAUI/A/3=+N!K<<D:LA@*^65/)S0!Z[XA^(F
MB>&M8MM,OC,9[A-\?EIN!%2>%?'VC^+IKBWL?.BN+<_/#.FU@/7%<'J6GR#X
MP^$;>Z@,PALBLC,N5W!:MZ)%]F^.&NS+;LD2VF[*K@-B@#UJBN;\(>,K+QA;
MWDEI%)&;68PR*XP<UTE !1110 44F1G&1FEH *0D 9)P*;+*D*%G.!6'>:B\
MYVIPM %^YU2.+(3YFK)GO99SRQ JO10 445-#;2SL BGZT 0U(D,DA 52:U[
M?2D3!EY/I5Y8TC&%4"@#(BTER 7;%7$TV!!R,U<)I":8B)8(4^Z@IV%'112D
MTA- !FDS2$TTFF I--+4A--)H$.)I, ]0*86I-W-,".[LFN;9A"0LG8UP&N^
M%]8N8C%<JDT!/;C%>D0R -@]ZG<!XV5AG(K.44S:G5<-CRVRCM-,LDM;-%B=
M5PS,>OO213B"[>.TN4>5ADO(>"?05J:YX>N'NGD2'<A.=HXK*U3P[-+;I-/;
ME4C7Y%C."*X90DF>Y3JTVEKN076OWUM+*ETL9;80%C;FJ-AXTTV6Q\N>0QM#
MG*MU8URY\C4;]HVGEB>(X*YY/XU+=>"K*\B\R"9DE'(R<\UG?74Z_9QY=$=+
M9W-OK$2S@(Y+[CG[PKUG1(VATN,,NTXZ5Y3\.?"-Q;WQEOFWJI^7'0U[)\L<
M>!P *[*,;*YXV/JWER+H1D]:0&F%J :Z3RR4&ES4>:<#0,?FG4P&G T@' TM
M-%.S0 M+3:6@!U%)2T@"BBB@8M%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% $4MM!.RF6)'*'*EAG%2$!E*D9!&"#7G_Q/\;:M
MX133(](MX9KB]F\I1*.,GI63IOQ#\3:3XIL]&\8:7# +[B":#IGWH ]/%A:+
M 8!;1"(G)3:,$_2N1\4_#]=<UFUU>RO3:WMLNU-PRF/I6W=>+]!L]0%C/J<"
M7&<;2W0_6KNH:QI^E6?VN]NXH8#T=FX/T]: .6\,?#JVT;5KK5[^<7FH7*['
M;;A-OIBNS6")8?)$:B+&-F.,?2J.G:]I>K6CW5C>130IRS*>GUHAU_2[C2Y=
M2BO(VLXL[Y0>!CK0!833+&-55+2%0IR $'!J3[+!YK2^2GF.,,VWDBJ<GB#2
MHM)&JR7T2V3#(F)P#7'3?$7[1X\TO1]+>WN;"[0EY5Y8&@#O%L[9(&@2"-8F
MZH%X/X4X6T"V_P!G$2"'&-F.,?2LS5?%.B:).D.HZC!!(_16;FL[Q=XZTSPG
MX=&KR,+A'QY21G[^?0T =%;6=M9J1;01Q ]=B@9IKZ=927(N'M86F'1R@S6'
MI?CK0]2\.PZR;M(;=R$;?_"Y_AK5N];TZQ:U6YNDC-T0(03]\GIB@"GJOA>R
MUG6++4+PLYL^8H\\9]:VG1)$*.H93U!'!K)N_%6B6%Q-;W6HP130C,B,V"!4
M4GC/P['IR7[ZM;"V<X5]_4T :$>D:=%()([&W5QR"(QD5=QD8[56CU&SEL!?
M)<Q&U*[O-W?+CZUGZ9XJT/6+E[:PU*">9>J*W/X>M &A#86=O,TL-M%'(W5E
M0 FN7LO <-MXYU+Q'+,)EO4V&!ER!6Q<^+-"M+N:UN-2@CGA.'1FP0:GUK7+
M/0]#GU:[?%O%'OR._IB@"X+6W%O]G$,8AQC9MX_*GQQ)%&(XT54' 4# %>/1
M?$'Q]JEB^NZ9X>A.C+EE5\^8Z#N*[_PIXRL_$WAH:PR-:(F1,LWR[".M &Y'
MI]G#.9X[:))3U<( :6YL;2\V_:;>.7;TWJ#BJ&E^*-%UJ=X-/U"&>5>JJ>:9
M+XMT&"ZEMI=3@6>)]CQEN0WI0!KB*,1>4(U\O&-N.,5%;6%I9EC;6T41;J44
M#-9VI>*M$TB=(+[48897 (4GFL7Q]XQG\->';;4]-$,XFF5-S'*[3WH ZZ*V
M@@9VBB1"YRQ48S3$L+2*X,Z6T2S'JX09K*TKQ;HVJ316D6H0/>M$KM$K<Y(Y
MQ4UWXHT6QO'M+G488KA,;HV;!&>E &DUM \ZSM$AE7A7(Y'XTR2SA<RNL:I+
M(I4R <_G7-:5KNHWOC2\L3/:OIR1!X@@^?GUKK: ,?P[X;LO#=I+!9AB9I#)
M*[=68]ZV*** "BBB@"EJ,;>5YJ$AE]*SX=6E0X?!%;C*&4J>A%<Q=0F&X93T
MSQ0 ^[O'NGY.%["JU%% !2@$G I*OZ=]G#[I3\W84 .L],:0AY.%]*V8XTB4
M*@P*571E^4@BEH *::6DIB$S32:4TTF@ )IA-*33":8 332:":C)IB%+4TFD
M)IA-,0XM32U-+4PM0*Y)OQ]:NK(?)#]:S"U7[1A) 4SS2DM"HO4=]_D\U'=0
M+<6LD1_B&*4':2IXIVX9QFN4[/0\EN?A[?-JTCP':K-G<.M6+/P7JUM? ,Y:
M(GFO4]P!Y(S2,X ]ZAQB]T;1Q%6.S*VD62V=L$ &X#DU8EFRV,\"G$F*W)/4
MU2W5U06AP5)7DV3;J<#4(:AID3J:T,RR&IP-4&O54\"HFOW[5-QV-8&G@UA_
M;I<]:7[=-ZTKC-T4HK#749@>:E357!^910!LTHJA%J4+XW?*:N)*D@RK T 2
M44E+2 6BD%+0,*6DI: "BBB@ HI&944LQ  ZDFHXKJWG)$,\4A'4(X/\J ):
M**:\B1(7D=40<EF. * '44R*:.>,20R+(AZ,IR#3Z "BBB@ HJ"2\M86VRW,
M*-Z,X!J6.6.5=T;JZ^JG(H =1445S!.[I%-'(R'#!6!*_6I: "BBB@ HHIDD
ML<0!D=4!XRQQ0 ^B@'(R** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH \9^/ F,GAQ;9E2Y-XHB9N@;/&:OV?P]\1ZKXDM
MM:\8ZM!.EDI,,5L#@''6O0M8\-Z3K\EL^IV:7#6KB2$MGY6'>M7'&.U 'S1J
M]C#I+:UJMG<66KZ8USF:*5CY\9ST%:7C2\N-5U/P2\2+!ID\09([O(C#?[=>
MO77P]\+WNHM?3:5$9V;<Q!(#'U('%:>J>'=)UG3EL+^RBEMD&%0C&WZ8Z4 >
M1>$]/EL?&VM"/4]/=9+)_,L[(DJ#CKZ5F:'KVE6?P2UVPN+U$NV>51"3\V2W
M%>TZ'X2T/PXDBZ7I\<!DX=NK'\36<_PU\(R7-S</HT!DN01*><-GVH \>UG8
MWA/X>V]\S#2';_2N3M)[9K8\GP_;_''1D\/^4$\GYUB.5SBO6I_".A76A)HL
MVGQ/I\8PD1Z+]#5?3_ ?AK2[RWO+/2XHKBW&(Y 3D4 >3:#!H=]XL\9-XO,;
M72.XA%P2-J=MM9%M:O?? _77FC>:VM;HFS>3)*IGM[5[CK7@;PYXANENM3TR
M*:9?X\E2?KCK6F-%TY=(.E"TB%B4V&$+\I% 'B7BR+34^!^D/IJQ^5Y\3SF(
M]&[DU9\:Z[I>IZMX#M[&]CGE2:(L$/08 YKU.S\$^'K'1;C1X-.C6PN&W20D
MD@G\>E5+3X;^$[$V[6^CPHUM()(FR258=Z .!M]!TS7?CMK,>I6XN(T@&(V)
MV]*P/ ?AG1M1LO&PN[19DM))5@1F.(@ <8KW6#P_I=MK<VL16JK?S+MDF'5A
M4.G^%-%TM+Y+.Q2);XDW &?WA/7- '@QGOO^%"6RQ2R&U^W[+A@22(\]/I6E
MXE@\/V&I>#Y?"!0:HTR!A;L3N3C.[]:]ILO#&C:?HSZ1;6,2V#DEH2,@D]:I
M:/X#\-:%?&]T[2XHKCL^22/IGI0!YIHN@Z;KOQQ\1?VG )_)56",3@-@<UV?
MQ;TJYU'X<WMO8QEFB ;8O]T=JZBU\.Z59:U<ZO;VB)?77^NF'5JTV4,I5@"#
MP0>] 'FGA+XA^&K7X=6TLUY%%):6^R2V;AMP'3'O7*^-O$=UXC^%2:CIVGMI
M]I+=A74+MW+GJ<=J](N?AEX/N]0-]-HL!G+;B1D GZ=*Z.32[&73CI[VL1M"
MNWRMORXH \'L]*DM_%7AF[@U71[67*A8[0DM*OHU:GA'0-,UGXN>+I[^W%Q)
M;S;HE8G ;CFO2])\ ^&=#OOMMAI<4=QV<DMM^F>E:%AX=TK3-3N]1L[1(KN\
M.Z>0=7- 'S_9VMYJ7B[Q0M_+IR3*S+_Q,"053'&VIM8B:W^"D,$^I1WMNEZ
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MM@4 >^5G:UKNG>'[!KW4[E((1T+'DGT%>7^!?%6M1>-/[#GDO-0TV=-T=U-
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M?4].\83:]JNKK?-<0>5*NW'48./:LV;X3:U;)>Z7H_B 6NA7LIDF@*9<9.2
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M8^V7#6SHD,*[8QQZ>M>=^!/"/B+7O"FJ0Z=J[:?:W-Z\<\,L9R5SR1Z5]"$
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M9_#6FZW8Z7=W,-])L"*!N3G&378+(#$KM\NX X/:@!]%)N7&=PQZYH+ #)(
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MND>&7L5E>810,-\ARS<'K61-X#MIO$>CZP;IQ)IL(B1,<,!W-=5/$)[>2(G
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MMK4?O)JW+OX0V[W%PEAK5Y8Z=<OOFM(CPQ[X/:M#7OACINK6NEK;7,UI=:8
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M"MM.T:0/_%CM74^%?'FH:UHFNZ;K!%EK&EHRRRQ]./XJ /4L45P6A^,++1O
M%GJNL:J;H2DA)6^](<]!6QX;\<:3XFGEMK5I([F(;FBE7!QZT =+1CG-<1??
M%/PY8:D]FTTDBQ-LEF1<HA]S6QK7C'1M"TF'4KJY!@N,>3L&3)GTH WZ,5S'
MASQYHWB6>>WMG>*Y@7<\,HPP7UK.D^*WAM-0:V$TCQI)Y;3JN4#>E '<45SW
MB#QGH_ARU@ENYBS7 !ABC&6<>H%/\->+M*\4P2/82GS(CB2)QAD/N* -ZBBB
M@ HHHH **** $P/04N!110 8'I1@>E%% !@>E(:6D- "4E+24Q#3333C3#0
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M.IM.I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0HH \DLOAA?W?PSF\/W\J17JW!G@=>@.<C-2:?X<\>ZOJVDKK=W#9V&F$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^_UK%TOX7>&=*U*.^BMI9)8CF(32%U3Z UT::WI[ZP^DK<J;Y%WM%W ]:T*
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M<U%/C!#JL=LPTZ.Q\E9>P;M7'>*O"GB+5KJ^MYO#L;:A)+FVU.V)4!<_Q8H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHZT (&!Z$&EK&U"*6V??$[;3^E
M5%U"Y5<!Z -+4+\1 QQG+'J?2L0DL<DY-#,68L3DFDH ***DAB\V0)G&>] "
MP6[W$@5!^-;]K9I:H,#+=S3K6WCMXPJ8)[FIS0 E(:6D-,0@%-=N:<3Q49Y-
M #EY/-*.6)]*3HI-(>$^M AI'[HGU-13C:B_2I&R% ]:@NWPN":I;B90DY)-
M5I*G=ACK4#X]:NZ1-F5VZU-NVNK>E-VJ>V33NO48Q1SH7(S=AF0Q E@.*AGN
M(]C -D^U9\$#W'W7Z58DL1%&S%B2!674UZ&!)ITLTK-D $U#)I*+S)<(/QIM
MQ=3%F&\@ ]JS#.DX)282 '!*G.#72E+JSF?+ND6Y;73HP=UP6/H*I/+I\)RB
MNQ'K4#C)KG;K4+NXUG[%8E0D0S*Q_E2J**5I:W.C#4YU)/DLK*[;Z(ZQ-6@/
M'E?B:>;^)^@Q7/O3(WD$BHK<L<#-<%;!-)N+.VCC(MI31T1O$'0&J\MUYG!(
M ]*RYGFCD\MFY'I3H^:QH81U%S-Z&]?%QI/E2NRZ&W8V]*E9XX(7FE8*B#))
MJ*+H*S?%<A71EA!QYT@0UZ?+&A3;CT/-IJ6+Q$82>[+^A:M)J\DSK;F.U4X2
M0_Q5T5M&/.3/K5'3H5M[&")%"JJ#@?2M. ?O$^M7%-1]YW9C6E"55NG&T>AT
MT";0"!4MPV(6X[4Z!<HOTJ&_?";?6N9;FCVN9:(-V?6G,@WU(B]*&'[RMF8H
M6-:LH*B05.G2I9HBS!VJR!\YJK"<&K63N%0RD->%)HRK@'WK%N]/>W^9?F2M
MT=2*,!@589!I#.5I58HP93@BM'4+#R_WL?W>X]*S:0S;L=1$N(Y3ANQ]:TZY
M($@Y'!K<TV]\Y?*<_..GO0!HT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWB2;19$M;N*,_:[F,?*K>OUKRF^>>PT&QU[3YM1,SWBXOY)?EE!/3%>X:/\
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MGXDBTVYTMXGFLI/,^RRM@2CTQWKEM&UC2+KQI8PZ]X<?0=<V^7;RPKM1SZT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ****  @'K1110 4444 %%%% !1110 4444 %%%% !1110!QGCSP;>^)
MA9W>EZI)8:A9-NB93\K>Q%<Y9?#SQ+K/B6QUCQ?JT-P; Y@C@C"Y/OBO5J*
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M,, !"Y;U- $D<GF#.TCZT\T4&F(::8:>:8: (S3&IYIC50B%JA:IFJ%J:)9
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M4:U(M24B0=*D'6F+TIXZU(QPIPIHIPH *=3:=2&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 (S*BEF8*!W)Q38YHI?]7(CX_NL#7E
M7QM;6UT_3C8K<G3?,_T[[/G=M_"L7P/%H;^);>[\)^(KA%"?OM-NW.9&].:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAR./Q'KMY]IFS:W31A,\-SU->[T %%%% !1110 4444 %%%% !1110 4444
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MCY2WKFNWHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "DI:* $HHHH ****!"4F*=10,;2T8HQ0 AI1
MTI** $/-)BEHH 3%&*6B@!,48I:7% #<4X48HH 4]* :** "BC%% !BEHHH$
M%%%% !1110,*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "DHHH **** "BBB@ HHHH$(:***!A1110 4444 %%%%  *6BB
M@04444 %%%% !1110,**** "EHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>forms-1_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !G /H# 2(  A$! Q$!_\0
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M;W*75M-:G3_+F^@_$WQEUCX\?\$M_B/XZ\3-'-XOC\!ZIX7\7W,,*P0W^O\
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MDO\ Q?J&OW1@?4H=#N-'^_/^#-WC]F[]LLD''_"X/A3R >?^+97/(X.<Y&"
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MX*D0?%/_ ((Z_P#!?#PA_P %$;/P/?>+OA-\8_&-Y\6_#4D@2'3_ !I:^)O
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M^%P_$%2K2E5C.?L\-'%QA)MM2FH^QYE-_P#/M--Q2=OZ7_"'_!-/X(_L2?\
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MT>[T+Q!I$US83VM];1:EI5_<V<DUC<V]S$LV^WFBD5'7Y]_9#_8/_90_8/\
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MAO"L'B-YH]#N]8C\"^))8;#59+<B>*SOHUFM99X/WUMYRSQX,18?HB%4#
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MP-WW\#(&["_* *FI  ,X &22?<GN?>EK-)*_FVW\REL@HHHIC"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>forms-1_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-1_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +: ^@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:$02L@)9LD \'\1@UM"A.>D495*T*:O(]AHKQ/\ X7;JO_0)L_\ OMJZ_P
M>/;SQA>WD%S9P6ZV\:N#&2<Y..]7/#5(1YI+0B&)IS?+%ZG>T4E%<QT"T4E%
M "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E<CHWC*;5?'>J^'6LTCC
ML8V<3!R2^&4=,<?>_2J46]A7.OHI**D8M%)7)>!O&,WBZ+4'ELTMC:3",!'+
M;LYYZ#TJE%M7%<ZZBDHJ1BT4E% "T4E% "T4E&: %HIH8-T(/TI: %HHHH *
M*** "BBB@ HHHH **** $KDO'K,NFVY4X/F'^5==7(^/3C3[;_KJ?Y5M0_B(
MRJ_ S0TW4[.RT*T-S<(A,8.TGD_A5RSUS3[UML5RF[T8X)KD-!\*C5K1;N\G
M81'Y41>O'%2:[X02PLFN[&20F/DH>N/8UJZ=)RM?4S4JBBG;0[O/(KDM+TN.
MW\437/\ :D;LSG$0/S'V//:K7@_5Y=2L7BG;=)!M4'U7''\JP=)P/'DG3_6M
MV]C4QIRCSQ?1#E-/E9Z!E5&XG  Y)K.N?$&F6K[7ND)]$^:N?\9:O*&32[8D
M%P#)CJP/0"G:?X'MVM4>]F=I67.U. *4:<5%2J/<J4Y.5H(Z>TU*TOES;W"2
M'^Z#R/PJ>::.WA>65U2)%+.[' 4#J2:\\US0IO#DL-[93N8]W7&"I'KZBMZ[
MU/\ M;X?ZG=$88V4ZLOOL-*5):2B[IA&HVW&2U+,GC7PU%I\U\VN6)MHF"O(
MDRL 3T'!/)P>/:KNB:]IGB&P^VZ5=I=0!MI=01AO0@\@\BOF[X8>!K?QK?W<
M-]=30V5NH=HX,!G;) Z@@8SZ&O0_'%['\+O EEX?T*1DN+QWQ.^-P7(+,??E
M1^%:3H14N2+U%&I*W,]CT'5O&_AK0W*7^LVL<@ZQJ^]Q]57)%2Z-XNT'Q!QI
MFJVUP_\ SR#[7_[Y//Z5XQX(^&WA_5='CU7Q-K$;370\Q(%N%5E'^V3SFL_Q
M[X'TWPH(-<\+ZPC)%(N8Q,K2Q/GAE([?6J5"DWRIN_IH+VDK<UM#Z1KG]:\;
M>&]!E,6HZQ;0S X,2MO<?55R17(:#X_O-9^$FI:JC?\ $WT^!XY6QG+ 9#@?
M0_F#7F'PWT7PQXEU34&\5ZAB8;6B22<1B4DG<2QY)Z=^]1"A\3GT*E5V4>I]
M!:/XP\/:^0NFZM;3O_SSW;7_ .^3@_I7*_&'6K6V\%7MC'J,<.H.8F6!90LK
M)O&<+G)&,UE3?!3P]<:E9WFBZC)!:QR!IXED$FX#GY6'(/US4'QJ\'VLVES>
M)S<2K<6T<5NL6 5(+XSGKWHA&G[6-G^ 2<^1W+/P3UG3+?PE%ITM_;)?RW+[
M;=I0)&SCH,Y->K33Q6\32S2I'&O5W8 #\37A?P=\"6=_:V?BI[J9;FVN6Q"%
M!4XXZ]>]5OBGXEU#Q1XOB\(:27\B*41,J'_6S'KT_A7.#[@U=2DJE9J+]28S
M<8)L]3N_B7X/L[CR)==MB^<$QYD4?4J"*WM,UK3-9@\W3;^VNT[F"0-M^H'3
M\:\STSX":%%IZKJ=]=W%V1\SP%8T4^@!!_,UY]XBT+5?A'XML[[3KSS8I TD
M+%<;P#@HXZ$X(_.DJ-*?NPEJ-SG'62/I*_U*RTJU^TW]U#;0;@OF3.%7)Z#)
MK&U#QWX9TNUM[FYUJU$=Q_JC&WF;AZX7/'OTKA_B=JZ:_P#!VRU1%V+=2P2;
M#SL)/(_ US'P_P#A18^*_#":MJ5].!(2+>.$CY &(.<CN0>!4PHPY.>H[:V&
MYRYN6)[U#?6T]BE['<1M:O&)5FSA2I&0V?2N.\0>,O &HPOI&KZI97,+D;D&
MYTSV^9> ?QKS3XJ>*;W5?$2>"])4PVEO*EOMC./-<@ #C^$9QCZUT^E? ;14
MTU%U6\NY;PCYF@9513Z %2::I0@E*;M?8'.4G:*.AM-)^&VCVT.IPQ:*D3MB
M*XEE609'. S$\UM>)-=TVS\*W%U_:$,*7%L_V642@>8Q0E=ASR?3%?.GQ!\%
MWO@F_CLC</<Z;.IDMY",#=T8$=-PXZ>HKUG4?"=KXG^$&B>?/)!]@T];I/+4
M'<PBZ'-7.E#W9N3:;(C)ZI*S1R7P1U[3]-O-;DU;48+=Y_)VO<S!2Y!?/)//
M45U'QZA\SPEIMPO(2]7!'NC?X5YO\,_ =EXXEU)+N[FM_LHCV^4H.=V[KG_=
MKUOXS6>_X;R$<BVGA?/X[?\ V:KJ<JQ$;;DQNZ3N:GA3Q'IFG^ /#\VI:A;6
MHDM$1&GE5-VT8XR?:NKLKVVU"TCNK.XCN+>3[DD;!E/;@BO(])T)/%W[/]K:
MK&)+RWCDDMSC)$B.^ /J./QJ+X$>(I9+;4/#UP1MMO\ 2( >" 3AQ^!(/XFL
M)TDU*2W3-8S=TGLSU74O$6CZ/,L.HZI9VLK+N"33*A(Z9P3TJ_'/%);B=74Q
M,NX-GC'KFOG+[+)\3OC)<%&$FG1S;BV,@6\9 _\ 'L#\6K>^-GC"[BO(O"]B
MYAA\I9+EDX+D_=3V&!^M'U>[C%;]1>UT;Z'I6H?$;PEI<YAN-=M3(.JQ$R8^
MNT&MC2M=TO7+<3:9?P72$9/E.&*_4=1^->0^'?A-X232HVUW689;UQEDBN51
M8_;U)%<OXETM_AEXDM-6\+ZND]I)NVCS%<J1C*.!P00>#CL:I4*<GRQ;OZ"]
MI):RV/I>EK,\/ZM'KN@6.J18VW,*R8!^Z3U'X'(_"M(5R--:,W3NKBT444AA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 C,%4LQP ,D^E<%JFH2:
MC=M(21&O$:^@_P :[/4XYIM-GC@7=(Z[0,@9SUZ^V:Y+_A']4_Y]O_(B_P"-
M:T[;LEF97)?%+PS+9WEMKL$9-K=Q1K,0/N2A0.?8@#\0:] _X1_5/^?;_P B
M+_C3[OQMX,-G+I&JZC VQ?(N()(78!EX(X7L1U'I713JN$U*.IC5I*I#E9\[
MUZI\$?\ D*ZM_P!<$_\ 0C7+Z_HGA47#2Z#XHMFA8Y\BZCE#)[!@AR/KC\:Z
MWX+0^7JVK[98I5$,8W1MD?>/X]J[:]6,Z+L>?0HSA55T>B^)_%VF>$H+>;4A
M/MG8JGE)NY R<\CUK*N_BEX9L],M+V2><FZ0O';K'F7:&*Y(S@<@XR>:YGXZ
M?\@O1_\ KM)_Z"*=\-/ >B:AX5@U?5+1;VXNB^T2DE8T5B@ '3^'.:\U0CR*
M3/5N[G1Z%\4?#6O7\=E%+<6MQ*=L:W484.W8 @D9^IYINM?%7PSHM])9O+<7
M4T3%9/LL88*PZC)(!_#->1_$O1K/PUXS,.E(;>%H8[A$5C^[;)'!//5<_C7K
M6C?##PS;Z%!!>::ES<O$#-.[-N+$<X(/RCTQ3E"G%*7<+LU_#?C70_%7F)IM
MRWGQC<\$J[7 ]<=Q]":Z&OG'PK V@_%Z"QMY&*P7\MKN/\299.?P_6OHZHJ0
M47H-,YKQ%X\\/^&)_LU_=DW6 WD0H7< ^O8?B17/Q_&GPN\FUH=209^^T*X_
M1B:\HTNYTS5_B&U[XDF"V$UQ+-.6)P?O%5XYQG:/I7HVK3?"N[TBY@@.FQ3&
M)A%)#"R.KX.#D#U]:T=.,;)IL5ST;1M<TWQ!8"]TN[2X@)VDJ""I]"#R#]:M
M75U!8VDMU=3)#!$I>21S@*!W->)? Z]D3Q%J5CN/E2VGG$=MR.H'Z.:[OXMB
M8_#R]\K.T21&7']W>/ZXK.5.T^4=]"M<_&7PK!(5C^W7('1HH  ?^^B#4EE\
M8/"EY,L<DEW:;CC=<0_*/J5)Q7GWPTU;P7IMG=CQ'';_ &YYOW3W%L9E\O:.
M!\I"G.[/3/%=!K^D_#WQ==VSV&O:?I4J!E<11+$)LXQG.T9'/YUHX03LTQ79
MZZCJZ*Z,&5AD,#D$5F:[XCTKPW9K<ZK=K CG:@P69SZ!1R?Z5+HNGC2=$LM/
M$YG6VA6)92,;@HP/TKP_XU7KS>,H;<L?+MK10%]&8DD_EM_*LJ<.:5AMG<O\
M:O#"OM$&IN/[RPIC]7K=\/\ Q"\.^)+H6EE=LEVPRL$Z%&;Z'H?H#FH--^&G
MA:UTR"";289Y1&!)+(6+.V.3G/'/I7C7BW3X?!OQ&9=-W1P6TL5Q""Q.SA6Q
MD]1G/X5I&%.>D17:/I6O'-(UBPT'XN>*[_4KA8+9(7!8@DDEX\  <D^PKV.O
M%]&T>UUCXZ:P+R%)HK4R7 1QE2P*J,CVW9_"HIVL[]ALZ-_C/X;7D6>JO%_S
MU6!-OZO75^'?%6D>*;9YM+N?,,>!)$ZE7CSTR#_,<5LX&W;@;<8QVKR6TAB\
M/?'O[+91B&VU"!MT:#"C,9<\?[R9_&A*,D[(#UNO+?@M_P >VO?]?:_R->I5
MY;\%O^/;7O\ K[7^1I1^!_(#U"21(8GED=4C12S,QP% ZDFN"N/C!X9CN&AM
MH]0O2.]M;C!]QN8']*Z[7M-_MC0;W3C<&W6YB:-I0,[5/7CCMFN/\.ZWX(\%
M:2FE1Z]9RRJQ,L\:$F5B2<DKD<#CKVHBDUM<"WIGQ5\,ZC>I9R/=6$SD!1>1
M;!D] 2"0/QP*[:O*/B?JN@>)/!)NM/O;6[GM;A"-C#>BME3D'D Y^G KT3PW
M</=^%](N96+22V4,C$]22@)HE%))H$0>(O%>C^%K>.75;DQF4D11HI9WQUP!
M]1R>*Y0?&?PX>18ZL8_^>@@3;C_ONL7XER0V'Q+\-ZAJ29TQ43<67<N5D)8X
M[X#*<5Z/#XM\.3J#%K^EMGL+N//Y9JN5**=KW C\.^+M%\4Q.^E7?F/& 9(G
M4JZ9[X/4>XR*C\7>*=.\+Z8LNH^;LN2T2>6F[YMI//-5=,\*:4GBZX\5Z=?,
M[W*%'CA9#">%!Z#U4'KUKH[Q5:SFW ']VW4>U0^5/38#Q#X:>/\ 0_"/AVYL
M-2^T":6\:9?*C##:41?4<Y4UZMX7\9:5XO2Z;2_/Q;%1)YJ!?O9QCD^AKD?@
M@B-X-OBR@G^T7ZC_ *915Z:JJOW5 ^@JZKCS/34$.HHHK H**** "BBB@ HH
MHH **** "N0\?Y.G6V/^>I_E77GI6!XHT:YUFUACMF0,CECO..U:46E43>QG
M43<&D'A.^ANM%@B5U\R,$,F>1SUQ5G7]0AL-)F:1EW.NU5/4YKF)O!FH6T<<
MEA.JS;0'&\CGV--M_!^JWDRG4K@",=PY9OUK=PIN?/S&7-/EY>4L> 8'_P!+
MGQA/E4'UX-5-*!_X3N3(Z2M_(UW%C80:?:I;VZ[8U_4USUEX<O+?Q.VHNT7D
MERV QS@BCVJDYM]0Y&E%=C'\4*]CXI@OW4F+*L/?'45W=I=PWELDT+AU8 \'
M.*K:OI$&L61@GR".4<=5-<:WA/7;20BTG0QD\;9"#^5).-2"3=FBK2A)M*Z9
ML>-[Z%=,6U#J97<'&>@%4K*W>W^&NJF0%2]K.P!]-II-.\%3R7 FU68, 00B
MN3GZUU&K6+7N@7UA %5YK:2&// !*D#-$I1C%0B[ZBC&4I.;T/&/V?L_;=9]
M/+7_ -"JS^T#87#IHNH(F;>,R0NW96;!4?C@_E70?"OP!K/@RYU!]3>U9;A0
M$\ERW0YYR!7>ZWH=CXBTB;3-1A\VVFX8 X(]P>QJIU5'$>T6J'&#=/E9X9X/
M^%&A>+=!@U"W\0W F*@3PK&"8F_ND9J[K/P?\+^'K=)M5\63VL<C!5\R(9)/
MMG./?M4%W\'_ !=H&J/<>&-54Q9S&5F,4@'HP'!/O4MA\'?$VOZJMYXOU3,/
M\>)S)*P]!D$#\_PK=U->95-/Q,^72W+J=YX#\&Z1X4T?4)K;5QJ.GWR*[R-M
MV!5#9Y!QC!_2N>NO@_X1\20'4/#^J2VZ2$D"!A+$#Z!>H_.N]NO!VF3^#F\+
MQ"6WL/*\M?*<AASG.>_->2?\*G\;^%]2EN/"^K1>6QP'27RW9>P=<;37/3E=
MM\]F:25DO=T.8\1^%]>^%NIV=Y;:JI\XDQ2P.5+;<9#*>W(]17J7C_4I-;^"
M U*2/RWN(;:9UQC:2RY_"N=L/A-XH\1ZVM]XTU,/"N-RK+O=\?PCLH]Q7LUY
MI5I?Z1-I<\"FSFB,+1CC"D8X]*JK5C>.MVMR80=GV9YY\"KF!_ K6ZRJ9H[E
M]T>X;AT.<>G/6O/+NX_X0?XYR:AJB,MM]KEFW[<YCE##</7&[]"*[#1/A!J'
MA[Q[;7MCJ1.C1_.WSE93_L,.A'O78^/?A[8^-[2(R2&WO[<$0W &< ]5([@_
MI3=2$:C=])?@'+)Q7='66]U!>6Z3VTR2Q.-RNC @CZBO#/CSKUE>3Z;I-M-%
M--;^9+,4.=F< *3V/!X^E9J?"KXBZ:'MK&_5;=^&^SWK*K#MD<?RKIO!'P4_
MLV_CU/Q'-#/-"X>*V@.4)'.7)'//8?G13C2I2Y^:]AR<IKEL5/%=C+I_[/ND
M6]PK)('A8JPP1N9FP?P(KL?@T3_PK33<^LG_ *,:M#XC^&+[Q7X4.FZ>T*S^
M?')F9BJX4\]!4WP\\/7GA?P=::7?M$UQ$7+&)BR\NQ&"?8BLY5(RHVZW*46J
MGR/#/$LK>&OC;-?7D9$*:BET2PZQDALCUX_45]*VEW;7ULEQ:SQS0ORKQL&!
M_$5ROCWX?67C>RCWR?9[^W#>1.!QS_"P[C@?2O)(OA-\0=-#VME>1QP2<.8+
MQD1Q[CC^57+V=:*N[-$KFIMZ7N:GQW\16%W+8Z):R++<6^Z>9E.0F1@+]>^*
M]'T6)IOA):1QJ69]&"J!W)BKS&Y^ ^K+H<!M[JTDU9I&\_,A6)4QP%^7).>]
M>U>&].GTKPQIFG7)0SVUM'$Y0Y7*J <4JKIJG&,'>S""DY-M;GC7P!N[:'4M
M9MI)E2>9(C&C'!?:7SCUZBO3/B? ;CX;ZT@&2(0__?+*?Z5PWB+X+3IXA@U/
MPQ>_9HVF$DL<DA5HCNR3&P'IV/YUZ?KVF/?^$M0TP.TDDMD\*LQR6;;@$^^:
M52<958U$^PX1:@X,XSX&S>=\/!&>1%=2)CZA6_K7G/Q M-3\ _$.ZU73B(K?
M4EE>)R,@[UQ(I]P23^5=[\!<CP3> C!&H.,>G[M*Z3XB>#/^$ST6"U1@EQ!.
MKHQ/&TD!Q_WSG\0*?M%"N[[,3CS4U;<YSX(^%CI/AM]8N 1<:E]Q3_!$I('X
MDY/TQ7GWQHL3!\1_/N0Z6US#$PD"Y^4#:V/4C'3W%?1]K;16=I%:P($AB0(B
MCL ,"N?\9^"].\::8MK?%XY(LM!-'UC8CT[CIQ4TZ]JO.^I4J?N<J/-['X&Z
M)J=I%=V?B:XG@D7*/'&""/\ OK]*H7WPH\(Z3J4.G7_C)K>ZG!*1RHH_,DX'
MMG&:@M_A=\1?#LDD6B:HBPN?O6]VT8;W*\<UK^&/@E<3ZB=1\87:7+%MY@CD
M+%V]7<\GZ5NYVN_:&?+?3E/4/".@1>&?#=MI,-VUU%#N,<K  D,Q;M[DUN"F
M11)#$D4:!8T 55 X '05(*\]N[N=*5E8****0PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH #24II*8@KY.\3?\C7K/\ U_S_ /HQJ^L:^7-7T;5-
M3\7ZO'8Z==7+-?SX\J)F_P"6C<Y X'O73A]V3(YVO=/@GHTEIH-[JLJE?MTJ
MI%GNB9&?^^F8?\!K,\(_!LO']J\3EDW#Y+.&3D>[L/Y#\^U>O6MK!96D-K;1
M+%!"@2-%Z*H& *=:JFN5 D>6?'3_ )!>C_\ 7:3_ -!%=5\+O^2<:1])?_1K
MU=\6>#=/\8V]M#?SW42V[,ZFW9022,<Y4^E:&@:);^'=$MM)M))9(+<,%:4@
ML<L6.< #J?2LG)>S41VU/#_C5_R/"?\ 7C'_ .A/7OUO_P >T7^X/Y5R/BGX
M;:1XMU8:C?75]%*(EBVP.@7 )/=3SS78(@2-4&<* !FB<TXI+H"1\]67_)<F
M_P"PS+_Z&U?0]<7%\,]'A\6'Q$MW?F[-TUUY9=/+W$DD8VYQSZUVE%22E:P(
M^9_"=AIA^(B:9KL2-:F>6!UE8J X#!02"/X@!]37LU]X"\$Z?83WMQHT"PP1
MM([&5QP!G^]4>O\ PM\.^(-1FOYOM5M<S'=(UO( &;UPP(_*L@?!/16VK+JV
MJ/&O1=Z#'_CIK24U*SO85A?AWJ_@_4?$$\7A[0+FPNUM69YI#D%-R@K]\\DD
M'IVKKO%^N:=H'A^6ZU6TEN[.1A#)#&BMN#9ZAB!BD\,^#='\)QS#3(7\R; D
MFE?<[ =!Z <]@*T=8TBRUW2YM-U"+S;:8#<H)!R#D$$="" :RDXN5^@SS'P]
MX+\">.+*XO\ 3+74K!(YC$T1G&0< Y )?CGU[&N8^)7@32_"$-C/IUW.YN'9
M6AG96;@?>& ..Q^HKO5^#FD6TQET_6-7M'/>.91^H4&E'P;T.6?SK[4M5O).
MYDF7GZG;G]:V51)WYM!6-7X6SSW'P[TMIRS%1(BENZK(P7\@,?A7EGQGMVB\
M<>80<36D;@_0LO\ 2O>M/L+72M/@L;*(16T"!(T'.!_7ZUC^)_!>C^+4A_M*
M.420@B.6%]K 'J.X/3N*SA42GS#:T-33-2M=3TNWOK:>.2&6,/N5@<9'0^A%
M?/OQ"N(=>^)D\5G(LR/)#;(R'(9L*"!Z_,2/PKOW^!V@EB4U+40OHQC)_P#0
M16SH/PJ\.Z#J,-_&;NYN(&WQFXD!"MV.% Z>^:J$H0=TQ.[.WKR+PQ=);_'?
M78W8 W$<L:#U8%&_DIKUVN+N_AEHM[KEWK$MSJ"W=P_F!HI@GDOQ\R$#(/U)
MK.#2NGU&SM*\GN6^W_M"V@A.X6<!$I'\/[EOZN!75MX.U(@QKXRUL0^A:,O_
M -][<U9\-^"-)\,7,]W:FYN+VX&);FZEWR,"<GG ')Y/'-.+4;Z@=)7EOP6_
MX]M>_P"OM?Y&O4JY_P +^$+'PG'=I8SW,HNI!(_GLIP1GI@#UJ4THM#,KXKW
M4]K\/K[R"R^:\<3LO9"PS^?3\:;X(\)>'1X/TFY;2+&XGGM8Y9)IH%D8LR@D
M9(/0G&/:NLU33+36=,GT^_B$MM.NUTR1GG(Y'0@@'\*Y>T\ /I40@TCQ/K-G
M; DB R)(BYZ[05XJE)<O+>PNISWQ8\+Z!8^$VU"TL+6RNTF14-O&(_,R>5(&
M >.?7Y:[SPE_R)FA?]@ZW_\ 1:U@:A\,=.UB'&JZQK-[*/N2S7(/E\\[5V[1
MGIT-==IUC'IFEVFGPL[16L*0HSD%BJJ%!.._%$I)Q2O<$<SX@U_0I?$]EX1U
M;2VNWO$62-I(T:-<[@.IR#\IY [T2_"[P;,Q+:*H)_N7$J_H&JYXD\$Z5XHN
M;:ZNVN8+NV&(KFUEV.O.1S@]#R/2JI\'ZF!L7QEK0C]"8RW_ 'UMS0FK*SL!
MQ6CV<?@_XU1:+I,L@T^]B/F0,Y;;^[9@.>I!7()YP:]<N_\ CSG_ .N;?RKG
M-#\ Z5H>L/K'VB^OM28$&YO)M[<C!/ ';CGM74]1@TIR3:!'F7P.(_X0Z^&1
MG^T6./;RHO\ "NDT7QB=8\8ZOH L!$NG@_Z1YV[S,$#[NT8Z^IZ51M_AK:Z7
M<3RZ%K6J:4LY_>0PR*R>V 1GC)P<FM?PSX/TWPL;J2T>XGN;M@T]S<R;W<\G
MK@=R3[]ZJ;BVWW Z&BBBL"@HHHH **** "BBB@ HHHH **** $HI:2@ I:**
M (;FYBM+=YYFVH@R3C.*>CK(BNO(89!QVK%\51-)HTC+(4V$$X_BK0TJ%X--
MA1YC*0@.XCUH$7*KVU[!=M(L+;C&VU^,8-6*XW3K"ZO9-1$5\]O&DV?D')/Y
M]*$!V5+61X=O)[W2]]R094<QDCOBM:@8'% KDK[5&OM4N+5[J:U@@.T&%22Y
MJ_X?U":6:>TD=YHX_P#53.N"P]Z!&]117/:G]INM>ALHKIX(WC+-LH Z$4M1
MQ(8XE0L7*C!8]327$OD6\LIZ(A;\AF@9)FBN7LK?4M8@746U!X)&)\N)%^7
M]>:M^%KFYN;*X-U(7=9BN3]* -TT?YZ45R5G!?ZM>:@AU"6""*;:-G4G\Z+
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MHQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
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MW[%'V"S_ .?2#_OV* +%%5_L%G_SZ0?]^Q1]@L_^?2#_ +]B@"Q15?[!9_\
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M1PS+,I*@C!QS14M6&24444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !3)O]4:?3)O]4: *M%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!;3[B_050O
M_P#7K_N_U-7T^XOT%4+_ /UZ_P"[_4UI3^(F6Q5HHHKH,PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T-/\ ]4_^]11I_P#J
MG_WJ*YI_$S5;%NBBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !3)O]4:?3)O]4: *M%%% !1110 4444
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MEQJ7BR\N!%(@2WM)D56ZY+L  5] #ZGCI7H=%"?<EI= HHHI#"BBB@ HHHH
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M<GUI:**H04444 %%%% !1110 4444 %%%% !1110!H:?_JG_ -ZBC3_]4_\
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M.<>]5OB;96P^%VJ0+!&(K>%#$H7 3:RXQZ<<5)J>GVB?!ZXM! GD1Z,65-O
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MT.!7?4EJK^;7Y?YCV84444 %%%% %M/N+]!5"_\ ]>O^[_4U?3[B_050O_\
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MY.WX7$]&O-?K8****8!1110 4444 %%%% !1110!H:?_ *I_]ZBC3_\ 5/\
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MB^T^.'26ETNZ0C-QN>?>.^Y6;'Y8KE?C=876E^$O"MC>7S7]Q;F6-KEDVF3
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MLWG6<[+N7)X9&']T\9_R*P[WPWXP\6>18^)[C2+;2$D62>'3O,+W)4Y"DO\
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M^[*^=TC#V!XSW!%=_0OA7S_%W&_B?R_!!1110 4444 %%%% %M/N+]!5"_\
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M.+6U&TJ @//.<DXS]>\)/E^3^^W^9K%KG3>UU]UU^AROA7P?J/B7P+9:M?\
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MU%G"1L.-T94=^X/OUXP_P+X7O/#=GJ#ZA+:M>:A=M=2Q6:E8(B>-J \X]_\
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M HHHH *9+%'/$\4J*\;J596&0P/4&GT4 06=E:Z?:I:V5M%;V\?"10H%5>_
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M %%%% !1110 4444 :&G_P"J?_>HHT__ %3_ .]17-/XF:K8MT445 PHHHH
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MOI(7&#'O/ /O@ _C5+Q&,_&/P9_UPO/_ $77?T4[*\;=/\F@OO?K_G<X#QZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 6T^XOT%4+_P#UZ_[O
M]35]/N+]!5"__P!>O^[_ %-:4_B)EL5:***Z#,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** -#3_]4_\ O44:?_JG_P!ZBN:?
MQ,U6P_?>?\\(/^_Q_P#B:-]Y_P \(/\ O\?_ (FK%%0,K[[S_GA!_P!_C_\
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M_P#OHT>R?<.8V**Q_.E_YZO_ -]&CSI?^>K_ /?1H]D^X<QL45C^=+_SU?\
M[Z-'G2_\]7_[Z-'LGW#F-BBL?SI?^>K_ /?1H\Z7_GJ__?1H]D^X<QL45C^=
M+_SU?_OHT>=+_P ]7_[Z-'LGW#F-BBJMB[/&Q9BW/<YHK-JSL4M2U1112&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !3)O]4:?3)O\ 5&@"K1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 6T^XOT%4+_P#UZ_[O]35]/N+]!5"__P!>
MO^[_ %-:4_B)EL5:***Z#,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** -#3_]4_\ O44:?_JG_P!ZBN:?Q,U6Q;HHHJ!A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4R;_5&GTR;_ %1H JT444 %%%% !1110 445B>)?%>D^$[6&YU>9XHI
MG\M"D9?)QGM2;2W"QMT50T76K#Q!I4.I:;.)K67.UL$'(.""#R#FLK0_'>@>
M(M9N-)TZYDDNX%9G5HF4 *P4\D>I%/K8.ESI**** "BBB@ HHHH **** "BB
MB@ HK)\3ZM/H7AJ_U2VM&NYK:(NL(_B]SCL.I]@:P?AKXQU#QIH4][J%C';2
M13>6KP@B.08SQDDY'0\FA:W\@>B3?4[2BBB@ HHHH **** "BN?\8>++3P;H
MRZG>6\T\;3+"$AQG)!.>2/2JT'C_ $0^#[3Q/>R2V5A<N8T\R,NP8,PP0@/]
MTT=&QV>AU-%4='UBQU[2X=2TV;SK2;/ER;&7."0>& /4&KU#5A!1110 4444
M %%%8GBOQ-;>$M!DU:[@EFB1U0I%C=ECCN:3:6K&E<VZ*Q_"_B*W\5>'[?6+
M6&6&&8L DN-PVL5[?2MBF2G<****!A1110 4444 6T^XOT%4+_\ UZ_[O]35
M]/N+]!5"_P#]>O\ N_U-:4_B)EL5:***Z#,**** "BBB@ HHHH **P_$WBW2
M/"-I#<ZQ.\44S^6A2,ODXSVK2T_4;;5-+M]1M7+6UQ$LT;%2"5(R.#2YEKY!
M8M45S7AGQ[H'BZZGMM'N9)98$#N'A9,#..XKI:8!1110 4444 %%%% !117F
M7AKXE:QK7Q*O?#=QHJPVD+2J'4-YD03.&<GC#8'0#[PY-*_O*/4+:7/3:***
M8!1110 4444 %%17$RVUK+.P)6)"Y ZD 9KD?!GQ(TWQH-0:UM+JV6Q17D,^
MTY!W=-I/]TU+DD[-^8[.USLZ*P/#GC30/%CW":+?&Y:W"F4&%TVALX^\!GH:
MWZH04444 %%%% !112,VQ&8] ,TF[*[ 6BN*\$_$G3O'%[=6ME975NUM&)&,
MVW!!..,$UVM/I</(**** "BBB@ HHHH **** -#3_P#5/_O44:?_ *I_]ZBN
M:?Q,U6Q;HHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4R;_5&GTR;_5&@"K1110 4444 %%%% !7D7Q_
M_P"1<TG_ *^S_P"@&O7:\B^/_P#R+FD_]?9_] -9U-EZK\RX;OT9R?PO\377
M@K7X=(U?,6F:M''-&S'Y49P-C@^A^Z?<?[-2?"N[AL/B1XAO)VVPP6=U+(WH
MJRJ3^@KJ-9\$CQ9\(-!N+2,'5;'3XG@QUD78-T?X]1[CW-<-\'K'^U?$NLZ?
M*[+]JTB>%F[C<R G]:MWYGW2:_R(5N1=FU_P33M?$/Q!^)NKWAT*^.GV=M\P
M2.;REC!SM!8#<S'!]N#TKH/AOX^U[_A*Y/"/BAFEN072.5P-Z.@)*L1PP(!(
M/ZG/''>&?$VK?"+5]3T[5-&:;[1M^4R&/)7.&1L$,IR?\C%;/PVTK5O%GQ'E
M\9WEJUO9K)),'*D*[,I544GK@'D^WO51M=<NUM13V=][Z&1;^-?'<_B_4]-T
M>]NKRXDEFAAB;#B(!_O '@8 QD\#-:/CGQ!XR\-:+X:M[K5+RUU%[>9KH+,"
M6;S/ER02#\I%/^%/_)8=:_ZYW/\ Z-6I?V@?^0MHG_7"3_T(5A%_NZ?G;\F:
M/6<_*Y3\0W_Q3T.QM_$M_J<D-O,RXBB=2L6[E0T>,?GGW.:M2ZQ\3?&6A2>(
M=.G%EIUNAQ#:R>6TI0?.P[MR#P3[#-=K\7_^262_[\'_ *$*/AA_R1R'_KG<
M_P#H;U<I64_[NWW7)AKR?WMS(\!_%&ZN?!6MWNN$7%QI"*XD "F8/D(IQQG<
M,9QW'OGE],OOB=\0$N]7TS4W@MX'*K%#-Y"%L9V*!U.".6/?K53X8:%)XD\+
M^,M)A8+-/!;F(DX!=6=E!]B0!2>$_B'J7PVL+[0+[0V>;SC*BRR&)HV( .1@
M[EX!&,?KQ;M=WWMH);:=SM/AQXWU3QC:ZEX:U>ZEAU..!FAO8@$D !VG(&!N
M4D?49S[\Q:_$?Q3X&U+6M&\0R37]RJ%;=Y3NV2?PN">J$'./8=.:T/A+I%WI
MMSJWCC70UI9?9W*O(NWS-Q#,X'IQ@>N>.E<K?V>O?%/5==\0VL!\FRC!BBQS
ML!^6-?5MNYC[_44I7OKVU&K:VVOH=SX>F\5Q?##7/$^JZU?-/-:LUBCO_JU'
M_+3ZGM[<]Z9X-\?ZCI_PNUK7M4NI=0NH+SR;<3MG+,J8'T!))_&H-%\;KXC^
M#^N:3=N!J6GV!7_KK$,!6^HX!_ ]ZR?!GAVY\3_!G7;&R7==IJ FA3.-[*B?
M+]2,@>^*4[\T[;60H[1OW8VQF^*GB72)?%%CJERT*.=D$,FTR8/.R(## =.>
M3CO7K7P^UO7=9T!O^$BTVXL]1MW\MFE@,0F7&0X! YZ@XXX[9Q7COAWXJ:GX
M-\+/X<_L<?;K=W$4DS%?+W-DAX\9)!)[CK[<^R> -0\2ZKH)O_$L$5O-,^8(
M4B*,(\=6!)ZGMZ#WK1=;;$OI?<YOXM_$"^\+)::5H[+'?W2&1YBH8QIG V@\
M9)!Y[8]\CDVC^+OA::SOVEO-36?YGME+707N5=<?+]5_.M/XX^%]0N;FQ\1V
M,,D\=O%Y-P$7)C 8LK8].3D]L"J#?&GQ)KD]E8>'M#B6]?B13F;S&_V0,;1U
M))S^G,0\M[_@7+\+$_Q6\8Z]8W&@RZ?=7NE?:K+SI;;)1E8GD,/4=*[3XKZM
MJ&C^ C>:==RVUSY\2^9&<-@YR*XGXTZ#K,^EZ'K-Q&)Y+> Q7SP*=D;G!SCL
MN=PS]/6L#QC\2[WQGX-CL5T5H(X)(VNKI7+IN ( ' VY//))X[]:E_"UUO\
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MOFQ;CQ@ YX#?G7::;XHUR7X_2:-)JERVFBYF06Q?Y,")B!CZ@&N3^&OB&\\
M>,)]%U#2)#<:A/#:N'?RS"=Y&[&#N'S9[9]:M^,VU'P!\9&\2FQ:>VEF,\);
M*I*&3:Z[L<,,M^AQ6BDDX.^FH6TFNIT7QL\4:YH.NZ5#I6J7-G');LSK"^ Q
MW8R:J?%SQAX@T#QMI\.F:G<0P?8HI6@1L*[;WSD>^ *X?XC^+KKQGJEAJ4FE
MR6%H(3';AV+>8 QW,#@9&3CCTKI_B^,_%+0P>GV6V_\ 1KTH7;2OO(*C23?]
MTZ72_%'C7PSX:\0^)/%\$F^181IUO*550[%AC8IRH&5)S@D#UKBH=>\=ZSI4
M_B3_ (3.SM?*W.MDU\L4CA>NV(#![X#<G'?//M'Q-\-W/BCP/>6%DN^[1EGA
M3.-[*>5^I&0/?%?.UEJ/A[2M&FT_5O!K7&NQ,5$T]U-$,D\!XU8<CI@8S[4I
M-J37:UOZZE*UD_O/3M*^,UVWPUU#4+N.*36[.5+9#MPDI<$JY Z8"N2!Q\O;
M/&#H5Q\5]5TJ7Q79ZE+<6HW-Y$TBD3JI^;;%C&.".,'TJS%X U'5OA3?W,/A
MZ#3+^2XCN8;2 S%YHXPPY$CL0<.Y &,X'J*SO"?Q4U?1?#"^$[70C=:@GF0V
MSAR&4L2<-'M))!)[C]*J>\K[VT^X4;65MKZE_P#9[_Y#^L_]>J?^A5] U\_?
ML]_\A_6?^O5/_0J^@:W7PQ]/U9BOBEZ_H@HHHH*"BBB@ HHHH **** -#3_]
M4_\ O44:?_JG_P!ZBN:?Q,U6Q;HHKF_'7BN/P;X5N=6:-99@1';Q,<!Y&Z9]
MAR3["LV[*Y25W9'245X'I]I\7O%&DCQ+;:V((Y 9(+3S/+,BCIM0+MP>VX\_
MK73:?XN\577PO\03ZWI][IFL:?;$QW4ELT(FR#A@" -PQSCCD>M$GRIM]!+5
MJW4]6HKS[X4ZUJ6M?#IK_4KR6YNA+,HED.6P.E<3X%\8>(=1^'?C2^O-6N)K
MJS@#6\KD9C.USD?D*<O=YK]%?\O\Q1?,D^[M^?\ D>[T5P/P>UG4==\#"\U2
M[DNKC[5(GF2')P,8'ZUY[\0V^('@M5U"7Q;));75RZ110L04'+#.1CIQ1/W'
M9_U<<?>5T?0%%>16UGXVT'P1K>MZKXG-X)-,\VU"$EH7(#;N0.<<5N?"G6M2
MUKX=-?ZE>2W-T)9E$LARV!THE[O-?[*N_P ?\A)WY;==OP_S/0:*\(\"^,/$
M.H_#OQI?7FK7$UU9P!K>5R,QG:YR/R%8^D7GQ*U#P9=>+;;Q7BTLRY>*9\N0
M@!. 5*GKT)H>C:?1)_>-:V\[_@?1]%>#:W\2->U'X.Z?K4%T]EJ2ZG]DGF@&
MWS (V;(';/RY]P:C^(GC/Q'I7A_P7<V.KW$$UYIJS7#(1^\?:AR>/<_G1+W=
M^]OO5P6JN>^T5Y!J_P 1KC6O@M/KNF736>K0210W/E'!C?>H./9@<CZX[&J]
M_P#$[4?#WPDT"\\S[5KFIHX2:8;MH5B&<CN1E0![]\8(]+^5E]^P+6WG?\#V
M>BO"&T7XSV]@NN+K+2SL YL!*&D /K&5\O\  &O6_".IZKJOAV"XUO37T_41
ME)H6& 2/XE]C^G(IV%<W****0PHHHH **** "BBB@ HHHH *9-_JC3Z9-_JC
M0!5HHHH **** "BBB@ HHHH ***3(SC//I0 CQI(,.BL.N&&:=29&<9Y%9GB
M&ZU6TT6XFT.SAO=14KY<$L@13DC.22.V3U% &I16)=>);>PUW2-%NH9!>:DD
MC*4(*1E%W,"20?IQ4-SXE>#QW8^'1;*T=S9O<F??RI4D8Q^%.W]>G_#!TO\
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M%NBBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "F3?ZHT^F3?ZHT 5:*** "BBB@ HHHH
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MT58\A?4T>0OJ: *]%6/(7U-'D+ZF@"O15CR%]31Y"^IH KT58\A?4T>0OJ:
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MGKZ&CSU]#5>B@"QYZ^AH\]?0U7HH N Y /K44URD+A6#$D9XJ1/N+]!5"_\
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M7]U_R'^-9U%'LXAS,T?M\7]U_P A_C1]OB_NO^0_QK.HH]G$.9FC]OB_NO\
MD/\ &C[?%_=?\A_C6=11[.(<S-'[?%_=?\A_C1]OB_NO^0_QK.HH]G$.9FC]
MOB_NO^0_QH^WQ?W7_(?XUG44>SB',S1^WQ?W7_(?XT?;XO[K_D/\:SJ*/9Q#
MF9H_;XO[K_D/\:/M\7]U_P A_C6=11[.(<S-'[?%_=?\A_C1]OB_NO\ D/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBN],^S3H'AFA\MU/1E(P17@GA/4_^%:_$#5M.U%V%H(Y$8GC=M!>-OJ1P/\
M?K24N6=GMK^!G%7@FM]#VIO%N@IK8T8ZE%_:.\1_9P"6W$9QTQ4.J>.?#.C7
MAM+_ %BWBN <-&,N5/HVT''XUYC\(-*FUSQ-J?BN]&YD=A&V.#-)DL1] ?\
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M10 4444 %%%% !1110 4444 6T^XOT%4+_\ UZ_[O]35]/N+]!5"_P#]>O\
MN_U-:4_B)EL5:***Z#,**** "BBB@ HHHH *\X^)?@#5?&=[I\VG7%E$MO&R
M.+AV4DD@\;5/I7H]%3*"EN--K8\Z\+^&?'^FZ_:7&L^(;>ZTV/<)8$F=BPVD
M# * <'!Z]JXSXY06?_"2Z:T!)OY;<B9%'50V$/U/S#\!7O%<!-\,_MOCX>*-
M0U?[0JSB5+3[-M "CY%W;STP#TYQ[U,H\SBNEQIV39O>#O#D?A[P?9Z5(@\P
MQ[KG_:=N6_GCZ 5Y]_PK#Q;X?O[L^%==ACL[H;&69BK[>>"-I!QG[PP?I7L5
M%5**D[O^O(46TK'GO@WX91:%X=U2PU6X2YEU-!'.(<A$4 X"DC).23G [<<<
M\G!\(_%^E7LT.D>(HK>QF.'DCGDB9E_VD48)Y/?\17MU5-1U.QTBU^U:A=PV
ML&X+YDK!1D]!2<8WNQIO8\U\#_"_5?"GC ZG/>64UDJ21IL9O,(/W205P/?G
M\ZC\4_"O6;OQ9-KWAS5H;.6=C(V^1XGC<C#;60$X//IUKTS3-8T[68'GTV]@
MNXD;8SPN& .,X/YU=IN*:2["3M?S/,_%?PQO-?M=+O[;44AU^TMXHIIF9MLS
MJ!\VX#<&!R<XR>.E9%I\*/$6M:S!=^+]:2Y@AP-B2O([@'[H) "@^HY_G7IV
MO^(M-\,Z>M]JDK16[2",,J%CN()' ^AKG_$'Q*TW2/"MEKUI;RWT-[(8X%YB
MSC.220<?=/;FI?*FY/O^+*]YJQVBJ%4*HP , #M7E7BKX13W>M/K/AG4$L;F
M23S&BD9D"N>K(Z@D9],?B.E>A>'=;A\1Z!::M!$\4=RA8(_52"01[\@\UJ5<
MH7>NY,966AXQ8?!S6M2U5+OQ7K8N8UQD),\LD@'\.YP-H_/\*Z[QY\.H/%>E
MVD=B\5G=V*>7;Y7]V4P/D..0!@8/..>.:[FBI<$UR@I-.YX>_P )/&6H:8;7
M4?$$,B6X M;>2YEDC!SCNOR@+G& ?3BNA7X<:P/A8_AC[38_;3=>=YF]_+V[
M@>NW.?PKT^BAP337?_.X7U3[?\,<YX%T"Z\,>$K32;V2&2>%I"S0L2IW.6&"
M0#T/I7,^#/A[JWAWQQ?ZW=W%D]M<+*$6%W+C>X89!4#H/6O2:*?*N92ZH7V>
M4\X^)?@#5?&5[I\VG7%E$MO&R.+AV4DD@\;5/I5CQY\.#XJ6TOK&Z2UU6UC$
M8=L[) .0"1R"#D@@'KT]._K/?7=(CU(::^J62WQ(46QG429(R!MSGH:GV<=N
M[O\ ,KF>_E8\IB^%'BC7=4MY?%FNI/:P<829Y'*^@R !GUZ^U;'Q!^&^J>*-
M9L+K2YK&"VM;98-D[NI&&)XPIXP17IU%6HI6MT=_F)-Z_< X KA?B+\/?^$S
MBM[BTN4M]0M@54R [)%/."1R,'D'!ZGCT[JBE**EN";6QXK-\-/'FO)!9:[X
MAA:QA8$;IGE/ QD+@;C]3WKHO!/@KQ1X+U6:&*_T^[T.:3+QN[K(.P<#:0&Q
MC(S@^O<>D44**3N@;NK!1115""BBB@ HHHH **** "BBB@#0T_\ U3_[U%&G
M_P"J?_>HKFG\3-5L6Z***@84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %,F_U1I],F_U1H JT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E/Q(^%][K>K+XB\.3+%J8VF6(OL+
MLOW71NS# '.!P#D=_5J*5NHTSP&^\*_%KQ9'%IFM2%+)6&6FFA5..A;R_F;\
MC7;W_P *;5_AJOAFSG7[7%)]J6YD&!)/C!+ = 0=O? QUQSZ/13>S7<2T=SP
M#3?"GQ7ATJ3PRC&UTE@RL6EA*A3G(5AE\'T'KSCFMGX=^!?$FA:'XKMM2TWR
M);^R\JV7SXVWMMD&,JQQ]X=<=:]FHH>M[]1IV:MT=SR[X.>$==\*IK UJQ^R
MFX,/E?O4?=MWY^ZQQU'6L[Q%X'\17_QEM=?MM.WZ9'<VLC3^?&,*FW<=I;=Q
M@]J]BHJN9\REV$M$UW.%^+'A[5/$WA&.QTBU^TW*W:2%/,5/E"L"<L0.XKGI
M?AC?ZS\)M)T>Z5+/6M/:62-7<,OS.Q*EER,$%3D9Y KUNBIZ-=[?@5S/3R_4
M\'31_C%/I]IH0:2SM;?:BW$=S'&0HX&71MQ '8<^N:Z3QUX'U^^^'.E:+92W
M&LZC;W0EGGGN &;Y7R<R,. 6  SG&*]4HH>JU).?\#Z;=Z/X*TK3[^+R;J"'
M;)'N#;3D]P2#70444Y.[N**Y59!1112&%%%% !1110 4444 %%%% !1110 4
M444 %%%% %M/N+]!5"__ ->O^[_4U?3[B_050O\ _7K_ +O]36E/XB9;%6BB
MBN@S"BBB@ HHHH **** "BBB@ HHHH **** "O%_C3J<NHZOI'ABTR\A82N@
M[NYVH/K][_OH5[,[K&C.[!549)/0"OFN!_$7C'X@7VN>'K;S[J&;SXRY0"-!
M\J9WG&< ?EFLIZR4?F_D7'2+9TGPHNIO#7CS5/"]XV#*60>ADC)P1[%=Q_*N
MI^)?Q%NO"]S!I.D11OJ$R>8\DB[A&I)  '=B0>O3T.>/+O$,?BWP[XLLO$?B
M"V$5])*LJ.K1XD\O:"#L.!Q@>^:W/B8TMGXUT?Q;;Q&>PN8X+B%C]UBF#M)[
M9&#^/M4\SY(IOK9CLE*37:Z*/C37O&EQX;@T_P 5:<8XI9EGAN&B"-D _*=O
M'0]" :V[K5YM'^!?A^2&"TF\VZ:-DNK=9D(W2G[K C.0.:H?$?XDZ=XOT*UT
M_3K.ZCV3">5YPHVX4@ 8)S]X\\=/?A-?_P"2"^&O^OYOYS4-^[/U7YC_ )?F
M=%K_ (YUK1OAUX9U&P>WAGNU*R!8%V  <!5Z ?2NPO\ Q!J$'PK&OQN@OSI\
M<^XH-N]@N3C\37FGBVPGN/@OX6NXD+1VQ_>D#[H;(!/MD ?B*2\^)FG77PN3
MP[':77]HBU2V8E1Y8"XRV<YZ#TZ_G3J2:]HNM]/N1--)J#Z=?Q-:T\=^*[WX
M8WGB"*Y@^UV=^(Y#Y"X,)5>WKN8<^E=+HOCV2Z^%=UXCNGC-]:I)')A<*90<
M)Q[[D_.L;X/V$.J_#G6-/G&8KFZEB;Z-$@KR:;4-0T?2]4\+29"M>*90#T:/
M<I&/<[3_ ,!%*4FKKNE8<4G9]F>M^$_B#K!\&ZSXFU]XY[>V=8;:*.,1EY.X
MR!TRR\]N:PM,^(/Q%U3SM8L]-2ZTR!OWD4=N-F!U /WB0/0G'I71>(?!US:_
M!2'2K6)FNK5$N98UY+-G=)]<;C^5<UX(^*NG>&O!PTFZL+F6Z@+F$Q!=DFXE
MAN).1R<=#Q3DVIM7V6GG_3)6L4^YL?#WXA:_XCU75(=0EA:*"QDN(U6(+M8,
MN.1UZUC:!\2/'^O&YLM,M8+Z[VAP_E*HA49R>H&3D=?3H<U0^$)+:]KA(P3I
M4Q(_X$M;?P$_X^M=_P!R#^;T*[E%7^S^K*G9)OS-3P!\2-9U'Q,WASQ% @NF
MWK'((]CK(H)*L.G0'TZ=\\>;W]QXH/Q+\^6 #Q%YZ%8P%QNVC;QG;]W%=7;<
M?M&-_P!?+_\ HDU4\:7@\._&T:M>PRFV22&<; ,N@15)7) /((Z]JF$N;DD]
M!25N:*5SV[P_)J4N@63ZP@343$#<* !AOPXK2JCHVJV^N:/:ZG:K(L%RF]!(
M & ]P":O5TO<SCL%%%%(84444 %%%% !1110 4444 %%%% !1110!H:?_JG_
M -ZBC3_]4_\ O45S3^)FJV+=%%%0,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "F3?ZHT^F3?ZHT 5:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"VGW
M%^@JA?\ ^O7_ '?ZFKZ?<7Z"J%__ *]?]W^IK2G\1,MBK111709A1110 444
M4 %%%% !1110 4444 %%%% #)8HYXGBEC62-U*NCC(8'J".XJK8:/IFE>9_9
MVFV=GYF-_P!G@6/=CIG:!GJ?SJ[10!4O]*T[58TCU&PM;Q$.56XA60*?4!@<
M4DFE:=+IPT^2PM7LE  MFA4Q@#H N,5<HI60&1'X5\/16K6J:'IHMV8.T9M4
M*LPS@D8Y(R?SKR3XN:FGG6G@O3-'2)()$N(_LPP&+*PVK&J\<L37N5%3*'-H
M4G8P/".E26'@C3--OX5\Q;8+-$X! SR5([]<59@\+^'[995AT/38UF7;(%M4
M =?0\<CVK6HJWJ[D15E8JV.FV&EPM#I]E;6D3-N*6\2QJ3TS@ <\"JTWAO0K
MB[:[FT73I+EFWF9[5"Y;UW$9S6G10,*RU\-:$E_]O71M/%V&W^<+9-^[USCK
M[]:U** ,^TT'1K"626STFPMI)%*.T-LB%E/4$@<CVI]AHVEZ49#IVFV=F9,;
MS;P+'NQTSM SU-7:*+ 4!HFDKJ7]HC2[(7V<_:1;IYN<8SNQGIQUI]_I.FZJ
MJ+J.GVMXJ'*BXA60*?;<#BKE%*RV BMK:"SMTM[6"."",82.) JJ/0 <"I:*
M*8!1110 4444 %%%% !1110 4444 %%%% !1110!H:?_ *I_]ZBC3_\ 5/\
M[U%<T_B9JMBW1114#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\'_?D_\ Q5 %BBJ^R\_Y[P?]^3_\51LO/^>\'_?D_P#Q5 %BBJ^R\_Y[P?\
M?D__ !5&R\_Y[P?]^3_\50!8HJOLO/\ GO!_WY/_ ,51LO/^>\'_ 'Y/_P 5
M0!8HJOLO/^>\'_?D_P#Q5&R\_P">\'_?D_\ Q5 %BBJ^R\_Y[P?]^3_\51LO
M/^>\'_?D_P#Q5 %BBJ^R\_Y[P?\ ?D__ !5&R\_Y[P?]^3_\50!8HJOLO/\
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MH J;&_NG\J-C?W3^56Z* *FQO[I_*C8W]T_E5NB@"IL;^Z?RHV-_=/Y5;HH
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M\FCR9?\ GD__ 'R:V**/:OL'*5;%&2-@RE>>XQ15JBLV[NY2T"BBBD,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "F3?ZHT^F3?ZHT 5:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"VGW%^@JA?_P"O7_=_J:OI]Q?H*H7_ /KU_P!W
M^IK2G\1,MBK111709A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!H:?\ ZI_]ZBC3_P#5/_O45S3^)FJV+=%%%0,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"F3?ZHT^F3?ZHT 5:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@"VGW%^@JA?_P"O7_=_J:OI]Q?H*H7_ /KU_P!W^IK2
MG\1,MBK111709A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!H:?\ ZI_]ZBC3_P#5/_O45S3^)FJV+=%%%0,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F3?
MZHT^F3?ZHT 5:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;'^TCHP7;;9RCLI#2;N1QG"GG^&J<&JZ[X8^+]EXA\0Z4-)_M*7;/&A_=LC
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M@^MO_P"U*O\ Q_\ ^1<TG_K[/_H!JA^SW_J_$'UM_P#VI5_X_P#_ "+FD_\
M7V?_ $ T8C[/_;HJ?7YG":Q\/[#2/AU8>*8=9=;R6.&46S[1N9\9"$'.1G/?
M@&NRL/B7K&C?"33-8FA2]NS>FR,ER3\Z ,0Q(Y)XQGOBJWA?X*:3J^A:9JMY
MJEYBZMTF>&)57!8 X!(/\JO_ !GTNST7X<:3IVGP+!:P7RK&B]OW<GYDGDGO
M3D^5-=VB(ZV98\+_ !BD\2>)=*T@:;% LZ.;J=G.%8(S?(/3Y1R3ZU1U;XVW
MMQJTMEX5T3[='$3^]D5W,BCJP1<$#W)_ 5T?@S2%D^"\=MI\*1W5YI\PW* "
M\C!@"3^5><_"#Q9HOA&ZUB#79&LY9MFR1HF;!3=N0@ D'GT[?2J:]]QOM^(X
MN\%+N>C_  _^*5KXQGDT^[M18ZDB%P@?<DJCJ5)Y!'H>W.>N.:U?XW7LNNO8
M^&=%2^AC<J'<.[S =2JKT'Y\>G2N5\.J_BSXP7]_HD;16\GVF4/C&U6C90Q]
M,LP_.E^$GB?2/!VM:K%KY:TDE18UE:)F,;*QW(0 2,Y';^&I3NU?32XWI>VN
MMBE_PD(\4?&32=6^RO:M+>VJO"YR492JD9X[CT%>JR?$B^3XK#PB+&W-KYPC
M\_+;^8P^?3K7EUSK-AX@^.5EJ>F*1:3:E;;&*[2^"BEL=LD$\\^M:7B:^B\.
M?'\ZGJ"NEJL\4I<*3\AB"[@.X!ST]#51V@GMK^@5+^\UOH>B?$SXA7O@>;38
M[.RM[C[6LA8S%AMV[>F/]ZK/C3XE6GA#2;*1K;[3J-[$)([</M"C RS'G R>
M/7%>5?&3Q;H_BC4=+71[G[2EK%)YD@0JN6*X R 3]W]:E^+$$EGXG\.:G<PF
M6R:P@ !Z-L8EE_)A^=1&[2OI=V^0F[2TUTN;UA\;]4M-0@3Q)H MK2<!EDB5
MT8(?X@&SO'TQ6!\;=:N=3U^SMOLP73[>/?:70!Q<"1$8D'H0..E=MXD^*W@.
M<6BR:>NNY!(!M%/DYQQ^\ Y/MZ5SWQS7?I?A69+-K2+RI0("H'DY$9"$#@8Z
M8'I1+9/S*CO\CH] ^(]WIOP\GU77-(>W^Q>5;6D05D-SE1M.6[<9)&>/6L2/
MXT^([9+?4M1\+JNC7#[8Y4#KN^CGY6/!XP,X-:VM>)_"&M_"J%+QKV[LX1!;
MS-9PXDMYMF0?GP,<$9Y'..]>;MJ5SX5T>SO_  WXS%Y9R2$?V;.F)(CR3NA)
M90/]H'N,5<W^\E?O_7W[D07[N-OZ\OEL?2^G7]OJNFVVH6C[[>YB66,D8)4C
M(KPK3_\ DY1_^ON;_P!$M7L_A;4Y-9\+:9J,L"P27-NDC1J,*"1V'IW'M7A^
MNWB^#?CTVK:C')]D,WG!E7.8WC*[AZX)/_?)J&K55\QIWI/Y'1?M!?\ (-T/
M_KM+_):T]0^(47@;X>>%U2T^UWMWI\7E1EMJJ%C7+,?J1QWYY%<5\7/&FD>,
M'TFQT&22[,+.S.(F7+-M 4!@"3P>WI6U\1;7P_9>&?#.C>(EU*WU"WL42&[M
M(5DC4A55U8%ANP0#QSTYYH5^5^<OT-&TVO)%_2?B_J]MK]KIGBW0/[.6Z*A)
M0CQE QP&*OG*YZD$8Y^E;GC[XGQ>$KZ+2;"R_M#590#Y>XA8\_=!QR6/]T8^
MO2O,(_%&L>#_ !#86UKXEM_$VGR;"(SF7Y2<;/FR8V] #Z9]*;\1+>;3_C'+
M<75]/IL4[Q2Q7T:%VC38%W  @G!!'!SQ5/7E]69JZOZ([31OC)?V^MPZ9XOT
M(Z89B )=CQ^6"< LC\[??/X5I?$#XLKX4U/^Q]+LTO-050TK2,=D>>0N!RQ(
MYZC&1U[>6Z];Z5JFLVME/XWU?7K@[8XI(=.\P L?N@O,#GIT&*OZG-'X0^.(
MO=:626UBG67S&3)*-'A7 [[3Z=U-+>R?F/:[78H?$/QO?>*[33;75-(?3KZS
M9V=2& =7"X(#<C[I]?K7T-X1_P"1+T+_ +!\'_HM:\+^,7C#0O%-SI2Z--]I
M-LDAEG\MD'S;<*-P!.,$],<_6O=/"/\ R)>A?]@^#_T6M7'^&_7] ENO0V:*
M**@ HHHH MI]Q?H*H7_^O7_=_J:OI]Q?H*H7_P#KU_W?ZFM*?Q$RV*M%%%=!
MF%%%% !1110 5QGQ.\+VGB7PC<-=331'3XY+N/RB/F98VP#D'BNSK(\5_P#(
MGZW_ ->$_P#Z+:LZB3@[FE+XTO-?FCQ?X%WRZ9I?B^_896VMXIB/7:LI_I6/
M\.O!,7Q,U+6=2UV_NP8V5F:!E#22.6))+ C QTQW'I6O\#K'^T]'\86&=OVF
MVCASZ;EE']:SOA5XUT_P%>:UI^OI<0&1E^['N*2)N#*1USS^E+W>9<W\HM>5
MV[_H7?A9<W'A/XJ:GX8:=I+5S-"0> S1997QV.U3^=97@WPZ/BQXWUB^UF[N
M8X0#,QA8;\LV$0%@0  ,=.PK3^&D;^+?C!J7B".)TM$,\YW#[OF95%/OAC_W
MR:H?#SQ%;?#3QGK&GZ^DL<9!@=T0L59&RIQUVD$\CU%*-O<Y^S_,)_:Y.Z+G
MA"&;P#\<'\/07,DEE,_V=]W\:LF^,GMN!(Y^OK6%XP2VB\2^,(_$5O>OK4UP
M#I;C.T)YA]^04V@=>GK6[X;NO^$[^/7]M64,BV<<GV@EQRJ1QA%)],D+Q[U[
M=XMU^U\+^'+O6;I58VZ?NE/5Y#PJCZG],U-OW492>U_N_P QIOVC2\CQ#Q;K
M.M:WI'A;P"AD?4WBA:^#D[MY'R(_?Y5PS9]CVKW;P[H=KX;T"STBT'[JVC"[
ML<NW5F/N22?QKYWTF75]%\+ZE\17^;5+^Z^S6D[H&\O<29)0#QVV#TYKMO!'
MBGQ!:?$*S\.ZAKT6NVE]:"X\U,-Y+%"^,CZ8QZ$'BM8/5I[O?[KI?<1)62ML
MMOOLW]Y[-7R?XXO;KQIXRU_5+-3+:6*\$'($*,L8(^I;=^)KZ'^(NO\ _"-^
M!=2OD?;</'Y$&#@^8_ (^G+?A7S[X-G\3Z7HFIII?A2?4[/5X3!).;25QL&Y
M2%9>.I/XCVK*I[TK=E^)I'2/J_P/=OA3K_\ ;_P_L'=]UQ:#[)-ZY3&#^*E3
M^-</_P +QU1->OM-7P]'=R1R20VT=LS;W<-@9Z\8!/ _QK)^!>L3:1XLU#PY
M>J\+72$B*4%62:/.5P>AV[L_[HI/A.BM\9=9+*"52Z*DCH?-4?R)JY2<JD;/
M1I_?_7YF:7+!Z;-'3^$?C-<ZGXGCT+Q#I*V$\\GE1NFY=DAZ*ZMR,GC/KCCN
M*'B;6=,@^.=E9R^&[&>[^T6T8O7DD#Y8+ABH.TD9X)!Z#T%9'Q%14^/.C,BA
M2\MFS$=SYF,_D!^51^+_ /DXRQ_Z_;+^244I<[A?NU^9HXI<Z\D_Q.E\1?&>
M^\/^-K[1FT>&YMK:0QKL=A(YVY4>GWB.QXJG8?'>]M=9^R^)- ^R6Y/)B#"6
M('H2K?>_3\>E9,"+)^TR0ZA@+QC@CN(20?S%3?M"QH-;T20* [6\BEL<D!A@
M?J?SK&-22IQDWN[?F#BG.4>Q;N_CQJUO=QW/_","/2I2?*,S.KRKZA\;?P /
MUKT/4_B-H^G^ X/%:B26WN5 MX,@.\AS\A[ @ALGG&#UK"^,<$2_"G:(U BD
M@\L ?=[<>G!(KS/6[.YG^ WAFZC#-!;WLXE Z+N=PI/MD8_&KE-QYH]FM?4F
M*4N67=,Z.U^.VN&.:]NO#4;:=RB30[P$?'RAF/!YQD<5KZ3\0+WQW\/O&;7E
ME;VQL[!PODDG=NCDZY_W:S;?XD>$X_@X=%9B-0&G-:?8_(;YI"I7?NQMP3\V
M<Y_&L+X7_P#)//B#_P!> _\ 1<M4]IJ]TE_D"V3\SHO@->VFG>&==NKZZAMK
M=+F/?+/($1<K@9)X') KU#_A-?"G_0S:-_X'Q?\ Q5>1?!W0+3Q/X&\1Z/?-
M*MM<7,.\PL PV_,,$@]P.U=/_P *#\)?\_>K?]_X_P#XBM9.6ENR,X6U]61_
M&^[MK[X;6MS:7$5Q;R7T926)PZL-K]".#7 ^$/A_X.U[P_8W6H^+HK/4;@LK
M6?VB$,IWE5&TG.2 #^-=G\7=&MO#_P )=.TFS:1K>VO(T0RD%B-LAY( ]:J?
M#;X6^']8\+:/XANGO?MK.TI"2@)E)& XV_[([U"BG.6FFAK)M4X]]?S-3QEX
MSNOA38:%H>G6L-["+4KYER2&PF /NU/X:^,=MKNIZN]Q9K9:3I]F;GSG;=(^
M& Z=!G/ YYQS7)_M"_\ (8T/_KA)_P"A"N[^(NB@?!^\LM*M5C2"&)_*B7'R
M(RLW3T )_"LXSERSD^C:_KT#E7-&*71?U\SCY?C=XCO6N+W1_"GF:3;D^;*Z
M22;0.<LZ_*G'/.<>]=[X:^)FC:_X3O-=ES9BP7-Y S;C'QQ@_P 0/0<#)XKP
MOPQ=6\7A2Y\WX@W^C>67W:9#;._F9'5<. <].<8[\<UHZ+X?AN/AEXNN]#N=
M1NH\0"1;BS6 'RWWMC;(^["\GIC\:?-))^G^0K7:]3II?C=XCO6N+W1_"GF:
M3;D^;*Z22;0.<LZ_*G'/.<>]>D^!?'%CXYTA[NVB:WN(6"7%LS;C&3T(/<'G
M!P.AKY_\,75O%X4N?-^(-_HWEE]VF0VSOYF1U7#@'/3G&._'->C? K3+"%=8
MO]-O+^X@?RX6-U9K -PR>-LCY(!]L9'K6D&[M/L3+:_F>QT4458@HHHH ***
M* "BBB@#0T__ %3_ .]11I_^J?\ WJ*YI_$S5;%NJ]]86>IVK6M_:07=NQ!:
M*>,2(2.1D$8JQ14#,V;P]HES80V$^CZ?+90',5N]LC1QGGE5(P.IZ>M/NM"T
MB^N(+B[TJQN)K< 0R36Z.T>#D;21D8/I5^B@"A:Z'I%C?2WUGI=E;W<V?-GA
MMT21\G)W,!DY/)SWI=1T32=8\O\ M/3+*^\K/E_:;=)=F<9QN!QG _*KU% %
M"/0])AU(ZE%I=DE^PP;I;=!*1C'W\9Z<=:2_T+1]4GCGU'2K&\FB&(Y+BW21
MD&<\$@XYK0HH IZCI&FZQ (-3L+6\B4Y5+B%9 #ZC(X-)INCZ9HT+0Z9I]K9
M1L<LMO"L88^IP.35VB@"A:Z)I-E?S7]II=E!>39\VXBMT623)R=S 9.3R<]Z
M-1T/2=8:-M3TNRO3%GRS<VZ2;,]<;@<=!^57Z* (YH(;FWDMYXDEAD4H\;J&
M5E(P00>",=JKZ?I.FZ3 T&FZ?:V43MN:.VA6-6.,9(4#G@5<HH QAX1\-+=_
M:AX?TH7&[=YHLX]V[KG..OO6S110!1T_1=*TEY7TW3+*S:;'F-;0+&7QG&=H
M&>IZ^M.U'2--UB 0:G86MY$IRJ7$2R 'U&1P:N44 4M-T?3-&A:'3-/M;*-C
MEEMX5C#'U.!R:;:Z)I-E?S7]II=E!>39\VXBMT623)R=S 9.3R<]ZOT4 9<7
MAK08);B6'1--CDN4:.=TM4!E5OO*Q ^8'N#UIO\ PB_A[[!]@_L+3/L?F>=]
MG^R1^7OQC=MQC=CC/7%:U% %=K"S;3_[/:T@-EY?E?9S&/+V8QMVXQC'&*9I
M^EZ?I,#0:;86ME"S;VCMH5C4MC&2% &>!^56Z* ,>?PEX;N;MKN?P_I<MPS;
MFE>SC+$^I)')K750JA5   P .U+10 4444 %,F_U1I],F_U1H JT444 %%%%
M &7KWAW2O$UBEEJ]J;FV602!/-=/F (!RI!/4U/I.D6.A:9#INFVX@M(<^7&
M&+8R23R22>2>M7:* .=NO OAN\\1+K\^G9U19$D$ZSR+\RX"G:& [#MSWI;;
MP/X=L_$;>((-.V:HSO(9_/D.6<$,=I;;SD]JZ&BA:; <_KW@CP[XFO8KS6-.
M^TSQ)Y:/YTB87).,*P'4FC4?!/A[5M<AUJ^T_P W4("ACF\Z1=NPY7Y0P'!]
MJZ"B@'KN<]=^!_#M_P"(DU^YT[?J<;I(L_GR##)C:=H;;Q@=JG\0^$]$\5)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %M/N+]!5"__P!>O^[_ %-7T^XOT%4+_P#UZ_[O]36E/XB9;%6B
MBBN@S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#0T_\ U3_[U%&G_P"J?_>HKFG\3-5L6Z***@84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,F_U1I],F_U
M1H JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% %M/N+]!5"__P!>O^[_ %-7T^XOT%4+_P#UZ_[O]36E/XB9;%6BBBN@
MS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#0
MT_\ U3_[U%&G_P"J?_>HKFG\3-5L6Z***@84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,F_U1I],F_U1H J
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% %M/N+]!5"__P!>O^[_ %-7T^XOT%4+_P#UZ_[O]36E/XB9;%6BBBN@S"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#0T_\
MU3_[U%&G_P"J?_>HKFG\3-5L/^WV?_/W!_W\%'V^S_Y^X/\ OX*L45 RO]OL
M_P#G[@_[^"C[?9_\_<'_ '\%6** *_V^S_Y^X/\ OX*/M]G_ ,_<'_?P58HH
M K_;[/\ Y^X/^_@H^WV?_/W!_P!_!5BB@"O]OL_^?N#_ +^"C[?9_P#/W!_W
M\%6** *_V^S_ .?N#_OX*/M]G_S]P?\ ?P58HH K_;[/_G[@_P"_@H^WV?\
MS]P?]_!5BB@"O]OL_P#G[@_[^"C[?9_\_<'_ '\%6** *_V^S_Y^X/\ OX*/
MM]G_ ,_<'_?P58HH K_;[/\ Y^X/^_@H^WV?_/W!_P!_!5BB@"O]OL_^?N#_
M +^"C[?9_P#/W!_W\%6** *_V^S_ .?N#_OX*/M]G_S]P?\ ?P58HH K_;[/
M_G[@_P"_@H^WV?\ S]P?]_!5BB@"O]OL_P#G[@_[^"C[?9_\_<'_ '\%6**
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?ZOY4>U\@Y2M8 B-L@CGO15H #H /I163=W<I:'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>forms-1_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-1_006.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S 'L# 2(  A$! Q$!_\0
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MF-3UMCH::Q@$#"Y],D<-D'!_('X3?LZZY\=_VE?VV88/BWXM^&_@_2OC ?\
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M*)?V)_\ @G[??M)_M5^+?!_[1?ASQ5^TW^TA\;OA[9CQ+^T+KVEZWHY4^"_
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M^T/H_AO_ (2/4K;3[KXP?\(Q_P *]_X0_C_A QHN/^$TUS7/?\>* /RMT?\
MX(?_ +6_Q'U7X3?!W]LO_@H#KOQU_8^^"/B[PQXI\(?!.S\-#3?$OCO3/ A7
M_A!-#\<^-L[SX?\ "O\ 8FB%0J,/D;)5BJO^F'P3_P""<VA?#'X_?M\?%GQ'
MKVF>+/!'[<NC^%=%UGX>W>CC^S=!\+^!O!>O^ QHVN:X1PK>'=;(!]=P!W+Q
M[_\ M6_$CQ%X$G^&^F:)XWG^'%AXGU?Q38:MJ]GHI\2%1H?@S^WM%7^QB/\
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MA?\ $EU\C6];ZCCQ)CPP"#V&.U?<^F_ZNX^G_LIH _FM^&/_  1W_;RT&_\
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=K?Z1L_><'CGIQ]*LV  AX'<?RHHH O4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !* R # 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M!G[7?[<WA?\ 9J\0?#CX.>#/ GB#]H']JCXVS7,'P<_9S\":AI^E:]KME8"X
M.I^-?'/BG4TET;X9?"_119WAU7QMK\-POE:?K-QI.E:M:^'/$USHG#6?P_\
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M0^+O"E[I6L>%C'*NZ?4K/5K*]@@61;5+J9DM)_SK_P""0/@K5M>\*_'+XO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME8_\MIM06WAB'(\V2/U!K\XM=^!_[<?@?_@J=\3_ -N;X??L]>"?'_PM\1_
M6T_9RLO">M_'7P_X$\=W^D6.N>#_ !'/X]MX8]"\5Z!!)+KGA:>/2-$U'5K6
MXN?#.HQWNIS:'KGGZ%'J?MH:)_P4D_; ^"GQM^!/AS]F3P=\(?#'Q"^#.N^
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M6]#U>U?3]6T;6-*U".:QU/2M3L;BYL]0TZ\MY;6]M)I+:XBDBD9#^.O['/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX<M?'OAOPQ>^(=&U;2;>YO+?5=%M[^P'V.^@EN([BQNHH_ M._;=\,>(+/\
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MCLX+6>298V^>&_;/TO\ M[7_ (8)X#N8OCOH/Q2U;X6S?#V^\6:-:>&%72O
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M::Q'K/@_PC\1O%3_  H/A'P%JOA!O$?CIM4\ 6'A>Q\$Z[X9@\1Q_$72-?\
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M#&_UKQYX'T'XYP6NB2Z59/XHTWQ;\2?@S\1;G4K30OLL&F^ /AUXT^*?PO\
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M\"Z;\7K#3?"/Q T'QO\ %O5($N?#WQK^"/PS\":7XV^)?Q%NM7^'GT[:Z_\
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M:XZQ^(G@'4HEFL?&WA*\C8 [K?Q%I$NW@9#JMWO1@3AE=5=#PZJ>*CO?B/X
MTU&EO_&_A.T11D^?XBT=&/RE@$C-T))'(&52-6=A]T'@'IO&U[QLNMU9:>O8
MY.65W[DK];0DVM>MHZ:][:G9,$5=Q  XSDXP,C))/3;U)]NM<#\-O%[^._"5
MOXH>"WMX-2U?Q+%IBP&7;-HVF^)M6TO1[N03%B+FZT^SM;BYPWEM.[RP+%$\
M<,?S%\:?VFM#NM"U/PM\/9[B^GU.VGLM3\3M!-9V5C831E+N/24NHX;NZOIX
M6E@^V^1!;6:.+JSGNIPAA^F_A9H4GAOX<>!]$EA-O=67AK2C>PL-K1:A<VL=
MYJ*$  Y2]N+@=,G'(#;JQA4C4JN,&G&$6Y2C9KF<ERQOULE)NVEV;3HRIT5.
MI%QE4J6A&2LU&*O.33U7,VEJD[+7<^*/VNF4_$G0D Y7P+IS9SR ^O\ B5>F
M.!E#@YP>F!@5]4_LY?\ )&?!1]8]:S_X4VL>W^R>.@QCTS\=?M2ZK!J/Q:N(
M()%D.A^&]#T>Y*D$1W!DU+6#$Q&1O6+6("PSE2=I.5Q7NG[-OQ9\%V?@?3O!
M.NZ[I^A:UHEYJBP+K-U%I]MJ=GJ&IW>J6\EE>W)CLY)XWOY+62R,R7FZW,RP
M-#(LAYZ<E];K7=D[I-O1.+BTE?17LUTTN=E>$G@:"2D^6TI**DVHM5'>VKLG
M*-].MW;<^PL#T'7/3_/M6)XD^R)X>UY[S8MJNBZLURSXVBW%A.UP6R0-OE!R
MP) (!SQDTLOB7P[#;&\EU[1([14\UKJ35;%+98^,2&=IQ$$Y'SEPO(YYKY.^
M-7QML_%%A<?##X6>=XOU[Q+&VFZG>Z%"]]:1:7,"M_8Z=<1J8[^:_M\V]Y?0
M;]*L-,GNII+Y;A08.JI.$8MMIMIJ*5G)NUH\J5V]7NEIO?0X*5*=2<5&+LI+
MFDU:,%=7E*3LHI)=6F]$NZ^6/@3H-QX@^*/@*UA5R-/U2WUZ\D )$-KX?4ZH
M9)"!\J27=O;6:'&#/=1(3\Q(^L=6^(>I67QXT3Q-]KU\_#^;Q-=?L^WEL-.U
M0^$#JFIVMCJFF^.H-9%FFD-K"?%6WD^"EQ8&]>>'4)#B!<2N.X^ WP7/PTTB
M\U'6I(I/&6OVR17SVS)+%H>GY$D>CV5P59)IQ*J7.IW2AH+B[CMX8EFM[""Y
MN.[N/A#X+O/A]=?#*\MM4NO"U]>7.IW/G:]K']NOJUUXHD\:R:ROB6*\CUV/
M6E\5R-KD.KQWZZA!J 2YAN$E1&7+#T94Z23TE*7.UJK6^&+WNK735VEHDM&C
MIQ>(A5K-KWX*+II]^:3=2<=>]N5]5%ZJ^O+Z;J_Q6U'QIXD\)+K?P]A;PSI7
M@W5;F]/@CQ*XND\4GQ.DUO!$OQ$38VG2:#$T<LAQ?+<NCQV)C5SA^#_B1XZ\
M0W7A32KJX\'KJGC*R\>:U;W$/A[7+:TT70_AKXHL_"^O226LGBZ^EUW5-9OO
M$'A5-+M(KW0;?2K:37=1NKK57LK+3+[VO2O">EZ1KVL^)+9K^75_$&FZ#IFJ
M7-W?W%S%/;>&TU!=+,=K(WV:TF4ZKJ$MU-:Q0O>RW&^Y\SR;<0\W%\*/"5OI
M/AW3;)=7LI?"6J:OK'AO6H-:OQK^DWNN75]=:NJ:G+++)>Z?J4FHW(OM%U5-
M0T6ZC6SCGT^0:=IQM.JUGNWH]WUT\EJ[;G'[KWBMEM%)WL]]7]K7[[6>_BOB
M;XV^*_#<^OZ7?-X(TG4O!VN>+='U?5=4L]:.@:^NE_#/0_B=X<O=-$6N07?A
MYM2T_6AHFKZ?>R^([JQU.VFN+(ZA:-I_]I>A/\5+W3O&\'AGQ7X?B\-Z3JUA
MX2T[2_$QO!J=GI'Q"\2PW;P>"?%9A6W@LDU:<6VG^#=>MKK^RO$>OI=>%+FX
MT;Q#JO@FT\7=>/A=X0:\L;^:SN;R[M+W7=3O)K[4;R]'B&_\2Z)%X<U>X\4P
MW,LD'B!9="MK71[.VU&*:RTG2K*PTO1[6PTW3K"TMH-(^$O@O1]'UKPXNGW6
MJ^'M>T>Q\/:AHOB/5-0\2:?)H6FV]W:6.DJFM7%Y-]DMK2\EM4\V:69K>.VC
MDED%K;F)6=MTW>Z=EM:W9Z^>_GT#W+?#;W;:::W3NDK>MMOS/,_#_P 2_'7B
M/6-!T))O#>DWVM?"/X<^.8W?P+XS\0:>GB+QO;>-UO+*_P!4TKQ)%IWAW2--
MN_"]G-8MK-PDVKK<76EVM]]M$5RD,GQB\5-X5N_%W_".1:5IOA.73/#?Q&B3
M0M<\37_A?Q7::E):>/KVQTS3]1TJ_P#$OA#P3%#;NU]I$-Q)K6FZO)XEL+@V
MOAFZTG6_5]+^%_AK1=4TK5=)FU[3Y]*\,>%?!T,$/B'5WM+OPYX*DU6?PYI^
MI07%U*U^UG/KFIRW-[-)]OU7[3Y.K7-[;1QP);A^'^E6=OJ5OIVH>(M+.J^*
M=2\87=S8:]?K<C5]7AEM]22)KB2XB32[B&>81:28FL;&=HK[3XK34+6SNX$X
M^KZ]-UM9V[_/S0>[_+VMTZZKTM:RVNMGL=/HEX-2T72;\W^F:I]NTRPN_P"T
M]%;=H^H_:;6*?[=I#_:;S?IEWY@N+!OMEWNM9(2;FX),KZ@51T &?;W)_F2:
MSM'TC3?#VD:5H.C6D=AH^B:=8Z1I5C"7,5EIVFVT5G8VD1D=Y#';6T,4*&1W
M<H@W,S9)TJL3L_->?]>@4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'D7Q_^&%W\;?@7\8O@S9>(;?PE/\6OACXY^&A\
M3W6AR>)8M M_'7AK4O#%YJPT&/6O#K:I-8VFJ3W%M:'6M/CDN4B\Z8Q!XW^;
M?%W[$.D^)_B7X8^(T'B;1='ETCX6?M ^&/$6FVNA_$B.\\:_%/\ :#UCX+ZW
MKOQ/U[Q9I_QMTOQ7=Z-X>D^!GA#0M!^'>HZIJ:6/@I8?"&G>+M,TKP_X1'A_
M[OHH _,_0_\ @G4ND_!3XA? *?XPR7?P^^/GP"^'GP%_:,M8? *VFH>,;'P5
M\&](_9YUOQ?\,[Z7QG>R?"S7_B!\&=$TCPEXAM-5'Q*T32[[0M#\3>$]/T#6
MAXEG\4>KV?['9B^-VB?M"R_$7[!\2-"\>?$?5YW\*>$I/#_AKXA?#7Q3X:\=
M:;\//AM\8M!N_%>NGQU?_!GQ1X\U;Q?X&^(&FW_A'7=+;4?%_AS0K/PYH'Q%
M\=6NN_;-% 'P?^SM^QKK'P&TKX*:!=>/O GC?1_@OI6FV6G7E_\ !_49/&E[
MJ%I\(C\(]2US0?&7C+XK_$"[^&UYKVD:9X4;4=-^'=EX=\.MI6CZMX>71OLO
MB>^NK?7^+G[*FN_&;Q?\4O'VH>+O"W@CQ;XD_9J^+7[*W@+4-%\'WWB%=+\"
M_%[7/#>L^(/$_P 2GN/$/ABX^(NM:1<^#=#NOAOX:M)?"NC_  TGUSXE1#5?
M&0\>W-QIOVS10!^>4_[ VF:IK6C:KXB\;>'==B/A_P#9F;Q1!=?"^&2_@^)/
M[*>O6?B'X>_$7X2:]?>,]1U?X4OKUQINCZ;XYT.:X\;RW6E:%I4O@[7?!'B.
M77O$>O=N/@'^T/<^.4\5^+_C5\%_B3HS?#G3_A[JF@>)/V;-5L_$.L:6_@W2
MX?'FB67BK_A>.N^"O"GA/XP?%'2+3QE\1M.L_@UK&I:CX0L_#WP_.IW$O@SP
MEXLTG[6HH _,N\_X)H?#R;1+73;35?!<;^*/ 'QB^&WQIT?5/@SX4U7X<^./
M#?QGL_ACIU[_ ,(-\-1JEGHGPNN?A5H'P?\  /P\^!]O)<^.-"\,_"G1H?"W
MQ#T3XK>(H-.\;Z?]=:5\(-9DC\&Z-XY\7P^./#/@QOB6UKI]SH<^GW&IP>)[
M_5-$^'=GK-X^LZE<:I_PKGX1:YK'P_U._P!1NKRX^(.MWJ_$#5;?2M9M+6UC
M]ZHH _.[PK^P':^#M4^$/C/2_BM>WWQ*_9W\,?"/X<_!7Q1KWA!-1TNS^&WP
M<\#_ !T^&6D:5\2M"M_$VGZCXZ\5>+O!'[0_CE/B!XF\.^)_AUHVM^+= ^&O
MBC2/!OAY/"5]HWB/4^&/[ 7@OX477A;1_#WC35KWX;:)X_\ AC\:==\'ZSHU
MC-K'B[XW_"WX1Z3\(-*\=ZEXKT^[TV&ST[6K+PEX"\=:_P"&++PTHN/B/X0A
MUJQUFPT+6=:\,7GW)XCFUZWT#6[CPK8:5JOB>#2=1F\.Z7KNJ7>AZ+J>NQ6D
MTFDZ=K&MV&E:]>Z-I=]?K!:W^K6FAZU<Z;:RRWD&D:G+"MC/^,'A/_@K#\5/
MB#X ^*'B'P'^R9#K7C_X8_ #0?VBKOX5WWQ2\3:3K'B#POH/AOXD:-^T9X(\
M.ZP?@U>V>I_%GX ?M+?##7_V9+WP7!:^5XP\3SZ9XMCUKPYI%S<Z;IX!^E7[
M1/[(_P"SG^UG9?#K3_VB?A7H/Q1L_A/\0-(^*/@"'6[G6[(:%XUT-)8[._9M
M"U729-6TJXCE,6L^%-<;4O"?B*&.WBU_1-2CM;98OHT9P,G)QR>F37X^67_!
M4;6]9^'GQ;^,.@_!WPOJ'PJ_9_\ BEX<TSXT>*KCXD^++&70?V;_ (@:Y\+M
M>^''[5'A&P/PCN8/&GA#6_V:_B3<?M-^)?"YU+0;GP?X6\(ZKX0?Q!K.M7EI
MJ0OZ3_P53T31_@CX^^+_ ,9/ 'ACX6:O\/-3UWX=ZW\*K_XJ1IXYC^,W@_X]
M+\&/B#I,UGXH\(>$KU/@U\--'\8? WXL^/OCE::1J.F^'_AS\7X=8O\ PQ:R
M^&'M=< /O?QQ^SMX2\=^.]?^(U]XD\>Z)XJU[X1ZA\&H]0\+^(+?1I?#GAS4
M=6N]8EUWPC<KI<^H>&_'=M<W]VNG>,=-OHM7TV*8&PDMYK>UF@\M@_8.^ ME
M_P )AI>GV.JZ7\//B'K7ASQ%\0?@MIMIX+L/@?XVU?PQ\.K'X76,_B/X5VW@
MZ/PE=65[X7TK1#KFB0V%MH&N:MX<\*:KJ>EW-UX2\,G2?EGXL_\ !33QC\*+
M#]I^Y7X"^#?B'<?L>?#[QI\1/C<O@G]HSPS;6=OH&B_ [XU?'WPIJWA2'QAX
M.\-^+_$NE>(/#'PW\#>$-9N=%\%:K%H7Q)\?^.-!TNZ\3:'\"?%7B;Q#@>.?
MV[OV@[#XK^)_A7XI^'?PQ\ :3X*^)?\ P3<TC5-?^$OQ^N?&'C:YL?VROVO!
M\*])M[:S^)O[+=OX:\0^%=:\':9:VWQ'TNUTOPEXFT+2=4\46'P\^(J^)KKP
M]XZ\'@'Z5?"GX(:/\(])T;1]$\=?%KQ/%X=^&WA;X6:3+\1?B/XB\;M#X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !65;:%HEG++/::/I=K/.MZD\UMI]I!+,FI:A<ZMJ*2R11*\B7^JWEYJ
M=ZCLRW6H7=S>SB2YGEE;5HH Q(_#7AR+3[_28M T6/2]5M5L-4TR/2K%-/U*
MQ33(-%2SU"R6 6UY:)HUM;:2EO<QR0KIEO!8*@M8HXERM4^'O@'7)I;C6_!'
MA#6+B?3_ !+I,\^J^&]&U&:;2O&=O86?C#399;RRF>2P\66FEZ9:^)K-V:WU
MZWTVP@U6.[BL[98^PHH \;F_9T_9\N+/3-.N/@3\&Y]/T7P9?_#G1K&;X8>"
M9;/2?A[JDCRZGX#TRV?0V@L/!FHRR22W_A>U2+0[N1W>XL9&9B9M;_9\^ GB
M9M&?Q)\$/A#X@?PYHFA>&?#SZW\-?!FK-H/AOPO>-J/AGP_HS7^BW!TO1/#N
MH.]]H6DV)@L-(O':ZT^WMYV+UZ]10!X5:?LN_LSV$;0V/[.WP*LH7_LG?%:?
M"/P!;1M_8.M2^)-#W)#X?1&_L7Q%/-KVDY'_ !+M:FEU2S\F^D><V+C]FC]G
M&[LY=.N_V?\ X)76GSFY::QN/A3X$FLYC>:[=^*+LRVLN@O!(;KQ+?WWB*Y+
MHQGUV]N]7EW:A<37#^VT4 >+G]F[]G<V=SIQ^ GP7.GWEIX4T^[L3\+? YL[
MJP\!V<NG>![*YMCH7DSVG@W3YY['PI;2H\/AVSFEMM(2SAD=&FU[]GCX >*6
MD?Q/\#/@]XC>6'3;>5M>^&?@K6&D@T;19/#>D0.VHZ)<%X=*\.S2Z!IL3$QV
M.B22:5:K%8NUN?8J* /#?^&8?V:OM=]J'_#//P-^WZI8ZUIFI7O_  J7P#]L
MU'3?$FAQ^&/$6GWUS_PC_GW=CKWAJ*+P]K5I</)!JFAQQZ3?1SV"+;CHY?@E
M\&)[32]/G^$7PPFL-#\1:!XNT6RE\ ^%)+31_%GA3P]I7A+POXHTNV?26AT_
MQ%X;\*:%HGAG0-:M$AU+1_#VC:5HNG7-MINGVEM#Z?10!Y???!#X+:I+=SZG
M\(?A?J,]_P"*]-\>7TU]X \*7<M[XXT:]U+4M(\97<EQI,CW/BO2M1UK6+_3
M?$4Q?5[&]U;4KJUO(I[^ZDE?X3^"GP:\!:K::[X%^$OPR\%ZW8:5JF@V.L>$
M_ ?A7PYJMGH>N:VWB76M&M=0T?2K.[M]*UCQ&[Z_JFG0S)9ZAK;OJMW#-?,9
'SZ;10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !2 2P# 2(  A$! Q$!_\0
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MW[_X&DWKG;SG)' SR!GM2;2W:7JTOS:"_P#6O^0ZBF;QD]>..G?&<?J*=D$
MC/)QT_SP/6CFB]I)^C7KW[!?^K/_ "0M%&1Z].M)N& >Q./H>^?ICFBZ[@+1
M3=PYX/'Z_3USD8^M+N'&>"1G'? ZTP%J)\[3D%@< J.G4DDY]1QSG)XQS3R<
MC )&<X([8^HZ=OQJE<7*6UM-<7%RD$5LLLUQ/(42.&&!#),\C,=JQQQJSLS$
M!54ECZ+1WNURZW?2R6MVKV]5J@VWUZ6L]>G37^M![LBX!5@2N."I"HN?F8D@
M*%#<G/0J #\P7P?QS^T;\,?!4T]@=3F\1:Q:Y6;3/#L:WH@EVHZQ7FJ,Z:5;
M,P="\9NI;A#E9848 -\T_$[XS>+/C!XCC^'OPS%W%H5Y=-8+-9-);W_B9\-)
M-?7-W&P?3_#UO'$\IA50TD"O/>R.)(+4?1'PK_9S\'^!;>VO-9L[;Q1XJ$:R
M7&I7T"OIEC*=^;?1=.F5XXH44K&]W=":[NIA)=?Z-&\=K#R*M*;=.C90BVG-
MZ*SLDX.[;5^:[=NGRZ50IT;3Q/.JDHIQHPFXMP>L6WK&SNFM;]6M[>91_M'?
M%#Q,[-X#^#>H7-NX+07<R:IJ@)W*K.UQ;6EE8^6)&0@M.B ':[C#O4X\??M8
MR_O8_A?I\4;#<L;6ED'"CJ"DWB%)E;@85P-Q(P%VM7VE'"D40A15$8&U45%1
M$3@!510% 4= !_A3@B]Q\IQ\N#QC@=.!@<'(//.>M:>QG_S^G_7D2Z]):1PM
M)1?\[E*7>\I)I7;=FTE<^$KWXZ?M"^&]TOB+X6+%;Q!M]S)H6M);E5P68W=C
M/=6:JA;YVW+@%2"X^:G:7^V4,[=>\!OQ( TNC:VH,2@$ &UOK16$N0,*+N)-
MI^8C//W4R#HJD@\XW$*1C!!'0C&."#^E>-?$7X'>!?B#;7(NM+AT;7'B/V;Q
M'HT$5K?03??$EU%&JP:C 74++#=I(SHS"-XY%659E2K1NX5D]&U&I!/5=5+=
M?UZEPJX9O]YAE&_VJ4Y0MY\KNGOM?5::&5X"^/GA#XCZK+H'A_3O$%OKHTJ]
MU6*UUFUM[6RGCL#!&\<FIV=U?0Q/(]U$H+1LYB,L@0E"M4/%_P 7?B%X%TV3
M6?$'P>:71X-GVG5M#\=:=JEK8^8?+3[9"=%AO[='E(0W'V-[*-MHFNXF95;P
M;]FKPMJ7A3XU^-?#^N1)_:/AWPIJ-K(ZAO*E676]$:&\@+J#Y-[92+)'GY@C
MG?\ ,./L;XE64=[\-O'\#1B0R>#_ !,B@(KL7CTF[>':A&UG66*-H\C.Y5[B
ME!U9TFW)QG"^ME9M1U4ENUOI;=J]R:U.E2K\L4I4_<D]]8S2EH]>CW>VOD?,
MMK^V);74L%M9_#75KF]N91;P6=MKUO<3S22;?DAB@T=YI'W;MT:1&0;)#MP!
M77GX]_$..(74G[/'CN.R"&1YFN+@L$4'$H1/#^4&"S'>%=@=I3<0I^*?@PQ/
MQ8^&C%@0?%=F=Z\AMVG:DQVGD["1QGEE)W'J*_78*#(-Q(.PD'G=NW=21SR&
M'![8 S\V8H3K5XSE*HDT^6RIQ?*]/M.UU;JU?>UK&N*C0P\HQC04E*-VY5:B
MLGU22LFK+1[,^4= _:W\#7-Z+'Q3H7B'P=<)/Y$DDT(UBVMG\S8R7@LXHM2M
MF1L^9%_9CL#D!=S 'Z@TK7-+US3[35-%O[75=-O8OM%IJ%A+'<VL\)4L&BEB
M9D;# *R9$L;?+)&I4X^;OVDOA-8>*?"^I^,](L8[?Q7X9LYM1FN+>%4.LZ1;
M(TU]:70C7-Q/:P"2YM)I5,F8Y;;F&=0OS)^S;\1;_P )^.=,\,S3._A;QC>1
MZ;-:NVZ.RU>ZA+:/J5F@DVP>=<".PO5 _>QW:2XWVY#*565*I"G54)J<DHS4
M8Q5GLY:[)WN];,?L*5;#RKT>:,Z:2G2<N9=VT[7VV757ZW/U%'0<@\#D=#[C
MVI:B610 .1A>G7&.#_ATYIX8$9'3&??BNY2B]$TWT2:;^Y,X;_U9_P"2'444
M4[H HHR!U.** "BBD)QV/(SC'/;]>?YT +11GG'?D_EC/\Q11OL 44@.<\$8
M]>_TI: "BBB@ HHHH \M^+7QD^&7P(^'WB+XL?&3QWX8^&OPY\)645[XB\8>
M+M3@TG1]-BGG2UM(C<3,&N;_ %&]EM[#2]+M$N-1U34+F&PT^UN;R>&WD_/?
MP]_P4A^(/QAMI->_9@_8&_:O^,7@6YM8K[0/B9XUT_P9^SUX*\7V<S.(-4\)
M#XOZ]HOB;6M&NHEBN++48O#L,5Y;SB>&/R5>2OS_ /"NIZ7_ ,%3O^"N_P 4
M?"_CZ6Q\3_LH_P#!,QHAX/\ AE?2#4?#'C_]H;4;_6/"+^.?$FF*HLM7M_"^
MMZ+XJ73K6_:XB@;P]I*;9=/UK6K.?^DI87,2*VUE&!@[0I ., #&T 8 4*%5
M>%]OJ\TRS \+PP&%Q^">:9_C,MP6;8S"5\5BL'EN3X?-*$<;EF"JPP,J6,QV
M8U,#.GB\74^L4,%AXXFAAZ5.M7]O.'PN7YGF7%<L=B<MQZRC(\'F&+RO"XJA
M@\)C<QS;$Y;7EA<QQD/KJK87!9?2Q<)X;"0C1K8RO.C4KU9TJ'L8U/R$^)7_
M  5 ^-/P"T>X\4_M"_\ !-+]K'P=X*TV"74M<\<_#K4/AM\;/#?A[1X&/VG5
M/$$_@37Y[O1K>UC#3W4^IVEI8VT"/<75[!:KYP^X_P!D']KKX5_ML_!31OCW
M\%8_%2^ M:UG7]!M$\9Z"OAS7A?^'+TV.H&;3([_ %*-;8SD?9KB.\E2>/YU
M4"OI9K>1&3;MP2"PW;<Y.2KG!#*RJ4P0?E4@XSBOQR^,EYXS_P""0/[%OQG^
M*GP@\ ?##X@_##P1\:?&WQ7N_AI=Z_XB\$76C>#?C;\7/#EE8:#X/O\ 3]"U
M;2;0>$+WQ==7T]A?6"Z?_9%BECID\3I&K94HY3GU"AEN7Y'/+>)L5F>7X3 3
MP^;8N>58V&+E7P];#U<-FLZU7#8IXB6!C@ZU/&QH-5*OM4I.-2.LO[;X?Q%?
M,,QSN6:<.8?+,;BL?[?*<'3S/ 5<+"E6I8BC7RJ-&&*P]2D\4\31GA)5J,:"
MG3<[\C_90O( QX. QQC')'0A#G)!!YY'\X_.E&%V#&3U#'H">#P5) S@D'G(
M/<_DWJ/[4O\ P4@O?@=X9^.O@C]D/]F3Q1H'B7PEX=\=Q^']/_:A^(5UXTM/
M#'B/3]/U,/%H=U\ =$TO5M<L-.O_ #Y](MO%$(N'MI;>SOY7DA:34_X*0_MU
M?&#]@_X>_#?XL^&_A7\./B;X2\>^-?!OPQN-&U[QIXF\&>)-%\;^,X]1:ROU
MN;/PUXATV\\*6_V:TCN8GBMM8AS-*$NBT<:\]+A?-:^8X7*<+/+,7F&,QF)P
M-'#8?,\'67UG!JI[6C7JJ3CAZB5&O*GS^Y7G0E3C-6YGVUN*LJI9;B\UQ$<S
MP^!PF&PV,G7K99C:+EAL3.BJ.(P]*4.;$4VZU'VDHI.-&JO<O+3]5/,)VOC(
M4#@9(Z'D <8SQNQZ8YZ'FR'L.N.1@\8."?X<DC SNSTQ7Y(?M)?MR?M7?L.^
M&K+XN?M,_LN_#CQS^SE:ZKH^E_$GXG?LP_&+Q#XC\8?"%-;U6WT+3]<U_P"&
M/Q-^'/@J7Q/X=EU2^L-/DU#P_P"*DN;&XNXUN=.1&ADE] \6?M.?MC^//'UO
M<_L9_LX_!?XT?L\-\.OAWXOLOC#\6OCAXE^#D7CK6_B%I^I>(A8_#VVTGX9_
M$*?4M+\/>&O^$9?7;W5](THVFL:V^E0M=WUAK%KI>$.'LSG1P^,4\!#+L5]8
MAA\SJX_"4\ME7PBHRQ6"GBW.+I8VE#$T*JPE6C3K2IUE4C&=%>UCM+B3+HUJ
M^$Y<>\QPSH2KY;#+<;4S"-'%>U6'Q-/ QC4=3!U)8>O%XNG6G1ISIRA*<:KC
M3E^EY>08Y!SD#!Y[Y P03R!DX)7KV.?C3]K#XCRZ?IUC\.M)G,-SKL2:AXBE
MB=D;^QA)(MKI;L"#''JEU&7N0=OFVD @<M!<2(WPDG_!0W]NF?\ :YU/]B2#
M]CW]F^;XWZ5\%=*^/%Q+_P -:^-D\!/X3UC4;_2;72X/$;?LX'5O^$A74--O
M(+B)O#$>G+&(KQ;Z6&917SOKGQI_;,\??'/QIH_Q0^ OP1\ #5? ?C#7_!GB
MOPM\:O$7Q3\(W/BGP-XH\$^&%\&ZQ?VO@_P=J^FV&HZ-KVI:QINJ0>' ]Y/9
MQR0&.%;R"/;&\)9OAZ<54Q.21E7P6'S"A2CGF7JKB<#C9NEA\3AHM3G*A4C&
MI5YTU4Y*=1QIJRC)Y7Q9E>+Q+Y,/G4X8?%5\%B:L\CQZH87&8:G[6K0Q7O05
M.K!NG&UG!RJ04IV;E']@?V3_  !!IOAR\^(%[!"VI>(II;/1)9HD$ECX=M"4
MEEM>!Y,NLWH::Z*HJM;6ME&HP&!^OHY&.&+ @_-M.>,X .#@E1T!Z$DM[U^3
M_P#P2E_:_P#B=^VI\#/$'Q$UWX4> ?A%X/\  OBK6OA%X:T71O%_B/QCK^K^
M)/!EII7]MZUJ]Q>Z+HEA8:%<7NHR6UO9VCWVK236DT\MQ%&\2',^%?[<W[1O
MCO\ X*&?%S]@W5_A)\%]'_X4GX2\+?$7Q5\5M-\=>-=1MO$7@OQ=HOA#6-+M
MO#O@V?P[9W>F^(HQXIDTR[@U779]-CGTF6_BFG@N[:$9/A3.,+BLYRNI2P\<
M5PYA*N,SFFL72OA<+0>#C6J0E[-*O6A/,,%!PC*Z6(I6C-RE[-KBS*,7ALGS
M*E6QDL)Q#C8X#*9SP57VE?$5/K?L8UHN;>&A*.!QDXRDE!PH.SBDE4_7?SCE
ML;3U P&SD*#C'KUX//!&." Z%RX.1C&.Q&6.2Q.0,9/X9./:J>XJHC8MEF"9
M^]][*@D@*H88!8#@$GKG-?#_ .Q5^V[X3_:XO?VE/#UCI=OX=\:?LU_M!^,_
M@IXL\/P7[7YN='TR^N#X(\=0-*L4D>E^+].MKV+9M,=MKVB>(-/B:5;(32^=
M0P>,Q&%QV-I8>=3!Y8L++'8F%W3PL<;B)83"NLK-1A6Q,'1IU'))SLI<MU?T
MJV/PM#%X+!5:\:>(S'ZS'!4)Q]_$RPE!8G$QIR<H^_2H-5)PY6^5^[S.]ONY
MWV*6R!R>O3N/PQC/X<]S4>]F5@0,%2IV@/G*Y!/;'/ Y!SR.U1RSKC!5B R@
MDKP <@L<YP!SG@X'/J*^'O!O[9GA3QW^W9\7/V*_#]M;W6J?!GX'>#?BAXN\
M1Q74LLL'B3Q3XD;3G\'?95_T<2:9H%WH.L7LXD,T4VLQP,H$)!5#!XO%K&5,
M+AZE:GEV"JYCCJL;\N&P=&KAJ,JDW9J,'5Q>'A)ROS2J0C!2?,H&*QV%P<\)
M3Q->%*6/Q=/+\)3=N:MBJM.O6]FDW=R]EAZLM/AC"3;5X<WOUIX8O[7X\:SX
MMBTV1-(U#X6:9I4^K*D:VUWK<'B1V2T)5LO=Q:;!#ORHVP"!"=JICN_&K$>#
M/&*$#!\+>(L\'&3I5YNR3E&VGY>_<$XQ6_)=1!6E=A#&GF22R2[$6%(X\O+(
M[-M1%C)<R,2%5#NPN2/S7_8Y_;[\#_MW_#[]K>]\(V5GI;_ SXM?%GX66L%I
M>W]^?$_P^L+*_?X:_$\M>6&GK9Q_$31;>_OETJ'[4-+GL9K669CL9REE^,Q&
M S+,</AJE;!Y<\,L=7IZ1PSQ]>MA\(IMQ^*OB*%:E&*2LX+FE!3@Y&(S3!4,
M=EN75\52I8S,E6C@:,FG+$0P%"EB,3R+F4DJ.&JTZDIN^DE92E=+S?X)$_\
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M<#O9-J4UT++S88G-HL.]%8M7P3_P4#_X)K>'OB+X T+XP_L7>$/ WP!_;/\
MV<_$'_"S/@1XS^&_A7PW\/Y?%%]8M(->^&?B^X\/:7IHUO0/&^BOJ&FVMIJS
MRZ>NJW,,.H[M#U77K:]]U_X)U?M\>#/VZ_@U>:VVGCP+\>OAIJ%OX/\ VC?@
MCJ1FT_Q5\+_'RM?0/)=>'[^4ZS8^%O$MUI&LR^&+^_CV2R:7K6AR7,FJ>'=7
MBMOGL3AO:\#86>3XBOB\HP>>XG%Y_AJ\**Q^69EB<'# 93B:E'#2FI97C,MC
M7HTL73]W^THUL-B7&HL JGO87$.EQQB7G%"AA<UQ62T<#D&(PU6K_9V8Y?A\
M94QV:X=5\5"#CFM#,JE"I/!U;R66JE7PO.GC;?#^G.R?\'%WC@H P'_!.+P7
M*NT<EE\>>+R@&02<G&U<\>G'/7Q']WF7>5D#RR'*E0&#/(>=V0$8D* %( 3:
M0!GB-)N8_P#B(X\70K)$V[_@G;X*@F0E0R2KXR\57/E;20RS^1)',T0&Y8)(
MY&4*ZD^C:OITVAZGKVC7:H+C0]5U_2;@^5\@DTJ[O;:1U(&2CK;N\1P#(C(R
MY!R>7C6G_M/!+<7'FX.X2VO&4U*.8Q27*U=2JOF5[ZJ*:L['L<#2@Z7'"T;I
M\7<0N[LXQMA\$O>5G;E24Y6:UYM+MVY+_@WKVC]B+XA[%^4_M9_'C8%) V_V
MGI 3&[)^Z <$G.<YQQ7/?L_$G_@X6_;T&0<?LL? XX !(SX-^%0!/?KT'.>1
MGI6E_P &[%Y%>?L-?$#R2S>1^U9\;E=V78&:>;0;Q",'('V>YA;<P!9R>O!.
M!\ M2LX_^#B#]NRR:9?M-W^RW\&(H80\6YIK/P+\([V>V:/=Y@F2UO;>Y:'8
MTB031SLJQO&Y^_S"$EQCXU>Z[QX8SIM-2<DHXO@&[=KI6>KE*T4VTVM$?G.7
M2B^%/"1N4;/BK*TFG%+F>'XU24>9J[?97;\S]^[^^@TVSOM0<92PL[N_E7=]
MY;.W>X<#G@808;/4D'(Z?QM?LE^*M6_8?^,'[&7_  4":]U!?V?O^"C>K?%S
MX)_M-P32R2Z?X?\ BGJ?QP\<:W\)/'4]Q<B6"R@O=*O;.&SAMPAM(/"7C,M<
M,/$C8_J3_:T^,WAWX-_ [XK:QJ.M6>F^*)?@]\;==\&:=</(;C5[WX??";Q7
MXYU62&, -'I^EZ7HDMY=W[O#9J_V6S:X6[U"SAN/SB^&'[%GAW]J?_@B#\$_
MV9==L8+75_%7[,'@?Q+X5OP(8)_#WQ9&F'QIX<\0079539R_\)3=>1?7$6UW
ML-0OH)B\<\H?YS@G,\)E658]YHJLLBXDSS+.&<Y2=J<LIJ93F^*G7J1<&ISR
MW,:^7YM1=.49QK9;-IVYHOV^-,!BLVSC!/*YP6<\-Y+F7$F5/G?M(YK#,\JP
MM*C!0E;EQ^78?&9=.%6,J<EC8*<;SC(_4;]IK]H#PA^R[\!?BE^T!XXAO=1\
M/?"WPG>^)'T73"LFK^+M6C"6GAGP;X?0I()]?\:>([K2_#>A1!)1)JFIVP*,
MK-7\\_[&/P9\>?LM?\%@/A%IOQIUZ+5/CI^U1^PM\1_B=\?M:@N)6TOQ!\?=
M9\=V?CGQCH6@J'D@3P_X+L]/?PQX8MH'$46@>$HYB[RRUT_[!7QD^)__  46
M@_91_9R^,^@:U!=?\$_=6UCQ)^VO!K^F7']F^*OC?\%O$M]X#_9@\,:G+J$-
MQ:Z[?W;Z/J'Q8\4VKLKV/C#P/%<-&%_L^X/N?[=4+^ _^"U?_!(KXH7S(FC^
M,M+_ &@/@]'+(=B-K.I> /&FG10/+D!C+-\0=-$$3LV^Y:$*K2%!7K9-E6(X
M>Q/$W!U>JO[1S+A?B^>-<9TY4<31R_+7C^&:$)<DVZ>.6#J9])QE>5#'X*=F
MJ*MY.;YI2XCH<-\8T*,YX#*>*>%:6 52%2G.E7S''?4.):\J;E2YG@GC*62T
MW5IM*I@<;**3J.3^_/\ @I)\5M:^&7[*7C#0_ ET;?XK_'K6?#G[-7P@%O-Y
M5\?B!\;M27P?:W^GLV29_#6@W'B#Q6S*"T5OH<DQ.(R3^5.H?#_2_P#@FW_P
M4_\ A?X5\-NVD? #]NW]DO2_@)<B03?9%^/?[/?@33O!/@V[=@!:VU[XI\,:
M5X;MI)]K7&H:UJVJWUS+]JU"83_67[0GA+P?^W+_ ,%)/AI^S!XU\-6GCSX!
M?L5_!;5/VAOC5X=U*!]0\):K\??CB[^ ?@)X1\5VT;K]GUKPQ\.[+XD^/],T
M^5H+EK77K:]V/#Y9'SY_P5A_X)C_  (T#]B[X@?%_P#95^"_A'X4_&[]GN^T
M7XZ:#XI\!6-_:>(GT7X?7O\ :_BNSBEMKBXN)1;Z1#)XAV1F.07.@0RI<K(G
MS8\)U\JP=+*^%\SQV*PT>,\MQU#-XQI85X2BN)H4\-PIB<7BZV-I5</++*V"
MR_-)R6#DXPQ\ZMX+$,Z.):>:XROF?$^6X+"8J/!N/P-3*JGML0L55_U>J3Q7
M%.&PF'HX/$4JT<=3Q6*RQ\^+AS5,N5'EFJ$8KQ;]N6Q74O@S\,M,N!:-#JW[
M7'[&6G72:A;PW5A):7W[0W@2QNH[ZUF1X;NQ>&>5;JUGC,5S;M*CJ8R0>'^*
MWPX_:#_X(:_%>X^(GPK\4^*?%7_!-WX\>-XF^*.@Z)ITU_=_LT>,=4N(8E\1
MZ=87+7DMCHUY+<RIIMS8S"TUZPMQX6UZV37K+PSJNH<S\?\ XWZ!\=/V+_V=
M_COH<UM'9>._VCOV+_$EY;0B+R](\1VO[0'@Z'Q=H,L4$DB02:-KNGZO$EH&
M5X;&.V=D3S%W?U>>-_!GA+XC^%/$W@+QYX:TGQAX*\7:7J'A_P 4>%O$-C#J
M6B^(-%U**2WOM/OK&Y5X;B"6)V!RFY7"3PNDRHXY<%FV+X1R/*\ESC!3QN3X
MK-^,LIXEX?Q,XNG7GA<SR?!+%X"K*E"6"SC U)U,1E^:0C&I3E*E2JPEA9R@
MO7SC*\'Q7G>-SW)<=#"9OA,GX4SCAWB"E#VD\-]<PF:XKZIC*$*L_K638Q0A
M1Q^4R=6G+FK3I252"1^'?[:=CXQ^*/[#7QY^*=IXP@^,_P ,/'/[)WQ>U7PI
M\0?"6K/K7AZ^T+5_AKX@FM[NV18;6;2RP/EW:SV-O);7<<]E=R17,,T*_6?[
M!W[2FD']FO\ 9B\(^,K./0FA^ 7P1T_2_$%N\DFD7*+\.?#,%NNI1S%[G3IW
M^5?M"O-9/(RF1K4-D_C'\<O!OQ:_X(R:-^T7\%F;QG\3/^"77[67P]^,7A;P
M'X@6WO/$^O?LH_%[XD>!_$>D6/AW541G>'PQKFJ7-G&MVGDV/B?S?[7-L/&M
MOKC^)OT/^%WPSN?!O[,W['6LV\$HTCQ=^S-\ Y6C+_;([#7U^%GA'^T]+$Q9
MVF2?S6O+<,SHR-*D9\J ;?+XIR6GD7"6$GEV*6;Y'F/$6)S#),V<E&IBL'/A
MSV&*P>84?:.I@<ZRVL\#@\PP56-W6C'$4IU,-B*-67J<*YO_ *Q<65Z6:8+^
MRL]RWAC#Y?G. BG&CA\3#B-8RECL%6Y8TL9E>8T88K%X/$TVTJ"]A5IT:V&G
M27P-_P $Z_@BWQM_X*6?\%A+./XR_'3X/2^&OB9X.E@U'X$^/[3P3>:TFO>/
MOCA$(_$GVO0/$5EKL&EG2X9]"\V*--/:^U;*7*:@?)Z?]I6T_:H_X(E?&R\_
M:Z\*_$+Q!^V7^S)^T+XN\)>'/V@(OC;INAZE^T/H.I:+I8L?#UI:_%K1-,\/
MQ26*Z/975OX"M6TW3_"$.J12:%KGA<WM[;^+3@_\$&/%NEWG_!0+_@J-:3:G
M;?;_ !9?>#-6T:W6>-CJ-KX2^*/QELM9>U#2O)=/I[Z_IHG,9F>W^T-YAC4*
M#^D7_!>'Q;X4T[_@G=\2OA[J,G]H_$7XO>*_A?X)^#/@;3K:;5_&_CSQ^_Q#
M\-:I:Z+X%\,V<=UK6MZVNFV.H'R=(LII5B81,R_:55_T_.,=7H>+&"X;S'!P
MS+(<_P LX(RC-\MQ&&I26(RZMP]DD:N*PV,EAJ6-PE3+Z]*OF5'&T\="C0GE
M]L0YX:,Z:_+<OR_"3\,<9Q#EV*J9?GF0X_C',<IS/"XNLG#,*'$6<.CA:F$>
M)J8/%4\P3^HU<(\)[:M#&VH251)R^S_C#^U]\/?!7[$/BO\ ;5\)Z@-?\!CX
M&P_%KX=_)#;7OB>X\6:#:S?#?P_';2EA#KGB7Q+K>A>'8=.E+W UB]&G/&\X
MVM^$7C[X2>(?^"9GQ8_X)._MBZZEP\_B+0M2_9?_ &W]9CTX6T6L>*/CQ=KX
M_M/%^OO:R168ETWQ]XF\:Q27UP$59M%\/V"SR0PP6Z^O0_L^:C+\-?\ @DQ_
MP2'^(*2ZYY.BP_M1?MH>%9+N/5],MOA=\%H;KQ=!\*O$PTZY99?"/B#]H'QC
MX0\(6C2R1:9?V?@]A8W%XJ"V?ZU_;0_X)$?LD_$[]EGXY^$_A#^SW\.O _Q8
MO? VK:M\//$OA?2;NWUFQ\9Z#&=>T6WL)8KJ=U.K7%G+H[10Q*S6^HRPY1)B
M*^3R>>1<,9EA<NQ68XF>5\1YIG6%Q>)HT8.ACN%,5/-.$<GQ6*G/&8:=.E[2
M=?B.#IX?$1Y,+#$0@TJ<E]#F]+/>)\+B,TPV7X*&9<.95D^(PE"O5J?6<%Q1
M0_LWB?.*>$A'"8BG[>%"-/(9*I7I5/:8F>&JS^-'ZC?&9E/P:^+&Q@Z-\+O'
MY#JP970^$]6:)U(8A@\9#*X;#*<\'('Y._\ !O=A?^"6'P&4]M<^)!.,]5\:
MZCGUYP3CGCZ9-=9_P3Z_:N/[5O\ P2KA\?>*=3A7XD?#[X-_%#X1?&FSNYDC
MU30/&GPO\-Z]X?EU#Q#:,XDTZY\4^&;/0?'*)<B%S:>(E;:N'$?#_P#!O3=Q
M3?\ !++X(1V[>=+:^)/B7:WL4>^22TNE\87<KV]TJ<P3K%/'/Y<H1S#)')L/
MF 'R\5EF)R+@_C/*L9&7M\KX_P"'\%6ERRC'_9LKXAH4JBE**2ABHPIXFCS6
MG.C7IU%S0:E+W,+F='.N+>$,UPW*Z&9<#<08JA%2C4E>OCN'ZU2G+DFKSP[E
M4P]5)-1K8>=-N,XR@OK'_@JX<?\ !.#]LS+# ^!WBT#D' ,=J".Y'<'CC@\C
MIA_L7L!_P2>_9X'&#^P[X3RRAF(+_"%<D=OO8 R0 H8< "L__@J-XV\,>(?^
M"=?[>FEZ%K%IK-_X$^%?B/PGXNM;&43RZ'XDN]%\.^(8]&OF VIJ T;Q'I&H
M26^2\4.HV_FJDK%!=_8AN[:Y_P""3'[/$L$L<D _8D\-0M(C,J"6S^%#6ERA
M9@ K0S0SQR$X"M&QZ$$\V&C)< 9?S1::\2L&W>#<N9\.Y;.-G)))N/LYQG:5
MG)2Y)+26N)FJGB!CO95(M/PVQUIJ2>JXAQD)<T%+I-23C>-Y0LYWBT?AI\-/
MV0_C'\(OV+?V!_\ @J;_ ,$][);?]H#P5^R9\&1^T1\%+&VN)/#7[2WPTTSP
M3I6GZR\OARV CU#QG;:3%>SZW%%MU+6#!8^)?#4ECXV\.V:Z]_13^P[^VW\(
MOV[_ ((Z)\9OA+??9Y89(-$^(/@'4;B'_A)OAGXUAMX)=3\,>(;9,2':2\^B
MZL(HK76M.*W4"QRK<6MIX[_P1WNC>?\ !+?]@V8NX9/V;?A]&6PBD&SL&M2O
M!9<@P$*I)QM 8*2RU\$?MH_LA_%_]@WX\7__  4S_P"">'A:XU&SOO,?]LO]
ME#PS8RPZ#\5?!?GOJFM>/?"?AW3(GC?Q#83BZUB_M[*T?4]'U&\O?%>@,(;_
M ,6Z3K/L9EC<+QEF&:\.9WB88?B3+\RS7#\)Y]BG&G#%TJ699E*'"N>XMN"<
M*TZCCP]C\5.V7XM_V?B9RP&)P[P?D9?@L5P;A,OXARBA5Q'#F,P.6U>*,@PT
M?:U,)4G@<&JO$V2X54W:JDKYYE^'@I8ZA">.PT8XNC6A6^VO^"5]NMEIO_!0
M.VV10+%_P5&_;.VQQG"*ESXH\/7T93&?FD2Z260'GS'?=CH/U80Y4'V'Z@'^
MN*_&_P#X(V?$[PM\;_A#^UK\:/ 7V\^"/B]^W_\ M&?$?PK_ &E;?8=3BT3Q
M98^ =6CBO[..6X^Q7\,]S<Q7$0ED3S4::-FBEC-?L>A7:,=@!D\GD X)[_>&
M3Z]:^*XIHXK#<29QA\;1JX?&8?$8?#XK#5THUJ&)P^69+1K4JJC*HE.$X-/E
MJ35^:\FU=_:<&SH5>&\JK82K&OA*M/%UL-7IJ2I5Z&(S;.J]*K3<U"7+*%6+
M2E3IRLTW%7M%]%%%>&?4!1110!DWUA:WUM<65Y9P7EI?03VMY97<$5Q:7=K=
MQ20SV]U!-')#<031R%+B":-XIE8HZ%217Y:?$_\ X(P_\$_OB+XLF\?Z9\)-
M3^#'C^XN9KP^,/@!XW\5?"/58KNXN!<336]OX4U&UTNV,TP5S%:V$-N"BNL*
ML@(_5_:,8R<?7V_R<=,TSR@<Y8G/487;^ *DX';+'WSDUVY?FV;91*53*\PQ
MF73JQ4:_U/$U::K6MRQK04_8XB,;1M&O1K)<L4DDDGY.9Y'E&<PIT\TRS 9A
M&C?V7US#4ZLJ3E>\J,U"-:A)W=W1K4KMMM-^\?CC??\ !$W]E7Q1$-.^*?Q-
M_:^^-'AH%1)X.^*7[4?Q-\2>%+D)@HMYI"ZA:Q7D:H60Q3LZ,C%74[B3]A>,
M?V$?V9/'G[/?AS]D_5_AY)8_LY^%H],BTSX2^'/$OB'P]X8N(M#\0VWB_2(]
M:_L_4H]3UA=-\6V=OXEM!?7TP&N1)J,RR3HCK]EB%=VX]0>,8Z#L>._!(  R
M.G7*,@49 )[<%<@YZ\CL,#@\]#DDD]>(XFXDQ53"2Q&=YE5^H8A8W!6Q/U>.
M%QB2C'$T*>$IX:E2Q$(JT,0J#K1^S65ER\6%X4X<P5+%4L/D>6T88W#O"XR*
MH>W^LX7FYWAJT\55KU)T)RUG2=6-.;2YH3LC\T#_ ,$FOV08_!TGPZL[3XWZ
M7\.WT^713X"TO]I/XXZ?X1&A3H\5QH,>A6WC9+"+1KF*62&;38U%I)%++&8P
MK;:]C_:'_89_9Q_:K\->"_!'QS\%:GXM\#_#L6 \'>#K;QAXAT#0-&NM,LWT
M_3-4AL-!U#3_ #M7LM.D:QM;Z>=GMX-HCVLHE/V9Y88 ;C@X+8(!X X/7VSC
M%(8T&<,<@DX(RN2>3C&1D>A ],5SRSS/'B*6,>;YD\50JU:]#$QQE;ZQ0KUH
M2A6JPJVI252O"4J<ZC<ZLE)MU;.2GI2X;R&&'Q&%IY)E4,-B:=.CB,.L'2]A
MB*5&:J4*=>G&4U*G0J*-6E3BX0C4C&7L^5)+DO"OA>/PIH5CH=MJGB+68; ,
M(K_Q/KESXBUJ6)VR(KG5K_-U=" *D<#7#&3RU_>22LQW_+7BK]@?]F3Q)\=)
M_P!IFV\":EX%^/5W;BTUCXF_"_Q?XG^'GB#Q);AK;,7BJ+PWJ=CH_B9'^R6I
MG&M:=?\ GM%')</<2Q1R1_:OE8Q@G@YZ]_0]]HP  #W).3S08E(();!Z\C\L
MXSCO]?;(KCHXW'8?V]3"XO$8:6*I3HXET:TJ7MZ-1ISHXA1<88BE-J,JE.K%
MTYSIPDE!QC(]'$9?@L73P]+$X/#8BGAJL*V'C7HTZL</5IIQA5H\\7*%11<E
M&=.4)QC)Q4K:'PC_ ,.\_P!G$?'>3]J!-.^(2?M"S:9;Z-/\78_BAXPC\5S:
M)::;!HEOHKE;Y=)?2TTJWBM6L?[*$+ O/(&O)&N3XM^UA\.5M?&FNQSOJ-CH
M7Q&T][U[O1[VXTN^6YF5;;7K6VU&UECGMIG.)9IH62:2"Y9$V;G<_JLT:+\Q
MS@ @+U'))Y_B/)[D@ #C@8\J^+OPULOB=X2N]"EDCMM4M)1J/AW4W7/V#5X8
MY(T67;M9[*_BDDLKZ$%OW<HN$0W$-NZ3B\7F&,^K3Q&-Q6(K8"E2I8*=:OSO
M#4L,KT:6&YE>A"FW^XIQDZ-"6M.&LG+HRW"8++IXB.'P>%P]#&RJRQ=.E1M#
M$U*R<:E7$QC)JISIVJMWJU87C*I)M-?FQ_P3A^"'P-_9PF\7?#_X3Z5KO@6U
M\2:E)XQC\/1^,/$>K>&/$>KG2K;2-6N;W1M9U&[MEURRT[3K":UN[003WELL
MKW*W$NFP9];\3_\ !+']COQC\7?$7Q]UKPA\03\</%EW'=^(/BOI'QD^)GA_
MQU?2PZ+I_ANUB.M:#XCTR6WL[3PWI6D>'+6QM4@LHM'T?3K-(3'""WSS<0>)
M? ?B9[>X%UX?\4>&[Y)%;]VLUG<P,CQ7,3%/+GMYT :-_P!Y!<6TN!DR#;^E
MOP:^-FD?$[3;>SNY+?2_&EI S:IHI=0MX8"5?4M%9\&ZLW11-/!S<6$CR6\@
MDCCCN7TP_$6>3Q6-Q-3.<PAF.84GA\?C%B9PKX^E+V7-3Q7O25:$XT*$)TZB
MG"HZ,*E2$VJ?L\\=PKD7U7"4*>3Y7++,)4C6P>"6%A*A@:EZDN;#1]WV;]I5
MJ5(SCRR@ZLH1<$Y^T^5;[_@EI^R;K%YK=_XCT_XP^,;CQ#X$\4_"[59O&G[0
M/Q;\5[_ASXX6PC\:>$;(Z]XIU Z;I7BR'3-/MO$$>F?8Y]1L[9;6:]-L7BE^
MRO@]\(_"'P.\!:#\,? *:S:^"_"=E;Z3X8TC6M=U+Q$V@Z/96T%I8:)I=]JD
ML]W%I.GVT$26=I+/,8MSGS"#D^II&&&[< #[9X8Y!0 C ;*A<ALX!'<&81@G
M.6P"#@8YSGG/<<X/)X7''.=,5F69X_#_ %7&8_%XG#1G&I##UL0YTZ=6%.5&
M,J<%"-+F5*4HW=-.*G*$7RN2?)@\GRS 57B,'EV PF)G"5.5?#T%"=6G*HJL
MH3E>52WM$I)>TLVHR:<HQY?*/ ?P:^&?PS\1?%/Q?X%\%:+X8\0_&GQK#\0/
MB?K&EVYCN_&'B^U\.Z3X4@US4V9V'V@:+H6GP>7;+# \[WFHR0?VGJ.HW%SY
M'^TC^QA^SS^U?J?PZU_XV>#+WQ%K_P '=2O=>^&'B#2?%7B3PGK/@?7;^\T:
M_N=;T&^\.ZCI\MKJQN/#NC31WC-)+$]C$L9122?K*2) O5A\V<X#8R2<<CMD
MX/7G!.#3",*X).#QG@DJ20K8V]& V\ $G&"36=+&X^CBECZ.,Q5#'*"IQQ=.
MO*%>G%4%A>58A.=9P^K15%07NJE^ZM[*],TK9;@*V$>!Q&"PN(P,I*<\)6H>
MTHU)^WEB>;V?N4E-XBI*JYZR]K^];YVYGR7\#_V./@A^SW\0/B1\5?AK8>,K
M+QY\89--F^*OB+Q%\0/%?B^Y^(-_HWVTZ%?^)(_$&H:A'/?:%%J6J0:--;QV
MBV-MJ-S;Q)Y+K'%[O\2M)L];^&GC_2-2@$UAJ_@7Q;I>H0<C[18ZAX?U"TNH
MBT91E\RVFD0-R1N# 9R*X"77_P#A(/VAM,\-6-V_V+P)X \0:GJT<,DBQOK/
MB2^T.VM[>[0,(Y39V$4,R!D+0R73+N!5MWI/Q%E%O\-_'ESN(,/@SQ2X9>"I
MCT2_(;C #@J.0,# VJHXK*OC,7C*T\3B,7B*^)4:5/V]2O5=7_98QIT%&JY.
M:5*G3@J:5%*"A"$8J$*<(ZX7*\'@:,,)A<'A,-AI2G4>'I4*4:3>+J.M6YJ2
M@H2E5E4FZKE5E[5U)5*CG.<YO^=7X0_\$YOV2KY_ ?P6F\">)U^$VI>.]"\0
M7GP_B^*'CM/#1\2:5IUP-/\ $D=G%K44L.M64D-O<0WD%Q"_GVYN)(YKI86'
M]&O@WPS#X4T:Q\/V^HZ]K-IIL$D-OJ'BG6;OQ#K<R>:&1;W5[]FN[[R%*Q12
M3EI5C"J\DQ&^ORL^#,B0_%/X:NSGRX_%>GQMP"5,EM=6T?0G&Z>6*-C_ +3L
M  2!^O\ $J!F(QNR0>QZC.>>QZCUQGG!+JYWG.;+_A6S3&YERXFK.'US$5L3
M)5:J@ZM92Q'LIQE4]E3]I)0E*HZ<95)5&HR6SR/)LIKQEE658#+W.A3IR>#P
MM.A>E!S<*4N2=2*C2<ZCC"F_9P]I)4^7FFGQ'Q,^&O@3XN_#_P 6_#'XE>%M
M'\9> O'6AWWAKQ9X7URV2ZTO6M&U2$V]W:W$1^9&"/YMM<PO#=6=S'%=VL\%
MQ#',GSE\=/@WX7T7]E4?"_PXNJ:%X8^&/A3P/H/A#^RM7OK;7M$\->#8](\-
MV=G8^(O-;4X;X>&(9-/GU,3->7"23;W#S-)7V/)RN"2%.,L,94@YR<@@+P 2
M0<9S7@O[2&K6^D?![QA]ID42ZK!9:%8Q'&9[[4]2M55%';R;:*XNG4GB&W=B
M< 5$Z^(A0<(UZL:-*<L5"ES.4(8ATE3>(HTI\]*&)=.%.FZLZ34H0IPGSQA%
M1<,-1EBH550I.M5A'"U*B@HU*F&52514*M2GR59X=3J3DJ4:B:E4G*#CS3O^
M"_P2_P""9_['DWQG\(7NE^!/&/AG7[S5=6$WBOP?\7_B=X7\5A]2M+V\O;A?
M$FC^);35?,O+H&:\5I@MV\D@E):2OUC^%O[)O['_ ,'?CMIMWHOA+4/%'[0F
MG^ IM<T+Q]\6/%7C3XN^.]!\$R:JVDS0>&/%7Q"UG7Y/#327K3>;%H(L+V>U
M^UF::6V\Q:Y#]E[PM#?>,]1\<ZG)!9^'_ FG2O)J%]-%;6<&JZG#/%"7N)7B
MBC.FZ<MU=WLLSF*)9[4MS(I&UK6L7W]@Z9^V+9:SHESX7TOXF7?BV\2RL[BZ
MO$^!AV?"R\*ZY;:_)I\MG9^'=/'Q(N],710;+4KB]AGD-U;3M-Z$^).)LRH_
M\*.?9QC.:E]74L5F6)K3EA>5)4*DFJ-65&RC!X?ZPJ#BN5TY4XJF^2?"W"^!
MQ$'@,@R?!RHN-6*PV PU**Q//*HZT$E5I1J\\I5/;^P=;VCY^=5&ZIZAX6_8
MO^"/A#X]WW[3NDP^/+OXZ:MX?_X0S7/'NM_$;Q9K5[KG@N"YM[V+P=J.FW^H
M3Z,_ANWOK.QO(M+M+&TC@NK6*=)3,TKR_63/&40+AV4KDH 3C@9"@9(8*P3
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M%/Z^H22BL;&G2ITH8GD]M[&G3I.GR0@==+),HI2C4IY;@*=2.%^H<T,)3C;
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544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex5-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_003.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  = /H# 2(  A$! Q$!_\0
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M2_$^'[/;6_C*#4]9LO MO8^)K>ZT7Q1JNAM^D_V5&^8I@MR0#@ GG '&!Z#
MQ7GYQ1PV%A@X99+ZUB94*-3,']8CB,+"K5P].<H4*E&%&I&I3Q$,13K49Q<:
M4'AUSNK.:CVY3B,;B*F-GCX*AA8XBM3P">'J8?%3ITJ\XJ=6G4J5H2I3H2HR
MI58RC*K4CB&J<:48N5DQ*6!P.!P>^<,/RPQ_'VXI!$@'(( W<ENQSGGJ 03W
MX'3%2TA 8$'&""#D C!&.0>"/8\'O7-RJ[=EO?SU23OZI)>=EU/5M_7]?/\
M(_.^[^*OC+X4W?Q@B\?)XC?XO^"OA7\=?BY\.WU#Q'?7?P6^.OPZ\-7^F:['
M)H^FV+/'X9\2?#^TD\(^&-4T1;.SUOP_'XGNM<TR;Q7HFMWDL?O&N_$KX@:7
MHNIZE;V7@BXGTG]GFX^*<R3)X@2*;QC:V_GC2XRE])+!X7NUM+Y$N6\W5K<F
M%BEWY<RR>FZ%\'OASX;E:72_#4!QHNM>&K6#5;W5/$%GI7AKQ)?VVJ>(_#>@
MV.OWVIV?A_P]X@O[#3+C7-%T6"PT[5QHN@0:A;W%MH&BPV&9I/P(^%^A>$M:
M\"Z7H-];>%M>T!?"=]IS^*O&%W+;^$XK5[&V\*:'JE]K]SJWACPO86,DEEIG
MAWPW?:3H^E6CM;Z;9VL>%#:3W2?JEZ=ET_,+?U\[_GJ?,E[^TYXSLO"/P\\8
M7,?@JWT;QOK^OV%UJ0\$?%J\N] T[2/A'!X^EED\&6\">);^ZM/$VG>)-"DF
ML1+I>J^'3H?BO3[JW:>YTIO1-5^./C>.T^,=UHWA'PM//^SYHNDW7Q TN_\
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MO;/3H-0AFU/4F6Z_T^[$W'V'[/\ \)M,\+>'O!MEX7>+0_"/B:_\9^$B^O\
MB:YUOPMXHU6^U/4-3UOP[XKN=9F\4Z->ZC<:UK27S6&LP)=V6LZOIEQ')IFI
M7EG,K+7SWVU]=-=?\][6++>ROWM_730\E^)_QA^*?PZUCX5>&KW1_A_%K/Q
M?XF:=+>):>//$NFQZIX2TF+5O",]O;Z#:#5]/TGQ,KQVOB&6^M[M?![2F\6[
MUZUMB)_I#2=9FU75?$FAWGAO7-+70;C2[9-8U"&WAT;Q*-3TJ'4+FX\,W5O>
MRWEW;:5).^EZA/>6VG2Q:C%*D,<L061^1O/@7\-;ZYT&^FTG68M1\,#Q4="U
M2Q\:>-].U:PG\;\>*]0&K:?XCMM1N-7UN,""YUF[NKC58;<>19W=M&2IZ?P[
M\._"'A.YUV\\.Z4=*N?$L&@V^M307^J2-=0^&-"M?#.@K$+F]G6P;3=$L[:R
MBDT\6LDIB6ZN&FO"UPR22V27HK7?=^>K]+_,++LM7=_=;^O+38_-2Z^)?Q"T
MG]@KX^Z_96_QAU+Q1H_@S]J#Q!HGQ;_X3&&\OM(U3P?JOQ 3POJVGZW>>*(O
M$%KIOA>/P[I$<5G#;^4+73)H1:W FFCF^S?B1\:/"WP6\4_!7X=7LUE?+XT\
M1Z3X5U.\UOQ?91^(=#T;4K6[\/>&/$7V#5)Y-:\8WNN_$27PSX=U!X [6=CJ
M&M^)M2NECT8PW770? 'X40?"S7_@M'X:N?\ A5_BF/Q%::_X4D\3>+9X-1L_
M%=S<3^)K"74YM=DUN/3M=GN[V34].M]2BLKLW]^DL#1WMTDMC7/@9\-?$NG>
M*-(\0:3K6LV'C;3_  MI?BB+4/&WCFXEU2S\$R>?X:0W;^)/M=E-87!:ZN+O
M3I[2\U:[=[O6+C4+F225AI/=)[W\[I*S=KM:)]KKN[@TGNEO?9=K=OZ1Y'I?
MQI\?ZI:?%J2/1?""7GPY_:?\%? K3HA'KSPW_A?Q7J_PGLKCQ1?AKV*2WUO3
M-+^*O]H0Z7;A].O9/#AA_M&V@UY;S0W^'OC5\0M;^)M[X"A\):%>6+>-_BOX
M+AUK38?$TG_")VW@3PWHNN>'O%WBW=%)I4VC^(M3UB/PK<Z7%J^BZLFKM876
MAC7K&77'\,^TVWP<^'5IXRF^(%MH,L7BN[ETR\U&_P#[;\0O9ZQJVC:%%X8T
MKQ'KF@OJS>']=\6Z?X;@MM!M/&&KZ7>^*(='M++3DU<6ME:Q0ZN@_#CPIX8C
M\7QZ%:ZEIX\>:UJ/B+Q0Z>(O$<\U]KFK6T5GJ&I6=Q=:M//H=Q/;P0(O]@R:
M;';F""2VCAEB1U++LE\OZ[!9=E_6OYGR7X._:N\0W_P;UOXK^+_!&A:7';_"
M?X+?$#PY<#7+SP[X2UKQC\;O#.FZEHWPPN/$OBNRMK"TOM(\0Z[X>T>[\5VM
MS>Z7)8:_8ZGJ>G^'[P3Z-'Z-X9^.6H>._'GP/T[PK!X;N/ OQD^!WB_XL)K$
MQU*[U;3+_P -7OP_LX=*M1;W$&F7UC>O\086GED:WNK9M!O8XFNEU6.;2_5]
M+^#?P_T72?AAH6E:5J%EI'P9:(_#2PB\2^*#;^&E@\-ZEX.M8L/K+MK$%EX4
MUC5/#UA;Z^VJ0V.EWLUM:)""I7G;;]G#X/V6DZ/HEAX:U+3K/PWK_B/Q)X=N
M=-\:^/--US0-4\7EW\5+HGB:Q\3V_B/2M*\0RRR3:QX?L=5@T"_G<S7&F/+A
MP67:W]?IT"WDOZNOU?\ 3=_*M#_:"\3Z[J_@KP.=.\&Z-XNU;X):A\>/&'B3
M5;G51X)\-^$!KZZ!H-OHU@)H-9U^XU.X,MSJ^H3:GI.F^&]*M!J<[7LFK:7I
MLK?$OQ\\66GB7X4Z)H$?P[OH/B;\.K?Q98ZA9/XR\9Z#J'B:;Q9X+\-VFC:1
MXJ\(6,EG#X2UV7QC!)IWQ U+2QIMC%;PZC=6=Y9W9%K]!ZY\)OA_XB;PQ+J'
MARUM[GP787NC^$KW0+B_\*:CX=T+4[.TT_5/#NDZEX7N](U"S\-:I::=I<6I
M>&X[D:'?'1]&FN;"6?2-,EM<*Z^ GPNNDT5!HFJ:>OAWP,WPUT,Z'XP\:>'V
MTSP-(MNDWA^VDT3Q#82+!<):6BW%VSMJ4_V2U:2]9[:%D++LMK?=M]W3[^X)
M+LM7=[>2735JVE_E8V/C \=G\*?B7>FYU.Q.G^ _%FI)>:-J=[HVK6DNF:#?
M7\5SINJZ=/;7UA>0S6Z20W5M/')&ZCJI8'XENO&WC3PG8^#/V>/C#XP\1R>,
M+OQO\&KKX-_&2VUFZ\(ZI\>/AX/BAX$TKQ9X?\17FAW>G6[_ !@T/P5K&JV?
MQ)\.:>R6OC#1'N_B3X>TC3K!-5T_PM]H6WP;\"Q^'/B/X2FTZYG\._%;5M>U
MCQEI4.I:AIEM>-XFTZTTC6+*R;2+JPN-*LK[3;&&WO(]-GM7O));RYN'DN+V
MYDDV]2^&O@G6M#\+>'-;T*WUW2O!.L>$_$7A9->GO-;OM&\0>!KVTU#PKKUM
MK&J7-UK#ZUI5S9PL-5N;^>_OHGNK;4KB\MKZ^AN6DE?1:N][)-26SVUMU33N
MODQ_U]ZL_O\ RT/E*[T#QYI'QP\4_ >3QKXRN_A_\;-*G^-WACQ2OC+7HO'/
MPPM/ .J^!_#'Q/\ A?X=UQ=174--\*:Y=ZWX'USP5<63&\T:7Q5\4M/EFCM+
M7PH;/UG]H74M=\*^&/A?>>&->UK0)1\>?@#X:OQIUQ;R+K7AOQ1\3O#'A+7M
M"UJ6_L[ZYN-.U#2=5G\U[2XT_4&O8[:5M0:#[5:7?J&H_#3P?J7C_1?BE=V%
M\_CGPYH.I^%]%U=/$'B&"VLM UNZLKW6=,&A6^JQ>'[B#5;O3=,N;]KO2YYK
MF?2M*EDE+Z98&W7QY\,_!OQ,LM#T[QGI]]J5GX<\1:-XMT:&S\0>(M!^R>)/
M#MW%J&@ZNS^'M5TJ2ZN='U"&'4-.2\>XM[:_AAO(X1<P0RQKRLM+6^2LO6RL
MM;^2%97O97[V_KKZ?H>8^/=8\1:7^T+\ -'TW7]4M/#GBC1/C#%K_AJ(V9T/
M5+K0=$\.ZAHNHWD9M/MYOM/N+JY6W\K4(;3RI9!):22B*>+S'Q7H?CKP?/X\
MU2W_ &G?B&D7@WX;^.?%?B;5O&^F_#:[^'GA37]?T/6T\#0#0_#7PUTSQ-<V
M?AN\-QXL&CCQ5J6K6^D:%X9TK5[?Q$?%]O?'Z:UGX8^#O$'C'PEX^U:QU"Y\
M6>!8-4MO"NI1^(?$5E!I4&N1)!K,9TBQU:VT74%U6"*&&_\ [3TZ]-S%;VT<
MA*V\(CT'\">%KG2?%VAZEI5OK.D>/)]6E\7:?K*+J5MKL6MV":3?V.H17(=;
MC3GTF*#28;&4/!!IL$-E$JP1(BEMK));/KW_ ,^OY[,_.RU^*/Q,E\(^(]/A
M'BC0_B;:_$_X)>';K]G+Q%XLNK_QOX@NO[$D\5^/M \ ?%":]A\[3OB3X0T/
MQ'XV\.:VMQ;:.NE^!?$\'BP>!O[1\6/X5^S/V<=>/B_X.^$O$,WB6_\ %;Z@
M^OL;[5X;F#7=,^S^)=8M1X2\1?;%CO+CQ'X(%NOA#7K^\C6ZU#5-$N[R;>T_
MF/T,GP3^&DVFIID_APW(BUK0?$<&KW6L:]=^*[77_"]NEEX=UBT\9W&J2^++
M74-&TY)-+LKF#68Y$TJ\U/3)#)8ZMJ=O=]WH'AW1O"VDV6@^'M/MM)T?3XVB
ML["SC\N&$2327,S_ #%WEGN;F::ZN[F9Y+B[NIIKBYEEFD=V;]$O^&MZ[:;W
M[W#??\EH_+0T_LZ$ $'@<<]\Y.1T/...?;M4P& !Z #\J6DVCT'Y"DTGND_E
/_P ,+R27Y?@MO3;L?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>brtx-20250930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaWNabP9z5Z8qekhvWB2bRkqfyEg0VC4xiJfKpF20eQO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:BRTX="http://biorestorative.com/20250930" elementFormDefault="qualified" targetNamespace="http://biorestorative.com/20250930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://biorestorative.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" id="StatementsOfChangesInStockholdersEquityParenthetical">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
          <link:definition>00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity" id="BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity">
          <link:definition>999009 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
          <link:definition>999011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999012 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/FairValueMeasurement" id="FairValueMeasurement">
          <link:definition>999013 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999014 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999015 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>999016 - Disclosure - INTANGIBLE ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999017 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/Leases" id="Leases">
          <link:definition>999018 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
          <link:definition>999021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999022 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
          <link:definition>999023 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>999025 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999026 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999027 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative" id="BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative">
          <link:definition>999028 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" id="ScheduleOfRevenueRecognizedDetails">
          <link:definition>999029 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" id="ScheduleOfWeightedAverageDilutiveCommonSharesDetails">
          <link:definition>999030 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:definition>999032 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>999033 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" id="ScheduleOfStockOptionGrantedAssumptionsDetails">
          <link:definition>999034 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>999036 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails" id="ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails">
          <link:definition>999037 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999038 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" id="FairValueMeasurementDetailsNarrative">
          <link:definition>999039 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" id="ScheduleOfFairValueValuationAssumptionsDetails">
          <link:definition>999040 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" id="ScheduleOfFairValueMeasuredOnRecurringBasisDetails">
          <link:definition>999041 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:definition>999042 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" id="ScheduleOfPropertyPlantAndEquipmentDetails">
          <link:definition>999044 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
          <link:definition>999046 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" id="ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails">
          <link:definition>999047 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" id="ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails">
          <link:definition>999048 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" id="ScheduleOfStockWarrantsDetails">
          <link:definition>999049 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" id="ScheduleOfInformationRelatedToStockOptionsDetails">
          <link:definition>999050 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" id="ScheduleOfUnvestedRestrictedStockUnitsDetails">
          <link:definition>999051 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" id="ScheduleOfStockOptionExpenseDetails">
          <link:definition>999052 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" id="ScheduleOfIncomeTaxProvisionBenefitDetails">
          <link:definition>999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" id="ScheduleOfStatutoryFederalIncomeTaxRateDetails">
          <link:definition>999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999056 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999057 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" id="ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails">
          <link:definition>999058 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" id="ScheduleOfFairValueRecurringBasisDetails">
          <link:definition>999059 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="BRTX_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ATMSalesMember" name="ATMSalesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_TwoThousandTwentyFourATMProgramMember" name="TwoThousandTwentyFourATMProgramMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ATMProgramMember" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_MedicalEquipmentMember" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ManufacturingEquipmentMember" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AuctusFundLLCMember" name="AuctusFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RothCapitalPartnersLLCMember" name="RothCapitalPartnersLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_BoardOfDirectorMember" name="BoardOfDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_BeneficialOwnershipMember" name="BeneficialOwnershipMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" name="TwoThousandTwentyOneStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" name="TwoThousandAndTwentyOneStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DemandSalesAgreementMember" name="DemandSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExistingWarrantMember" name="ExistingWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_NewWarrantsMember" name="NewWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_BlackScholesOptionMember" name="BlackScholesOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SubscriptionAgreementsMember" name="SubscriptionAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ComputerSoftwareAndEquipmentMember" name="ComputerSoftwareAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PatentsAndTrademarksMember" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AccumulatedAmortizationMember" name="AccumulatedAmortizationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PatentsAndTrademarkMember" name="PatentsAndTrademarkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" name="ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SectionThreeHundredAndEightyTwoMember" name="SectionThreeHundredAndEightyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_MelvilleLeaseMember" name="MelvilleLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredOfferingCost" name="DeferredOfferingCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_GrantIncome" name="GrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_GainLossOnExchangeOfWarrants" name="GainLossOnExchangeOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_StockIssuedDuringPeriodValueAbeyanceShares" name="StockIssuedDuringPeriodValueAbeyanceShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares" name="StockIssuedDuringPeriodSharesAbeyanceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" name="StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" name="StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" name="StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" name="StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesHeldInAbeyance" name="SharesHeldInAbeyance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" name="ProceedsFromExchangeAndIssuanceOfWarrantsNet1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PaymentsForProceedsFromDeferredOfferingCosts" name="PaymentsForProceedsFromDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" name="ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_IssuanceOfCommonStockHeldInAbeyance" name="IssuanceOfCommonStockHeldInAbeyance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ReclassificationOfDeferredOfferingCosts" name="ReclassificationOfDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredOfferingCostsIncludedInAccountsPayable" name="DeferredOfferingCostsIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_TaxLawChangePolicyTextBlock" name="TaxLawChangePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredContractCostsPolicyTextBlock" name="DeferredContractCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_WarrantAndOptionValuationPolicyTextBlock" name="WarrantAndOptionValuationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock" name="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" name="ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ProceedsFromWarrantExercisesNet" name="ProceedsFromWarrantExercisesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AccruedGeneralAndAdministrativeExpenses" name="AccruedGeneralAndAdministrativeExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_EquityTable" name="EquityTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="BRTX_EquityLineItem" name="EquityLineItem" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PaymentsForCommissionsLegalAndAccountingFees" name="PaymentsForCommissionsLegalAndAccountingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_InvestmentsAllOtherInvestmentsTable" name="InvestmentsAllOtherInvestmentsTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="BRTX_InvestmentsAllOtherInvestmentsLineItem" name="InvestmentsAllOtherInvestmentsLineItem" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DerivativesLiabilities" name="DerivativesLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_LegalFeesAndOtherExpenses" name="LegalFeesAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_CommonStockVestRemainderPercentage" name="CommonStockVestRemainderPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredTaxAssetsRightOfUseAsset" name="DeferredTaxAssetsRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredTaxLiabilitiesDepreciation" name="DeferredTaxLiabilitiesDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ChangeInValuationAllowance" name="ChangeInValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" name="EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" name="EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_LeasesTable" name="LeasesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="BRTX_LeasesLineItems" name="LeasesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_OperatingLeaseLiabilityReduction" name="OperatingLeaseLiabilityReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ChangeInFairValueOfDerivativeLiability" name="ChangeInFairValueOfDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_GainOnExchangeOfWarrants" name="GainOnExchangeOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>brtx-20250930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#Cover" roleURI="http://biorestorative.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BalanceSheets" roleURI="http://biorestorative.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfOperations" roleURI="http://biorestorative.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfCashFlows" roleURI="http://biorestorative.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfCashFlowsParenthetical" roleURI="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity" roleURI="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StockholdersEquity" roleURI="http://biorestorative.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#FairValueMeasurement" roleURI="http://biorestorative.com/role/FairValueMeasurement" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SubsequentEvents" roleURI="http://biorestorative.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#PropertyAndEquipment" roleURI="http://biorestorative.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IntangibleAssets" roleURI="http://biorestorative.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IncomeTaxes" roleURI="http://biorestorative.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#Leases" roleURI="http://biorestorative.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StockholdersEquityTables" roleURI="http://biorestorative.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#FairValueMeasurementTables" roleURI="http://biorestorative.com/role/FairValueMeasurementTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#PropertyAndEquipmentTables" roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IntangibleAssetsTables" roleURI="http://biorestorative.com/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IncomeTaxesTables" roleURI="http://biorestorative.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#LeasesTables" roleURI="http://biorestorative.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative" roleURI="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfRevenueRecognizedDetails" roleURI="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockOptionGrantedAssumptionsDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockOptionActivityDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails" roleURI="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StockholdersEquityDetailsNarrative" roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#FairValueMeasurementDetailsNarrative" roleURI="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFairValueValuationAssumptionsDetails" roleURI="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFairValueMeasuredOnRecurringBasisDetails" roleURI="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfIntangibleAssetsDetails" roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockWarrantsDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfInformationRelatedToStockOptionsDetails" roleURI="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockOptionExpenseDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfIncomeTaxProvisionBenefitDetails" roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStatutoryFederalIncomeTaxRateDetails" roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IncomeTaxesDetailsNarrative" roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#LeasesDetailsNarrative" roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFairValueRecurringBasisDetails" roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredOfferingCost" xlink:label="loc_BRTXDeferredOfferingCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_BRTXDeferredOfferingCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GrantIncome" xlink:label="loc_BRTXGrantIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_BRTXGrantIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GainLossOnExchangeOfWarrants" xlink:label="loc_BRTXGainLossOnExchangeOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_BRTXGainLossOnExchangeOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="loc_us-gaapInterestAndDividendIncomeOperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInterestAndDividendIncomeOperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_NoncashLeaseExpense" xlink:label="loc_BRTXNoncashLeaseExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BRTXNoncashLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GainLossOnExchangeOfWarrants" xlink:label="loc_BRTXGainLossOnExchangeOfWarrants" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BRTXGainLossOnExchangeOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:label="loc_BRTXProceedsFromExchangeAndIssuanceOfWarrantsNet1" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_BRTXProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:label="loc_BRTXPaymentsForProceedsFromDeferredOfferingCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_BRTXPaymentsForProceedsFromDeferredOfferingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity" xlink:title="999009 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquity" xlink:title="999012 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurement" xlink:title="999013 - Disclosure - FAIR VALUE MEASUREMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="999014 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipment" xlink:title="999015 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="999016 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxes" xlink:title="999017 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="999018 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityTables" xlink:title="999022 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementTables" xlink:title="999023 - Disclosure - FAIR VALUE MEASUREMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:title="999024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="999025 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesTables" xlink:title="999026 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="999027 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative" xlink:title="999028 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" xlink:title="999029 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="999030 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999032 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="loc_BRTXAccruedGeneralAndAdministrativeExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:to="loc_BRTXAccruedGeneralAndAdministrativeExpenses" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999033 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:title="999034 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999036 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails" xlink:title="999037 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:title="999038 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" xlink:title="999039 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" xlink:title="999040 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:title="999041 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999042 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="999043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="999044 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:title="999047 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:title="999049 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="999051 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:title="999052 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:label="loc_BRTXDeferredTaxAssetsRightOfUseAsset" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_BRTXDeferredTaxAssetsRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_BRTXDeferredTaxLiabilitiesDepreciation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_BRTXDeferredTaxLiabilitiesDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:title="999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ChangeInValuationAllowance" xlink:label="loc_BRTXChangeInValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_BRTXChangeInValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:title="999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:label="loc_BRTXEffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_BRTXEffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:label="loc_BRTXEffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_BRTXEffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:title="999056 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="999057 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="999058 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="999059 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>brtx-20250930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#Cover" roleURI="http://biorestorative.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BalanceSheets" roleURI="http://biorestorative.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfOperations" roleURI="http://biorestorative.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfCashFlows" roleURI="http://biorestorative.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfCashFlowsParenthetical" roleURI="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity" roleURI="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StockholdersEquity" roleURI="http://biorestorative.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#FairValueMeasurement" roleURI="http://biorestorative.com/role/FairValueMeasurement" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SubsequentEvents" roleURI="http://biorestorative.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#PropertyAndEquipment" roleURI="http://biorestorative.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IntangibleAssets" roleURI="http://biorestorative.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IncomeTaxes" roleURI="http://biorestorative.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#Leases" roleURI="http://biorestorative.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StockholdersEquityTables" roleURI="http://biorestorative.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#FairValueMeasurementTables" roleURI="http://biorestorative.com/role/FairValueMeasurementTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#PropertyAndEquipmentTables" roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IntangibleAssetsTables" roleURI="http://biorestorative.com/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IncomeTaxesTables" roleURI="http://biorestorative.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#LeasesTables" roleURI="http://biorestorative.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative" roleURI="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfRevenueRecognizedDetails" roleURI="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockOptionGrantedAssumptionsDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockOptionActivityDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails" roleURI="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StockholdersEquityDetailsNarrative" roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#FairValueMeasurementDetailsNarrative" roleURI="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFairValueValuationAssumptionsDetails" roleURI="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFairValueMeasuredOnRecurringBasisDetails" roleURI="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfIntangibleAssetsDetails" roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockWarrantsDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfInformationRelatedToStockOptionsDetails" roleURI="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockOptionExpenseDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfIncomeTaxProvisionBenefitDetails" roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStatutoryFederalIncomeTaxRateDetails" roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IncomeTaxesDetailsNarrative" roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#LeasesDetailsNarrative" roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFairValueRecurringBasisDetails" roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_30" xlink:type="arc" order="58" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_60" xlink:to="loc_us-gaapAssetsCurrentAbstract_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_60" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_60" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_60" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_60" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_60" xlink:to="loc_us-gaapAssetsCurrent_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredOfferingCost" xlink:label="loc_BRTXDeferredOfferingCost_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_60" xlink:to="loc_BRTXDeferredOfferingCost_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_60" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_60" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_60" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_60" xlink:to="loc_us-gaapAssets_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_60" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_60" xlink:to="loc_us-gaapAccountsPayableCurrent_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_60" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_60" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_60" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_60" xlink:to="loc_us-gaapLiabilitiesCurrent_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_60" xlink:to="loc_us-gaapLiabilities_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_60" xlink:to="loc_us-gaapCommitmentsAndContingencies_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_60" xlink:to="loc_us-gaapStockholdersEquityAbstract_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_60" xlink:to="loc_us-gaapPreferredStockValue_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_60" xlink:to="loc_us-gaapCommonStockValue_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_60" xlink:to="loc_us-gaapAdditionalPaidInCapital_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_60" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_60" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_60" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_60" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodValueAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodValueAbeyanceShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodValueAbeyanceShares_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodSharesAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodSharesAbeyanceShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodSharesAbeyanceShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:label="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:label="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_60" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ATMSalesMember" xlink:label="loc_BRTXATMSalesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_BRTXATMSalesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharesHeldInAbeyance" xlink:label="loc_BRTXSharesHeldInAbeyance_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesHeldInAbeyance_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity" xlink:title="999009 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquity" xlink:title="999012 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurement" xlink:title="999013 - Disclosure - FAIR VALUE MEASUREMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="999014 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipment" xlink:title="999015 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="999016 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxes" xlink:title="999017 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="999018 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityTables" xlink:title="999022 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementTables" xlink:title="999023 - Disclosure - FAIR VALUE MEASUREMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:title="999024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="999025 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesTables" xlink:title="999026 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="999027 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative" xlink:title="999028 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandTwentyFourATMProgramMember" xlink:label="loc_BRTXTwoThousandTwentyFourATMProgramMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_BRTXTwoThousandTwentyFourATMProgramMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapNetIncomeLoss_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_WorkingCapital" xlink:label="loc_BRTXWorkingCapital_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_BRTXWorkingCapital_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ProceedsFromWarrantExercisesNet" xlink:label="loc_BRTXProceedsFromWarrantExercisesNet_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_BRTXProceedsFromWarrantExercisesNet_120" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" xlink:title="999029 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaapRoyaltyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapRoyaltyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="999030 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_270" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_MedicalEquipmentMember" xlink:label="loc_BRTXMedicalEquipmentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXMedicalEquipmentMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="loc_BRTXManufacturingEquipmentMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXManufacturingEquipmentMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredCosts_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharesHeldInAbeyance" xlink:label="loc_BRTXSharesHeldInAbeyance_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_BRTXSharesHeldInAbeyance_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="loc_us-gaapInterestAndDividendIncomeOperating_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInterestAndDividendIncomeOperating_170" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999032 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999033 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:title="999034 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_70" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999036 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EquityLineItem" xlink:label="loc_BRTXEquityLineItem" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EquityTable" xlink:label="loc_BRTXEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BRTXEquityLineItem" xlink:to="loc_BRTXEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BRTXEquityTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BRTXEquityTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXEquityLineItem" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXEquityLineItem" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXEquityLineItem" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_140" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails" xlink:title="999037 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:title="999038 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember_510" xlink:type="arc" order="512" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_NewWarrantsMember" xlink:label="loc_BRTXNewWarrantsMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXNewWarrantsMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BRTXAuctusFundLLCMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandTwentyFourATMProgramMember" xlink:label="loc_BRTXTwoThousandTwentyFourATMProgramMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_BRTXTwoThousandTwentyFourATMProgramMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RothCapitalPartnersLLCMember" xlink:label="loc_BRTXRothCapitalPartnersLLCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXRothCapitalPartnersLLCMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_BoardOfDirectorMember" xlink:label="loc_BRTXBoardOfDirectorMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXBoardOfDirectorMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_510" xlink:type="arc" order="511" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_380" xlink:type="arc" order="382" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_BeneficialOwnershipMember" xlink:label="loc_BRTXBeneficialOwnershipMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_BRTXBeneficialOwnershipMember_290" xlink:type="arc" order="292" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember_310" xlink:type="arc" order="312" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:label="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="loc_BRTXTwoThousandAndTwentyOneStockIncentivePlanMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXTwoThousandAndTwentyOneStockIncentivePlanMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember_450" xlink:type="arc" order="452" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DemandSalesAgreementMember" xlink:label="loc_BRTXDemandSalesAgreementMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BRTXDemandSalesAgreementMember_440" xlink:type="arc" order="442" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_580" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_580" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_580" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_580" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharesHeldInAbeyance" xlink:label="loc_BRTXSharesHeldInAbeyance_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_BRTXSharesHeldInAbeyance_580" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_580" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_580" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_580" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_580" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_580" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_580" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_580" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross_580" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_580" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_580" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_580" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PaymentsForCommissionsLegalAndAccountingFees" xlink:label="loc_BRTXPaymentsForCommissionsLegalAndAccountingFees_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_BRTXPaymentsForCommissionsLegalAndAccountingFees_580" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_580" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_580" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_580" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodSharesAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodSharesAbeyanceShares_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodSharesAbeyanceShares_580" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_580" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_580" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_580" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_580" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_580" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_580" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights_580" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_580" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion_580" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_580" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_580" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_580" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_580" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_580" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_580" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_580" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_580" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_580" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_580" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_580" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_580" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_580" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_580" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_580" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GainLossOnExchangeOfWarrants" xlink:label="loc_BRTXGainLossOnExchangeOfWarrants_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_BRTXGainLossOnExchangeOfWarrants_580" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_580" xlink:type="arc" order="46" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" xlink:title="999039 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_InvestmentsAllOtherInvestmentsLineItem" xlink:label="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_InvestmentsAllOtherInvestmentsTable" xlink:label="loc_BRTXInvestmentsAllOtherInvestmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_BlackScholesOptionMember" xlink:label="loc_BRTXBlackScholesOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_BRTXBlackScholesOptionMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapDerivativeLiabilities_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" xlink:title="999040 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_InvestmentsAllOtherInvestmentsLineItem" xlink:label="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_InvestmentsAllOtherInvestmentsTable" xlink:label="loc_BRTXInvestmentsAllOtherInvestmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_270" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_270" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_270" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_270" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_270" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_270" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_270" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_270" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:title="999041 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999042 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="999043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SubscriptionAgreementsMember" xlink:label="loc_BRTXSubscriptionAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BRTXSubscriptionAgreementsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_LegalFeesAndOtherExpenses" xlink:label="loc_BRTXLegalFeesAndOtherExpenses_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_BRTXLegalFeesAndOtherExpenses_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_140" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_140" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_140" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_CommonStockVestRemainderPercentage" xlink:label="loc_BRTXCommonStockVestRemainderPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_BRTXCommonStockVestRemainderPercentage_140" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="999044 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_MedicalEquipmentMember" xlink:label="loc_BRTXMedicalEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXMedicalEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ComputerSoftwareAndEquipmentMember" xlink:label="loc_BRTXComputerSoftwareAndEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXComputerSoftwareAndEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="loc_BRTXManufacturingEquipmentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXManufacturingEquipmentMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_150" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="loc_BRTXPatentsAndTrademarksMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarksMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:title="999047 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="loc_BRTXPatentsAndTrademarkMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarkMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_160" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:title="999049 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceOneMember" xlink:label="loc_BRTXExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceTwoMember" xlink:label="loc_BRTXExercisePriceTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceThreeMember" xlink:label="loc_BRTXExercisePriceThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceFourMember" xlink:label="loc_BRTXExercisePriceFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceFiveMember" xlink:label="loc_BRTXExercisePriceFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RangeOneMember" xlink:label="loc_BRTXRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RangeTwoMember" xlink:label="loc_BRTXRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RangeThreeMember" xlink:label="loc_BRTXRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="999051 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:title="999052 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaapGoodwillLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaapScheduleOfGoodwillTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGoodwillLineItems" xlink:to="loc_us-gaapScheduleOfGoodwillTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfGoodwillTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfGoodwillTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGoodwillLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGoodwillLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGoodwillLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:title="999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:title="999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:title="999056 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:label="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SectionThreeHundredAndEightyTwoMember" xlink:label="loc_BRTXSectionThreeHundredAndEightyTwoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXSectionThreeHundredAndEightyTwoMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="999057 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_LeasesLineItems" xlink:label="loc_BRTXLeasesLineItems" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_LeasesTable" xlink:label="loc_BRTXLeasesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BRTXLeasesLineItems" xlink:to="loc_BRTXLeasesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BRTXLeasesTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_MelvilleLeaseMember" xlink:label="loc_BRTXMelvilleLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_BRTXMelvilleLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BRTXLeasesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXLeasesLineItems" xlink:to="loc_us-gaapAreaOfLand_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXLeasesLineItems" xlink:to="loc_us-gaapPaymentsForRent_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLessorOperatingLeaseOptionToExtend_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXLeasesLineItems" xlink:to="loc_us-gaapLessorOperatingLeaseOptionToExtend_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BRTXLeasesLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="999058 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="999059 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" order="1000" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>brtx-20250930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="BRTX_SeriesBConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SeriesBConvertiblePreferredStockMember" xlink:to="BRTX_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ATMSalesMember" xlink:label="BRTX_ATMSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ATMSalesMember" xlink:to="BRTX_ATMSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ATMSalesMember_lbl" xml:lang="en-US">A T M Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandTwentyFourATMProgramMember" xlink:label="BRTX_TwoThousandTwentyFourATMProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoThousandTwentyFourATMProgramMember" xlink:to="BRTX_TwoThousandTwentyFourATMProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_TwoThousandTwentyFourATMProgramMember_lbl" xml:lang="en-US">Two Thousand Twenty Four A T M Program [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ATMProgramMember" xlink:label="BRTX_ATMProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ATMProgramMember" xlink:to="BRTX_ATMProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ATMProgramMember_lbl" xml:lang="en-US">A T M Program [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_MedicalEquipmentMember" xlink:label="BRTX_MedicalEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MedicalEquipmentMember" xlink:to="BRTX_MedicalEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_MedicalEquipmentMember_lbl" xml:lang="en-US">Medical Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="BRTX_ManufacturingEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ManufacturingEquipmentMember" xlink:to="BRTX_ManufacturingEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ManufacturingEquipmentMember_lbl" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US">Royalty [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AuctusFundLLCMember" xlink:label="BRTX_AuctusFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AuctusFundLLCMember" xlink:to="BRTX_AuctusFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AuctusFundLLCMember_lbl" xml:lang="en-US">Auctus Fund L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RothCapitalPartnersLLCMember" xlink:label="BRTX_RothCapitalPartnersLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RothCapitalPartnersLLCMember" xlink:to="BRTX_RothCapitalPartnersLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RothCapitalPartnersLLCMember_lbl" xml:lang="en-US">Roth Capital Partners L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_BoardOfDirectorMember" xlink:label="BRTX_BoardOfDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BoardOfDirectorMember" xlink:to="BRTX_BoardOfDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_BoardOfDirectorMember_lbl" xml:lang="en-US">Board Of Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_BeneficialOwnershipMember" xlink:label="BRTX_BeneficialOwnershipMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BeneficialOwnershipMember" xlink:to="BRTX_BeneficialOwnershipMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_BeneficialOwnershipMember_lbl" xml:lang="en-US">Beneficial Ownership [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:label="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:to="BRTX_TwoThousandTwentyOneStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_TwoThousandTwentyOneStockIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Twenty One Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:to="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand And Twenty One Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DemandSalesAgreementMember" xlink:label="BRTX_DemandSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DemandSalesAgreementMember" xlink:to="BRTX_DemandSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DemandSalesAgreementMember_lbl" xml:lang="en-US">Demand Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExistingWarrantMember" xlink:label="BRTX_ExistingWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExistingWarrantMember" xlink:to="BRTX_ExistingWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExistingWarrantMember_lbl" xml:lang="en-US">Existing Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_NewWarrantsMember" xlink:label="BRTX_NewWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NewWarrantsMember" xlink:to="BRTX_NewWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_NewWarrantsMember_lbl" xml:lang="en-US">New Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_BlackScholesOptionMember" xlink:label="BRTX_BlackScholesOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BlackScholesOptionMember" xlink:to="BRTX_BlackScholesOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_BlackScholesOptionMember_lbl" xml:lang="en-US">Black Scholes Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SubscriptionAgreementsMember" xlink:label="BRTX_SubscriptionAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SubscriptionAgreementsMember" xlink:to="BRTX_SubscriptionAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SubscriptionAgreementsMember_lbl" xml:lang="en-US">Subscription Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ComputerSoftwareAndEquipmentMember" xlink:label="BRTX_ComputerSoftwareAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ComputerSoftwareAndEquipmentMember" xlink:to="BRTX_ComputerSoftwareAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ComputerSoftwareAndEquipmentMember_lbl" xml:lang="en-US">Computer Software And Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="BRTX_PatentsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarksMember" xlink:to="BRTX_PatentsAndTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PatentsAndTrademarksMember_lbl" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="BRTX_AccumulatedAmortizationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccumulatedAmortizationMember" xlink:to="BRTX_AccumulatedAmortizationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AccumulatedAmortizationMember_lbl" xml:lang="en-US">Accumulated Amortization [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="BRTX_PatentsAndTrademarkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarkMember" xlink:to="BRTX_PatentsAndTrademarkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PatentsAndTrademarkMember_lbl" xml:lang="en-US">Patents And Trademark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceOneMember" xlink:label="BRTX_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceOneMember" xlink:to="BRTX_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceTwoMember" xlink:label="BRTX_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceTwoMember" xlink:to="BRTX_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceThreeMember" xlink:label="BRTX_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceThreeMember" xlink:to="BRTX_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceFourMember" xlink:label="BRTX_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceFourMember" xlink:to="BRTX_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceFiveMember" xlink:label="BRTX_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceFiveMember" xlink:to="BRTX_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RangeOneMember" xlink:label="BRTX_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RangeOneMember" xlink:to="BRTX_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RangeTwoMember" xlink:label="BRTX_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RangeTwoMember" xlink:to="BRTX_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RangeThreeMember" xlink:label="BRTX_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RangeThreeMember" xlink:to="BRTX_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:label="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:to="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_lbl" xml:lang="en-US">Expire From Two Thousand Thirty To Two Thousand Thirty Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SectionThreeHundredAndEightyTwoMember" xlink:label="BRTX_SectionThreeHundredAndEightyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SectionThreeHundredAndEightyTwoMember" xlink:to="BRTX_SectionThreeHundredAndEightyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SectionThreeHundredAndEightyTwoMember_lbl" xml:lang="en-US">Section Three Hundred And Eighty Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_MelvilleLeaseMember" xlink:label="BRTX_MelvilleLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MelvilleLeaseMember" xlink:to="BRTX_MelvilleLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_MelvilleLeaseMember_lbl" xml:lang="en-US">Melville Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Investments held in marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredOfferingCost" xlink:label="BRTX_DeferredOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredOfferingCost" xlink:to="BRTX_DeferredOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredOfferingCost_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 75,000,000 shares authorized; 6,919,919 and 4,706,917 shares issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss From Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GrantIncome" xlink:label="BRTX_GrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GrantIncome" xlink:to="BRTX_GrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_GrantIncome_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GainLossOnExchangeOfWarrants" xlink:label="BRTX_GainLossOnExchangeOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainLossOnExchangeOfWarrants" xlink:to="BRTX_GainLossOnExchangeOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_GainLossOnExchangeOfWarrants_lbl" xml:lang="en-US">Gain on exchange of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Share - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss Per Share - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Outstanding - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Common Shares Outstanding - Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance and sale of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance and sale of common stock, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodValueAbeyanceShares" xlink:label="BRTX_StockIssuedDuringPeriodValueAbeyanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodValueAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodValueAbeyanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_StockIssuedDuringPeriodValueAbeyanceShares_lbl" xml:lang="en-US">Common stock issued in connection with abeyance shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodSharesAbeyanceShares" xlink:label="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares_lbl" xml:lang="en-US">Common stock issued in connection with abeyance shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_lbl" xml:lang="en-US">Stock-based compensation:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted share units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted share units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Common stock issued in connection with warrant exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Common stock issued in connection with warrant exchange, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:to="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_lbl" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:to="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_lbl" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of Series B Convertible Preferred Stock into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of Series B Convertible Preferred Stock into common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_lbl" xml:lang="en-US">Common stock issued in connection with abeyance shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_lbl" xml:lang="en-US">Common stock issued in connection with abeyance shares, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Aggregate fair value of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharesHeldInAbeyance" xlink:label="BRTX_SharesHeldInAbeyance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesHeldInAbeyance" xlink:to="BRTX_SharesHeldInAbeyance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesHeldInAbeyance_lbl" xml:lang="en-US">Shares held in abeyance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeOperating" xlink:to="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xml:lang="en-US">Dividend and interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_NoncashLeaseExpense" xlink:label="BRTX_NoncashLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoncashLeaseExpense" xlink:to="BRTX_NoncashLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_NoncashLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainLossOnExchangeOfWarrants" xlink:to="BRTX_GainLossOnExchangeOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_GainLossOnExchangeOfWarrants_2_lbl" xml:lang="en-US">Gain on exchange of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided By Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Net proceeds from issuance of common stock in at-the-market offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payment of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds from issuance of common stock in direct-offering</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:label="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:to="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1_lbl" xml:lang="en-US">Proceeds from exchange and issuance of warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:label="BRTX_PaymentsForProceedsFromDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:to="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Decrease In Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and Cash Equivalents - Beginning of the Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and Cash Equivalents - End of the Year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationRelatedText" xlink:to="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xml:lang="en-US">Cash paid during the year for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:label="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:to="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_lbl" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_IssuanceOfCommonStockHeldInAbeyance" xlink:label="BRTX_IssuanceOfCommonStockHeldInAbeyance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_IssuanceOfCommonStockHeldInAbeyance" xlink:to="BRTX_IssuanceOfCommonStockHeldInAbeyance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_IssuanceOfCommonStockHeldInAbeyance_lbl" xml:lang="en-US">Issuance of common stock held in abeyance</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ReclassificationOfDeferredOfferingCosts" xlink:label="BRTX_ReclassificationOfDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ReclassificationOfDeferredOfferingCosts" xlink:to="BRTX_ReclassificationOfDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ReclassificationOfDeferredOfferingCosts_lbl" xml:lang="en-US">Reclassification of deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="BRTX_DeferredOfferingCostsIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredOfferingCostsIncludedInAccountsPayable" xlink:to="BRTX_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Deferred offering costs included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="BRTX_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DisclosureLeasesAbstract" xlink:to="BRTX_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Investments Held in Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Customer and Revenue Concentrations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Contract Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredOfferingCostsPolicyTextBlock" xlink:label="BRTX_DeferredOfferingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredOfferingCostsPolicyTextBlock" xlink:to="BRTX_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TaxLawChangePolicyTextBlock" xlink:label="BRTX_TaxLawChangePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TaxLawChangePolicyTextBlock" xlink:to="BRTX_TaxLawChangePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_TaxLawChangePolicyTextBlock_lbl" xml:lang="en-US">Tax Law Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredContractCostsPolicyTextBlock" xlink:label="BRTX_DeferredContractCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredContractCostsPolicyTextBlock" xlink:to="BRTX_DeferredContractCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_DeferredContractCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Contract Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_WarrantAndOptionValuationPolicyTextBlock" xlink:label="BRTX_WarrantAndOptionValuationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_WarrantAndOptionValuationPolicyTextBlock" xlink:to="BRTX_WarrantAndOptionValuationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_WarrantAndOptionValuationPolicyTextBlock_lbl" xml:lang="en-US">Warrant and Option Valuation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">SCHEDULE OF REVENUE RECOGNIZED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANT ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock" xlink:label="BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock" xlink:to="BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:label="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:to="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME TAX PROVISION (BENEFIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash flows from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_WorkingCapital" xlink:label="BRTX_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_WorkingCapital" xlink:to="BRTX_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Sold shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ProceedsFromWarrantExercisesNet" xlink:label="BRTX_ProceedsFromWarrantExercisesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ProceedsFromWarrantExercisesNet" xlink:to="BRTX_ProceedsFromWarrantExercisesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ProceedsFromWarrantExercisesNet_lbl" xml:lang="en-US">Proceeds from warrant exercises, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC insured limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">FDIC amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred contract costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reporting segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property plant and equipment estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeOperating" xlink:to="us-gaap_InterestAndDividendIncomeOperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDividendIncomeOperating_2_lbl" xml:lang="en-US">Dividend and interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued bonuses</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:to="BRTX_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Accrued general and administrative expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants, Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Warrants, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants, Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Warrants, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_2_lbl" xml:lang="en-US">Number of Warrants, Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options, Outstanding ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life in Years Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life in Years Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic Value, Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EquityTable" xlink:label="BRTX_EquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EquityTable" xlink:to="BRTX_EquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_EquityTable_lbl" xml:lang="en-US">EquityTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EquityLineItem" xlink:label="BRTX_EquityLineItem" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EquityLineItem" xlink:to="BRTX_EquityLineItem_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_EquityLineItem_lbl" xml:lang="en-US">EquityLineItem [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average remaining amortization period (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_3_lbl" xml:lang="en-US">Cash issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock issued during period shares new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrants for cash and the payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Cash fee for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xml:lang="en-US">Grant date fair value of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Vesting of options description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PaymentsForCommissionsLegalAndAccountingFees" xlink:label="BRTX_PaymentsForCommissionsLegalAndAccountingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PaymentsForCommissionsLegalAndAccountingFees" xlink:to="BRTX_PaymentsForCommissionsLegalAndAccountingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PaymentsForCommissionsLegalAndAccountingFees_lbl" xml:lang="en-US">Commissions, legal and accounting fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Net proceeds from shares sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Deferred offering costs reclassified to additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Repurchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares_2_lbl" xml:lang="en-US">Abeyance shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_3_lbl" xml:lang="en-US">Shares issued upon exercise of options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price of options exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xml:lang="en-US">Gross proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidation preference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xml:lang="en-US">Preferred stock voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock voting percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Preferred stock conversion term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt conversion, converted instrument, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Number of shares issued in conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares of common stock authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Common stock authorized to issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested common stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Net proceeds offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Stock issued during period value warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average estimated fair value of warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_InvestmentsAllOtherInvestmentsTable" xlink:label="BRTX_InvestmentsAllOtherInvestmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_InvestmentsAllOtherInvestmentsTable" xlink:to="BRTX_InvestmentsAllOtherInvestmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_InvestmentsAllOtherInvestmentsTable_lbl" xml:lang="en-US">InvestmentsAllOtherInvestmentsTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_InvestmentsAllOtherInvestmentsLineItem" xlink:label="BRTX_InvestmentsAllOtherInvestmentsLineItem" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_InvestmentsAllOtherInvestmentsLineItem" xlink:to="BRTX_InvestmentsAllOtherInvestmentsLineItem_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_InvestmentsAllOtherInvestmentsLineItem_lbl" xml:lang="en-US">InvestmentsAllOtherInvestmentsLineItem [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_3_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Fair value of derivative liabilitiy</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Fair value measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk free interest rate, Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk free interest rate, Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xml:lang="en-US">Balance, July 1,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Issuance of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_4_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xml:lang="en-US">Balance, September 30,</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DerivativesLiabilities" xlink:label="BRTX_DerivativesLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DerivativesLiabilities" xlink:to="BRTX_DerivativesLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="BRTX_DerivativesLiabilities_lbl" xml:lang="en-US">Balance, January 1,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DerivativesLiabilities" xlink:to="BRTX_DerivativesLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BRTX_DerivativesLiabilities_2_lbl" xml:lang="en-US">Balance, September 30,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilities_2_lbl" xml:lang="en-US">Balance, January 1, 2024</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_3_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilities_3_lbl" xml:lang="en-US">Balance, december 30, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Marketable securities, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Warrant liabilities, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Description on sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_LegalFeesAndOtherExpenses" xlink:label="BRTX_LegalFeesAndOtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_LegalFeesAndOtherExpenses" xlink:to="BRTX_LegalFeesAndOtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_LegalFeesAndOtherExpenses_lbl" xml:lang="en-US">Legal fees and other expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xml:lang="en-US">Options to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US">Legal settlements paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Grant options shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Grant options shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_CommonStockVestRemainderPercentage" xlink:label="BRTX_CommonStockVestRemainderPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_CommonStockVestRemainderPercentage" xlink:to="BRTX_CommonStockVestRemainderPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_CommonStockVestRemainderPercentage_lbl" xml:lang="en-US">Purchase of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property plant and equipment gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Gross, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_3_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Net, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite Lived Intangible Assets, weighted average amortization period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrants outstanding, exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, number of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants exercisable, weighted average remaining life in years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants exercisable, exercisable number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Options Outstanding, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options Outstanding, Outstanding Number of Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Exercisable Weighted Average Remaining Life In Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Options Exercisable, Exercisable Number of Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xml:lang="en-US">Goodwill [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillLineItems_lbl" xml:lang="en-US">Goodwill [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:label="BRTX_DeferredTaxAssetsRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:to="BRTX_DeferredTaxAssetsRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_DeferredTaxAssetsRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredTaxLiabilitiesDepreciation" xlink:label="BRTX_DeferredTaxLiabilitiesDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxLiabilitiesDepreciation" xlink:to="BRTX_DeferredTaxLiabilitiesDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_DeferredTaxLiabilitiesDepreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total Deferred Tax Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net Deferred Tax Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Asset, Net of Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Federal:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">State &amp; Local:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ChangeInValuationAllowance" xlink:label="BRTX_ChangeInValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChangeInValuationAllowance" xlink:to="BRTX_ChangeInValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_ChangeInValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax, net of valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:to="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_lbl" xml:lang="en-US">Tax return to provision adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in federal valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:to="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_lbl" xml:lang="en-US">Adjustment for stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior year income taxes, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Operating loss carry-forwards subject to expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Operating loss carry-forwards not subject to expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Net operating loss description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Income tax examination, description</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_LeasesTable" xlink:label="BRTX_LeasesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_LeasesTable" xlink:to="BRTX_LeasesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_LeasesTable_lbl" xml:lang="en-US">LeasesTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_LeasesLineItems" xlink:label="BRTX_LeasesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_LeasesLineItems" xlink:to="BRTX_LeasesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_LeasesLineItems_lbl" xml:lang="en-US">LeasesLineItems [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseOptionToExtend" xlink:to="us-gaap_LessorOperatingLeaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lease extension description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DisclosureLeasesAbstract" xlink:to="BRTX_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Net Lease Cost And Other Supplemental Lease Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost (cost resulting from lease payments)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Net lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease - operating cash flows (fixed payments)</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_OperatingLeaseLiabilityReduction" xlink:label="BRTX_OperatingLeaseLiabilityReduction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_OperatingLeaseLiabilityReduction" xlink:to="BRTX_OperatingLeaseLiabilityReduction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_OperatingLeaseLiabilityReduction_lbl" xml:lang="en-US">Operating lease - operating cash flows (liability reduction)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Non-current leases - right of use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current liabilities - operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current liabilities - operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_2_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainLossOnExchangeOfWarrants" xlink:to="BRTX_GainLossOnExchangeOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_GainLossOnExchangeOfWarrants_doc" xml:lang="en-US">Gain loss on exchange of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredOfferingCost" xlink:to="BRTX_DeferredOfferingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredOfferingCost_doc" xml:lang="en-US">Deferred offering cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodValueAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodValueAbeyanceShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_StockIssuedDuringPeriodValueAbeyanceShares_doc" xml:lang="en-US">Stock issued during period value abeyance shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:to="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_doc" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_StockIssuedDuringPeriodSharesAbeyanceShares_doc" xml:lang="en-US">Stock issued during period shares abeyance shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:to="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1_doc" xml:lang="en-US">Proceeds from exchange and issuance of warrants net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:to="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_doc" xml:lang="en-US">Payments for proceeds from deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:to="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_doc" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ReclassificationOfDeferredOfferingCosts" xlink:to="BRTX_ReclassificationOfDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ReclassificationOfDeferredOfferingCosts_doc" xml:lang="en-US">Reclassification of deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredOfferingCostsIncludedInAccountsPayable" xlink:to="BRTX_DeferredOfferingCostsIncludedInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredOfferingCostsIncludedInAccountsPayable_doc" xml:lang="en-US">Deferred offering costs included in accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PaymentsForCommissionsLegalAndAccountingFees" xlink:to="BRTX_PaymentsForCommissionsLegalAndAccountingFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_PaymentsForCommissionsLegalAndAccountingFees_doc" xml:lang="en-US">Payments for commissions legal and accounting fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_CommonStockVestRemainderPercentage" xlink:to="BRTX_CommonStockVestRemainderPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_CommonStockVestRemainderPercentage_doc" xml:lang="en-US">Common stock vest remainder percentage.</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ChangeInFairValueOfDerivativeLiability" xlink:label="BRTX_ChangeInFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChangeInFairValueOfDerivativeLiability" xlink:to="BRTX_ChangeInFairValueOfDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ChangeInFairValueOfDerivativeLiability_doc" xml:lang="en-US">Change in fair value of derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_OperatingLeaseLiabilityReduction" xlink:to="BRTX_OperatingLeaseLiabilityReduction_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_OperatingLeaseLiabilityReduction_doc" xml:lang="en-US">Operating lease liability reduction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:to="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_doc" xml:lang="en-US">Adjustment for stock-based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChangeInValuationAllowance" xlink:to="BRTX_ChangeInValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ChangeInValuationAllowance_doc" xml:lang="en-US">Change in valuation allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:to="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_doc" xml:lang="en-US">Effective income tax rate reconciliation tax return to provision adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxLiabilitiesDepreciation" xlink:to="BRTX_DeferredTaxLiabilitiesDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredTaxLiabilitiesDepreciation_doc" xml:lang="en-US">Deferred tax liabilities depreciation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:to="BRTX_DeferredTaxAssetsRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredTaxAssetsRightOfUseAsset_doc" xml:lang="en-US">Deferred tax assets right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:to="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_doc" xml:lang="en-US">Schedule of share based compensation warrant outstanding and exercisable by exercise price range [Table text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Non option equity instrument exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price, expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">ShareBased compensation arrangements by share based payment award non options exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options granted in period weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GainOnExchangeOfWarrants" xlink:label="BRTX_GainOnExchangeOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainOnExchangeOfWarrants" xlink:to="BRTX_GainOnExchangeOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_GainOnExchangeOfWarrants_doc" xml:lang="en-US">Gain on exchange of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:to="BRTX_AccruedGeneralAndAdministrativeExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses_doc" xml:lang="en-US">Accrued general and administrative expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_doc" xml:lang="en-US">Recently issued accounting pronouncements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesHeldInAbeyance" xlink:to="BRTX_SharesHeldInAbeyance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesHeldInAbeyance_doc" xml:lang="en-US">Shares held in abeyance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_WarrantAndOptionValuationPolicyTextBlock" xlink:to="BRTX_WarrantAndOptionValuationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_WarrantAndOptionValuationPolicyTextBlock_doc" xml:lang="en-US">Warrant and option valuation [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredOfferingCostsPolicyTextBlock" xlink:to="BRTX_DeferredOfferingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredOfferingCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred offering costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ProceedsFromWarrantExercisesNet" xlink:to="BRTX_ProceedsFromWarrantExercisesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ProceedsFromWarrantExercisesNet_doc" xml:lang="en-US">Proceeds from warrant exercises net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_WorkingCapital" xlink:to="BRTX_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_IssuanceOfCommonStockHeldInAbeyance" xlink:to="BRTX_IssuanceOfCommonStockHeldInAbeyance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_IssuanceOfCommonStockHeldInAbeyance_doc" xml:lang="en-US">Issuance of common stock held in abeyance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoncashLeaseExpense" xlink:to="BRTX_NoncashLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_NoncashLeaseExpense_doc" xml:lang="en-US">Noncash Lease Expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_doc" xml:lang="en-US">Stock issued during period value common stock issued in connection with abeyance shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_doc" xml:lang="en-US">Stock issued during period shares common stock issued in connection with abeyance shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:to="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_doc" xml:lang="en-US">Stock return and cancellation of shares in lieu of payroll tax withholding shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GrantIncome" xlink:to="BRTX_GrantIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_GrantIncome_doc" xml:lang="en-US">Grant income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_LegalFeesAndOtherExpenses" xlink:to="BRTX_LegalFeesAndOtherExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_LegalFeesAndOtherExpenses_doc" xml:lang="en-US">The amount of legal fees and other expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredContractCostsPolicyTextBlock" xlink:to="BRTX_DeferredContractCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredContractCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred contract costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock" xlink:to="BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of cost recognized for award under share-based payment arrangement by award type.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TaxLawChangePolicyTextBlock" xlink:to="BRTX_TaxLawChangePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_TaxLawChangePolicyTextBlock_doc" xml:lang="en-US">Tax Law Change [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DerivativesLiabilities" xlink:to="BRTX_DerivativesLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DerivativesLiabilities_doc" xml:lang="en-US">Derivatives Liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:to="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_3_lbl" xml:lang="en-US">PaymentsForProceedsFromDeferredOfferingCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:to="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_3_lbl" xml:lang="en-US">ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredContractCostsPolicyTextBlock" xlink:to="BRTX_DeferredContractCostsPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredContractCostsPolicyTextBlock_3_lbl" xml:lang="en-US">Deferred contract costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_2_lbl" xml:lang="en-US">Deferred Offering Costs [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DerivativesLiabilities" xlink:to="BRTX_DerivativesLiabilities_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DerivativesLiabilities_4_lbl" xml:lang="en-US">DerivativesLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:to="BRTX_DeferredTaxAssetsRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredTaxAssetsRightOfUseAsset_3_lbl" xml:lang="en-US">DeferredTaxAssetsRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxLiabilitiesDepreciation" xlink:to="BRTX_DeferredTaxLiabilitiesDepreciation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredTaxLiabilitiesDepreciation_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesDepreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChangeInValuationAllowance" xlink:to="BRTX_ChangeInValuationAllowance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ChangeInValuationAllowance_3_lbl" xml:lang="en-US">ChangeInValuationAllowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>brtx-20250930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#Cover" roleURI="http://biorestorative.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BalanceSheets" roleURI="http://biorestorative.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfOperations" roleURI="http://biorestorative.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfCashFlows" roleURI="http://biorestorative.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StatementsOfCashFlowsParenthetical" roleURI="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity" roleURI="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StockholdersEquity" roleURI="http://biorestorative.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#FairValueMeasurement" roleURI="http://biorestorative.com/role/FairValueMeasurement" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SubsequentEvents" roleURI="http://biorestorative.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#PropertyAndEquipment" roleURI="http://biorestorative.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IntangibleAssets" roleURI="http://biorestorative.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IncomeTaxes" roleURI="http://biorestorative.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#Leases" roleURI="http://biorestorative.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StockholdersEquityTables" roleURI="http://biorestorative.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#FairValueMeasurementTables" roleURI="http://biorestorative.com/role/FairValueMeasurementTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#PropertyAndEquipmentTables" roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IntangibleAssetsTables" roleURI="http://biorestorative.com/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IncomeTaxesTables" roleURI="http://biorestorative.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#LeasesTables" roleURI="http://biorestorative.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative" roleURI="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfRevenueRecognizedDetails" roleURI="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockOptionGrantedAssumptionsDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockOptionActivityDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails" roleURI="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#StockholdersEquityDetailsNarrative" roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#FairValueMeasurementDetailsNarrative" roleURI="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFairValueValuationAssumptionsDetails" roleURI="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFairValueMeasuredOnRecurringBasisDetails" roleURI="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfIntangibleAssetsDetails" roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockWarrantsDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfInformationRelatedToStockOptionsDetails" roleURI="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStockOptionExpenseDetails" roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfIncomeTaxProvisionBenefitDetails" roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfStatutoryFederalIncomeTaxRateDetails" roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#IncomeTaxesDetailsNarrative" roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#LeasesDetailsNarrative" roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="brtx-20250930.xsd#ScheduleOfFairValueRecurringBasisDetails" roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" />
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredOfferingCost" xlink:label="loc_BRTXDeferredOfferingCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_BRTXDeferredOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GrantIncome" xlink:label="loc_BRTXGrantIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_BRTXGrantIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GainLossOnExchangeOfWarrants" xlink:label="loc_BRTXGainLossOnExchangeOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_BRTXGainLossOnExchangeOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodValueAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodValueAbeyanceShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodValueAbeyanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodSharesAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodSharesAbeyanceShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodSharesAbeyanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:label="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:label="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ATMSalesMember" xlink:label="loc_BRTXATMSalesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_BRTXATMSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharesHeldInAbeyance" xlink:label="loc_BRTXSharesHeldInAbeyance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesHeldInAbeyance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="loc_us-gaapInterestAndDividendIncomeOperating" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInterestAndDividendIncomeOperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_NoncashLeaseExpense" xlink:label="loc_BRTXNoncashLeaseExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_BRTXNoncashLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GainLossOnExchangeOfWarrants" xlink:label="loc_BRTXGainLossOnExchangeOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_BRTXGainLossOnExchangeOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:label="loc_BRTXProceedsFromExchangeAndIssuanceOfWarrantsNet1" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_BRTXProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:label="loc_BRTXPaymentsForProceedsFromDeferredOfferingCosts" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_BRTXPaymentsForProceedsFromDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="loc_us-gaapSupplementalCashFlowInformationRelatedText" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:label="loc_BRTXReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_IssuanceOfCommonStockHeldInAbeyance" xlink:label="loc_BRTXIssuanceOfCommonStockHeldInAbeyance" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXIssuanceOfCommonStockHeldInAbeyance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ReclassificationOfDeferredOfferingCosts" xlink:label="loc_BRTXReclassificationOfDeferredOfferingCosts" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXReclassificationOfDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="loc_BRTXDeferredOfferingCostsIncludedInAccountsPayable" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXDeferredOfferingCostsIncludedInAccountsPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity" xlink:title="999009 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquity" xlink:title="999012 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurement" xlink:title="999013 - Disclosure - FAIR VALUE MEASUREMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaapFinancialInstrumentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapFinancialInstrumentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="999014 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipment" xlink:title="999015 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="999016 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxes" xlink:title="999017 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="999018 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_BRTXDeferredOfferingCostsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BRTXDeferredOfferingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TaxLawChangePolicyTextBlock" xlink:label="loc_BRTXTaxLawChangePolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BRTXTaxLawChangePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredContractCostsPolicyTextBlock" xlink:label="loc_BRTXDeferredContractCostsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BRTXDeferredContractCostsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_WarrantAndOptionValuationPolicyTextBlock" xlink:label="loc_BRTXWarrantAndOptionValuationPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BRTXWarrantAndOptionValuationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_BRTXRecentlyIssuedAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BRTXRecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityTables" xlink:title="999022 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock" xlink:label="loc_BRTXScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_BRTXScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:label="loc_BRTXScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_BRTXScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementTables" xlink:title="999023 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:title="999024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="999025 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesTables" xlink:title="999026 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="999027 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative" xlink:title="999028 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandTwentyFourATMProgramMember" xlink:label="loc_BRTXTwoThousandTwentyFourATMProgramMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_BRTXTwoThousandTwentyFourATMProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_WorkingCapital" xlink:label="loc_BRTXWorkingCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_BRTXWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ProceedsFromWarrantExercisesNet" xlink:label="loc_BRTXProceedsFromWarrantExercisesNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_BRTXProceedsFromWarrantExercisesNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" xlink:title="999029 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaapRoyaltyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapRoyaltyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="999030 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_MedicalEquipmentMember" xlink:label="loc_BRTXMedicalEquipmentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="loc_BRTXManufacturingEquipmentMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXManufacturingEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharesHeldInAbeyance" xlink:label="loc_BRTXSharesHeldInAbeyance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_BRTXSharesHeldInAbeyance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="loc_us-gaapInterestAndDividendIncomeOperating" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInterestAndDividendIncomeOperating" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999032 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="loc_BRTXAccruedGeneralAndAdministrativeExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_BRTXAccruedGeneralAndAdministrativeExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999033 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:title="999034 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999036 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EquityTable" xlink:label="loc_BRTXEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_BRTXEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EquityLineItem" xlink:label="loc_BRTXEquityLineItem" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXEquityTable" xlink:to="loc_BRTXEquityLineItem" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXEquityTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXEquityTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXEquityLineItem" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXEquityLineItem" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXEquityLineItem" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails" xlink:title="999037 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:title="999038 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_NewWarrantsMember" xlink:label="loc_BRTXNewWarrantsMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXNewWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BRTXAuctusFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandTwentyFourATMProgramMember" xlink:label="loc_BRTXTwoThousandTwentyFourATMProgramMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_BRTXTwoThousandTwentyFourATMProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RothCapitalPartnersLLCMember" xlink:label="loc_BRTXRothCapitalPartnersLLCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXRothCapitalPartnersLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_BoardOfDirectorMember" xlink:label="loc_BRTXBoardOfDirectorMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXBoardOfDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_BeneficialOwnershipMember" xlink:label="loc_BRTXBeneficialOwnershipMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_BRTXBeneficialOwnershipMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" order="110" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="120" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:label="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="loc_BRTXTwoThousandAndTwentyOneStockIncentivePlanMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXTwoThousandAndTwentyOneStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="130" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DemandSalesAgreementMember" xlink:label="loc_BRTXDemandSalesAgreementMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BRTXDemandSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SharesHeldInAbeyance" xlink:label="loc_BRTXSharesHeldInAbeyance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_BRTXSharesHeldInAbeyance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PaymentsForCommissionsLegalAndAccountingFees" xlink:label="loc_BRTXPaymentsForCommissionsLegalAndAccountingFees" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_BRTXPaymentsForCommissionsLegalAndAccountingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_StockIssuedDuringPeriodSharesAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodSharesAbeyanceShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodSharesAbeyanceShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_GainLossOnExchangeOfWarrants" xlink:label="loc_BRTXGainLossOnExchangeOfWarrants" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_BRTXGainLossOnExchangeOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" xlink:title="999039 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_InvestmentsAllOtherInvestmentsTable" xlink:label="loc_BRTXInvestmentsAllOtherInvestmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_BRTXInvestmentsAllOtherInvestmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_InvestmentsAllOtherInvestmentsLineItem" xlink:label="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_BlackScholesOptionMember" xlink:label="loc_BRTXBlackScholesOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_BRTXBlackScholesOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" xlink:title="999040 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_InvestmentsAllOtherInvestmentsTable" xlink:label="loc_BRTXInvestmentsAllOtherInvestmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_BRTXInvestmentsAllOtherInvestmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_InvestmentsAllOtherInvestmentsLineItem" xlink:label="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXInvestmentsAllOtherInvestmentsLineItem" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:title="999041 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DerivativesLiabilities" xlink:label="loc_BRTXDerivativesLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_BRTXDerivativesLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DerivativesLiabilities" xlink:label="loc_BRTXDerivativesLiabilities_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_BRTXDerivativesLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapDerivativeLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999042 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="999043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SubscriptionAgreementsMember" xlink:label="loc_BRTXSubscriptionAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BRTXSubscriptionAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_LegalFeesAndOtherExpenses" xlink:label="loc_BRTXLegalFeesAndOtherExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_BRTXLegalFeesAndOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_CommonStockVestRemainderPercentage" xlink:label="loc_BRTXCommonStockVestRemainderPercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_BRTXCommonStockVestRemainderPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="999044 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_MedicalEquipmentMember" xlink:label="loc_BRTXMedicalEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ComputerSoftwareAndEquipmentMember" xlink:label="loc_BRTXComputerSoftwareAndEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXComputerSoftwareAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="loc_BRTXManufacturingEquipmentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXManufacturingEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="loc_BRTXPatentsAndTrademarksMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:title="999047 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="loc_BRTXPatentsAndTrademarkMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:title="999049 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceOneMember" xlink:label="loc_BRTXExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceTwoMember" xlink:label="loc_BRTXExercisePriceTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceThreeMember" xlink:label="loc_BRTXExercisePriceThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceFourMember" xlink:label="loc_BRTXExercisePriceFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExercisePriceFiveMember" xlink:label="loc_BRTXExercisePriceFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RangeOneMember" xlink:label="loc_BRTXRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RangeTwoMember" xlink:label="loc_BRTXRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_RangeThreeMember" xlink:label="loc_BRTXRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="999051 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:title="999052 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaapScheduleOfGoodwillTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfGoodwillTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaapGoodwillLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfGoodwillTable" xlink:to="loc_us-gaapGoodwillLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfGoodwillTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfGoodwillTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:label="loc_BRTXDeferredTaxAssetsRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_BRTXDeferredTaxAssetsRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_BRTXDeferredTaxLiabilitiesDepreciation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_BRTXDeferredTaxLiabilitiesDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:title="999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ChangeInValuationAllowance" xlink:label="loc_BRTXChangeInValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_BRTXChangeInValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:title="999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:label="loc_BRTXEffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_BRTXEffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:label="loc_BRTXEffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_BRTXEffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:title="999056 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementScenarioAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:label="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_SectionThreeHundredAndEightyTwoMember" xlink:label="loc_BRTXSectionThreeHundredAndEightyTwoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXSectionThreeHundredAndEightyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="999057 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_LeasesTable" xlink:label="loc_BRTXLeasesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_BRTXLeasesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_LeasesLineItems" xlink:label="loc_BRTXLeasesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXLeasesTable" xlink:to="loc_BRTXLeasesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXLeasesTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_MelvilleLeaseMember" xlink:label="loc_BRTXMelvilleLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_BRTXMelvilleLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXLeasesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXLeasesLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXLeasesLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLessorOperatingLeaseOptionToExtend" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXLeasesLineItems" xlink:to="loc_us-gaapLessorOperatingLeaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXLeasesLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="999058 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_OperatingLeaseLiabilityReduction" xlink:label="loc_BRTXOperatingLeaseLiabilityReduction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_BRTXOperatingLeaseLiabilityReduction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="999059 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="brtx-20250930.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIORESTORATIVE
THERAPIES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001505497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-1341024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40
Marcus Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite One<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-8100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40
Marcus Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite One<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-8100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Lance
Alstodt<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 602,444<span></span>
</td>
<td class="nump">$ 547,890<span></span>
</td>
<td class="nump">$ 884,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments held in marketable securities</a></td>
<td class="nump">3,887,383<span></span>
</td>
<td class="nump">10,184,701<span></span>
</td>
<td class="nump">10,181,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">13,400<span></span>
</td>
<td class="nump">188,400<span></span>
</td>
<td class="nump">19,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">204,237<span></span>
</td>
<td class="nump">223,230<span></span>
</td>
<td class="nump">305,231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">4,707,464<span></span>
</td>
<td class="nump">11,144,221<span></span>
</td>
<td class="nump">11,390,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredOfferingCost', window );">Deferred offering costs</a></td>
<td class="nump">69,066<span></span>
</td>
<td class="nump">148,697<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">309,498<span></span>
</td>
<td class="nump">362,936<span></span>
</td>
<td class="nump">356,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">151,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">556,634<span></span>
</td>
<td class="nump">623,945<span></span>
</td>
<td class="nump">713,692<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">5,642,662<span></span>
</td>
<td class="nump">12,279,799<span></span>
</td>
<td class="nump">12,611,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">859,898<span></span>
</td>
<td class="nump">483,070<span></span>
</td>
<td class="nump">189,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">607,470<span></span>
</td>
<td class="nump">744,485<span></span>
</td>
<td class="nump">711,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">162,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liabilities</a></td>
<td class="nump">1,968,315<span></span>
</td>
<td class="nump">2,520,851<span></span>
</td>
<td class="nump">1,543,953<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">3,435,683<span></span>
</td>
<td class="nump">3,748,406<span></span>
</td>
<td class="nump">2,607,345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,748,406<span></span>
</td>
<td class="nump">2,607,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">13,982<span></span>
</td>
<td class="nump">13,982<span></span>
</td>
<td class="nump">13,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 75,000,000 shares authorized; 6,919,919 and 4,706,917 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">797<span></span>
</td>
<td class="nump">692<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">168,905,254<span></span>
</td>
<td class="nump">164,195,434<span></span>
</td>
<td class="nump">156,689,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(166,713,054)<span></span>
</td>
<td class="num">(155,678,715)<span></span>
</td>
<td class="num">(146,699,334)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">2,206,979<span></span>
</td>
<td class="nump">8,531,393<span></span>
</td>
<td class="nump">10,004,375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 5,642,662<span></span>
</td>
<td class="nump">12,279,799<span></span>
</td>
<td class="nump">12,611,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 13,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,978,117<span></span>
</td>
<td class="nump">6,919,919<span></span>
</td>
<td class="nump">4,706,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,978,117<span></span>
</td>
<td class="nump">6,919,919<span></span>
</td>
<td class="nump">4,706,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,543,158<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="nump">$ 233,600<span></span>
</td>
<td class="nump">$ 340,100<span></span>
</td>
<td class="nump">$ 357,700<span></span>
</td>
<td class="nump">$ 401,000<span></span>
</td>
<td class="nump">$ 145,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">10,570<span></span>
</td>
<td class="nump">18,243<span></span>
</td>
<td class="nump">22,208<span></span>
</td>
<td class="nump">24,733<span></span>
</td>
<td class="nump">28,072<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">215,357<span></span>
</td>
<td class="nump">317,892<span></span>
</td>
<td class="nump">332,967<span></span>
</td>
<td class="nump">372,928<span></span>
</td>
<td class="nump">145,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,594,750<span></span>
</td>
<td class="nump">1,453,363<span></span>
</td>
<td class="nump">7,467,532<span></span>
</td>
<td class="nump">5,004,794<span></span>
</td>
<td class="nump">5,348,709<span></span>
</td>
<td class="nump">4,034,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,115,491<span></span>
</td>
<td class="nump">1,048,987<span></span>
</td>
<td class="nump">4,672,192<span></span>
</td>
<td class="nump">4,193,225<span></span>
</td>
<td class="nump">6,579,413<span></span>
</td>
<td class="nump">11,331,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">3,710,241<span></span>
</td>
<td class="nump">2,502,350<span></span>
</td>
<td class="nump">12,139,724<span></span>
</td>
<td class="nump">9,198,019<span></span>
</td>
<td class="nump">11,928,122<span></span>
</td>
<td class="nump">15,366,574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss From Operations</a></td>
<td class="num">(3,709,011)<span></span>
</td>
<td class="num">(2,286,993)<span></span>
</td>
<td class="num">(11,821,832)<span></span>
</td>
<td class="num">(8,865,052)<span></span>
</td>
<td class="num">(11,555,194)<span></span>
</td>
<td class="num">(15,220,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">57,740<span></span>
</td>
<td class="nump">158,547<span></span>
</td>
<td class="nump">231,621<span></span>
</td>
<td class="nump">497,089<span></span>
</td>
<td class="nump">616,077<span></span>
</td>
<td class="nump">552,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GrantIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">930<span></span>
</td>
<td class="nump">566<span></span>
</td>
<td class="nump">3,336<span></span>
</td>
<td class="nump">150,498<span></span>
</td>
<td class="nump">150,850<span></span>
</td>
<td class="nump">169,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainLossOnExchangeOfWarrants', window );">Gain on exchange of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,711,698<span></span>
</td>
<td class="nump">1,711,698<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">612,064<span></span>
</td>
<td class="nump">1,036,464<span></span>
</td>
<td class="nump">552,536<span></span>
</td>
<td class="num">(837,466)<span></span>
</td>
<td class="nump">97,188<span></span>
</td>
<td class="nump">3,997,780<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income</a></td>
<td class="nump">670,734<span></span>
</td>
<td class="nump">1,195,577<span></span>
</td>
<td class="nump">787,493<span></span>
</td>
<td class="nump">1,521,819<span></span>
</td>
<td class="nump">2,575,813<span></span>
</td>
<td class="nump">4,803,070<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (3,038,277)<span></span>
</td>
<td class="num">$ (1,091,416)<span></span>
</td>
<td class="num">$ (11,034,339)<span></span>
</td>
<td class="num">$ (7,343,233)<span></span>
</td>
<td class="num">$ (8,979,381)<span></span>
</td>
<td class="num">$ (10,417,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Share - Basic</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss Per Share - Diluted</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Outstanding - Basic</a></td>
<td class="nump">9,116,172<span></span>
</td>
<td class="nump">8,121,499<span></span>
</td>
<td class="nump">8,742,085<span></span>
</td>
<td class="nump">7,643,437<span></span>
</td>
<td class="nump">7,763,932<span></span>
</td>
<td class="nump">4,218,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Common Shares Outstanding - Diluted</a></td>
<td class="nump">9,116,172<span></span>
</td>
<td class="nump">8,121,499<span></span>
</td>
<td class="nump">8,742,085<span></span>
</td>
<td class="nump">7,643,437<span></span>
</td>
<td class="nump">7,763,932<span></span>
</td>
<td class="nump">4,218,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GainLossOnExchangeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GainLossOnExchangeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,182<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 146,556,418<span></span>
</td>
<td class="num">$ (136,281,630)<span></span>
</td>
<td class="nump">$ 10,290,339<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,518,158<span></span>
</td>
<td class="nump">3,677,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">2,348,692<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,348,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">4,633,655<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,633,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share units, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,141,803<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,141,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,417,704)<span></span>
</td>
<td class="num">(10,417,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of Series B Convertible Preferred Stock into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,200)<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of Series B Convertible Preferred Stock into common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(120,000)<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">156,689,256<span></span>
</td>
<td class="num">(146,699,334)<span></span>
</td>
<td class="nump">10,004,375<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">4,706,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">985,028<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">985,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share units, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,043,336<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,043,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,223,255)<span></span>
</td>
<td class="num">(2,223,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued in connection with warrant exchange</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">4,742,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,742,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued in connection with warrant exchange, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding', window );">Return and cancellation of shares in lieu of payroll tax withholding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">(48,406)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(48,410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares', window );">Return and cancellation of shares in lieu of payroll tax withholding, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 677<span></span>
</td>
<td class="nump">163,411,257<span></span>
</td>
<td class="num">(148,922,589)<span></span>
</td>
<td class="nump">14,503,327<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">6,769,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">156,689,256<span></span>
</td>
<td class="num">(146,699,334)<span></span>
</td>
<td class="nump">10,004,375<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">4,706,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,343,233)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">164,019,809<span></span>
</td>
<td class="num">(154,042,567)<span></span>
</td>
<td class="nump">9,991,916<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">6,919,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">156,689,256<span></span>
</td>
<td class="num">(146,699,334)<span></span>
</td>
<td class="nump">$ 10,004,375<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">4,706,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">985,028<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 985,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share units, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,827,528<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,827,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,979,381)<span></span>
</td>
<td class="num">(8,979,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued in connection with warrant exchange</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">4,742,043<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,742,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued in connection with warrant exchange, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding', window );">Return and cancellation of shares in lieu of payroll tax withholding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">(48,406)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(48,410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares', window );">Return and cancellation of shares in lieu of payroll tax withholding, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares', window );">Common stock issued in connection with abeyance shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares', window );">Common stock issued in connection with abeyance shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">164,195,434<span></span>
</td>
<td class="num">(155,678,715)<span></span>
</td>
<td class="nump">8,531,393<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">6,919,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 677<span></span>
</td>
<td class="nump">163,411,257<span></span>
</td>
<td class="num">(148,922,589)<span></span>
</td>
<td class="nump">14,503,327<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">6,769,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockIssuedDuringPeriodValueAbeyanceShares', window );">Common stock issued in connection with abeyance shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockIssuedDuringPeriodSharesAbeyanceShares', window );">Common stock issued in connection with abeyance shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">324,322<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">324,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,028,562)<span></span>
</td>
<td class="num">(4,028,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">163,735,564<span></span>
</td>
<td class="num">(152,951,151)<span></span>
</td>
<td class="nump">10,799,087<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">6,919,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">284,245<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">284,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,091,416)<span></span>
</td>
<td class="num">(1,091,416)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">164,019,809<span></span>
</td>
<td class="num">(154,042,567)<span></span>
</td>
<td class="nump">9,991,916<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">6,919,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">164,195,434<span></span>
</td>
<td class="num">(155,678,715)<span></span>
</td>
<td class="nump">8,531,393<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">6,919,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">42,408<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">901,561<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">901,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockIssuedDuringPeriodValueAbeyanceShares', window );">Common stock issued in connection with abeyance shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockIssuedDuringPeriodSharesAbeyanceShares', window );">Common stock issued in connection with abeyance shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,009,126<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,009,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,339,799)<span></span>
</td>
<td class="num">(5,339,799)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">167,148,523<span></span>
</td>
<td class="num">(161,018,514)<span></span>
</td>
<td class="nump">6,144,741<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">7,504,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">164,195,434<span></span>
</td>
<td class="num">(155,678,715)<span></span>
</td>
<td class="nump">8,531,393<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">6,919,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,034,339)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">168,905,254<span></span>
</td>
<td class="num">(166,713,054)<span></span>
</td>
<td class="nump">2,206,979<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">7,978,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">167,148,523<span></span>
</td>
<td class="num">(161,018,514)<span></span>
</td>
<td class="nump">6,144,741<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">7,504,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">888,091<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">888,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">468,708<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">468,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,656,263)<span></span>
</td>
<td class="num">(2,656,263)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">168,505,322<span></span>
</td>
<td class="num">(163,674,777)<span></span>
</td>
<td class="nump">4,845,324<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">7,978,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">399,932<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">399,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,038,277)<span></span>
</td>
<td class="num">(3,038,277)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">$ 168,905,254<span></span>
</td>
<td class="num">$ (166,713,054)<span></span>
</td>
<td class="nump">$ 2,206,979<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">7,978,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the
aggregate fair value of <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHaF4Odvuz81" title="Aggregate fair value of common stock">3,351,580</span> shares of common stock, which includes <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI9x89Qv0BMb" title="Shares issued">2,000,000</span> shares that were issued at the time of the warrant
exchange and <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_ecustom--SharesHeldInAbeyance_iI_pid_c20240331_z1PxY0VQzHHb" title="Shares held in abeyance">1,351,580</span> shares that were held in abeyance at the time of the warrant exchange. See Note 4 - Stockholders&#8217; Equity
- Warrant Exercise and Issuance and Note 5 - Fair Value Measurement for additional details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the
aggregate fair value of <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpPD4xdmm3mj" title="Aggregate fair value of common stock">3,351,580</span> shares of common stock, which includes <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5nhgzoqroak" title="Warrants exercisable">2,150,000</span> shares that have been issued and <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zQNmiOi5AQNa" title="Shares held in abeyance">1,201,580</span> shares
held in abeyance. See Note 6 - Stockholders&#8217; Equity - Warrant Exercise and Issuance and Note 9 - Fair Value Measurement for additional
details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Represents the
gross proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zPkGpeUXA026" title="Gross proceeds">1,083,915</span>, less issuance costs of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_z11HcIisOgnd" title="Issuance costs">182,305</span>, resulting in net proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zlB0kglfAiyl" title="Net proceeds">901,610</span>. See Note 4 - Stockholders&#8217;
Equity - ATM Sales for additional details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Represents the
gross proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zKw9V4fZzg5l" title="Gross proceeds">927,335</span>, less issuance costs of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxsQLuhgdqDh" title="Issuance costs">39,197</span>, resulting in net proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxHhFmIh8c7k" title="Net proceeds">888,138</span>. See Note 4 - Stockholders&#8217; Equity
- ATM Sales for additional details.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockIssuedDuringPeriodSharesAbeyanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares abeyance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockIssuedDuringPeriodSharesAbeyanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common stock issued in connection with abeyance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockIssuedDuringPeriodValueAbeyanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value abeyance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockIssuedDuringPeriodValueAbeyanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock issued in connection with abeyance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return and cancellation of shares in lieu of payroll tax withholding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock return and cancellation of shares in lieu of payroll tax withholding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds</a></td>
<td class="nump">$ 888,138<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 901,610<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesHeldInAbeyance', window );">Shares held in abeyance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,351,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,201,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,951,634<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds</a></td>
<td class="nump">47<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Aggregate fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,351,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,351,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,150,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=BRTX_ATMSalesMember', window );">A T M Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">927,335<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,083,915<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">39,197<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">182,305<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds</a></td>
<td class="nump">$ 888,138<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 901,610<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the
gross proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zKw9V4fZzg5l" title="Gross proceeds">927,335</span>, less issuance costs of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxsQLuhgdqDh" title="Issuance costs">39,197</span>, resulting in net proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxHhFmIh8c7k" title="Net proceeds">888,138</span>. See Note 4 - Stockholders&#8217; Equity
- ATM Sales for additional details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the
gross proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zPkGpeUXA026" title="Gross proceeds">1,083,915</span>, less issuance costs of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_z11HcIisOgnd" title="Issuance costs">182,305</span>, resulting in net proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zlB0kglfAiyl" title="Net proceeds">901,610</span>. See Note 4 - Stockholders&#8217;
Equity - ATM Sales for additional details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Represents the
aggregate fair value of <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHaF4Odvuz81" title="Aggregate fair value of common stock">3,351,580</span> shares of common stock, which includes <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI9x89Qv0BMb" title="Shares issued">2,000,000</span> shares that were issued at the time of the warrant
exchange and <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_ecustom--SharesHeldInAbeyance_iI_pid_c20240331_z1PxY0VQzHHb" title="Shares held in abeyance">1,351,580</span> shares that were held in abeyance at the time of the warrant exchange. See Note 4 - Stockholders&#8217; Equity
- Warrant Exercise and Issuance and Note 5 - Fair Value Measurement for additional details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Represents the
aggregate fair value of <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpPD4xdmm3mj" title="Aggregate fair value of common stock">3,351,580</span> shares of common stock, which includes <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5nhgzoqroak" title="Warrants exercisable">2,150,000</span> shares that have been issued and <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zQNmiOi5AQNa" title="Shares held in abeyance">1,201,580</span> shares
held in abeyance. See Note 6 - Stockholders&#8217; Equity - Warrant Exercise and Issuance and Note 9 - Fair Value Measurement for additional
details.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesHeldInAbeyance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares held in abeyance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesHeldInAbeyance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=BRTX_ATMSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=BRTX_ATMSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,034,339)<span></span>
</td>
<td class="num">$ (7,343,233)<span></span>
</td>
<td class="num">$ (8,979,381)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (10,417,704)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">157,149<span></span>
</td>
<td class="nump">138,687<span></span>
</td>
<td class="nump">189,056<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">165,735<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Dividend and interest income</a></td>
<td class="num">(235,878)<span></span>
</td>
<td class="num">(492,476)<span></span>
</td>
<td class="num">(623,801)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(569,068)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,877,766<span></span>
</td>
<td class="nump">2,636,941<span></span>
</td>
<td class="nump">2,812,566<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,782,967<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">111,750<span></span>
</td>
<td class="nump">151,447<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">90,313<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainLossOnExchangeOfWarrants', window );">Gain on exchange of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,711,698)<span></span>
</td>
<td class="num">(1,711,698)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(552,536)<span></span>
</td>
<td class="nump">837,466<span></span>
</td>
<td class="num">(97,188)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,997,780)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="num">(145,700)<span></span>
</td>
<td class="num">(169,100)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,300)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">18,993<span></span>
</td>
<td class="nump">23,124<span></span>
</td>
<td class="nump">33,591<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">57,851<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">357,070<span></span>
</td>
<td class="nump">211,990<span></span>
</td>
<td class="nump">293,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,487<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(137,015)<span></span>
</td>
<td class="num">(29,449)<span></span>
</td>
<td class="nump">32,799<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">581,616<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(119,903)<span></span>
</td>
<td class="num">(162,317)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(139,328)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="num">(8,373,790)<span></span>
</td>
<td class="num">(5,882,501)<span></span>
</td>
<td class="num">(8,230,346)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,430,211)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">9,212,343<span></span>
</td>
<td class="nump">17,370,243<span></span>
</td>
<td class="nump">21,508,641<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,964,373<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(2,679,147)<span></span>
</td>
<td class="num">(18,294,566)<span></span>
</td>
<td class="num">(20,887,923)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,541,287)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(36,400)<span></span>
</td>
<td class="num">(93,755)<span></span>
</td>
<td class="num">(106,189)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(171,043)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided By Investing Activities</a></td>
<td class="nump">6,496,796<span></span>
</td>
<td class="num">(1,018,078)<span></span>
</td>
<td class="nump">514,529<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,252,043<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock in at-the-market offering</a></td>
<td class="nump">2,011,250<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">494,783<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs</a></td>
<td class="num">(72,805)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">42,411<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance of common stock in direct-offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,853,990<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1', window );">Proceeds from exchange and issuance of warrants, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,528,027<span></span>
</td>
<td class="nump">7,528,027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_PaymentsForProceedsFromDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="num">(49,308)<span></span>
</td>
<td class="num">(22,381)<span></span>
</td>
<td class="num">(148,697)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="nump">1,931,548<span></span>
</td>
<td class="nump">7,505,646<span></span>
</td>
<td class="nump">7,379,330<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,348,773<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Decrease In Cash and Cash Equivalents</a></td>
<td class="nump">54,554<span></span>
</td>
<td class="nump">605,067<span></span>
</td>
<td class="num">(336,487)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(829,395)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents - Beginning of the Year</a></td>
<td class="nump">547,890<span></span>
</td>
<td class="nump">884,377<span></span>
</td>
<td class="nump">884,377<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,713,772<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents - End of the Year</a></td>
<td class="nump">602,444<span></span>
</td>
<td class="nump">1,489,444<span></span>
</td>
<td class="nump">547,890<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">884,377<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding', window );">Return and cancellation of shares in lieu of payroll tax withholding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">48,410<span></span>
</td>
<td class="nump">48,410<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39,308<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_IssuanceOfCommonStockHeldInAbeyance', window );">Issuance of common stock held in abeyance</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ReclassificationOfDeferredOfferingCosts', window );">Reclassification of deferred offering costs</a></td>
<td class="nump">148,697<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredOfferingCostsIncludedInAccountsPayable', window );">Deferred offering costs included in accounts payable</a></td>
<td class="nump">$ 19,758<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes gross
proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20240101__20241231_zSqmWfzB3Fwf" title="Proceeds from debt issuance costs">8,123,391</span>, less issuance costs of $<span id="xdx_908_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231_zFrZALfkTkQg" title="Issuance costs">595,364</span>.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredOfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredOfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GainLossOnExchangeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GainLossOnExchangeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_IssuanceOfCommonStockHeldInAbeyance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock held in abeyance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_IssuanceOfCommonStockHeldInAbeyance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_PaymentsForProceedsFromDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for proceeds from deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_PaymentsForProceedsFromDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exchange and issuance of warrants net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ReclassificationOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ReclassificationOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return and cancellation of shares in lieu of payroll tax withholding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt issuance costs</a></td>
<td class="nump">$ 8,123,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 595,364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zsU4hcvrI9i8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
1 &#8211; <span id="xdx_822_zOFIWkF7PVi9">BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#8220;Stem Pearls&#8221;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#8220;BRT&#8221; or the &#8220;Company&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Business
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#8217;s
website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated
by reference into this Quarterly Report. BRT is currently developing a Disc/Spine Program referred to as &#8220;brtxDISC&#8221;. Its
lead cell therapy candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal
stem cells collected from the patient&#8217;s bone marrow. The product is intended to be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect
to a platform technology utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic
disorders and has labeled this initiative its ThermoStem Program. In addition, in continuation of BRT&#8217;s mission of developing and
commercializing cell-based biologics, it is seeking to develop a biologics-based cosmetic products business. Pursuant to such business,
BRT would formulate, manufacture and sell products designed for cosmetic and aesthetic uses. Further, BRT has licensed a patented curved
needle device that is a needle system designed to deliver cells and/or other therapeutic products or material to the spine and discs
or other potential sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form
10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for
complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring
items) that are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company
as of September 30, 2025 and for the three and nine months then ended. The results of operations for the three and nine months ended
September 30, 2025 are not necessarily indicative of the operating results for the full year ending December 31, 2025 or any other period.
The December 31, 2024 consolidated balance sheet data were derived from audited financial statements but do not include all disclosures
required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and related disclosures of the Company as of December 31, 2024 and for the year then ended, which were filed with
the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 28, 2025 (the &#8220;Form 10-K&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying unaudited condensed consolidated financial statements have been prepared on the basis that the Company will continue as
a going concern, which contemplates realization of assets and satisfying liabilities in the normal course of business. For the nine months
ended September 30, 2025, the Company had a net loss of $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250930_zOfSbFUsKVRj" title="Net loss">11.0</span> million, and negative cash flows from operations of $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250930_zLdueRSXo8hc" title="Cash flows from operations">8.4</span> million, and as
of September 30, 2025, the Company had working capital of $<span id="xdx_90D_ecustom--WorkingCapital_iI_pn5n6_c20250930_zFNA1zhTFMo" title="Working capital">1.3</span> million. The Company anticipates that it will continue to incur net losses
and negative cash flows from operations as it executes its development plans during 2025 and beyond, as well as other potential strategic
and business development initiatives. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going
concern for at least twelve months after the issuance date of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable
securities and additional infusions of cash from equity and debt financing. During the nine months ended September 30, 2025, the Company
sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdCaEuIrsY41" title="Number of shares sold">965,424</span> shares of its common stock under its at-the-market offering agreement (the &#8220;2024 ATM&#8221;) with Rodman &amp; Renshaw
LLC (&#8220;Rodman&#8221;) and raised approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPlQGqAjsPsd" title="Gross proceeds from sale of shares">2.0</span> million of gross proceeds. On October 8, 2025, the Company closed on the sale
of an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251008__20251008__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOOexdVmT2li" title="Number of shares sold">678,125</span> shares of its common stock for aggregate gross proceeds of approximately $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjAihl2MxHXb" title="Gross proceeds from sale of shares">1.1</span> million. Concurrently, the Company
issued to the investors warrants to purchase an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251008__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwRgmBQVTSx4" title="Warrants purchase">508,592</span> shares of its common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251008__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWG5Cpl1Q6c5" title="Exercise price">2.75</span> per share.
See Note 6 &#8211; Subsequent Events for additional details. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable
operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its
development, marketing and promotional activities, which would have a material adverse effect on the Company&#8217;s business, financial
condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate
continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of
business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not
necessarily purport to represent realizable or settlement values. The accompanying unaudited condensed consolidated financial statements
do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zad1yrVgoFC6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
1 - <span>ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_823_zt5CeRGTE1T3" style="display: none">BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#8220;Stem Pearls&#8221;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#8220;BRT&#8221; or the &#8220;Company&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Going Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which
contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2024,
the Company had a net loss of $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zpyfxt7l3Ml4" title="Net loss">9.0</span> million, negative cash flows from operations of $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zbxaUj3RB9Eg" title="Cash flows from operations">8.2</span> million and working capital of $<span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_c20241231_z46fDtgeQMRg" title="Working capital">7.4</span> million.
The Company anticipates that it will continue to incur net losses and negative cash flows from operations as it executes its development
plans for 2025 and beyond, as well as other potential strategic and business development initiatives. These conditions raise substantial
doubt about the Company&#8217;s ability to continue as a going concern for at least twelve months after the issuance date of these financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable
securities and additional infusions of cash from equity and debt financing. During the year ended December 31, 2024, the Company raised
net proceeds of approximately $<span id="xdx_903_ecustom--ProceedsFromWarrantExercisesNet_iI_pn5n6_c20240101__20241231_zN7GIeS7Bo81" title="Proceeds from warrant exercises, net">7.5</span> million in connection with a warrant exercise program which is further discussed in Note 6 &#8211;
Stockholders&#8217; Equity. On November 6, 2024, the Company entered into an at-the-market offering agreement (the &#8220;2024 ATM&#8221;)
pursuant to which the Company has an ability to issue and sell shares of its common stock up to an aggregate offering price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241106__20241106_zicrnDnE8Hjb" title="Offering price">3,614,170</span>.
Subsequent to December 31, 2024, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zD3UaD052txg" title="Sold shares of common stock">492,000</span> shares of its common stock under the 2024 ATM and raised approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z22hnIqNkwu3" title="Offering price">1,084,000</span>
of gross proceeds See Note 10 &#8211; Subsequent Events for additional details regarding sales of the Company&#8217;s common under the
2024 ATM subsequent to December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable
operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its
development, marketing and promotional activities, which would have a material adverse effect on the Company&#8217;s business, financial
condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;), which contemplate continuation of the Company as a going concern and the realization
of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented
in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying consolidated
financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#8217;s
website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated
by reference into this Annual Report. BRT is currently developing a Disc/Spine Program referred to as &#8220;brtxDISC&#8221;. Its lead
cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal stem cells collected
from the patient&#8217;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders
or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect to a platform technology
utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled
this initiative its ThermoStem Program. In addition, in continuation of BRT&#8217;s mission of developing and commercializing cell-based
biologics, it is seeking to develop a biologics-based cosmetic products business. Pursuant to such business, BRT would formulate, manufacture
and sell products designed for cosmetic and aesthetic uses. Further, BRT has licensed a patented curved needle device that is a needle
system designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zuAGmzPkV0Bb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
2 &#8211; <span id="xdx_82C_zl0oSPJPiYw">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zuoYoou5Mad5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reclassifications</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
prior period statements of operations amounts have been reclassified to conform to the Company&#8217;s fiscal 2025 presentation. These
reclassifications have no impact on the Company&#8217;s previously reported net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zWKRFvYaCgp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Cash
and Cash Equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#8220;FDIC&#8221;) coverage of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20250930_zJD8tEm9PdDb" title="FDIC insured limit">250,000</span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_c20250930_z4MdKwMJTX04" title="Cash in excess of FDIC limit">290,180</span> and
$<span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zox3igVmFcxj" title="Cash in excess of FDIC limit">252,801</span> as of September 30, 2025 and December 31, 2024, respectively. As of September 30, 2025, the Company has not experienced losses
on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zA8EOTyYL9Ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Investments
Held in Marketable Securities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2025 and December 31, 2024, investments held in marketable securities consists of U.S. Treasury securities held in a
trust account. The Company&#8217;s investments held in the trust account are presented on the unaudited condensed consolidated balance
sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities
are included in interest income in the accompanying unaudited condensed consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zOKc1nRk6qEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Customer
and Revenue Concentrations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s contract service revenue is derived from one customer. Additionally, all of the Company&#8217;s product sales
revenue is derived from one customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z0Iff1vBFCL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts
Receivable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of <span style="background-color: white">September
30, 2025 </span>and December 31, 2024, no allowances for credit losses were determined to be necessary. Management estimates the allowance
for credit losses based on existing economic conditions, the financial conditions of the customers, and the amount and age of past due
accounts. Receivables are considered past due if full payment is not received by the contractual due date. Past due accounts are generally
written off against the allowance for credit losses only after all collection attempts have been exhausted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--DeferredChargesPolicyTextBlock_zPTZ9bBDS0tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
Contract Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs relate
directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying performance obligations
in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as cost of revenues in the period
when the related revenue is recognized. Deferred contract costs consist of consumables and labor costs and are included in prepaid and
other current assets in the unaudited condensed consolidated balance sheets. The Company had $<span id="xdx_902_eus-gaap--DeferredCosts_iI_c20250930_ztAqpn7wZG9" title="Deferred contract costs">7,491</span> and $<span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zlvqQHgH5kek" title="Deferred contract costs">10,250</span> deferred contract costs
as of <span style="background-color: white">September 30, 2025 </span>and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_842_ecustom--DeferredOfferingCostsPolicyTextBlock_zUPPJ97vXR12" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
Offering Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs, which primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized
as non-current assets on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the
offering proceeds. If the completion of a contemplated financing was no longer probable, the related deferred offering costs would be
charged to general and administrative expense in the unaudited condensed consolidated financial statements. The Company had $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20250930_z4s2RZanSigj" title="Deferred offering costs">69,066</span> and
$<span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20241231_zxOLA0MPGa7g" title="Deferred offering costs">148,697</span> of deferred offering costs as of <span style="background-color: white">September 30, 2025 </span>and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zZv6KZulSXol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
Financial Instruments </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated
statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option
pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zkANa1kvlmrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of <span style="background-color: white">September 30, 2025 </span>and
December 31, 2024, the carrying amount of cash and cash equivalents, investments held in marketable securities, accounts receivable,
and accounts payable approximate their fair value due to the relatively short period of time between their origination and their expected
realization or payment. The warrant liabilities are measured at fair value (see Note 5 &#8211; Fair Value Measurement for additional
details).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zDWt9x0oUJT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, &#8220;Revenue from Contracts
with Customers&#8221; (&#8220;ASC 606&#8221;). The core principle of ASC 606 requires that an entity recognize revenue to depict the
transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled
in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible
more judgment and estimates may be required within the revenue recognition process, including identifying performance obligations in
the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price
to each separate performance obligation. The Company recognizes revenue primarily from the following different types of contracts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    sales</b> - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty
    revenue</b> - Revenue is recognized as a usage-based royalty from customers&#8217; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#8217;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    reason for the bill-and-hold arrangement is substantive </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    customer has requested the product be warehoused</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product has been identified as separately belonging to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product is currently ready for physical transfer to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company does not have the ability to use the product or direct it to another customer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zUp6hfR82OB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s revenue recognized in its unaudited condensed consolidated statements of operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_z0f5J2lLd7qj" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250701__20250930_zmrJbKyBvxUd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zDeGk3t9GU94" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250930_zqyeKJkPHFF6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20240930_z6BY4V2rHPqk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zayVoAdXqGSe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">230,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zSCqOCQLgYXg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,900</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,100</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">57,700</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zuuQYkToU9Ka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">233,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">340,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">357,700</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zjMjD1SO5q28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z0O1dsrwFqPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss Per Common Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. For the three and nine months ended <span style="background-color: white">September</span>
30, 2025, the Company had <span id="xdx_903_ecustom--SharesHeldInAbeyance_iI_pid_c20250930_z56gNeuQxRLa" title="Shares held in abeyance">1,138,055</span> shares held in abeyance included in basic loss per share given that they are issuable for no additional
consideration. For the three and nine months ended <span style="background-color: white">September</span> 30, 2024, the Company had <span id="xdx_90B_ecustom--SharesHeldInAbeyance_iI_pid_c20240930_zrGTXIJeWwD5" title="Shares held in abeyance">1,201,580</span>
shares held in abeyance included in basic loss per share given that they are issuable for no additional consideration (see Note 4 &#8211;
Stockholders&#8217; Equity for additional details). The dilutive effect, if any, of stock options and warrants are calculated using the
treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning of the period or at the
time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect
to losses, options, warrants, restricted stock units (&#8220;RSUs&#8221;) and convertible preferred stock have been excluded from the
Company&#8217;s computation of diluted net loss per common share for the three and nine months ended <span style="background-color: white">September
30, 2025 </span>and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zlziMoWXAXQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zOfUfoHaWSgi" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three and Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z0ddViGBv088" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zbwOLXMER4jb" title="Antidilutive shares">5,262,973</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zYLGQoxDHrqk" title="Antidilutive shares"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zGzgyZjSdSIg" title="Antidilutive shares">3,401,608</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOdb46xTIhE6" title="Antidilutive shares"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zMTo0rnFgyg8" title="Antidilutive shares">3,951,384</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z7e261Idjqe2" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2gQOA9BOJdi" title="Antidilutive shares">3,952,504</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zoAdP24LL9se" title="Antidilutive shares"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zxbicpBg5Pw7" title="Antidilutive shares">1,398,158</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBhtwPFuQYH2" title="Antidilutive shares"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjFYUbw8vdZ1" title="Antidilutive shares">1,398,158</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930_zw7VAXrfvgbh" title="Antidilutive shares"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zLSC5ZNyZcJk" title="Antidilutive shares">10,612,515</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930_zU0LwLcMz8y8" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zZuTFrCR4u39" title="Antidilutive shares">8,752,270</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zJWezSIb5gNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkl4bVbUTfu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segment
Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20250101__20250930_z6uvo58Te011" title="Number of operating segments"><span id="xdx_90F_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20250101__20250930_zVqE0Gyb38X7" title="Number of reporting segments">one</span></span> operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#8217;s Chief Executive Officer serves as
the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial performance.
The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated expense
data beyond what is included in the unaudited condensed consolidated statements of operations is not provided to the CODM. Since the
Company&#8217;s operations consist of a single reporting segment, the segment assets are presented on the accompanying unaudited condensed
consolidated balance sheets as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFqg54WqZt0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Issued Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09
should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of this
update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; (&#8220;ASU 2024-03&#8221;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--TaxLawChangePolicyTextBlock_zJjlyrjJprU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
Law Change</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 4th, 2025, the President signed into law significant federal tax legislation, H.R.1 (the &#8220;Tax Reform Act of 2025&#8221;).
The legislation includes numerous changes to U.S. corporate income tax law, including but not limited to: permanent 100% bonus
depreciation for qualified property, immediate expensing of domestic research and experimental expenditures, modifications to the
limitation on business interest expense, increased Section 179 expensing limits, changes to the international tax regime, and
expanded limitations on the deductibility of executive compensation under IRC Section 162(m). Most provisions are effective for tax
years beginning after December 31, 2024, with certain transition rules and exceptions. </span>The Company does not expect the
enactment of the Tax Reform Act of 2025 to have a material impact on its  consolidated financial statements. </p>

<p id="xdx_857_zj3PHAK8EAmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKzKY88P6szc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
2 - <span id="xdx_828_zMyXsBBEEUzi">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zntv9Aiyyqwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zdk4PxG1qrLi">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#8217;s consolidated financial statements. Such consolidated
financial statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity
and objectivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zxDKCiAlpgg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z0fNjlbqN8zj">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany
accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--UseOfEstimates_zEU1sFsNaugc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z4poG7D1ldXh">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkkM4rTKhXL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z3GH9BVMoxqk">Segment
Reporting</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has one operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#8217;s Chief Executive Officer, serves
as the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial
performance. The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated
expense data beyond what is included in the consolidated statements of operations is not provided to the CODM. Since the Company&#8217;s
operations consist of a single reporting segment, the segment assets are presented on the accompanying consolidated balance sheet as
total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zutuEXoDmQC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zLcOVvLUxfTa">Revenue
Recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).
The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC
606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required
within the revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable
consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company
recognizes revenue primarily from the following different types of contracts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    sales</b> - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty
    revenue</b> - Revenue is recognized as a usage-based royalty from customers&#8217; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#8217;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    reason for the bill-and-hold arrangement is substantive</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    customer has requested the product be warehoused</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product has been identified as separately belonging to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product is currently ready for physical transfer to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company does not have the ability to use the product or direct it to another customer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s revenue recognized in its consolidated statements of operations:</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z7tV6GJV8wQe" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">101,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">401,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zucK4GFra5g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z82RXuAQ9m83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zPY8JAe2pUG9">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#8220;FDIC&#8221;) coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zd4LGIJOhtt9" title="FDIC insured limit">250,000</span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zkZR8JFpwxA1" title="FDIC amount">252,801</span> and
$<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zuUVXiGB8vo1" title="FDIC amount">604,226</span> as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrHslI4Q5v9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zMa1AmFIfaIk">Customer
and Revenue Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s royalty revenue is derived from one customer. Additionally, all of the Company&#8217;s product sales revenue is
derived from one customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z96cN1ak7Q7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zjqSBcHeCS88">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of December 31, 2024 and 2023, no allowances
for credit losses were determined to be necessary. Management estimates the allowance for credit losses based on existing economic conditions,
the financial conditions of the customers, and the amount and age of past due accounts. Receivables are considered past due if full payment
is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only
after all collection attempts have been exhausted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--DeferredContractCostsPolicyTextBlock_zBfyPacgQe1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_z9v0S1hZqQUi">Deferred
Contract Costs</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs
relate directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying
performance obligations in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as
cost of revenues in the period when the related revenue is recognized. Deferred contract costs consist of consumables and labor
costs and are included within prepaid &amp; other current assets in the consolidated balance sheets. The Company had $<span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zZfVwr6cQXkb" title="Deferred contract costs">10,250</span>
and $<span id="xdx_905_eus-gaap--DeferredCosts_iI_c20231231_zdJ4p8ov21Hk" title="Deferred contract costs">0 </span>deferred contract
costs as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_844_ecustom--DeferredOfferingCostsPolicyTextBlock_zCSW2VIkUIsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_zv1g22C3EyB3">Deferred Offering Costs</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Deferred offering costs, which
primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized as non-current assets
on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the offering proceeds. If
the completion of a contemplated financing was no longer probable, the related deferred offering costs would be charged to general and
administrative expense in the consolidated financial statements. The Company had $<span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_c20241231_zRqgz5xgN36j" title="Deferred offering costs">148,697</span> and $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20231231_zQ0rJYVdgKF6" title="Deferred offering costs">0</span> deferred offering costs as of December
31, 2024 and 2023, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrNWYT5nz4ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zheceqDJFsi8">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_z7kFHq54efw8" style="display: none" title="Property plant and equipment estimated useful lives">3</span>three to <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_z9lXBJdFqlhj" title="Property plant and equipment estimated useful lives">fifteen years</span>. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfnq9MSy6d45" title="Property plant and equipment estimated useful lives">3</span> years. Medical equipment costs
are capitalized and depreciated over <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZ4jRpsDJgA6" title="Property plant and equipment estimated useful lives">5</span> years, while furniture and fixtures are depreciated over <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjMrGwd0Prad" title="Property plant and equipment estimated useful lives">4</span> years. Office equipment is depreciated
over a period of <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zFxufD0aVXDh" title="Property plant and equipment estimated useful lives">3</span> to <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcK9bTYPatcf" title="Property plant and equipment estimated useful lives">5</span> years, and manufacturing equipment over <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRGoTgdUsUR5" title="Property plant and equipment estimated useful lives">4</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNoLqgQf3lLh" title="Property plant and equipment estimated useful lives">5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zvYszRC8Li8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zEt2msSsRFC2">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records its intangible assets at cost in accordance with ASC 350, <i>Intangibles - Goodwill and Other</i>. Definite lived intangible
assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over
which the cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhNRS1Aqq6jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zFhYORrqYOJc">Impairment
of Long-Lived Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, the Company determined that
there was <span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20240101__20241231_zkUKhwWoBDvg" title="Impairment of long-lived assets"><span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20230101__20231231_zJwaUYA1d6li" title="Impairment of long-lived assets">no</span></span> impairment charge for its long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_ecustom--WarrantAndOptionValuationPolicyTextBlock_zI9N9CDazI73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zUd3lVu9E2Sd">Warrant
and Option Valuation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221;
method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry blended with the Company&#8217;s historical
volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining
term consistent with the expected term of the instrument being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQ9biVqlTD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_86F_z6RhMrU5RzF3">Derivative
Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option pricing model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGbcb7LJWe47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zhJEhRPQrt7k">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of December 31, 2024 and 2023, the carrying amount of cash and cash equivalents,
investments held in marketable securities, accounts receivable, and accounts payable approximate their fair value due to the relatively
short period of time between their origination and their expected realization or payment. The warrant liabilities are measured at fair
value (see Note 9 &#8211; Fair Value Measurement for additional details).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company recognized aggregate dividend and interest income of $<span id="xdx_90C_eus-gaap--InterestAndDividendIncomeOperating_c20240101__20241231_zg5oD0W09dNe" title="Dividend and interest income">623,801</span> and $<span id="xdx_909_eus-gaap--InterestAndDividendIncomeOperating_c20230101__20231231_zU0r2WazoLE7" title="Dividend and interest income">569,068</span> respectively,
on its marketable securities, which was included within other income on its consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zV62cxfcykAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zSfIv1elO46k">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The Company has <span id="xdx_90D_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zLHCITQpABQj" title="Shares held in abeyance">1,201,580</span> shares held in abeyance included
in basic loss per share given that they are issuable for no additional consideration (see Note 6 &#8211; Stockholders&#8217; Equity for
additional details). The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding
convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant
to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants,
restricted stock units (&#8220;RSUs&#8221;) and convertible preferred stock have been excluded from the Company&#8217;s computation of
diluted net loss per common share for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1GIc8cffMY8" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total">3,263,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total">1,466,892</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares">3,951,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares">4,791,019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1741">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">8,613,259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zh9UmzbEuc23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4rqRiibYMW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zXmhvArh15nb">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be
provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified
warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction
of amounts previously expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zyorW7NGWskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zwBN5Q5WlHH">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes ASC 740, &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#8220;more likely-than-not&#8221;
that a deferred tax asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zUyYKWUBRBq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zvsoDK4W79Yj">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets and operating lease liabilities in our consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value
of lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement
date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company&#8217;s lease terms
may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for
lease payments is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXTkrjpty3U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zpKTHgzD4l67">Recently
Adopted Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
&#8220;Improvements to Reportable Segments Disclosures (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;), which updates reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis.
The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after
December 15, 2024, with early adoption permitted. The adoption of this accounting standard on a retrospective basis did not have a material
impact on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_845_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zmtEdleuNQYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zNfZlr2uXiec">Recently
Issued Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; (&#8220;ASU 2024-03&#8221;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p id="xdx_850_zSD8QCfCQlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zeyEgGadysl5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
3 - <span id="xdx_82D_zKZw4PePgXI9">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zIgMfJkz32R9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_z1vUJk1Sfkua" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20250930_zjbaifrt9Od1" style="font-weight: bold; text-align: center">September 30 ,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zzBgOOifDuWf" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALAOLzJ5Y_zQfcVLxZ3IUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">538,875</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">704,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_z5TEQmTk5Bmb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">68,595</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,485</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtALAOLzJ5Y_zKbjZiqer5me" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">607,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">744,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zQLHNtTM2Af1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zcCzM4pARQo3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
5 - <span id="xdx_820_zMsUx2ILh5Tl">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7ve0gvNg4Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z3T5qunqNukl" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zEWk23Yc0nC" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zeM88DjmnpU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALAOLzJ5Y_zfKjliCICsKd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accrued bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">704,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">638,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zWjZXZQ1wT92" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,485</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73,686</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtALAOLzJ5Y_zh0kRlaqDaTb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">744,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">711,686</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_ziyjOByjOsNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zHG5tvmySONa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
4 - <span id="xdx_821_zhU25ADtybPh">STOCKHOLDERS&#8217; EQUITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Exercise and Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2024, the Company entered into agreements with certain holders of its existing warrants exercisable for an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx5gSnUYYHZ" title="Warrants exercisable">3,351,580</span>
shares of its Common Stock (collectively, the &#8220;Existing Warrants&#8221;), to exercise their warrants at a reduced exercise price
of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAtgLyiYvwt2" title="Exercise price">2.33</span> per share, in exchange for the issuance of new warrants (the &#8220;New Warrants&#8221;) as described below (the &#8220;Warrant
Exercise and Issuance&#8221;). The aggregate gross proceeds from the exercise of the Existing Warrants and the payment of the New Warrants,
as described below, was approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGq6BKn2nqkc" title="Proceeds from exercise of warrants">8.1</span> million, before deducting cash issuance costs in the amount of $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZCTpSpST2xl" title="Cash issuance costs">595,364</span>. The reduction of
the exercise price of the Existing Warrants and the issuance of the New Warrants was structured as an at-market transaction under Nasdaq
rules. Of the <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZGqM0uZWQdb" title="Warrants exercisable">3,351,580</span> shares of Common Stock underlying the Existing Warrants, <span id="xdx_904_ecustom--SharesHeldInAbeyance_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zDzEd4E6Vyw8" title="Shares held in abeyance">1,201,580</span> shares issuable to Auctus Fund, LLC (&#8220;Auctus&#8221;)
were held in abeyance as of December 31, 2024, due to Auctus&#8217; maximum beneficial ownership limitation <span style="background-color: white">(the
&#8220;Abeyance Shares&#8221;)</span>. On March 20, 2025, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20250320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zjDxgAVSTwd7" title="Warrants exercisable">63,525</span> of these shares, reducing the remaining Abeyance
Shares to <span id="xdx_90A_ecustom--SharesHeldInAbeyance_iI_pid_c20250320_zdbB6qiEiMn4" title="Shares held in abeyance">1,138,055</span>. As of <span style="background-color: white">September</span> 30, 2025, the Company had issued an aggregate of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Pv2ppO2EI7" title="Shares issued">2,213,525</span>
shares of Common Stock. Such Abeyance Shares have been fully paid for and are issuable upon notice from Auctus to the Company. See Note
6 &#8211; Subsequent Events &#8211; for additional details regarding shares issued to Auctus subsequent to September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 6pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of the Existing Warrants for cash and the payment of $<span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWpB6FU3W7G7" title="Warrants for cash and the payment">0.125</span> per share underlying the New Warrants,
the exercising holders received the New Warrants to purchase shares of Common Stock in a private placement pursuant to Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The New Warrants will be exercisable for a period of five
years into an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zhVPmr7uhBbe" title="Warrants exercisable">2,513,686</span> shares of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zXqt8vRCbOyj" title="Exercise price">2.43</span> per share. The securities offered in the private
placement have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company agreed to file
a resale registration statement with the SEC to register the resale of the shares of Common Stock underlying the New Warrants issued
in the private placement. Such resale registration statement was filed and was declared effective by the SEC on April 18, 2024. In connection
with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5, 2024, with
Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which the Company has paid Roth a cash fee of approximately $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240205__20240205__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zFmR4GeV6Rh6" title="Cash fee for services">528,000</span> for
its services, in addition to reimbursement for certain expense. During the nine months ended <span style="background-color: white">September</span>
30, 2024, the Company incurred an aggregate of $<span id="xdx_90A_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zCgxSb4KVd5h" title="Issuance costs">595,364</span> of cash issuance costs related to the Warrant Exercise and Issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Prior
to the Warrant Exercise and Issuance, the Existing Warrants were classified as derivative liabilities. Additionally, the Company analyzed
the form of the New Warrants and determined that they should be classified as derivative liabilities</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
accordance with ASC 815-40, Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity. Under the New Warrants, the Company
does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the New Warrants and
not result in a change of control of the Company. As a result, such New Warrants do not meet the criteria for equity treatment. Additionally,
certain New Warrants contain adjustments to the settlement amount based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221;
option as defined under ASC 815-40 and, accordingly, such New Warrants are not considered indexed to the Company&#8217;s own stock and
are not eligible for an exception from derivative accounting. <span style="background-color: white">See Note 5 &#8211; Fair Value Measurement
for details regarding the valuation of warrants accounted for as derivative liabilities.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">See
Note 5 &#8211; Fair Value of Financial Instruments for details regarding the valuation of warrants accounted for as derivative liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zo19fZvsrdp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s warrant activity and related information follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zZ3PlS8QnNqe" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zULU5j9OkiMg" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning balance">3,951,634</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDQmWH9JHqqe" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">5.22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znMqdO0blV22" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired">(250</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJvBG1DUXmO2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">60.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy0i7C8bnsd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending balance">3,951,384</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKtxZKhWUYia" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">5.21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJq4qX3eMsTb" title="Weighted Average Remaining Life In Years, Outstanding">2.55</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRx5Q2Zfx1zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable">3,951,384</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIJFLzpYIhEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">5.21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7joyKclZvt3" title="Weighted Average Remaining Life In Years, Exercisable">2.55</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_za5lKfk8sxSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2025, the Company granted options to purchase an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zGPLhmcTQmWj" title="Options granted">2,152,908</span> shares of the Company&#8217;s common stock at an
exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlj9v5UYoXb2" title="Exercise price of options granted">2.46</span> per share to employees, the Company&#8217;s board of directors and a member of the Company&#8217;s Scientific
Advisory Board. The options had an aggregate grant date fair value of $<span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWQIcTolxNzg" title="Grant date fair value of options granted">4,044,250</span> and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zBVsBX5FSfXa" title="Vesting of options description">vest as follows: (i) options to purchase an aggregate
323,459 shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of 1,829,449 shares of common stock
vest to the extent of 50% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant.</span>
The Company is recognizing the grant date fair value of the options on a straight-line basis over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 5, 2025, the Company granted an option to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0ZuBXJ7t5ne" title="Options granted">25,000</span> shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zimgpjmGrocl" title="Exercise price of options granted">1.78</span>
per share to an employee. The option had a grant date fair value of $<span id="xdx_90E_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNV5n0akZLDa" title="Grant date fair value of options granted">34,250</span> and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQzCyRduK3gk" title="Vesting of options description">vests to the extent of 50% immediately with the remainder
vesting quarterly over two years commencing one year from the date of grant.</span> The Company is recognizing the grant date fair value of
the option on a straight-line basis over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2025, the Company granted an option to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpoibAmWqss3" title="Options granted">25,000</span> shares of the Company&#8217;s common stock at an exercise price of
$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuL7CY8ZzLY8" title="Exercise price of options granted">1.62</span> per share to an employee. See Note 6 &#8211; Subsequent Events for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znYuBL1ziLZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_z1wWVGt9vlj2" style="display: none">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z37XMit7f4ka" title="Risk free interest rate">4.03</span> - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxfdSV77vPHc" title="Risk free interest rate">4.40</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zz2zKecFH9Ic" title="Risk free interest rate">4.14</span> - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zy4srh72s6Ag" title="Risk free interest rate">4.30</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zw2WookFhCm4" title="Expected term (years)">2.77</span> - <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziuM2v5u7cOj" title="Expected term (years)">5.38</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjyJG6PA6aS9" title="Expected term (years)">2.77</span> - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zQR6mDHTPdJi" title="Expected term (years)">5.38</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zoRgnEW4J5qk" title="Expected volatility">98.14</span> - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zgMcQ5QsoGw9" title="Expected volatility">99.22</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_ze1M3w366Qp5" title="Expected volatility">101</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziXN0JVmgKc5" title="Expected volatility">102</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Expected dividends</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHhTEVNeZJ58" style="width: 18%; text-align: center">0.00%</td><td style="width: 1%; text-align: left"></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaogLqcGvEN" style="width: 18%; text-align: center" title="Expected dividends">0.00%</td><td style="width: 1%; text-align: left"></td></tr>
  </table>

<p id="xdx_8AD_z4yJkz1L6Zk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_do_c20250701__20250930_zaJ7QgaILCP3" title="Weighted average grant date fair value of stock options granted"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_do_c20240701__20240930_zLmTZh77Jbza" title="Weighted average grant date fair value of stock options granted">no</span></span> stock options granted during the three months ended September 30, 2025 or 2024. Options granted during the nine months ended
<span style="background-color: white">September</span> 30, 2025 and 2024 had a weighted average grant date fair value per share of <span style="background-color: white">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250930_zxPzPvInIHY" title="Weighted average grant date fair value of stock options granted">1.87</span>
</span>and $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zWohCJHGjAC5" title="Weighted average grant date fair value of stock options granted">1.11</span> per share, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWv2M3qYRMph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity during the nine months ended <span style="background-color: white">September 30, 2025 </span>is
presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zlBKQWNVMBRg" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding, January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhd1fbMc1OAf" style="width: 12%; text-align: right" title="Number of Options, Outstanding Beginning">3,263,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyqcbmh3G9A4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning">2.63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYJikieUBiU1" style="text-align: right" title="Number of Options, Granted">2,177,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Utpi7z1E8a" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #0D0D0D">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcjxWNpZEXC2" style="text-align: right" title="Number of Options, Exercised">(29,249</td><td style="text-align: left">)</td><td style="color: #0D0D0D">&#160;</td>
    <td style="color: #0D0D0D; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4LZRf2tNRW8" style="color: #0D0D0D; text-align: right" title="Weighted Average Exercise Price, Exercised">1.45</td><td style="color: #0D0D0D; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbFGtbkRLn" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(149,153</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY5MaYv8AMn1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">2.23</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMyvapoNh9d" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding Ending">5,262,973</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNC1OSsrXyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending">2.58</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlT9rvVz6pDg" title="Weighted Average Remaining Life in Years, Outstanding">7.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4ggKcamAFA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxCRQYm4YeMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable">3,805,964</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1EzeOBaB595" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable">2.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCLZZ4ZLn9q8" title="Weighted Average Remaining Life in Years, Exercisable">7.3</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zy6EeZ7DMJXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zcOQfjQkTMcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zSDcZLOPTYXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B2_zKoGZ1kN5cRa" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250701__20250930_zdcPCx4xRGV3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240701__20240930_zLNJc59cbcLh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250930_zsq10U8gkd72" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20240930_zLqIBApcfsX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrecognized at</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average Remaining Amortization</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"> Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJ3sW3wPgOJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">175,398</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">133,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,308,322</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,314,298</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYpkGCwTTDmi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">224,535</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">150,912</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,569,444</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,322,643</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_ztRikAHkmre9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">399,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,877,766</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,636,941</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20250930_zQSnElFKLth" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense">1,878,612</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930_zyXAPbw3kbTa" title="Weighted average remaining amortization period (years)">1.76</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zgACj4pdDPxa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">399,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,877,766</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,636,941</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20250930_z5a460ZK7FN7" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense">1,878,612</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930_zjo2gjtyVdXi" title="Weighted average remaining amortization period (years)">1.76</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A2_zFjpcsrR5B6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_ecustom--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock_zsBI1ipxGnoh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents stock-based compensation by award type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span id="xdx_8B9_zvDA3KujAUgd" style="display: none">SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250701__20250930_z6ZTqHehz6Vi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240701__20240930_zn2OOoEhzk98" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20250930_zFXjSdEXksPb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_zTjmJ2NseNQ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV3WJPGewlZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">399,932</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">284,245</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,877,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,651,903</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zd3IddrYGPx2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">RSUs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">985,038</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_z91a9z3GNKxg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">399,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,877,766</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,636,941</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zp3s2uAPl9o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ATM
Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025, there were <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_do_c20250701__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL1oEMYxf3bk" title="Number of shares sold">no</span> sales of common stock under the 2024 ATM. During the nine months ended September
30, 2025, the Company sold <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztj50j89INd7" title="Number of shares sold">965,424</span> shares of its common stock under the 2024 ATM, generating gross proceeds of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0o9TgpNyNj4" title="Gross proceeds from shares sold">2,011,250</span>. For the nine
months ended September 30, 2025, the total commissions and related legal and accounting fees incurred were $<span id="xdx_904_ecustom--PaymentsForCommissionsLegalAndAccountingFees_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcd44cifUHC4" title="Commissions, legal and accounting fees">72,805</span>, resulting in net
proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMoj4wiTQdof" title="Net proceeds from shares sold">1,938,445</span>. During the nine months ended September 30, 2025, the Company reclassified previously capitalized deferred offering
costs of $<span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20250101__20250930_zHf4xVAtpgtl" title="Deferred offering costs reclassified to additional paid-in capital">148,697</span> to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Repurchase Program</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2025, the Company&#8217;s Board of Directors authorized a common stock repurchase program under which the Company may repurchase
up to $<span id="xdx_90F_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20250616__20250616__srt--TitleOfIndividualAxis__custom--BoardOfDirectorMember__srt--RangeAxis__srt--MinimumMember_zcltBrP2zzyl" title="Repurchase of common stock">2,000,000</span> of its outstanding common stock through June 16, 2026. <span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfCommonStock_do_c20250930__20250930_zVnjpa6GnRNa" title="Repurchase of common stock">No</span> repurchases have been made as of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Issuances</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025, there were <span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesAbeyanceShares_do_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKFJ7f2cOdH9" title="Abeyance shares issued">no</span> issuances of common stock by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2025, the Company issued <span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesAbeyanceShares_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8WVx7DEr5j2" title="Abeyance shares issued">63,525</span> shares of common stock to Auctus Fund, LLC in partial satisfaction
of shares held in abeyance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2025, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztYvkBJs1qg4" title="Shares issued upon exercise of options">29,249</span> shares of common stock related to the exercise of an option at an
exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU4nhYmNIsRh" title="Exercise price of options exercised">1.45</span> per share, which resulted in gross cash proceeds to the Company of $<span id="xdx_903_eus-gaap--ProceedsFromStockOptionsExercised_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHs8DohRpmCl" title="Gross proceeds from exercise of options">42,411</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJPEBtlN7YIk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6 - <span id="xdx_82B_zUgzUG841pcg">STOCKHOLDERS&#8217; EQUITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2021, in connection with the Company&#8217;s public offering, the Company&#8217;s Board of Directors adopted a resolution
allowing for the designation and issuance of <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAv4O5ACYYm2" title="Preferred stock, shares issued">1,543,158</span> shares of the Company&#8217;s Preferred Stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQNlJEUEDcQa" title="Preferred stock, par value">.01</span> par value per share, designated
as Series A Preferred Stock (&#8220;Series A&#8221;). The Series A had a liquidation preference of $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3hczMMtKpU8" title="Preferred stock, liquidation preference">0.001</span> per share. On September 8,
2022, the Company issued <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zo0GcvUNCdN2" title="Preferred stock, shares issued">1,543,158</span> shares of Series B Preferred Stock (&#8220;Series B&#8221;) to Auctus Fund, LLC (&#8220;Auctus&#8221;)
in exchange for an equal number of shares of the Company&#8217;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#8217;s Board
of Directors cancelled the Series A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
B Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 8, 2022, the Company issued <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYC3O1qRrCy6" title="Preferred stock, shares issued">1,543,158</span> shares of Series B to Auctus in exchange for an equal number of shares of the Company&#8217;s
outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is <span id="xdx_90D_eus-gaap--PreferredStockVotingRights_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKAmHWfyKJBh" title="Preferred stock voting rights">9.99</span>% of the then outstanding Common Stock of the Company instead of <span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuT87XMZHkJ6" title="Preferred stock voting rights">4.99</span>% as
provided for the Series A. The Company is required, at all times, to reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to
redemption by the Company or any Series B holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Voting
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7GqZ3KTuVV4" title="Preferred stock voting percentage">9.99</span>% of the then outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional
Conversion - <span id="xdx_902_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zL2VXQ8WU4De" title="Preferred stock conversion term">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock;</span> provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znCDeplQWuW5" title="Preferred stock voting percentage">9.99</span>% of the outstanding
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automatic
Conversion - From time to time, in the event that an event occurs which has the effect of reducing a Series B holder&#8217;s beneficial
ownership of shares of Common Stock to less than <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zphxO48CaFTi" title="Ownership percentage">9.5</span>% of the then publicly disclosed outstanding shares of Common Stock, then, within
five business days, the Series B holder is required to provide notice to the Company to such effect, which notice shall state the number
of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard thereto, including
the number of derivative securities compromising a portion of such beneficial share amount. Such notice shall have the effect of a notice
of conversion with respect to the conversion of such number of shares of Series B as would increase the Series B holder&#8217;s beneficial
ownership of Common Stock to <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zf50yJldC0Qg" title="Preferred stock voting percentage">9.99</span>% of the then publicly disclosed outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 25, 2022, Auctus converted <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_z5AXhJwz8bFi" title="Debt conversion, converted instrument, shares issued">25,000</span> shares of Series B into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zlLsZqLS1tRe" title="Debt conversion, converted instrument, shares issued">25,000</span> shares of Common Stock. The number of shares of Series B remaining
outstanding after this conversion was <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLoD9gwPh8vg" title="Conversion of stock shares">1,518,158</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2023, Auctus converted <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zFD1ODMs5Buk" title="Number of shares converted">120,000</span> shares of Series B into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUB0LKFisLvh" title="Number of shares issued in conversion">120,000</span> shares of Common Stock. As of December 31, 2024, the number of
shares of Series B remaining outstanding after giving effect to such conversion was <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zveV0mvbGEcl" title="Preferred stock, shares outstanding">1,398,158</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Stock Incentive Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company&#8217;s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &#8220;2021
Plan&#8221;). The 2021 Plan was approved by the Company&#8217;s stockholders on August 17, 2021. Pursuant to the 2021 Plan, a total of
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210318__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember_zQB2Po9BLkKg" title="Number of shares of common stock authorized">1,175,000</span> shares of common stock were initially authorized to be issued pursuant to the grant of stock options, restricted stock units,
restricted stock, stock appreciation rights and other incentive awards. On December 10, 2021, the Company&#8217;s Board of Directors
approved an amendment to increase the number of shares of Common Stock authorized to be issued from <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zVPMbYgrWnQ2" title="Common stock shares authorized">1,175,000</span> to <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zncC5eiUPWt1" title="Common stock shares authorized">2,500,000</span>. Such amendment
was approved by the Company&#8217;s stockholders on November 3, 2022. On July 13, 2023, the Company&#8217;s Board of Directors approved
an amendment to the 2021 Plan to increase the number of shares of Common Stock authorized to be issued from <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zo1X1po4yASk" title="Common stock shares authorized">2,500,000</span> to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zVCTDa6pQi4" title="Common stock shares authorized">3,850,000</span>. Such
amendment was approved by the Company&#8217;s stockholders on September 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 23, 2024, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s 2021 Plan to increase the number of
shares of common stock authorized to be issued under the 2021 Plan from <span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240722__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zVT1EXT7QkA9" title="Common stock authorized to issue">3,850,000</span> to <span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240723__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_z0fNr8c0ddHb" title="Common stock authorized to issue">6,850,000</span>. Such amendment was approved by the Company&#8217;s
stockholders on September 19, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensatory
Common Stock Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231_ztpy3rsk930e" title="Vested common stock, shares">1,442</span> shares of immediately vested common stock with a value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231_zKuKeGD0i2fd" title="Aggregate common stock services rendered">7,500</span> to a consultant
for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;)
under which the Company had the ability to issue and sell shares of its Common Stock, from time to time, through JonesTrading, up to
an aggregate offering price of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--DemandSalesAgreementMember_z2vE6NAiKWPj">6,109,000</span> in what is commonly referred to as an &#8220;at-the-market&#8221; (&#8220;ATM&#8221;)
program. During the year ended December 31, 2023, the Company sold <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zXplo7pD9iOk" title="Sold shares of common stock">132,827</span> shares of its Common Stock at a weighted average price of
$<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zpEUTC3wNX2l" title="Weighted average price">4.68</span> per share and raised $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zunGcHy30dsd">494,782</span> in net proceeds under the JonesTrading ATM program. In November 2024, in connection with the ATM
program with Rodman &amp; Renshaw LLC (&#8220;Rodman&#8221;) discussed below, the Company terminated the Capital on Demand Sales Agreement
with JonesTrading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2023, the Company sold an aggregate of 	<span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713_zGeXKDbsQOZf" title="Sale of aggregate shares">685,033</span> shares of Common Stock to several institutional buyers and accredited investors
in a registered direct offering at an offering price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230713_zcVAT4OtM4yi" title="Offering price">3.03</span> per share. The offering closed on July 13, 2023 with net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230712__20230713_zP7zaht68Fhf" title="Net proceeds offering price">1,853,990</span>.
The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy
candidate, BRTX-100, pre-clinical research and development with respect to its metabolic ThermoStem Program and for general corporate
purposes and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the Company entered into an At The Market Offering Agreement with Rodman, under which the Company currently has the ability
to issue and sell shares of its Common Stock, from time to time, through Rodman, up to an aggregate offering price of approximately $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zH6H9vwuMDQa" title="Sold value of common stock">3,614,000</span>
in an ATM program. See Note 10 - Subsequent Events &#8211; Common Stock Sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Exercise and Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2024, the Company entered into agreements with certain holders of its existing warrants exercisable for an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJLLRuKcXiXh" title="Warrants exercisable">3,351,580</span>
shares of its Common Stock (collectively, the &#8220;Existing Warrants&#8221;), to exercise their warrants at a reduced exercise price
of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWIprX6rqLng" title="Exercise price">2.33</span> per share, in exchange for the issuance of new warrants (the &#8220;New Warrants&#8221;) as described below (the &#8220;Warrant
Exercise and Issuance&#8221;). The aggregate gross proceeds from the exercise of the Existing Warrants and the payment of the New Warrants,
as described below, was approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLxbdAHUuGN7" title="Proceeds from exercise of warrants">8.1</span> million, before deducting cash issuance costs in the amount of $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAFNeSFqflDl" title="Cash issuance costs">595,364</span>. The reduction of
the exercise price of the Existing Warrants and the issuance of the New Warrants was structured as an at-market transaction under Nasdaq
rules. Of the <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzsKaWfvjyT2" title="Warrants exercisable">3,351,580</span> shares of Common Stock issuable upon the exercise of the Existing Warrants, through December 31, 2024, the Company
had issued an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z68Q6vqjUh11" title="Warrants exercisable">2,150,000</span> shares of Common Stock. The remaining <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zvVWO1PSwBY4" title="Warrants exercisable">1,201,580</span> shares of Common Stock, which are issuable to Auctus
Fund, LLC (&#8220;Auctus&#8221;), are being held in abeyance due to Auctus&#8217; maximum beneficial ownership limitation (the &#8220;Abeyance
Shares&#8221;). Such Abeyance Shares have been fully paid for and are issuable upon notice from Auctus to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of the Existing Warrants for cash and the payment of $<span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zBxG29Eh8Uv" title="Warrants for cash and the payment">0.125</span> per share underlying the New Warrants,
the exercising holders received the New Warrants to purchase shares of Common Stock in a private placement pursuant to Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The New Warrants will be exercisable for a period of five
years into an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNlyN1DFbIFj" title="Warrants exercisable">2,513,686</span> shares of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRsdklXiIqW9" title="Exercise price">2.43</span> per share. The securities offered in the private
placement have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company agreed to file
a resale registration statement with the SEC to register the resale of the shares of Common Stock underlying the New Warrants issued
in the private placement. Such resale registration statement was filed and was declared effective by the SEC on April 18, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5,
2024, with Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which the Company has paid Roth a cash fee of approximately $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240205__20240205__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zzl7n2lB0Vtl" title="Cash fee for services">528,000</span>
for its services, in addition to reimbursement for certain expense. During the year ended December 31, 2024, the Company incurred an
aggregate of $<span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zT0D139u7t1a" title="Issuance costs">595,364</span> of cash issuance costs related to the Warrant Exercise and Issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Warrant Exercise and Issuance, the Existing Warrants were classified as derivative liabilities. Additionally, the Company analyzed
the form of the New Warrants and determined that they should be classified as derivative liabilities in accordance with ASC 815-40, Derivatives
and Hedging &#8212; Contracts in Entity&#8217;s Own Equity. Under the New Warrants, the Company does not control the occurrence of events,
such as a tender offer or exchange, that may trigger cash settlement of the New Warrants and not result in a change of control of the
Company. As a result, such New Warrants do not meet the criteria for equity treatment. Additionally, certain New Warrants contain adjustments
to the settlement amount based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined
under ASC 815-40 and, accordingly, such New Warrants are not considered indexed to the Company&#8217;s own stock and are not eligible
for an exception from derivative accounting. See Note 9&#8211; Fair Value Measurement for details regarding the valuation of the Existing
Warrants and New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the Warrant Exercise and Issuance to be an exchange by investors of Existing Warrants with an aggregate fair value
of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zwsYJKgpvCMb" title="Fair value of adjustment">1,115,334</span> along with aggregate cash consideration of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zfFm1YZsZXZc" title="Proceeds from issuance of warrants">8,123,392</span> (consisting of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zCSVqe8YkOf2" title="Proceeds from issuance of warrants">7,809,181</span> paid to exercise the Existing Warrants
and $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zbHEcEn03OHl" title="Proceeds from issuance of warrants">314,211</span> paid for the New Warrants) for an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zF7lId3Nr2Q7" title="Stock issued during period shares new issues">3,351,580</span> shares of common stock with an aggregate fair value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zefA77ZQfLn9" title="Stock issued during period value new issues">4,742,244</span>,
New Warrants with an aggregate fair value of $<span id="xdx_909_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zk6OWlB7V2rb" title="Stock issued during period value warrants">2,189,420</span> and aggregate cash issuance costs of $<span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zWjJHU1kOYy9" title="Issuance costs">595,364</span> and, accordingly, the Company recorded
a gain on exchange of warrants of $<span id="xdx_907_ecustom--GainLossOnExchangeOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zoVcOH6TDVVd" title="Gain on exchange of warrants">1,711,698</span> during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Activity Summary</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zSZin8yUZKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the warrant activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zGJJPKtZyAE5" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znAqvvT4Qbx9" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding Beginning">4,791,019</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z87TDq6moIv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price,  Outstanding beginning balance">10.57</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdjrTKuhx9z6" style="text-align: right" title="Number of Warrants, Granted">2,513,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjdzOfyxLbwc" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzgG1cCZ4vr1" style="text-align: right" title="Number of Warrants, Exercised">(3,351,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zki4H944FIMe" style="text-align: right" title="Weighted Average Exercise Price, Exercised">2.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOsoduSVUaRk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired">(1,491</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrBkx7PzwuQk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">1,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfvfXo0Eesnl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding Ending">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsOAZv5WGZd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding ending balance">5.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZ3LPAMieATi" title="Weighted Average Remaining Life In Years, Outstanding">3.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSXFmGrNy028" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable Ending">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlHDUWyygGWc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">5.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4jobdqNbrP3" title="Weighted Average Remaining Life In Years, Exercisable">3.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zXSUQ9QnVqc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average estimated fair value of the warrants granted during the year ended December 31, 2024 was $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDO6RUoak3l1" title="Weighted average estimated fair value of warrants granted">0.87 </span>per warrant. See Note
9 &#8211; Fair Value Measurement &#8211; for details regarding the fair value estimates of the Warrants that are classified as derivative
liabilities. The Company did not issue any warrants during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zpOFtra6fg6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock warrants at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zJhgTLHPR6Ie" style="display: none">SCHEDULE
OF STOCK WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBIP5ZD4QC56" style="width: 22%; text-align: right" title="Warrants outstanding, exercise price">2.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl2Jku2lXkle" style="width: 22%; text-align: right" title="Warrants outstanding, number of warrants">2,513,686</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zU6Nhvq6d4e2" title="Warrants exercisable, weighted average remaining life in years">4.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zC60jbXs1afd" style="width: 21%; text-align: right" title="Warrants exercisable, exercisable number of warrants">2,513,686</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z17wx76SisWa" style="text-align: right" title="Warrants outstanding, exercise price">2.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUseg3QpPL84" style="text-align: right" title="Warrants outstanding, number of warrants">51,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyTCTVYqM8Mh" title="Warrants exercisable, weighted average remaining life in years">2.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zwoRloxfJKD9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">51,370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuBvZFdF9pE2" style="text-align: right" title="Warrants outstanding, exercise price">10.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWunI15vUYcb" style="text-align: right" title="Warrants outstanding, number of warrants">1,150,358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOE3aHbPJii4" title="Warrants exercisable, weighted average remaining life in years">1.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCyYxBCsyVJe" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">1,150,358</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zroKiGu0kyKh" style="text-align: right" title="Warrants outstanding, exercise price">12.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvBqal267Qf4" style="text-align: right" title="Warrants outstanding, number of warrants">235,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zsRzI4SStm05" title="Warrants exercisable, weighted average remaining life in years">1.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zjlWnxsI3Tue" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">235,970</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcUo7cIEyFd6" style="padding-bottom: 1pt; text-align: right" title="Warrants outstanding, exercise price">60.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4H9FGqoOWtj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, number of warrants">250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlijR7PFbo2l" title="Warrants exercisable, weighted average remaining life in years">0.0</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJksqF3ibGo6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants">250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zMTGD0WHNxH" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, number of warrants">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zfJ2T3TGfPA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, exercisable number of warrants">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_za7feX7DXOtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfNfCP9eNvD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the option activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zrN9b2GV9bbk" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTvM4oSXln82" style="width: 12%; text-align: right" title="Number of Options, Outstanding beginning">1,466,892</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zoDROm8SpfK" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning">4.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z1Abs0lPnAC2" style="text-align: right" title="Number of Options, Granted">1,934,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zf56QyHtDan2" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zBqFaBP2hRrg" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2097">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zQdf2naQfNwc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(138,141</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zPDXmZhZIG01" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.76</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zcyRTNE1DYVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding ending">3,263,467</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z6AUvmyFe4hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending">2.63</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zTVIyvLVQU9e" title="Weighted Average Remaining Life in Years Outstanding Ending">7.5</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_z0jhmSrRb99" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl2109">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z6OaUmtzPBzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable Ending">2,499,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zLxmZKqE199h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending">2.95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zv88ELOpOHR9" title="Weighted Average Remaining Life in Years Exercisable Ending">7.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231_z0nAmGqFN17c" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl2117">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zoAlkje3gnuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of the stock options granted during the years ended December 31, 2024 and 2023 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zHbmqifX8bie" title="Weighted average grant date fair value of stock options granted">1.45</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zRFePEuvUmbe" title="Weighted average grant date fair value of stock options granted">3.00</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRtaMfXkznRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock options at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_ztcIUlTEysz5" style="display: none">SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeGpMtvcx146" style="width: 22%; text-align: right" title="Options Outstanding, Exercise Price">1.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFR9VoHQVghd" style="width: 22%; text-align: right" title="Options Outstanding, Outstanding Number of Options">1,825,067</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBesCUmhfgB8" title="Options Exercisable Weighted Average Remaining Life In Years">8.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOElztZCIEXk" style="width: 21%; text-align: right" title="Options Exercisable, Exercisable Number of Options">1,138,579</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zlN1nxbD5Qm7" style="text-align: right" title="Options Outstanding, Exercise Price">2.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z5su5TfUL9I1" style="text-align: right" title="Options Outstanding, Outstanding Number of Options">626,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmxifRgIyVvh" title="Options Exercisable Weighted Average Remaining Life In Years">6.7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrvHndT1tcGc" style="text-align: right" title="Options Exercisable, Exercisable Number of Options">548,368</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGAMtsYhR5eh" style="padding-bottom: 1pt; text-align: right" title="Options Outstanding, Exercise Price">5.08</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoR8Y98253Y8" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Outstanding Number of Options">812,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1xz1zj7zjja" title="Options Exercisable Weighted Average Remaining Life In Years">5.9</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIZKhcRWSsw5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Exercisable Number of Options">812,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231_zbocWCIXa5Vc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Outstanding Number of Options">3,263,467</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_ziXBWM6T6LZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Exercisable Number of Options">2,499,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zrKbEgsvNC01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzhvGPbrfrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zZxbFDb2dxqf" style="display: none">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zGOcrqNV9u6b" title="Risk free interest rate">4.14</span> -<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zlS2vh9EUFd4" title="Risk free interest rate"> 4.30</span>%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoHTrUNaM9yc" title="Risk free interest rate">4.22</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z1KylLmbD0Dj" title="Expected term (years)">2.77</span> - <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zar0bL5bcuah" title="Expected term (years)">5.38</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx5RjK2kIGab" title="Expected term (years)">3.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zWWPgchvXA8e" title="Expected volatility">101</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_znbbAp1dPtUe" title="Expected volatility">102</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEkATAdzvs76" title="Expected volatility">175.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zauNMGbqKima" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0OQS4xjFub7" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AC_zjeFEbC9TUoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the 2021 Plan, the Company may grant restricted stock units (&#8220;RSUs&#8221;) to employees, consultants or non-employee directors
(&#8220;Eligible Recipients&#8221;). The number, terms and conditions of the RSUs that are granted to Eligible Recipients are determined
on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Recipient one
unrestricted, fully transferable share of the Company&#8217;s common stock (or the fair market value of one such share in cash) for each
vested and nonforfeitable RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zbjCRCDfsw47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the unvested RSUs as of December 31, 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z7qX6TjqzmYg" style="display: none">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Non-vested at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z54caD9t4qNf" style="width: 22%; text-align: right" title="Number of shares outstanding beginning">97,827</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7rNzZRrwG7c" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl2181">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6DHLnyY2Zc" style="text-align: right" title="Number of shares forfeited">(97,827</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVJwCiRoFDV8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2185">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z984AZuQj4Zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending"><span style="-sec-ix-hidden: xdx2ixbrl2187">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zHAVwHeWUTFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zKMX8JsmytWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNmDZQdJkQIj" style="display: none">SCHEDULE OF STOCK OPTION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unrecognized at December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Weighted Average Remaining
    Amortization Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8mg1PWdtnvh" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense">2,812,566</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0lPbAx67Oo4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense">7,782,967</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAfZqmoXHmha" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Unrecognized expense">774,470</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbb2sY1Dla3" title="Weighted average remaining amortization period (years)">0.95</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231_zbrAVj7QZ22e" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense">2,812,566</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231_zf5gaaCKHH4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense">7,782,967</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231_zZzUIJJBw2k1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense">774,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zOzUVTj3znM8" title="Weighted average remaining amortization period (years)">0.95</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zFWRUvqoB1Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zWIei0oZrkef" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
5 &#8211; <span id="xdx_825_zVWiYOnlMsV5">FAIR VALUE MEASUREMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2025 and December 31, 2024, the Company estimated the aggregate fair value of warrants that are accounted for as warrant
liabilities to be $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJcqWDj8PgBd" title="Fair value of warrants">1,968,315</span> and $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20241231__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAEe4M7r7e25" title="Fair value of warrants">2,520,851</span>, respectively, using the Black-Scholes option price model (Level 3 inputs). The Company recognized
a gain on the change in fair value of these warrant liabilities of $<span id="xdx_901_eus-gaap--DerivativeGainLossOnDerivativeNet_c20250701__20250930_z30hwbndc2y6" title="Change in fair value of warrant liability">612,064</span> and $<span id="xdx_909_eus-gaap--DerivativeGainLossOnDerivativeNet_c20250101__20250930_zvlwGBvcD9K3" title="Change in fair value of warrant liability">552,536</span> for the three and nine months ended September
30, 2025, respectively. The Company recognized a gain (loss) on the change in fair value of these warrant liabilities of $<span id="xdx_90E_eus-gaap--DerivativeGainLossOnDerivativeNet_c20240701__20240930_zYATYdoL83V1" title="Change in fair value of warrant liability">1,036,464</span> and
<span id="xdx_90E_eus-gaap--DerivativeGainLossOnDerivativeNet_c20240101__20240930_zmWrjebF3sBf" title="Change in fair value of warrant liability">($837,466)</span> for the three and nine months ended September 30, 2024, respectively. The following table shows the detail of the valuation
assumptions used as of September 30, 2025:</span></p>

<p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zYbR150SpqHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zcgeC8MqrZ5" style="display: none">SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zxEA6d76kmYb" title="Risk free interest rate, minimum">3.63</span>%-<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2LyC3yTSKN2" title="Risk free interest rate, maximum">3.68</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zEjOyYzWXZL1" title="Expected term (years)">1.11</span> - <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zs74j345MWhg" title="Expected term (years)">3.36</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zChsDNjScRgl" title="Risk free interest rate, minimum">71</span>% - <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zNNZYtdpL4bk" title="Risk free interest rate, maximum">95</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Expected dividends</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: center"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znlFqfExj7h4" title="Fair value measurement input">0.00</span>%</td><td style="width: 1%; text-align: left"></td></tr>
  </table>

<p id="xdx_8A5_zRfP3IV2E5k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: left; text-indent: 0.5in">&#160;</p>

<p id="xdx_89B_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z0molxKWjZA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span id="xdx_8B7_z9xuaMvT1xX2" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the three months ended September 30, 2025 and three months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250701__20250930_zeCR0vBVgfgi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240701__20240930_zYoNyQCUs5b5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilitiesCurrent_iS_zxmARxdlRPSa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance, July 1,</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,580,379</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,491,969</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfWarrants_zmQMZLHyGDHg" style="display: none; vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Issuance of warrants</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ProceedsFromWarrantExercises_zdS9hwqjGvhf" style="display: none; vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Exercise of warrants</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zqccaL1gKsq8" style="vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">(612,064</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">)</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">(1,036,464</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DerivativeLiabilitiesCurrent_iE_zPCfqZ6CcHFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, September 30,</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,968,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,455,505</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the nine months ended September 30, 2025 and nine months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20250930_zyDniDIA96xf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20240930_z1eIEDR8hka7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DerivativesLiabilities_iS_zDuXqE4pQ9I1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance, January 1,</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,520,851</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,618,039</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zOrza3ZtG34b" style="vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">(552,536</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">)</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">837,466</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DerivativesLiabilities_iE_zf8kCHzACY72" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, September 30,</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,968,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,455,505</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_ze9GaU9FQCCj" style="margin-top: 0; margin-bottom: 0">&#160;</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zJgEq6fVipC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities measured at fair value on a recurring basis are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BE_z9AJ9ruwatC" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%">Marketable securities as of September 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx0XRgOrIwVj" style="width: 12%; text-align: right" title="Marketable securities, fair value">3,887,383</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXy6QSa4CiKj" style="width: 12%; text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAfGqdOs7p1c" style="width: 12%; text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250930_zDJYVBVmVbjk" style="width: 12%; text-align: right" title="Marketable securities, fair value">3,887,383</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsnvRgnScII4" style="text-align: right" title="Marketable securities, fair value">10,184,701</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXWj3LcyLswf" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIV6QKf55UAg" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1118">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20241231_z2kNUxQuWnph" style="text-align: right" title="Marketable securities, fair value">10,184,701</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant liabilities as of September 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zlbrjHmcywRe" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNRVZ9KTxIxe" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdIugE6kW3E7" style="text-align: right" title="Warrant liabilities, fair value">1,968,315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930_zRmBTjm57Jcc" style="text-align: right" title="Warrant liabilities, fair value">1,968,315</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrant liabilities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXF2LovcwaF1" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl1rAwhJDX96" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1132">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDK5hyhn8tm4" style="text-align: right" title="Warrant liabilities, fair value">2,520,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231_zPIjIUPYLfFk" style="text-align: right" title="Warrant liabilities, fair value">2,520,851</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zeUnMi7Tq9Q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80B_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zltmBzWqEc73" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
9 &#8211; <span id="xdx_822_zkzDTDJn5Zsa">FAIR VALUE MEASUREMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the Warrants as liabilities in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging &#8212;
Contracts in Entity&#8217;s Own Equity. For certain Warrants, the Company does not control the occurrence of events, such as a tender
offer or exchange, that may trigger cash settlement of the Warrants and not result in a change of control of the Company. As a result,
such Warrants do not meet the criteria for equity treatment and the Warrants must be recorded as a derivative liability. Additionally,
certain other Warrants contain adjustments to the settlement amount based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221;
option as defined under ASC 815-40 and, accordingly, such Warrants are not considered indexed to the Company&#8217;s own stock and are
not eligible for an exception from derivative accounting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2024, in connection with the Warrant Exercise and Issuance, the Company estimated the aggregate fair value of the Existing
Warrants (see Note 6- Stockholders&#8217; Equity for details) to be $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20240208__20240208__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_ziBScYzZ13xb" title="Fair value of adjustment">1,115,334</span> using the Black-Scholes option pricing model (Level 3
inputs). The following table shows the detail of the valuation assumptions used:</span></p>

<p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-ZMNRFLS_zGWiyj8eGB08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zy4Lx3EQdX9j" style="display: none">SCHEDULE
OF FAIR VALUE VALUATION ASSUMPTIONS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_z3vjeUokVdy1" title="Risk free interest rate, minimum">4.20</span> - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zsQwgnRfo9ne" title="Risk free interest rate, maximum">4.28</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zqcGcNRJo4Xb" title="Expected term (years)">2.75</span> - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zMr7mo2LgO82" title="Expected term (years)">2.76</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zT7MOzpWsO63" title="Expected volatility">102</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zByUcEfDP6Vl" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A7_zWTVHDTVNATa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2024, the Company estimated the aggregate issuance date fair value of the warrant liability related to the New Warrants (see
Note 4 - Stockholders&#8217; Equity for details) as $<span id="xdx_909_eus-gaap--DerivativeLiabilities_iI_c20240208_zaZ4oNIOeEXf" title="Derivative liabilities">2,189,420</span> using the Black-Scholes option pricing model (Level 3 inputs). The following
table shows the detail of the valuation assumptions used:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_zFEXuwxSsfh3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<div id="xdx_C07_gL3FVAALMORAN-ZMNRFLS_z9jIJ08bBYOb"><table cellpadding="0" cellspacing="0" id="xdx_300_zBSJWV5SGvha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zD3oN4V56Q5b" title="Risk free interest rate">4.12</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8SRKjJEIcZ3" title="Expected term (years)">5.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0OvHJjsBvog" title="Expected volatility">101</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmGV2nd8un74" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C04_gL3FVAALMORAN-ZMNRFLS_zRoWvOb3mFlc">&#160;</span></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2024 and 2023, the Company estimated the aggregate fair value of the warrants classified as derivative liabilities to purchase
an aggregate of <span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zLLHtFGQXIk2" title="Fair value of adjustment">3,900,014</span> and <span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_z5RerJc1v6T2" title="Fair value of adjustment">4,737,908</span> shares of common stock, respectively, to be $<span id="xdx_907_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zC0D4h0jC5k6" title="Fair value of derivative liabilitiy">2,520,851</span> and $<span id="xdx_90D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zSAOIQsG5Qm9" title="Fair value of derivative liabilitiy">1,543,953</span>, respectively, using the
Black-Scholes option pricing model (Level 3 inputs) using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_z6Jk0lFnAFsd"><table cellpadding="0" cellspacing="0" id="xdx_307_zKLVcIhIzVE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv7eKFqVeiu7" title="Risk free interest rate, Minimum">4.12%</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBHAeic1Mmv" title="Risk free interest rate, Maximum">4.34</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvyycNHmduL7" title="Risk free interest rate, Minimum">4.04</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zA8LVCxdYpp9" title="Expected term (years)">1.86</span> - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMhtVWrrmuYj" title="Expected term (years)">4.11</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z570pw5hpvj8" title="Expected term (years)">2.86</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCRrHeM4Aqyi" title="Expected volatility">97</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zQRlaizdtMj2" title="Expected volatility">110</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmLHGhk0izj8" title="Expected volatility">87.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1AoHDe9wf58" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4BAeX5Y6SXd" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_C01_gL3FVAALMORAN-ZMNRFLS_zQgLe4Ufswxb">&#160;</span></b></span></p>

<p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMC0qycoxwah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zKAQQdINnHu1" style="display: none">SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance, January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_c20230101__20231231_zq0KZ6eETEId" style="width: 16%; text-align: right" title="Balance, January 1, 2023">5,541,733</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20230101__20231231_zzNM3R7N5ZQa" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(3,997,780</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_c20240101__20241231_z9mQLh7c0ln7" style="text-align: right" title="Balance, January 1, 2024">1,543,953</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231_zKGDn9WG9Bhf" title="Issuance of warrants">2,189,420</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_iN_di_c20240101__20241231_zF9LX4FrXUh9" title="Exercise of warrants">(1,115,334</span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20240101__20241231_zpDBZORmgt8b" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(97,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iE_c20240101__20241231_zNGCeauSjfRl" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, december 30, 2024">2,520,851</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_z3mL6NzRpPKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities measured at fair value on a recurring basis are as follows:</span></p>

<p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6tGfwS6kgK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z5r5D5GaLK3d" style="display: none"><span>SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%">Marketable securities as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4WzJJjC4wS1" style="width: 12%; text-align: right" title="Marketable securities, fair value">10,184,701</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxeusrZDKjP6" style="width: 12%; text-align: right" title="Marketable securities, fair value">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2459">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2rpFzeBYrv1" style="width: 12%; text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2461">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_c20241231_zmKh1dwd0rfe" style="width: 12%; text-align: right" title="Marketable securities">10,184,701</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zC3pfJMA2Vod" style="text-align: right" title="Marketable securities, fair value">10,181,618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFxBE74S8NCj" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2467">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUaeaX3Cxbrj" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2469">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zkPmSxUWuL6e" style="text-align: right" title="Marketable securities">10,181,618</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant liabilities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaDiGqMl6dni" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2473">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZUD9addK6D7" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2475">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlzurmG7ynm" style="text-align: right" title="Warrant liabilities, fair value">2,520,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_ziSFoXIxNsge" style="text-align: right" title="Warrant liabilities">2,520,851</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrant liabilities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRXvDdOz7IR8" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2481">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWQ1XwDflpwh" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2483">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzV5BGldJR4" style="text-align: right" title="Warrant liabilities, fair value">1,543,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231_zyQUQAE5wWT5" style="text-align: right" title="Warrant liabilities">1,543,953</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zHZFVjyZEVW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/825/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_znPakqqd9Om6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
6 &#8211; <span id="xdx_821_z4TzsZfGHP7e">SUBSEQUENT EVENTS</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registered
Offering and Private Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2025, the Company entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with several investors
(the &#8220;Purchasers&#8221;) pursuant to which the Company agreed to sell and issue to the Purchasers an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251006__20251006__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlzNCmTpDIOh" title="Sold shares of common stock">678,125</span> shares
of the Company&#8217;s common stock in a registered direct offering at an offering price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQmPGfkniFB3" title="Offering price">1.60</span> per share (the &#8220;Registered Offering&#8221;)
for aggregate gross proceeds of approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20251006__20251006__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zQJfYMcLg6A6" title="Gross proceeds from sale of shares">1.1</span> million. Pursuant to the Subscription Agreements, in a concurrent private placement
offering (the &#8220;Private Placement&#8221;), the Company agreed to issue to the Purchasers unregistered warrants to purchase up to
an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251006__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zrbksF93MJw3" title="Warrants exercisable">508,592</span> shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPb5B4OeqpL6" title="Exercise price">2.75</span> per share. The Registered Offering and
the Private Placement closed on October 8, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SaleOfStockDescriptionOfTransaction_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkCj8neueAD8" title="Description on sale of stock">In
connection with the offering, the Company entered into an engagement letter, dated August 11, 2025, with Alere Financial Partners (a
division of Cova Capital Partners, LLC) (the &#8220;Placement Agent&#8221;), pursuant to which the Company agreed to pay the Placement
Agent a cash fee equal to 6% of the gross proceeds of the offering from investors introduced to the Company by the Placement Agent (the
&#8220;Placement Agent Investors&#8221;) (4% for other investors).</span> The Company has also agreed to reimburse the Placement Agent approximately
$<span id="xdx_908_ecustom--LegalFeesAndOtherExpenses_c20250811__20250811_z4Ue4YpUWl03" title="Legal fees and other expenses">8,300</span> for out-of-pocket expenses for legal fees and other expenses. In addition, the Company agreed to issue to the Placement Agent,
at the closing of the offering, a warrant exercisable commencing six months from the date of issuance until the five year anniversary
of the date of issuance to purchase up to 6% of the number of Shares sold in the Registered Offering to Placement Agent Investors (4%
for other investors), at a per share exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkv2vIYEvaBg" title="Exercise price">2.75</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Grants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2025, the Company granted an option to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zam1vFGvqj64" title="Options granted">25,000</span> shares of the Company&#8217;s common stock at an exercise price of
$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6s4OO6iNKok" title="Exercise price of options granted">1.62</span> per share to an employee. The option <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zORSOjGXk9u9" title="Vesting of options description">vests as follows: (i) 50% immediately, and (ii) the remainder quarterly over two years commencing
one year from the date of grant.</span> The Company will recognize the grant date fair value of the option on a straight-line basis over vesting
period.<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 27, 2025, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251027__20251027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zgQcx7pN8rN3" title="Number of shares of common stock">220,000</span> shares of common stock to Auctus Fund, LLC in partial satisfaction of shares held by abeyance.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zQwk95xqwdn2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
10 - <span id="xdx_827_z8pGpu2YREya">SUBSEQUENT EVENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to the year ended December 31, 2024, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKg7Zk2AAER1" title="Sold shares of common stock">492,000</span> shares of its common stock under the Rodman ATM program with a weighted-average
gross price of approximately $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFw7mnG04Qni" title="Share price">2.20</span> per share and raised approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zus5kgmQYQ7" title="Gross proceeds">1,084,000</span> of gross proceeds. The total commissions and related
legal and accounting fees were approximately $<span id="xdx_904_eus-gaap--PaymentsForLegalSettlements_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuIqcQVJa93f" title="Legal settlements paid">178,000</span> and the Company received net proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zfCSxkZoeUo1" title="Net proceeds">906,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Grants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2024, the Company granted options to purchase an aggregate <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9OxoGbvnv17" title="Grant options shares">2,152,908</span> shares of the Company&#8217;s common stock at an
exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8mtyATWWQi7" title="Exercise price">2.46</span> per share to employees, the Company&#8217;s board of directors and a member of the Company&#8217;s scientific
advisory board. The options had an aggregate grant date fair value of $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP0528XPAvEi" title="Grant options shares">4,044,250</span> and vest as follows: (i) options to purchase an aggregate
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zA3ysS42tju2" title="Options to purchase shares">323,459</span> shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoMpjuVT8AZf" title="Purchase of common shares">1,829,449</span> shares of common stock
vest <span id="xdx_908_ecustom--CommonStockVestRemainderPercentage_iI_pid_dp_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSBDnzWykyNg" title="Purchase of common shares">50</span>% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant. The Company will
recognize the grant date fair value of the options proportionate to the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common Stock Issuance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to the year ended December 31, 2024, the
Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zn754CUGeFkd" title="Number of shares of common stock">63,525</span> shares of common stock to Auctus Fund, LLC in partial satisfaction of shares held by abeyance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zEvV1FTo67xk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
3 - <span id="xdx_829_zsg9IrEIAfo9">PROPERTY AND EQUIPMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2ZdwaDNWsb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zRiW19Duyqmj" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zcvb0j2Mshvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zCrUODQYb0Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zLOXDxjVNdhb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,133</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,133</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zHKi6c2fM66c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,486</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zTPXuLfpmrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdSPeVh24a7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,779</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zHLEEhyimZOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manufacturing equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">501,421</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395,232</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb0uKt79Uwyg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">342,048</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">342,048</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzKiZ_z4su14VN8qy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    plant and equipment gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,474,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,367,883</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKiZ_zeJSxm1HRBa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,111,136</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,011,828</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKiZ_zPMObeOSxMXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">362,936</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zZiYqaFLPewe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
depreciation expense for the years ended December 31, 2024 and 2023 was $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zvtQEHghKRO7" title="Depreciation">99,309</span> and $<span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zi5SeumhaRl8" title="Depreciation">75,989</span>, respectively. Depreciation expense is reflected
in general and administrative expenses and research and development expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--IntangibleAssetsDisclosureTextBlock_z7XcTOpi2I3c" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
4 - <span id="xdx_82E_z8jFnJ0P8vsc">INTANGIBLE ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a license agreement with the SCTC (as amended) (the &#8220;SCTC Agreement&#8221;). Pursuant to the SCTC Agreement,
the Company obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from the SCTC
to utilize or sublicense a certain method for culturing cells and a worldwide, exclusive, royalty-bearing license from the SCTC to utilize
or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine
(and other parts of the body).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, the Company received authorization from the Food and Drug Administration (the &#8220;FDA&#8221;) to proceed with a Phase
2 clinical trial. In February 2022, the Company announced that the United States Patent and Trademark Office issued a notice of allowance
for a patent application relating to the Company&#8217;s BRTX-100 clinical program. This patent was issued in March 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdsSzvPsMxw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zovX5FmRjKn8" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zMa8DpLEhmyh" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgkIpLlGFbo2" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance">1,593,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zqY3dA0k41Sl" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance">(793,768</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20230101__20231231_z6h1cAws7Od" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance">803,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zDUNrjLtHqbj" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,746</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231_zRrGfdmJ09Eb" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,746</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zTRGfffLeNbf" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBVozX7VDJlj" style="text-align: right" title="Beginning Balance">1,593,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXRYXWxN8sRe" style="text-align: right" title="Beginning Balance">(883,514</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20240101__20241231_zqwLjk2xJY0j" style="text-align: right" title="Beginning Balance">713,692</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zytthitOTw2k" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,747</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231_zAM5NMN8yS06" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,747</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zQuRKUBmR8mh" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zoYjoWDb33X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">1,593,530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztG665tY4AIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance">(973,261</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_pp0p0_c20240101__20241231_zjzg3CCnlNxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, Ending Balance">623,945</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period at December 31, 2024 (in years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zFTAQg0U6qf8" title="Finite Lived Intangible Assets, weighted average amortization period">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zWn6aGIbVlz8" title="Finite Lived Intangible Assets, weighted average amortization period">10.3</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zQnJWoLGRUxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zyr8t0Ym6OWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zIE3bG4EPzp9" style="display: none">SCHEDULE OF FINITE LIVED
INTANGIBLE ASSETS AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zAQRVTNxCnRa" style="width: 14%; text-align: right" title="Beginning Balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zTV1EfXZQxkj" style="width: 14%; text-align: right" title="Beginning Balance">790,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuMtebEZOmgf" style="width: 14%; text-align: right" title="Beginning Balance">793,768</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zY8aapJwfbif" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl1846">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgEjKj6jTWI5" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2rXVJBGP7il" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zgRAH3stiYi7" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDe9KaWcOYI7" style="text-align: right" title="Beginning Balance">879,838</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXVvp6oFTRTa" style="text-align: right" title="Beginning Balance">883,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zuHhehAQNkik" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl1858">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6qgnUqvdCNe" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zygSxwRoDT8e" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zpDaKpFlcUXl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_ziQYvOYoF2Vh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">969,585</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z21atXqH7Mrd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">973,261</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zXJeZ8EsBx54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zO5E84hy3qC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the next five years is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zDxhPMghSJb7" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">For the Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zLqGmLhSvkA" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz89Q_z1vNDKxW98G5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">89,746</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz89Q_za7zLx3utHS9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz89Q_z9FWK80aZ1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz89Q_zCZfaJK7po9f" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz89Q_zlr2Quf6AHf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz89Q_zivgdmaXPRBi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">448,730</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zRFY1LD10kBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zVozmWE0SJyc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
7 - <span id="xdx_826_zR22wSIZcwLf">INCOME TAXES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company identified its federal and New York tax returns as its &#8220;major&#8221; tax jurisdictions. The Company is no longer subject
to income tax income examinations by these tax authorities for taxable years ended December 31, 2020, and prior. The Company reviewed
the prior New York state income tax filings and concluded that the prior year return will be amended to change the apportionment from
zero to <span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20240101__20241231_zUkrmcjJv7h4" title="Prior year income taxes, percentage">100</span>%. The Company believes its income tax filing positions and deductions will be sustained on audit, and it does not anticipate
any adjustments that would result in a material change to its financial position. Therefore, no liabilities for uncertain tax positions
have been recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company had approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zePnVp7cedXh" title="Operating loss carry forwards">68,200,000</span> and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zRa5IkvBOzVf" title="Operating loss carry forwards">51,800,000</span>, respectively, of federal and state net operating losses
that may be available to offset future taxable income. As a result of the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;),
certain future carryforwards do not expire. At December 31, 2024, approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_c20241231__srt--StatementScenarioAxis__custom--ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_zDqomiSyERfd" title="Operating loss carry-forwards subject to expiration">7,800,000</span> of federal net operating losses will expire
from 2030 to 2038 and approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_c20241231_zXc6BzRqcNMd" title="Operating loss carry-forwards not subject to expiration">60,400,000</span> have no expiration but are subject to a utilization limit equal to 80% of current taxable
income. <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_z84EZ3UauGO9" title="Net operating loss description">The state net operating losses have a 20 year carryforward period and will begin to expire beginning 2035.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zywpKWkgXOba" title="Income tax examination, description">In
accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#8217;s net operating loss carryforwards are subject
to annual limitations due to several greater than 50% ownership changes.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not performed a formal analysis for the year ended December 31, 2024, but it believes its ability to use such net operating
losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections
382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit
use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred
over the three-year period ended December 31, 2024. For the period ended December 31, 2024, the Company has recorded a full valuation
allowance against the gross deferred tax asset balance as management believes that it is more likely than not that the results of operations
will not generate sufficient taxable income to realize any of the deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this filing, the Company has not filed its 2024 federal and state corporate income tax returns. The Company expects to
file these documents as soon as practicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOmgaPOBaQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zZUwWPmupGV3" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zL9QFC7L3Yig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zhbF1s19zvl7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zEjIVolmYEU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzcBK_zW8G8vTtyQJk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">18,004,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,311,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGzcBK_zFIFQbADeNHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,695,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,788,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTAGzcBK_zdxqp5f1BD88" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,694,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,676,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGzcBK_zOXQBzh1v0Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsRightOfUseAsset_i01I_maDTAGzcBK_zZJt7OwUWjwa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2240">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcBK_zwScf9aTi8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">600</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGzcBK_maDTALNz6jW_zRxljnsv5rrj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">29,724,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">32,134,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zlws6xNcz8z3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred Tax Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxLiabilitiesDepreciation_i01NI_pp0p0_di_maDITLz8iB_zvhfLWJlS6a1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(153,200</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_maDITLz8iB_zMvdEk1EX2Mf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41,700</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_i01NI_pp0p0_di_maDITLz8iB_z5JN7o7R2Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2258">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLz8iB_z626f9pOcRZd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(95,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(86,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pp0p0_di_mtDITLz8iB_msDTALNz6jW_z5ov3kRZfdYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(289,900</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(294,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNz6jW_zDuuMmzJjzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Deferred Tax Asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,434,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,840,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8Hs2v6wALU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,434,100</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(31,840,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_z8GkK0NwV2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred Tax Asset, Net of Valuation Allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2273">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2274">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Change in valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20240101__20241231_zmS2WbGfj5n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">2,405,900</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20230101__20231231_zc9ckzJO7A9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">(4,064,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AC_zgRHuIkbL9D3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zltwcQOflIb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision (benefit) as of December 31, 2024 and 2023 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zewWuR64PcD5" style="display: none">SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zRwhUVQspGih" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zxkSMrPCvzR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlI2aJg7XIZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maDFSALzNuk_zO5ShPfW6jN4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2286">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zk51qR840bie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%">Deferred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,567,000</td><td style="width: 1%; text-align: left"></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(3,090,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zTDgkAmF6Uzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State &amp; Local:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maDFSALzNuk_z2FcUaberu53" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2294">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2295">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zRDQK8KB7bX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Deferred</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,161,100</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(974,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBz5Bf_mtDFSALzNuk_zPjhdL5jZTtd" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,405,900</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,064,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ChangeInValuationAllowance_i01N_di_msITEBz5Bf_zhzlgQSBeSpj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,405,900</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,064,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz5Bf_zTflNXI3Iww2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2306">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2307">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zE62j2LkqvZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbnotrZxBuda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zkPZz0PDfa4f" style="display: none">SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zIN1SWuTCKCd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zYoEk77mdqyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR_zoD8GqfTv0Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR_zBasGeNwUdq5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR_ztCkHqhYvo49" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_maETR_zeaqqe9LYYr1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax return to provision adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.2</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR_zu0T4TNCIfFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in federal valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">39.7</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-29.7</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_pid_dp_uPure_maETR_z06HeVNrY5Z7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Adjustment for stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">-62.1</p></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2327">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR_z9fAJvH2U32l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AB_zWRkjNmqbrWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zgcg9trQLw4b" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
8 &#8211; <span id="xdx_82A_zZqO5mhrGS0j">LEASES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a lease for <span id="xdx_90B_eus-gaap--AreaOfLand_iI_usqft_c20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zh4cxmaJnd2j" title="Area of land">6,800</span> square feet of space located in Melville, New York (the &#8220;Melville Lease&#8221;) with respect
to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zmpZ4l7IQSC6" title="Rent expense">132,600</span> and
$<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zOjbIvPdVbN8" title="Rent expense">149,260</span>. In June 2019, <span id="xdx_908_eus-gaap--LessorOperatingLeaseOptionToExtend_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_z4SYxbAeZm8h" title="Lease extension description">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zIdUhKaj4omk" title="Rent expense">153,748</span> and $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zAvMxkpiKrlg" title="Rent expense">173,060</span>.</span> The lease
expired on December 31, 2024 and the Company is currently leasing the premises on a month-to-month basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zrQlabrxcXu" title="Weighted average incremental borrowing rate">12</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zfhOXOmxfDS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8BA_zYd7fINKNxyl" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zAim7KPlS8Vd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_zJY5zkeqo6Qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease Costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzEnl_zdxX3SOKOhwd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">173,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">168,028</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zNJI74DdZmgh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">173,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">168,028</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zaVUvxrI8Xgk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease - operating cash flows (fixed payments)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">173,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">168,028</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OperatingLeaseLiabilityReduction_zlA1fMwWsVF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease - operating cash flows (liability reduction)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">162,317</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">139,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current leases - right of use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20241231_zlGR7yPRwte5" style="text-align: right" title="Non-current leases - right of use assets"><span style="-sec-ix-hidden: xdx2ixbrl2362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_z3Cs3WdUJgzk" style="text-align: right" title="Non-current leases - right of use assets">151,447</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20241231_zait734oCTT3" style="text-align: right" title="Current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_z5SMTMDgFzqf" style="text-align: right" title="Current liabilities - operating lease liabilities">162,317</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zXJzCNst9qGg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23OperatingLeaseLiabilityCurrent"><span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zRFYux9HxGJ8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23OperatingLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl2369"><span style="-sec-ix-hidden: xdx2ixbrl2370">Non-current liabilities - operating lease liabilities</span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20241231_zqhxJYXaknKk" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2372">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_zSdrEeHsTO37" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2374">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zHFgvhk3iHe6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no future minimum payments under non-cancelable leases following the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zuoYoou5Mad5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reclassifications</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
prior period statements of operations amounts have been reclassified to conform to the Company&#8217;s fiscal 2025 presentation. These
reclassifications have no impact on the Company&#8217;s previously reported net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zWKRFvYaCgp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Cash
and Cash Equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#8220;FDIC&#8221;) coverage of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20250930_zJD8tEm9PdDb" title="FDIC insured limit">250,000</span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_c20250930_z4MdKwMJTX04" title="Cash in excess of FDIC limit">290,180</span> and
$<span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zox3igVmFcxj" title="Cash in excess of FDIC limit">252,801</span> as of September 30, 2025 and December 31, 2024, respectively. As of September 30, 2025, the Company has not experienced losses
on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z82RXuAQ9m83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zPY8JAe2pUG9">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#8220;FDIC&#8221;) coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zd4LGIJOhtt9" title="FDIC insured limit">250,000</span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zkZR8JFpwxA1" title="FDIC amount">252,801</span> and
$<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zuUVXiGB8vo1" title="FDIC amount">604,226</span> as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments Held in Marketable Securities</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zA8EOTyYL9Ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Investments
Held in Marketable Securities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2025 and December 31, 2024, investments held in marketable securities consists of U.S. Treasury securities held in a
trust account. The Company&#8217;s investments held in the trust account are presented on the unaudited condensed consolidated balance
sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities
are included in interest income in the accompanying unaudited condensed consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Customer and Revenue Concentrations</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zOKc1nRk6qEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Customer
and Revenue Concentrations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s contract service revenue is derived from one customer. Additionally, all of the Company&#8217;s product sales
revenue is derived from one customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrHslI4Q5v9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zMa1AmFIfaIk">Customer
and Revenue Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s royalty revenue is derived from one customer. Additionally, all of the Company&#8217;s product sales revenue is
derived from one customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z0Iff1vBFCL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts
Receivable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of <span style="background-color: white">September
30, 2025 </span>and December 31, 2024, no allowances for credit losses were determined to be necessary. Management estimates the allowance
for credit losses based on existing economic conditions, the financial conditions of the customers, and the amount and age of past due
accounts. Receivables are considered past due if full payment is not received by the contractual due date. Past due accounts are generally
written off against the allowance for credit losses only after all collection attempts have been exhausted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z96cN1ak7Q7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zjqSBcHeCS88">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of December 31, 2024 and 2023, no allowances
for credit losses were determined to be necessary. Management estimates the allowance for credit losses based on existing economic conditions,
the financial conditions of the customers, and the amount and age of past due accounts. Receivables are considered past due if full payment
is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only
after all collection attempts have been exhausted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Contract Costs</a></td>
<td class="text"><p id="xdx_848_eus-gaap--DeferredChargesPolicyTextBlock_zPTZ9bBDS0tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
Contract Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs relate
directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying performance obligations
in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as cost of revenues in the period
when the related revenue is recognized. Deferred contract costs consist of consumables and labor costs and are included in prepaid and
other current assets in the unaudited condensed consolidated balance sheets. The Company had $<span id="xdx_902_eus-gaap--DeferredCosts_iI_c20250930_ztAqpn7wZG9" title="Deferred contract costs">7,491</span> and $<span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zlvqQHgH5kek" title="Deferred contract costs">10,250</span> deferred contract costs
as of <span style="background-color: white">September 30, 2025 </span>and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p id="xdx_842_ecustom--DeferredOfferingCostsPolicyTextBlock_zUPPJ97vXR12" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
Offering Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs, which primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized
as non-current assets on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the
offering proceeds. If the completion of a contemplated financing was no longer probable, the related deferred offering costs would be
charged to general and administrative expense in the unaudited condensed consolidated financial statements. The Company had $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20250930_z4s2RZanSigj" title="Deferred offering costs">69,066</span> and
$<span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20241231_zxOLA0MPGa7g" title="Deferred offering costs">148,697</span> of deferred offering costs as of <span style="background-color: white">September 30, 2025 </span>and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_844_ecustom--DeferredOfferingCostsPolicyTextBlock_zCSW2VIkUIsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_zv1g22C3EyB3">Deferred Offering Costs</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Deferred offering costs, which
primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized as non-current assets
on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the offering proceeds. If
the completion of a contemplated financing was no longer probable, the related deferred offering costs would be charged to general and
administrative expense in the consolidated financial statements. The Company had $<span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_c20241231_zRqgz5xgN36j" title="Deferred offering costs">148,697</span> and $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20231231_zQ0rJYVdgKF6" title="Deferred offering costs">0</span> deferred offering costs as of December
31, 2024 and 2023, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zZv6KZulSXol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
Financial Instruments </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated
statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option
pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQ9biVqlTD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_86F_z6RhMrU5RzF3">Derivative
Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option pricing model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zkANa1kvlmrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of <span style="background-color: white">September 30, 2025 </span>and
December 31, 2024, the carrying amount of cash and cash equivalents, investments held in marketable securities, accounts receivable,
and accounts payable approximate their fair value due to the relatively short period of time between their origination and their expected
realization or payment. The warrant liabilities are measured at fair value (see Note 5 &#8211; Fair Value Measurement for additional
details).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGbcb7LJWe47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zhJEhRPQrt7k">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of December 31, 2024 and 2023, the carrying amount of cash and cash equivalents,
investments held in marketable securities, accounts receivable, and accounts payable approximate their fair value due to the relatively
short period of time between their origination and their expected realization or payment. The warrant liabilities are measured at fair
value (see Note 9 &#8211; Fair Value Measurement for additional details).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company recognized aggregate dividend and interest income of $<span id="xdx_90C_eus-gaap--InterestAndDividendIncomeOperating_c20240101__20241231_zg5oD0W09dNe" title="Dividend and interest income">623,801</span> and $<span id="xdx_909_eus-gaap--InterestAndDividendIncomeOperating_c20230101__20231231_zU0r2WazoLE7" title="Dividend and interest income">569,068</span> respectively,
on its marketable securities, which was included within other income on its consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zDWt9x0oUJT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, &#8220;Revenue from Contracts
with Customers&#8221; (&#8220;ASC 606&#8221;). The core principle of ASC 606 requires that an entity recognize revenue to depict the
transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled
in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible
more judgment and estimates may be required within the revenue recognition process, including identifying performance obligations in
the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price
to each separate performance obligation. The Company recognizes revenue primarily from the following different types of contracts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    sales</b> - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty
    revenue</b> - Revenue is recognized as a usage-based royalty from customers&#8217; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#8217;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    reason for the bill-and-hold arrangement is substantive </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    customer has requested the product be warehoused</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product has been identified as separately belonging to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product is currently ready for physical transfer to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company does not have the ability to use the product or direct it to another customer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zUp6hfR82OB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s revenue recognized in its unaudited condensed consolidated statements of operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_z0f5J2lLd7qj" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250701__20250930_zmrJbKyBvxUd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zDeGk3t9GU94" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250930_zqyeKJkPHFF6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20240930_z6BY4V2rHPqk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zayVoAdXqGSe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">230,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zSCqOCQLgYXg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,900</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,100</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">57,700</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zuuQYkToU9Ka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">233,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">340,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">357,700</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zjMjD1SO5q28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zutuEXoDmQC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zLcOVvLUxfTa">Revenue
Recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).
The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC
606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required
within the revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable
consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company
recognizes revenue primarily from the following different types of contracts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    sales</b> - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty
    revenue</b> - Revenue is recognized as a usage-based royalty from customers&#8217; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#8217;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    reason for the bill-and-hold arrangement is substantive</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    customer has requested the product be warehoused</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product has been identified as separately belonging to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product is currently ready for physical transfer to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company does not have the ability to use the product or direct it to another customer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s revenue recognized in its consolidated statements of operations:</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z7tV6GJV8wQe" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">101,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">401,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zucK4GFra5g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z0O1dsrwFqPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss Per Common Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. For the three and nine months ended <span style="background-color: white">September</span>
30, 2025, the Company had <span id="xdx_903_ecustom--SharesHeldInAbeyance_iI_pid_c20250930_z56gNeuQxRLa" title="Shares held in abeyance">1,138,055</span> shares held in abeyance included in basic loss per share given that they are issuable for no additional
consideration. For the three and nine months ended <span style="background-color: white">September</span> 30, 2024, the Company had <span id="xdx_90B_ecustom--SharesHeldInAbeyance_iI_pid_c20240930_zrGTXIJeWwD5" title="Shares held in abeyance">1,201,580</span>
shares held in abeyance included in basic loss per share given that they are issuable for no additional consideration (see Note 4 &#8211;
Stockholders&#8217; Equity for additional details). The dilutive effect, if any, of stock options and warrants are calculated using the
treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning of the period or at the
time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect
to losses, options, warrants, restricted stock units (&#8220;RSUs&#8221;) and convertible preferred stock have been excluded from the
Company&#8217;s computation of diluted net loss per common share for the three and nine months ended <span style="background-color: white">September
30, 2025 </span>and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zlziMoWXAXQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zOfUfoHaWSgi" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three and Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z0ddViGBv088" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zbwOLXMER4jb" title="Antidilutive shares">5,262,973</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zYLGQoxDHrqk" title="Antidilutive shares"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zGzgyZjSdSIg" title="Antidilutive shares">3,401,608</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOdb46xTIhE6" title="Antidilutive shares"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zMTo0rnFgyg8" title="Antidilutive shares">3,951,384</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z7e261Idjqe2" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2gQOA9BOJdi" title="Antidilutive shares">3,952,504</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zoAdP24LL9se" title="Antidilutive shares"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zxbicpBg5Pw7" title="Antidilutive shares">1,398,158</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBhtwPFuQYH2" title="Antidilutive shares"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjFYUbw8vdZ1" title="Antidilutive shares">1,398,158</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930_zw7VAXrfvgbh" title="Antidilutive shares"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zLSC5ZNyZcJk" title="Antidilutive shares">10,612,515</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930_zU0LwLcMz8y8" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zZuTFrCR4u39" title="Antidilutive shares">8,752,270</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zJWezSIb5gNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zV62cxfcykAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zSfIv1elO46k">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The Company has <span id="xdx_90D_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zLHCITQpABQj" title="Shares held in abeyance">1,201,580</span> shares held in abeyance included
in basic loss per share given that they are issuable for no additional consideration (see Note 6 &#8211; Stockholders&#8217; Equity for
additional details). The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding
convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant
to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants,
restricted stock units (&#8220;RSUs&#8221;) and convertible preferred stock have been excluded from the Company&#8217;s computation of
diluted net loss per common share for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1GIc8cffMY8" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total">3,263,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total">1,466,892</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares">3,951,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares">4,791,019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1741">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">8,613,259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zh9UmzbEuc23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkl4bVbUTfu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segment
Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20250101__20250930_z6uvo58Te011" title="Number of operating segments"><span id="xdx_90F_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20250101__20250930_zVqE0Gyb38X7" title="Number of reporting segments">one</span></span> operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#8217;s Chief Executive Officer serves as
the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial performance.
The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated expense
data beyond what is included in the unaudited condensed consolidated statements of operations is not provided to the CODM. Since the
Company&#8217;s operations consist of a single reporting segment, the segment assets are presented on the accompanying unaudited condensed
consolidated balance sheets as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkkM4rTKhXL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z3GH9BVMoxqk">Segment
Reporting</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has one operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#8217;s Chief Executive Officer, serves
as the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial
performance. The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated
expense data beyond what is included in the consolidated statements of operations is not provided to the CODM. Since the Company&#8217;s
operations consist of a single reporting segment, the segment assets are presented on the accompanying consolidated balance sheet as
total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFqg54WqZt0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Issued Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09
should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of this
update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; (&#8220;ASU 2024-03&#8221;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXTkrjpty3U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zpKTHgzD4l67">Recently
Adopted Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
&#8220;Improvements to Reportable Segments Disclosures (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;), which updates reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis.
The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after
December 15, 2024, with early adoption permitted. The adoption of this accounting standard on a retrospective basis did not have a material
impact on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_TaxLawChangePolicyTextBlock', window );">Tax Law Change</a></td>
<td class="text"><p id="xdx_849_ecustom--TaxLawChangePolicyTextBlock_zJjlyrjJprU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
Law Change</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 4th, 2025, the President signed into law significant federal tax legislation, H.R.1 (the &#8220;Tax Reform Act of 2025&#8221;).
The legislation includes numerous changes to U.S. corporate income tax law, including but not limited to: permanent 100% bonus
depreciation for qualified property, immediate expensing of domestic research and experimental expenditures, modifications to the
limitation on business interest expense, increased Section 179 expensing limits, changes to the international tax regime, and
expanded limitations on the deductibility of executive compensation under IRC Section 162(m). Most provisions are effective for tax
years beginning after December 31, 2024, with certain transition rules and exceptions. </span>The Company does not expect the
enactment of the Tax Reform Act of 2025 to have a material impact on its  consolidated financial statements. </p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zntv9Aiyyqwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zdk4PxG1qrLi">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#8217;s consolidated financial statements. Such consolidated
financial statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity
and objectivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zxDKCiAlpgg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z0fNjlbqN8zj">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany
accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_zEU1sFsNaugc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z4poG7D1ldXh">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredContractCostsPolicyTextBlock', window );">Deferred Contract Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_ecustom--DeferredContractCostsPolicyTextBlock_zBfyPacgQe1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_z9v0S1hZqQUi">Deferred
Contract Costs</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs
relate directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying
performance obligations in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as
cost of revenues in the period when the related revenue is recognized. Deferred contract costs consist of consumables and labor
costs and are included within prepaid &amp; other current assets in the consolidated balance sheets. The Company had $<span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zZfVwr6cQXkb" title="Deferred contract costs">10,250</span>
and $<span id="xdx_905_eus-gaap--DeferredCosts_iI_c20231231_zdJ4p8ov21Hk" title="Deferred contract costs">0 </span>deferred contract
costs as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrNWYT5nz4ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zheceqDJFsi8">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_z7kFHq54efw8" style="display: none" title="Property plant and equipment estimated useful lives">3</span>three to <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_z9lXBJdFqlhj" title="Property plant and equipment estimated useful lives">fifteen years</span>. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfnq9MSy6d45" title="Property plant and equipment estimated useful lives">3</span> years. Medical equipment costs
are capitalized and depreciated over <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZ4jRpsDJgA6" title="Property plant and equipment estimated useful lives">5</span> years, while furniture and fixtures are depreciated over <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjMrGwd0Prad" title="Property plant and equipment estimated useful lives">4</span> years. Office equipment is depreciated
over a period of <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zFxufD0aVXDh" title="Property plant and equipment estimated useful lives">3</span> to <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcK9bTYPatcf" title="Property plant and equipment estimated useful lives">5</span> years, and manufacturing equipment over <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRGoTgdUsUR5" title="Property plant and equipment estimated useful lives">4</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNoLqgQf3lLh" title="Property plant and equipment estimated useful lives">5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zvYszRC8Li8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zEt2msSsRFC2">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records its intangible assets at cost in accordance with ASC 350, <i>Intangibles - Goodwill and Other</i>. Definite lived intangible
assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over
which the cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhNRS1Aqq6jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zFhYORrqYOJc">Impairment
of Long-Lived Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, the Company determined that
there was <span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20240101__20241231_zkUKhwWoBDvg" title="Impairment of long-lived assets"><span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20230101__20231231_zJwaUYA1d6li" title="Impairment of long-lived assets">no</span></span> impairment charge for its long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_WarrantAndOptionValuationPolicyTextBlock', window );">Warrant and Option Valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_846_ecustom--WarrantAndOptionValuationPolicyTextBlock_zI9N9CDazI73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zUd3lVu9E2Sd">Warrant
and Option Valuation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221;
method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry blended with the Company&#8217;s historical
volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining
term consistent with the expected term of the instrument being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4rqRiibYMW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zXmhvArh15nb">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be
provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified
warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction
of amounts previously expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zyorW7NGWskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zwBN5Q5WlHH">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes ASC 740, &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#8220;more likely-than-not&#8221;
that a deferred tax asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zUyYKWUBRBq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zvsoDK4W79Yj">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets and operating lease liabilities in our consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value
of lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement
date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company&#8217;s lease terms
may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for
lease payments is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zmtEdleuNQYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zNfZlr2uXiec">Recently
Issued Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; (&#8220;ASU 2024-03&#8221;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredContractCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred contract costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredContractCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_TaxLawChangePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Law Change [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_TaxLawChangePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_WarrantAndOptionValuationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant and option valuation [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_WarrantAndOptionValuationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">SCHEDULE OF REVENUE RECOGNIZED</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zUp6hfR82OB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s revenue recognized in its unaudited condensed consolidated statements of operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_z0f5J2lLd7qj" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250701__20250930_zmrJbKyBvxUd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zDeGk3t9GU94" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250930_zqyeKJkPHFF6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20240930_z6BY4V2rHPqk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zayVoAdXqGSe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">230,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zSCqOCQLgYXg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,900</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,100</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">57,700</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zuuQYkToU9Ka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">233,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">340,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">357,700</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z7tV6GJV8wQe" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">101,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">401,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zlziMoWXAXQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zOfUfoHaWSgi" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three and Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z0ddViGBv088" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zbwOLXMER4jb" title="Antidilutive shares">5,262,973</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zYLGQoxDHrqk" title="Antidilutive shares"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zGzgyZjSdSIg" title="Antidilutive shares">3,401,608</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOdb46xTIhE6" title="Antidilutive shares"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zMTo0rnFgyg8" title="Antidilutive shares">3,951,384</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z7e261Idjqe2" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2gQOA9BOJdi" title="Antidilutive shares">3,952,504</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zoAdP24LL9se" title="Antidilutive shares"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zxbicpBg5Pw7" title="Antidilutive shares">1,398,158</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBhtwPFuQYH2" title="Antidilutive shares"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjFYUbw8vdZ1" title="Antidilutive shares">1,398,158</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930_zw7VAXrfvgbh" title="Antidilutive shares"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zLSC5ZNyZcJk" title="Antidilutive shares">10,612,515</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930_zU0LwLcMz8y8" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zZuTFrCR4u39" title="Antidilutive shares">8,752,270</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1GIc8cffMY8" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total">3,263,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total">1,466,892</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares">3,951,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares">4,791,019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1741">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">8,613,259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zIgMfJkz32R9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_z1vUJk1Sfkua" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20250930_zjbaifrt9Od1" style="font-weight: bold; text-align: center">September 30 ,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zzBgOOifDuWf" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALAOLzJ5Y_zQfcVLxZ3IUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">538,875</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">704,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_z5TEQmTk5Bmb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">68,595</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,485</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtALAOLzJ5Y_zKbjZiqer5me" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">607,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">744,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7ve0gvNg4Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z3T5qunqNukl" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zEWk23Yc0nC" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zeM88DjmnpU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALAOLzJ5Y_zfKjliCICsKd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accrued bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">704,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">638,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zWjZXZQ1wT92" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,485</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73,686</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtALAOLzJ5Y_zh0kRlaqDaTb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">744,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">711,686</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zo19fZvsrdp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s warrant activity and related information follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zZ3PlS8QnNqe" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zULU5j9OkiMg" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning balance">3,951,634</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDQmWH9JHqqe" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">5.22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znMqdO0blV22" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired">(250</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJvBG1DUXmO2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">60.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy0i7C8bnsd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending balance">3,951,384</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKtxZKhWUYia" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">5.21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJq4qX3eMsTb" title="Weighted Average Remaining Life In Years, Outstanding">2.55</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRx5Q2Zfx1zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable">3,951,384</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIJFLzpYIhEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">5.21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7joyKclZvt3" title="Weighted Average Remaining Life In Years, Exercisable">2.55</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zSZin8yUZKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the warrant activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zGJJPKtZyAE5" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znAqvvT4Qbx9" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding Beginning">4,791,019</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z87TDq6moIv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price,  Outstanding beginning balance">10.57</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdjrTKuhx9z6" style="text-align: right" title="Number of Warrants, Granted">2,513,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjdzOfyxLbwc" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzgG1cCZ4vr1" style="text-align: right" title="Number of Warrants, Exercised">(3,351,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zki4H944FIMe" style="text-align: right" title="Weighted Average Exercise Price, Exercised">2.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOsoduSVUaRk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired">(1,491</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrBkx7PzwuQk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">1,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfvfXo0Eesnl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding Ending">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsOAZv5WGZd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding ending balance">5.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZ3LPAMieATi" title="Weighted Average Remaining Life In Years, Outstanding">3.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSXFmGrNy028" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable Ending">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlHDUWyygGWc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">5.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4jobdqNbrP3" title="Weighted Average Remaining Life In Years, Exercisable">3.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znYuBL1ziLZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_z1wWVGt9vlj2" style="display: none">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z37XMit7f4ka" title="Risk free interest rate">4.03</span> - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxfdSV77vPHc" title="Risk free interest rate">4.40</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zz2zKecFH9Ic" title="Risk free interest rate">4.14</span> - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zy4srh72s6Ag" title="Risk free interest rate">4.30</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zw2WookFhCm4" title="Expected term (years)">2.77</span> - <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziuM2v5u7cOj" title="Expected term (years)">5.38</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjyJG6PA6aS9" title="Expected term (years)">2.77</span> - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zQR6mDHTPdJi" title="Expected term (years)">5.38</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zoRgnEW4J5qk" title="Expected volatility">98.14</span> - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zgMcQ5QsoGw9" title="Expected volatility">99.22</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_ze1M3w366Qp5" title="Expected volatility">101</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziXN0JVmgKc5" title="Expected volatility">102</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Expected dividends</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHhTEVNeZJ58" style="width: 18%; text-align: center">0.00%</td><td style="width: 1%; text-align: left"></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaogLqcGvEN" style="width: 18%; text-align: center" title="Expected dividends">0.00%</td><td style="width: 1%; text-align: left"></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzhvGPbrfrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zZxbFDb2dxqf" style="display: none">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zGOcrqNV9u6b" title="Risk free interest rate">4.14</span> -<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zlS2vh9EUFd4" title="Risk free interest rate"> 4.30</span>%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoHTrUNaM9yc" title="Risk free interest rate">4.22</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z1KylLmbD0Dj" title="Expected term (years)">2.77</span> - <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zar0bL5bcuah" title="Expected term (years)">5.38</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx5RjK2kIGab" title="Expected term (years)">3.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zWWPgchvXA8e" title="Expected volatility">101</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_znbbAp1dPtUe" title="Expected volatility">102</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEkATAdzvs76" title="Expected volatility">175.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zauNMGbqKima" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0OQS4xjFub7" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWv2M3qYRMph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity during the nine months ended <span style="background-color: white">September 30, 2025 </span>is
presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zlBKQWNVMBRg" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding, January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhd1fbMc1OAf" style="width: 12%; text-align: right" title="Number of Options, Outstanding Beginning">3,263,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyqcbmh3G9A4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning">2.63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYJikieUBiU1" style="text-align: right" title="Number of Options, Granted">2,177,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Utpi7z1E8a" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #0D0D0D">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcjxWNpZEXC2" style="text-align: right" title="Number of Options, Exercised">(29,249</td><td style="text-align: left">)</td><td style="color: #0D0D0D">&#160;</td>
    <td style="color: #0D0D0D; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4LZRf2tNRW8" style="color: #0D0D0D; text-align: right" title="Weighted Average Exercise Price, Exercised">1.45</td><td style="color: #0D0D0D; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbFGtbkRLn" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(149,153</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY5MaYv8AMn1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">2.23</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMyvapoNh9d" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding Ending">5,262,973</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNC1OSsrXyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending">2.58</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlT9rvVz6pDg" title="Weighted Average Remaining Life in Years, Outstanding">7.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4ggKcamAFA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxCRQYm4YeMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable">3,805,964</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1EzeOBaB595" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable">2.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCLZZ4ZLn9q8" title="Weighted Average Remaining Life in Years, Exercisable">7.3</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zy6EeZ7DMJXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfNfCP9eNvD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the option activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zrN9b2GV9bbk" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTvM4oSXln82" style="width: 12%; text-align: right" title="Number of Options, Outstanding beginning">1,466,892</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zoDROm8SpfK" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning">4.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z1Abs0lPnAC2" style="text-align: right" title="Number of Options, Granted">1,934,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zf56QyHtDan2" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zBqFaBP2hRrg" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2097">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zQdf2naQfNwc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(138,141</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zPDXmZhZIG01" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.76</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zcyRTNE1DYVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding ending">3,263,467</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z6AUvmyFe4hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending">2.63</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zTVIyvLVQU9e" title="Weighted Average Remaining Life in Years Outstanding Ending">7.5</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_z0jhmSrRb99" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl2109">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z6OaUmtzPBzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable Ending">2,499,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zLxmZKqE199h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending">2.95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zv88ELOpOHR9" title="Weighted Average Remaining Life in Years Exercisable Ending">7.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231_z0nAmGqFN17c" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl2117">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">SCHEDULE OF STOCK OPTION EXPENSE</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zSDcZLOPTYXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B2_zKoGZ1kN5cRa" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250701__20250930_zdcPCx4xRGV3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240701__20240930_zLNJc59cbcLh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250930_zsq10U8gkd72" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20240930_zLqIBApcfsX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrecognized at</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average Remaining Amortization</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"> Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJ3sW3wPgOJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">175,398</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">133,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,308,322</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,314,298</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYpkGCwTTDmi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">224,535</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">150,912</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,569,444</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,322,643</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_ztRikAHkmre9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">399,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,877,766</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,636,941</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20250930_zQSnElFKLth" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense">1,878,612</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930_zyXAPbw3kbTa" title="Weighted average remaining amortization period (years)">1.76</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zgACj4pdDPxa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">399,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,877,766</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,636,941</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20250930_z5a460ZK7FN7" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense">1,878,612</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930_zjo2gjtyVdXi" title="Weighted average remaining amortization period (years)">1.76</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zKMX8JsmytWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNmDZQdJkQIj" style="display: none">SCHEDULE OF STOCK OPTION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unrecognized at December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Weighted Average Remaining
    Amortization Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8mg1PWdtnvh" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense">2,812,566</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0lPbAx67Oo4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense">7,782,967</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAfZqmoXHmha" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Unrecognized expense">774,470</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbb2sY1Dla3" title="Weighted average remaining amortization period (years)">0.95</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231_zbrAVj7QZ22e" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense">2,812,566</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231_zf5gaaCKHH4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense">7,782,967</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231_zZzUIJJBw2k1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense">774,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zOzUVTj3znM8" title="Weighted average remaining amortization period (years)">0.95</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock', window );">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock_zsBI1ipxGnoh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents stock-based compensation by award type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span id="xdx_8B9_zvDA3KujAUgd" style="display: none">SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250701__20250930_z6ZTqHehz6Vi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240701__20240930_zn2OOoEhzk98" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20250930_zFXjSdEXksPb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_zTjmJ2NseNQ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV3WJPGewlZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">399,932</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">284,245</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,877,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,651,903</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zd3IddrYGPx2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">RSUs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">985,038</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_z91a9z3GNKxg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">399,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,877,766</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,636,941</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock', window );">SCHEDULE OF STOCK WARRANTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zpOFtra6fg6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock warrants at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zJhgTLHPR6Ie" style="display: none">SCHEDULE
OF STOCK WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBIP5ZD4QC56" style="width: 22%; text-align: right" title="Warrants outstanding, exercise price">2.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl2Jku2lXkle" style="width: 22%; text-align: right" title="Warrants outstanding, number of warrants">2,513,686</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zU6Nhvq6d4e2" title="Warrants exercisable, weighted average remaining life in years">4.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zC60jbXs1afd" style="width: 21%; text-align: right" title="Warrants exercisable, exercisable number of warrants">2,513,686</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z17wx76SisWa" style="text-align: right" title="Warrants outstanding, exercise price">2.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUseg3QpPL84" style="text-align: right" title="Warrants outstanding, number of warrants">51,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyTCTVYqM8Mh" title="Warrants exercisable, weighted average remaining life in years">2.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zwoRloxfJKD9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">51,370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuBvZFdF9pE2" style="text-align: right" title="Warrants outstanding, exercise price">10.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWunI15vUYcb" style="text-align: right" title="Warrants outstanding, number of warrants">1,150,358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOE3aHbPJii4" title="Warrants exercisable, weighted average remaining life in years">1.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCyYxBCsyVJe" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">1,150,358</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zroKiGu0kyKh" style="text-align: right" title="Warrants outstanding, exercise price">12.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvBqal267Qf4" style="text-align: right" title="Warrants outstanding, number of warrants">235,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zsRzI4SStm05" title="Warrants exercisable, weighted average remaining life in years">1.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zjlWnxsI3Tue" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">235,970</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcUo7cIEyFd6" style="padding-bottom: 1pt; text-align: right" title="Warrants outstanding, exercise price">60.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4H9FGqoOWtj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, number of warrants">250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlijR7PFbo2l" title="Warrants exercisable, weighted average remaining life in years">0.0</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJksqF3ibGo6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants">250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zMTGD0WHNxH" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, number of warrants">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zfJ2T3TGfPA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, exercisable number of warrants">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRtaMfXkznRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock options at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_ztcIUlTEysz5" style="display: none">SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeGpMtvcx146" style="width: 22%; text-align: right" title="Options Outstanding, Exercise Price">1.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFR9VoHQVghd" style="width: 22%; text-align: right" title="Options Outstanding, Outstanding Number of Options">1,825,067</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBesCUmhfgB8" title="Options Exercisable Weighted Average Remaining Life In Years">8.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOElztZCIEXk" style="width: 21%; text-align: right" title="Options Exercisable, Exercisable Number of Options">1,138,579</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zlN1nxbD5Qm7" style="text-align: right" title="Options Outstanding, Exercise Price">2.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z5su5TfUL9I1" style="text-align: right" title="Options Outstanding, Outstanding Number of Options">626,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmxifRgIyVvh" title="Options Exercisable Weighted Average Remaining Life In Years">6.7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrvHndT1tcGc" style="text-align: right" title="Options Exercisable, Exercisable Number of Options">548,368</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGAMtsYhR5eh" style="padding-bottom: 1pt; text-align: right" title="Options Outstanding, Exercise Price">5.08</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoR8Y98253Y8" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Outstanding Number of Options">812,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1xz1zj7zjja" title="Options Exercisable Weighted Average Remaining Life In Years">5.9</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIZKhcRWSsw5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Exercisable Number of Options">812,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231_zbocWCIXa5Vc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Outstanding Number of Options">3,263,467</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_ziXBWM6T6LZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Exercisable Number of Options">2,499,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zbjCRCDfsw47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the unvested RSUs as of December 31, 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z7qX6TjqzmYg" style="display: none">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Non-vested at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z54caD9t4qNf" style="width: 22%; text-align: right" title="Number of shares outstanding beginning">97,827</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7rNzZRrwG7c" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl2181">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6DHLnyY2Zc" style="text-align: right" title="Number of shares forfeited">(97,827</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVJwCiRoFDV8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2185">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z984AZuQj4Zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending"><span style="-sec-ix-hidden: xdx2ixbrl2187">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by award type.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation warrant outstanding and exercisable by exercise price range [Table text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zYbR150SpqHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zcgeC8MqrZ5" style="display: none">SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zxEA6d76kmYb" title="Risk free interest rate, minimum">3.63</span>%-<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2LyC3yTSKN2" title="Risk free interest rate, maximum">3.68</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zEjOyYzWXZL1" title="Expected term (years)">1.11</span> - <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zs74j345MWhg" title="Expected term (years)">3.36</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zChsDNjScRgl" title="Risk free interest rate, minimum">71</span>% - <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zNNZYtdpL4bk" title="Risk free interest rate, maximum">95</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Expected dividends</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: center"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znlFqfExj7h4" title="Fair value measurement input">0.00</span>%</td><td style="width: 1%; text-align: left"></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-ZMNRFLS_zGWiyj8eGB08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zy4Lx3EQdX9j" style="display: none">SCHEDULE
OF FAIR VALUE VALUATION ASSUMPTIONS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_z3vjeUokVdy1" title="Risk free interest rate, minimum">4.20</span> - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zsQwgnRfo9ne" title="Risk free interest rate, maximum">4.28</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zqcGcNRJo4Xb" title="Expected term (years)">2.75</span> - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zMr7mo2LgO82" title="Expected term (years)">2.76</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zT7MOzpWsO63" title="Expected volatility">102</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zByUcEfDP6Vl" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><table cellpadding="0" cellspacing="0" id="xdx_300_zBSJWV5SGvha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zD3oN4V56Q5b" title="Risk free interest rate">4.12</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8SRKjJEIcZ3" title="Expected term (years)">5.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0OvHJjsBvog" title="Expected volatility">101</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmGV2nd8un74" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

&#160;<table cellpadding="0" cellspacing="0" id="xdx_307_zKLVcIhIzVE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv7eKFqVeiu7" title="Risk free interest rate, Minimum">4.12%</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBHAeic1Mmv" title="Risk free interest rate, Maximum">4.34</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvyycNHmduL7" title="Risk free interest rate, Minimum">4.04</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zA8LVCxdYpp9" title="Expected term (years)">1.86</span> - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMhtVWrrmuYj" title="Expected term (years)">4.11</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z570pw5hpvj8" title="Expected term (years)">2.86</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCRrHeM4Aqyi" title="Expected volatility">97</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zQRlaizdtMj2" title="Expected volatility">110</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmLHGhk0izj8" title="Expected volatility">87.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1AoHDe9wf58" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4BAeX5Y6SXd" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z0molxKWjZA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span id="xdx_8B7_z9xuaMvT1xX2" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the three months ended September 30, 2025 and three months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250701__20250930_zeCR0vBVgfgi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240701__20240930_zYoNyQCUs5b5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilitiesCurrent_iS_zxmARxdlRPSa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance, July 1,</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,580,379</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,491,969</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfWarrants_zmQMZLHyGDHg" style="display: none; vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Issuance of warrants</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ProceedsFromWarrantExercises_zdS9hwqjGvhf" style="display: none; vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Exercise of warrants</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">&#160;</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zqccaL1gKsq8" style="vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">(612,064</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">)</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">(1,036,464</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DerivativeLiabilitiesCurrent_iE_zPCfqZ6CcHFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, September 30,</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,968,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,455,505</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the nine months ended September 30, 2025 and nine months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20250930_zyDniDIA96xf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20240930_z1eIEDR8hka7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DerivativesLiabilities_iS_zDuXqE4pQ9I1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance, January 1,</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,520,851</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,618,039</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zOrza3ZtG34b" style="vertical-align: bottom; background-color: White">
    <td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">(552,536</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">)</td><td style="color: #0D0D0D; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right">837,466</td><td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DerivativesLiabilities_iE_zf8kCHzACY72" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, September 30,</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,968,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,455,505</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMC0qycoxwah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zKAQQdINnHu1" style="display: none">SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance, January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_c20230101__20231231_zq0KZ6eETEId" style="width: 16%; text-align: right" title="Balance, January 1, 2023">5,541,733</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20230101__20231231_zzNM3R7N5ZQa" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(3,997,780</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_c20240101__20241231_z9mQLh7c0ln7" style="text-align: right" title="Balance, January 1, 2024">1,543,953</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231_zKGDn9WG9Bhf" title="Issuance of warrants">2,189,420</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_iN_di_c20240101__20241231_zF9LX4FrXUh9" title="Exercise of warrants">(1,115,334</span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20240101__20241231_zpDBZORmgt8b" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(97,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iE_c20240101__20241231_zNGCeauSjfRl" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, december 30, 2024">2,520,851</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE RECURRING BASIS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zJgEq6fVipC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities measured at fair value on a recurring basis are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BE_z9AJ9ruwatC" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%">Marketable securities as of September 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx0XRgOrIwVj" style="width: 12%; text-align: right" title="Marketable securities, fair value">3,887,383</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXy6QSa4CiKj" style="width: 12%; text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAfGqdOs7p1c" style="width: 12%; text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250930_zDJYVBVmVbjk" style="width: 12%; text-align: right" title="Marketable securities, fair value">3,887,383</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsnvRgnScII4" style="text-align: right" title="Marketable securities, fair value">10,184,701</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXWj3LcyLswf" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIV6QKf55UAg" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1118">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20241231_z2kNUxQuWnph" style="text-align: right" title="Marketable securities, fair value">10,184,701</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant liabilities as of September 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zlbrjHmcywRe" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNRVZ9KTxIxe" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdIugE6kW3E7" style="text-align: right" title="Warrant liabilities, fair value">1,968,315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930_zRmBTjm57Jcc" style="text-align: right" title="Warrant liabilities, fair value">1,968,315</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrant liabilities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXF2LovcwaF1" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl1rAwhJDX96" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1132">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDK5hyhn8tm4" style="text-align: right" title="Warrant liabilities, fair value">2,520,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231_zPIjIUPYLfFk" style="text-align: right" title="Warrant liabilities, fair value">2,520,851</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6tGfwS6kgK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z5r5D5GaLK3d" style="display: none"><span>SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%">Marketable securities as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4WzJJjC4wS1" style="width: 12%; text-align: right" title="Marketable securities, fair value">10,184,701</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxeusrZDKjP6" style="width: 12%; text-align: right" title="Marketable securities, fair value">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2459">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2rpFzeBYrv1" style="width: 12%; text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2461">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_c20241231_zmKh1dwd0rfe" style="width: 12%; text-align: right" title="Marketable securities">10,184,701</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zC3pfJMA2Vod" style="text-align: right" title="Marketable securities, fair value">10,181,618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFxBE74S8NCj" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2467">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUaeaX3Cxbrj" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2469">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zkPmSxUWuL6e" style="text-align: right" title="Marketable securities">10,181,618</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant liabilities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaDiGqMl6dni" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2473">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZUD9addK6D7" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2475">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlzurmG7ynm" style="text-align: right" title="Warrant liabilities, fair value">2,520,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_ziSFoXIxNsge" style="text-align: right" title="Warrant liabilities">2,520,851</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrant liabilities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRXvDdOz7IR8" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2481">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWQ1XwDflpwh" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl2483">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzV5BGldJR4" style="text-align: right" title="Warrant liabilities, fair value">1,543,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231_zyQUQAE5wWT5" style="text-align: right" title="Warrant liabilities">1,543,953</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2ZdwaDNWsb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zRiW19Duyqmj" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zcvb0j2Mshvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zCrUODQYb0Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zLOXDxjVNdhb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,133</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,133</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zHKi6c2fM66c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,486</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zTPXuLfpmrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdSPeVh24a7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,779</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zHLEEhyimZOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manufacturing equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">501,421</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395,232</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb0uKt79Uwyg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">342,048</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">342,048</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzKiZ_z4su14VN8qy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    plant and equipment gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,474,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,367,883</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKiZ_zeJSxm1HRBa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,111,136</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,011,828</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKiZ_zPMObeOSxMXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">362,936</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdsSzvPsMxw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zovX5FmRjKn8" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zMa8DpLEhmyh" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgkIpLlGFbo2" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance">1,593,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zqY3dA0k41Sl" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance">(793,768</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20230101__20231231_z6h1cAws7Od" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance">803,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zDUNrjLtHqbj" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,746</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231_zRrGfdmJ09Eb" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,746</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zTRGfffLeNbf" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBVozX7VDJlj" style="text-align: right" title="Beginning Balance">1,593,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXRYXWxN8sRe" style="text-align: right" title="Beginning Balance">(883,514</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20240101__20241231_zqwLjk2xJY0j" style="text-align: right" title="Beginning Balance">713,692</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zytthitOTw2k" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,747</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231_zAM5NMN8yS06" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,747</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zQuRKUBmR8mh" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zoYjoWDb33X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">1,593,530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztG665tY4AIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance">(973,261</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_pp0p0_c20240101__20241231_zjzg3CCnlNxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, Ending Balance">623,945</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period at December 31, 2024 (in years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zFTAQg0U6qf8" title="Finite Lived Intangible Assets, weighted average amortization period">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zWn6aGIbVlz8" title="Finite Lived Intangible Assets, weighted average amortization period">10.3</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES</a></td>
<td class="text"><p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zyr8t0Ym6OWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zIE3bG4EPzp9" style="display: none">SCHEDULE OF FINITE LIVED
INTANGIBLE ASSETS AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zAQRVTNxCnRa" style="width: 14%; text-align: right" title="Beginning Balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zTV1EfXZQxkj" style="width: 14%; text-align: right" title="Beginning Balance">790,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuMtebEZOmgf" style="width: 14%; text-align: right" title="Beginning Balance">793,768</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zY8aapJwfbif" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl1846">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgEjKj6jTWI5" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2rXVJBGP7il" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zgRAH3stiYi7" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDe9KaWcOYI7" style="text-align: right" title="Beginning Balance">879,838</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXVvp6oFTRTa" style="text-align: right" title="Beginning Balance">883,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zuHhehAQNkik" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl1858">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6qgnUqvdCNe" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zygSxwRoDT8e" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zpDaKpFlcUXl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_ziQYvOYoF2Vh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">969,585</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z21atXqH7Mrd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">973,261</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zO5E84hy3qC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the next five years is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zDxhPMghSJb7" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">For the Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zLqGmLhSvkA" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz89Q_z1vNDKxW98G5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">89,746</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz89Q_za7zLx3utHS9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz89Q_z9FWK80aZ1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz89Q_zCZfaJK7po9f" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz89Q_zlr2Quf6AHf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz89Q_zivgdmaXPRBi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">448,730</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOmgaPOBaQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zZUwWPmupGV3" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zL9QFC7L3Yig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zhbF1s19zvl7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zEjIVolmYEU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzcBK_zW8G8vTtyQJk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">18,004,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,311,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGzcBK_zFIFQbADeNHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,695,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,788,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTAGzcBK_zdxqp5f1BD88" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,694,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,676,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGzcBK_zOXQBzh1v0Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsRightOfUseAsset_i01I_maDTAGzcBK_zZJt7OwUWjwa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2240">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcBK_zwScf9aTi8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">600</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGzcBK_maDTALNz6jW_zRxljnsv5rrj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">29,724,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">32,134,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zlws6xNcz8z3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred Tax Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxLiabilitiesDepreciation_i01NI_pp0p0_di_maDITLz8iB_zvhfLWJlS6a1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(153,200</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_maDITLz8iB_zMvdEk1EX2Mf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41,700</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_i01NI_pp0p0_di_maDITLz8iB_z5JN7o7R2Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2258">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLz8iB_z626f9pOcRZd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(95,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(86,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pp0p0_di_mtDITLz8iB_msDTALNz6jW_z5ov3kRZfdYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(289,900</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(294,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNz6jW_zDuuMmzJjzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Deferred Tax Asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,434,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,840,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8Hs2v6wALU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,434,100</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(31,840,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_z8GkK0NwV2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred Tax Asset, Net of Valuation Allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2273">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2274">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Change in valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20240101__20241231_zmS2WbGfj5n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">2,405,900</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20230101__20231231_zc9ckzJO7A9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">(4,064,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF INCOME TAX PROVISION (BENEFIT)</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zltwcQOflIb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision (benefit) as of December 31, 2024 and 2023 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zewWuR64PcD5" style="display: none">SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zRwhUVQspGih" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zxkSMrPCvzR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlI2aJg7XIZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maDFSALzNuk_zO5ShPfW6jN4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2286">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zk51qR840bie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%">Deferred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,567,000</td><td style="width: 1%; text-align: left"></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(3,090,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zTDgkAmF6Uzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State &amp; Local:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maDFSALzNuk_z2FcUaberu53" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2294">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2295">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zRDQK8KB7bX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Deferred</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,161,100</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(974,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBz5Bf_mtDFSALzNuk_zPjhdL5jZTtd" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,405,900</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,064,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ChangeInValuationAllowance_i01N_di_msITEBz5Bf_zhzlgQSBeSpj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,405,900</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,064,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz5Bf_zTflNXI3Iww2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2306">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2307">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbnotrZxBuda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zkPZz0PDfa4f" style="display: none">SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zIN1SWuTCKCd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zYoEk77mdqyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR_zoD8GqfTv0Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR_zBasGeNwUdq5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR_ztCkHqhYvo49" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_maETR_zeaqqe9LYYr1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax return to provision adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.2</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR_zu0T4TNCIfFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in federal valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">39.7</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-29.7</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_pid_dp_uPure_maETR_z06HeVNrY5Z7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Adjustment for stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">-62.1</p></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2327">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR_z9fAJvH2U32l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zfhOXOmxfDS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8BA_zYd7fINKNxyl" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zAim7KPlS8Vd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_zJY5zkeqo6Qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease Costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzEnl_zdxX3SOKOhwd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">173,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">168,028</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zNJI74DdZmgh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">173,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">168,028</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zaVUvxrI8Xgk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease - operating cash flows (fixed payments)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">173,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">168,028</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OperatingLeaseLiabilityReduction_zlA1fMwWsVF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease - operating cash flows (liability reduction)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">162,317</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">139,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current leases - right of use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20241231_zlGR7yPRwte5" style="text-align: right" title="Non-current leases - right of use assets"><span style="-sec-ix-hidden: xdx2ixbrl2362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_z3Cs3WdUJgzk" style="text-align: right" title="Non-current leases - right of use assets">151,447</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20241231_zait734oCTT3" style="text-align: right" title="Current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_z5SMTMDgFzqf" style="text-align: right" title="Current liabilities - operating lease liabilities">162,317</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zXJzCNst9qGg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23OperatingLeaseLiabilityCurrent"><span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zRFYux9HxGJ8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23OperatingLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl2369"><span style="-sec-ix-hidden: xdx2ixbrl2370">Non-current liabilities - operating lease liabilities</span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20241231_zqhxJYXaknKk" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2372">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_zSdrEeHsTO37" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2374">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="9">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 08, 2025</div></th>
<th class="th"><div>Nov. 06, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 27, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,038,277<span></span>
</td>
<td class="nump">$ 2,656,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,339,799<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,091,416<span></span>
</td>
<td class="nump">$ 4,028,562<span></span>
</td>
<td class="nump">$ 2,223,255<span></span>
</td>
<td class="nump">$ 11,034,339<span></span>
</td>
<td class="nump">$ 7,343,233<span></span>
</td>
<td class="nump">$ 8,979,381<span></span>
</td>
<td class="nump">$ 10,417,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,373,790<span></span>
</td>
<td class="nump">$ 5,882,501<span></span>
</td>
<td class="nump">8,230,346<span></span>
</td>
<td class="nump">6,430,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,614,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">888,138<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">901,610<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,951,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ProceedsFromWarrantExercisesNet', window );">Proceeds from warrant exercises, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sold shares of common stock</a></td>
<td class="nump">678,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sold shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,337<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">492,087<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | A T M Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sold shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sold shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,829,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase</a></td>
<td class="nump">508,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member] | A T M Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sold shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=BRTX_TwoThousandTwentyFourATMProgramMember', window );">Two Thousand Twenty Four A T M Program [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sold shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,011,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="19"></td></tr>
<tr><td colspan="19"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the
gross proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zKw9V4fZzg5l" title="Gross proceeds">927,335</span>, less issuance costs of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxsQLuhgdqDh" title="Issuance costs">39,197</span>, resulting in net proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxHhFmIh8c7k" title="Net proceeds">888,138</span>. See Note 4 - Stockholders&#8217; Equity
- ATM Sales for additional details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the
gross proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zPkGpeUXA026" title="Gross proceeds">1,083,915</span>, less issuance costs of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_z11HcIisOgnd" title="Issuance costs">182,305</span>, resulting in net proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zlB0kglfAiyl" title="Net proceeds">901,610</span>. See Note 4 - Stockholders&#8217;
Equity - ATM Sales for additional details.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ProceedsFromWarrantExercisesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrant exercises net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ProceedsFromWarrantExercisesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=BRTX_TwoThousandTwentyFourATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=BRTX_TwoThousandTwentyFourATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF REVENUE RECOGNIZED (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="nump">$ 233,600<span></span>
</td>
<td class="nump">$ 340,100<span></span>
</td>
<td class="nump">$ 357,700<span></span>
</td>
<td class="nump">$ 401,000<span></span>
</td>
<td class="nump">$ 145,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">230,700<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 40,100<span></span>
</td>
<td class="nump">$ 57,700<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="nump">$ 145,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">10,612,515<span></span>
</td>
<td class="nump">8,752,270<span></span>
</td>
<td class="nump">10,612,515<span></span>
</td>
<td class="nump">8,752,270<span></span>
</td>
<td class="nump">8,613,259<span></span>
</td>
<td class="nump">7,753,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">5,262,973<span></span>
</td>
<td class="nump">3,401,608<span></span>
</td>
<td class="nump">5,262,973<span></span>
</td>
<td class="nump">3,401,608<span></span>
</td>
<td class="nump">3,263,467<span></span>
</td>
<td class="nump">1,466,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">3,951,384<span></span>
</td>
<td class="nump">3,952,504<span></span>
</td>
<td class="nump">3,951,384<span></span>
</td>
<td class="nump">3,952,504<span></span>
</td>
<td class="nump">3,951,634<span></span>
</td>
<td class="nump">4,791,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">97,827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 20, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC insured limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">FDIC amount</a></td>
<td class="nump">290,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,801<span></span>
</td>
<td class="nump">$ 604,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred contract costs</a></td>
<td class="nump">7,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 69,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,697<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesHeldInAbeyance', window );">Shares held in abeyance | shares</a></td>
<td class="nump">1,138,055<span></span>
</td>
<td class="nump">1,201,580<span></span>
</td>
<td class="nump">1,201,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138,055<span></span>
</td>
<td class="nump">1,351,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reporting segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Dividend and interest income</a></td>
<td class="nump">$ 235,878<span></span>
</td>
<td class="nump">$ 492,476<span></span>
</td>
<td class="nump">$ 623,801<span></span>
</td>
<td class="nump">$ 569,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember', window );">Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesHeldInAbeyance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares held in abeyance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesHeldInAbeyance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">$ 538,875<span></span>
</td>
<td class="nump">$ 704,000<span></span>
</td>
<td class="nump">$ 638,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_AccruedGeneralAndAdministrativeExpenses', window );">Accrued general and administrative expenses</a></td>
<td class="nump">68,595<span></span>
</td>
<td class="nump">40,485<span></span>
</td>
<td class="nump">73,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 607,470<span></span>
</td>
<td class="nump">$ 744,485<span></span>
</td>
<td class="nump">$ 711,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_AccruedGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_AccruedGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding Beginning</a></td>
<td class="nump">3,951,634<span></span>
</td>
<td class="nump">4,791,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding beginning balance</a></td>
<td class="nump">$ 5.22<span></span>
</td>
<td class="nump">$ 10.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Warrants, Expired</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(1,491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">$ 60.00<span></span>
</td>
<td class="nump">$ 1,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding Ending</a></td>
<td class="nump">3,951,384<span></span>
</td>
<td class="nump">3,951,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding ending balance</a></td>
<td class="nump">$ 5.21<span></span>
</td>
<td class="nump">$ 5.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life In Years, Outstanding</a></td>
<td class="text">2 years 6 months 18 days<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Warrants, Exercisable</a></td>
<td class="nump">3,951,384<span></span>
</td>
<td class="nump">3,951,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 5.21<span></span>
</td>
<td class="nump">$ 5.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life In Years, Exercisable</a></td>
<td class="text">2 years 6 months 18 days<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,513,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,351,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Warrants, Exercisable Ending</a></td>
<td class="nump">3,951,384<span></span>
</td>
<td class="nump">3,951,634<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non option equity instrument exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBased compensation arrangements by share based payment award non options exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options granted in period weighted average exercise price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.03%<span></span>
</td>
<td class="nump">4.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">2 years 9 months 7 days<span></span>
</td>
<td class="text">2 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">98.14%<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 4 months 17 days<span></span>
</td>
<td class="text">5 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.22%<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding beginning</a></td>
<td class="nump">3,263,467<span></span>
</td>
<td class="nump">1,466,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning</a></td>
<td class="nump">$ 2.63<span></span>
</td>
<td class="nump">$ 4.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,934,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,263,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life in Years Outstanding Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life in Years Exercisable Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, Outstanding Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding beginning</a></td>
<td class="nump">3,263,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning</a></td>
<td class="nump">$ 2.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">2,177,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(29,249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(149,153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 2.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding ending</a></td>
<td class="nump">5,262,973<span></span>
</td>
<td class="nump">3,263,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending</a></td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="nump">$ 2.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life in Years Outstanding Ending</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding Ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable Ending</a></td>
<td class="nump">3,805,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable Ending</a></td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life in Years Exercisable Ending</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, Outstanding Ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="nump">29,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_EquityLineItem', window );"><strong>EquityLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 399,932<span></span>
</td>
<td class="nump">$ 284,245<span></span>
</td>
<td class="nump">$ 2,877,766<span></span>
</td>
<td class="nump">$ 2,636,941<span></span>
</td>
<td class="nump">$ 2,812,566<span></span>
</td>
<td class="nump">$ 7,782,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense</a></td>
<td class="nump">1,878,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,878,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 774,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining amortization period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_EquityLineItem', window );"><strong>EquityLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">399,932<span></span>
</td>
<td class="nump">284,245<span></span>
</td>
<td class="nump">$ 2,877,766<span></span>
</td>
<td class="nump">1,651,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 774,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_EquityLineItem', window );"><strong>EquityLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">175,398<span></span>
</td>
<td class="nump">133,333<span></span>
</td>
<td class="nump">1,308,322<span></span>
</td>
<td class="nump">1,314,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_EquityLineItem', window );"><strong>EquityLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 224,535<span></span>
</td>
<td class="nump">$ 150,912<span></span>
</td>
<td class="nump">$ 1,569,444<span></span>
</td>
<td class="nump">$ 1,322,643<span></span>
</td>
<td class="nump">$ 2,812,566<span></span>
</td>
<td class="nump">$ 7,782,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining amortization period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_EquityLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_EquityLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 399,932<span></span>
</td>
<td class="nump">$ 284,245<span></span>
</td>
<td class="nump">$ 2,877,766<span></span>
</td>
<td class="nump">$ 2,636,941<span></span>
</td>
<td class="nump">$ 2,812,566<span></span>
</td>
<td class="nump">$ 7,782,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">399,932<span></span>
</td>
<td class="nump">284,245<span></span>
</td>
<td class="nump">2,877,766<span></span>
</td>
<td class="nump">1,651,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 985,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="10">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 27, 2025</div></th>
<th class="th"><div>Oct. 13, 2025</div></th>
<th class="th"><div>Oct. 08, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 16, 2025</div></th>
<th class="th"><div>Jun. 05, 2025</div></th>
<th class="th"><div>Mar. 20, 2025</div></th>
<th class="th"><div>Feb. 14, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 06, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jul. 13, 2023</div></th>
<th class="th"><div>Apr. 04, 2023</div></th>
<th class="th"><div>Oct. 25, 2022</div></th>
<th class="th"><div>Sep. 08, 2022</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 27, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 06, 2025</div></th>
<th class="th"><div>Jul. 23, 2024</div></th>
<th class="th"><div>Jul. 22, 2024</div></th>
<th class="th"><div>Dec. 10, 2021</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,951,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,951,634<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,115,334<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cash issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 72,805<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesHeldInAbeyance', window );">Shares held in abeyance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,201,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138,055<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,201,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,351,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,138,055<span></span>
</td>
<td class="nump">1,201,580<span></span>
</td>
<td class="nump">1,201,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Cash fee for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,934,716<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,614,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 888,138<span></span>
</td>
<td class="nump">$ 901,610<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,348,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,011,250<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 494,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Deferred offering costs reclassified to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">148,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Gross proceeds from exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 42,411<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,853,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,853,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,189,420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainLossOnExchangeOfWarrants', window );">Gain on exchange of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,711,698<span></span>
</td>
<td class="nump">$ 1,711,698<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember', window );">Two Thousand Twenty One Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">Two Thousand And Twenty One Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Common stock authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,850,000<span></span>
</td>
<td class="nump">3,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock voting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Preferred stock conversion term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Beneficial Ownership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock voting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Auctus Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member] | Auctus Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Auctus Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Two Thousand Twenty One Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Two Thousand Twenty One Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">678,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Auctus Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,177,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued upon exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Gross proceeds from exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 42,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,152,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,044,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting of options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vests to the extent of 50% immediately with the remainder
vesting quarterly over two years commencing one year from the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest as follows: (i) options to purchase an aggregate
323,459 shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of 1,829,449 shares of common stock
vest to the extent of 50% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Employee [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting of options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vests as follows: (i) 50% immediately, and (ii) the remainder quarterly over two years commencing
one year from the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=BRTX_BoardOfDirectorMember', window );">Board Of Director [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cash issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">473,337<span></span>
</td>
<td class="nump">492,087<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">817,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,213,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 47<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockIssuedDuringPeriodSharesAbeyanceShares', window );">Abeyance shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">63,525<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued upon exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Demand Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | A T M Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">132,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 494,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,829,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">323,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member] | A T M Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Roth Capital Partners L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Cash fee for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 528,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,513,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrants for cash and the payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Two Thousand Twenty Four A T M Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">965,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,011,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_PaymentsForCommissionsLegalAndAccountingFees', window );">Commissions, legal and accounting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">72,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,938,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Auctus Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesHeldInAbeyance', window );">Shares held in abeyance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,201,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,201,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,201,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockIssuedDuringPeriodSharesAbeyanceShares', window );">Abeyance shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,968,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Roth Capital Partners L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,364<span></span>
</td>
<td class="nump">$ 595,364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember', window );">Existing Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,809,181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember', window );">Existing Warrant [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,742,244<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115,334<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,123,392<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=BRTX_NewWarrantsMember', window );">New Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=BRTX_NewWarrantsMember', window );">New Warrants [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595,364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Stock issued during period value warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,189,420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainLossOnExchangeOfWarrants', window );">Gain on exchange of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,711,698<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="40"></td></tr>
<tr><td colspan="40"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the
gross proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zKw9V4fZzg5l" title="Gross proceeds">927,335</span>, less issuance costs of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxsQLuhgdqDh" title="Issuance costs">39,197</span>, resulting in net proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxHhFmIh8c7k" title="Net proceeds">888,138</span>. See Note 4 - Stockholders&#8217; Equity
- ATM Sales for additional details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the
gross proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zPkGpeUXA026" title="Gross proceeds">1,083,915</span>, less issuance costs of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_z11HcIisOgnd" title="Issuance costs">182,305</span>, resulting in net proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zlB0kglfAiyl" title="Net proceeds">901,610</span>. See Note 4 - Stockholders&#8217;
Equity - ATM Sales for additional details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Represents the
aggregate fair value of <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHaF4Odvuz81" title="Aggregate fair value of common stock">3,351,580</span> shares of common stock, which includes <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI9x89Qv0BMb" title="Shares issued">2,000,000</span> shares that were issued at the time of the warrant
exchange and <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_ecustom--SharesHeldInAbeyance_iI_pid_c20240331_z1PxY0VQzHHb" title="Shares held in abeyance">1,351,580</span> shares that were held in abeyance at the time of the warrant exchange. See Note 4 - Stockholders&#8217; Equity
- Warrant Exercise and Issuance and Note 5 - Fair Value Measurement for additional details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Represents the
aggregate fair value of <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpPD4xdmm3mj" title="Aggregate fair value of common stock">3,351,580</span> shares of common stock, which includes <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5nhgzoqroak" title="Warrants exercisable">2,150,000</span> shares that have been issued and <span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zQNmiOi5AQNa" title="Shares held in abeyance">1,201,580</span> shares
held in abeyance. See Note 6 - Stockholders&#8217; Equity - Warrant Exercise and Issuance and Note 9 - Fair Value Measurement for additional
details.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GainLossOnExchangeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GainLossOnExchangeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_PaymentsForCommissionsLegalAndAccountingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for commissions legal and accounting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_PaymentsForCommissionsLegalAndAccountingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesHeldInAbeyance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares held in abeyance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesHeldInAbeyance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockIssuedDuringPeriodSharesAbeyanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares abeyance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockIssuedDuringPeriodSharesAbeyanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BRTX_BeneficialOwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BRTX_BeneficialOwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=BRTX_AuctusFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=BRTX_AuctusFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_BoardOfDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_BoardOfDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=BRTX_DemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=BRTX_DemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_RothCapitalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_RothCapitalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=BRTX_TwoThousandTwentyFourATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=BRTX_TwoThousandTwentyFourATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BRTX_AuctusFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BRTX_AuctusFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=BRTX_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=BRTX_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 08, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 612,064<span></span>
</td>
<td class="nump">$ 1,036,464<span></span>
</td>
<td class="nump">$ 552,536<span></span>
</td>
<td class="num">$ (837,466)<span></span>
</td>
<td class="nump">$ 97,188<span></span>
</td>
<td class="nump">$ 3,997,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="nump">$ 2,189,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,851<span></span>
</td>
<td class="nump">1,543,953<span></span>
</td>
<td class="nump">$ 5,541,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=BRTX_BlackScholesOptionMember', window );">Black Scholes Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,014<span></span>
</td>
<td class="nump">4,737,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Fair value of derivative liabilitiy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="nump">$ 1,543,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of adjustment</a></td>
<td class="nump">$ 1,968,315<span></span>
</td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember', window );">Existing Warrant [Member] | Black Scholes Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,115,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_InvestmentsAllOtherInvestmentsLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_InvestmentsAllOtherInvestmentsLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=BRTX_BlackScholesOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=BRTX_BlackScholesOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 08, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.12%<span></span>
</td>
<td class="nump">4.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Existing Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="nump">4.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Existing Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Existing Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Existing Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Existing Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_InvestmentsAllOtherInvestmentsLineItem', window );"><strong>InvestmentsAllOtherInvestmentsLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_InvestmentsAllOtherInvestmentsLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_InvestmentsAllOtherInvestmentsLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Balance, July 1,</a></td>
<td class="nump">$ 2,580,379<span></span>
</td>
<td class="nump">$ 4,491,969<span></span>
</td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="nump">$ 1,543,953<span></span>
</td>
<td class="nump">$ 1,543,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,189,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(612,064)<span></span>
</td>
<td class="num">(1,036,464)<span></span>
</td>
<td class="num">(552,536)<span></span>
</td>
<td class="nump">837,466<span></span>
</td>
<td class="num">(97,188)<span></span>
</td>
<td class="num">$ (3,997,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Balance, September 30,</a></td>
<td class="nump">1,968,315<span></span>
</td>
<td class="nump">3,455,505<span></span>
</td>
<td class="nump">1,968,315<span></span>
</td>
<td class="nump">3,455,505<span></span>
</td>
<td class="nump">2,520,851<span></span>
</td>
<td class="nump">1,543,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DerivativesLiabilities', window );">Balance, January 1,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,851<span></span>
</td>
<td class="nump">2,618,039<span></span>
</td>
<td class="nump">2,618,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DerivativesLiabilities', window );">Balance, September 30,</a></td>
<td class="nump">$ 1,968,315<span></span>
</td>
<td class="nump">$ 3,455,505<span></span>
</td>
<td class="nump">1,968,315<span></span>
</td>
<td class="nump">3,455,505<span></span>
</td>
<td class="nump">2,520,851<span></span>
</td>
<td class="nump">2,618,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance, January 1, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="nump">$ 1,543,953<span></span>
</td>
<td class="nump">1,543,953<span></span>
</td>
<td class="nump">5,541,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,115,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance, december 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="nump">$ 1,543,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DerivativesLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivatives Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DerivativesLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="nump">$ 3,887,383<span></span>
</td>
<td class="nump">$ 10,184,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="nump">1,968,315<span></span>
</td>
<td class="nump">2,520,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="nump">3,887,383<span></span>
</td>
<td class="nump">10,184,701<span></span>
</td>
<td class="nump">$ 10,181,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="nump">$ 1,968,315<span></span>
</td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="nump">$ 1,543,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 27, 2025</div></th>
<th class="th"><div>Oct. 13, 2025</div></th>
<th class="th"><div>Oct. 08, 2025</div></th>
<th class="th"><div>Oct. 06, 2025</div></th>
<th class="th"><div>Aug. 11, 2025</div></th>
<th class="th"><div>Jun. 05, 2025</div></th>
<th class="th"><div>Feb. 14, 2025</div></th>
<th class="th"><div>Nov. 06, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><sup>[2]</sup></th>
<th class="th"><div>Mar. 27, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,614,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 888,138<span></span>
</td>
<td colspan="2" class="nump">$ 901,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,951,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_LegalFeesAndOtherExpenses', window );">Legal fees and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,934,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,011,250<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 494,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,177,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">2,152,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting of options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vests to the extent of 50% immediately with the remainder
vesting quarterly over two years commencing one year from the date of grant.<span></span>
</td>
<td class="text">vest as follows: (i) options to purchase an aggregate
323,459 shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of 1,829,449 shares of common stock
vest to the extent of 50% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">678,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Description on sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In
connection with the offering, the Company entered into an engagement letter, dated August 11, 2025, with Alere Financial Partners (a
division of Cova Capital Partners, LLC) (the &#8220;Placement Agent&#8221;), pursuant to which the Company agreed to pay the Placement
Agent a cash fee equal to 6% of the gross proceeds of the offering from investors introduced to the Company by the Placement Agent (the
&#8220;Placement Agent Investors&#8221;) (4% for other investors).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Auctus Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">63,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting of options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vests as follows: (i) 50% immediately, and (ii) the remainder quarterly over two years commencing
one year from the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">473,337<span></span>
</td>
<td colspan="2" class="nump">492,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 47<span></span>
</td>
<td colspan="2" class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | A T M Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,614,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906,000<span></span>
</td>
<td class="nump">$ 494,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,829,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">323,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Grant options shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">2,152,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Grant options shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,044,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_CommonStockVestRemainderPercentage', window );">Purchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member] | A T M Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Legal settlements paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subscription Agreements [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">678,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="21"></td></tr>
<tr><td colspan="21"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the
gross proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zKw9V4fZzg5l" title="Gross proceeds">927,335</span>, less issuance costs of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxsQLuhgdqDh" title="Issuance costs">39,197</span>, resulting in net proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxHhFmIh8c7k" title="Net proceeds">888,138</span>. See Note 4 - Stockholders&#8217; Equity
- ATM Sales for additional details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the
gross proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zPkGpeUXA026" title="Gross proceeds">1,083,915</span>, less issuance costs of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_z11HcIisOgnd" title="Issuance costs">182,305</span>, resulting in net proceeds of $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zlB0kglfAiyl" title="Net proceeds">901,610</span>. See Note 4 - Stockholders&#8217;
Equity - ATM Sales for additional details.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_CommonStockVestRemainderPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock vest remainder percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_CommonStockVestRemainderPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_LegalFeesAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of legal fees and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_LegalFeesAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=BRTX_AuctusFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=BRTX_AuctusFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=BRTX_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=BRTX_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,474,072<span></span>
</td>
<td class="nump">$ 1,367,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,111,136)<span></span>
</td>
<td class="num">(1,011,828)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 309,498<span></span>
</td>
<td class="nump">362,936<span></span>
</td>
<td class="nump">356,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember', window );">Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,133<span></span>
</td>
<td class="nump">352,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,486<span></span>
</td>
<td class="nump">123,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ComputerSoftwareAndEquipmentMember', window );">Computer Software And Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,205<span></span>
</td>
<td class="nump">136,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,779<span></span>
</td>
<td class="nump">18,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember', window );">Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,421<span></span>
</td>
<td class="nump">395,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342,048<span></span>
</td>
<td class="nump">$ 342,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ComputerSoftwareAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ComputerSoftwareAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 99,309<span></span>
</td>
<td class="nump">$ 75,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning Balance</a></td>
<td class="nump">$ 713,692<span></span>
</td>
<td class="nump">$ 803,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="num">(89,747)<span></span>
</td>
<td class="num">(89,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Finite Lived Intangible Assets, Net, Ending Balance</a></td>
<td class="nump">623,945<span></span>
</td>
<td class="nump">713,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember', window );">Patents And Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Beginning Balance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, Gross, Ending balance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Beginning Balance</a></td>
<td class="nump">1,593,530<span></span>
</td>
<td class="nump">1,593,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="num">(879,838)<span></span>
</td>
<td class="num">(790,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="num">(89,747)<span></span>
</td>
<td class="num">(89,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, Gross, Ending balance</a></td>
<td class="nump">1,593,530<span></span>
</td>
<td class="nump">1,593,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance</a></td>
<td class="num">$ (969,585)<span></span>
</td>
<td class="num">(879,838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite Lived Intangible Assets, weighted average amortization period</a></td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember', window );">Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="num">$ (883,514)<span></span>
</td>
<td class="num">(793,768)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="num">(89,747)<span></span>
</td>
<td class="num">(89,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance</a></td>
<td class="num">$ (973,261)<span></span>
</td>
<td class="num">$ (883,514)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 89,747<span></span>
</td>
<td class="nump">$ 89,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember', window );">Patents And Trademark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">879,838<span></span>
</td>
<td class="nump">790,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">89,747<span></span>
</td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">969,585<span></span>
</td>
<td class="nump">879,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember', window );">Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">883,514<span></span>
</td>
<td class="nump">793,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">89,747<span></span>
</td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">$ 973,261<span></span>
</td>
<td class="nump">$ 883,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 89,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 448,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF STOCK WARRANTS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">3,951,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">3,951,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 2.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">2,513,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">2,513,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 2.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">51,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">51,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">1,150,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">1,150,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">235,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">235,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 60.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">3,263,467<span></span>
</td>
<td class="nump">1,466,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">2,499,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Exercise Price</a></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">1,825,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">1,138,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Exercise Price</a></td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">626,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">548,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Exercise Price</a></td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">812,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable Weighted Average Remaining Life In Years</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">812,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding beginning</a></td>
<td class="nump">97,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares forfeited</a></td>
<td class="num">(97,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding ending</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 399,932<span></span>
</td>
<td class="nump">$ 284,245<span></span>
</td>
<td class="nump">$ 2,877,766<span></span>
</td>
<td class="nump">$ 2,636,941<span></span>
</td>
<td class="nump">$ 2,812,566<span></span>
</td>
<td class="nump">$ 7,782,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense</a></td>
<td class="nump">1,878,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,878,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 774,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining amortization period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">399,932<span></span>
</td>
<td class="nump">284,245<span></span>
</td>
<td class="nump">$ 2,877,766<span></span>
</td>
<td class="nump">1,651,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 774,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 224,535<span></span>
</td>
<td class="nump">$ 150,912<span></span>
</td>
<td class="nump">$ 1,569,444<span></span>
</td>
<td class="nump">$ 1,322,643<span></span>
</td>
<td class="nump">$ 2,812,566<span></span>
</td>
<td class="nump">$ 7,782,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining amortization period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 18,004,100<span></span>
</td>
<td class="nump">$ 14,311,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">8,695,100<span></span>
</td>
<td class="nump">15,788,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">2,694,200<span></span>
</td>
<td class="nump">1,676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">330,000<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredTaxAssetsRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total Deferred Tax Assets</a></td>
<td class="nump">29,724,000<span></span>
</td>
<td class="nump">32,134,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(153,200)<span></span>
</td>
<td class="num">(122,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(41,700)<span></span>
</td>
<td class="num">(47,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(39,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(95,000)<span></span>
</td>
<td class="num">(86,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">(289,900)<span></span>
</td>
<td class="num">(294,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net Deferred Tax Asset</a></td>
<td class="nump">29,434,100<span></span>
</td>
<td class="nump">31,840,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(29,434,100)<span></span>
</td>
<td class="num">(31,840,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Asset, Net of Valuation Allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 2,405,900<span></span>
</td>
<td class="num">$ (4,064,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredTaxAssetsRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredTaxAssetsRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">3,567,000<span></span>
</td>
<td class="num">(3,090,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State &amp; Local:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(1,161,100)<span></span>
</td>
<td class="num">(974,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">2,405,900<span></span>
</td>
<td class="num">(4,064,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ChangeInValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(2,405,900)<span></span>
</td>
<td class="nump">4,064,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of valuation allowance</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent differences</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment', window );">Tax return to provision adjustment</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in federal valuation allowance</a></td>
<td class="nump">39.70%<span></span>
</td>
<td class="num">(29.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation', window );">Adjustment for stock-based compensation</a></td>
<td class="num">(62.10%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax return to provision adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior year income taxes, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carry-forwards not subject to expiration</a></td>
<td class="nump">$ 60,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Net operating loss description</a></td>
<td class="text">The state net operating losses have a 20 year carryforward period and will begin to expire beginning 2035.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember', window );">Expire From Two Thousand Thirty To Two Thousand Thirty Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carry-forwards subject to expiration</a></td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=BRTX_SectionThreeHundredAndEightyTwoMember', window );">Section Three Hundred And Eighty Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination, description</a></td>
<td class="text">In
accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#8217;s net operating loss carryforwards are subject
to annual limitations due to several greater than 50% ownership changes.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 68,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=BRTX_SectionThreeHundredAndEightyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=BRTX_SectionThreeHundredAndEightyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_LeasesLineItems', window );"><strong>LeasesLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_LeasesLineItems', window );"><strong>LeasesLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseOptionToExtend', window );">Lease extension description</a></td>
<td class="text">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $153,748 and $173,060.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_LeasesLineItems', window );"><strong>LeasesLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 153,748<span></span>
</td>
<td class="nump">$ 132,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_LeasesLineItems', window );"><strong>LeasesLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 173,060<span></span>
</td>
<td class="nump">$ 149,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost (cost resulting from lease payments)</a></td>
<td class="nump">$ 173,060<span></span>
</td>
<td class="nump">$ 168,028<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease costs</a></td>
<td class="nump">173,060<span></span>
</td>
<td class="nump">168,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease - operating cash flows (fixed payments)</a></td>
<td class="nump">173,060<span></span>
</td>
<td class="nump">168,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_OperatingLeaseLiabilityReduction', window );">Operating lease - operating cash flows (liability reduction)</a></td>
<td class="nump">162,317<span></span>
</td>
<td class="nump">139,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Non-current leases - right of use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">151,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current liabilities - operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 162,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current liabilities - operating lease liabilities<span></span>
</td>
<td class="text">Current liabilities - operating lease liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current liabilities - operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_OperatingLeaseLiabilityReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability reduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_OperatingLeaseLiabilityReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="nump">$ 3,887,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,184,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">3,887,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,184,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,181,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="nump">1,968,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liabilities</a></td>
<td class="nump">1,968,315<span></span>
</td>
<td class="nump">$ 2,580,379<span></span>
</td>
<td class="nump">2,520,851<span></span>
</td>
<td class="nump">$ 3,455,505<span></span>
</td>
<td class="nump">$ 4,491,969<span></span>
</td>
<td class="nump">1,543,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="nump">3,887,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,184,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,181,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="nump">$ 1,968,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,543,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Feb. 09, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001505497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">BIORESTORATIVE
THERAPIES, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Feb. 09, 2026 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Units, consisting of<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.<span id="xdx_C0F_gIFON-DYDU_zB3f64l95Zvf"><span id="xdx_C0E_gIFON-GHQRUYJ_zf49cdNGa2I4"><span id="xdx_C08_gIFON-SKI_zIhKc3G4tQfe"><span id="xdx_C0B_gIFON-UEJ_zZfXxrlNQts7"><span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"><span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"><span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc">Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</span></span></span></span></span></span></span><span id="xdx_C0E_gIFON-DYDU_zpg86F7pLEj8"><span id="xdx_C02_gIFON-GHQRUYJ_zQSy3JjIeSN4"><span id="xdx_C04_gIFON-SKI_zqVRBVBoDev9"><span id="xdx_C03_gIFON-UEJ_zjgS3N808BA5"><span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"><span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"><span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6">Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.</span></span></span></span></span></span></span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 10,000,000.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 1,381.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.<span id="xdx_C0E_gIFON-GHQRUYJ_zf49cdNGa2I4"><span id="xdx_C08_gIFON-SKI_zIhKc3G4tQfe"><span id="xdx_C0B_gIFON-UEJ_zZfXxrlNQts7"><span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"><span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"><span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc">Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</span></span></span></span></span></span><span id="xdx_C02_gIFON-GHQRUYJ_zQSy3JjIeSN4"><span id="xdx_C04_gIFON-SKI_zqVRBVBoDev9"><span id="xdx_C03_gIFON-UEJ_zjgS3N808BA5"><span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"><span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"><span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6">Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.</span></span></span></span></span></span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=3', window );">Offering: 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Pre-Funded Warrants to purchase shares of Common Stock (4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.<span id="xdx_C08_gIFON-SKI_zIhKc3G4tQfe"><span id="xdx_C0B_gIFON-UEJ_zZfXxrlNQts7"><span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"><span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"><span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc">Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</span></span></span></span></span><span id="xdx_C04_gIFON-SKI_zqVRBVBoDev9"><span id="xdx_C03_gIFON-UEJ_zjgS3N808BA5"><span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"><span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"><span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6">Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.</span></span></span></span></span><span id="xdx_C04_gIFON-UEJ_zuQ987MkBvlb"><span id="xdx_C05_gIFON-EBFK_zHHgbUJ57zx2">No
    separate registration fee required pursuant to Rule 457(g) under the Securities Act,</span></span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=4', window );">Offering: 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock issuable upon exercise of the Pre-Funded Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.<span id="xdx_C0B_gIFON-UEJ_zZfXxrlNQts7"><span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"><span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"><span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc">Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</span></span></span></span><span id="xdx_C03_gIFON-UEJ_zjgS3N808BA5"><span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"><span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"><span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6">Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.</span></span></span></span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=5', window );">Offering: 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Warrants to purchase shares of Common Stock (4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.<span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"><span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"><span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc">Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</span></span></span><span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"><span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"><span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6">Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.</span></span></span><span id="xdx_C05_gIFON-EBFK_zHHgbUJ57zx2">No
    separate registration fee required pursuant to Rule 457(g) under the Securities Act,</span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=6', window );">Offering: 6</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share, issuable upon exercise of Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 10,000,000.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 1,381.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.<span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"><span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc">Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</span></span><span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"><span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6">Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.</span></span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=7', window );">Offering: 7</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Placement Agent Warrants (4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.<span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc">Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</span><span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6">Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.</span>No
    separate registration fee required pursuant to Rule 457(g) under the Securities Act,<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=8', window );">Offering: 8</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share, issuable upon exercise of Placement Agent Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 875,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 120.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457oFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection o<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457oFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=6">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=6</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=7">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=7</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=8">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=8</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Feb. 09, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 20,875,000.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">2,882.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 2,882.83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>336</ContextCount>
  <ElementCount>357</ElementCount>
  <EntityCount>2</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999009 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity</Role>
      <ShortName>BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999012 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999013 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/FairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999014 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999015 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999016 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999018 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999022 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999023 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/FairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/FairValueMeasurement</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/PropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999025 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999026 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999027 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999028 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative</Role>
      <ShortName>BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999029 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails</Role>
      <ShortName>SCHEDULE OF REVENUE RECOGNIZED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999030 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails</Role>
      <ShortName>SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999032 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999033 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999034 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999036 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999037 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails</Role>
      <ShortName>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999038 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/StockholdersEquityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999039 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/FairValueMeasurementDetailsNarrative</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/FairValueMeasurementTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999040 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999041 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999042 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/SubsequentEvents</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999047 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails</Role>
      <ShortName>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999048 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails</Role>
      <ShortName>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999049 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockWarrantsDetails</Role>
      <ShortName>SCHEDULE OF STOCK WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails</Role>
      <ShortName>SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails</Role>
      <ShortName>SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999052 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999056 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999057 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/LeasesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999058 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails</Role>
      <ShortName>SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999059 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ex107.htm">
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>brtx-20250930.xsd</File>
    <File>brtx-20250930_cal.xml</File>
    <File>brtx-20250930_def.xml</File>
    <File>brtx-20250930_lab.xml</File>
    <File>brtx-20250930_pre.xml</File>
    <File doctype="S-1" isDefinitelyFs="true" isUsgaap="true" original="forms-1.htm">forms-1.htm</File>
    <File doctype="EX-FILING FEES" original="ex107.htm">ex107.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>forms-1_001.jpg</File>
    <File>forms-1_002.jpg</File>
    <File>forms-1_003.jpg</File>
    <File>forms-1_004.jpg</File>
    <File>forms-1_005.jpg</File>
    <File>forms-1_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1227">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="82">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "forms-1.htm": {
   "nsprefix": "BRTX",
   "nsuri": "http://biorestorative.com/20250930",
   "dts": {
    "schema": {
     "local": [
      "brtx-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "brtx-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "brtx-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "brtx-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brtx-20250930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "forms-1.htm"
     ]
    }
   },
   "keyStandard": 289,
   "keyCustom": 45,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 37,
   "memberCustom": 32,
   "hidden": {
    "total": 170,
    "http://fasb.org/us-gaap/2025": 138,
    "http://biorestorative.com/20250930": 30,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 327,
   "entityCount": 1,
   "segmentCount": 75,
   "elementCount": 567,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1227,
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://biorestorative.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://biorestorative.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://biorestorative.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://biorestorative.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_us-gaap_CommonStockMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://biorestorative.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://biorestorative.com/role/StatementsOfCashFlowsParenthetical",
     "longName": "00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity",
     "longName": "999009 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY",
     "shortName": "BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "999011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://biorestorative.com/role/StockholdersEquity",
     "longName": "999012 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://biorestorative.com/role/FairValueMeasurement",
     "longName": "999013 - Disclosure - FAIR VALUE MEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://biorestorative.com/role/SubsequentEvents",
     "longName": "999014 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://biorestorative.com/role/PropertyAndEquipment",
     "longName": "999015 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://biorestorative.com/role/IntangibleAssets",
     "longName": "999016 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://biorestorative.com/role/IncomeTaxes",
     "longName": "999017 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://biorestorative.com/role/Leases",
     "longName": "999018 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "999021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://biorestorative.com/role/StockholdersEquityTables",
     "longName": "999022 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://biorestorative.com/role/FairValueMeasurementTables",
     "longName": "999023 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://biorestorative.com/role/PropertyAndEquipmentTables",
     "longName": "999024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://biorestorative.com/role/IntangibleAssetsTables",
     "longName": "999025 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://biorestorative.com/role/IncomeTaxesTables",
     "longName": "999026 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://biorestorative.com/role/LeasesTables",
     "longName": "999027 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
     "longName": "999028 - Disclosure - BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY (Details Narrative)",
     "shortName": "BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "BRTX:WorkingCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails",
     "longName": "999029 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)",
     "shortName": "SCHEDULE OF REVENUE RECOGNIZED (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30_us-gaap_ProductMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails",
     "longName": "999030 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)",
     "shortName": "SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "999032 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "999033 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)",
     "shortName": "SCHEDULE OF WARRANT ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
     "longName": "999034 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "999036 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "shortName": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails",
     "longName": "999037 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE (Details)",
     "shortName": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999038 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-122023-07-13",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
     "longName": "999039 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)",
     "shortName": "FAIR VALUE MEASUREMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-08",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
     "longName": "999040 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails",
     "longName": "999041 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "999042 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://biorestorative.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2023-07-13",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-08-112025-08-11",
      "name": "BRTX:LegalFeesAndOtherExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
     "longName": "999044 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)",
     "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails",
     "longName": "999046 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
     "longName": "999047 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)",
     "shortName": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_PatentsAndTrademarkMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails",
     "longName": "999048 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)",
     "shortName": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails",
     "longName": "999049 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)",
     "shortName": "SCHEDULE OF STOCK WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
     "longName": "999050 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)",
     "shortName": "SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_RangeOneMember",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
     "longName": "999051 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)",
     "shortName": "SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
     "longName": "999052 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "shortName": "SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails",
     "longName": "999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)",
     "shortName": "SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails",
     "longName": "999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)",
     "shortName": "SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://biorestorative.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999056 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://biorestorative.com/role/LeasesDetailsNarrative",
     "longName": "999057 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails",
     "longName": "999058 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)",
     "shortName": "SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails",
     "longName": "999059 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "BRTX_ATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ATMProgramMember",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A T M Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ATMSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ATMSalesMember",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A T M Sales [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r823"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "BRTX_AccruedGeneralAndAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "AccruedGeneralAndAdministrativeExpenses",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued general and administrative expenses",
        "documentation": "Accrued general and administrative expenses."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_AccumulatedAmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "AccumulatedAmortizationMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Amortization [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r128",
      "r575"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r454",
      "r455",
      "r456",
      "r457",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r454",
      "r455",
      "r456",
      "r457",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r823",
      "r1108"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r959",
      "r960",
      "r961",
      "r962",
      "r1046",
      "r1110"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs reclassified to additional paid-in capital",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "verboseLabel": "Total",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r361",
      "r370"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finite Lived Intangible Assets, Amortization expense",
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r147",
      "r239",
      "r245",
      "r734",
      "r741",
      "r742",
      "r744",
      "r746"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfLand",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r105",
      "r131",
      "r155",
      "r156",
      "r157",
      "r190",
      "r199",
      "r211",
      "r212",
      "r222",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r416",
      "r418",
      "r480",
      "r560",
      "r561",
      "r566",
      "r653",
      "r758",
      "r759",
      "r766",
      "r823",
      "r837",
      "r838",
      "r850",
      "r986",
      "r987",
      "r1067"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r135",
      "r155",
      "r156",
      "r157",
      "r222",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r416",
      "r418",
      "r480",
      "r823",
      "r986",
      "r987",
      "r1067"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities, fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464",
      "r814"
     ]
    },
    "BRTX_AuctusFundLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "AuctusFundLLCMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auctus Fund L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "BRTX_BeneficialOwnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "BeneficialOwnershipMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beneficial Ownership [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_BlackScholesOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "BlackScholesOptionMember",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black Scholes Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_BoardOfDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "BoardOfDirectorMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r865"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r126",
      "r735"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents - Beginning of the Year",
        "periodEndLabel": "Cash and Cash Equivalents - End of the Year",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r69",
      "r154"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Decrease In Cash and Cash Equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r69"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FDIC insured limit",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FDIC amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ChangeInValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ChangeInValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "documentation": "Change in valuation allowance.",
        "label": "ChangeInValuationAllowance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r132",
      "r133",
      "r134",
      "r155",
      "r157",
      "r181",
      "r182",
      "r184",
      "r186",
      "r192",
      "r193",
      "r222",
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r273",
      "r274",
      "r276",
      "r277",
      "r279",
      "r282",
      "r285",
      "r286",
      "r288",
      "r291",
      "r297",
      "r480",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r641",
      "r661",
      "r679",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r883",
      "r954",
      "r955",
      "r963"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Warrants outstanding, exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r159",
      "r298"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate fair value of common stock",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable",
        "verboseLabel": "Warrants purchase",
        "terseLabel": "Warrants exercisable, exercisable number of warrants",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding, number of warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r94",
      "r568",
      "r640"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r841",
      "r842",
      "r844",
      "r845",
      "r846",
      "r847",
      "r959",
      "r960",
      "r962",
      "r1046",
      "r1106",
      "r1110"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r641"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53",
      "r641",
      "r659",
      "r1110",
      "r1111"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; 75,000,000 shares authorized; 6,919,919 and 4,706,917 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r274",
      "r281",
      "r570",
      "r823"
     ]
    },
    "BRTX_CommonStockVestRemainderPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "CommonStockVestRemainderPercentage",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of common shares",
        "documentation": "Common stock vest remainder percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ComputerSoftwareAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ComputerSoftwareAndEquipmentMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Software And Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer and Revenue Concentrations",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r479"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r748"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued in conversion",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r288",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock conversion term",
        "documentation": "Description of conversion terms for preferred stock."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r30",
      "r32",
      "r52",
      "r78",
      "r79"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r521",
      "r742",
      "r747",
      "r810",
      "r944"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r953",
      "r957",
      "r1033"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r953",
      "r957",
      "r1033"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt conversion, converted instrument, shares issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r23"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Contract Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "BRTX_DeferredContractCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "DeferredContractCostsPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred Contract Costs",
        "documentation": "Deferred contract costs [Policy Text Block]",
        "label": "Deferred contract costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred contract costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r893"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r957",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total Deferred Tax Liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r93",
      "r390"
     ]
    },
    "BRTX_DeferredOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "DeferredOfferingCost",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Deferred offering cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred offering costs",
        "label": "Deferred Offering Costs [Default Label]",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "BRTX_DeferredOfferingCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "DeferredOfferingCostsIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs included in accounts payable",
        "documentation": "Deferred offering costs included in accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "documentation": "Deferred offering costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r957",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Deferred Tax Assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Deferred Tax Asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry-forwards not subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry-forwards subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "BRTX_DeferredTaxAssetsRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "DeferredTaxAssetsRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use assets",
        "documentation": "Deferred tax assets right of use asset.",
        "label": "DeferredTaxAssetsRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "BRTX_DeferredTaxLiabilitiesDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation",
        "documentation": "Deferred tax liabilities depreciation.",
        "label": "DeferredTaxLiabilitiesDepreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Lease liability",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "BRTX_DemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "DemandSalesAgreementMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Demand Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r146",
      "r741",
      "r742",
      "r744",
      "r746"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r630",
      "r632",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r667",
      "r668",
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r695",
      "r696",
      "r699",
      "r701",
      "r736",
      "r737",
      "r740",
      "r811",
      "r812",
      "r840",
      "r842",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of derivative liabilitiy",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails",
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liabilities",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "verboseLabel": "Change in fair value of warrant liability",
        "negatedTerseLabel": "Change in fair value of derivative liability",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r1040"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r630",
      "r632",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r667",
      "r668",
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r695",
      "r696",
      "r699",
      "r701",
      "r736",
      "r737",
      "r740",
      "r811",
      "r812",
      "r840",
      "r842",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities",
        "periodStartLabel": "Balance, January 1, 2024",
        "periodEndLabel": "Balance, december 30, 2024",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r446",
      "r463",
      "r464",
      "r471",
      "r475",
      "r476",
      "r477",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r654",
      "r656",
      "r657",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r736",
      "r738",
      "r739",
      "r740",
      "r1049",
      "r1050",
      "r1051",
      "r1107"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "periodStartLabel": "Balance, July 1,",
        "periodEndLabel": "Balance, September 30,",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "BRTX_DerivativesLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "DerivativesLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, January 1,",
        "periodEndLabel": "Balance, September 30,",
        "documentation": "Derivatives Liabilities.",
        "label": "DerivativesLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Net Lease Cost And Other Supplemental Lease Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r864",
      "r865"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r144",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r179",
      "r181",
      "r184",
      "r185",
      "r186",
      "r189",
      "r272",
      "r360",
      "r411",
      "r414",
      "r460",
      "r461",
      "r559",
      "r579",
      "r750"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r144",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r181",
      "r184",
      "r185",
      "r186",
      "r189",
      "r272",
      "r360",
      "r411",
      "r414",
      "r460",
      "r461",
      "r559",
      "r579",
      "r750"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r188"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r778"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r158",
      "r378",
      "r401",
      "r778"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in federal valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r778",
      "r953",
      "r958",
      "r1025"
     ]
    },
    "BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment for stock-based compensation",
        "documentation": "Adjustment for stock-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r778"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r953",
      "r958",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior year income taxes, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r958",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax, net of valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r778",
      "r953",
      "r958",
      "r1025"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r778"
     ]
    },
    "BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax return to provision adjustment",
        "documentation": "Effective income tax rate reconciliation tax return to provision adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued bonuses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining amortization period (years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized expense",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r115",
      "r116",
      "r117",
      "r141",
      "r142",
      "r143",
      "r162",
      "r163",
      "r164",
      "r166",
      "r173",
      "r175",
      "r177",
      "r191",
      "r223",
      "r224",
      "r252",
      "r271",
      "r299",
      "r360",
      "r399",
      "r400",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r493",
      "r506",
      "r578",
      "r592",
      "r593",
      "r594",
      "r610",
      "r679"
     ]
    },
    "BRTX_EquityLineItem": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "EquityLineItem",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityLineItem [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r407",
      "r480",
      "r885",
      "r886",
      "r887",
      "r1034",
      "r1035",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r480"
     ]
    },
    "BRTX_EquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "EquityTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ExercisePriceFiveMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ExercisePriceOneMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ExercisePriceTwoMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExistingWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ExistingWarrantMember",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expire From Two Thousand Thirty To Two Thousand Thirty Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of adjustment",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r466",
      "r817"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE RECURRING BASIS",
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467",
      "r470",
      "r471",
      "r473",
      "r475",
      "r512",
      "r513",
      "r514",
      "r731",
      "r764",
      "r765",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r814",
      "r817",
      "r821"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r312",
      "r317",
      "r319",
      "r464",
      "r471",
      "r475",
      "r512",
      "r731",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r814",
      "r821"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r312",
      "r317",
      "r319",
      "r321",
      "r464",
      "r465",
      "r471",
      "r475",
      "r513",
      "r731",
      "r764",
      "r765",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r814",
      "r821"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r464",
      "r465",
      "r466",
      "r467",
      "r471",
      "r475",
      "r514",
      "r731",
      "r764",
      "r765",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r814",
      "r817",
      "r821"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467",
      "r470",
      "r471",
      "r473",
      "r475",
      "r512",
      "r513",
      "r514",
      "r731",
      "r764",
      "r765",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r814",
      "r817",
      "r821"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Beginning Balance",
        "negatedPeriodEndLabel": "Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r225",
      "r244",
      "r734"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r729",
      "r734"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r729",
      "r734"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r729",
      "r734"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r729",
      "r734"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r729",
      "r734"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r522",
      "r523",
      "r599",
      "r729",
      "r734",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Finite Lived Intangible Assets, Gross, Ending balance",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r244",
      "r523",
      "r734"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r244",
      "r247",
      "r248",
      "r250",
      "r522",
      "r729",
      "r734",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r599",
      "r729",
      "r734",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r980"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets, weighted average amortization period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_GainLossOnExchangeOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "GainLossOnExchangeOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfOperations",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on exchange of warrants",
        "negatedLabel": "Gain on exchange of warrants",
        "documentation": "Gain loss on exchange of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r663"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r763"
     ]
    },
    "BRTX_GrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "GrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income",
        "documentation": "Grant income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r104",
      "r155",
      "r156",
      "r157",
      "r222",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r480",
      "r754",
      "r758",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969",
      "r986"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r74",
      "r815"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r76"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r255",
      "r256",
      "r421",
      "r427",
      "r444",
      "r445",
      "r468",
      "r469",
      "r472",
      "r481",
      "r482",
      "r483",
      "r589",
      "r591",
      "r664",
      "r729",
      "r731",
      "r779",
      "r780",
      "r812",
      "r813",
      "r816",
      "r821",
      "r1038",
      "r1039",
      "r1077"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r421",
      "r427",
      "r444",
      "r445",
      "r468",
      "r469",
      "r472",
      "r481",
      "r482",
      "r483",
      "r589",
      "r591",
      "r664",
      "r729",
      "r731",
      "r779",
      "r780",
      "r812",
      "r813",
      "r816",
      "r821",
      "r1038",
      "r1039",
      "r1077"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r378",
      "r379",
      "r386",
      "r396",
      "r778",
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r378",
      "r379",
      "r386",
      "r396",
      "r778",
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r158",
      "r374",
      "r378",
      "r383",
      "r384",
      "r385",
      "r387",
      "r394",
      "r402",
      "r404",
      "r405",
      "r406",
      "r565",
      "r598",
      "r609",
      "r778"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax examination, description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax provision (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r112",
      "r155",
      "r176",
      "r177",
      "r190",
      "r202",
      "r212",
      "r377",
      "r378",
      "r403",
      "r580",
      "r743",
      "r745",
      "r747",
      "r778"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r375",
      "r376",
      "r387",
      "r388",
      "r393",
      "r398",
      "r603"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r153",
      "r395",
      "r396"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r950"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r249",
      "r251",
      "r728",
      "r729"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r522",
      "r749",
      "r978"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Finite Lived Intangible Assets, Net, Ending Balance",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r980",
      "r982"
     ]
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndDividendIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend and interest income",
        "label": "Dividend and interest income",
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r99",
      "r100",
      "r101",
      "r745",
      "r1112"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r745",
      "r966"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r151",
      "r152"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_InvestmentsAllOtherInvestmentsLineItem": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "InvestmentsAllOtherInvestmentsLineItem",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "InvestmentsAllOtherInvestmentsLineItem [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_InvestmentsAllOtherInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "InvestmentsAllOtherInvestmentsTable",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "InvestmentsAllOtherInvestmentsTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestorMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1064"
     ]
    },
    "BRTX_IssuanceOfCommonStockHeldInAbeyance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "IssuanceOfCommonStockHeldInAbeyance",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock held in abeyance",
        "documentation": "Issuance of common stock held in abeyance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r822"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r504"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "auth_ref": []
    },
    "BRTX_LeasesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "LeasesLineItems",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LeasesLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_LeasesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "LeasesTable",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LeasesTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_LegalFeesAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "LegalFeesAndOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal fees and other expenses",
        "documentation": "The amount of legal fees and other expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://biorestorative.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_LessorOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LessorOperatingLeaseOptionToExtend",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease extension description",
        "documentation": "Description of terms and conditions of option to extend lessor's operating lease."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r51",
      "r155",
      "r156",
      "r157",
      "r222",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r417",
      "r418",
      "r419",
      "r480",
      "r639",
      "r753",
      "r766",
      "r850",
      "r986",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r95",
      "r572",
      "r823",
      "r837",
      "r838",
      "r953",
      "r956",
      "r976",
      "r1061"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r125",
      "r155",
      "r156",
      "r157",
      "r222",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r417",
      "r418",
      "r419",
      "r480",
      "r823",
      "r986",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities, fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r1047"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r993",
      "r994"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ManufacturingEquipmentMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments held in marketable securities",
        "verboseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Held in Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r257",
      "r258",
      "r259",
      "r260",
      "r323",
      "r353",
      "r354",
      "r355",
      "r371",
      "r467",
      "r517",
      "r588",
      "r590",
      "r597",
      "r631",
      "r632",
      "r685",
      "r688",
      "r692",
      "r693",
      "r703",
      "r712",
      "r713",
      "r715",
      "r716",
      "r726",
      "r727",
      "r762",
      "r767",
      "r776",
      "r779",
      "r781",
      "r782",
      "r817",
      "r818",
      "r819",
      "r820",
      "r833",
      "r988",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r817",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r465",
      "r466",
      "r467",
      "r779",
      "r781",
      "r782",
      "r817"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r779",
      "r781",
      "r782",
      "r817"
     ]
    },
    "BRTX_MedicalEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "MedicalEquipmentMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medical Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_MelvilleLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "MelvilleLeaseMember",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Melville Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r257",
      "r258",
      "r259",
      "r260",
      "r323",
      "r353",
      "r354",
      "r355",
      "r371",
      "r467",
      "r517",
      "r588",
      "r590",
      "r597",
      "r631",
      "r632",
      "r685",
      "r688",
      "r692",
      "r693",
      "r703",
      "r712",
      "r713",
      "r715",
      "r716",
      "r726",
      "r727",
      "r762",
      "r767",
      "r776",
      "r779",
      "r781",
      "r782",
      "r817",
      "r818",
      "r819",
      "r833",
      "r988",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided By Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided By Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used In Operating Activities",
        "negatedLabel": "Cash flows from operations",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r71"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r71",
      "r98",
      "r117",
      "r123",
      "r138",
      "r139",
      "r143",
      "r155",
      "r156",
      "r157",
      "r161",
      "r165",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r183",
      "r222",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r272",
      "r275",
      "r278",
      "r283",
      "r360",
      "r411",
      "r414",
      "r461",
      "r480",
      "r577",
      "r660",
      "r677",
      "r678",
      "r743",
      "r745",
      "r747",
      "r848",
      "r986"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_NewWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "NewWarrantsMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Noncash Lease Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r965"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reporting segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r761",
      "r965"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss From Operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r743",
      "r747",
      "r754",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost (cost resulting from lease payments)",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r822"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "verboseLabel": "Current liabilities - operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities - operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "BRTX_OperatingLeaseLiabilityReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "OperatingLeaseLiabilityReduction",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease - operating cash flows (liability reduction)",
        "documentation": "Operating lease liability reduction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease - operating cash flows (fixed payments)",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "verboseLabel": "Non-current leases - right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average incremental borrowing rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r822"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r118",
      "r119",
      "r121",
      "r600",
      "r601"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r810"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "BRTX_PatentsAndTrademarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "PatentsAndTrademarkMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents And Trademark [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_PatentsAndTrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "PatentsAndTrademarksMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents And Trademarks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_PaymentsForCommissionsLegalAndAccountingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "PaymentsForCommissionsLegalAndAccountingFees",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commissions, legal and accounting fees",
        "documentation": "Payments for commissions legal and accounting fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal settlements paid",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "BRTX_PaymentsForProceedsFromDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "PaymentsForProceedsFromDeferredOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred offering costs",
        "documentation": "Payments for proceeds from deferred offering costs.",
        "label": "PaymentsForProceedsFromDeferredOfferingCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase of common stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlowsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs",
        "negatedLabel": "Payment of issuance costs",
        "verboseLabel": "Cash issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock voting percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r686",
      "r689",
      "r691",
      "r704"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, liquidation preference",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r52",
      "r953",
      "r954",
      "r990"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r841",
      "r844",
      "r845",
      "r846",
      "r847",
      "r1106",
      "r1110"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r285"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r641"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r285"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r641",
      "r659",
      "r1110",
      "r1111"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r274",
      "r280",
      "r569",
      "r823"
     ]
    },
    "us-gaap_PreferredStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockVotingRights",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock voting rights",
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r52"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassifications",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from debt issuance costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ProceedsFromExchangeAndIssuanceOfWarrantsNet1",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exchange and issuance of warrants, net",
        "documentation": "Proceeds from exchange and issuance of warrants net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of common stock in direct-offering",
        "verboseLabel": "Net proceeds offering price",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "verboseLabel": "Net proceeds from issuance of common stock in at-the-market offering",
        "terseLabel": "Net proceeds from shares sold",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of warrants",
        "verboseLabel": "Issuance of warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of stock options",
        "label": "Gross proceeds from exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Exercise of warrants",
        "negatedLabel": "Exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "BRTX_ProceedsFromWarrantExercisesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ProceedsFromWarrantExercisesNet",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrant exercises, net",
        "documentation": "Proceeds from warrant exercises net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r747",
      "r768",
      "r769"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r521",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r732",
      "r742",
      "r745",
      "r747",
      "r768",
      "r769",
      "r832",
      "r833",
      "r834",
      "r836",
      "r839",
      "r889",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r945",
      "r946",
      "r947",
      "r948",
      "r984",
      "r985",
      "r1076",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "auth_ref": [
      "r214",
      "r521",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r732",
      "r742",
      "r745",
      "r747",
      "r768",
      "r769",
      "r832",
      "r833",
      "r834",
      "r836",
      "r839",
      "r889",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r945",
      "r946",
      "r947",
      "r948",
      "r984",
      "r985",
      "r1076",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r504"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r109",
      "r110",
      "r111"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property plant and equipment gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r127",
      "r576"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r504",
      "r564",
      "r576",
      "r823"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r109",
      "r110",
      "r574"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://biorestorative.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r504"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property plant and equipment estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r257",
      "r258",
      "r259",
      "r260",
      "r311",
      "r323",
      "r353",
      "r354",
      "r355",
      "r359",
      "r371",
      "r467",
      "r515",
      "r516",
      "r517",
      "r588",
      "r590",
      "r597",
      "r631",
      "r632",
      "r685",
      "r688",
      "r692",
      "r693",
      "r703",
      "r712",
      "r713",
      "r715",
      "r716",
      "r726",
      "r727",
      "r762",
      "r767",
      "r776",
      "r779",
      "r781",
      "r782",
      "r817",
      "r818",
      "r819",
      "r820",
      "r833",
      "r842",
      "r983",
      "r988",
      "r1050",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r198",
      "r257",
      "r258",
      "r259",
      "r260",
      "r311",
      "r323",
      "r353",
      "r354",
      "r355",
      "r359",
      "r371",
      "r467",
      "r515",
      "r516",
      "r517",
      "r588",
      "r590",
      "r597",
      "r631",
      "r632",
      "r685",
      "r688",
      "r692",
      "r693",
      "r703",
      "r712",
      "r713",
      "r715",
      "r716",
      "r726",
      "r727",
      "r762",
      "r767",
      "r776",
      "r779",
      "r781",
      "r782",
      "r817",
      "r818",
      "r819",
      "r820",
      "r833",
      "r842",
      "r983",
      "r988",
      "r1050",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "BRTX_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "RangeOneMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Recently issued accounting pronouncements [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ReclassificationOfDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ReclassificationOfDeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of deferred offering costs",
        "documentation": "Reclassification of deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r160",
      "r161",
      "r218",
      "r318",
      "r322",
      "r507",
      "r508",
      "r567",
      "r573",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r658",
      "r684",
      "r1109"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r160",
      "r161",
      "r218",
      "r318",
      "r322",
      "r507",
      "r508",
      "r567",
      "r573",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r658",
      "r684",
      "r1066",
      "r1109"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r729",
      "r743",
      "r744",
      "r758",
      "r1075"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r80",
      "r571",
      "r595",
      "r596",
      "r608",
      "r642",
      "r823"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r162",
      "r163",
      "r164",
      "r166",
      "r173",
      "r175",
      "r177",
      "r223",
      "r224",
      "r252",
      "r271",
      "r360",
      "r399",
      "r400",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r448",
      "r450",
      "r451",
      "r453",
      "r459",
      "r491",
      "r493",
      "r592",
      "r594",
      "r610",
      "r1110"
     ]
    },
    "BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Return and cancellation of shares in lieu of payroll tax withholding",
        "documentation": "Return and cancellation of shares in lieu of payroll tax withholding.",
        "label": "ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails",
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues, net",
        "verboseLabel": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r190",
      "r200",
      "r201",
      "r210",
      "r212",
      "r214",
      "r215",
      "r217",
      "r308",
      "r309",
      "r310",
      "r521",
      "r743",
      "r747"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r730"
     ]
    },
    "BRTX_RothCapitalPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "RothCapitalPartnersLLCMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roth Capital Partners L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r993",
      "r994"
     ]
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockDescriptionOfTransaction",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description on sale of stock",
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r90"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of aggregate shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "auth_ref": [
      "r120",
      "r122",
      "r178",
      "r324",
      "r884"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "BRTX_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by award type."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION EXPENSE",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INCOME TAX PROVISION (BENEFIT)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r778",
      "r1025"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF REVENUE RECOGNIZED",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r407",
      "r480",
      "r885",
      "r886",
      "r887",
      "r1034",
      "r1035",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1048"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r244",
      "r247",
      "r248",
      "r250",
      "r522",
      "r729",
      "r734",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INTANGIBLE ASSETS",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r979"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r763"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r504"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r81"
     ]
    },
    "BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK WARRANTS",
        "documentation": "Schedule of share based compensation warrant outstanding and exercisable by exercise price range [Table text block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANT ACTIVITY",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r981"
     ]
    },
    "BRTX_SectionThreeHundredAndEightyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "SectionThreeHundredAndEightyTwoMember",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section Three Hundred And Eighty Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "auth_ref": [
      "r195",
      "r215",
      "r216",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r560",
      "r561",
      "r562",
      "r563",
      "r625",
      "r627",
      "r629",
      "r687",
      "r690",
      "r694",
      "r705",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r733",
      "r751",
      "r768",
      "r770",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r835",
      "r842",
      "r1076",
      "r1078",
      "r1079",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r213",
      "r215",
      "r756",
      "r757",
      "r760"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896",
      "r989",
      "r991"
     ]
    },
    "BRTX_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896",
      "r989",
      "r991"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting of options description",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average estimated fair value of warrants granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares outstanding beginning",
        "periodEndLabel": "Number of shares outstanding ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividends",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359"
     ]
    },
    "BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Warrants, Exercisable",
        "label": "Number of Warrants, Exercisable Ending",
        "documentation": "Non option equity instrument exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants, Outstanding Beginning",
        "periodEndLabel": "Number of Warrants, Outstanding Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83"
     ]
    },
    "BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding beginning balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding ending balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares of common stock authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant options shares",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Exercisable Ending",
        "label": "Options Exercisable, Exercisable Number of Options",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Exercisable Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Granted",
        "verboseLabel": "Options granted",
        "terseLabel": "Options to purchase shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic Value, Outstanding Ending",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Outstanding beginning",
        "periodEndLabel": "Number of Options, Outstanding ending",
        "label": "Options Outstanding, Outstanding Number of Options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average price",
        "verboseLabel": "Exercise price",
        "documentation": "Change in the weighted average exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "ShareBased compensation arrangements by share based payment award non options exercised in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Weighted average exercise price, expired."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Share based compensation arrangements by share based payment award non options granted in period weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Exercise price of options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Exercise price of options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r331",
      "r350",
      "r351",
      "r352",
      "r353",
      "r356",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock authorized to issue",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding, Exercise Price",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life In Years, Exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life In Years, Outstanding",
        "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term2."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intrinsic Value, Outstanding Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life in Years Exercisable Ending",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life in Years Outstanding Ending",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Grant options shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested common stock, shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable Weighted Average Remaining Life In Years",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "BRTX_SharesHeldInAbeyance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "SharesHeldInAbeyance",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares held in abeyance",
        "documentation": "Shares held in abeyance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State &amp; Local:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r132",
      "r133",
      "r134",
      "r155",
      "r157",
      "r181",
      "r182",
      "r184",
      "r186",
      "r192",
      "r193",
      "r222",
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r273",
      "r274",
      "r276",
      "r277",
      "r279",
      "r282",
      "r285",
      "r286",
      "r288",
      "r291",
      "r297",
      "r480",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r641",
      "r661",
      "r679",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r883",
      "r954",
      "r955",
      "r963"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53",
      "r56",
      "r57",
      "r115",
      "r116",
      "r117",
      "r141",
      "r142",
      "r143",
      "r162",
      "r163",
      "r164",
      "r166",
      "r173",
      "r175",
      "r177",
      "r191",
      "r223",
      "r224",
      "r252",
      "r271",
      "r299",
      "r360",
      "r399",
      "r400",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r493",
      "r506",
      "r578",
      "r592",
      "r593",
      "r594",
      "r610",
      "r679"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r215",
      "r216",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r560",
      "r561",
      "r562",
      "r563",
      "r625",
      "r627",
      "r629",
      "r687",
      "r690",
      "r694",
      "r705",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r733",
      "r751",
      "r768",
      "r770",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r835",
      "r842",
      "r1076",
      "r1078",
      "r1079",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r191",
      "r273",
      "r274",
      "r276",
      "r279",
      "r493",
      "r521",
      "r602",
      "r611",
      "r622",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r679",
      "r745",
      "r747",
      "r843",
      "r1109"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r120",
      "r122",
      "r178",
      "r324",
      "r884",
      "r888"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r191",
      "r218",
      "r273",
      "r274",
      "r276",
      "r279",
      "r493",
      "r521",
      "r602",
      "r611",
      "r622",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r679",
      "r745",
      "r747",
      "r843",
      "r1109"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period value warrants",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options",
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant date fair value of options granted",
        "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation:"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_StockIssuedDuringPeriodSharesAbeyanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesAbeyanceShares",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in connection with abeyance shares, shares",
        "verboseLabel": "Abeyance shares issued",
        "documentation": "Stock issued during period shares abeyance shares."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued in connection with abeyance shares, shares",
        "documentation": "Stock issued during period shares common stock issued in connection with abeyance shares.",
        "label": "StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series B Convertible Preferred Stock into common stock, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r30",
      "r52",
      "r53",
      "r80"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and sale of common stock, net of issuance costs, shares",
        "verboseLabel": "Sold shares of common stock",
        "terseLabel": "Stock issued during period shares new issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r53",
      "r80",
      "r604",
      "r679",
      "r707"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in connection with warrant exchange, shares",
        "verboseLabel": "Shares issued",
        "terseLabel": "Shares issued upon exercise of options",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted share units, shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r80"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r53",
      "r80"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options, shares",
        "negatedLabel": "Number of Options, Exercised",
        "verboseLabel": "Number of Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r53",
      "r80",
      "r337"
     ]
    },
    "BRTX_StockIssuedDuringPeriodValueAbeyanceShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "StockIssuedDuringPeriodValueAbeyanceShares",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in connection with abeyance shares",
        "documentation": "Stock issued during period value abeyance shares."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued in connection with abeyance shares",
        "documentation": "Stock issued during period value common stock issued in connection with abeyance shares.",
        "label": "StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series B Convertible Preferred Stock into common stock",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53",
      "r56",
      "r57",
      "r80"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fee for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and sale of common stock, net of issuance costs",
        "verboseLabel": "Net proceeds",
        "terseLabel": "Offering price",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r53",
      "r80",
      "r610",
      "r679",
      "r707",
      "r849"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in connection with warrant exchange",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted share units",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r53",
      "r80"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r52",
      "r53",
      "r80"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53",
      "r56",
      "r57",
      "r80"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r1041"
     ]
    },
    "BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return and cancellation of shares in lieu of payroll tax withholding",
        "documentation": "Return and cancellation of shares in lieu of payroll tax withholding."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return and cancellation of shares in lieu of payroll tax withholding, shares",
        "documentation": "Stock return and cancellation of shares in lieu of payroll tax withholding shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r56",
      "r57",
      "r72",
      "r643",
      "r659",
      "r680",
      "r681",
      "r823",
      "r850",
      "r953",
      "r955",
      "r956",
      "r976",
      "r1061",
      "r1110"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r447",
      "r458",
      "r682",
      "r683",
      "r711"
     ]
    },
    "BRTX_SubscriptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "SubscriptionAgreementsMember",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r511"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationRelatedText": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationRelatedText",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the year for:",
        "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "BRTX_TaxLawChangePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "TaxLawChangePolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Law Change",
        "documentation": "Tax Law Change [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1065"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r973",
      "r974"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "TwoThousandAndTwentyOneStockIncentivePlanMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Twenty One Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_TwoThousandTwentyFourATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "TwoThousandTwentyFourATMProgramMember",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Four A T M Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_TwoThousandTwentyOneStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "TwoThousandTwentyOneStockIncentivePlanMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty One Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r194",
      "r196",
      "r197",
      "r198",
      "r560",
      "r562",
      "r752"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "BRTX_WarrantAndOptionValuationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "WarrantAndOptionValuationPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant and Option Valuation",
        "documentation": "Warrant and option valuation [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants for cash and the payment",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r841",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term (years)",
        "label": "Warrants exercisable, weighted average remaining life in years",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Shares Outstanding - Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r186"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Shares Outstanding - Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r186"
     ]
    },
    "BRTX_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20250930",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/BusinessOrganizationNatureOfOperationsBasisOfPresentationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital",
        "documentation": "Working capital."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    }
   }
  },
  "ex107.htm": {
   "dts": {
    "inline": {
     "local": [
      "ex107.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 16,
    "http://xbrl.sec.gov/ffd/2025": 15,
    "http://xbrl.sec.gov/dei/2025": 1
   },
   "contextCount": 9,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 82,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R60": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2026-02-09",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-02-09",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2026-02-092026-02-09_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-02-092026-02-09_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2026-02-09",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-02-09",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r877"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/825/tableOfContent"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001493152-26-005827-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-26-005827-xbrl.zip
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M7)_LA2=8T2P%M9MHFU IB8)E8*!>)AL0%^1V 5_5WCJ>$T:Q9ZX56&U'T=:
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M0SD=4/4^0C*.$](NR664B]9K>G,EH@:"_#5NF1"S(<?%BST:7'IM _N"A31
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M=JH_HQ^2/58GVK@L'X!:68:TI)N>A'D5R2MA96X>?!5PF9R97C*DAB:<3U"
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MT.W3*[5IO.;S"TVY?_+Y(@0G33UHKR[+S2F3Q ,GU*;" ?;4KQMI@_99 *-
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MODT73T0B0>PN$9HFJ+DNZZ0T,; B_:"=TK;H51)<O.#I4)58%?<QJ/,#86?
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M__K%03ZA[FD]0,_(%1]H5?LWQDKFY OT.&D'-.5B";(LR$Y8.8?1<R3."1*
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M%[PF6[H*5:#6ET#H:K3P'98:TW[T44REL,R*J(LF(U=TDF%UKHQ;= _MB+2
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M# B_**.'B[-IW-Y!0/V.=I6B'KD'TA.@*8*6,MXBB9D4M-$%NLG!G-H5H]8
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MH*'!(N=1:EQ0B?HZL;_OZXQO'U+?-75=B5W XKX&HZ-(O''QG7V*#U[?HIY
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M'6WV&<H:JK6*=:6"F?2=<B15:G@AH1RZD'F\.#RZ23'*.792C8;%"6)JZ#N
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M<+D9=RCHG50FZ/A$>3NQP\Z^'W'R'"<)9M'\\E%(*.9LS%& ;$<8@8SWIM<
MXY-"5)*(B?IZ]ZY^I"TB0U=1X.(NN$_PP"ZYF*L7\%0@FV?P1#+>*:$!QKDT
MU5-XK2SZF4E[YL15G.(%&=!$CR+*13UQ@P,KX4<K!Y$C0W!ZGE -Q%1<D^4B
M"UDN?IIE46!9_\^N2"$"U1"A^S<0C2\ Q&\?5B(LEZ7C!IZ1#T?TXY=)\""
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M.2,1!D0=-4()@^B]U+Z63R+1^];Y)NN$.]27;,^S2.ZA:+3<DLK(A#ZUE"J
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M @AA-4W?^R.(1A<AXCI_KZT]#?GSU_"1/M<CN9 @%G,]](M #H?_K@P("BB
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M)#*CCF?":+<@C+G2/\&[@LD8O9'>.*(A!UA6*.D B0;T]EU<A5W1F,",9;G
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M-[F"V_E6![P_V\JDP3!,"Y&?:8L296N4UX3RSJ4/>584-WFVED9Y]"1<LD4
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M2 ORSODIT O?4#IE6M0]:-7\7QY0338K3(R*P[+. 3E["?*(W6\?X?DKR@+
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MF$I9X:<@3EGH>74M81LD=SA_>B]M'@](W+I%WJJZ/P(XAP'(2?)ENW8P: M
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M-338?K_'HF+_'*A>D1S3$GK/'*@>8<!RN[W8/GH)_66/&?W%BX.A@?O@D8X
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MVL.;SW]9/;Q?J6Y[>/7M?Z >WC/8O(=7:E]6#Q^<OWS.$E(:W9*B%>6B@30
MCK:7&U7LP?JY\NO0/&SGEDM]]>=6VON>>F='\'R;Y\1DX_W-6M[QC8<J&N2V
M#/+2;#==@7C80&=!0D.Q3M#_W29OZ-T)H)LJ>X7+'<6=% %>[M#*,E;.41L-
MWE?6MM!0'G;[2-%*$Q7[;YT#G1G^P4T[?5^U4\J>=8_N=*G/S7&;'AP*-M^_
MB)G*[9EO-5/-TVCT/"4[\&WGJ5M2>YCEG/CN6^5LM4=0R YA(3^T54HZ"_I0
M0VV#/,1BD+P8/4RYZQ*DVR#WX+U,T (^/$E)_S2!N7^WA!N[<#Q.O8$WWW8)
M1(:W/WP)'J.CF:SOB8SV&&7S&$B/<51W.1;/0N]21#ALARYM=QF_$5GD96<3
MDOQKMP%)_O'+31*4ZRQ_6A)3:9'G^=NFS&9%@4M1D+.9B@L_Q 8\I96)O/<M
M<PN0W&6W6@TU>B>HTD1,=:J YJE)=E4'P []7',U &3CC# @7*L#G71#H-;$
MNS*+;';S3"F%5+3[S!=Q$289C222C.T*>:?/D.I@]YX=E0E[9YHIPB'%/@;Y
MK[AD]S(*'&YS-L.>=/92O/.J,_.;DTNGY))A9@9T::;6 ,,U(YC<;;1!0#\T
MNMUN[PO\]RTFOO\S^1^1IZ86=7H,JP#;.S 5R(&AD0(<=[6Z%45,]K"NUWC6
MR%POO;A']@A=+9TL5!;I7"N>29!\J4XZH0M<A'G,#NR7ZSLR=!9!6,K?5#+2
M])3F26>*)..33 T.]8RQ\C>56G%$4TR2@ECF;=V#V7L<A5SAAR"YQ)@&:;,K
MDS2B(RW$IR$*86<'(EK [8Z\5-([4XS@#<G!Y-$:TW3>:80RJH)PK0/U*6=-
M4KY^1@/VPJRP]T__&7"/?1_01"[=7/W8<IFA#3'DD11ID,?6782F-A&IKZR@
MZA2= /-EJI)7,@$@&0=K0A>76<Z&N5M<EDGU(+GL<$:EX301G!YZ[PA,+@Z&
M.GJ,XKFIV,FA31!#?6O"_I&4YR!.Z,*25 @;9Z<>P[6?.XI8;L-*.\3[/,-O
M@>E*!S9PV _9WU!6S^]><]/_OS3:O032X.)A852'-'P"AE\RS>L2C5?>[HK+
MGAX\W.>.[UT3>:5-_[8)_RV0O?5P=NX[C^RQ =5YXHR"7.&G(*;/)TD?X3;6
M<K8E96Y"NS>E5_'NPMCAY&(5FHV%SGN!,+88;O)L@_/RC3[*5<Y2EG9S0_M+
M;_N)CP54*CE./6Y@P"#N4J'AG6E6, 6IQYD2VE MMC6*&SWT0!6],VX6AMNG
M;4+C32_P)L=AS$9O\G."V3">1K.G+"_CW]COI=4@B_&8K'BG@3835THO+F>B
MLJ%%)$]L%[^+4Q0_H&#W$11UON(OQEQLA.3*FTK>\2JLS,H@4;6G$5;I@-<;
MZDY0BOVGYNJR4F)S7\1MGD(>7#\,?O=W,'.B !1_:FS62=VLF,-''&WI ?AE
MG,8EOHJ?Z;JC)(#C^P17\8C**"J+ IRN:JT-ZZU3C;7!,,\:,I^/N9&MXI-/
M4%70*2L)3*R6PKHK3=R6F:K3MZ\LC.D]@66@!X:9%F"YQ)9=!@X)6L"*^E*8
MJ5JJZM6 $%*Z7-7I0+S':8B9NZ.&'^(TI4\"U;?5(+.NL_SH+C/L:T1:$!!F
M:@PUY*JD%!^+RIN]2:PV9B]:'["-AU:0==7\-4RV]-3J0Y9%+W&2B%K51 _F
M?7(KY/!'HR[7ENNA<;)M$HV2TVTN(P-ZFU=*#7!;4B9HQ5X8DGAA)ZA;:!/B
MZFD$.8C_ B@IB#5FV[9DVB=HSB(%T+W7Z<#;E.^HP463_OAVUQECW:L[&\O=
M EMR?,&^ L!D&E:X;=OZFF[WF#>K[Y5-=:Y-P/:.3U@MRF)U1I<&9(UC8K+A
MJ*<JZA@VC0SPV_+_9?C(9M!U::K^^8\V"?H8 P^QY)7F&P*RZ)U\R>'6755U
M8D.@PY8YCO7$87N?HT2O$ZTY=%9P<<-'XVITS:EO?%[CU_+N!2?/^&.6EH\C
M-O:-"@7B>%A4@"GE]26"&<$F,6/(?LJ_(^/\3SC([UZR26JI+0LNPP?FCB=V
M7="1\KF/7D#C?SU&&I,ORZ)91I<&G,I=D_<D,RWJF.G<P2\@]!^/D-"7I$HG
MJY^J,-AT[AJ\'YMI24=,Y@Y\ 9?_[1BY3&2GJQY6&' N=PS>D\M$]IBYO(,O
MX/+WD+DL?_M=IP2$FY+8?+4&K-A\(ZQ#8MW14KTS:Q>Y*[[D7><4V):/61[_
MAJ-/]$8?N^-7W1:EUQ&*L[?>C>T5O6AJ%K=]F(_ZB?4^9 6*X\,/\44PH[@3
M,X6)CD[9MU!]-1IU;DZ?H*KL$]0F'V#E(E8PF##U/2J,KZXK74+2 WW,?QZ;
MJ2I,GUEDWR_!Z;2'-&_BSGIE%K]_0-J=)T%1M \_+O,5/0CNU</N5<CZKX7P
MP'U40?#RS.QGAB1=>(&R7?J9$X1A98T1FMS)EV-34STUE\.GJ1%:RG9TP QI
MAD#-V)>R5%T 'GQJX,W2J.I''8ON</XD:C*=#J##?V.HTF:KQPGJT E"=/(F
M# @E\9H](?J&@]Q78PHIVF:%:]_F. ^2!$=G;\,AU+A[FA<)+67N5.:8T:7S
M#\L>?WS+@T^;#<YK=^TIMDMW.=4GCW:I(*F\@RT8!M\#,UP[,%*6V'K9G9[[
M"X7CSX99C7#FM-KC(XY'?'LV36&;$8DZ_T#7[>A?B\(8_+GL@".[VGPWT=7V
M#3)YMN'2YUE:YD%8;H.$^E_O54T' 9W_))C>FD2?,],Y-%A#"YCZD U'G8)1
M4R2JRT1MH>B*+ET6*?K)X])EW[&Z8^KA)CON(X!6NH>SS8!=)SVJ 9WLQE0.
MS:Y6OBW2HLRW[)$"]NK.W6.0UJ9=9^DSRY/;9]U4C6/_??]KH -6ZR2=V?;C
M$*\@N39^. ;LNGB5H;>[NXGNFTM-7W"_[[^=Y+R5AI__,GJ]N%+==/K^MX]_
M6A]GL+:?/U M?,3/]&CKI9_VWGFS##__9?1L<:6ZZ=G];T-+AN/8;FT'7V?Y
M&L=?=A>_;&STULL%"+Z,CBZM6C=]G?O\/\!$+K-YFJY^E"P$M7P$F+G+O?%6
M"TC,_N-_ FHCCYO<1F;![ -I/U'H0LCB\/&>*)P!4XF/>WVJE@$3>]T NM*$
M30OD7!)&"K-+%4X(#$EDR.3TN *4K?L"KW&>X^@N>&UO"<WN"W;$(S%8K>+V
M:0P]^/Y3&7)Y,'PR ,D_I5&I(*)3Y_+Z 1ZSEL0O()-\^G"5%<5YD.=OQ/NC
M,[IL7+(JP2OO]*8I:2A7A\M*+6;.W<+T:<9:"25$"X5=-7B$)3\TOZLOZ/9<
MU30ZPRE>QV4A]F7/L\)X")WD4UZ[P(25I>PK$WP'VEV3 ]K(W5.BD2"G+&J$
MOF_9JL#K? OZ#ER(BV*%"TS:YY&8?8&?<9*I'A6T+\9KIS$T4MDA-&7 G4',
M@ \9W BS=^2BG3BA<P$@H%W4E\_)O^.R-T<V5EB,",I2? _]!B;J1G5%$7 Y
M;(3;G,*LJ$,]6<V!KZZ/K3\558*(@<V&.LZ>JS:%WSY6K5. X@;8@.6H1*5.
ML_7IML H8(KPAD"V06N\KJB$_2[GNH#5*S<J"7=XZL+C8BCIW^"11?5&G$S8
M*UFD[ZF()6&E"U)B%*8)0H+-)D@LNHJ#^SAA5RBMMC)E>IZXI39#0C.Q$L3A
M28E4N;W9T=Q[CU/O*'6^IG@DVEC+A[.D,4'D+DE4H,0MV<$%_>ZTV(KFJ(@L
MB(=)W S?DIN@7/\#WXAJT ^,%H5"X?O4!BE>O(:WA.A8>H6#@CYWLXL1L:._
M4-\_S15FZ>DL4#X.VLJ!#^E))3%*:M4WH.0T7.3R&OX):++<'8H?!\F.9_V[
M2,/L"??1:TP5J_B@DPJ\B$\B>1^$NC-='BL &RR2.TI@^-8N^/LK,=-M@J&6
MUQT8L0G*K9B^"O ]&2%847@%OS4#CV^?@V1;'6,G2?9"G[TRK0:1IE?>R4U1
M<H]7 SR9:B#SOEI1_(">&W$4-/+PB&@QVOD?XDS'-=>#F6T@HW$ (WN+E\;F
MM]1#,S!<XKO#T-;S1[JJ6:2SIVPK#5:Q+\8E!\<:V>6G;1G0!L*1^(?TKH1H
M:DZ((^,ECG >)*V/6X><U3%F--]/G&[)4KV.^,S20G.JLD^!3E\"V=OPWBLA
MHTL#,V+O;0+WWG15H/]@]/,MZ;1I6>/A3)/4AU;+:69K,Q-ZF7/5*F!X9X:3
M&U4K+>_<:J8$=>_1.$DZ91_>IYE!(G]4K0F&=U9P93ZK=_[=EL2-F:71%2E]
MPEE\_V*=WCJ=J!)ZUU/W+!,,SR<RA+],0(I%_QP\;?Z$6-%@YOF>P9:SO4[7
MPYQO9HY@YE<K0@F '0,:NC-@TN4TLY)9$3X< QOC1.Z!B3XT<H[ #M9C&/@]
MHT9+RS(\^J_VHZ=5 3 /CVR@'^0Y4$EL9;-?ICT&TDH[BZ740VYC*.6B4'8V
MS6 >UP:FW?0*8B:UF#0AS(_:8<=N(JRD41F\HDV>/<<%Y=/7]Y7.[[SS:;Y>
MX[",GW%KU8ITIQ6F[1HG5>3PK.R,L%N"X:TG+*FF24IVR=,)JZ++Z0F*!;.X
MGLX6R>XY*AHE1-;E_H=;$X/%7K(TI&V_(J%U")WQMCU!5MY1=0&-$>*])3)#
MG*"T"@2 Z'F8&,[B3&?1W[9%J0I9'U<4-.K+C+6E_+"<HZ*Z!/R0XC<X?PI2
M>N\_BDFI.28M<*B[_R:PZ2]QN<W3N^RF\<IV5HC6$5.4ZFP9-UT5M,N]_8OT
MSNMI[>!V$HB'GS,M5&8=7S]H%8]B"&_6R^.#62?_"K2!?T05V<X)%I_PWJT.
M:Y=\>V9=+QD.X"SM,;,L.B/%958]1\>]7#=V8#(L'-0\8U4A5M.-4<G>N\=!
MS!GVBITF33-/5M% 4]^)ZT%T'F\UR(@+\#]OJ S33PDB;5A;H=:XA[QM"V ;
MI$>SY:-*3&^A[Y^@"K-L7198Z>QM$<N)66_@4_>>%H'Z98!)@&]B\)4F.;YE
M&=#HRYEG2^$K< GWQZ >3^4K0,GZ32R_R>,LI\\H3[/K+BX.&LM51ML27E36
M47%?80"W!4E%T1N1)8O'YDP6%R>(^"@A<9R#!_^^A_6S 5!>";![%. (W@"P
M3OF_%*3[1W#S_<OMN]W>_XWTN[ML_KJ)<]%VQ52% GW&0E$!(U^V$)0(ANB3
MF&'2&4Z;8E!1E4.WR7%;TC%UD>NL/$@OD94+M*.HJV%D7Q$7>HS=16F)78])
MLQ)HKZ%),##>50+-7W:!BS"/-XH^H=5RR7A#$[I\UJB 8:L93H/7BZ*=DG?*
M=>(O@Z<X9?U 3SFMEJ>06)4)DM!8D0H8RIGA5$3)XIW>R92\DYSIL3Y1B#9T
M^3\[.U<3@&I/QCI_\][H$D#"K):5Q%3[I<K6E.USBD4<MZIPEU+T=TBMJ]MC
M'$C!VDJ<Y3A8KJ^"5/;P?%? Y33  ^N.^+N_>F>"%!)W#DT$:  K^:7_JW_U
M2]KTQ?:5_!DU3LHE R00NS08B(#A@A@7__Y36M+U"KTHXYT0U!W.\KX[7#VD
M3E=H)98.$":*KI<L9H8,5RUJ+3#D,H8J3J"-J0B+OH2T<.F;\R.F[UGA:/9,
M?ON +^(BI&G5Z!G'374BH=V:-BW&STF G9'B\P&S,L#0=B3P(8D;1114FO3
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MZ7#^3/2IK]+ZG]LTPGDEQA8D&8.*-N33OGU14L]/!">MN2O\$"1DLJZ[,:G
M2RQ83MHHPV+7".1*7S3<%8(26@IS3(*V'+3&GE:4U#SZ5@ AVV=<E"O\%,24
M@S=M/B*N6?4JL!K3&"\7TL 4ZY[XC%D$;*W;R=>D;+8)'NZZ#.*<[6=2YRB/
MGP.:C:H]=A,:;*CI_$$O,U.XQ[W4:L#(9H-9D5::J-<;T,RI;4IHST;?O(P6
MT\<<@FH\0[2ZV$-!C*&7UCJ&Q-B@VG]JLT8FR/;C"$SRZ"*HYM3BM'IU$6P7
M=O^&"JA6GLP>><K:7:I.=MV1#.N]E+6E]M$5K]M/Q/BK7435!=X0^+%X7->K
MP&I[8[S2K27:=MUHM*BCZ[O5JMQNBHL!1@I@6TR%5ME>U04 P:4 /YM_]3W<
M^K2"VY.J3R8[NTVS-*IWF.B.Y=E;;[MI1:<@EI[H#K^69V3%^"N_Z7?P3\(B
MC3-[I7>LFV,CQ'MKS8$QRG:?9]L[> < W;\U_VPV"ME&99V("I4$![JG0)11
MV ?=O^:<6'XS]5Z^F=JI[<%F:K7?PLX 4G:C?1LD=SA_XN,3_,  1G6?=<#1
M7T;Y8(>'4KO;->I;FRB@H%!*3^4J6+W^\#+</<\;:.1#+3;2+PBX(SW2F?]]
M&Y=OB[0H<];DW7:YWC[=XUS< 0[\48!T=V.QX#Y"<[R"61G$S6\*Z7$U9:7X
M8^%^HX'\E$LV&KP_Q, \ @9 IOJJ@\,.S%W'Q6)@?@]S8"[T)[\L$3:-0ZC"
M1*<]<)_V^P [@7/CM4?O?=?ZI$I-CJ,CYF=ECT^&6B#X$CEJ;[YPC#Y3#M&%
MM?-<!3W5@>G<6-WO!T=+_P\L=,8?^2V^_^51W][X,<Z)!?.K0"H+WA\H'H->
MN%1=.^TVA%S66<R%#F[OENQQW)"UO1T+Z6+L+ SS+8X^X)0^%TZ#R*(GXE;3
M'(_TB&E>)2?F6\=0#U9CV8'F3LDK;?10J5>A<KT"FES.GFYC[A]Z*M^B.WBT
MK^&G81'*N=T>=T(!.'$K3&,;D[?J1N4NW/4FSU+R8UA-X3=9$H=O\E.J4:7
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M ",\8'-J/YL,237J(YXF!S)'Y31$[@)7_]T]U4&OK\3/PX=*;/0 S>16<+G
MSEH9?=VH_XZ&5S0EH%T18!KQ)L>;((Z:L]3: VG.T.5;J>-* MW05@88-GU=
M9K/>82MY5ARJR@/# \630\9*H%M7AM6V#]?ZD!J.WHGN[S,QBNURUJLWD/<M
M$WJSCS'%G!7L0OIPLZ[JXKM%M_^=;KYF)$\:F#%$H@R:"CK,AFW>:57VU[8@
M7YLIN#P/BD>6O3S"T=G;)Y:=J(4YHYG*I9W?7!N P[X':"ZA/[WST11 HV>^
M_E2E4/I=IX'K<MY.4/5 '?W=15S0>+,XI?V^%LU23VW?/"5UE\VJ=\0^!OFO
MF!WLW.*0K#1DS6ZD"*@WV^&5OKA59JC61[L"T*X$*,U(B$F85;[=)-7-9WKX
MLQF^V6"O#;E!]:!-6K4IY02Q<D[:HS-6%*P1>I'2E\/&CM ";4#-.P*TQ0C=
M%@-WA!X^%GC@][K]S\WC,<OZM4DAL'KT99P&:3BV1PNTX?=H%6B+'MT6 [='
M-Q5!K:#_1V>5YR#!;&NP*/,X+'%$_T FK_XO.I+5OB^_-JDM;;+8T7>*JD>&
M1/QQBP 0!ST9+N+Q"6)LWI5_@G9?1I4$]3T&O^PI5(B08)W9)7\##%%DJ(+&
MBOYR>D5K+#%IDQ5!\B'/MANBT36QM5 XIKK\/H#9UJO9A^H/P ;\.L_;V,NY
MG$,WOB@ A)O* C[WW=@B/:_5Z>N]]V63RH5SX0W$ 4VL)BBER^]LC:@6:M/:
M^/#,#WQG%D@'M,)Z//=EVV!I7!08LVUU5;,9B /J6R8HN>!OIG-2G3! :B'M
MUH52$%"KJ/%)NTXC7HUQ0&YF'>"IK$Y<)/\BF<OO AAYO9@K#%@]K1X-Z7X>
MS?J7P+MR-0;$0)P@ N.TPE%?)D$=)+U06"++T!QI#G7Y:UH'SZ%N^&D ]\=\
M62Q_#.?0$+Z<T9D]E"7?"SGL%P%-XHX,=3\6=U <Z1A\!.]8^/<L?%E\@#'8
M$,*7- ;7SZXY&X'K[WWIX^_03!^C;XWAV-@ZWO]U_&D 8Z\OBP] YQK)8 G7
MOH5:PVEIC8YR)*Z-O,SR-8[++3L=J Y0#\%CP6>^A''7P+I#\K/S778YAGWY
M2(DXPL%U_.DOB+"V%A^2Q!TLH ?9,2_2\]6]2,L\3HLX9!>@WTGI?)"O06/P
M88UT1MH6 &((CFT O@SBG &?%<7VJ;)P,"I\SF@@ ;V40X.F)AV#K;\.C<1N
MC3X J2F8BKFH T<P%N\@L=BYX\N["N240(-.D7/5_[W'?<?MS[CHO'G>]H.#
M3(2R;T$;00YIXB$GP>KCNY5'=RCQE:LV#+=/6S),X>@";W(<QLPZ\G."6<VF
MT>PIR\OXM^K)2YM[85.5#8A^DYLD>&&\^0#J?N$$M=]@8:S=KYS O'5V&:=Q
MB:_(,$SZ6TF,C(GS5V6=8%D/1931Z0#:MS.&.FSB2O&4::*=*FJ25S-M>&W6
M86:7?):M*"GEEW\YAG;5@;=MZ6YG[Q8(K_$';\B::0 :MPV!VC8@T3VVQ2L?
M D93A=P]!LU!ZG7&+K?BZ !Q=[8?!S3<N[?Y )XH?]A89XHI"9R=G]HB\A2'
M=_@Z[R\#W'*\_VU @Z1SD_TQ?+@2\QS-?A>\5E,*^6&0_JW7%&ETAE.\CLM"
M_A:4*AA^RN\ (NY!S9.&XM.'EAI'@/[<_J'^Y$F?PW1)UGSV!$FI3K_M\^I2
M6X<KNIFY7'\J*C])L&6H5@ P=]OAE#6T3!'*F"%=3(LE(??;/D"CGN=CM3SD
M56>7N;MGH^HR$A6 G4:'5-%M)*K^.TX'V(<LBU[B)"&3PG!E./RWIH^-*Q1F
M=]S3%F7/[;ULQ2VJ09&#7G^DJ64Z#W*:DT"@#+ZQ59C-&[4NI>NVPVI7MB0P
M;TDF#K[M^BC-6XOI>6Z>Z@&2OCVJ]A') VP@)4SS%O)Y(L#Y:!UDDEUAC0K
M=M(A-?)$_6T&<V;0$^5JJ9LDV0O-B6'43KP:Y+92H#5JKU8?M05X:C_>DJ&Q
MU6/.BW3V1)/ BQK3M@Q +3L:^K"9!2UZ@OBV/Q%G/*L*]Y6^K'KA];8,2OKB
MPU46!C3=4+V55.\;B=K=2!%08]OAY3)]5=J(J;,M-58 :]OFB8NOZT)\O6+6
M$*YG8NL)Z%O41A]0PXZ"+1VHAPU<OU 'L9TO<83S(+'ONE8% &QI.]S2IJZ+
M.1FV^0F(UF;;8<W\H_:K-*)0]O8,$'+#KE3%WVLBIL,I_)'3=I $.!9666'C
M9]S:0@/>SZL4FG'ZH,Z=:JX-J-5&@.;>0V^*Z$YO+,ON"M-*)RO1)L 3$^3^
MGDBG'K+L;+G](Z"VX3'Q">Z"ZH16>-K:_=45^8G\NOD5^1\:6TY^\_\#4$L#
M!!0    ( .B+25S7K]YS&EP   ]0!@ 5    8G)T>"TR,#(U,#DS,%]P<F4N
M>&UL[;U]<^,VLC?Z_ZVZWT$WI^K4GJHS268FV63VY3XER[*CN[*DE>3)9O])
MT2)D<T.1#E]L*Y_^ GR1*)( &B2AAC0Z]3Q9CPV Z/XU&D"C7_[V?]XV;N^%
M!*'C>W__ZOW7WW[5(][*MQWO\>]?W2_>]1>#T>BK7AA9GFVYOD?^_I7G?_5_
M_M__^__JT?_[V__S[EWOQB&N_9?>M;]Z-_+6_E][$VM#_M*[)1X)K,@/_MK[
M;+DQ^XU_X[@DZ W\S;-+(D+_D'[X+[T_?_V=U7OW#C#L9^+9?G _'^V&?8JB
MY_ OWWSS^OKZM>>_6*]^\%OX]<K?P 9<1%84A[O1OGW[-ON_M/O?7,?[[2_L
M/P]62'J475[XE[?0^?M7[+O99U\_?NT'C]]\^/;;]]_\ZVZ\6#V1C?7.\1C;
M5N2KO!<;I:[?^T^?/GV3_#5O6FGY]A"X^3<^?I-/9S<R_:LC:%^82>C\)4RF
M-_975I2@+OU,C]N"_>M=WNP=^]6[]Q_>?7S_]5MH?Y4S/^%@X+MD3M:]A,R_
M1-MG*DFAPP3AJ^QW3P%9__VKAR!ZHP-]^/[;3Q^_9</\U\"G\OE5CPU 8=]-
M]\'Q Q)2^:)4O!"&]S>LR3=9\V\Z^OJ5Y3+.+9X(B4+X+$K=M,QF9@7$BYY(
MY*PLM^'42F-T-4^VJ,B&CAQ.U]-GI@>HI"FPC]=?Q_P&3Y;W2,*1MXC\U6]/
MOFM3K33\/7:B;;,)"P<\,@4-9:39Z%IHL\*G&]=_;2@\A>Y:9]<%GSEC=:8[
MXM#Q2!A.@T?+<_Y(EM2$[GT!*:ZQ*RMTZ&1F=+IT$LGO^IX]=BC>MM**Z.AS
MG:$6;S96L)VN%\ZCYZPI:[VHOUKYL1?1L\[,=YV50U2$##A>5_.G8P<QL8=O
MS\0+24B9-*4B$@SB@ G+V+$>'->)E$A0&+*[M=-&Q>K3IC>6$R0'P#MBA51$
MV9*$SZR^=W>2^Q"2WV,ZYO"%:0H5&2WW[&I.L\"G2SC:4IEA4#RK\:N^=U=S
M&U$]XCTZ#R[IAZ'2H:W:L[LYT8^0I?6FLCX/.G4UDS$5495)Y.V/JX=UZ>/N
M]3+LNTN+"E7GU.2C'GV/425'>6!]^XTR$MP1=.X]JK,4C:%3YZO.4S2&+OVO
M.D=>?PU[@?K4*EV[W1=4)W38RZB;RC6)+,<-)U:03OK(-Y?JYSO3::LG8L<N
MG<R<T&-=3(=9^727^(/8V4<5M!M@K.[G_3-Q'I\B8O=?*#,?R;7CQFQ: W^S
M\;W%$[W^ABTH41G]N*> YB+9=/SNL0-OY2T05/^&!AEE3&1,II/<+^=&\L@9
MJ?LY)V>5Z3-31;?LDW0-A&&\27[1!@_8N%KIZ0 'T6B:YOZ./8O8[+V+"G*R
M160RW98,^<#'INAJVW^U GM)A]9&7-TW]-T46FAKP%@Z;P_-9PX;K7O9VGV7
M_2<]2W6BN6#C:J0GXZ,]]>C)BNY?=+=.#HY=T"0=6\/NG]R(DG/N;A/.I]&/
M=C/KD-JV7]1EA6USEI.-U#UN^;U[YK*32.'RW0(9^9@Z+0_-^0\;K7L,RG:%
M%JSG#J5!DSF>$Y$QG8A=_FI_XP=1=C_.S^IM]%K#+QV5YIN8V0&.1SG@>YI.
M>MFUI?6]H3*.CI6U]H--PITY<2UZ/UGZA=-^NY4&'+I[JNZ]%SHW8L_I?P-G
M17]*/GQ/9:4-1:!AM=[E.KH#U0_6_<PGA&X/:Q+0 \?2>JL[C[2@1&%P'>LF
M,R?3+?'%89Z85\0C:Z?-J4 ^I@[9LJ*83FI[0^B5RW)W<YC3!=M*S"#C:G@7
M:'ZX$0[2[5M!\TGR^FM9N\G'!GX8Y6;$1?Q,QV"G/LM-_EC0\>U6<K-/:;Q]
M=G_G!-VRG@MO(F/ZBP-BR%M$/)O8.3GL2U"GWFP<)V)=,C?M][UWS*<[9ERF
M/Z8ML^GD$W+]U<$<7.;[[ >'',W]R!,/YY"LOG[T7[ZQB?,-XS+[(6%WPFKZ
MCU^3#_4?Z"9JK:)\)-=Z(&XR_J^T3:G)-T>8U="CW-GV;9NR,7^9JY]<?<OR
M'(M0]H/#^5K!*A^:_GB 8]53/&OQS7/BW/AN]>2X.Q%8!_Z&Q[3L@[YDWGY
M-?3?OWK_[;<H?*923D81V80@7A=:X_-;)#%\MA=(R%C_ 8GUV0_,*-Q_<V
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MT0XF[(9]_Y7SO;Q= ;B CM4M\2A9+IUDW]XXGL-(8L=(*5K2CM@7856\@)Q
M1ZQ"EX+.P[\'JZ+"I?8<=J]4\8_]VO)J9084&V-?F!ON6%5Z3QC%B>_YAX3E
MF;ND9Q% 5^PD0&H(@WF!KCV3NI8DC YF*4S6Q.^!G0@(SO5*KADA#]J"Q''%
MN TL+_LFQ]_BH 5ZWAYE]E9(,$3FD]!_+C6"K4?2#SV]3],% &.(KF5@.1[;
M J?>\&WU9'F/9+K^V0J8W-0= Q*A$G9!3\73;*$ V("^<O9A_?OI[G\GW#8
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M\;"_:+A >"Z)N^'3:0AD/O&[XS;'D?8QH2J1'&9KAUR*9/VP)%[,XUI9A['
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M"I2^CEW'JK-355<'A0;8-;Z2/J>%8B(KB'0]\K=B09'D4E+#@QH#(M>!(TW
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MO!#7?V:SS/9768P?J#-V& M('$N@*7 %_4IY2SQZ^77I5/OVAMY^V=['CE-
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M@=1Q-SLH:]"U'3--D]]C-L$7^A_Y,97;P8REU=%[22V%!5.T,6!)SY_\+F8
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M";I@^5: #Y2U.$EY@(Y2X:ZO!)6L'V9J@A: P=AACK-:_!"2WV,ZZ/"%J1%
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M9GE?WX?IVWT-5JR?O!MV#B<59& 4G:-"3NP7*H>\M#T0W#^; *Z$%%-5Z&U
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M&:1/+V'*SR]>O'S]$D7YW;$LQ9?SXC^3I)^=GL$$?_KN.1[&; :@<7@:O2Q
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M^P>_DI5IMF"-E?!C,K_H=P8S&%599(MH"8(!'U+:#L>YK1L#A]K,I4SH]=S
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M*8OIY%U3+CX,GVX2#*[QBDX$+L83B; C)OHS#//^_?MGT0;]Z!6XO7(ZN2#
M(D]JBN$IZ%-6P)'!!R8ZO^"J^^_6H#!1[[+&G!,2!6^1V=."A3<=1?88)CTL
MLM'%+VT& H@6U7!,<#?.3BP"M'@RR9&(*-Z4;9Y&&-EJ<D[@K<I<LA=D!R!
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M6X5L#'1$I>V".]D6!B4/-46&>EEL!.SEY2WGC-CO0><GFU5?]02P*J9LM3$
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MGODX?&K]_1YYA\,)[>6CP>[(O8JST?7_P]M3%&E_3\>WHU,:,&35L3W:LG\
M@3LV6Q8O_=$^XCP%38FXC@LB/^C;N<P'P,'5(ATLA+V3T6O=P%T6+U@/MYB\
MT6^P>.^XCC"8.RYDM',=1UOXZ/;WG6UAO4$^E2'L?WE<RW^<$C=D P<)K8,,
MX&3  #ZNI3Q*Z;EFX:GZ.J0H=YUT/?(17>HX.MY__"D37']9E>LN2G(8J&0;
MH GD.( ,>R8S+WEU"Y)5I$$9[3JK:^$T&RA!HQZK@\W_B& I#EAG]D"JU$AK
MC[J[,H5E.$9F. 0V\]B>YF6)D.BKZ-7IVU/+ [1K,O#0/%MC*1'1"JZS@FB8
M""M1#RZ$J;&D,ZM7S,FCAG2S*FLB[TS%\M?#$B8S4UW#G>E95,NT[2U-X4A$
MDVB>%!_($<5^1665P<C\0%*SR!,T3$Q&5$[R7L*&NG SQZ-#'R$?X:KD$>.R
MV(>QOJ&[$Q\MT0(5WLY&!B[*1U/GO7J12(][D"^8=I/EO 8X+QI-D0B=(34<
MA7NX#_"G:S+;E[(JZ^0*!HV-2M&QP/Y?K-*(V[$*AY&(UA,6,63'IGZEKAYQ
MS?TER3DA\Y]"3^BEQ%;878VN@<V97@DS;Q=I$\.M/L"4LB;*UIL*V1@9 T\S
M@G%DM47+N$*7#C2T0Z)\5/KHWT<%'X!:^7I$K8RHE2/:0;][/PW=4./RXNWE
MQ;N+U^_/W[]\\_H=]=7XY_GEY?GK]R\OWAW+^GPYTO"9Q/^A=->X'(AG_G-7
M/)-[<%PX=J' M<;KGF?U HYC;#IAFZK7%L,Z])TU(#UA94*LYM:X=DW8)3RY
MC3AH%)#^4M@V9/:6L*>,/O5/]@%9&?&BK-"M*PONEER;H/W"\'P&B(S9F DS
M'K>$BGNL2K]3-N3HM._O"QR#/8?@\BS-$L?:%IUC_-0*:\7\S"F1=]$?M?I!
M-X)*23=-K(P/$%F-8)?#0_D9[_V/II/R!J.TKFL$&=WV+VX[;!N02"ONFOF/
MK0."8=MFR[X'^&P>X^#F!EX#M@:AMB78B('2'3#>5YG!1\/G$C:66-TP&[$O
MN^T,I/\X7(AK>*$IS$?=#3]>MNC*;I(L10^PN)=@6PWV+V@<-%*XY0:C@!M*
MB9+F =\5G,"HRJY6C3"JS[G[*"'OF;.4?1/OJ9Y&+SM80&3#+8.7*$M,2UF9
M):PA&,*^(\:[X'U7JL_XVNHMU3,U<EVG?9((5!Y6*(!YFX[M!H]@TI35AYW_
MIKI*BNQ??#"B#/]?3NMQ,Y^>(O#]C2RAM):\K*;Z<3BN8*M3R516+*2_,T=W
M/.5TR0\V:3R=V%UH/F9U8_NB@-Q>E<BF;[>V+_?,DQNGUGZ&752GF3N%,^H$
MLO!=I>FQ:I:QQR%0,JG.&JS$O\%NU;3_)2)#C5) [=%@L$P0[[RIRHWAQD9T
M+>@%VPRV!(U3@5HI.6@R;VLP&QBKZ#O (*BA17*S4WA7'"C2.[_@O<L]NT1-
M9=39Y#HK)<2#UZ1FF2 YO*A(VX(!6:EJ"\KH=,!:X+#IO5+()$$G-&=-&2Q7
M',VWO+Z5Y;;7J\<A)%!A5:,[QDLKG.Y1(W6^72$AT?#Y8Z+YIG51JX824%LA
M #O+D<K7S/1F8+=$W=?,1PW+GXTU!0+B\N1,[$#=SF30[M'N'7%"D5[XEIG\
MJ4E5UHCU1@&J7_1^\23F<22<FC<4R2-#+\ER?!YG+NM2K0 =IZ&XQ[:1%F7T
MN2X:TZ1MGJKX:5EIBKLY&K(;1Y[G.@A\$\VR$UBV7MC.1?9X6R$U'\%Z:4-*
M+M\4L-H+D\RS7,*$$B>UQ\ET8L^3.,+L[NT/XH&1[.'JVAPP[Z;8O8D85]]!
M%#P@*)KY^*+6*2>.YGZ? ,;4?:Q@0;I9E3G'?RE+>/O0N\1N=EDP[,@998(?
M!T%2FP9"#4OQ=7Q5Q)2%>U1CJ5C%==;7'=?8-8)> +Q-66H[<"0S\519-BDU
MG819J8 ^BUL18@T^TOU3LZ.DYEAV9ANF</V]=/X(=Q)2BGT@.:6(/?X>WU%;
M@;N4RU^U,1_(2R)AA.N-7*TNE2Y1J'^C4/W"-<'F&NV2+W?2!P1MS^Z/4=OC
MC=J.V^CSFO<+-N_/69NR[?8DNN"S' ^3OFF_$H/#6\7.=A_4SQB/0G<>G?K2
MV<!PC+7KM6 3N7=B8IN-8C -_.4\<=RF <E"U[=@<V[8<26_WSD3WOANF]ZA
MZN'(8@[89B$,:_;]5/!KAQ#J]^N[R_ &>OMQ\%!6!Z]F4Q(SG=V5BH*%LJW/
M[.#G6YUV1E-:WLF_I,$5)LE=,QW;'I;-%XJ5#AA)13F=V.9K\HNL]F"[<#H<
MT'Q:)E6*]WI.8:"RJG<@#S@" X96BN#P$!*.\R%WC'_*?UB_HUDEQ2X(^:4=
MVOD&W9XDKU&8=[ROG2\*!8?] 4PKUQ),WCI+:#K!WJ#$Y^D$@WI<NA=PLI?5
MG)$5A!7>2VE$ D"]J%4<N_',B!CR5FWL\'(RT>FZ><:>D9?Y[AMV)CS&KZX2
M-.^"[P=&A)N(1N0<&7(A8!,+0 -G*J@/#N[1W05CDEO_V%/5(7BB:C?-@JH&
MX62^!K-@BP2GH7.NP!5NCSN'WSY0[LO>1T*V+:Z \>J-(H 5TM*6OE>NQ.4<
M6,7Z*W6D)D7/J@QZV[X]ES!H.!?(H;#%Z,>%HU*_G]N"_6VX S(SAP%06HD*
M\Q8V@L!N!R[(,JFD 8-9%]ZCE#;.397-64LI+U_8LM3@_8+#BTIN1I/Y""8]
M2_FL?UTBL< 2WG]3^]/='6^Q5V'4<],+[B :MJ=*;SORN%-F3Y?&+EI/CZ(P
M>9*[J(N&Y^P[)'O6Q&UGY'22EH05<WV)\0]48@M9I,@>/!Q;,]S%UNZNC@YU
MAYE$UWV SGVS(\)&08E=(;;HX B;#5)TQA]+9,1W.+6QP1F--#+7MEL@O!Z<
M<$$-W@AJASX0S1,Q?_ !2/=*>@/.S:)<J]N=<&Q"MZ6D=P5^BCUQ;+*&S\LP
M+FF#IAA4E*!IYXSJK2O-[ I5*<9A<9EJ3N:R$L>?4[=+6=($5BGE(!3F2^^E
M6=[:N*#-RWBVTAH;5B\6)C<^>KA  <TERCJSPF'; O.RQ<.+AL!P1KXEOA<?
M'S_1,EED'%5+S;SQ[YQIUKG!^LP@86M!/(F)7A(5!PY^3>$N?R]Z-[X/8JF"
MG#O75]L[.(VMW;ZR#23L67%8[M;7A;?COL;4"7M)44@56>O4^?7MM]@)M@@J
MQ3:ML"4J BZR!EL(Q+'-J5?J59N+()"S'SLH(5H;?"BS"EQ0ZJYRN31X"3YY
MP"58+=K((*A7)6C+ F^")H?V>X:7M[,:=L8SWZ][:5*V7PH*]#8Z#<B&!W[C
M9U.?@)S2RXGN^&YN>S-/K%EG-W+"4FT=G$6.U(BU&$B8\Y0X(X7K,*=!:N*.
M@6@8UP[ _&BI',&D9X8ME1<4(88+P5ZIG3OO-$$_-)'5)&FZ^*N<(RY'=BS=
M!1RE!.V;V/G#*O^74IE[S <*I=CD',2FT0@U3SX8@2[;Z#4S@<OYP&>MU@^B
M061+Q[R?X7PH%RHM$>W0(?;[Z40:?N]P<W^M];8CWQ]'WK/FI! EIOAU3"=N
M?8<HTQ^=/AKJ.$L*PM\E( MT%0F6Y=#2_<9R*!2NV:SR%O%IU*'7 IZ4%QG"
M\PE409DKR1N'78X5-,U^1#^0>[!_75@-2.<Y_@16M5"4&U+\,]_&XK!=G[ 2
ME&6C1%)ENI6)!#*3L),?_[#2GV% FO.TN1C,/IESZ<81;!";QQD5YY<[Z4.R
M(F=C5F3,BHS;Z//8'TNV/U[::$0O"/$$'!-_ZGM#1(<I*M.+NOLPKP(2(GR0
M#IQ^>%48+H)S;>BTIKC%W#X/[AGB%6,%5)0P?N&ABO$0H!+N1X!*+*(J:T&T
M*/.!IQN>FN'4]H:O94$MB;&?P?Z!HS5VUY%'0P/7N2S$4E?7<"&581)A<>>U
MA1#1!GO4KI./5')X<+NOP%;:$3:SR]$?XZ8RFZ02@0&#PJ0\#"V%7"FXYM9L
MY"2#Y8=&9(ACJT+"A+ E@L74S\T"N]DPIH68?(KHA9E7+?J)9V=Q].#^@[]&
ML] "N;!73R=8 ZJM#_2NK7/;-?&X$R?:;S8T4\MG(/<R6#*M,'O(P6R?U]+6
M5&,K:,7\!$O(\4_1BNY:K5I-=%>S"(N# 1G8B)\ +P6#9A;$PM6I=H;NC@71
MLLAJ[QA!^/,RN#7^K&6G&Z7A+28,,)Q5;75?##%PU2<>I</[$0,W'7M;IK1Q
MT!XQ?%=)@^**VT<MM4+[*"*8#T5Y ^)X93K1A9@48+/"P)\IA@J0):_JKL^6
MO41BU=H,D8IUJ ?)G6+!)^/&Z"[#D)^AMR)V"9E.'CUX-)N?G$;GC;?Q][PO
M\D(PBN<EUDIH=^?$MIQ42V9G[_,5TTFG@OI7/5_VO:@*4JORT6Y>'WF56CTX
MB1W8!6F6]B/F4@!#PVJ+IFK%B;%)-H686R8+=HP1X87@]\9&U<-+E&?%4,B&
M8OB-E.3 '7SZ&JX@UQR'[)Y;NVMQA/#VX9! ,7^B.LL<TG1&EGLZ4>M-6[:G
MH-S;=A)TV!,D3.KN'][>O=R;I);M+!CDH%)9Y.832<#P =$5 (S!]B3@5PI
MYP+_<NEEI]Q+;<];9@Y5]O.O5B[<N<@J,)2XT;.%3KK +)R.B+M%+SSN2,GH
M,1_!I&=7;.H_8Q-/8H'>H%\$G_<@,6Z7:.:.K YK& =JIZZH=LI:6^K;Z<1_
M;0DE\KH4\XDE_U:;DS#HH#$+L\P0_9Q+3*K$$Q9-<LPL1N=+C$PQWT1W6D[]
MJWGUK5+<+\Z1V7;,9-!("RZ&6)<U*O,%ES:P];J!]U&FV4+8-I39=?%12"+0
M' T@/MW"4+SWNXMG<$CB+6HIFU)&M@FZZV(2N-P:8RN]-AI+O1./)-=-)YL\
M*>I.EGKW*\"8I#RO[HVJ^Z#.R%SM%SV2?42Y@ZOD F6+:1&QXKY"_+V::C"4
M"]#IX%:Q3E<E<!WAE7\?_++8FM1OZS1Z7482IT;Q<%E8O/<RJ^C&R[;&*+BJ
MB*-+8G_EAC+BV<;EZ1A9KFOF"$;O+C-.[^]._(M!.>@_Z\KCQ":A;$[:OHM;
M  DLF]1NU%<M[[;5]Z@$.LS(> ;37+\O$=C8UOK"OZB5T% 9(<I)C)PMN91$
M@.W;N&.=-BO(+2P$G85)4Y?FFF+9#LX4,S#?3C)V^?0J $VR'#89]PS'?(N3
M1$87T=\L([:SD,W8<P77UHJ,%Y>A@LAD0:8)YU9VZ;U*<I2=BLY.J93%0C2X
M )1/=JL3ARER-LQPM:^, VP>F#.G9-'6 B0XL8K8%U*849)RC0H.<^=D=F_C
M:G"2:@2LK'?!:6 U% &2->#DO9I;Y@9OA^>P>^"LM%7Z@H"_[DW/O%*7WH^.
M%/B$!CZ\ =3]2HV+N!TC8GO6:MP.>;F,]*AY%%:#QDJ[QDYZ!6< !Y!KR451
M"QG5-AR3!;>$9X6?0#<9UZOG^]]9!YJT=M7 O2(]' !@D /,@@=C#Y:R8_E,
M6P?9&X*]0X,U:R2W=6O>FS"]D^X^L-^GI:D]%H$T"8ELLH'S""PEKEARBDY"
M6QMX_V"X8G$A7&P;G_'AC.-7)*3A6867!%<$!?D'EJ,'AED%6[<3G8SO&.Q5
M 1T7J(5EWH IZ *U%$RY#8,2LP\*M_>;86!.WF<-ZU-%974-@5H#L>Y8(#^=
M@ 'BX.F2!:47$";ZE_[5,]Q\'U)=(&4:YF[3R8>HU\X^#C#N7G+@)99<T1P(
MD^A1"TOSW^VAC?0X0Y8D$=MA.%* [3H@IC<WS0V*#JXI:/PK#=_;!^<??>DO
M=]*'9)\?C-GG,?L\;J//$Y):"9N/#VT\@;=O*]E=%J#>S9HUX%ZNO'L9Q'#8
MPV>R?7H6>I66D8K\6:SM4<%67VWC,.==3!/?LV/B[DVL]0(_*E\8Q#XLRNSL
M(=%L5]'9XUEZ(ABM9>R.YN:FC+8FJ2AUNC N+:?C=#-K+M:KDD#T'.>PA IV
MX#=)4.%&!3."^Y.4%$Z;<D]T-QO%/N'\**J!JY+X8.6+NIL--1]7V3S3:4X,
MLKO5#<A1YEM/[".0,V13;<HK0R_%Y;L.2CS$TC-% \OX_O(V)7\B2^)SO4HX
M=9Z7^KIUR M@J3C-OC#9-3&Q<4T:<:E9W!^M'$/EEQ8BB,-5(FKI!73(+R @
M-A\W627%7M;&PQ^X!X'Y;7VDK-*D)R@5$MO3=V>S6+ ,@WF3 U/KT\EN0<>@
MDP-XQ)$VJ3OC$7P%+4>L&.<.3[G!NH"[)FCKX:Q+9ROOR[D=FI:).ED9]K9_
M=5J&/#K/[*$>V/&6)&;N*/EZKW;KFN[M>+,*>8-8EI8S\L&[MB_UP%1UQW+G
M_4Y=6Y"'ABE$= K1[893<&H)3#HP;]6MPN)$!M W(<6T8N)>X %"*44_1UV@
MN>%-0#L;,=19322(O+M3$'%18ZP^<2;76+:91C.O+[X_/W\; D*,.[>D/-$5
MK(#'PF63/(]ZY[Q%UX-\F%!WRKTIVM$6"6A:G/G@/?#A0?827=^R;.BF"NH,
M>A?GP!MTF6153KYK+7";'6G50%(W99T-9I&0PXADLB"KEW:<IJ)Q77T*[WN2
MRK+GGI?"(<8<!D@E-:QB7M[4[A;V?36H58A8/;;%*&[/VGH/MXI$L=18K[7!
MVKEJC1'];&WG']/)>\\0"P"6-JEZJM$1/())4V\NQ2\4/:/S#LS8GPKA3 4)
MO[AF&7J5<<&TQ#.?&S!"RHVR<-]1)K&;J,*\3MU$>S>W/0&X4JQ_#&@MM-=Z
MSL1ZEE((XMRO77,/PFK%EH&_X*K)U,^#%=$*TZJK)(TLQ(I+HWY3.92JJ^@E
M9@O5#R!7:SQ#50<ZFRH*.X6"/MDZ.S_AI@C@P6[Q!)0\UV)182@/QUE@X9=[
MC*PN'#F<\,+Z%]8=FC'-'AYT(FV2&J/IQ-%O.)HX>WH2#+9;SC-'';?,>8VR
M8:ZM05'0.5A4Y/2*G"QFA:]NH8J, =B8+4896NPD;YBS 4\4,,1+BB/Z\S3F
M>I"AG[J&$!3U3CDLG694Z)G2"TH1 F;+^BE$7*]\=-"5^6%>INFP:*A :1I+
M_+SS*!55U#T1R,'A<#LF)GR FDZJ($A-[VW'[!0\0*A=^UFA<KF$]U]9VEB.
M[SIT@MNC@1_H*"#M WDHJ"D*,NDI/+\O^F_1EARHZ9IIB?000Q6SY'3A$M](
M@V+5(*B1*W*I9IM*K(AZS'KCO0AQ/VM\"\D-%6T>II20E$54D-TZVYBL^3BP
MLO=I*'Q?KH,(Y6RSFBTL"GP[%:7U$UWO+A; ^G!0FFZ$<(T. 6W/$[.ZPFA6
MOUB5AL<#5(!X)[_I'?\?^AF@9FVA>E>/^-T_&*G0U5C=XML XT<+%!"'9S5O
M+UICW'"B5.PQ0$+(]GH[AX?D6S48N 0\'5C/,U?%]CS9AIZN]'2D<>Q\_&AJ
M'<&D9S^SJ?4*Q/-*8=<.C K^'(!.J'Q6>)W0%<C(#\!-LXT='\32Y_!B!1VG
MDPH\/U"8EEW(X]D/R"PII+BE'G)EZ-;!]-#R,&5<:B;KK')*B,X!3RHAFI[K
MY%V)+@+5YUE#;$)Q6(>+]TVQN11#L#%E?(5L1"KZ5U9;5:X[ZU3Y(AL3& !;
M5>XKE+0GW6).,+F\MWR^L&_2E6]&KU50Z%P@3@>]6[+&A:44W7U:TEK(0V (
M:)FS17T'7M=]U</6+W\7X!2XH2?9O(3U9Y&C, \AAI?)=5F1N@6+*&.#Z]-0
M!@Q1*',3K2Z3B/U,&R)BG?@0LP]ID@JGH)=0.,CBG%L288R#,%<'V'C9.M@\
MY*-7R)-EEY;/'9MWQ^#T8!4PT3:X^V&VB:D8P#YI%TP!TC8./Z*/&\%R]+>B
MJPQQM&U6&S1J%P<F"V_"<,/W>\SY)1@ ?0C=M>R*-4(*AQ8^U!3.I+./&+ T
M58V.,Y/YSWU%.O;MZ7I^%>T8SFKT\2O#2-:!/7$^LEE\R9,^)"W^<$R+CVGQ
M<1M]'DOW@UBZ"0A_=&DDQ<+F[NL2SL8YQTHVR&_F_-<#3$\D6(?CI'!Q*>7#
M*EO'X?F[]/&VC.,3Q/-",V^ 4Z[K1,MWTXFO-B!,U]K8&I$$3B2'=R6 MQ%$
M':9&Y5?N$95=UU6V"8)@._"5DK!D RLP(YPQ)3&C7@<0P9WA(JO\<S0'<0/[
M/P##.1!J+V<2W'6.7)K71OQ^&UOP$_+Y6OC"+QA"\["G I@6MXD*!GN9:@<-
MTT$#I6\28%T:\_*12743",6<&YSV<)$NF80%\_9#'C-9(Q:$&P>A*>:/\\W%
M2HX/PNHT,!!,=[I8E5]=RNJ6Q3W,B9HF"[]T!1AL1MG'!K!6>XEC2<,^(N!(
M%0DGQ\BTMW-H5EF53B="^JC(','-H\BRGZ/E&9,L?G?=73S/<<;UW\*0\,FV
M=H:W\,@-[_H OM$@E+'7YZ;W !2H':C:GT[?G0YS07'\VW8L&2)Y"]AFU3)1
MQM/_:0/JF)XCL@6AAN6@6.U+H=R/;Y(K">^O,&@/\GI+4Y)P<H[B+:9F7]?@
MAU!BF0("].ODZ@J[1C5$P;=+/3(FNZ<9IY.1^>UH)CW+I1S329><[[N;("E%
MRU1EW [(TINR.\:B&"C9F; ?,/%I$/]F%M0@4$N4<?R--(:ZA1\UEKBS/O3M
MF [S(4\H'L'CV'^Y@U;Y&)V-$-!)R$2[0XL2?JW7Q_KW^*)AXX-.R$NN9A"^
MTI[VYP,B^%C5P^Q@4"\5:676=+2VBMU9;LKI9 9*23QZ4?[P4]?HJE*3<"$:
M?GFV%TY_KO1,3P2JR#^%#W X6NBSIWOH^X2X.XP9#3T?SX*6-&3+K892RFB8
M#M10KM8/A)/#/E$C"RTC+=%^RY%/X!8Z8>+.*43JGZ.4?6;SY"-N6E-<9U5I
M9PDOIS$2*L:=P_6:.)J527(JM\*BB*7!4<'%U+>+&O4T6_5=]_2B89 I+^=M
MK!A(75/X YA%\1 ;J47WMVZV9\S3[XYL[K,UGS,7@4B_ L$?;F78,_&HR\%N
M,V^8[;-GX-E-1BGM#?A CHK:[R[<\:L6)A7)OI)(HMJ-FCHX6<\SVD=9A2F<
M:IG@N%#BX^BJ0A4J?^3,L<07D&,WE[\PZ D*+@E8FWI*P4@ MF:'8P4OELJ$
M#68O;7;7Y73\Q\MHL8+?+@@'S7/F8F9"X&&UM+"8XZ)\S!:L./^55&G9$EFR
MA8S"YS=)W9@>+Z;/H_S@?F?W?(!6YHKESF+&+F9,+6."5X27PIMH,;>.AR+G
MO^J:$!X:IA$C95/L@0(H"&4%9C9=MBFI!IZJU:F@GJ98I+EPDPX,FW#"-P8;
M?"!@.,_#FC9:OA37GP\O^@>,-&6_D_\=Y48TJJ>ZKCT#=HWP@06A>FRVKY9#
M%HT*]V,Z%-%)V""O.F7G;2FD<E9B5XYHJ)=O2HNU;O,KV^.3"_0LN)A-$H48
M'=Z:]M4]X;,<-3^F^RRT'-9%1N7FXE, MB)0P?E+:7[;2_GWGZ[;3^Z!+3P1
M'!.W"=RM(7:Y9@ZUSO-P[\2O&(R'_3)W(!('M^KVIWFX.\Y;70KT68Y/@D4,
MHCMP:0]QZ,;S]-_W/#TDQ_%HS'&,.8YQ-WU6Z[1@Z_328TS>\JDV;)U28EE;
MIV!@U-0=&;G??+N9ND-Y+]Q"<F ZGDC6\!L.'!.]SD[R>FO-#J!A"+VK^?D.
M.#S1R $KA@K]A\IV;HE,VFFK\U.[B;\I,Z--$]\W5[T67]FB,B*W!*PZA7%T
MC8W@:%;.;ILQ;)(K?;_03EZ7J6\$)C:$FP8/\=@.X^.,GI:L-]YG34X;XIS@
ML0<J#8JB4&]Q[FZ G1/(%F[H=IC'08JR#*Q'NCG7#',D2/4^%P6R9CMX[_W$
M7*^)!FGX+A*AK%4^C+> *RH8**;J3HV)(7WP: ]KM(LV+2EV=R)<TJB7N$V8
M'8=#TM'3P"AO/0N*FPK7\79^AX.!?R\)_F8SK&UM+"0_I=\3%EBUB.C=>T?K
MT# 1Q9Z(G84K_$JV#KW>B0(Z9TEB?O@3:2GD#P1+F:TK#P7@#),:IC+GH@LB
M0%=#(.R91']KIS2QA4F!!FA#.E.UA-H8$!6F53FGA*,6'*[,6]C2D1483>+8
M4>SAD!4#H47,'/[2"B#?@1"15!Y72^$!Q2U5PTR);]!<^T0KPZ^GZQZ.6OH(
M)CW;2'<!T (4MFKQE!8AOH.NCCELY(F38']0U(G4*L;=*#9#_] ]<^J8"[M0
M(Z-J=']T+L(MCK8(7R?%8$5"<^,_:HPU-11/(K9RB4-MMCP@'T]2I!&9GK7;
MNOP#/C(ZY$_>ABQ]LQW22Z@SA_LA#=N7MUF7G O'K<M EC!L0BM]2-!DGPVY
MKX'/H#Q,)Y>T#"$6? C=G_41X!M7($28HM]@F;HV6+.;"@D$BB!(>L*G-&?N
M>%J#DXEX+G1O(FO J*#MSLA!03I+DCD,%,:<6M",76(I_<)?4GS9_I1_J7]G
MZSUORFCVX$2H0*C!@ZN?Z7&Q'YIFYI2L79Q8F&[#^]ZM/C7:59Z:1':]>ZG=
ML';3$:YZ[)(%0>U_%[:I*1W:2ZSE-\Q=2'Z&ZZ'IV1MUS2QM!Y*- Z#ZGG=O
M-_KM5@ 6ZC:R@_;N%CI9@V[6CL.0:UQ<^:"=,QDC5!;":DJ8*L-JAWT+&2AM
M5F2]I!'-ODD^4-\*62;CR0S7\%E;,4!)\C]<78!J%GM@=Y!>D71Z8<LS<<R"
M6:AEB<W15<\%_K/2<*G$AC\+E&> 23I\Y_@Y)EGJ2)7P(9,/D6!CMU3<RO 8
M?(=,)V/CY)Y%D*W[QCI#W3<(WON>5]@?EL5*8)R2LT_2LZ;E]Q@V&_3#<(<@
MG\_THO:.0[0I$@8.Q4]0K/8>:3N8?_R?HYGYY4[ZD)#\XS$D/X;DQVWT>;RU
M7ZRW!F>S!R3>ZJ&Q;X_G.842^)]5;7LP7!746<Q;A>BO(#V&U +:&EBR=7**
M:[-1467U!];GEAHI66.-J>LONJG:U *I%K!&,$OFZM)1,R+NN$N8PA17(.FI
M0H2 YSCG?N>,,*.3WW,XB,_'4.V:YR]H8=  "1_S?SZ+']^_']^_?_]0V]LW
M%B#C@QC5!?;O#FA':$XN 9_,E2G@E>/1J4R_WI 2ZP,:65OW#3L=C&IQY[SU
M5.U5TPF9)?9C]\X]QU7W0"?,>WBB6]A> O<!*<&X/J'H%Q4%L<CAK<=X_C%,
M>E9)/%^WM?@GQCA4[Q84V M;RW*GXO\J# _0SG,;EFJI' UV6"$\ $'FP.[M
MY3/^2;[^YE;6^JRV5&L8/=>%0UA/HDK0APJ6.O=2O0<HB"11+MJD;DBQ7P?N
M=R4+H1%QJ(ZWJ@PG #X+X,C3WW/C 4+2V2C\LJV*K%X)YLN-@WMHS!DTJWY2
M"2?!DJ/>9>52)\[!V\J/40MU?T[:OZRJ\D8>N(9WL64_"IT46^5MO^ [:1P<
M1MZ(&I!#][5Z&',$#?+X!&5FA]7C4:43J,9FZP^I09X@WQQ&/X3#,XF%"A)C
M#V5<#'-*(/J\&+I94\&V-B8.F>%M)5U%8E?@1T$R"?_XN)!,U)_/'M!Q9KNV
M.S'#5)+/>2!9O$0TD1.KS>E 6N)F"&2R0E8^BI)1%J<RV7J.K%I<CX[D##T:
M+BS#-ZLD7W:65</26#K=2^%&44U 2ZM['VF** '*.<(EN8(['82%^D>FK(_S
MA*J%JSJIY@F8+_?>?,P-/!7C&Q5F=<\]I>@S5)5EWCNC A:V7@3TP"0:,HMT
M0);R \+*>F#G(%%O,'JF:UA&#^[??\#TO&LBQ_1A&=\M=K !G/1F] =;T)[1
M]>X<&-L@AZR&S?89-A1XMC\^2QS:&6"T>WR?\,6LP43F<-AT4F]!LU(9:V8E
M0Y'-+D0R0&6C5LZD7H@/,*-CI4EM;7:<+-=[!4V_:/I4*3I(@HM$7$7"1[*K
M>18J7#JMF'AVT4-7,\UB]TG<3<_08@:F/8./A([7X7*<MZ=)5(>:-=M<.3,K
MVV5$,(==-D?S)D#C!9U U"&9&-'09*(Q4%ZER+>?;#%B014(X9]?@F!@=#KY
ML>#F)))#9Z$Y-XPO DEM](LF,2&L-LFJPAZ(J0<WY4CZ4.UNFBV%(KV^DT!/
M)[<C9,"*@!&"X69276GM9%@ ' NPL]%AG%&$=DE$W?#4@!/FDO;[V</DWMGC
MF2'<=G3V..6_3HA\_S",1VK05S321_N 46$:C;Q3<9I56?@NEKQN!WB[AM(V
M@(+R66ZD,^Z<L'<[N'"(LH[%QI50,/GP&LXU"HRP$L0[ZVP>OB$JLK34Q0%1
M=*@9/:6!TZK4S""(W?AF.822W+()+*8_OVY,L%@.]!U=O0]8\ -02DHCF\*6
M)MB>!!1B\ = T*41!.4./36C&0N)ZS&M2BYXKD3FU6G@'D:\Q!OC9;<M/KD.
MX\X]/ND#6#:P/&O-F3[T1I(Y1D9Z+R+JO0<T!X9?Q!RI4",^.)$%PDU9KW]G
M(30%<><K2Y;E@5#8((WICLDLP=^X,T\&%>'+#&)_N#XX4]06W H!61^R0'5T
M%^YD%X]X2'8@M<S7I@]=\PEVE<K+LP]($T<G3^=ZZ7YZ\&R&/)#N $<WX<N=
M]"&YJ+^.N:@Q%S5NH\_C;3?"C@%BBQ[!B[T1W_UH /[*]P&"8VM>E1\D-4/Z
M'+:7YU0WQG<2YKI?QLHJ'(00Q=].;R%6.C\O5D='DEYG-<<-)2Z68.TLCX7J
M3!<<^T(>UB86^DG&,H,'3W?#__H0K.!XAOHE_MIFT6@(^8:UTJ2=#E@DXO;-
MD0<]$[N.0]\1K$NHH^>T;D$P3T^(XX1+B9XG4;/=F& .TA(;CG;;,8L,?4E#
MI>TNY.2O794CVXG'J7Y:FPJWN\[N\7Y.G,EC.58@1+))X=-6#HV:K=<FQ4_(
MR&RH!_G"9!OI!+]UD6[REGP[<N3L\EE>@7_V'V"=&Z\H.!2!GA^W\57(R[5)
M"F6V]J=I(X-G7S^ZKR.#I].)GCMKA$&X%E68P5H7R$5;#F6LJ>/Q(0-751$A
M8ZUWL^XP@R,3Y>/<O]>NK-2)2^3AY<2B*>>E0UE0RS;$*A#%P*W'NO$E45HH
M!YL_<E,\2WF@N,)O20>/LGH$DY[=V+X&OMKJ1XR$&R;%NE1IG.#T68.TO>->
M,+7(( 7.=/\?UT3TP6S.340?S*Y<.*73GA&Y-+0\$AT;19Y=KP0??T4$E*N8
MDX8\/M&=U2JZPF!P%\KBR@DI:+#\Y*%B5\T$W21WQ-0*81O3 ^_5&;N285<I
MH)G;M?5'X_%CFTXH1J5'-X2=]EWDSAX@JJ!9[>G&&O=8["RPP+5!^9%*2-$H
M5D4ZW5>N:=9R?/E45@(GID#3U8KK:2NC98BQA0HZ1!2)FLQ)HFL1Z#**M#;A
MF ^NV+D9Z-*+W+&V%6I1>N!;I'%O8.\K,T*6'>,,M>$*B&7;V/@T8<X\]>P0
M.PW##M7>4S,.4JC]?8=DMY;:'ZNC0&UD- "$*R#DO2J+;,%^QI)DMRK;*U[B
MYX9Z)"*-P'L$8X2'@, 65/Z%$/Z<0>0&N=RZ*0US.7X\.%V%PJ U,IP.V?MX
MURGXL"&<A,Z5\,LR2*6_ N-Y=@23GGWD\^S<EUBB!+Z'@X3"YV\=W]N><OVG
M95)18NBY0^:IDB+<MSX);;OX9&1?Q:Y9+Y70,:X(/M,-;BV:K<PCZO8&MX!]
MSBU+8]W$;SVG<X#Z_Y09*J,-*AY-0D<Y6-6U3F!#MBK& 8I.%(>FA<TB9.M>
M8Q>&0 !U:$,.)^^(XH0A!EH=T-ZU0%V85Z,[EY\(FQXU]7;M[:04OGLG2T5
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M_ 'JG6&J&\);-Y)J?U%*BUUM?G7#%YI0U(],U7(1SA'T]<<3>J#>"3@R)HF
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M)"F9N37]P7V.H@_&;&SY#L80.-A3V=93$E[DH&3#!8 YU0/9%&OP3BQ6V89
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M:_W:]J6E;L/PG@UG[+<AVLMJ&WNV>$5B0_H'+B*70]"N _TKG%6W5GZPZCU
M[4;2DIGFYTN0L= !/K9$+,LNM;1M(D9AP7ZHCW+QJH+ ACSKH2*JSJF]YT1V
MK@*HJD%_E@?%7%C>(D+%YF*5^ >5?\+$5]D\TTD(4NRXPZSJH@.@Y>;)9&M2
M(<MT(I4L\I[M6=LIT$[-M<EA%5-[&C,)Q"Y[35-AXR %\62LJPGK51$)$<HW
MZ1X*!6-HWU+[+MWM[8%GAV8#RS(BM75ZH^V,:_3%CF#2W>GN">P^N#\&=L?
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MURVHJU_=,W55]K[X0*2^P]@(M)S 9 !+0A[C(*P.>V>3"S:5Y *4Y/AO&3;
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MY]).&Y/J>:[;DN,EM,7H(<1]@C5AF;@R"A_5G3*V(H*WO>"&[Y;=)&N&!D(
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M3."\@]1]'D<)ZS7)C@[+3=.Z36ZLZ&KS/NY;]<52UVM!1HXL$+4M<3/(S#D
M#\T\%7Y->+"$2*ZH9R,H<F'/2Y8)+N<8S0)X!2 4D-R?Z5*;'NL_@Q8<&_+
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M3%@Z2JJ@BJRD/:15H7C4'*O,GX@7"%>.RG1[\\6T-(FQI*ZS$<I-%?.+:>+
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MVVE;21FZM7NUTATVFY;( D[!I0(];_-9LY?PAW<0W\6?XG*T!9L8<LZP-"?
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M1] Q=&R:EE#C@KMM>S5\8;W0OMU":S!/OV+W'FC+//AQ^_HPG,8MA^KR:_D
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M(W?T62LW;9S/*#MLF&*M43GQ=G9FVMFA,<)N'MC%7YZ)3"&KU9Y)QN\M")=
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M'B_;$[-:45*7(GU1"$A0<_NPHEU6S:LRK%'][JI U094A@Y?7KH3&\9E<U>
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M"0;XC(".M,6(%$6=8KR)0:+V+I(_4+G__ILC2?SW<G'[)O'[YZE-*F2'GPY
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M=SA!T2X*KY56;912+A-J]RTK7">; _R/HY%$1Q/'Z-^^I<CG_P]02P,$%
M  @ Z(M)7(\I*6HD P  /Q$   H   !E>#(S+3$N:'1M[5A?;]HP$']'XCO<
M(JU/I &F=AJDD8"$-1,%1,*J/IK$$&])G-I.6_;I9P-I@75=*Z53VPV).#Z?
M[W[WQ[E+S%/_;&!5*^:IT['E".IG^JX_<"S36(]RU=@LF]V1?0&>?S%P3K0Y
M344+&O5,@$\2S&&(KV%"$Y36UH0:>)B1N28WRJWC8I_ -T)',5FD+0AP*C!K
MPV-EM2%!;$%27="L!9+]EC"C0M!D1=,LLS\:^MLX]3E*2+QL_4GZBI>3'W@-
M1K,.TAG/VJ:A!$J/C/=L>2KN%;Z[?QNVG<'((BH5O-FUG)N(S(BH5IH?#ANF
MT;5*,^7!$.P:MHYRR985D7E#)IE3JS<:>L[0KU9&?7"'MC-VY$5JF#B?7<]W
M)HX-XVEWX/:@T^N-ID/?'7Z&OCLY,XVI59(S[CN@;_C8?<NY(/-EF?#/<;42
MT)1+YX&@("(,) WBG!.:RCM)(!PF>$&X8$@HHB>0P(GBEY,^90EX>@/H'&C.
M@.&,,@&A9 GA#+$@@N;'&C3KS:,:7!,120Z>X>!6V9RD* T(BJL57@CF2EJ7
MT GF@BJM5QC\"#.4$66*FP:U-<A0*GD8XR&<8T QI[!G),-SS' :8$7(.>1I
MB)E:J58BC$*2+N @#B]SVG9N,LP$/V"KF=+'<VG6;_3]Y40HLF^CS>]T!P[T
MG,%@W+%M>>!.M+JVFGOC3J^8;Q#-*),VZP&-8Y1QF1'%W5.*W#4)1:18Z^]5
M]33]22'^2GJ-!"@N,,L#N6M$C.="6U5RT[>?[J:-YB.EN+SS8' #?I5VA1A!
M"AA/4!SK@?229JGTSA.%7[K[-NZ;P;=?FF5[#RH)4%XFNS%[/,;GC>[SVOTB
M0?T;P9!G)A94\JDM7S#C>/D_,B\B,GT\8SEB2_BT*M?'KR8LQJKHE5MM7T^#
MJ-V)?*?KT"<X#ELP1@M9Q3U\F:L61XIOPRA3G0IOP0!Q ;J^>84V;?=K 66O
M43Y6S?.F22AHW1@%WZ$A-7,:DU!J+ZOEV&HD[GOE>')?L96O.SU*$8XB@XK\
M,0WIB<(I6ZXTE"_7_GI5"6:H#R#K+R+JP\E/4$L#!!0    ( .B+25RCMV<;
M+$X  "83 @ )    97@T+3(N:'1M[7U[;]M6MN__ O0=>(LY ^N"<>VD[9PF
MF> ZL3L-;IKDQDX[@\'@@!(IFPU%:DC*CN;3W_7<#SYD*;$3RU6 F282Q?U:
M>[W7;SW]^>R75\^&@Z<_GQP=PW\#_//T[.79JY-G3[_E_\*WW\K73Y^_.?Y'
M<'KVCU<G?_UF6N3UX^#P8%X'9^DLJ8+7R57PKIA%><@?A,%I4J;3;^"'\-.W
MF_[N23"+RO,T?U 7\\<!/&X^&!=U7<SDLSKY6#^(LO0\?QQ,DKQ.RF^>/?WI
MS>LS=[P'TVB69LO'UXU(SU;I?Q*>X#?/_IR/J_F3I]_B"V%'WG[F6FC.]G_^
M[,OT_**^R<D_??[LY.-%.D[KX>"[_8=/OWW^[,NLY/=%5:?3Y;8>Q,V3$9S$
MBS>__/+F]7!P>O;FQ?\-WKY_]^+GH].3X+>C=^^.7I]M]=G ZO1XOM0J;OJ(
MY.UU&>75M"B!N2SF\Z2<1%5"ZWN>%N^2JB[*J$XOD^'@["(IHWF*+WR93_;O
M[\+[#_;LZ/FKD^#%R:M7;X^.CU^^_MM?OSGXAOY]^O;HA?[[^9MWQR?OZ*\;
M;\=5&M<7^.C!?ZTE#%#2/#U[M_E ETE9IY,HTTV&0;XA:?CT['CSMW7<-K.6
M[P_^ZR9OWF]1"0=7XU1/+Z(RJ1X'_\-_S&F='6_%2E[F:9U&&4[UY"/07UHE
MP7%4P_?_Y 7]*PP>'CS\P5T7_-\[4D^(%(DJ;^[>/=K_/LU[MH ^3/,XP0$.
M\,&[+NK66<CAS2[C[.>7I\,!B[V@6^H%>_5%$OPYB_^]*)X\?:_D_/3;]\_^
M7-*'(V!X<#>GP&F#^B*J0QBG#"ZC;)$$93))@!G'H=(\_PG@@;2N@JBJ8+$5
MC3$<V$%^+K(X*;TQTBJ '4CK#%^VF!=Y@/,"/CN#U^1Q4"W&OR>3&O@"?9&E
ML[0&05# V^'91.D5'\7O)T4>I_PUB(DDS:,IO"NH$KBH,/WZ(@RB&IY>!C5L
M(;X"ILS/X,]C('OZ83%M;I#<$O^*>$O!.? +YV4*_P]3_O[QP4$PWY_M!WMX
M>O\HR@]P+FG-PX_P\7_:*_;H\.GI^[?/#I]^B_]I3N ,]@36@XMKCSU>U$%>
MU+B(,J'UA#@^[%XU*=-Q0F>'$YPORLD%2!C8CK*8!;YP#1JR%38+J.XRBB/8
MV').3\'HC8F]*&9SV%%W/GB4.+Z0144,,MB+*O<\HQ@OPRQ!)HK37L!EP&EW
MT:7P6&_-<$8P] PF=%H7DP_[.'NS/CR#28+/%'G"$VC^(* !83R@0</-X<DL
M"V##DG\OX+2%[,RAO\6WPK9409Q,TSR)@Q3>!@O"?7FX-Q[M?U%5\K;Y(1R
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MET8?154<_3MX$<U3C*2[E0[RU=^R8KSRFU,*LOL/:$A<*E?4>QHVZP[V)'>
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MV1)#&Z9_I95FR,>VVOD&P \VSG':!"G!IF)=3]\;WIJ7#0#O*,TJ@S@G9;!
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M&IV:2UZ.>#\J'!(4\BRJ*J[Q%C^[9\!1.8+C__(V>1+-4TSFX(DV_1'D1,$
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M;:Q[=>/2J++N K]]J';R$W0I34MVS[_A:\CA[&AC*J)4KTZ^.2XJO<ZCTBZ
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M_T5!M^)6[4A_*UQ, OSX-Y!H)>7&OXJN+/+COQ=)Q62$K>CD"<DA<\(3BJ8
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M"+-S%!^]RR@T:% 8@T:90GM'=GFXRN8,IH0!9"OA8.<EI6P^IUSMQ/6KAM8
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ME&(V_X/$:06Z=SE+%B%H[S!KXFGR"(N]9>9] A(Q!YV>?_]+#KPGN(35+5$
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M,\LT.HNF^H>@#.L^(^G/XS'\%2<S749X5V-6Q:4P8K6@0>UW\!5HTU$ABNM
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ML:99,IUA@L8)*'T?.G. Y+!AE=DH6< H?FX1$<KZ7"C9"/.Q@5)7Q_A53L=
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MBT3T$7X?^$M2J?\8&=K2PA#4X@C2#W@<<WZS^7P8I<0#]=?$"W%%IS$QF;R
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MZ-IMX?=WX$%AFD\]M&4Z'V#WB<RIYFR_H%@A><W&6SJM;3]\T;;[IE;03JU
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M(:8&:K%OES>@D9AJQVB"%<2-YMKJQM%%@=61[/9M=#;$02S'R*<\E4#$F//
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M??IH/H?!1<X*B==< V8H\S4+5#!*Y7 $%)I4RTI E 2VLL00#% SR"AJ,/!
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MY'S:'R:@,L"[9W2([G7]B9=^#W98T_#2G7$W]$YPW0U)EWO#B*QE5T0EV';
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M&UUNLE#Y&Q<%[&J.>AE\2W:F6H =5\"7T=QB[D!675GDZ0C-UU@%'.#%>2[
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M7HO,<8$O>9,D^8#4EJ<H.78$?O>YV]9,=,>&[_[A[_U]QX9OBPUWQH3) F8
MN*$X3M$(H":+B9==YS:LRS$L7I0Q.5FI0Q/98M23J?'P6/ *<1[FE5?H&?:]
MI>@FM0^44660?J-F&M-!^\7;>!/2]G3.7;.+;]_LHNM@ODH^+XQS7]:QN9QK
M)US8[QT!6>*]GLV'63J"G\:<"C7C:& ]B6)K5GF#+)!'NRR0#6:!/-IE@>RR
M0+[SP/SK<;]73^XK$UW6E(I3LT5MDJ)?S)C%[W2F+[:I>-HG^W O&NS]K"L+
M^CT?NRMLB[AS4+N*/B7:^:RC_3#=$3P3C3#R#WLW4K6@/68OH]PP<7@_A92F
MK.M&"QZ":KD*Q1UP=?(V!V&<3K68Z'Y;F2A'AP\/'G>TNZK1QO[#(WST:\:\
M5^!F#9:USEY(5[!F S"/V7VQ97PC@ZL>=R;&N(D7;>ST8B]^?1>MRF>_/G^;
M(-8(W%:6(*O^JU40-8TX:\!] S:]O_G#W%W%Z[-E#C9U$S><E9$>;,%%/)'X
M]MKWL":A?T6'CY_?UZS4&"'X1YM\-^4?ZTW#YHYRMR,J?+.%C9)+PK5P!&[C
MI^Y1@QW0(-)*!X!199EC5NJ:F]','J 4OPK#TUP+8CX?1AFI1#(4JT:X52<)
MZ1P(:WR.6-]Z[]:;C.ZECF/+&W$J6&")17_8^ C>C%V%XC3*I:.1FT)Q\OOQ
M2R][(AW;\/^J__2Q:]B3B%5&S/!@]Q_IES(X83"DY*W;.Q[8I$^87GO2YWIS
ML1FB,RR?K<QA7Y_ER8VHHJSCD?7F <0F9(=I%2\&-2]G0T\-+M-6!=R@%%QQ
MS>=ZLS!=L]S$%A@'^3)U&*/D5)CKL"@^80XIEBTZRK:4<=81F2E)?+V9Z)?J
M5^91/1.G?H="DZ#;[8XN=#W@.E-QAH1S,(FS;D()$:QQ+NOBN3@N\7!LE:O7
M^YD2?M>=1WM=KTF?<5O0KE(JK5.!UIO(DJ+RCCFN5Y.]_K8L*>!V8'37G7:X
MWD2XI-64,3A5@3@*Q1],)2]!-#FTP$75C4MOKON:U[@UUVDT"/8,SA(;T@T4
M%+XI@9;[A"-0J\9?9R(D]Z]/DFNI#;:M"@E5#-4#W<<"EP>B:UT."WM!1;3#
M!"C-:T3$)9P%-_ULX?4DA.&'F9RLSJJW9[6F8M(HF@Z#M)0!4)P5?D9<?0/]
MZ86!;A&Y[KT!7C&+%KH3]5+L@3VG,Z9PY)$I(&V(H<%Z,TF5+D&(;7'W!K >
MUIO%FL 0-C?P>OI>\]:\KH&#1VFF#+B>5/T"&1K0"$]K;?./&::T)D-;(FZ6
M\(NPI?![%BW\>:[)6[$'*5 99?1D*3!1;AL21]/H0H"Z*,L:<T1G21YEU8+U
M >H2\J>C\/#PL$4AD)U9FY'X\M[B\-E<]>YDYJ6)L3=V> Q"6.4AE>2Y%P1[
MD2+%"(S<GQXT'Y%IP;4#.K_IS7'$[!+*&-@C::HAM*?>E]><A3N2H%XTW\FN
M;)L6#/.1BP-_&Z78T-4[7#)4;V;>B/,8MMW 'D1U+%2ML#5,(-S)5\=GY\C<
M+\IH&J@U+Z_M6>M!5>!45 ,8SVEG=Q <*^PO&PM,2>@H"9H=KC>3!N_LZ!.D
M>:VRS\_H^1!!^%"59@O#EJFM,XN:NAEJNJ_;*L#^IQ%9V5Z105T'L+=[S<W0
MP(AI;J \\J72OAT(QX>665N%-YC,86-E%A=CC[L5&];OW!K"GC+E)T</G@![
M1231]6;1"DPJV]$*?!6*[B7 $79";K]&8B?KVQ#T72XS'<U=0 S=Z2HXMEVK
M7 EG[[D+XW0CS; AL%U $3P.D+Z/]%ZOM7WK<G0!&>L\":NF7\/S-1K(#31V
M!WE$J[@;T5K79AQM*JZGM0X7+:+&WX>O$XTX6B,:L6&']@U25Q[O4E<VF+KR
M>)>ZLFVI*RM?USO=NN,KK:(MB)8>$(;$B:,SX;=-=D=+X.EU+8/8P5=K(MDQ
M"$/#G@TU-@4Z]!A^&B&]':0O2G&V '?UM&7'HQ[6<2ZN<_>TV_V@%=N%]WL)
MBLM\I!T9@ECJ.] 13E#K-OCQ/+= :S6C"1$'Q1=70SK5*IDSNFPI^K<C@R$N
M&J:B1' D!XHS2':W?=VMY<S<SR2Q;WGUY.Y]1+M94:O?CT1ESC6K.[& XFR4
MMR7X*A':ZUU:K?7R&I-U11=5[HYQE;H@BW1=V(E/3H&:3^#>'>9]I=%+)E$D
MPB17%!XF'O9BOMA_31"WKX N$:T6SAI?EBTTH:R0P@!OB.(X=0$EA=<QM[70
M01J358,"I;=Z.3H*:"Q") '\U)&,HV%QZ<,51&Z13AUM>NGM<@TOZ0TUH572
M5HO/"_1UV.]^+YXG>ONBD>Z"D>;RLQ\SK3LKO'LY"'6C#L>C*'%1-X1KHG#P
M;HP@#\OB$WH,7'FXQZ"H"*JAVUW0 =@9FBC[0.-)U7(\^+6H-8[3<NI$Y0U>
M:1@(E',-/XVFHL4\YD, Y:JQ'IKZ;6#:@;\U';&K.@)4E+.;$=WG;+^BCB#J
MBN?5COH]!SN#;HP;"G1XJ._KQS0-]/>+S[Z%7AGBDZX!M9)':&J:Y][G0<M.
M:MA<<S@,/[?'[59Q^G:K1["-+(V4?O_ ) :T[S;V/[&*3_(9VZZH8&\Q<.9J
MD*[Z/2PK0[S?6;; H3$DM3SI8"+ZG=ZEJTAYD,[M^EQ*R<6Y7%)SB1/CSZ%+
MI.:) ,<C:@7?<MP;++LS)Z\2U,+0"D/P59QT*6D*'GPNK!&X,S-)G*-&AN=;
MA3DILI!BYF$::Z8F63KH-*:L&IY.*[@L.YUA"RZ!CN'7SLW#DY.N*QYQXOPP
MX#,I\@*W<8_1TS38=.WI>DA9I'H2T]7MCJ/9:750CE/?: R(?D\2Y2>1#X%<
ML7S!$&.62JB3^$_BIDE8[=^<AH/!>X ]S.$+$;PC,7)$IFRQI_W^/C U<O0'
MK=<(UO2G(PZ0H00J""Q92\BF<QCA_Y/IK$IBKX*S8X/P^T"JN>.C(];%0Z]*
MC33%0YQB*,A#W"F,6(U05CL4%'5G0"E(E.KSJ3JR>N2Q4XX9>IC6$LID5Z1_
MI4M,*\S%44L=G\&T,WF#Q$(0CWG!T-N-FZYW6-8BFP_D$#)GMF:F.RQ<.;;R
M;#Q1F)6@Z&2%4A0L<&'G>159"JJ$M5F-T#*:+RD"B:O4X-6AN@Y'K0'Z==VT
M<!NRZ$H #'%OJ4N3<&D.-13SB@>/N%%@!!0_*A,&X994J1$&?K!S!.="YO&/
M],8_J $6I?O!!1IWQ62\<,[8ZG=R__1U[Q*]+<7)#M]R6'>]H0\7*-]NG^X[
M9B(L=^_^M'/O;M"]^]/.O;MS[WY?[ETQWX'^7Y5L_6"O8N';97 V*M,9F^+P
MR-@^HLPC"A^QC9I0##:?,^J *&XD 7QEN^:_I20)L5GU^\0P(W.X876QCN@D
M9OL(O$;I:=IAGO>9>O^(^YDTQXSM Z-\HQ(C6!<61KNF8; Q3LU0S-S;6X#P
MD_H9L7I2,8)P6G7\)= 2X VX@UHHYD @TOR*MN8[$8S;OZQ+<>^^A%.[P ?/
MH\^2:7<J+3'%"^842K06YDH;-*/]C>B--7-+IS>R2<O-6-D!5D6?J3\::Z$(
M!(HKIHX\-(T6_=FMW6A) 0MUTR.YIF9AIM?GLA:?(=HS<6MJ69V1+*]=D(O.
M?RWIOPH53)W< DKFJ*I7#3S%3H,Z&P(/(*13FA17"4A1^B#@#C$ZB_;2Y)FU
M),)Q992=;B33L>Z[]@6$?CCK:H)VKPEW2:2H:7^C6Q(WT2F&.*9V.,2F7E&O
M..HN9YO%^4WJ?)=7O<D0[%R_)_HY@[^A#T5[:/F%ND;=9)  SYY/X?_'8'>D
MXFL%0VDZ!/4^0?M&DZ9+D2X=RHN]DC9AU,R/X;\U=RYUE[7% "BH8(OW8\+T
M+4:)4H+DV]YHC,OIX;5C23S")757B.W1 OA,P8H$TRU5N,.C+(D(-65D.[=K
MRXN,9^E0;!H/#SKF3&*H+'(PW)8'+W?<?TN6=:FC>R^S0M/BBZ+XI)K%FQ0Y
M0U\<X^.B6J+0DI;B"JP44UPK1RV_6-7 NYKGB7;N@7J&;$J9.#C?^7;E*]Q9
MWM=9WG_96=X;M+S_LK.\M\WRWF$";7A9"3?KJ7F+C4+RQGAT6R2$;68J&>_X
M81?\(T>;(M_G3J$>2<X #4_[J)W R<*/-'5)"Q/T]B*XH18DL(5&6^88LH0H
M9.+:)M8&!I@"])3;YU<EI#)6$YV*O13]WBM]W*N*BX34-!/OJVWX,6BI&48Y
M5&@:2M(R^KT/2:DP5H36.I=^1,$%F.-HBK>_-1#%MAVBP XE9:,R@%L0<EQ5
M93KD;/D/#/ODAH@'8)QH],\\0?TZPL:UQ14Y'##2JDQ.V@OS1/#^"C0#-4EG
M#EEY_2JH@?" 8V$ZM5R_QU0VF-A/R%1S;3"O/L=6<P/5&V=G\*.633 9<!CZ
M2)Q8(D<YVL=?$1ZUO1J5<QV2RND!;D #N DYS%"F!1N/T^*4E&NWA=_? >**
MB2/U6 D7&5' )R]RFT[9<4&Q:_(U&V_IM+;]\(>VW3=EH79J)5J"(.V4$XR>
M.Y,KX&A@MOQ0Y<_6QL"<)B=^*,Y)1N@(<YEW>)M[:F+@8%R9:D3T+#K?#AAH
MS,S>Y3=YE!47Q=Q8@<ZW;$LSB?RMM\_]WK4;?0!L#/O7^FPOU4U;ZD'8T*L%
M,71@$Y$P@\=.DJ9(?$!;TT.LW\A&V)E&W!4=(')'#_=B$QF&.4ZB''2,XU%E
M7 ;E/!-"*4VK&^6UN*F<N&9:\54"?F]![>J[UTCTD-8_GO>YGF2@^[OI=<G%
MI>P/S!/H6)L811V+LZE.G&-%[ +6E^HV=B25T<M"N^!&P8>8K90U=I<V Z=Q
MX*6]H2^LQG4BXQAGX8.I('/R:R$])K FVEW.-G,2,_@=-SQ6=LFM>ZYM J1!
MCVEN)M?L4^W642I!?:GQS]#J,NC8*_$X1#%8]IX&&Z;(\SACER!,2L!P&@'O
M::$J2NQ"SLKUDPB0BV>>HUN?6R7)(1N%X*5)FPJY:%3J^]D7&7+V#[R[3.3=
M&GD7WEK,X:#(F^8[2@G)YN4 2<3]8BU7HOF=EO1'+ FEV TQF)7$EK.E!Y2\
MR>).CX[J7TG;83(K(L>W65=>G:;@;N4RD#3G]I7$4TE!R&F,MKN^BA) .77>
MW%_G&C\DJ7?@7H%LVFZ8J]GV>U:UI5-OES,XX2[9%]H4CYKFW9 N2\4WJ+!:
M>TJ%YW#V9J2LLYY=YNOLP)73'XSM$B>KL47I[/>LUNE6*IN=?'3P\\__I?=@
M'3KT<I0ZS LW?/'ERJ*;OB2I1'+M_'29D"ZZ8 4DG!0G/Y/N?)URWM)\WN>B
M?OWF*OI^FE-?5XI>2$YFO_?S=5NO>=DFMK_[4%N3A!P5?9)D7:&*:W9*0^$5
MJ"U(7C28CXN#X#AW#HA5K.O/Q?AF,=YLT-(8&P%G\],1P:JKBG'5J6NADSNM
MT]G</FH^X0@\0LNJ9E$97931;&(O#JQ*525&FHA18@HCB@T=>1*/L V2Z[I=
M^%(*QX/,%B,3U:*C*02!!=NMI&S&LJ23]6>T)RJ0UO'9<SRH%Y?K_:)@'4X>
M$<FT!4:4@GHM4O5U?$1KX%8EY\+Y*0(*LQK#Z0KSF6P*J(X)FL<(14#74:6E
MSKF#W0;!#D1\@;.KN2:L 2!G8S]0SOAIWGY,1&U$=O@ZG &,;G&2OD:IUAWS
MW2WWM/]UYVG?H*?]KSM/^]9YVN_.3=WN)2&^CJYD?,A.=(R_ MD@<M"QR>92
M/K;U?5CZ/8V91!PS847T)*5<_9B=$V>S+&VOE T]+!O02+(DJ,-".DHM]\B>
M(79=Q''W():1O!!'OX>Z!CX4(U*N=N2A:N'\KJAEK=%YT5SSM>G2<61*?G]A
M?G(*>AQC4:H>@C3O<I$$>Z1XL7LPNBS26*O?<3$?5J$3!-(>=;',NRRCI)ZT
MU6XFF387 ^E,K>9#WCVUBF4)ZA\Y:C&=K6R8(Z%T1QX5TR&H7,JK5\,JL 4#
M3Z*Y#<?#9Z>0+@9K#*ZF6)G?-CJU9[X<\'XH'!)4X2Q2BG$'Q+?MF4Y4(>.X
MG+Q-'D6S%-.=>*)U%P#Y+3"H$^D2K);\4)L/:%))<5Z1ET,K"+UBX25E5!4.
M*.A*-O<>1SC((8$&T[Q<F&W1-8%=AJ&4N'(.[B5YT0A3>>PD]<+M*LCAN?;,
MEINC=M#0&(SFE>0$I_+>U>)$-H<1S 4V=&0LW1&5AC,&>2>*4B->PV_F, \8
MDVR_Q&RB.EG'E/3II^HXUB[V>3%S)$16:Z V=X;C2H31&@NH%).([WS&C;>Y
M1\K+L1:P)HF4.3S28XB4VKG&K+3_#!^@F370486GL&^5F4&D>6^9[/M7\CNQ
MJ;9_64.1[?.A(BNE$O"+X+VTHE.=& 'VBK3B6/#-H/@(<RM''7 EV@4AW(12
M;LKN@R3+%#W=%60DHN.)NF4'BB,55P*;$WK.7IUZS6Z'BE)4L8%F1 OB3&K.
MR^ +JB^?1$Z)P)<QZ\ISR1JT/0LFTE)Q[J)V^+44&**3!&!3Q\%>(B</0SM+
M:H.%-498^W.SK&-D2W]EU-AT1)!'L J8_($KR0=^B^7N% 0$%M?-YO=TM!GG
M7,::R!RO#^A;CIA@7Y?KLV\+5Z_@H1VTB4WCLT?G(^U6)'P;Z90::.6F'/^"
MHP36WUH&NIU"^^D4#)V1R^D)O>GWANT1 T=T"&4N\ZO;I'@G8-(RX6MG&^QI
MGW<82':^SLQG%RI(#B?;J"4!QY;B:FA8%B\&4,,?45(T8%&@7&DQ)$3(#G0=
MO[S.6]F\9U8!KQ<N^5-KFY9%Z:#5[A&,2#/&K_?1J#DM =!(KZY]SVM##0)3
MI[%\2D93HGN*.SQ,%AR T2=O8/H-JC#R8Z)&/EE$=*W,F4GM I\(YP#<Z%3<
MZ[93#;9D62-6#3Z E/R(4O+$-;!9*SB94]V%(:0&4+-OY#< @YAB8[3G2N)$
M4]V9T%%L@<V1W/8-?K;J020GR*,\=4!$F// P!?QKFAOOZ6A9]I6\S(G9JMM
M1S_ITJDRHHK%57*HZHM1VB]13] *K;Z"?YV)*+33B\Q>@;HSP^#^>!PV;.30
MZ3L!IB2>SH5@ &,"#==%.1\[4Y'J&0<V:!#L18ZJXQ*&I^<0N(N/9]R(3/J1
M=F38H;&_):.HJ['&=0S<G9<!J\!BGZ!=8KD(*,[[)-4&WNK#E-Q4(Y*HZR94
MHN!+-:)^[P8JT;BF$@6>1M38^I7TG7YO!85GV?8NTW?L84I$OC''8&_5<L26
M#.N;Z#S>X-T:#RI7:PC7+]1XO$GYR@57W\G<NO2>)=[,-JUGR7 #FVA@\U=9
MK?*^U:GRF+/GN9J2VLTH0& $[#2@+PLX_[P+.&\PX/SS+N"\=0'G>P&J\NUX
M3LSFR:MY'D=3KF _MRJJ#DFN&88,*0SI1808OR!;</J4_HV45$RC1?M$TH(Y
M(]S1DY5XW=F7.4THOL8E',2PC+/?M8DH*XO&(GV/E7"N60IMDS GSQC_@_[;
M%!2V$F$=NF;L3@9=/B%<'5*NLW2$>!$H_#2(06A@ D+.I5UHUY8QQDSS>)3\
MA,R(,0+<R8I*,P0UVS/4S*9A0 $.EC6%MJW384?G#-SUA [ WIAF66F$\C%O
M<B)Y]6BXX4=[5Q.N'FMF:ON[3"TQM';NPZ.Q8NIHHPT=5+JOLHZ%?FP],<+^
MT'/"":0&NFW<:O:1*5DX[FK4B$S+O6B$!2LV/NS,Z0+X>*4-TL>')L_TLJ@H
M47H&2JV!6=7![UH8E"*NZUV#8+5;T#!,T=]>E!=1GO['B2>)I6T^:TN)9=+'
MDYIGJM"Q4;O)S9-KO"-5-C"&%&OKINCZ.4<6KWA,'+#^LMT#8]7=/F07\^F4
M"_6LIX!7:ZY!I+OZV$LZG"N,V"LO7'>M=R+PSX,.R#\.=C3LDZ/!<K56/\*
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M4FTF0R](?6$0SS?GV4CX!:+:<%HLY/>Y&/PL0@?(_JU284=2!/XN.^/G8@\
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M2F.7S]C>OT]AX6LXC<U_GWCZ(/CWE>>:H8&BX-\H%)H-^.WG#A#BST_QWA%
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MYM1BM(L\]Q?QO;C8J>71GLOWPC$CG0 6*Q0XS9P!M H7K4L:0!YZBHLT>\4
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MUZ2>S%_ENZ$GW@07X3"LCX(K-+HG*KGQ>Z*[8(.$W5)^&7UMF?C#P&*>1H,
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M0]>S_LO,;X[)/,JLOZ2:E!CV!QA)L2/14HRPDLVKMPB4VP=7 65.H$2\>I-
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M?W@E!5A9&"6;*28.6E<GY^R@^>/PH!AM8V]6#.00M/6YW=ANMCO-1JLSIQ"
M?WG+W3[F?]R25102ET2=ZVEN,&2>]I]$-CGH+<6LQG4OP;)0^N[*LT!!F]2
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M;"7NO$T].%[V@"ZGY @Z>3$MCPLS7$\7NF_J/[5C?6P%L,2_<H$B=S'^J]P
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M!<"[@1Z\CPYR$G). OBH>W)S'$$87B;6%0C U(.$ZA;?=BMO2AW<L$<7#ZG
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M&AIPQI:5<V5M+LW0_:$VL-T'86-'S6W]&MYXL--)WD=-_')&)-[\X'H_1!<
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M#R<8(H=9O^#^F2M>3B/3I)Q>(>OOJ@:@NELNWK:'HT624IQ)8 Q"B]PK!G4
M+,,3:[ (]-@UY 5M,8+AH8^FU'A-1[>-A#:7AVC;(I&97X+['=DNP"Y$E(!E
M)-6^Q0$7H;UBV.")?3(B)Y6RM2N'\-X9%_;F]7T?UO>:)9N7UU73!./V35;Q
MCA4W90W3"4O;YB8TNXR<\BD:'I2B$BWM #& 65S3ZW(["B*V6IH;3')R(;M
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MCQXYDP!R'8Z!#7)0Z!X%5CR@,&'54"44X)?">54N\!FMPIJB*)N,/^#,T<'
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M4M'+S,.GN6G$':9.,(M9S/H"[QZK"5"Y>@3Y_AR;[QEEE?EE3^2X3-@-!D[
M0'\B< 0^O"C4B-1 C(W'PA&@,P/5A_JX;W3!=(VR132C*_<C"URCQL_7OM[3
MXRS"YK(_=+2-0(\3F-!H5U,D%*"I,2_X><&_MS5F-8/<QEJC3KVYW),GN!&"
M NV@IJ]Z-HYVE:7GMM7!R 1&U;T()(EI<_<['0E=ELO)Z&QQ-_](RAR_*VSB
MKS-LX@/")O[T.&$3?,,SV0T/)IK/J2T OP,;M("J-:%WLGZ*4B/Z'ANFA"0[
M><O91.%QD/IJJ['TF%G)B2]<%#]>!TTRPCYWJV/G(J^C3RL<5'G-8P2E!J6/
MHXK+BZ@1\:K"$,NP0M^="-]PKL.JM@QT[!+"_40;9>2$<L#*6M""-3<#\LE0
M"0713XZ[/-%'%#D\]>ETT61,E-1%@@G/*<$>G=3:Y?$O%AG%("H;>>-BS,@6
M(Y#KT[Q2,HU1'34_N1:KC\9L\?M "\]F]%E_$NJ865& 71WF/.'7?-DC@[NJ
MT2;Y9%WM/E%O?4[3WC/#3N^3*T.GWQC,#]^<!B/[][IBT=8 >?#\=Q:W<5BG
MFCR.=$S.!&>6I%A %N4-AX&O15SY BBG'U%=QE&Q2#)35GBR \$*:UX:CYTX
M)'&SD0UHIQXBRYQH*$@B9;BNM[&H!617*>O[NHH\UZG]2(Z6,4$_&ZK\CKK>
M 9Z/6GZ*9%IR>E>^OF;\H$QT$G,H3HLYH.%]K,8@]*KX.)O3A<VI[+IYQ_T^
M-O/5NM!4'[U[6K(;\3L\;2U+BJ0J[&!5$C:FC 6(&^JIT!Y$G2HIO,8_*[$N
MYP-=A33U!Q=3_<&HELY6^3Y99:ZA:L%^9$N]EHJG#V!MOIWPQL&5HE=\$$[U
MQ0E2]%=K(7%T1-O";3V,-9*MEPD&4[MD6L]UR0;/<<,KAV%$CV+8G3R.K.\R
M=DTF.HL[NOVOJV9W3.':3Z$B(Y$TVUT\3F])]2KVY"=B\5M/(*Y4[H)/V&F
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MNW5'I!&\4GG!"O/-X2D:;<H1;YA5;IYV[*UP#AVQ<@RBF6R2 FL X9CL*O;
M@%5AC4R#T:7!OQMUP21 JHNGO&!<GL.L,E?"'*^<8\LQ9'"UR#]\5NI'*]3
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MH3 V'<%KU.MW+%OD2F(,-<CV-_9_^[[;HI"]&V1#4*C?L)*2&<=GSY^R!5B
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MU8O@,@ CDC7@R8C'IS2TY$M>7C@>-ED(K$%?.31SEC904N]:K/6!L"-XM1;
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MN0 H:M%ZQEBB*.J:J7 ]^7V$?\U=\V?O2KUJBPG%=%4H#%7/.F";O,=]Q=C
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M'#>SJI9;T5;?+@=%H@!DT1M$6\-^*W: ITC;(8W21^.W'A)Q.$ B'A(2\72
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M#<*V_6I:)J+YQN[FTR6^D&]L 4X>QCC9X@5X&//T2]>!#AE?S'0#A_2@2>@
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M:3Q.&W!?EAS3XPH-S@ER0,B3#FD@1([(1?B4&Q-KM"A.!>P,)1Y8QXD+-<F
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MR.977 &&4]?,P&@G3/#D9>FQ["!-HC[RV7WRVA0D4@79!XF2=;&4HNC"QSI
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M3T5:3A)5,"A=XF8O9CV)8!(W.=CGBZ::+J+2T&4YPVLFCA$URYO4%C/A.:*
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M83.:?:8+/+9WY/):5E?'F/1I,XKN,J/EKF\R*?<%8;/6DY$*,$A=3Z%UH(F
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MEV"_IF X2EOJ 2MK.:VMG08;JO,U=D/<Q#/6Z@:49=)Q->K%*A0-RB8&OT;
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M*"SRM\:)+1[EU-6>C/;*-3Z+:[HM*LF+8PE2M)1'"<ZN[@WR4]H]1]:A>PH
M>FD-& R3&S%N^*;)EU[M,1RXS,6@Q7" FWIU7V8LZA@L/ 0#[A_Q(D^0,!A7
MXR)\<G85IZ#:>1KQM_\WKJ@3OZ>D5/P[\IY_FV'1^(F"^A]?QY=Y7!81D^K^
M%M.-RKA.@)"\:B1P3E^<796D5A=S*"/OLIAFA-XJD[=J0KK=E:XL]=/U1UX9
MF%=ZK_%@R5_'.:D!D,<FIY-9)NB.KVHMEQ-%A61_.D<I.:"!+$;3"Q39ZI1%
M=G:D#VXN_*ZX;FS2J7SL8O^,M65>V$':K]&^(FG/)H9:,R*/Z8>+3B9/!.AB
M+R.<ZUZU]%L!HR37AS&N/>-*["$ZWM>,-P3SIQF!V]N5/]@?D@ES7637#A>L
MRVV^#'?;ACTQ/;(=-67#MHAX$ IK/:)6-<%, 2F@5&#U)ME"6 X%$B'JN![J
MJ[)H+J^6-DY[B[AR<J^*S"^Q$:R$Q,=]$,P] 5=@//JJ!D9]4;(;C;>L[.2*
M](6QC[4S0OXLS6\)AX1AL)&&HI#NVW)1Y*A1 X1B O1?\UTS@WD_]F#I@CG-
M&>YS,!)D1:%8=1^3C'\X:ZIQ-KAFUWM$9U;2@4U&@068"P!\,K112[^,PN[_
M;F&. 4,T8(6)P9_A0D8H5>K@>9U4Q0CZ4!2^2D<EHX=4*7T!'?#7A+9>Q3K3
M.:F*X7/E-ZC@\==^.E^MGB@I'UMB/4@%$P9..K#@C.@M]4)1Z^-14G.YBD#D
MO"FN"_J?DD;PD16W8II&P6L2Z_3/EUE*2EX&R_Y],;ZB ;V;TOPY2$#-^S\%
M@-VLR1-1:0&OP@9_K5AX"LXXHHD T,V6@%,H"X>IL*-_7M,TL:Y)#U]FS1C!
MD:TL_9C0:9O79,)L[89/?OW]W=;N4W[)O(;R2@^1]AI.RL9-ACOS?R27Q;4,
M_NV_D]F<SO>3*IG%U#Y:?.JCJ0BN5Y,+Y5"KIP4 M;0M9-7'>0,OWM[.WC.#
MRI6$7LG>U$X[;"#(,R;OR&O.-Y="WHE-6E5=S.P_\U-!S]AT*7)[*/IP"$7?
M9RAZ;PA%#[=@:T2O41&@04$CB^ &E$)D QW@?R-9V8*8JUC&EY!\H.I)\S@?
M,U2AT_K98%GE%XY4RL&[Q*^D.P .*<:P$@4.UUX.A_1$H X <%S4RMT#XR@>
MCYLR'B]8$B=CNF'#FZL$1(((J$CMJ35K^/[$I9)QM$88D.B9M+2W1[!TE2J.
M49JWQ+4&YEF+5&@Q-#Y''07J-3=IFVS>QD<.AM6RPG<EK&;/,<(;]9QVFF*Q
MG8[K%J[=\W=GYZ<6UJY*ZDIYM% ;.QH!-9AKB>=Q?743.Y10!_([A15?I=3[
MN P$X8/.T)@V^V7"]Y/AN&HQ$V&CC8LFFR#,QP'^T4(I6?U3&F'K,W.X@8!<
M@@]SZJ11<X+1@OO(:(3 P3 ]0(5F:;]"D%-^(8_H&!S16@KB1CJ%) XF'K:&
MIAE8D$(Z@;,D!ET:@#8 $$\/ 80[("7U!@5QC F2Z,=V"(;^'/'40LG .GU
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M<3.[ACJI_(]>G]O*)DDAB)O:F.0%0]LV.1Z<%F5+!:N*(C=]<+0$D^W@U!)
MPWW!-,$R7>K8,4"9?B\F12+,%9B#A;I05&LT2ET?R";S2XH*"6YL)#?INP->
MR3)V$Z6/]JD(\&662<%+E[)DL P:>F'U"3VC"OB;2U64CCZARDI@B1$Z]VG)
M)IUH]B Y9AW$0".;9TG8Q>$5P_R.6=DMBRD\P(R@J_M7=A!^S0C/G.,U"+2U
M'A$38RK%R#0>M]U2C.33Y':'=4%<^7P(QI:HH\X1)IX+U;B4P(/+M!6130@V
M6"WC!+WMX$52S5,!<L.WV+2[1[]4/B1;DM.KQE(/'E\"(J=>T3W3#YM@ZS)P
M&\0+GOPM_7L;K^2Z#6\4<$(!1Q& BH-$@R<HX ]?;)]MAV=IN?TT"OL:X5QM
M1I(X0T_.6 OTV]C;#7=W_U8U\[_75[23Z+_2')_&;HL!M7B&2Z H<Q(@KMT/
M=J;/>*8CTGO'VYPA_(0SNDZ67X'6D<*W378XR;8)GGX*&4D:(+V\<B#QG(U)
M<ECY>Z"?!Y_9!\KU<Y5>7H5(\81.BT7VURPC&5;'2J+.P@>9A*(CLWZD^1Z<
M2;GTZUB@S"T_"QQ^1J6V'@-CV"__L+);IC5@.EIT"4P:P"3.Z-+8*J1^W$P$
MR5W2O^,\8369'=TB+YD!6:1P_\'Q0JO:EC@+^">J2YIT3<:EA!"]+-0Y7,%C
MS'-$!WA+N&:[[,0<D.)3E<:JM.*H;+K(O=UQ_&QP'-^GXWA_<!P/*D-K1!=)
M'8C'BTRAXD;L#%:8R=B09) .:0:DFPV"VHN]@S-O[8N-1^?XZA')<=D!YD%'
M2/%GRP+@H?$9#F_#9SC<W9U_LB+H:&=G_LE'9Q@6=PU'U/%O+!WD*R[4447G
MFE.+R?I&A4G_&3?6XS(:#_R*I-0\T&$? ';6!V#G6^>#;CSJSH-/*")DZ)LZ
M[#W")4G',Q$-9/Z!9!;FO7@:V<?V3ZDJB&QT6&,'<!FE=&R>I !^]YC*KE,R
MS7^&\4V;\&G7*<A=B6E@U-HLXW(XSQ<'']J X/'H$3P>?$__MI@7G](Q]P]L
MU$(3Q/YF28O3U"S#&I2E4T5Q=_MXCKLM':<UE[R97Y#>&X]+Y/\ETVFB;M5.
M@U537J=LL2,R)#O:A;:&_3OLW\_U]=0*8>[B'-G165*'V:*"JUUKO2I#10 F
MK,+X7SD> /8]BRBAU-:QT<:@GXT25%ZU]^NP,X>=^;F^_E[<<-_::H#>^>,"
M7-AYY4/L<\ZPC8%"6OZ[*/("X<,G<9[.A*&>T_V?(JB65[.4(TT; LOTMY'=
M=8^V!@O%9-1J,4O*ZA$/8_,L^'_,BSSH)83D1,]^0DG.4A"\#SFBHT13'S6Y
MZ6I1 94"<1L)_DLD.%P*!=,#5P4">?C3,5$C[H+0LH1^>N&IO2*Q$/0 0,O8
M#L\E4\9%^.5&<QU"Y;/0890QVP92CP/&;RY@T_@DIS#-.1,GS=5 45R/D<0<
MO29G*"URJ:(<3>1:#\6K]EKH<78R[$?/"G#LJ$H"O^\<"S(U&7Q-<Z8$!]7Y
MN;A&!7$5/I%?H<3(U*.X=I[2E *78V:K?&D6D@H)L.)3K5 9T6X^0+*"^9(G
M+4^:LJ"+_S*A@?W8,:2C(89TGS&D@R&&]+ANJ7O6%'Y%;E,.N41RY[WE,Q\0
M1_Z,D+QG&8G,D^V+[<"M5>A6"O?:!HWU^R_>0]0T^"H9O8G>#.;2BE-RLH71
M2%Q9?RO12"HX39;4I=T$D2WH-H3TDP1UW@YJC41G/F:\ 4[ZXX*&K!BW6M%T
M'X,_P&0\6\*R&H_')6DTDA84%N4E:8*"*E!%ML\"=%#DJ'#@OO>-%8 '53'F
MU$J3NZ\O+N;JR]-Q<A*-UJ#&)5_+OL*F(PJ9'M*\7L;49O<13Y_E[!F#OI1I
MR],9"A0"KUBJE>WF49>8*H%6:913VF>6U3R)H()2\Z/&EJG8$BKHH09VP0W=
M5K@&*)*M(I?"&_5 1U2JH+KQ.R0]W1C1TGQ G000G%NJE4!@#C7.U%G1J6#X
MF<XP.>U9? <@B(W4EQ"I?S6]1OTT#2&+$:O$STE]^AA?\I^,FWG9F2SL)*[@
M_Y@D<W[,SG# I)LVHTHWF3PS805*4 [H^UDA;54Q,JY0/H#EGR%)F?],/O&?
M/4NAI\L&/SEE0I(-LQ"GY#I-;I0OD;-F#96HRE].LP3TG@>(9+&8-DF.?7_)
M?/_7*@D;7^FA5>Y+XV30)-TNPW6[YML4UZUD,(O0DS143XAAE06OI#<IF>]-
M>UFYNJ_&ED#%37U%8JA>F-*D=X+7\YM<?!>"X1EP<:)F_;_[[<+5)1H)^TIO
M]%=%,0%>6',IHO^LJ&:(MBZ5-[YZ<7;JJ,$N'%OVF 8S2CPUPG8V\-.U?^-1
MGTE\X8. M>@K#5LR\S7Q-UO/.41F]KVG<59V6+^=??CY764'1@J 35@?.0+4
MN@BZB>,3'JRY\B+^91LKR1.P=+G$ AP!/T]3<74ATML&\;K.HH7$*V^XX$]O
MN$'FKOG>Y?+0X$(1*_>?[5K)2'(OLN5MRD8-=%I&@_25*#%(3'F99K>(?($:
MSP*[:O,AO@.FU>[>$;_M0UJ3I;"W:S2ULV+"31@AVR>^SEZ]M[++E[/\6O\7
MYBDWE#:"9@,DF0X=GAA;BN%8+?BN02C7_G+F**/]VTGQKQG;6L9O$'S< %C"
M&M<TAY>K'DUT4N1%&9 :?IEJL;5!K99F?@D92Y@F\Q)@60*L1<UQX4>"9$):
M$M:E$7663$( B]O\(!^GYRHNKXW%H-U?LAX":P#TF@<"AN0L@U\\(X>;G#1E
MHNBI8#66NDD_82EJA20CA7^BNYTK#(&-U^12!1?0BY #,JCHZSTB:'-+QY'V
M\111%A4/J-R%,SU+;)4ES%,]"%R<FE<.3%5T/U&<X+*0:\D!+]A8&X._DSF)
M+%K>70'O+N\#8+XWE3A'9.M-::\J=ZR\AXS;= [\VVV#[HK#O#PD;/LQZHK0
M68Z7B16^F+=.G?0SL(CR1N&KB@P1L5AEQG;X2I-,>.P3Y;05@2'P?Y?*V$V=
M3.?:C0@8+5H7F_CE\*TYH:&1O:T)+],F'Z_^J44S$'("0YR2(_- %0!J$&0!
M*GT8>2QW;BFO,:L\:BH7HQ,"\9\!(=1G,RHF"_L@:='QJ(!J;GH)" I%AT'8
M$Y59B%*B)%O3;FI?2QG[6HI\HR")=CD<47219XL > LS0=$P\YJ0<M_:5W:I
M,9EN*G'I1=*>5*#=8=ITUM27-=9^!UK4J80(LCVY8=3#F^F[9<*J6=2UFDIL
M PRQ51=GN$E<]A)=CI%B/02"8:R;S#0T"=O^OWA2S&OCKLDD0NI)>Y.=K@ZG
MKAP/K1P/SZ<,H %3HB@MF@6-YSH)3,J5W8_)IW%"FL$D:FW7&U.X[0X6PP*T
MS17G/.HU7+S"<OH_.8Z;))*_.&)[/$1L[S-B>SA$; <EJ4V+F(QCNCP"Q3JC
M5GFSS<N4[SD6<4E<DNQV6KP+N[#LM=>.EMGCFG( F2'KV]"2N'K:_=: 8@ G
M*D7J-IP]+B-(?.:2K.,%<1"H:"HKH<LR7K14'%;;#4N\07&;\4.D7S'>7*L2
MJBIF3MYSY:(KBPB>5$DVW:+3GUXGDZ?.YV=:UC0C0\ME,K'XDI42^D5_S[HH
MI:,20",&POC)-*Z?&IN*=;8;G[:ID951]@04KL\*=NAY[ E1N*3FM;' 5/]U
MGLDEM;(-/(/?L>I(ER;S+YEK6V!-4@WS<6*H:HIV=DNV A5+IPLRX,U0X4B,
M#+;$+$EJ [.6&?,+&GSJ]E_R*9G-Y9\6Z\N,@J_VF\0G1&MKO;=, )/F:%E_
M(CH+D]ZTMG?0 BGPH3"Z?DM:X[A5XN)\P:X3<-/2Q(-=HA1(-9E]AI_H@%WP
MN6OF5R0YEYRDKFW1M"2&Y^:^QS6-5Z_$]>BVGXJ02!3V04_0LKG%2O-;4J!
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M,[;R,RU>"5W^&><L1F1"7*=EH6GLQE>,S^EWFK=9-; ^$Y.^AT1*TIBX,TA
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M494%P%=T/.A$/1UB8^NO5(DR^@YK&.[^E>/O:<[8R)?&^=M"5DV%2CV\1'J
M(B9E]=7"D!0T&M^@#:?%R$K&2$W:% 8A89D4%:1#761)"<,F"N(1F?!S21WP
MT3V7BI*33^,RD0RP#YP1J9O6 OJ;5'X!DDOP-[OK\S;URW;X0NQ"G0!["@)I
M,%I5"T!=:XPGNG>V+ */4E06'U,FI9?9,!^*!B]=JDQ 6M0?-B<1:YBEJO\E
M  '#F>X&&=I>>5X>.N/I1$>UUSW;@VGP* ;E'\V]O^I&[Q/3[5B/307-F]E(
MJF0Z9].@-=-XDYHT8P.HS(DQK*=/%X#8JU*H5:;^U>Q2WFT2Q0%%<Q5)SJDF
M<TNJ3B>&M4JBL#0P^/K2G61B07)%;OAMB\0(K,10( ,6(QFR7NE OVZR.IU3
MOU=L?G/*W*3I75C-B[SB8B%C@/@'WA022507:>)!A@Z7RBC&RU !)UG>NS\<
MND<Y*/_0[?]UU6+RL>,TP3K^2/=@/$5=UZH=-TEF I->:T T-IN6=O%ELN*4
M&.8YP2(L*\_>%PQ4> GD*."8ZI$$A7*:)9))M_((V$*]SY>\!>V[9]7NOG6F
MW%FKO5>B\JZJ]<+R\5O==>T"@8&5*2H5IDTIT-4T9YY:(3*)!2%PLVEC3&P8
MWB2<>Q(/=!9&8/1Y8+<[8C?P1N737)O>)'3QLO]#%KC#-.?)SF@Y"0!J<\PY
MJWDR3>LMC,2LYV?W2-Z:6Z[X4T_,**Y2P:$Q#[=P8'I, JY=9.IJ!,TJQR/B
M:C%OBE;>0]!525;M!A;G_FEH7Q:HWNG<%5U_YR!'U]U2.LVRH%?BC+JJRNUI
M*1&"',M!$]HS*>_ENB %FH^Z%,0;YR520>2F#CP^B9*VO"D%:4%@JK&\+6#&
MDD:*3.-*BU\,8C)]19+" D&O&J&P"7#"2@U UZH.XCQO6,AYT6NK-4Q+]MI
M<T@1#A)N5%6Z3*47QP",C-V-K&!GKK\51PUZCA;D:+ LF015,X8/<]ID6BC#
M@G)AM##X4-&#B:F7IFX;$>A*9UJY0XS0G&0P^TM;G.P'-HS4(=$^22=(J@V$
ME\,L#J^*O)8GEW:7)<2LK%KEL2PPYZG/7.G3LF[22=H\V?!!^0ZQ:_1DV]!J
MG",LBV_FX,V"XU[KYX&2UM[=*$&8)F5I@JYZ"@Z6GQ/5+/:]&+([D\EV<-'
MZ=^R"[@>/G;E]R))%-$@51<&;KHT;QAZD$,?NM\-^965%"NZQ4$[:F2:EK-
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MYBJ0BN*5,;0[A"<B]RI7BX-:YV7IQ?5J;I"R/UC7"OJ\7"NEF2V<=EIMH8'
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M9:[V->L0_"XI+ /<1"<54:10Y84TKA($+DAA*Y-!1U^KD7 H+)EP5LV'$ES
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MO*QHY!N3NM%(_1WG@TQ3=A2KZ]7/AP:BJM8.,LQXNP%-H"HOXSS]M\V0].Z
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MU']I*BO,3H\@3-Q,8B,8:_2>:90>>C,Y;='7#KO:XQ>/H:4\CDAMO:3K,I]
MT2S*O\)*JTFU6JE]_@7:DZ=BWOW%/<KH7U05<_KG%X_CP54ITD_7LI.,Q'\_
MO7Q@2<G'FWO'J$$%%";)\FM*1O#S ;C: L#DI+3PAZ?A')3Q\9AQ_8V7PX1
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M*>&7[NWL'0@OH#RHC&:B5L2PK4NA=\FAP8*J.BS%P*?W_[1[M!_M/)..ZJ.
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M=?'.@]'.[BYF!8+<M%F,4;6J :RB%H[O62K@KEJ$)&(]H\F7>#8)>XAF=JP
ME)5=F=V7[>WQ K 31_@2D1D3@)3&O+5G,+O1T?$)?BC*<CIA;;F22/KBELD-
M^R=WXI83@DW6,5A"]MX.3[E5XWG5SY]%HGUA$F;J*H,N-39YU>B7VZ"NZI?&
M ?_VSL&.4BI^P2;X+L)W;Y"^]RA]73#!EQ#/CHZCW;W#VS8Q@N0PY4@_8F$]
M(74 "%HJ\/A0F*,4?N8HG>SL\&$7&7OEQ.9PNS_J$;XJRJ MSU8P%=SY_H*
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M"'*,*5?D6_P/X)#0,Q9^XDG\E _R?P'H]1VI9>E$0=E;67W>_O@E?#*2WUR
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MF$/OIH>.M]IHPNZ FF;<)1Y'HJCF:C,J9<MV4]S'?>T#NJ93P#H[!;1>;*<
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MN2)9D?X:9-R%QT<RD7-P@__]G->)M);@U,O>7DOGPH=6WGHLR/X&Z\?!5:;
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M\?FGBY.SJ\'UZ?D9N_@X.&.G9Q_.+S_1!YLV;IY77#R."5??\&KL6E88EW6
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MS2A:O-1E/D?$=)(^2+LJ)UH&]88K2VMYC3V?ED;QP#0E<Q1@$V^,L:1GF$O
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MBX' M<J:JDS@>R/YT?D8^#I>#8[MC)"#4>D*<A7Q" \RFQ!7&V-CRO%QH2W
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M!+OU%41"=\F\&S#BH(H'?]GYG3^]*9>")]=(6P=A<L_UG7,6')N$=(&!T>)
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M[J@'JT%V8ITETD+/8KL%1QJ@T9C:.%ZI,IXBI)%X#T2O&*3*90Q+1T90$7$
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MY82-;)8&;8*]*N1K?=7]&OG0DV.+L>&6<U_T!GF)_M E.($CA?;\$S$"%V_
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M;,=A0NTXKP@!S8OSH];Y=>LHV)ISV#AMG#=;S/675BNB*2>_EJ[-=>,L$WQ
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M%V#7?E /'V;\T?FOR_:/NY]CX=URC$?Y\^:@\S=?%EE>J+-\I?(^@8IX]YE
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M9-L@?Y]O+JNE:"Y;U W(L65!9 4AOL5S*7+F&@#W$>&!]%D$NE??G%9C!5%
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MTNFNKJY;5_W*L/J(2%YUH">&#R_=FU[]=WY+ZN#+=[NE"; XD_,:F^/.2/5
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M[@RW?8B;HS$KO(T>,#.0W<;$FPR&DH6< Z9%3!1Z&DL=!^&CJY;E0%-=!AB
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MF$I'+1>?;NZ=B,/FAM)%"EX&AW5>T)05(IJRGLNMK7I)'C6S:8LD8P?XPIO
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MU,Z80Q?@+$R8A>3, LUZ'5&)= ZPA-(=W4&TP'N:+G/K&Q05XB#AHY;6XAA
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M.W*:-QZDR']Q@_N"&W4IOI7!T>G-@:0O.@#$,QYZG%P\*6/]Z6*HW^3V*>P
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M!K_)XUP0*%% #H/'A[2;7>1L_'QGO@*=,$/+%^UV)19P_F<W3]8,@%],9&8
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M'+?31^<3G2JO#(#OP /AE!?<QSS(LW)'ADY!:+V*N()S>,\E^#=UU?FL1LS
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M'(9-+C3VA702$\)O;9/UP&2?C.$28V92 .IZL'-#7D%K?2 &1 HOD-CN04(
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M/.:.V)<5[)"O>0GYK"%/D=4':!W"K- ; /#D% SLJ3!Q0? )_\:?:EO_#GC
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MP&Z.P[)Y^OJ>^[RIOTK='G\6"H87&^R\B&KN:FV0N'1S.IK^Z.L]0YK4I7!
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MM0.L:<[8]LILP?$%E-W8/7%2S#23H*%9-!NX\=V*9FD*<6+M1\Z\VF4.SKS
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M+HA 70YJ1%+'">I)2=*:-A&5X82 :-I4JV4IF,8C0^PBLQ%%IP^@YE?;[7O
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M&((6UFEW/N6&F<QIMC8[R3H6%F.M,\3"6IMC5K!(''BYW;W3IH%JT0"+!Y8
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MW&IK;\^MBSX2V#8QH!D=B'"$J<!\B^\]O9A>\3V51"2CH-#UB,A5*P-..F%
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M]C?T9/942'K09D\[@9/")TU;27'*Q%IX@!<6$.U0K87/"V<%,@O@2N'NK=;
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MXM7%HY@K'HB!&U5",[JHC=HWMYI11*0!"J0>K#C*'IFRWV;KHC$Z<&JN_-@
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MPW&J @4+K@]897\NHS\XN<V:M^YYCQ\P/K2#P:HHQHRIGR.#O:%4>N(,VFX
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M>R05I'I@HK4@#= [R-]<.#9>  0;Z"=E0R'X\7MP/[+X(1%;*&JM-AR.@]R
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MHAU1OQ3D-LAU31PAUPZ4!_WH$5.C4<&J5ZNYM'3JYYW9,XC[FDD?8?U>#>C
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M&K>U\^'HLMTJVD,5W=]==MD\GTTP9[.\0OX2FB+%D M7+K/9=%@&!#,.)EJ
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MW$ECDU'>IB>2X(E94+<K:6"!>G?Q\72V&=#_G' W8H,5[D!BCR67*['%;0&
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MP'PU4^N/ *$ARH:$<I4)(0(SL:C@@6N\HSGXW$_^U\_,KY0]0-:>8U8A$\<
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MXG3]T&+ZN!1L&6#HK88!E93<#H1^JLPLP="W_AR-I>\Z4>N8[=F--BHA'F'
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MT)X1U =@ Z\47UC"?ZZ=+[&!"RW^?FS,;T[F+S$"V;C/XP"LAL#^X]L'W)K
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M7;RIF=-[Q.A_$W]D;?X(J[[G,NNGH[/A,+N8/]@4^LA$!#P-49X=?X/ A(/
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M3;3=X+/*M:$_C]IY,2CXXYCY<4&H#LOV=RCDO46Y]:O;\\?IY==HIR!D>XJ
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MY<4,<1A@6 -W&-80Z;"&PF%8P^;Y?4-3&J(%#BUEO(%# 3)!D:'&X+KKF 1
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M=GM?Q()],K[K5+MG-X5[:5&P[0/<J%R[[7I-<5Y"R  R'2@_LS@MS3,I$SA
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MKYR*O9I_(K!%\?AA"YCN"7+",B&=L 6>')R=_+UN])_U4OMC.&$K6#T?.O;
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MKNW\!A&$*)(!N8*/9 !6S:@_D)0Q NWO)A5M!1.0H#B*V"/6%96&:CS3IR;
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MP.(M].)H9XE'-Q>$<G8&L)+G-$IF?AI+#%L1^\^,IG;@,6I?.V*?,IG"\<L
M1[V\A&WSIZ\;N:M/^AEMYBSB&CIS6/@Z3,(%Y'"+Q]T6[];S/:)@*G@M=P-P
M4<OI8J:4+F9+J3OL]N*7(+[3 ]]<$VER0NE^HZO>\G*O9<00ASR%G>69\%11
M&?CCC8J.P-/&<9K5Q(CW9Z?1\$<2L0]:9JYT4S-[@"PZ;&+FEV[;,.#4$K$1
MSP.Q5Y=\>=Q91;)S"^?,A=\-4DZMX]Q!E*^AG$F"\CE=D?+XRQTDCJ4QJ+Q%
M3:+M(*5WED5V=N$)L^Y3T[Z2Y1-A4&8:9&<%+]'&Q)MOV_%EG#S/*PJR1!@G
M;X#N-ZJB#1!D6F=IGXKAFBA6LN^ A[ JI-Y@AF77DCD6N]*&W=1_^/[@.]-
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M!2XQ0>&_/--34??_/O5T?:!]^_IU-!H=:ZAS_*P,OU;43D\<(NTK$IYY]:O
MZ_Q7-I_)Y\K%KYE,ALUP;+'(<MD,_!_W%;UGG[+'/;UOVZ4C_*0CO &5[^#M
M(LJJGWX$ [.&AE ;AX%<B^$%(Y6XO&9 JB[V=Y_2A!Q^/OXB@1LX5]0^4SKZ
M3;-B,H, ()FDA 4L.3B@Q1J>X<HD7\P1G&D56=W6@M(A=W30:PIPBCJ%J,+Q
ML2E_3/8X^^]7WKV+[8/)&W>0M\3(6\Z/O)T"+Y%V:9*/P68";X^W;Y!AK7@3
M)\P-$2S2G FYFET1O-R^"%[V('B)$;R\'\&C(".[(D?Y_9"CW,%AW)8<Y<I9
M-L]QN4PN6\J6L1SECE@_<N0(;*C!LBL-&M/+3P*_SEC0A"QG X=,/UU][_0
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M2;?_@8!)D.Y=C9VY_6DJY XEDTF2;U]=A1&FQM:3[YVMP>+VI^60.Q14)DG
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M$74-O\+ >Y'(G_H\YGQURG4:TG6)KGQF?7C]2"!E[)K1QN("',[#DU1R%/P
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M6EEB+ FB'R1##&W,1$AJ,<,5>6HQ,W[]O(VURBJG,BM/PG7PI_&MOJ7^N%U
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M=X?,)EC-#:>TI^+T*UHN,5Y"FUX)T.<$)5+8!3P\#E#)OX[,=%'I1VT:QP6
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MDRGO;"OPQGUE^J#=:-I/8^F%^LVXMFIREVUD4B2B[""MY//ZE46E8-^RN'M
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M)2-5XXN))AJ/L\?>F5[>#4]F=AC?%.XF[-JZ07 &Y'DFX"318HN"<!6AW0D
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MY'K?;EQS<*U31^S[ B]9I(>QPG]QK62&8137.P]A LKWH1000>PM_3Z4G"
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M-"/O]@MW@S+./+UU><W7:#WVB^'<Y<C7__XY5B@,%FAOP\3_ )0%BF3>#9
M!UR8D+9]-ZC.(=$I<]9<!N4&B56+4R>J0W!VV_IJ!TAV@QQ K5%V!GT4AL\9
M6-PU(["M659C]M.4\?%]&T+5<:06WN*<57R.\##TG&#2B)?H(^I._S3^*,^B
MWNA1BL#M(;'*F#!2$&UNAO< 0 L.> ,KO&_/P9 U$^ZH MZ/>_$^AR*.QZ#4
MH>453S!^P)HL[S_,MC:&-=ZO%QPJPN6< ZH*+-)C*;L%#I.(N">^OE!&?\<V
M3+%1U^D*^>7]Y*MW<)?KJD<*"W,/\U\7A;\]&[VA=NMX9VIE[+Q[N'7$'J-J
M_>LK%J'NS9'#WU[IZL/GHQBBB?G,<X6<RX7C5E_; &M>WE0#[2(.TO&D"N3)
M##!TGM3WZ3X6:KM&4WY#/ &\G20>75K2IK\DRJQ$=X_4;H9DTE>L-!'(H,BS
M+A8;WOUP):$"Y#R@J0(E<&A9-%F""5>$Q#&L43%\QD"9^A@AD,,*N3T+E\:'
MN$TVM#7@U3,K;VCHO5X_X7#$]K.]JS"(U&Y3^HXBBV+5W[\4==%]&R9Q]LL=
M.9F&_C36=U+D1Z,R_Q ]S%]<Z;V(5X%GOA8>6\!UD/O(DH/\$%*O/U%)N#@O
MD=E "B?->_-Z+9C-:HY\&>%;5!MM+1*,9^UMX?+7]%GFE7P9P6E@<"T-L&!=
MSGJ$5W]Y#:G\UHRT$[_XFO>5).7C2S!M?P%>H[']R&F+BE==_6NTJ8?'WK]"
MV$BVJ?,;L>./2W!#RI5W/MY=N-YV&5/DU:&?;]1VY,.&J\<2P\;]:MA2+',S
M&-K@,/LH::19%- BU!+80-';,,FSCV))TJ2^1"Y:!D()]]OX)/B._X!#?\49
M6O-QKO#0%',,:=[(H53I_!;G\B]EKK% @<9SAB3X%T22+JU'&[\D0(&#O#1@
M-(?@RQIXIO:GYNZW/VB[\8G]Q"//T9I0+1_3G--G,?^^*-U,BB2%P?F^6-G,
MW8PKN!5F''08(F_5(I3Y2%$P6H_>,A.X@J/+SD_PD@'E7!2KF-),H<O.4CA&
MU(=0AAN(RA7J0O(L5%^W-A>7BC#1IE.R%ZV!J%14F$T,MW*4(;L?M]1)9D3M
M@^3IV[#_B;HWC6HBB^)]HZB("%&9!"1Q8% 1(\J@$!*51@0:(JB@@*1M18:(
M:44D2DA4A#":%D2Z08B(B,@0E4FF1$@ ;<0HHX"0260,5#F$TE3"#6N]]=9[
M[\M[[].]]\-A 1^J<BI[__?O7W7.KC5-[FI^-I@.L7D)#/#)*RE%;2YT&5'A
MH&H7+N&>1T.;PF08Q6'U7S5&U_%_=-%%>#XW<0&A=YD^E,53;8:RP3HW#O".
M >H=5M[!H>"_$L0ER=0 '*,2\L"Z O>DXKJ;.VNT\7J4,''MG6(*GN_D%XG6
MQ1X7LY#>-8_97<;^&?LN6;_9YEF]S^^2QW%UB4G+8LYM*W9@86?E&8=D1B8^
MCZ[F9T7X9<4&7#!\TAT1'9=%??KIN>H=_8Q@V%GB+M.KH'WL7]QO$K9<F0-C
M%#NI<2"[E:@#\4(@*3 GP;' HRT%.O&>7NR47_EU20]Z+*&@#8%1V95%%>&!
M<"XGJ]BAT"'_M-3[BH+'L6)Z_!HX! T#87S:TB:H5#R7QEH=,Y=D$N>3LX!8
M^YV,I@0< PS2AKUUFO\+H;1V^+-X_5UDE[8FO?*AU/6/"]9_7O7U8=U/'O4:
M8,4G&,!J3+WY+#('MQ*J QWE7@ :WM G%:#4BG^ 8PKKG;J*C9&B!XF\D-U0
MRA-*YDF]@\T?NN9N?7<>OCI[(7&VE/1X N78#%V5DOZUZP,>0DS>SX+MP'@+
M<3T%H])N 04JK1B@1#+'FX/,F8N&'Y-4L)(D(WJ '4FJ-=0#RDH[]&WA$GLS
MAP6$6,A0;3KEF!)CS=6B>'.LTWHSM1NY2_')]H_[;&#[Q:T>QVN+=E^PJ_]Y
M=JC0YX+#?'W^*ONS4]:*ISY%C 9NFO&A71Z7'F:7X +,LRK\<DG'0P.+[=>/
M'/KJN2H*_S-V:YVEX/L_P'@;-Q%G"^ITW*)N 9W%<ZE- 1'B9G1[0,AZ8#P#
MZUA)21IN16VJ?=&L9N342KM3>_P:>@N!T?JPTHB!:[AZBQ>3N?DURKOR@*-M
M,1IO)HZKKJE,E4R5AJJ-BZ*+/A"9Q!<+"-XV]?2"E:4P6FS*'CK:WK"B41KE
M[@OEQ4L%"<(J^X&TQ^!O3JKZ\H\1%64E'>BT:]XCM5FDHF&D#N4V<;5- W2&
M1S/IKD9_WUIAI:F?WS,_U5+Y]%BQOK!HW#_^_*_ -RY1RH\>N"E/8E;:U'?2
MVZT/4V\DZOON7_Z_V3!X5'\,]^KOZ(&-=V[:]F#!=ROBW;1P<P==&KYE77?^
M>U]'\!]_:[6%30&>FTAE,2/FGH$GKIN_6;_AQ1-%]Z$5^]O']Q\+S=;_5AO8
MNB_XF?4$4F/C_>M[IWN>!\>M0LS^^OZP-"A8:ZGXAI_3^%[L_<OK<9RFK+K"
MQO_C]"@&+AMR!#(EA'1650<?/2R0NLM D"P_"['%!"9K XPOBVRH:Z<T[5'L
MIOUW12VX^'"N$;RA&W^.G(RNNE)3"H6)\,R*BO(FER+*'HEC*FW'A!.[@V!&
MZ6D+Y*;@#.$3T)7<CM9AS/)4V41U<-VUB"[[E8_JHMY\'[2)N:O/>-@\<"PG
M(+R>^UOFR&3LA<R+RL\/N09!\BEE*:>?5;VU#Q]Z6H'APOJ/Z"W8 ?E5NA;5
MC3CD^UP1X0CK*3E6;)GF D+[.NR"VT%(F5A 5!/@;0<4N^AOEOD#G51?U";-
M#M+/,XH]M%%AC68KG<&M.H\R!JW2.#OA(\I'^#\6$-!FY'487PX?K8/^5;A.
M%*P"%Q!\M2YP 3]"!G$]SI9(W=3#L8*=0*,V))KJH4Z+F7EDPH6*RX)4NJZ]
MP(0B](/HI5!9>XX<I<]PYUSTN?CE]M,WPT&#3]Z$=]<U[G4F1T1FE_>RK .&
M9,3'J0%U 6'&5L5907(59RN[E7!S 5'G*!L$OTGPM_"A\;N%<BJT!VRU%@PU
M\FG;H3%PCPC)CX]M*; !D#.3R)GSOPYE%=%>-SC*SCR@J'5#DT]<$TFLK4TL
MHM2Y@T*9AU2;I1-(73O0%/ X/%# H.V%4-]>T6VI)/6$SR/7N"O"(&Z[T(0;
MRDU6\X^C&I^GU/.E4+V:H-,*?"2]>F<I4*N08-H(0WKR5BA:PC2@&BE+:":J
M;O2*)M+IQU.<'9#KTTC5]OYJ[LK):^Q4ZEITJ^!63U?Q)]@*)#-5>^Y%M40)
MMK9CX$NW-LNB[C^25$I^9G.,WAE!W(:\V*_IC_IS&L?2LE2S3^=&\"6IUF"(
M0#ZN?)HK=5,6LC$+B'/ZRG]@5S58FO4M($0L.;XJC[)%XI(CVWMG<@%12UC4
MTH\T*_7OJ,=0&_XZUDWRDK:9<HT\A.$35VQ1_O/]="$5D<:_MEXM.6R*)\%D
M^B/^>9BL44&FNKU87(T,_ZY\A%%?[EAQ':P?)Z[DQC^"T")F*SF-J N3 $*'
M/WI)#7W(NO57UP*"V10+SDDX#-"YM6 +0+Z!C2B$TEK?4W%03!F$YP_-W^KQ
M F,SJILU@GJIO]TKM9OWC9PG;KCZL":UZFY,5161E#WA6#Q;^X4C//WUS8A#
MKE_/H;EN)?[B7WM%?^W:.Z&[6_/!W@UQ2,\C"-%JY %B KVF1+: 4)R!G2 U
MM2U?IGR,6STM?.%^"[>>UBHT8--66+5PF<+5-*M([AJ5!?2TLX6UX@<3\HI!
MIXT:*@NI6H64%=-M)AWM%9OG1/,M/R!;29>[A,V8P:[5@EAJ4;[M1"L!V"2>
ML$Y3UKS\*_4R&-HQT_A4U65+;_&A6=%>=5--@9)6?%H@L2-O;MD0;0"U5WF'
MAJ(&U$ ]I7#< %7+*,..;CP(N0:# 3P!Y&MDXIA.=2RAY(Z[@:R$&*;>Q!#R
MEDE PI.*U_7DG9\F/1WK['_>S:YXVW,E,[WRUG=J;91BR *N]/3G[GRW>_1-
M,:6V7#CKCYBP=:/C6*L7$)'H86TI/8,K2A6:TLSAX\K\:O(M>IU5&UN?&OJ>
MLYQJ_%YE1=&3T!.H2 D2LHR5W0'#>"QMVA:H*@@22%FK5;T<0R!TE"VZRMD$
MM?:(&:_RK5K5.((U$-G$$H#E@^"A-,WKC01F@9TZZWGT8=<.]'J:%=4?FJZD
MK@*8,@N%*=4*0*;B0^E#Q)8>BJL\L!XJQRV#+!<0\LO*&OR?45?F>8'N:>6+
M_8Z2N8;GFWR$)EL6NXPL!P4'H-.@5#Q;+-*Q$N$8@- =RBBU]AKR9%F/I]\W
MD5D7_S<Z\.7*E:R,F;N/QE"GJXNZ+C\LZHI]G)8KBXC?HN7YQN%AW@O/8%;#
MJR77$4L.(1"K=?]!)2!6(ST#59?QYYA#CO(F* X@B2SF^((4M(YJ!]54^80>
MR82VALV,%5*(QP%F^WIZ.)*1@T8*5:OTP*(6%6: 'N','<+XU8"<%(.<F?\X
M2VL!#$.%I-KU-AF(Z8;0-4$K:TTG;)M*WP#BJPBR:44$A2W_"ZJ7T!DHC#*9
M8TS%*F_13V,^=DK;*T3,U%$#92'.$I)*=#- 4[DFX"@SJH3H;70#JJ\B8)B2
M(YJ_*8N)W]..,@+J9%K@B@'YWR".&[6SX@G4R:.9@T8M:FJ-%*[O.C]VKFA]
MNU\4/C;W?F1CFY55IY;EIV-YM7>BGF1'114/1UB0XX39]F$/^WU)HY]K98_R
M\(_W/]V3J.'R%T)@_FWZC57!YX(O][A+8S##"OGD0),M6"6=OZ$G#WN/TX?Q
MRA?<<YA!HQ;Z$IHEO 9J# ,OJ8A#[S ?!UHY1F .GY4^A)<9*!/$.B0QD8\9
M^CJJ:*<M_Z!"3//X!1L@TE-*9"<_Q'0 >YHDP:] ZW%%A?A:;@LSQ6EN)EL2
MA1>-\X7,>6ZU.X_ *-"!Q@"BG C5E4&&R"3N&OQ9=@:W>J:BE/8FAUOC,I=!
M=04/=?HI\[%TD9>ICK6\K)OJ<E&,67.2&IQW68BDN@(=;?KBK;7W@X,OY%[Q
M <<N!3JPMF=F10P-5)'=5_E&3GEZW=O=T-CM_:31+O]35D;YR+Q_4\Y<C0&T
M!R#(AQ;[4-&ZT7H< ^HR8&QNA@=8=SC25BGK8#=06X+DDP<%$G=^LW-;UF*7
M _3BXSV4-A?@MI"U:4.X%0.<U5T2)5K:7H;FL]6?7[4#^M:.U\7&BS*(O%W3
M)IS<\U17>B^]!4>/6$ ,%<EKE4\TVS!K('5)ZDBB+8>&55K%B[5%^:"&-3@[
M+*[+L$];0*RF[H?&),3A(E?0"\9#^1?!ISUNW1>0&2I]0K0$OXZ$7FF?QT93
M[9]!QT5]'Z@Z$C1C:#RCZ=K]P)J9RKLUU[[6;2TU9Q?=#S8Z;K/A3[;YL!<[
MY-1.Y><B*]/A&.-MN%07\BRKKC= <KM*$4WKWUI@H2S\'N4E_X,PV,CC KXV
MCBHM%3TLC<40KK.G#P5Z_%#+#&^QMPMLXT*01I6TCV!>-1"2F7SN&C?%;Q!=
ME*IZYRB0T <A*&[_ B*QHDAMOR]"X[P0==@N^ZL.*KJJ6$N)ZV"M5VV:Q.MS
M-L(GH3*P3N+0++5QYHTZ 4IY40P=W,-'H>_9Q&#C0(;4?FRL+[\C:=;F^WK8
MN0SR:BDP!G93W%\5F "6S%#QEB?3UF5?T\\J%+*M9=?L+4>R<SUGY60W(ZY=
M,1I>:O-FIC:B?;@V#SH_]BO__[PE9O &*N'[3KQOB] H[9W[6CNQJWT4<="+
M,OUZB=8@@F9Q_[-UQVKQ?@?SWB(C;[*QSMA9STN[B,9G_57?_S@-_KUAYOSN
M9Q7F,1?K?=S'WRV9%AIW]#?-'SQIMJ;^SQ-F[RYYV'P)3<%FO38O(-17?ATY
M?"3Z5?#E=@]>F/&K]HNST05WE_SY/WE5ZO_K:(IK-]P-79/9.\>T9\?M?+-T
M/"I;FH0[B1!'S1ZV68+>$:V98%L6M"5.YQCW677?CLK+B@G_.*^7(<:2\QFO
MI4^?\=PW.Z"V'2F_XUEJ?KXR]97&NVKT&O>M^\]J/M'8I[GE,;+T.^SCH?DA
M*NSDD3_2__CC<XP+8D/,9R;UQBL$M>1)ONNKT<U9KKVAL>F2<>_FC=LC3>+J
M3SQ6&1BM^?N/YN0S_[WT>ZW3U-_=*<.M!_4#[FQ<W9C<,O[\E6:EC\NNI9\W
M%(1K])1]F>2>)PX>')8>XU9E#,@V 9Z=TL^!(R5)>#&!"'L!V4R^1Y,O75R&
M-/X(!?:TUN66F]3,I6*PZ-*/T(MAWKTK/=/14.3%RK8_?P5Z7&:Y\;:_+KO=
M>&#?7,$>U?[IZ?NT790M\BU0!7A4SE V-!V0+B!26.M4IE3#7KJH: &AP8T@
M(N#-M4  [S5L"C;RT57S,VV*I5"=6C1MB.V_N(GV^)1,2,-56<A9-?BXN1#2
M:..LSB+VT=9YB>M_=,;KSK?](B0?O7)ARGNKCW^JCW?'O0\>->7UN:E3,]5I
M=R6RRR/=U \>CJ%S#GGQ4::60K?8LA<Y,R,R64%^6.R32,<K_2;QB35M8\H?
M,V#@X.#)(?ZWD5,C(SY@"SDJ:BFVYY/W9K?5A[\>GDKE4YU+J&I#?_,J'*8L
MJJ:G#Y%GE H7ZA$U9W+0L+7R(6RK\ RB"4;-P/B!9*S%M0&:*;0/M&IE50]1
M3!80K;BMH.6_CR'?0@#;H,D_1>B@&0)'NNU/.0QX .3DRR394:!.S)RID2P@
MC"*$S_"\QKE!*_GK]]SP.$UH4L2&MENU(=-,!OA&D!M(E 1DJ('V/JN6R%-+
M98Z$G!'#3AXJN8F/J+"6Q'8P]0>%L#[4++*F;Z!8B^INPMZAP'_>)%&\D(FU
M 1XO(-)ZZ.?PPTL'Y 1 \P8WC)V@9B.=\)!URNMX42X>J=H-._6J)^;^?K:&
M;$#=I"Q38::X=3DWJMF,0*NV!<2@VMW@U_U0QO'\W"48TW"N#L<6(AQ1%JET
M/@E$7 9J+QC*XB-71S@-W_2[__#[V(OTBO#_P+Q+Z2S,R]R;WE]K\S\=O7(S
ML_K/GN;>^_=R_.^N2_/H'(WH&NH*K["V'%,Z( ?1\A-H,Z[XB?N,%-A+Z]Z4
MZPN*J#L  FS3<EEEL("XI?-CK3JJ9HB01WNY:IG&*W9YQN'(#%$V:AV))QXS
M^>L;'@7KJ;\T*A30J@8+/+A''#N3+18NCR0NN6S*-8#W@*Q$G%Y$H(5P1J#8
M3'+(92?^L EH->FZOT;]K<C/@%;,[R-'>;_*&^CP9N**)E>IF?61GIU4YZ>D
M6KU@-2<M4::I=E+4!:VJ@\&Q@N@2]U3N69LX>0LT(IE>0"0 *@%^_0+B#/O&
MJ"%T*DJQV'/J_1!F9A)TE9>HXWH'Q5%MTW) 4<2\? &Q0F7SB6H#J K!HQX@
M.K5:>./>J"Z4&"$A;KA,7X8_W;F>'L$:[%Z\CQH*SO/9B?U$I#H,GN.?7T@H
M4Q=ZX6W.[A8Q*^'7 @+6-S$+D#L"&'X4D=@,^M0\IAJI/= 9 RA#S$P:W0Y6
M=T,V*G3D%<[R/OO7CT%DHEU^L.>4TR/6;H^1X6SG$)PL+\>FO(;@@4FQ?C32
MF_<AKM1ZVG1J[G*.PWQL@&]F [T*#[2CGW7PR3?H2,XZUF"LG 229\!";PR3
M9DS%TV^AD37HI"&;^?33??8N[NVX=8!B O,H(I>=+H-/2K29:Z:'8II,F*DR
M.$!B,7"A9GV36[G-7"+U(&>QU> @E0QTM"!3MRDT)KG5FK>:S$2808:Z5NIB
M(TJHR![:)HC\*L3&!,4&JN17WE='A?0+CW93,1*K?NR^>&!<K'/_KXC<_/[G
M11YBHFY73.F@LN@S>[''B<H<(JE6\23(#3R )[\)VC!3<7M@0A]\%$1*, F<
M+= V' K>TDL_-WA9H#L5LD%9@D6J!0I?E2-#*RRGB&N_8U927-79ZBC%WQI=
M!\T#='7:IOT@#J&/UMSN%#>I-H..[X@U'2UXIFJ;L@@O>E"@#[S+4)R!4@>D
M83(;A2E\ "(J<)2C(L8-#/U/-?C$_J9&\##Y;SU4WZM@CSQK +>F0XJYI4(]
M!S5;!7J4HQVQ!6N5I1R3*1/+1!%D;Z,M#N/+SGT=?R74N[_N[@/VZT<]C:.8
MW/MZ5\;Z#EV:S\XN;=S;XK'_VJ$@A^SRVMBC48&RP9?LV*!O9:/>^VARGF(+
M[;]^H1E=_&2C,D^UPE5QV*CA+I7"%!-OZDDD(T+*&=6:.)D;;6-E,O9(;LT"
MXD8K9*DX<>KWR!R.SFWTJE.GNA[P# OR'Z< SJ*.I,O"6T..#)H^U>G]9>;U
MO^W9KY08=X#,^#[B+%)60>Y' 8UA>/>+JAYQ'8#U%D6%G0"BW<5/OO?AUO?9
MZZQDSG2^D3U2T6$#P%%:G,/'K!R.$&IR(Y2.\I\?N)&"VS1;92D^DK5V%!HB
MW,3KX\]&!;3A#<BRIGUG0,-IOA%+6[65N@O* ').0B01>;!$?@*(XI1*T8-%
MDLT0AG]MG#=WJXZH125(2427:F4*_3PRD5ME-=.IN2@)&8NM31<7I0'N<ZD<
M+64IU>,JJ-G^1H(T5/69$!CT/RL"7H$P8:#) \2TWE,#_K;EY:QJ 4]X$[_V
M C86& ^&HAUJ*BC1!Z!\==P.V2>5B&.>>HQL_790.^0%P^7G<>7KT8MW[]VY
M'V84M:\C*D2VS:7@^?CGFOFF"N.M4Y\VA$;UTN-Q%BH^_GE).]-L!#X"<15;
M:>^(^AQSXH0[SXG!Q&V"#:$8*=HHT@0I]U8E&/X;+T&OH<0>Z<-$5=B9$4^^
MKP:CHZTC&BSKV1&&R*@2TK6:FC$;DSFY^0!MZ2GJ:4 Y-R.HH+V]%I#6%*#P
M'86]/\SA3*:(RR[/F4&N$L,:,*A=S?"53<2P'2JM:C @4;5]$K4)2I"P4M8)
M.YY.%."Z?[#613;4L)-WD"](X%EUIOX.FT!LM565X&4ZDNE^T#&!HTE2K81L
MQ&PDU9;X<4X:,!, U)+3<&;U4&*\5'TJ9S%&9J0XH^IA&9A#-X<LZ\2$U?!9
M*.^,: &11-=5[1HY0;$Z_IX: #*)0$XJ]L!#FH_CC(N"O(C*7) P@WP,KX/2
MD"W"5-9S5NH"@L1<.W&TII=F^1X?SEH*KP$OX\R5R=]U3(:/9/F_KV&G<VMK
MLQ4.JG[_:U30S$ARG)&!/\]E!+Z57W/I8'S/WQ_KFV,=Z.;M/NK%*HCUMK;^
MVA/MES%GM;SKJN6Q +L'>1[[GCBHWH:NWQD:^^C8TZUOG..>7NA/\_IU'<#,
MA"I,*%LD>O!%*$J!4;WCZ$'%95"6+W2+:]!D###$LVG2(+8!)>\W\$)&.=0P
MT&Z"2R"75;(EWD82--/F1X9__T^K?BDH3-]IKW5A'/2IMU] N$F$@Z[R$'"^
M3;":2@,[9B8!?#MZ0Y/AKQV<=5"+A)Q(6SE LX NT5<+XJ+%<16F[4,%*=$2
M:VWNJD^1N=4JP\:ZWG7CO$O3)F]S-]3JE$T=FO[9K60O(,(6$.FYPH0%1-2(
MZ4GE??SYN11A[4 &EB"V(<IQT"! /P$EA(E8JVF=_J,Z$)$4!LRU<M=68XPF
M:$L@-[%0P_(.:'404BKLH)3O&#/:>]6^!A"9_AV_##Y&2"[8 )J5U$T*GUFE
M-,58M99 V2(TLVY<Z@X;TN438*S,80"MS]D]R8U2WOZ>S!65C<MCWK-]\J1!
M>,B5>XZH5\?G)B;A&:KU*AX4)_T"53G"Y@V6+T9=^C@C3XL-/_<==CL8N3:J
MK+HGN/->X"7V%?\7WO;&>X<&MS,S=_IFC^M>==OF[!QM][/QS>CVP.HY\]Q8
MI;0.T@*<!*Y 3E(4;@W5K@88O]YT2B) 4] 'Z@!WQJ8/\"8I"W62\NUWD)N.
MM2]Q+[%YS)"0C2:%^BK+$Y2\X)Z'M;TUG?ADG%UM;^6%TR#N10[+" I0:9U4
M;#X)AT#/P3T2JU?LP0%);9J$L(Z*ZN6L@-!MQ*H.GJ(1/UC7NH#05*V@6D"V
MQ13DJVM)Y0T_7@*]5?!&8""MNMGZMP]8]$/HVKPWT%?!2;GZA.+E 2Z!^X"P
MF6F0% PE%D'.P9"QXG"$L':V6'$!#NCC1A"&$OBYC-M'Y51P -:;XW--X9C8
M4@IN0))+*1@7UZ6I="G?Y ?Z8 R0('*?*14;-$)I"CP<FM.*P_>I4%3\@&H]
ME" U#PDJH;UC ;X9=#= QLJHYMZ>GV>MH=H7TEOT<5L_M4BLRU;6X >9+8;$
ME3:J3?060F4%:LI6'$7DUZGTE2^+(9)DPHK1SMG8H\+2!$LGACW.+,LUO-A8
MY=U64RS\=BAS8'3^_.?2$:NM3L<#YX]MF/6PGNFA_6#'_O>E/X-TN7AKB>6C
M$NW!^B<+",\>ZEK(\6*H)-Y!*B;R!A<;YE ]@8%V^OI!;Y%RJ9<:1X.!<Z6B
M9G(K7@]VU?BXFX3" YPJ0"B>+1.KZ9E8_DO.? *A6P-RXW\T=S"J<VK&:9M4
M;XE5C+9&\H9!V ]" @D2"R[_#=88SS<'63RV%G2G*2P6&)D]!T73)?OLH[9/
MG0HX"L6[C'4-W(AQKLLZ B1^^AI"N3+N4T]VX&+IY#E&%)O60Z^R2J7MI:Z#
MQA2N-/Z09BN&&8+NYYA1D1^H,5(EOA5=L[-.@DRH(Z[@;*(>@:R SJ-I[2CG
M'KHX9$)HV+0-Z.P (3*?8P2ME;IX?@L!M:&#X^TH-,AE<%WHI^<^:DJ,VIJ#
MCB_>"JP'SLCSTUX-$69DBM\F.0: H .305^+=9?@=6%WD #KC\L!D)U@'T^6
M&"72+*<="G8IB["F@"L?OZJ&O8Q*_4 ]J2YH$X&$E <@D4=(M@V$\A1^LT'5
M%M8.A5J"')F]][$+M@%5>8DKO[H?WQGIZXT[5GI(1M(?V^JN=FP7Y_.:?VZ<
M\LJ?K;!V]Q?.Y<#6A,$]\H/014R;CK4XK$5P Z^+/T=/H.NO&^:C5D-18N&J
M2:$6;J5';!AX1O(E6SQ,T)RP/37!0?;;DY=-<K @G0$[AXY1LO@HLYZ:LA&\
M7W^YS!*U3YK'@BQS9EAT0%,BX%LCU5XH;L".K"%4>ZU<;*S$1E-<QV.OFQ#J
M]!S..]6K,H$M^F:KE9C@[B934E&DHTEMH4B@ZQ%5=")0&#SZ*>)OX_$[7 1M
M"Q6I+*99J-K1:#OF,%)^3EF+#T</,Z5X6(\IDJ<HMD #K]C2G#HH5B(CJK3&
M 6F+T(RS?EJU&6"G83>)T6KC(WFA&KBW@$#!,0JW0*JGJC5'G@.= C5:T2OM
MTIC,YQ$784U@?BI6-B)BIP"4.956G92H2T+7T'EF>N*D?\&JWZ$4$"\_#)F*
MN4RT 0Y-D)!OAJ _5)NA%*]0&$A'X1E^)WQT6__WG]7.2L]Q<4BA0_[%95Z&
M]86,>U^"[OHU?DEGU:3K!0PJ0_^C??/I'&PY7SY5_>E^49=1K$?;I+$7-U#+
M@C1;8J6<Z/'YK\M]!H^@6*FT!L <>39+.L[#,+@OU 9..'1-*(YMI=^^HWI?
MH*,V@M@ :3Q!S&P;<9:XMZH!7J\:<]O))R5.,Z4"]A6K3>):#AJ*Y3LATVI<
M_AQH09F\!!2",+$-P:NVE\8!W&]@]0!!ZR_R39H9Q9U'6PY<227G'0;8MRY[
M._,XJ.YW)4]&229I$;]P6632Z7#RC\66TD>;=@45-G";&AK_:>9_;:3OH*_"
MA^*'A*TANB!V: 'QBG7;Q)T7[RIFS3CC97IJ1-#JQ"1RG%3=]"54EP7$<BTU
MA'"H09!@F1!(@J1^-=70/&C=LM@Z8ZFJAUC#G9E7IYG)M:E  I^9BJYB\X2K
M*W+4*@]D^?YHQHARTBN:CL=(O,GR2\K21^J#'3A%^X"RZZ\F?OQ*7TWUZU=M
M_%@S\(J0&+(!R&GS8@TZ=<\JI#$Y,Q2<PR3>R**'>Y;$U/(H"\<;8KW$W"'<
M-Q$J2]1)(JR#_.R\+<)G:B8I1_-"IB*LMKUT_5GBXQ.<ET$<O?"N:VB@,> O
MHD'SF'ZQS?G2_["5Q%6J/+S@)UPF4!E1CP+(=I9&.&N=R@C*[&D;70$:][8S
M)-;K,145,1I%)"<FHX:PW<RS^[\?N([R2:>,A)_]'\B9?:,V0/4E_+<\0"IB
MM&4@X$V]ZA(_*)3_![$56SJ*:3UW:&^$2^TJ8B7(=HR:>*L8J5@OQ1'*MS9\
MU7MHOH2*!V=+I:9HU"G:V_D%A Z,4>R# T%RNGT9^F-K)Z_ $D R:1;4S>"Y
MYY@4K-NO9C64Y4)DT$IL!.L)Y&'013"A-62WVGL*M*$@?C_'%BCA>P<*^2BG
M#S](W&3.[MZW.!O0K+BMKR2E1I$6-QS7Y<67YP0X%&RIKX^_T'_U ??VH4?5
M69Q/]T(NW9?T<(=\4[,\)[>YU9/.CF;8_(BHJ?)<Y<&>K0_/JXJR#R5Q/WAN
M?3)V;^OFS*N?;Z\_G3&6&W'J3.K6(K^O'N:W#YJ'7Z]J7//T0=6:)7;7VT&K
MY,MSVN'SU]Z56'ZTN;M2XH=5=);B@DC6H7B:Y$OPH7_Y%RLG'U-DDGO'?LZ[
M-?4V>3SMJHC<8?+EJ]L9DZS/PP=+U@3N1RY=J;?V,2T"^2\VL23SI*F@R5=:
MS]E&>8ZO"CD$W$O#/IOPJ'XXM?N;67NSW7F-<Q-(C+<'X]^H$@/ZSJ&I7RJ3
M^;D5$P6_K=VS4?#?_HV?+VQQ:;YV;<G]R_I+1L/EY[;>C<+'WL\28L,*/EV*
M3A*$5F8?>J\Y_@.;!=W/O3FZR02P[=6U;8^[C 4+G&[&]?TO\&Z8_P]#A-M"
M0:$W0#2OK:/6IR+?Y'X[T'MV]?*:K^Q=/A-L*WG\KR=U'#</!W;VE;_?Q(2=
M#_C,7DEIG?/L+>F..5S\O+=Z^M]R]LSLJI2H"[)/;5A"YZ;MKV1WM-OL0BV2
MW%,^#,]Y_G27IT/D:)<JF  T+9OZ9:$6N=:CIZ.,O\5DZ/;YV._-M+>,(K@R
M+(_LO_?-S?V6QXZ&<WEA6S7K*21BTJ^5I\XNVSU>>?&5^8;/-P8VQJIVCH\3
MA[;(NP#BC!0LD?\.V4K(&M3CH-N\+%0J,*5H+ZZ.N@JP)2Q^QI:6 (XN<'P\
M;?D"(HTE[KB!/;TB)[3T4T?H:?-?75\848435GS6VIBT//H22*/#9#2QB[H#
MNEYE\2PB8<LMXT^Z!Q"?'>(^K[U=5#\5P]D':X+$=G8RZP6Y3<!@K:,ZBI!&
MJK?T]35"M L[786*5/_/7BI< LV+PS)PZZBN0/CS#[C-U-U]6&M))QM)>5.#
M7P[-*\+XU_!)-?FV]#H<"FIO_5$1=:^.>2&T*Y94&9CO%Q4W^DYFV=U85?/(
MI3CJ)Q$#L4VO30J*7EQX4Q/WA+-V ='R&_XL\S9QW65,(E='M9%2Y#M C>38
MDQ,++$'-%N)MW%+H -B'0V&[)//*?)S+XD(";A)N)>V#Q^/)*W6J[=7DF_@U
MU&L-"XCKU?EDB15#ERWRUO,'S7*LI=RA:6G!<W"+%'\#?Y8[&'98671Y 3&8
M%]2#W00*0D"";,D#JG:N0N)3"GQK$1H.B(2O;/;X D;,<IP%U;<'9P8? %!5
ME<'4HZ"F6N//$/JP%\5SVAW@P[F0;M66(:K+5];@-Y66#&2*?2H49A1K"5)F
M+\8DLZH"8+T^3(Y<?3 &;FDP%0_QGG@4PZO ^9D:X(54G@;Q8L"X=HX^E+Z
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MC,)ETFF^C7D+M0*H9$DP6O!ORG\X6V'K;MS&X2G.GEH 52H:(1V!O/#]BR\
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MI&$'O435S=5\#1*2[)K=>?Z^4-F5^B<3WR9PUK7O:4MKU2Q[&#X&>0!Q$G7
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MDS\$=C:#6^31ROO<,X0;PA74BP]4[V@;@?%$&=9-L1*^TDO#P ;0#>D"@M'
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M!'S_&]ZWS^S#R7L/,96GZ_/&7*X],[\DEL.I;3PZ"]$\?E#5<3(>YQ.ZA;$
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MEQ<SPUV-!4W]KAOFU_8 1BIP2NPRH'\79VZM"^^<XU%W(<TW+4],;6(ET.=
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M[0IJ_[;'M]9^?5 ;RA&WH:L/0(]R),&JG0C,*$R$IXFRZ=_7MZ -(#-Y6JC
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M%P%N<3;S3)C-N8[VC_A_6*H5E9*#*48%%U]3(N5#AK%'3H9,N-$%C'YEITO
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M23 &MID37 ON?D9]69@XTRRM55X+I,P)4/,15">*5+_B W/F<SE%LX.I2]T
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MJZ67I2JB8B@OIQ4;X42H5!&LRL7K4P[)Z(@^[QB<[L1<23E$A#[^^$^0]P!
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MKUZ#P,&YL)3%KD#DTRSN7.NS1A5I!^3%?_/K_S'WG4%-=6&W442D*"*]1E]
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MZ(_=9A@5B2'GS]-?L,>XV'PQ[N3'V)F^OT5*TA#T .3P^'G"0PM"E#%5O>D
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M]V-.+H>RSP/\E<R+'Q.ZY&09L)U_/[5%T003H')H$>8C0(.*4-Z_,E0O> +
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M7Q=?YQR3C'W*S8(*8E@1,NC.-_^M-(<Z(Y_=SEVVS)#&-CS)GT!.PS3\*N6
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MU2@[L\2;MP0]"N%G8%(WMOH6/HRH:;$T7,>84&]ZR4S7^AO6^Z4>@YK5&F=
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M**HW9DZ^DY?\^ETH)KO/*.#BDPB9X%[7CX/__6.X]"S] *2._'KA:(0 [7O
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MQN)FZP?F5V#1;2IWF?]1F@PM'>\@\6>+C 6[[(_]'@EY.UQL>KECV+:-YU)
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MI$K3LYE9@?(1:!J^Q+>W!3"% 5%S9M\23\Q75-&UMK9A?-%EWKTR9MFZ$I-
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M,4/>Z/6DU3'L#RI!!&D3N#\>D</U>![RLA+OA"![SGK//+A1_VUJAONKTR_
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MK-!</1RVIGSM3505$D9GN_PL-!L=Q)S\CG[TFVO-;XNOY'FY8/[;2B;07R(
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M<5[EMWDV^;?!&&;0EB@P1)V ,8QP=: " 7SF QOK81P-/-5?'!(PB=VGH1\
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M6DEKOD'^[:^EI1YX..]68."A.@VY71*]NZ[OI>?8:!,.XPT$PSGVYR&!$?$
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MEO7&4 F*H:0]H)4 >BU91,C4D2^BLPU[CNK'0)J#E*8/!+;A!/EB"89I"A&
M8Y'RV$&F50=8T!OOBY".(:?!00/F8E(Y[A^ GPVJ]7:F91SGG@32#3>$3/J(
MTLL(B<ULA?[PIV$$.-+R9C3SX5130O"2G,6RG%OMLR']53G-!NN\ND]U<SY&
M&T=G:%^BIA*&SGVZS.H,FU4SGICU\S-<8&_#;*)0HDC[1)9NFO]?X(UJT092
M);-L-^1)C4^6T=+W.IG0&&R.KXL3+?1UBC+W[H^*.WICU9+ZX[CF':_*:^,F
MX<XN40\KM%7E'/1]:"X/*U3QG?VK,U$V-3;VX4>?]AS-Q22=M)%R/?B__9ZN
MH.V RC@W!!AZ\.<";8E]9PH5BDC&M)6MHSD'<1BPO4^!?(LL>PS28%JBS@+H
M?GA*9U[=\N^\G 8Z+]Z(_Q]HM%@@DUV-$/_ZNULF?Y5!W+_"IDGYJX\'@#O'
M(8L_?\/SB@A!91D+P!FR,E<.2@-U*7R!G]\)@!P%Z)&*5\8:4(/^ =V7^BT6
M:,;#_=6#\\>A-";YQ=?O<ZLS^"-@50?S(CRUQ4_W[_92;$NBK,W[GR(6HL83
M[)_@;WRU]*]'B8)9HP_\7L;(<"\^X0\C6FU; 2*C'M/:6/ $1V@%%OIXCO09
M8G<"1VX$1#E S?36HCZ,-$Y &!B^LH(Y:P9*]OJ+@$N#Z&3,?I*R0#?Z*R?9
MC.$<XYY!HXSL:J+JT(FH\*>,^/N1:\\2;#^WCR4X-,Y%.W@X.XD.N+EF.KL4
MLJ_[R1<T^_88A988Q08-2Q5W1!)&!7%'(%HCTGJ;<@J#N%(4YRE4"#Q#?J_@
M[O.Y,9 <.#$H>1Y"]WD&,?(%\XE*/H!T>HHE]-4@[V4'G)E>@NXGAA&BZY F
M-X"0&]H[;JIV!'$G)E#T1V52J' ,I(WBROZU>HKW=!MV%?X!O\1!L=V C622
M+G=_SR17FT',*-T-QO4FB,HRX^YP3T;&A52=A[Y34:DM9H;#GT3ZS0,WDC;K
M;C8F^8G4-&C]MAD3J.UM6+,=%9,<AQ*WVBO :TM0MY]V#M$\7=G$M>R"AAF1
M0CJYY?CWF -(.6#AGYD*,&^SJJ)\E7;4>S3#2%N!$B\8T@O3. /6 @)[@Y#Z
M6[D'GA[QV0<>"&S#UK]PY 5(1B7L1)IQ'' J4_SC;U@8.9P^9I<7U.6<Z(Y7
MQUE-(T\^P0XR+K\T:$A&2<5H-0EC<[ZQ&-TS]Z'Y1"$;,FA3FA3->*;@4<N.
M,%)B!4F;NQ(]/J$"%&:[GIUZR'RPF%R@C_OD5F;HT18R45CZ3B\;$Z:^&N%_
M\YUH>XC-TXE,U(,_N;+Y>S?IV[ 4%. *APX7K"EQ#* "=AED!/@P"+WP.7T&
M(50WI;"839!!2H)6:!'<&:BCBGL*5*/R4'VK#)](<:B9Z9Z2+$]*B:T.\;9M
M9EC,0'$5YT.4$06.K2]XLF0!?PH@_;6Z\%)M795CA1UD-_*>D YQ0WC/K0RX
M^M 4QQ8_729^;!SI!4H.R@_V*6Q(^V-5*/E6"I-7PM5. [Q,:)CJV=YN4EC:
MSBSQ/#^MJS:)M(LJ_X!UHY3*\A+;!%[T^$]:C@V,FR-B3HCN]".DT&^@UHK"
M2C3_&4:X!.XI8"C9V0#1WH\\!_%ZXSA,$S:AES9Z&RD5NPV3_SJO ^JFXK1K
MO\K$;]W]Z62U#7L&"I#>A*T$M%.(J6396#*MB-Z-$,.?F(7(KE 0,Q,C'U+8
MT)05TY1F$E+-14\;%OD=<UP__96\+U9.T@DBUW_T.EF%.S99Q+%@&BVDZIZ\
MY4#L.CKWH'C)^--Z:&ZUBVKX@1[-^,$\^U,:7SL<PCN.M7S)-CU:X'VMQ'B^
ML'T]J(*LE?NEY>GL#\)M@8RWV@F8#,(A3;N!54RFOQYI\L\#UWE1H#H)%U<^
M4O[U["Q7LPUHHA 5<*9W.'VRP>..#;Z^'Z#I)9?@S5<>ZM_JM9E65UV'['Y<
M%$#$@3^@@S,6; .Y?Q*3^R[/"S4+/G,B>/?7\9:0_@Q?V(\C%F*E.,/7QAUZ
M3]+BG@<'^S60A\%J>EM1Y8>/*_C=DT;P3/YQ@)S:?;*">P;(*2P42B<=^<H_
M-,9-C*U?YN\%X9L]S%%(/6U-CTZ0"N;O!SW7,8#N:5"Y(PS@N#Y_D<L42XH6
M#L;(A*_I6,E =6Z3:XV-,0WP7L(!L;JGLY#L0.<G=AD#);W2V5A0$1P_PFYZ
M-COK]!X_BFA#]R)H"7\2<@91R"F_JYI1F>3 T:SXK5Y$AO>5]J?9AOW,,OC)
MRY&QVL+!C4V7)I%FQA7&Y4^\_3ZVE=78UP;+ORHXG=H;,\<[?=9_0[/]B+V7
MY6&'6(2NXW7G5D?>TR]'ISJ>%!@5%X5M/8APWH9)K=CN<W2L'I'7:RMNL/&9
M_Q+Y2Z!@DWRV85?*T@GP;B>!54_R:EO+_N*/E\(A58X/[@84:+*V#6O$S^X!
M^),(&:X),(W.-E^Z:V7(]7W5\V)BH(.)3I<E'#0LB?0#/0JD!],VB8JH;&U#
M"Y[MJ!WG,ODL5\!BDR)(^[BG(0K(8NJN\3@A^#GR"[M;A+#$N/,SJ##$K( O
M14,-O"0@B24ZF&$U(= KZ43*S(V7-D\)??ZQ!*F2 &=0"F\!-#20,UI+A"C\
M@V-(A;@HQLUMF /_$*'WG$ R-0EQM7A/\>K8(-;,+9(N8C:3OD$54'B!"D3W
MD26#_8^ A'3<82#?WK!)9@18T6A5$)4= $+FC<,-&(T-3"6X5R= 3+$Z'%9H
MDM(=Q$2(K9BDB\^"Z/5AU&V\,/\-07R#M!.[RA*B$FFK _(F%.).'(+WJ#L0
MZ.I/12GZXR2@5G#+QQ%U5S"DD9F$RQM"H<KBP-9MJWW0=WN<?3TJ)=;/TR7)
MX<5XMUJ43M4=+8@6XC=@N.P72G,)U<M=??MX#OT)5^<D*1FA76-AYN"N'7&N
MV-NIH>.FXD.W<(?UNF\%0]YPKO@/=@ 4Q5J 5)?N\O=!N?]3;%A6$)O;(K/C
M4*+=.Z6,E551TD:$G&GO(] "E2#1[59[L%6"J>3F-[Z!<WKF'R*3SW8+-1_I
MSW]4];50-:>@DH9W)?1>1UU"[27TGA',RQ<8P($X&S'(0&5$KG?O9HPJ<=UX
MS_F&<]@@3ZL=[;Q'Q[GHIU#=24B/"9</,>[7YGHQ$]&OK:R K=2UQ:GCC4BE
M9[@08+Z;=J,BD-E>2F'_L!=,S@HL84"6+-:M!I %#+F1K\GU UO*6K/;T_'[
MH(ODRZ-BT!)C3P5'%N<!.0%!K!LE()R*DB*'P=/*]AJ%K'&CP&8&KSWE&TF<
M>Q:JKL06.4U&;/IHVX3'K%8YH<0(O4Y("]9&^D)SW"V\#'\(TVHB< %A_C1A
MST]!G%"A8P86Q/SY;VAP"D(&)^RG15>N9J'3X[S15 *M[O6"'-<R 'BS#0N!
MI\E'9N%4F[@J$Z2C*P+C O?^+(O<C5UR'L.<+<Z(.-O6G1?HI1H>ZF1FAFDI
M#C )&E:GY'DK_N>MDW@@NJK&?J5,U61X^/+T"]=B]QE#/^>@F]>;!_ZG\ D@
M$)V[^#2"$DF&/X,01H4TT>!L!*_12IIK,6DE^@$7R2N)A8X'@J@^;0>.V^1,
MKY4VT#]'HUPSM/@41W7%)GB\-R+ ?36QJ=\14M;,5RV876K)A!W_4U +L---
M);\D4PB0"F+-G6/IRQ\G'0/:J;J0ID#J=X=S;/CO.YV[ZD,)2H&@7?^G($9[
M,C<2G'$!-])B]HQ9*6*)E%+YE^/'N0I,!3\X>H)K)IOTT^__8._-@YI(^W_1
M*"H"0EQ8%(2,HX"*F%%!7"!Q&45D("(*(P@9QU$V(>."1 C=(PAA->_(**\B
M9!01E26C$%"6! @AKS(:=H8@9!L7EICN$<,SI!-N^YY[;M7OU+W_W*I[SCU5
M;Q7]1U/D&YZGO]_/TL\6%\)8S"RA+F461!@?419!<M@<VH%]C42UD><#LNH"
MW<9S&^0I[""R9954RUF"<K7AEVK*?&8;D5WRQ6^&>R>[(>>X$"?[)E1R-4'C
M04_K5.!J,JN+%=WMI%?!HIO87N3\;IR/(QRZA7B''()>PD@I.9&8*7!!I6QH
M,]0E-Z-&5872D;=\I8\/Q6%<;L^*N \L6DO<!B\(E\391Y:K+.=@X54Q8:?+
M8I0[4^GAC^L;4P-J=;_5-MQ:6W,K+:^X^,!!][C?#8\J?AA]D;CFGNQL(*2K
M":B@%10_+8\]GTN+YOTP]G%;U=_KQ/<JY:X-5;8%6!K \W;!6^CEQ4/&/QJT
MFDOZ/5 /7,\0<X=W*KU)<[P9:(JZ,+?J+NJ;9EP\YK0&X>1C;F7 ?O2%Q<1:
MU@FET!'SP:O5D2J._,(XTNNAH2NE5U8A@U>:/,N\<J>T=F/&?Y$0QJ"(,211
M"]M('.IRX1F.3*CK[(=/,>8QV4K)Y D%CU.RMI>,S=%[@O#V,$=)QNC$'D13
MU83$"=RZ69L'=I S/QT8%LD6_+S@9NF(1+D]D6R&^30CM$&!(UYW%:P-USWP
M_J8NA6QQ(*;J-[)V=0MV,M,55(VO:D(^+U9@"AKO&E^56*+2=KGCN*35N!3=
MV(@ZM,C@7+S8R. ZRE/T"9P1F53-RXB<ARYXJ+* YS ; DQ:[=_QC:^H=;@,
MZ>!DY2-%*L;D1S14=QID\U@NO<)H8J:3/;A3R=J*6DK;R>E>#6_8F?Q4?PU]
M$792;4&R8.T&C.JX4<M>G*-]!JKG@EA&5N1">!'@2FRG97^..EY\FYM?E'>W
M-R3FW-,C#74W"FLJ@N3J0P]=?R^P>1V6,/8QPFLDT'QF% TN"R0SU[5MBD4?
M_P5/?OKWH4/SD3BC&5U-!6O>Y0I6L;X&7(0FJ2,MF?34.F9T>Z] K;J-7S"K
MZ2N&8T=)*3M]&+L?#[ <5*O*QT>="H[V?-)\^7;:G\]IMW=Y7.:?4A:1>@H/
MBQKR$\E_D'3?(YS)YXGZW=A1PST/!GMZ<XQQ <H6CVT@M4?:@M239>]G2.F"
M%3%+QN[)PH!_BVQK/J.<F?SBBY_#POW6V"+A8?=LN_[Z//Z<=A]J%W@A=NV,
MK$'N\EH>6T ")U&]!*X)>49L/Y6[:R 1=P 6@(,Z* 7<.X#D5_.LO[HIZ1)J
M-:%DY'H'(Q]W(0_ZO:,JP8Z^V+#RC%J?/<-'>R[(GPBLL3!P NU5X@  K<?L
MT5G"%5R;;T7/>/4R&1*G!8.U\J4@+M38V4^N=?_>(B#TX--G?"^92W/9^*T%
MC>5^:Y(SV;RQY!)V1?BQ\89$S3W;U_P$X\S]T1L!^]V&&L->=,5='_*R.RV+
MWQ84='#=L?U'-_"?_%+N>ECVB>NU=>)FS.GKS>8Y:Q^N_;R66-HG5+^>);0(
MIQ;PV$:OU&'>S%OYS,98??K_TX3/!R8CPM/YK@=[!58@1!V(EQ E]4AL0^9#
MS_S\JGL--^ZXU#^\5SASY0:Z?[KPR?H'US[\^?SL%R:L_,B_""8$@@^! %U7
M"6O*L9]A//;@C;)90OG(X>;JVV7KGK\Z]\M;S:57AV^/E"YW>W7N=O&=A:V1
M@=UYWU<M[]@4E/?]LY/+.];K\DXN+[OXY^3=N]??K/,;<GMQN*"IS.7%VKO_
M:,M9ZSTW=:W)WS4 %RT+^J!7I)5&>TA.(N)N>UC%Y.J4AKK*64)"$;QD&, B
M:BQ8C5*(BS%:<T-/D]MW:Z[*VV6>TU>,7S$G6@]3A&N2EAP;MY7=72>LG4L+
M[<<1?93ZA[Y=:$?Q!*+VDO7@\D-L+?@\0JD%N$^>IZ:G_:O!.D0P!T0A#UA+
M"I32=J(9>/7VQ2PAJ$!%3OM$^DE@@5I=3JR.V7'_9[OL5?8W[MP?#^FRW,KH
M@C/I]6RV<=5K+ 1UX2$D-;F-.#2LT.918VCSF4*= #Q7S1*&]K;B)O+U#LYD
M.<J0P/.A]>-/4@MTMP>,'@!N0T"ODI=/\D/)^49+$'S V-(]'#%87>O@5K&5
M&\8 ZXB3)%P%Z%5OR_6A+)LN@=-8Y)9TY2N>BKB4*:4AG='"Q;PFUPJF=A^R
ML;YT0G-_0N:5QPI6C-A.MX]:( ,/RV1QE*W=W  !<KV$;\4O]00&C6/9#]>K
M4C;Z^D57][QA5?SPH?AVU:J.0/>G=;>+&L.V;P\XFNJ9</;P1<% 0[X*VL#:
M@BO0TQA9H<6%V6.[=DX6"0GB#?NKFX2_F7:0Y@"M+A'Q$J>>% F^ /$*>N8L
MP1(+4FBM09+2[@KFGFCS'+E>=\<U;2K 1.RTMIL_7P]?:?)1,"RC*2N1CNN*
MU"]'#%H1#N+3;:1%<"L.M&=@X%(FU%B@FR=:J754S2HOS2H5([N7>;(M6R4W
MG3C/K%"$YA2)PERNLO6VLP2_+2SSGC.C'Z8[F[Z*F[G]\]^'AX]=-ZSK@Q7W
MA+]1.*JJE-:P0<UY9/5>U#4CD>3P/G+]XT'*%]$-'DYV:*B(R4_YO"BBO:&Z
MW.?^S[^R]B*CUW^=@+[LHSB.3^N@;7C!!Q\4HF?LYXVNX!>&T ^ "/T)(YY&
M]G>0"UP+RC86%;UG]$&I5YN(RE3RP8'2".@C+E867?AE4/ E<-&+"G/C>.\I
MFY'][ WVDASO=2I'KX/H@OS[QV61\IBNX=&PYUL2#G?735T;T @N[;FGO5\=
M7+JB<>39GHFDW\\?\TS9CQ9>[PO+_7M_Z<%7 X5W_K9 O8R6T^"LBGY5.%\8
M+4PGU7$T*7H7[ A"FVQ$!G6[@%3%&Y**&^PN?Y)SN NA%8"^!\G($!OK;AV1
M<2YC<971 GOD=_O,Q_<[J]Z'L8P6B-,SI= BNH2,/$6WEK5CG]<E_DBQ8#F!
M</T<EGNO,(:6<VN JY\##=N1ZB3IGW9JS<">T0F5:4Z"=Q R(39M=5J3-I*7
M'/E3(<FJ4E,8U+NF(&A3;/VK%V$.A[A583R-%C'=!QIA9)9P%(4S/7@$D*(H
MU,Q!"SODCGSA<B:\&] 57QMN&GVBN34\L=P,5(0,))PYT9-(6XA]+1CTJ#I_
MJ/%9^C<]/&_7JF\C_'67S2A1:BUP2YJT4=!->!QWP?;WD3Z]&LIZXROZPB;:
M'4!PX:G)!&:Z[B[@/,"V@Z@'N.RZ44[)K@*K][LKM<N9\A!.NVT=M*JPQ<ER
M(%%JR83;"Y,$RWN:=AT,&#V<W%=8&S\\6M!^I'AJ*/5$__7F/SX^PUW\PONR
MH("G^\0;'Z[?=.6:5I^QO%F^/J?QFN\[LL8,QS(EM@ZW,W+=,_ 0*=3)#(^%
MIQAX9=3'EV=_8LBXNDO 51W@%0@8Z%Z5:_8%PTG]WO:&GP5U*9W<1<ST]IG1
M&A5W)2!%<MI-VGW%)13D1KZ*NA XB&.4S5^ZGS=:BD!X.<O#D/<=L-/_8.RE
MUC T7GIK[$N4W4*?9^R'S:IK?5:+2[:!?6KJ"F9OQV#D8G3PRN#SW_Z:LJ2I
M[/*#VZ8%*P8PZH9UJJH$VM+RG!\X(BYR%:IRQ:P==$RD/-/;3R7/ER\U6F,N
M/56";2Q?X*E86ZBZ>%.='Z6R%EIIJO@!>XP24;)5(3';0[LLQDBZH6Z/W(XL
M2MY?]0CSZ)K\X$FSE0_'=+T>#=<RIXWFSGIS;!,7ASVM[C%8IGR/Q2#3+<+E
MWIL>T%"B:#IY(P^)4AW]("QGNJF/[] 5)UVZ*T)"CS4CKZH2Y';5/ 5@E#7$
MS!*&*:Z]@V'=X8>L;P6NJZVRJ*CMR2G\DN&WIO1P[*N0@^?R*U_[=<O"XEY&
MG8KZ7?W[P(VD'W,;:-^*RU.\_LY%38V6*L-MC*Y?:93BX.R4H3]@''!:"KCZ
MK2QXEI!Y'R3IZ=1V)BL(?4N_6B!BQ"6IXF,GCO?>Z_ZNQ]W] F]A><84SS0,
M4$.09JE(.B\VI,3Y65]A1R'D]1+@>+_@;[!%!4LTYW59R#O-.WT<MARM[^#^
MY#0/S-?_0$,J.F9LL\_K0V.$1,$*)D.9R54);>6C,7;O1$ZKT/T%ROC-="?X
MM"PV1-9(*?=B%[:%C3:K+%..&OA@!!=+UH8BS.T^LU==V,ZS8'DBND95!+45
M<GB*VJ!7]>*2S?U5GHZ^@0B<7KOSP >^?#FS6GNPF]]\FFS%C KH3RRX\S[L
M0]V9S(*[XX4WN)3QSW.)J,#U0ZZRV+0CE,3'Y44<;HK!;\RAIE65X+Q$1LV-
M]SY)$AW#-MFU'VM:R7+?6N.:ZXZ9V.4U[7P(>MZ)'H\?8H;O;BYJ3_[SQHX%
M-Q^-A_CO+QDHB*5]S?6P\;+M"=NV_ZL?&W*#<LZR'KW<Z=&;E/\L,2FDX,&M
MP?UEE^[S&^-](F8)WM!<N'4>91DVG_]Y*EW8&+66V!Z12E7\8EQM>,CR5=@*
M$5ZFNX,*-Z5\TM4$[&SU,+,I_/>).WN5<;FEY6/Q=RMYJ0EIX06+RG&NBJ."
M+^AM-%FG*@FSYJD86<)H4K;3DL_3]'X!%KJ3"#&_MHHH<K(3U("8*/VF";K)
MIRJ+0TC33/JEF9?2'!>PJFQX'(V]N[!2,?AI=51#>)R?Z?OR#BE8JYV,0+Q$
MMZ :%2S;J^!WE*HX:7@O"B'']S?HR[R=US-Q#W>QHIS^FFG1,4/+^JXO@;7S
M/G!0W:_ZGN6.B"2RT=(32B*)>?];S$?I&!X^ *LBX^+D]5'L*:D)]+L]-X-B
MQHH!S]$4W1-P7+B<8@])N6;ND!--W4F?$Q-IC5"S,1@7&+9 J.*V$Z_,$DQ9
M#@H\>S]B!Q'33,]9PA)FHVKK9<-CE=R>26LS6O4V^:EHB\=D'E5>\]?PK%^K
MW3<4M=-EOD<K'DY&]/2?\XH^5G?M^ M_56U84O_ZC8'D5&O'I-/3NAO3M?XM
MQM5PJPNT$O,%GQ<3/@'<"M91](?#<.M&;P<5=S[32Z11:HF1,<+E4W);EA=(
M0GH,31<&3>P/UQ4B,Z/C*1%?RN)2;GK&#9\^DK8M'9Y'K36=K%'%ARNI'3!P
MI;:0AB:,%B>1"34CEQH=OY:U&']*<<P/*422L>/S*I&#T*JQ)&@S:#R+OFJ3
M[NVFK&<YT\W^ #<Z6Z!-PIX+)(OHGV-OT<4<&Q8-_<"^1V?M[YLE= =_@\?)
M-[Z4A;(]BK2<>N,Z P=+JL0?CUAHL4%@;NQ+#BQ4T'.2I1R6_:AEX9$NHU,X
MB(M$A9>-.V01T7@WLBQ4E@YB:LW@58H[TRNDI^GK[B&0$T 705MZFKPTLD'-
M*?UF)J/5N 1DJ'#_:7Z!2F!^5%H]T^]B4B7V]?FUCM36&;RFY(MDP'::#AI/
MJ<(K_JBE@U#[;TC+C Z&FHYED>([^[PX+%(L(V P:^J?"6\:/WJM4:\[<KNN
MIOC@(_XQK].\=9*;[_OHS3:!?IONW;U[C5^ZT#?TWHF GBLAC6N?[POS>QZV
M^7QNS R.XI;'P1;<K5S&2"EGYX^\RV"1E!S+D8AAT_"XBF*+O;_UE#^K/[;K
M^G<EX;XWEJRO3/,Z-+Y\\<X=8-CH9*=?0A9U4G/JZ;73;>Y;6I*$2S9"B_,9
MX>C1ZG3W0G$18UX<?6FA\B+_[L0>$1UG\O:(O2WV\V<)>1[D>1,-D<4JQI+H
MI6/V5]/OQQYBLG?%!^A(R"'N'^S@QR </JD/PNR?SA(RAE2&.*6\+=6#V1E(
M6\+\J*)FLFA*\@)FN5+(QMS=RK,3!*N9M';!#J3ZIDI.J"L@Y6(;9.6R1(-#
MX)/'?=5G/@0&_W*O]]SM,M?HYE/;7P0^W_BDZ$FD7V2[>/^FO.">34&A,6,+
MRRIZCRXO=Z^JN!B>FK^/E:%D#.MUSFC5N_9<\B(CGB FB5L03AME$TA'S?5&
M6Q+[#*Y2E5I1\3%<TZU6F0/VH>;:KD3.'-SO.8B5W"R!9U>B>[#(R03UUHVN
M1$]7E$XD??6MW])90NLN^/MI\#WE*U>- ]*/F4.K7K.^M#.K^,;H3+75>&Q2
M-?(R]BIG9-PL4]4I7OH*UJ7S"A+83U6ZIRM1)VKA =H"O#?_*KV9%+&#QX<B
MA;&O1B8UYR;UE&92P,R%B>&HJ#LZ&QN4GB-4E,I_"TUCI].RA7'2H5E"("T+
M(O1 &X#]47!36;R':(.M'>#DSN>*?:Q2-QO_<L!QX4>2"7B8")/:-$HRL>[G
M+R=D';<2SF1([V,1ABKJ:>%/!1,Z> 7% U@HW^!_?D'*3J[FE0%.6,Y@Z $*
MF<GN&%T*@F-.W-O_9#QYX!E*;I=;"KZ(CIR+C.;&/&"RQ3)NNK=_W*]C27]%
M3[?93LG]ZZY/-8:7I42,UX8F5WGN,81N_A@0:;PQH \/']HJ8-\5>B>2P7KV
M)-4N3QBE7<"DJ^ELHPM-OQ^+14,G#0I#DC*UGYWO[:F49H]:@2VG4-&Q+N^4
MAS'U1@9;NPH1"!7Q3@'K9;U'42NN2IH%6??PB^W\:VE+8R.=BD0P$DP>(M-P
M*'+#^<+1N!.; U:K:?FS!'-L&7JNM_4:QD"X5SW<3=N<*,*"O<A@S@=H]=BA
MF,_S]C/B5<1EK8E*NADK>#"^:9,"5Z?77FGW=C$^\%-B)E<OC8]PJY!-A#>6
MG8H;&2DKTR;&9;YZ-2:;N5];D]2_,5MXHXZZ9RWOVEM#$WPR',Z[@0N--Q*-
M&Y)#RIMVVDZUX(C&O.GE+L^BT.U3Z*,QW#/QCS_7X=QF)2S+3B2; =>0QB>H
M5]X&=[+6V[ULPG8F=0H/$G:HN"?NB"XNZKT.=OF_W<[]?\)%."\3FD$;X=:M
MPFANMMS6N!EP1&'TR7)DX[#$R=' J]4N944#5Q4I=]0$Y6G22UDP<$.CE' ;
MG,GE2R8_X>BT8(QD=E\ J"IB%C0/'>7K#XS+EU HF"^ZOQ$A'RAH&9T+_._A
M&HS*9GGI^?M<;=;T-I>MV#W$__!R6^?1TT4!%>7CQ==OQ1^KOG8XS+4R+,XW
ML30B-,4S">Z@R^*,9D(T6+V&^L2F/JUI'\(3=1FEU)J$#"2X711<U+YUW8/8
M!CL-G@SS6@QWX^FBQ6-.RYJ/>6\Q38>_I^>$N?^CCW3P:0WJFM-$9#C]XE'E
MVYY<SFZBZA* C?X(*P5$74+^=0R21MH9"J=F"6"#G29>'QC'7;8QD99-0KI0
ML1ZGX-93QIU0ESVQ+7^+<CER"5RJ/ ZTJJ@VFH4#1V;^41V2Y4&_ FWH:[*+
MTE,GPO"RF])FC:XQ;#74"C9AH2"IW"BE6T +8BEF2+V8)Y/HLGN%4;R%F!_(
MO3L*:MI(YI63 DLLRG"G*55=Q)L7(Y-F?FABJ#S "<2BP[@<,)3/6+ZET1^Q
M(-0KC4^T#H"5 3N/=WO2K@MV,-FZ#X;K&/G.<Q5-1FNCVC7-5TF'38QF-8B\
MA;M$2[%A4EOE3NY3Y'QA';=->X5:"XM(V0TN;.40Q1P4M44Z@_.JI_%&$FZI
M7#,H]DQ]F^0X:E68='\T[A:9+5C]34_"N>N]B7$'S^7Z[3\:VY]7YK:SS&9=
M^7)>XM.AL*#C/<_.E)9_&/NK*C'?T\QM8_W9]-!FS9\C]0(S8RMIB6#YYU</
M:>%,\N%!BH.T A)Q5T)KL4. FUKJ5^U<F%W+RZ+7D#5LY&P5-K>7&3N@TH8^
M0^LU2Y2DQ7%QJH6LG?%GR]X;UPB]ZF_Q!84G'F%E*A@X^TJ$5IA_OV ;YM//
M<E,S[..H2ZCQ[3#A&"03UL&3VY6:+<IIS19]&-Y#=Q%BK@*4ZYU!LEXLT^:R
MMB?QQI-)8L85@2N2\%!)RK*395[F,9-4C#0&-L=#N+A6\'E":P UQB=8,5E(
M6C1+B++@RG:QOC1D0R1(1K45K&(E&1XVS4=Z591Z)2.+:@V?82SDL"DK>P4V
MT+^2R2+I<M:W;)KA>J(#Q^0F:QU"5]X7QE<4>TD$7N 2_.LP,U<R6J_@X#HT
MO^D2RE816WE#$F7F'7185=A.RQN4X<SJH"[OB" IA&T,4TAJM#9<H2JX<"T]
MWSOJ(5/20J_A7,7.*^)-:2A)<Q,1M8:11+F<N<8N[A+67M1?TC!+R-9ZIRJE
M&7<C5BOW^-_P\[VT1N/@%7/X[N#FP/&I.]9%?F5FC>+&_.=^;OSHCV'CSQ_T
MW;I>].1BL6]B:NH]FUM=;VL9P)F>WV2J7PNW[A&>UK)GI*V&KXR]LX3?O$3"
M(1/%[S?(J/]!I#XCD3L'^M>H%S"-=\TF7O7DY).6LJA(QW"'8$-\5-NM@'?M
M]/P2=T22]K:DXV,XZL*/_:'/. 0L]=M9-'!>31LN%XUN$B)EDC:2+%2]OP;E
M*B7YF(V:O&Q,:#L50UF#N2 DD=:1N;-=L+@9^1IRPHU;&I\V%XYCVDF,]J!
M=;.)%L^3.#U4\.:-,G^@J6C.-09<J,32;5E[&>E"XBSAQ+;3H!'A*;@_05N-
M_= \D*\_Q%S6^I&Y0*JB7Q6X@]4M$,' ;?)3\$RP;Y%"B9;$U)%^$B[SCE?\
M"?*KC+]'FM<A">7(;8R&EK=I[4!G1^1B0'\)MU)G"?&D''D=*8?BANV^U2'W
M1=@YPI-DX$K7.".%BNK2A]&%.Q@B>!G4QUT K6'YHU$9"0*7F,CYW1A-E1)>
M?% J"O-YE_6IV6E\9_2%TWU31//W:3-ZOZ?.,0\?.N]4CI]?\ZSXX)*$\>>C
M"8?/Y86S>F(D(^-]QX^'=7=4>=G*CE^W?Y/;V)#C?RQ:'4,?I1P GZ'QV><Q
M2^,+R,Q0X)W"@SHC;;N$/\C_*-#=,-SX/.R-FRQBHC9KH@I+1CEBSA_#$OIC
MAHAKQXI!3FG;\G?2##<IRZ-+%J"IDCSC%RQG<%;%D\7@YB[+3*&A[T$3./=9
M&YYTLQ)G\/Z=;V<H:#JI/\H\KXODM D7&>>P&.D*5XU/#-HIEL\7QM#M0'J+
MW ):"\Y1AWIUN6"3$_L!LTB$<PE$>7TL]I9=CF +,THR<R1)OLBSF:*C+^B,
M<GYU/<FGY([I6RT;CM?*SK=!)@-GA-%R#GT)RQT=UP88_L$0N!I_+\0).HH-
MG];FD190G#%_0RUE'F8)[L#ZC:P3Z.<1<8Q@*(=/IEH*UHH5/.O8$H?'ACM8
MQ-UC=!#2H]?=1.KS('<F_0B2E'@';@T3>+,\06*YGWX/:[/A^I0TFVY#/4,:
MKE>P6X8U=%T%6B\27GFNH Z9Z#C@$Z*6)$LZ> X1QN?)=54*:R2 <YDU!^E4
M]K(HB&^'U@9CHJ0<#]I*9D&;<-Y4BM!>!HC^+UXD!>"D<Z\HT>5U40-GP^U[
M]WK2@@YN##KDMR_JU.\% 9%%>0P789+%UF?AAX]GN]6]+MP2&*BY?7T:6\*3
M0*X@52DW9<I5DG0XBK/PO1S7GXI[% MP7LD=^JAR%>=O:1,^X>7AR4F_"C_Q
M:N=>AJV,*T</<!<E4*@L2W#^(<L6I)]7X\\..\IN&5T(+E>"C]\ 6"E/$SB"
MXS/$# H)^B=SB^X[D!Z#UNLL@?CA>^$\R"&&6T.?C$"G=1 Z2VB#TTO#^?BG
MN ZL'YH,N9\<[78!XLFS2J+E,*^5.P<6;6=VBF;L)Y*CTOEQ-*L1\*4;W5S\
M-K:NP>M?H\Z&\EKI\$2;' DD+ABSMQF\0L)ML::S@BE2FV;4CH30;&*V1J[\
M;"=C9PF+!9LCP7 +9><.>D:PBM1*6V(<H.+M/KU<X,3R9^]"IDJV@S@TO"WL
M+0]WTQ;C#74\Q<CJCP/OC.9[]<DCT'.Z/0[")!59++<9;R!-UNN3L0!P4\6Q
MA41A\C8A;L1KJ-D"\_>"G45XZZB3>O2=9):PR-L="===?=:/G2QEGF^1247^
M*5S9'"P@KF(<7OP&):=A5$3='A:5^]8\Z ;G1FC=0UGOFU_+HN3#?VW?^?S<
M_;[RM1][0WL&N^OC7"MORYH_^0^=7U-Y718Y7D@>I[?@$L15TLY=R+H(.M%W
MZJWE2)&J78@<(IH#J8B*!'&OA/V>A(-Z6]7)0.1WKU%'PR\>U'19R#/%VJJF
M(%R.I<OG?G(,UIT&-:?4[G8M%[FU6W,?Q,P2')IVWP<,L6S^NY]8X1-X$BM*
MZ&87M)EXDXQ.T'/J0N-<Z%68+YMZAC<4K+N-ON(HJ(3W0DL/HO40:P%H5L K
MP74Y#7^Z_ZSZ1+,?AZR1K"X6-?'1\#[&&G1L(#FSJGP,O83\+<R!%:6PC7$1
M<[@=FFLH%9Z&YP&'H\CI1KT+*.@(JQ?19.1@4*:D+X)>4?F\#JZ3\54#M</]
M9#A*;B%?.1<&BA1R,=UTK)Z[DC7'.0WXBNAF3?O.HN0V^0KOZ%%;U#1#TR17
M2S$;D9AJKOE$709"=><1]^FV: '9V,^U:/)$>6JA9OLIO0?FC!9/3^968][@
MF$IK.LP*0,FM<CML$X!QDGVG,7W .@=.Z+=A7F!$S<V@6U'<F"GX\S9MOP3M
M!-]+VV] 3CW7$@Y:1DPL%%=%*)V?K^ WY/5RA(VZG]\6!(KX;[FRP_$^'K<W
MO X>>F%)32J]4EDK=!(B_B2\WI88;5F>AEQH*^A4!K G3^@]@86N!,!(E)AK
ME4A;,?[YQ5B^G;I^\B-:HSL SIJV<RR9Z6T[R)<%]GZ(KR[1<)?B#.#(9F0P
MG[*NOD.:==&X!%R>SVNM(@?T-9D^2H7UVR IG;]!3F+YZ/=!@[+RENLHMPT>
M>J37T0&CG#6GGY52^=ZXF8^6YWN;J'EYL#TK:I9@-IWA[8P+A[VJ!3P$5AZA
M+ 5NI:2LK;!%O ?#VD*>3U_V)QI0Q&2T0B3C"-<AD9=+H1I**!8L]R8PAO8>
M W_KOX^SM6=HW%%M&W4!WM(-@*3WF)@ES&FR4SGXT[/@>=135$=0,J^H0^[D
M;7D7<P>7'F ;0;TJ9>)KD%L%WNFN/*M%IMEW!F(C/OMN@0>3H7Z7!=FVZJFL
M WUP-"W7EO28>MFX'.J4VU"\,"+RKHV;(;>&-K+(AL<"#RRH'O42,S)@\Z:4
M*F;XUPBU;98PE*3RS8&^8/8&HKZ:O:X<AO=V!=4*6PW.*C1[#_=/?KK_2VD<
M[%;0'\&+,D](&3WWY]F[;WG1(^>&MJ^2!7ST8?1[ECYXU_EH.OA6XO93%<GW
MY0U'>N 3L$RD+,^?XF5%SLG5):*C-7JJ44:J\])XZJEC%!]0C*YNG7$5<^=!
M<J=U0*JFYI:8@]LR>@LORXM:(VSGILEXXI1X5V62F#%GGW[/MY@ODEFDIA$!
MIX5KZ=M>42&T-,CU=D8IY&[@XEI\7X%J:X4R7)Z-FU[!3NR(X1[%>8Q$M LB
M+?*V41-S[?E\C32-LO)EY9B,PJ^,ICCV>HRLEQ]#J_EW05((X*H?>M-1_T-(
M85HU*]9HU05MIH%UH1HB-2]4<87Z6/)3/!S]41\OA]JY"#M6SH^?))E)LRY(
M@6LS1V,XCQZ%W*-Q%,QL5M% :!@[HYHNLK>\)USX)=K_JMCEIBH@J8WB@/J,
MWD&D^_7#.IKAUP^SA!AR1C([[Y-T?BLR(7&R!.5H@8+3+C<9,[H62NSMV )G
MS )P5=R,R"V<MI)M7%'DHJ<H-XT?'][6 ]BMD+, 24K_5!S<)A/\3,YJ6J4D
M+\D/%X4=>G:-/W+[@@"K+TMR& X\Y?>R#-VFN>02X0,+M/'/!OG=?Y>M'QCR
M?"E<'S<6^]^&I/_/]9QP<\LXM'^,O@R+O5R<(-4O\GF:+]TF^3Y%_^XZKXX_
MYY_+9PD7MJ3^R.8,"':#^H0U=E]<O2-9X?WDS+9M8_\X7S(R9[7UG$EA3<\E
M> &V^)^KXTON;<>S?-7+0X,U@]<P<\X+$*0 :'Y= WNB<MQW9K#JOQGLW2OF
M)><%^?;\1%U1:#0[>H*$4\CP@9X-E$5,ANX!X.@C,;KAH0<U-Y3B-,@ZH:0O
MW1N/,_"N :'BCK!&+M+FWIC'](T8:%J5&*7\/*N72-D<8^\V'/&';!C<[6R5
M&6LL,_.K8X-&(!',=^V0RAJ50DT^JC6NZ&VAN"*\#MI0\LR$HEQ$LL<. +XR
MGZB8GFQ$)#I][U1\Y+ *AY1EV.HF])V89X<=,SS5>OZK]F_C(LP+&?P)<U3X
MK.^EH7;9K'V>;\OAUT-PZP'!ZO$MN$$JJY_L5J)Z1]8NPP,M?%+.AAW* 7K)
M3MPHS"DDV7M*AW);G;:ATDD]J36FEFN&S0>Y^H/1-^16WCYJDA4K :2C_H'(
M=+ZW&>H@)LWS<#>?Z*@;-?G;MXW$G]84EL&M3F=F"7&<+&@3.Q!\0J-TF< B
MYCY>*"$WX-KY@YF0/2O9P,>QR&+ @Y<I7U2%>[-9PI6?I2J<)^TZG-P1K8B<
MH<&)/T?P19]GOI<H[#Y?K<TN(:,NY4N??CSO7A1HY?W2<T7@A3L+RRH"^V.>
MRVFG/-V/5%K&O'$];#4X>,,FEO;DHB[XZJV/DNO\'U*/"!&:/,L2^8&U\^F
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MBRFE)$]PQBIU'RT/F6 WP8#,*</!!E'7 E\S4O1FH]F[UG*=HO9#6P+;PUO
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MVA:.4!OK.P1=\,43WRN4([N/D\2R-CZMJE3"V;(]1[AQ[[(IKC^!+P1_AR_
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MRGH6SMY;(*G>J6U?(YDC ) BZ7CA&D<?FSNC(;TIDQBFL@MS3"[8=5<9:"W
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MNV >*36T4E0<3GYT\'^[VDE2))#GY%:E_D"O@2V0+@<'-3/"E;#!BRY =%[
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M1/OSEB\YFZ.,EMU<ODUBW]V6C@OKR;YD=0XPTL4OJBF,A'/%1MO'UFIN13-
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MHBK1M77HZ_YV)6ECN)Z*<?FJASLBQZJGJ+1*))!7ZJ9Q;WW^4Q#?6#Z^G,2
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M3LFY8*LN;UN+SO8O?S,3@E4^?ZU8LY+^8FZQDL?W S AW%(C5-7$DAQO4=%
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M:;PLN=J-P,K8[4H^M9W^%@>@6:M^J?X:\T2J> U=G$,=%O7\5)OIRY3W_:1
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MSM;!#6&F;)H;"\'85X5B)37\\'*#+!U&0PLNA.]YX*/VA(T++TN3.VPI]?J
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MA8L+C>XG)KOF1%5AZ\$OY:RW0[Y^(8X<".O4O9-&AZA']R[]WG"*!PNIHAB
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M_[M_EKC#IJ&[(GMW")&.&R-0PP(]<(UH)&H]0MVQI 3@&.+@GNAIW<RW_<I
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M0080PB!^X*)[-ZFYV_V6>]7XV=2>^G &>XY*(:U^J7[U8Z(E:3:W8VO1\,Y
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M[7(B\W]6O9]2]V^E*>NR'^]N/=G0:X\V:O[CL'MT#<**B?]X>RS;#/<UX7A
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M5(!X*^Q"A)Q3YB7*?-KU?<;\)]IKT*N>&<'$W8(@I<@G]F&4.9L4U)^H;NN
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M,./2!=L[M#T[7_Q!@>KE0MKU\OQZ[S0$9<)KMDYAVG'^X7@(^B2:'3?,,E3
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MX9Q05*LNFZN0K'\,*/',K*8XT5C6+Y)GQ0_9=6X\#-W6L%M <,Q(:RB70 J
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MFV@U1-U-_9+=^M4U#7E]B$A4]!'S.TF*O]F\,&[ Z16 ^G)H^L>B&C\JZ3P
MF.2)STJ4C2ET=EY15\K KEBC"VQO"AV1"RD;1=4?JJB*"P1^0O:IG-\!)828
M.5^3K<,"7!,[<1,*ZM_@:VTUN/QBNIH@EO6-\U:/P)//AL>WDYL O$952(S=
M*6;QD@KVO1],<ZZ)#:Z!FQ,H,CN7,,_+SDT:I /5:55O"$UG2]*04C*H['X?
MN-8BIW_]SZDCL1UF9#B;_)=+CC@%GV:,;+Y?JD:@R3@KY'GL8_F*S$<[>!W
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M8)M_:4@"(0CC-)O5L,,7C/6Z,B]HB?S@Y'E+"::]Z"I1/BQ&CV!+7JNLJM,
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M*H?;3V[T&3N'3&J-MUTD=')J=45\2F5=OP<*#(8600:%Y[XX]68]6;LG+/'
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M_M'>#HLC63LR-D2Z#6H6KT6(9XIGYWNGMJTU=6E6+3>U@ W)8QP2Q8.C,C2
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MC(%8^J"*_Q&(%8Y[2+1.4H2_57P$&.H[$I_IE[L+@Y9',2YW,R?U3O\YY?Q
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MY3-4MA/B[W!!BO"=_3;YX&=18$(<RT5F)W'^YXMS+YK N4Z2=9N2PNM*#($
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MVZBDC0NMG<_]AS904I XXY%8<1J!<&$OP\P.)_ I("LIL2+Q9:-.4G%TEAF
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M415'S]^EO]33)A<4?YBF/D 0JT44QV'FH!HD]:YQO4TNJ<P8RN^MZO[T:O5
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M+ZB\0FJ+?7WI\#]ZN0,7T@PG*3P\)XHC*6)5-","L" <5-F!]#@5W=B/Y^M
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MYG=VF;3 #B%%;RIVME:RCBQ!#KB$""EU9_\_A47,\\.DSRA='8B<TQ3@STQ
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MIV,).V\ .]*0 5_\]-8YL/56>2I-XZ5LU6[Q*\<XW  >T\2!4.;.-X#!'S>
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MY4>M7C=>M\)P83FOK$O5V2V/>@R6'.B76';]<^C/OV?M;),U\F532,$#:?I
M]WN/O(==BR#A7V\#7$D$J9LI>QJT CRGV=$V\VI%5CD((S%BGUWS48C-::.5
M*:'1P17.DQ\AAKE&Y?;GR0QW(8$<+DN*084J7=5H33^'>9Z\7:T?30D$G_JK
MH:KSK%/^,]#)MW)X\FOT/93DD0W/['ER'<FAQ=!ES*GH W#^8.CDQGRNQ<O@
MZGIHDV6U3C)_,/&,L.2'?:@R&G9<=JUCJ8U(+@S3KT?'IRH[U>DY5.8'O:C
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M!+NL!+]<KH2;Y%.3O2NP@V5RN3D_57[B?=%FO8<J $5H(K"E+E:5#FLVC^5
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MJA<#6_1-ALQN)#0L8&,5BQN 4>L,.][>,^=O#/\,[WL/B;6,4GYBB:P[44.
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M/,U6:LL$>\V'0]DU&WU?M6R5]RQX%^[W9WAX/@T][W)-W3*66)\%Q+^RQR^
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MFU9&YFNK3J647(3<5NBG;_'S\)ZUH[\H^#IJS6 (VR8[.BNI7P9:U:3V7:V
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MYYGP<RZ<-;88Z]T4H!C&WWC%>^5[SV!/Y10O=Z% T:\IZY2AWU&+GL04%2X
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MLKNUE5$$ Y*#W]\T=*FC_HV?:ZV<>%XJ:ILNGD)-S=>T_/%7U9F+'/#>B;[
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M%]1,EKOY^ [@9)&C;78'\.,R(P<9SVR0TN%%8AC60H%:B9(1%U9"2,_(?E=
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MR1'U0^%\V_NI$MV0838JB5,:]];69<,__WS='R=I=\KS6 2T-$2/SQ%P%IP
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MB9?1X:LH]Y:MU"7$=B.\>'LSI9QMXK&:XKA>16K'V%KAY]1OF[Q7&^$A4N$
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M+"R5O&LZNABKY2C&EZ95WB,5ZJ+'Y!R*8XI1W:FJCJA57?LZ=%BL=H>/%=;
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MC@F57#0!;89PV,S^70VTGQ/(M$-WQ_\V<BU]J2K.UEJ75'^8L?3LJYPM$UE
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M7IYAP UM(X(/W;A%J#BKG7(RAN-,$^'54B$=509[?3J;( 'VA_WF&0REN".
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MF"J+P(M6D/:\5VIN8\-PZ$O5/U&1!2X[/EGG#D>4.':(S47\_-\C+4N$7+4
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MO4^&'0*1\6_R]C>M)+E+Q'4*8W^M3W;0?;-,4*+8 <H HGJ&J&BD 5*J;+>
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M&INM)\'>KVNGJ4W_$I)@.>:M]T',8Q$\.CP\2#O%37_]XX82<H)JQ9H@O[B
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M^MVMGCVK9[XB-P+ESM01\9-^IK;D[3."9-N.4LKPM'3*E(V3/*DLJW1).@
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M=<*TFF:./M4X6G3-H.G[2PW<6\6DCWV3V-^_97^<+[%PT_[W%= /7YQ#.P_
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M(95&C]_'Z41YJU(IDB<"D 7M;6\A;F*/PUNAW'Q^L%"5FOY\0(MC-N@DHM:
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MOF*,,,]& 9DA&5N#J6?3'-8_R-O<%'SFOUL\#!W<7'NSO)%A*3L^!9E D"!
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M)PCC@B/9/%8UNN%Q.<\T_V,;$>J>^VTF]V5WWO,9"9E0^9!#<?H >=GM4KH
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MP4E"/1*2YBG9(T(B]QNCS)C JML.B"  [OR,!7<<<&5 6(I4P_XZJPAUJO(
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MNK,8R;DE_27BNK3*1K,A+:W$:<PE>/:A&?H!4O8[.)A$C*:5AA7,"?>"L>+
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M4F%7L%AA)G;%XAU1QON!,.;\M6'!-W_YL5V ,"H)@YL86(U!P^.02DI1&D)
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M>S\SDYIO'&NU;[W7.:'[Y1BQ3F6D(^#^:J($8;Y6G<\S%-NNZ\\C]8='\WZ
MHA5INM3RO7OLJ55]C$6U36X;4"?IA8*0B?,9#5F\1AMYK-]Z4:[@_8[FVFA[
MS,]-TZ3,161@G-(KJF>T,2E6$(Y0Q^" @2LQO'0_G,8]FYM7(;U?-:3&U5M>
MQLIEOK%Q+LG9NW@'KTT?O5E]?WSC8:W84MM(:AC1"N+7Z09N,,>G9!A#R[DX
MV$I64:A;MKBK..]9B[9MP':?9F?4/^,R3>+92/V([%*VK\_^4P%!AZ[U[>!<
MCH!>]!S6VN"%04ZCQ<N2&9$HX6#%N<UP;?D?A8J;$$7_]-0QI-]_">[GY:RI
M4^*5GJKZ4^6NTSE-,+1W.13)I^%,+O,3:V"G[F=5QJQ(/M:) 'D:A[75%%R&
M(>]5(W:MZO$B%6XAD,!C=PW*S/% P:ZZ6;*/IS7+-GHWON$YD*6F+Y[?>C0C
MFD9TSN#Q3__:E5;F2C_"-R8%!L$WA[S=:9>,U-S5WO OQ?]=.89(NPSWB7O1
MN</-@)HU:DKIM1DU V=W[\^Q$/-X_2=*#<=.IK'VK6D\UGPXB!#N+J$34/EO
MQ@:>O%<ZP8X4R$$AM3Q@#^O^%2U\<656^C +SBS3\/87AOKR])'8+[>BE%^I
MC+V&#:TN=&&-^O-C-6[A Z()IF3YF%Q/=%#.Z,T#.Q4IWE[VE;D5!2H-U^_/
MB"9$E4F\B$Z=(Z N1E&A]$C#@'_T@P)H[#WKIV^3K,Y7*V=N^BR8D]7TQ#SH
M/H6-",*/>RV^8+5^HH=_?3<ENFH]APO*9CD:0-NO&AGG6KRX9'EX7'4@;6DJ
M\/;]<!+/F1Y5V8X<SGDOZT*,<!\W\4^7X>]@G1IS,,'B/4JJ;=N->!M5=ZN9
M[%B&GY=5QO>\6R6O07)AR+$NL;' /RE[6OA0[$3_-2BQ8MU 7;R7EW9.S>W\
M(*JB?A!"O[0])OT!=.QHI& Z>]>)KB#\U>L&4$CJP(75U43:3R#Z !;'^4 Z
M2MKZP0PF^7E@-2KU RNMF*)GI^1-ODKKT42&-Q^W4/O.N)Q'DSG]V6=Q)\%0
MG;RKE:%'->''XWBM(=_)O=;.2?_ TQ_BJ@?^L31L?!@*5!SAO_[HV\W3DO+O
M&Z![=SZT\^!O+/:_]EBT54MU,U.<,KH&\3_6/Z[;2AK6N.<TKHAM5 N\H$"<
M6> ?M>&Y^GBE<!? M$F'M?@N1^7^8E]CJ_;W<;RNL]O<UH(12]M7&@'G;NZM
M,(UT ',!1XH!XD4N2G-64?DI?U89=SB#,W,^ YX85,@$/%1-9LBG?/1&35T&
M27?]DV>YB2!)F%U)N9]&A'OEP,LJ'\48UA:1/)LMY:+:9%PWQ6/+Q"B''E!Z
M-V0 EI;WGQGC%:)SW;H>1@&,ZM9/'8I,-\ 8<A^P9V,EK7X,3C7F"M[]WK@X
M?_GT/M$P50LHY",!&C.0#8ZIE@]E99YI" 5;6RQ8[>BUQ!A/%R9SO7HT2Z%O
M?$S\;5U9$$2\U2%^NHRS:\+DJ+M-]*'?X$G/XE$$J6QB#K:7V2ZN4H>;PLAO
MZWK1&Y*Q'V(?>U&;4[I?@TBY@, R@AQ0CA>8Z#NO^@ZE:0"02HI9)*_:=K),
MC%@J \B?>PA82QS13MVJC=0<?[HV1Q[?]6PLR!CXB9?#\D:M>Q<@?(8XF<VN
M&'$;(,G.")3-MU]/9@0C=9 H6?1#>.+&7L_P+3KSF*YG"=>@J"<[ 5UT2'U7
M;)LT \(AF'J EV-N/7'!SBU@6$+.?4I7($/)?QP_!A<(PUHT>:GP08((4OBY
M<CP$LQK=[NU7M/ [BU>D-N))_=?X/YXO"QL^/,Q7P @_P2J/<RKR-Y&Q0V]"
MA':[FAK3BQ'I_5/;H71_EJTQ1I%(;7>,I _V8:K-$)RW4RJJLY!&AH+04E4Y
M^NQ["RDYZ+E3?FU7+RPQOV[@^S6(IOU>D!^V*\:D?SZ L[%&O'F2]\"P=][(
M08>OR5)$KY<VST9+0DG2.Z"K)F P5A@_U-?!A=6)$.V&< %S$/9<D0-VNG(/
MX4NTK=L/CH=D.N[OGBZ8:5*"PE7DB19<H4U;&67NZ(SQ3VM<^W<PODI>KN?2
M*<AARP;#!YJFDEM--Y^@583_"J87)40,>L-,"1!@%G.8Q,N6,Q#"'HV7$)@M
MGOSLBI7I4U]B_);LF(IO)G]X@XZ<*!;UIK++_AH4SZ9D-1$F10@M@D04&M?/
MG#3<3]BGEOK(-AK.QB >F#FUIG_\=BGO;O<YVZD_X($W6)M(% $\7IV:KY*=
M[ 8;F=;,V2?+O]L->#3=Z_3VUF@SHT6YLA".BQW$.UQQ-=5%KJ94@6BZCY=.
M_&\.V8X&%4S)8OK/L-FH<4MD_\1I$N?/KV>X:%W;R1M:=._5CE0/]W-QY#J
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M#^LJG"J/"MU,*:CJM+B_)&H *FMO[VIXX<_VC[%!8'(@H#^$$T?64H(84_C
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M':IK%3&&MEF\%XO)'%$<(V>'A9?7 =@<7#JZ!K[="HN5+25530<98HJT6I=
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MLPRVT]6ATL;W]JN3B?^(5K$SYQ)]V9#:*'GB./SJ9AQ(YP4UNP50R$<%G;-
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MO@[DP66.FWB^:M-$6:]_,P<K[,3H><DJ-8\UG>1K/6+7.UOU:OZKYMCF![@
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MK"(Q[UV=YEF1!M*MS1OD3V0(<&V8/@39J0@R<M59<PG*A?IL,,HZ ,R$#SS
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ME"2V\HT2TV[(I9-=3D_Z$EII<=G+2,38WIE)^2/O\7CT?3TKTN\/DQA>TA,
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M^FWIAOEFJ7<V5>9](S3<M0KB8:N6_G19F-755C5 TJDH:2HM;PC.2$96"#)
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M8Y<8"C5C9%LW4H[2Z<M$OEIW/,C58KD'D#^3ZJ=&.G%<=K>>_KE-X%5J^R:
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M88@2LELZ$#SIN MG1BK&[$9H)YX;=89V#CB]2E642&W*4:VBW) O6G).H5K
M8L*GE,_"F$M8"Q:-Y=BJ#BEW$$0$Z:UV+\6]3O1I*LJ5T_MU:0??TJ\A.EP@
MQ &[\%:.?Z('B(:L=11?'7A2:_;Q/+D6<F[(3W[ZG)%EVL %URW^JRG[)W;U
M$@UAIPZB9A@ _!?0=XQL!_V!,G3ZI%PIC3VCEW(WD2S;=GJE/.UT&57"X^*&
M%JS -VM;2[)+0URG>:/M=P#FU#CF=J<=7T$X=Q>9J2//>]J"E0>A!?A2%HDS
MYPO$:+],J5%7"5MB94[T[X^="TWV*),7!P/EK2=0+OTS9JKHT)7:0984IG%7
M&Z"+N[%FF 7<DR>2P'1Q++!4F:0.WY71^A79'6S\<&A9,_'AJ/\O -S0#:[)
M58;0']!-:4O3JO2*>PNBIHB<X^1Q2^8HAE"Q.[>?0F$<[08_!+0:&/RH](E\
M3J3P>S>7J4TGMMKF+/4&P&>%?OK=<?.YO13E!:F6SHL -Y\\?';D;EH\+!>[
M),JQ0P/TD7RPHF14^KIZOU>*P!P1\,JUXHC2J:C6DGKFN,6;I.>&9\LT;?,T
MPKXH,/'*Z1T'>T]M%J&?NQ;/%^#B ]XA-U)T=77E3UG5\-JBIIH6=HG=7P"Q
MAX29[I<!14_':^R7$@/^^IKY1?-!;'8@C7;O0G7JN;2FL=;":*[EKI0=A*N]
M7]5Z1%7BME9G9[C\@*2V#!K-97W;7N[F:1S%Q&09QMC39IP]1O]1*C\M;*CA
MO?ST)3ZNR5%M1[=MXU^ &24W-7Y+Z859%.A%NY.KIS,<6M419#G%[J3F9XOH
M*%%N:FU'#L==EE99AP]=-CB'O3'VVVH#9S_?^@O8P/7R<ZH>2_ULDF" NW@D
M32V9B3*2F?,DXPIH;_=L<:J=$C"R_'9'T5QS+S]S@:=[!YS=.OS%?!VW*D1B
MIFO*X?(BH\S0CL)_JG35M)<^OCY2)9*,QK<Z;>BJS>*F#IIPZI&MP6%>?PCD
M3MH(A$O3Y 1XYM>$Q4>:;D"_;9R0.:VE7Y9#\ =,& 8H$@]0@YY.XE%=O*XT
MTT>''%.5)2US#R]6<@GM:@1D UY_%N0U^WT0#=U8SAR3HK9/]1,_.VRSE/4>
M<7U!LQS?WC*-[;W1Z?S#15S5U;5RPAVO<KV#B'D^]$4_HJC^IGNS8D)!S.RB
MM##E2M&=T3!VJJX:?5BY>SY "H4^.2GRY-0U18>WPU]/PL"H=J&+VEZ2".[1
M_KEJF-'A^P>.W13QK&GLZIN(+>:HS2J+9;4N?O(3HH @D/.3=SDDJ*OXK8-J
MKE\!/ZNYIJ9P#V#!EX,?_5)S7]_T;U+ZE^+V4=+7\W,;? 0U%\A?N<11_!IS
M'B%<<AZMQK (EG"(WKNGV^;@(3-:4[8G3LA\'\/'$4.UH/QOC9A!/J1@;P<H
M8D1+_,A6/_HMWU:8),*WM&/?X6,C6M#^NSC.T-^0>MO.5/>QE^R=_W@TZGB-
M#;5/2XZD7\Y%X2:^)%&N\@]D(\(RU82:&L[RAFFQ8M!S,7W'7"9Q%5A\Z<9O
M\*R(.3TR]:GN25Z)N:(\<=$LD326/;^2N@#D YO [%PH7#E/+JJH1T*ZF+1H
M=>(-0WL].-/FY;=Z+V /N.L5@MN"U[A<'4VB9=#O+1]@4>+0&VW;VCPK>E);
M;2G; "^>JSX.KE:O:B1@F&V .^YW-RLO_.5XN[%5,25<];L/R[1^<>OF442;
M+R'U=PVO. Z.=\A?L\M%\.44I84=P\FGU>2RRCF[HHU+H!,9SYIU(U5V$T[K
MII>D@GNEBSYP]=3AL1PY2KFL"D]+X]8S(.55;$DJ2^1&M:]4K*KG1@7']X[O
MS%;);GSN$[:!GJ)_LGP]%%5MW5TJWS8$QZF>B-SU==J^C<V?W<9MUQ U2+X7
M0<8.=J)2?S>7YZ91X_FSC%'Y4 $XZF,<JWT6;YO3Z'\J:(*D[<-*L=HT.9,I
MC.=\2S"DA_>RU;"R\%Y3X7$)Z#9(X_QWMO)?7N;_<: 1-TUKC%I'4>6/II(/
M*DE;LRO(D+U>R+W71#55;1+#&6:Y-B%;5RYL;PMC<E*2BN_E4())6YD2E$,4
MQF]P3EY#7F1<Y^%KDI)^10LV>DO/PB080W11K3@HA;]@C'#R].> @_T=VW4_
MCEH>&'F;\DP[7J)92I:@&]M2JGI(@=I+P11!*;97[<LM^<$77L[X<$2PB MN
M@&C3# Q<9?K@ZEMJ7#WLU*+>E5X]\2'*_.RM _V0H&5,('M<=HV]'ZQPU7!-
M7H!MC"\G%T2W<-$>RVVBPO%]:9+S-)D&2W0:,Q3.::GWKC%,-BOXY4<'S?K>
MO<8N%=^X-Q/-B>Q9.:]G"V85*I@N5*WZZ2T^XKG" ^3O%.,%.FE5_?TS<1J9
M=DT-*0"GI),_7ML1/D4P'W[VD0H3-I)N>O1_"%Y'D/V(X[VHG# 8%&6.$I4K
M/7PCPW"A[PP6&UP3A8NS;,Y4?._;I*7140AZ",0#>.@CO! .\HT$ _@FT5CV
M-27OE=VX:1"DZ1YN(< (Z,V1W%R'V(MZYUE*;SK*3\C6!XKY=L3%$2G,*+,H
M9O4EW9,_9WX6P6R'7:_J$9Y?N621#9F2%O'BMHBF;,*WK(?DFEJ*6/7.]WH%
MAL;J+IZEO<33,=]C%E^_T_&9ZJ\[& FZA=4VN8<%_E$'V"D6V<\H,<8-K1J[
M/8VQTENQLH3IQVLWI/:8,8TKS%6?"GF/Q5?9'N2P3U]^36NJG<O+L3Z,7GF@
M:43+QPO+[IC@%)Q19/"TEGY6;3K6\W'99U\'1=7P+/52D(S<#=/1^*9!MK$=
M@MC6^2*R*>QATXM5@H"-2>#+Y>JW!Q@-TMS'/:3GX7Q!K!C]R9(C>Q1B<_QH
M+I4RL87PC!XVFG0/R?9,@ SJJLSB]B1C\Z=&3*NUP53Z3['HTWNV;0XI(A\[
M,&ZL750"W\39+X8J@+-BR8]^D1PQNT3=^3Z O;.C$X_@G^(U$:^+M;RM4OL@
MUAG/LC4\*:UP7X/RLKT,GJ\>9-S0IC3=S[915^+6K7@'TA1;K .F6K$!'9;.
MPH/R3N;V-H;+1O($SE!B7(07=*N*2"G[==><>;@!((P%,HBZCK%%+D0XP20$
MY(0AUNKC;NV:?H"C@J8O6%[1C++[G.\L!09J&Z,W)E-G.(<K0LDKJS@&VP3+
M!/03'%Y*'+VMGN%P3Q095/?>BB4=0AUS>Y)9M*@YQV8^L84"[(&-^**3,W0I
M/@8,"3=PQH:P\>JZ<E7Z%#ZTJ7UC1$KUH5"70$<=_U)75@)VY.O?OR^KFX)Y
M[\4VVWGPEE0QTRULOHUP-.M;KC7].R!G<^!M3MG+ITN;;=B<A\I%])*TC)*K
MY(0:\'H^"]],OI@B!MRU#[<%:;RJ+9][-!&L3[*>JW27!&9)'FA.+&IA5%X,
M?8M("KNH2M]62F;'?:[G8?U;B3XU^+D]M*B8CE^=.?E1HP,@Y@)%\&?%@$<U
M_ZQTI)A.55?YT0ZH\[[@4G_L:ES2U<K=M*"V>EI&*= XE\$QF3*:VKF*JFS!
M)?7U;_$Y;RVNP<H$VBTR*+8]NT^),_D0./G7A7CJ_N;QN<.L.+9#@^W'(WW.
M^U<51F: 21"];XWN"MI.S"Q_L,0AE<6UPLR 7MQX5=%[KNQ:::P-$:#%^_K%
M*?0LY>B5I+EYKOEYS/Q>'8,DJ^6RGCFZ4OL$4<CT>#U%%IX6>%ZWIQ3RY^[=
MBA?P<TF(X2?G- G[H%6A*HZ85>*"V@7M=!J'=_/&M!GR ,?9Z'Q2*,ZV]ZC#
MEDHB;@6&-.$_6AFSX)O.]!MH$?3?&0\%:WG. 8!HHH-P==4^HYRX#L$<0\A]
M*3J(M;@CBO!5POQ+M_=Q@$>-KA9MMQ^CC/N5GB:FY#7\)^!?R8^\Q#,$Z3+7
M..M:S 9%JHAEBK?"X=%A"7TPM;P\R3A1>Y&N(@-=/^8'E3\.( !K0?0C,ACK
M!M 2YM&V.5VE\0N"W?A8_T/^Y7\.?/(;)#.?CZM3AL[.&FM49IXC"M)MB[P>
M\*N)XH+5D!U.:Z2JJ/$:802[(CIQ#)%K234CCK?9$&-@110=5VY*A-_\,-FQ
M-*V P]6; ZXJAR9O4E!7^H((A,WP-RKK@@2ZK3H6:Z"+5!WXBI4A+I,HUA'9
M_ZG9M-,3>=UWW?;53!WZUM9F98 0@U8'FZ2DW,=;&>&Q6]M='VUD1?:.@3(H
M_4":1GY30M*(EA(L*Z&IZ9DX<C\F1J\2$M>5DI%_M*27V\OEU;=U27B<H_<R
MZ=RJF>18E#:T4>H%XU?H :K':G.Y@G8 X7X/1,:D"0GA%TI;M3Y1\>VW70H6
M]W^_N$9TX^\2,"X0X7)1K3'K;],DGHN_?.\ZD]3_H*7)LF\89R!< \KM$R5!
MA$(XEP(T2X;>)-!\O0"::2)IPQO;Q_S')+A9J[F&&+X1)4C3J.?UYJ_[- RI
M;YU3FC"TA!H3"I8XP1*<'*[7,2X7($*0)<3/3*$DQG+;9IA_'&S#Y85/^($S
M3(*/K=AL>T0GJ.4(9"D/3U,2U6J,-$Q>-,<Y>[PIT];WQKD;VB))2-UOTP!-
MD<@+YYWY7(JC-M.2"I\7:T-7(KO*!9PO+\@P()=B4D]N_(;E6V8VX(5&..&K
MC(R)S^[]]%0UPQ^(Z@2/70K[8IU>)S*/,!EZY[W 6I>! ]?CEL;]4EI:8E^3
MQ48MS]:*8V]F4VK7HVK;&]\GSBKK/[$1C@2X1E\;BDM!E\'N8 )0^?IXNU6Z
MI[G6P0/QC$=CEZH8<91+E!# ]CKT<@+@PYMS]T#,5#_(&;YP?,=-1J@4+R&9
M MUZ_+YYF8^DV5-BBD*USV'M1*W"DZ>(SN*Q?@K!W$+)!"=+PD41IGR&UTF(
M,KL'#"0B+,#%X_A1MF*2R@P'.<EH>Q#ND.*C;JH ^3\E@-P1O0\Q&A@?W$UR
M!SO9][5OW/U=+,EM(K$6NU>I*TIAR),4ZRKCPZNKR+0%LZ-B:E#C#SDV?4!(
M+W8GP+<DM(ONQF%A<[ZQP52>.#7UCK')F?(C->^I<4ULAZ+GEE28<NG!DK_]
M5>)JF"=.L]M^V;##Q=?<<%/\]CF\BR5.++?E*') ;HG*SYW97];PN)RK.DK9
M]H"J;FY6C-Y?%V5<]WJ;F2U $QJ$<:GA\3,N]EN@@X^B-!R8^S6'.^=AQ5C9
M1?!G2E2/LTB-ZFP QF;VB[OC)@IC[14O-U6G6UNHG:&/MPH<*-:I,#E#W]XA
M5O+-TUV:5NK'TIJ#*3=*=GVLA'%TO!OUAI%$S;6I&$$/_O3E6Z\DE/JXS32X
M03Z+?3]OPM\&MF'VPN?+3Q,'D)7;N%0,8=$?5T1)*S(NS+=PL&BB1!;!^U+G
MY1LT8K2M->9FY"7T-(0)V:IYC)4H\2!'.-Y"OFJ4\-,OJ!EU^-N3]6T?A[4K
M.0MEW=Q"P<':$R0BI2Q684HU6BSO3<W(,%R"0Y8'W_XC./&(=XG]D+!Z(;.5
M&&V?AIR@%]4\\+2;4QO$_4J<E>3GK6*DP(0GLY/@,<O+5L7E>^;T+FJXTZ58
MI_[:S"NMUOBQ1.,_FXL4WY&*(9;((N_3%'Y3#>L/G:\DP@">C?].]I%D5!B=
MQJA@,U39PQEE&!TC\HG11G6_\%,!U)WEB@8BN+TIFE)1BM=:SP'[A?4Y&I&N
M^ENSC"S</<^7#F:C 668T7WN'4GZZEQT>;(Z%'ATQ>@4_Q@NY6)T(C7F9$@,
MQ +=/G1:74&=%\W!W$$!2.Y@005*_U?/#G-3GZN;1';M M$<+"7$GN_MZ YZ
MI6\H1P^V0)2<55)%L(J:FB&6G906\5L3DH<S[^48HLPZS84+JV-@#1P3'L?L
ML4--3DW#CO5J_<SU554!/_X"_-JE*UZ1WEO;K&#+3ZFD%XU5'A<PM[2?Q[T*
M(S$>)2V@Y=&=@KX&9$$6IG<N24K<I]]9B;FYZY;2I+!OS\;I4WTOI7-?2C;Z
M[J^W"Z2'B"B.VY!9T?:KL?>7 NOQ9Y.'8N?E.5[L,9%47_$*;T>7">;26]70
MIT2X94LP)_*G6+!50C6>#C*]!E9Y:GP5V@=9&([[7^-UP<9T!ZI?V5E& ]:_
M_#+6&,WUT&L;GHDXI4(, H@;DQO_%3'L_060IYFX/&.Y>I.>ETR9@+_&MM:B
MB6UTX^#DK9[9W_9G+3.@4A)NZS7,[Q<'GN\(R&&E>&= \\I#B$#RP-P\EU<L
M^NSNF&% 4@1%D\"*S+WB3$VLF/(::_A([1H-.+J4BJ(8#Q+H1*ZE%036;Q&O
MQ)3$#R4N#]MO?7IR\QF(@X%WE4O)-=_T*<4=6W?>PRS&KV/))L>3\!MF(M/=
M<%Q!]<VG/@@*>?KUTO^(-/KNO>XN".T<;2F8$Y\V_FF %'(7D5OLF[ N$B.7
MJ'2KWQ6+HGV7-*3?]J*U !:_G!1889LTY%MMI(UL:N<)$2=R@%A-2$ GCT*'
M>6,N@7,^N?+SW ^</F9:X9/*G%7SH7"T/BOOO*= EVB#JJKU'S]% PS>' Q\
MC6(*<&:H7CH.8-CZJOG*CM?!*Z_4)67Z4I]:WN?/?HA+@-"6B?D^<F!I%781
MKNI+YR9HVV#1*;6)B'<M]+&V:(7GPW<3OJ;3B^!</H97O!W(W9JO7:(.?C:%
MP)XF0Z&P.%D1DL(BQ4_(TZWLW CS;LB1XIS6KSC]D9@YT<H@9N3ZX+'< *DD
M5=N<D_77,5T*U(3#C4O_&@-*,SX?Y1W%.1A*6JZ_-/WGURT$8/;<)UYS=A]5
M7)#*W6V>W=%3E$1' NZ7(O(T<;X=*9JU!%,.]8ESI<;_V7S7P99W=$5X@]#\
MU</4UN+5I/KY3 TV:>AC9-2"XDZ2C,TWL=,=Y#Y:L A(W<]N1%OSB=CBN@]B
M2NM_H)B-*PQTSCQY=E<J(=D("M TFL(Z;,NKYW6@,%]V!;/8_ 4\'YP3F'IY
MP[%%6KA%+:0<J _7B<%2"G]/><^>4A+B>;ZQ3NQ@D.H(Y#)I'K8+2:&)6 L6
MQ>/8"MSI(FM!D985=A9G)9Q$Q;^GG#8@V'9Y=1-A@MQ+OXV+YPKKG-AQ<>'C
M)3>^KD;\!?11Q,&0IM3XHV_6B]C?N@R/BQG057_J V_QX-C=RMW8V.GW^:3:
M,*3B#"G" %X/KU'WMQ(/N9O'S//<,.77!BZ\M>6\:VF*-UE *?PC?HGRX;(#
MZ=_3MNRN*P9"VSQ8:_W_1"J?+,<JWL/*^X&5:G)E&*6#4O)(1,$:!8KQ8!,*
MISCA:T)6$''\!71"  O3#ZP.!@_4;2C,DS!.4:<.IOO!?7];F%"_V>,2V%Q-
M0&>U*UTHGR*;0%+7878WWFH(SBZ"_@^I3SV90N,;C%_@2^#Y7F5L.CF[$![H
M'E#@349QZCAWV;",FJ\[ 0(QY.F_$*.[N8Y _Y?<PN=^.676A3\D]O+=ODF'
MI+E'[S9V1W<1SL/0K+$*"/6%=5F7R.XH=H+X/A7?E/1!),;#/.XRSOGVT6I]
ML!J#.&^,Y& WON[NF+&=E5?FH&<6TI5%'CM:V)[E/KEJ,Y<X')2MT5,^R^8
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M:W\;4O@4\<[!WI^D.)/2?=$$-2AA_I/U-_^7C=:>O_3GPE>'/#Q8AZ_1I5J
MIY*VO;[N<8P5.[Q9;'=Z%4][,M4)\ LD,9V\7=:JCSY#6"<^(^9K$2?0K>#
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M^.XW==V1-#4U25J>P[[13/X<S:R1',M]?=HI#Z)Q/J7KZ%\2T%4M=8(&2V9
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MPNYW8@$A!W.B<"2RO-Y2^M(?AGI7'E-NRC>E;(EQN5X:96:.62^!3+W_ L(
M[NLO]HU,#(:;\=Y\MFSY]KM[Y;J:1;<U!RZO[M=WK0<Y.I;^>J!,4,N21_*+
M-^ -?!/U EHZ[,VW=*C2MP>_,<RYC%G'=,I5>1A/,FH'L^Z<O_[:&+!/<X'V
M=1NM]&A-% F+ 64A+,YF0#:Q;;<HTQHL2)MBN.F@M6^HUIMUNC$A["HK]0TQ
M^P[%PB.L@P&((SVCVL<>;^"\YLN<-:6H'D]V342P>.Z&Q\?N,)B9!(/=P^)=
M<[ "G]\"<%-1U1V%?\<[:EA0%U.RBG=L0B6%T34.AW9'U>0WY<B>XEH"=OZ
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M8*X<Y"@O:;Q)<=*GVIHS_86Q/A0V]>,XE'%_#?8%[#XQ,$FDFI)*MB?K8/B
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M5A LOM"?@S'?B$]P1!"UD28[CR.0L+W_Y%9?P PO0+=0SK/H9W,JAD:.[)%
M688E=BWPEX<6=A98$C#GPGW/AUQCB'VSY_W-G>ZJXGH-O^O15+ELR6>0SHJY
ML-:@;*GEO8FUL../UE]TZ%9 ]S(E=K-7L\?;9P^M_ES(2:!59=9$-%=4WH#
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MKGNI%6! LLR@8D5LCJZY3 @OB]7!Z'LHY9$\XQ<DU".6RJ_%:;@6B"#^^))
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M5$U_,5=A?UG0WXBC,@1%;A0- YKT#E")7AI]:YD,^U)'YE8_P->8>#Z"M$^
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MC.DB7W\]#"1GL:*AH#:HQ4@/1AMN>TOB5ED^U52;^=0=A9$_W>*[2YM;4U]
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M!C<P-Z>?7WKG*&9+D<=%2#=6+62F?93M/7=_IP=/7-B+?-FOWM=XT-T<;_7
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M#*Q=T@?+#JYZ_<?WUR5],O"&PV$$ =];,$=$2TQ35N9(L9KB/$C+7W3]/+S
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MNY9&W,N#NJ4W,T5U%_IF/>T&U!LU6#ZQ^FU=S5F]=4T%#*U-L\?1FJ12_3&
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M$H._\J2*(( K/S81YD@F;(:RB"N<;]:U >8;2\'/P;6KR]*7'/6?0V03-/P
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MK%P) 75[[!5(?G].[W=9&K.OC6#;9%;\*&.'T[9Y9U5.0@+-\T']%SAQ'IO
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M]Q^YH&H@>I>/*1Y/3]@'<000NK"_7=*POB_^J8G.LNZ+/U*,N*M"7<^^W#=
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M$!L;7MB46VW9[/RU:[6T#"SJN)IY-M</RI+GH+-FF@;C?60%F8F>[93\ ;R
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MD9^- P&PY2 >O0ZD7^=-5Z[9R?!1F>3NU&7&UEFXV:+:Q[9R47+X7)7]<W6
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M)E,]:3W-"E$4XVG'YM%B_4B?L@$>]2*W<H;BI07FF;&*WP=*&$0"E+-UP97
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M66=ZN\T9KWV@Y%0A@H]I?NL=52 +VMNUC<.2E10[$,.-%VF]K\O8X,Z$0\S
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M^$OK-? ')-XK3]</02^ZX$!E]B6E[7HA-]1/<)]%,NV[#X4L:<*UQW O2H_
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M;;\;H>8=6E;F\D7U6*NHPU#JVCE!#];A\4)+&Q*S]CZAA2].J>R<[1.MI<(
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MLZ]!!TXV8Z3.(:1\'&'IVC83VYE+7R.#UG>@C!G3X7(MJ7/Y>U)5H^UE%W[
M3:88PI?Y<A4?AJ.JUO+.M8XGUV3C^K8A0D B^^$W%Q($@$(F'LO/1UR%M]V@
M7 PR9RGYS/^<IJUIEZ$YZG'[V<;-U-@BDG]UTK9G"W?(S3V^L1$#8>>*%6']
MD5;SL+*#NT<ZGW5>'P8UN<6WY^ .+L]5%WK]5C.UKOI6L2[^D[#6XP%A7_)*
M 8?$2*3P>K8P+3E<I JE[%A\NS^D5_+(TS9"]8V+@BIB,GQ/&U)5^DSA1UV2
M:G\%::O&LRA:2T^GLSFKIMM\&I5%_ZB^@IMSZFN8G7'6YMJI0ZL'LOQW<V>W
MOMBL5P$?L;O:,K3=(AU?=,AJ3DBF+U9WL&KLP":8IC9MFK+SY81CQ>JBU9&5
M$4=7Q-YP?,FK)NOM@.2.O*R53"ACJO<,6] S$<8#]'02(H@0R%?4T,=?[^NX
MWIDG_;CC2#XE;V\PX';!S<GWM))=)/5?<H[L XZ.9ESV?,M@Y)$,<2='@T5&
M")SO(D?^\^K)U$NEC+<2&(U$LG1HAV$C!@Q_YY)J4&\@U: 3PV&#I&A!"#:M
M4:[K1IYPIG(F')<!%Y?UB_)XG!*!ZR8Z&5.I0O:$<SE@BN5BV!R\RCXAXDOG
MA3@H5DQK9QL'Z!3TBUI_S.EZ7BM3CC0&6FU,5#H"WBSXIY1:H-H+B[^$ZXY]
M'?/CF%3[C/\),+%<S1AO\E%P)."-PF[(MI/.P,]$A=KY#O7NS*IZI?HL?[6T
M&F]F<2AN'IUO?+218C.%GWRY:)737D=B"!FU\.Z'R%!;0+&7<]]+CFS+,[#?
M\?1%LQ=]MQ7'&VZXDYG[$O2#CL;?%I^ T F\*8Q=X]G<QT9C"HL)&$DA"7<M
M-^?!K5GFE'[=@>?L8"2[9[>1QT!AF\^'"IC/N&E$+ZX"1ABN@,F./64N*J%)
MAYC0BZ'I3>C5F$-*E"&Z<(@NLP%-K@F]O"@_+S&&RG6H_P4,_XRZ_K^"U*_=
M(C52N0P0ET8J9Z,!0930:203'-VO*)O@TJ\SF91]\KD+?@2G1CFIRD'..@L'
MO'._47^7/X&X2R;JM-QMFN;JV._A4V$5'(:=Y]==KKI>)\L=\.3)RMTH=J3@
MMTXP4NR$4OST::@[$7_=I.M+[;%FH:OWJ=RXR.UIE>7EU)/C;2?^@'FXPTAS
M<LY8RM>@YP4[H2=''POKD^OT^S7L]K5,[L-BRZDHFM6?#A0?KZUVDY@L<Y3V
M$A[#IV**(.)5E6&\+PFD\%'!=I,;@S WS" 3J-LQ31X [\ !Z'69 ?@')K>H
M9!1H29,&P#,#BL50DLR ('F#"2C>GK>K[#/'?(G*-!_41^/KR5J.@EM4BVC!
M&82O]M(!:I77;^:)G-&]?P-9^O\TDH&-_F($:#H-M*,9@T8:&H4C<7:"2VP>
MP4T*F'IQ7+!Y+$1)3!QKAQ/'0F@D;)>JNCN9XY0TM^WB +/0=P^#VV MT!N"
M+1-U-KE,@::T8$JQGWE]<ON8H?AGL[.E5$1+$0'*%<_:UBJ9S)<J=RBP=_%?
M%RWL>M1#9E,@MF[;@IS*!?#H4IKG]$H < >47@6Q\.",QU"IJ-0JU!S%JLN3
M07'(%GPXD-9*NVK[Z&Y_"-TP_6J=O;\$B& 5>/'Q4B <]TPG:4'$,>=> H<=
M3=K[>=,UA-P-[QZ1R&(_8>OG2FK 9V8"V87BI8WU8;]-[K)361U'_.FAJ=YZ
M>=*2NO[8^VMTE1T$G@-["W8C&:8WW0!]M$P!((W!RFQ6_74BEB&]O,^-5S/T
MT4A4U0_)L,X(BZ"C!3,LW_:5?#6#SP$36C4R!V:WB =1Y3X:&.49G[RPG&)1
M?H^\N&@]N2YA^=%PIUO^Q*9]BM83C;FT(RZG)H%WJ!JNS89$XH'4EMZ'W#D2
MSD?)8'2H[E5IQT+*6"H;KB%@\_!4]">@\\I?FK$O,XV<]D,8-^:C]>,&)92@
MIJ( %=]WR/"K4820_(X&E_!TEMZ&09 6:\"JHW9F W^^8#7Q=;U9?0W.LZ@!
ML$ :C];C,-UBSZYJZT3L(W2<VOL,\YM]+5LE9O,?2Z2^#:4L3]X>K"(9\^AJ
MZEF$M?W+^\K?D4F$TOQ*T4S8J'LT=QK:40;86"*>:XIV%T ;@@]*N@'&$.G)
M-#3?W8@RX$N<I4]DZ+#RL'7*3ARM*+9*P^%%F&TL(QV9]9+:</S]D?J2;A".
M+@QA2-HRHP=H<]N^A&^G0V66\+="U)XRJK/@V"-\HM9-#,33>@'47.SRM_(I
M5?NFBH*>2L(Y;\Y<O&1R>IL IN]>\+_T1F_=<,;*Z+#D\.G8< $K\(&)E\R]
M7A+]H7J0A!'(EB870L/L"(;0,OMBF.ZS-O@$\3(-GGY S81_ZZ/8>;R(T4_,
M^&;G77"+0-""@KW_8S'ERE3YXQJ.&E7R*6?A&+Y]\[0NL/BD8 .KU62GODJ$
M,EZ8RP<@7,Z/^E>>AI4K7N&'F]T=G5"8H9]3N)/MU"0HD/%>XWQ[3HT-E54@
MSQZKUV[QX;"8X+L(TFJ'?.O+I"SA+,;'^J">@@/\CZ ZTPV\=W@37>N&?E.-
M ?6+9*&YM15]E9;QW]4%N"<I#0.(U,R&:M^&?X,]J3\##/8NH"M"RP#9>(E0
M,2)L/@FJ7 )SSX4 U!0L+H..K"?1 #.. K7VG>A + "4)LLM:[]^7?QIG'L2
M?,M8!OBTF/?8&@VX GN8?ITFKR@:N(((H=7/?'1K*4<\Q_)+XLR7M/[1'$61
M@=3%^""D8Y[66;[)XJWR+$,99B6P!4")V5'9W.",N3'X#V4R)S4[6?\S@/\O
M8$:MH;_YDDY*&DR&*A.)[DE0&D'KT2=HP-5!Z5_^[0:5%D7S\+ICLGD!4_!8
M4%$T[T[!'UM\RA  ]1V:[F\E2LOL^(_EMO_6>/)?!ZR<<=2'?]:C Z@1??#G
MD=@?TW/,/_<X6=J?G_X*4$L#!!0    ( .B+25P2WL?MJ$T  (5/   /
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M>Z![E?#=)\]Y@'S BG2?Q[*Z["EFX9ON_+6V^].C;V<???O=<>*]KWV.2FO
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MXE]A.CU#K64#L'IL3/*4+= Y'CKXPRI1,XW410*-^+7,3]R8'#!WBW?8FF/
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MUJ)I&SH/ T\A5YJ$63-DC@[6>8=?:=[R04M1JS]@M5NL*VS%=UZ'HL<\E',
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M6HK.Y0JDD?Y>8M^*M-?J7?8+_Y[D-:OU&@@+/_\E+G#>$_'*L2;6(8CI:]C
M,&OX(S$9I/KA(<_:AGR\7N#P.+'*(4TO^U1NA;1=9F:69D22)2DLQ=:F.$+6
MBQ/*"H.)PH]CC)A-<63D'NQ? Z?8T#@RM787$K0H_G5FTC1BAQA]L-B_A=G)
M'&5A4Z9<E%&JX5]]'>_8GVP30.TD(/QFQ3#:M)E]%-"YS/TG3ERV$_0)0=P8
MO;W!$M/ >U#84E4'FA+';H1X!:NU!]M2AJ4Z-Y=^?)X,3H+WH@\9U-0$U @(
M/?OAHFD:^^G\^#7[JHU$>YH/B;'8V9H26R5C6V$=[7KIMR7Z^=OHQMJ!Q%[
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M"$ WN!T! /C<7@^3MR2:+/<Y-T,JPRA9180O],4%E!0S5&1?1I4*39"7K\\
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MF2,UZLQI>AI/M+E@WF>@Z\I+?B%ER2C&?/6FP_R#Q_?L@OB(.2#,J7!%KGR
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M1H:F]::_QOM$26P>Z"(/\1WPA+9*PZL_CS)D B-\WWT <H3'B%FF9$&FBGU
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M:!\94:%'N6RM$:T &Y,-&5IP28L9ZB;(1'I1RF^JLM(;-&F;Q*5V].$)6 B
M&0\"<*AN]N3R-[R<"6Z52G67? -S*O)IT:.*@R[<:'U+X_PEBM;+?*<]);#$
MB!JG88L-H"SP4'OS]DO2]4(Z/)T% ?CUN^>!6G\:.C1T.:48.10YJ.(=Y#PY
M9^IK/3>Q"F2V=':;JO;ZKI.<6H5YG]OO1?41]BW#IH-(H#S'@-;:(D\8EX0(
M\YD!8Q[48.Z#TR<:^/6NA8H?!Y>P,7Y8GP8I]T+'#P'HW\"'A6EF/+LT&9O\
M]E9:O )0=KGV)HS78_1)D#97M3>706KEU\/H84?5KP38Q9;TR+?6:S>?% >)
MA[;.D/?[SYP,<^SQ953'L9^NQYCILBMK($%MI79T]&DGNHUIYW\47HSAVE6W
M"OI%,%BD#$CBS<!9:0;>A\/'?C%GZ*^>8L@<8DA\J::U5*H'?6YK7)/E$@1_
M$'K-3!.6*$.+R4 UKO96_Y#O=X#$9@^RS_;X-@+POFF^BD@D5I4PRXH&)1$K
M2 1ZZO@#EKJIRM7_8FFJU/3/_M:R$>6R82N]SP=\,?JR&F@0OCW9'.7G)TO]
M1H]UD>]!^3+%].@W(K;7M4V<>E=J^\#TW/*5W,5F72+O_6D]@2"R*8F1@2[.
M4HZA=]^*.RI&^X(9>&#Z:0&V+7:=;OLOW 2*G FFZQ$ Y;MJR7Z0\MQF7?TW
M>2=DU#@,87K0B<$SZZ59PO9\Y*.RR+O$4*8T<G O76&KA%CT'U*B7&[P]/R<
M +NINDI+=W..R,LT[L?4D&%%N4/Y@$<(]C:M_[85Q'"T@6D,KYZ7)N+3:P8_
M^&!"?\<=C#8O[94 YSNN0HJQ?ZS73X=2V)UB><?<&\/.Y\X,3I#,*"3LM7@2
M_)S[BJ_Y&)\'S_^L=\8,D -=(!NF<4LH;C1U>= /FCW)&5#P]ODSI5U+^]YZ
M'>>?O!9O@GWTZ \Y*I#KER@,3\"JS=GV0(4_LYTY>]T;C[)@3+4M6R2B)+A4
MF\OQIK[>.O[\-Y[:V*8Z@GR["01@P]]#+T!H,XYU@)QO#9R9&;,2$N7L7+S!
MA.SNVTN3HTXS%Z/9G?<Y]9_E55W*;0@ #DQVI-]MK3CVCC>F'#7AH#Z+,.<'
MRF(Q?\'T[]KH.VTP7++["H<K S)XVI7X:^I@#E("8^HWHZ4CF'4V5JIKS?$W
MV$NVSS.D:'C-;!4VG64);I_4?M^X^'GLYA'VM7FN!O0^*<==Y.\:HN]O\U<'
M2*:^"%."2#;8?L)B1&%4BLGID#%C^Y[.Q7GZME0"8MG_@);P=46C\5=3?0<P
M26-EF.F:UU<+'6DGUSRM8PHK>/1G?O"2Z 8"(%_]P8$>]_.9!8U#^W"#_^O'
MY$EW@O0I,7WGF9QL/$^P9ZR?3;I]:?^?&:/^Q$(1M.B*<-2='A)EX!#[*N%O
M6)CY=#%$(OVKIQ-GS3J$3 FL-%-H<HY2/BKU9A?_1N6RHZ^!A[.@C/4QG:CV
MD*K&)Z5/5#_ZK5--#7@?I^/CMQHGZZ63/XK"$@1,LQ6Y&,<?/IE3.LI*R5K^
MS6(#G2:Q*MG%D(;L;MU@4CLZ1F]3.,+4N[[=)_*EK3PV?Q YEC$)]>VK->E
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MJ%DHP[,^^^VB]RN;4Y$E]LP02P<GO)R?' 7&TD7W8>,G63NP+C%=5;:5002
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MGR$_/DJ>.E(YU)L8J1(SU^.BV6!+,V='+UVD1-\>O_&7H#JG 9<$[/B6PY5
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M?U()#2_BAB57\8U")80%$GR+82?;4]^JXBN+NC.MG05_4JUMQPNP[C,%<XP
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M,>8A(P+C#GZN",!7L:W)\%V(^2 X"],*>^55;$KCQR_"8.E=?4V(,%K+Y2\
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MUG/9)16FJM[ENQ\"\U9,JONC!8L_;^%.GZY-EJ'(>S"/$'6EV] ?]N[;9ZO
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MD9*L"!9@<>/;)R9U8RNA.5@ ^T\B0RQ H9L/$]'REW=H;C*N^1BO2<)CSTM
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M!"9>8SPZCF=NT,LWU2P!]"GX:GOFBG,AV\HR>N"XX&9LJ[" 0#K9'?!6&18
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M)@?Z=C*GRWFO"M"C).=VW7SJ!_3>9.+5QY\8ATF.0DT7^PV.=TP$!ICQ84M
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M[%?\J+8=#_SKAER9XF(!;\O @*\B">3=Q(2)SW*O [K>C(B?P)(P;@RF&5B
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MD.D])C^!E.CQEG^,D-L(2SYL47FS\F+-GVLC*-^:),!@%&*8$%%;0>>HH(\
M&8.JA71$SU\^$P;BK.DSQ'^B&:OC$L^'@HPN=W7K4J[&M";;14P:>DR4M%OB
MN<1:I'1_$R^P%71QKQ-_PE]_/S \+VN^;<!,>6K";4;Y>U=WP3!N9%WS49)T
MR45]7ZQ5B&3729F0#Z[.3#L%;*%G95MT^(*?M2E\$E?(]UNLX+K:GF)/$\!*
MDNGKCU9.Y$N#B0#!=O*Z\3A(;K:U^"A#N&YOIJB_^@UF3I@L]?]Y-0]LU*E+
MK6\OP )^'V*4+L>N_8HP869/H&.P'S!TQ&G.Y2GP&K_]?06TAQDX\ZDJVK3C
MZXU+#@GYO[,L5ND\8,J3T-5.V323(99F_LP+*=3I2U\8&,%VA3_2PO,Q=3%I
M4L<4KV@NP!2IDBRKX5@1R9I(RU)[+/OC4?P7;?X%IOD$A0J/.7!,ZRM/1$<O
M.=PO\.!SN?U9[X G^X^G'(.2YO=P708DUY+@SW*X'4_(9LH\Y0RCCP_#I"$%
M%0'2H.OG1T9?\GA_LB=N?)<V(%^^,4\1.BCO-0WXB.$JJ$P2U^CG^EN1NE'5
M=:[AQ<T.9? PNH_Z5\K!_@46D'1P8H"+\'\S[0G#)1C1/= H2ZA3R[:.X,2E
M8:[P/>P51[U?KC-Y:D8UQ%XW,YRO\[27@N'[J(JTZ[/K =MK8]?SU(F3.Y3K
M^I @\?& !Q5POZJHD>64%\>.3\D,J5G$#YYL,>AO=6>!="'MC&*8 E^^D?$T
M&[)!MUG&Q^DM(^":2BR ^8C,>Z/!I(/D6.YN-"+A%JJG5SJAIX/.S-0!2F[R
MII-NR8!5**O23>'AZTOEK=X*I:YT4[YZI"D?[W!ZM.UP8C!YL%X)?#R#*:YH
M@O,\#N0L@\&;.#$(!8')Q/95EP]R*A0]S@R3=\'6V79W88+W?M?@O4,WG=_]
MAHI:4WBP8\J,,!F)KW*]#<UP&'$95#UD=F#(EAO;>M:V>#5_:'"GM.FPUB#1
M 0MX4"E6%3(%;[:9>K,[KDXA(:_3%7=>+'EF[B;?N.?0A@7T[JOVP.Z+$HR)
M[!MN%L:3V8?OY[T.=Y-)2@7XG_??.^E(38=]YW/< G>>^?%TTRNCQIS-FU?A
M?+Q[N%]P'ML#Y*M3C[    B"9BW9;:Z*,&^$G$"G3A]\S*"BN9VP:F9UZ<8U
M:R#Q#V]L_"-:0_Z/X+TG?ZSD_=WR9PJKY)C\1T "G9K@=KGT2KC]]&?:?E_*
MSZOT%?I3RHU?E'Z$G^OHMAN3#3[04AM59ZT'ZCRA^ZC/#HURW!-;9%5N#E?T
M+6&++;C'1:N\T)FL>.FJO8!*748N)D0HU]1ZBSN[V<)^IK)9,8?)@$US$%V3
M6  4>"Q-QU4]Q%#6+&%@O,;MQC4=S%5!)Z4[6&Z0J#;*16<WY;3SP)N!_S5A
MCD,@@.+ELTCC7$]^*9YL9?XG++8I3PB4Q4QH;E7FD\>&+B79Q/U.97SS<258
MBA7^!-_JZ<I/+HN)R/67)5_5YI1H//E;4_&24+K)%&1J $^.8*J,ZJ]4W-$%
M\>JXM'G6JMH_=W_ZD;H1F2NOJK,AT1BZ*^'(U:F^Y1QOMG2"!N8X1L=K;^)T
M:3KE5SIA )(G7/9?G_%K2Z<SI(X]"F94YE!Q3<IY3O!X]PG:#L<>O\2\ES ^
M@I'+7E@H,]9O_-:$YIL'X]+2-=D?&$*?_RHNR HIWE7OI #4SL215NN]XAMB
ML1(M_;E+^UKX#PE-WZ]Q2K*1N9FW?N&) BX='JFTZ#Q->"*D]3]'6/Z;B;%W
M?/B@$:<=3 $V1A5 U8Z&"<>-[K:1'U]%A;(!O "9^4QP;2#/4G%)0VO!K/>Y
MX8&PSB=C'#3GK5;59:?WY?;2FQ4<1?FP-ZKL-:5U(RW]- ?;$C@9YW2#H+9W
M/M6.U,#@[7"HO\G%MU_D3E<M[IE6\\A]31[@EY_=?OU+L3//7D,='K]B#.XL
ML#'0+<_[>'K;F@XT0N% NZY\>YG*7.JD: J'\A4%=S!@&["C87P8*:O!$5/E
M ];2L$GU-(H(RVPG- >XW96"F^ V]_^I+U\OXTL;,\7#H*>YNUP2MUK>T\ S
MA &C*G)V.(QDRG.[Y>VQPER=YN8>^6PXR2IR]G: PD_CC6[1QAZ64A2R44P2
MS95:=]=B,W2?T++A'#XA4*]3HL*78"IB&%=C5*.X1?*49#*8*OI%B-K@8#[9
MP\1^1HWWR4WK012 7957%N& A*=<BK>M&:(MA^E;'C6GF[7F'LG7 BZYA$5B
M8R=5>=TJMQ=-W&-+!G/Q7KZP&V7XFLY($Z\L'0W@RB.5<BEKC:4:X,CZQ\N[
M=G_.IWS\YU5C U$,AT,]'Q0'&=,#S7Z(H*B>59E<,'S1\)2-UA9 VDF\1:@E
M5];Q]4=R,Y>,3#;["C N@RIE.4:&YPI47?QZOIR P@Y_N-9"[1VRDW9,RP]R
MEE,%SR$+HO<)5YW0'^&H]RFO'WR](#Z5:4TL\C['^-+ V7U%@=ATL6X1\KY@
MS&7 78,]_]VO0'76#.BSUQ,Z%-S%G=J"@"+VT:S+:'FX_G; ,>)\U2MA10#7
M='ON(_53C!2[71+K8&!/GM2%FM0HV/3C(6#'0#_G#MJF&$C/)I$H&.'2CXA4
MM-A/&U@&S3O+<JXL/D4L+ME)V_0-,]36S'T3879358BSU[!UE/OR9L29,*T\
MV^CI-C[E3DA1K+]NZGK!8EF0V?I]MIEZK1N#LN13=4,TF5"VBHB/ABH%);[4
MDZ92KUNCZ&7JW_\L8:XPO<[K6'\]><.[L8#MNVV,LK0K=NMO6!&0^,I\2IOJ
M2%)5%Z^9:U6U*4^?9#X@L+8MCMZMX!</R\M=7-Q0K:(.IW.SX+P#/Q J$U-=
M-%:*YFZLKGMZ3F[_T$IQYLLP#7/"\R-@1 =Y+?B^#]VYRG1N,S5RB.=9%)/2
M >/]L9^*H^Z7)U5Y5G&/XJSB*!\\>?6*!D <C#_4BLB)\"3H\?;-W4FGYG6;
M'':(_14XQ( 1!2Y]A*F#;UHD&+(1^W))8;UC$"GP+SHP%$QL*M S[/Q 2?;H
MC=C:_.(3FK"G@J^J#P>'#A,,+P^,9.SWYD9!/M9UUD=SU$^TJUY0REK-E0[D
M;B/M$PI5\V<+/D0(.-1O/[+J&GIA?L+8HGV:DE[0_B0UV;0C:K7C04<UL(N$
MI"-B]:AVJTWE&2<OS0#'\D"+TZ!8*A(O2V"EZ#IT%:-CT,9,:(<'I/,=/^FQ
MKO']NC"GNA'1+^'8+Q(O FQ$G$5YU0^[?]LYYBO]T$!FQ'I/SPI'6%ZG<V?G
M%=A7X9#SW(/<="TAQ<SW>*#/#'_1AT>OU5'$S4YZB4#EV[HZ9>C>61>MF:6J
ME2XJ1;&]!:6XO.\URI$F)\5.'D8[6\&A]& ;?_E:.9 27#B[FP9[._VNHHIE
MT)E[E3W)39I!D%7TRDC&Z'^P]]Y140=?GF@C*"))0'(6$"7GW" JL05$R0BM
M@D0!R4UL <G0""A)<LY(SK3D#!*;U$#3Y-A-;*"!=6;G]^;-O'W[WN[9/;OG
M[/Q1_WQ/W7MNU;=NU?U4W<#\HJ:F+F1Q]@XU0\[=". MV.T73@RS3FZ(O@)K
M_HNE==\=M XMCJO'(,>T(<,TR,14]YY19ZT%A9BR@!Z^T;%Q1-ZJE7<Y(;K0
M5O&.K23#HG1+HWU8W,M]JA_Z1$$3\AH75&:^_E28!>D/^\*46QJ?F3__^(0F
M8YYD<3\K2\FS3&L*+YGO^V\]H_F#I_1L,FB/H]_LSV^?QAD-(0&QBFZ\"P$Q
M'<W%&RW6*'VL1XC ;;3Q*$N_A#3?SZA/\FBN2JX*;^T=_2LWINJQ=!^4_&"8
M@A=Q^#Z/4R4D:S_[:><MR; 8?L6U5P'Z[C):H^UP&ES(*U^D'>YM.:HO3+N$
MZ1I K5B[9']-&&2$<0@-W3LP&2Y5R'%RJ=SGT_788&15!EY.I3FU_]EN^PN\
MOAJ05E1U<(8\2.J%WQ(KV%^UEO?SF; ;&,R/'-^Z#M3>DT88[E2<7Q.SK\#)
M;2YBN@Y(\I 1FDU?::X*Z=ZOGSN3)[?O[:F%M4B^+\2_P9R&]6&W*FV%RHA>
MBQU$@P!?@U+=1H$E95CAK];3%1)ISW6FEEY.U@RO,'8W#>69/?OU6'T7Z),2
MJR H#RD!(?9K18'=:0$UL2H-.K(QAJ@V<QUD^\6$01/<\V+&Y/!\5G@0#S-!
M/Z_$@+LJR*'O>J8]+GZEDS9_=+'PB[B72OU96:F@<30'? /HD]NX;E0ZE(PO
MQ3E=@KM,Z,I.X?R7?!K@@<,SK^9),FLN1]%->SM(RZ77AQ'DIJ',B)BH\:36
MA/-.D7-5BG\&8M5+N+,BM(T-X<]N;+X]'>/IZE)%P#6$[M?E A02=,!(+N+U
ML[!T%;88OTS8A;)'4_)XW'']*(M/VZE?*.->M[?3UQ:E&\#=^A"!8Z=:OY+=
M]M"TM5UDXZ!;?^];]]*?[*&GNA"0+N;D:M!L?NEM_V=+O<,YL2XJF [?4]DK
M?F/)H;VZC)0K(<U93\0AM*P-S66*^XA"BG?2>WJ[N9K8>;P"=IE$+,@D#ND+
M-L*<1V31C3W\A'IBN&DTJK(MP<C\@C^C1D&K,HG(#,>5^>XNNMI01SI 00UJ
M)5&FTX.@9U(FX(Z0EX#9OKDL>Z1QD>XZ8N]XT'$?5(9SO)AV=G#**BUB_17S
MV=WM[IU=;)0WR_C)P344(\&S..=D?0%MEZ4,8V/Y]6O"ESUSJX3G1_*T1;1"
MD:FOSZ$&F89L/Z^D86\;Y80"3_[6147PM-8CO%FOG56@ 4]L.[$L+V_6L.<U
M%V8)STTO)[%D?ZETZG!H;C&XM.YPS9;#;N[_'5+?"<9\W_IL[%>QVZ8_Z<F,
M;SV?<8VR=#_)8U=:QP.7QM?@0DLP>!F,N=><=*R%%R6-O1/ZH,Z[+HW;)6]\
M:/>0&F7JKS.<UI6!Z2MI0A;C!E>T*D)/I.,O'R)>TH_:Q3V@Z3-ZC(2I,[(G
MMKI?"V'.\#SF#"UC;5.GX)K=J[-$N"."?((+*#I=C7^^W#OEN.NN):Z7")K^
ME'.8TPP3Y7#;+P\-E+L27XQ;,JNX@":URON7'#=VXWH[F*Q#3@Y(1G-":^HR
MC+^ K+BMHE/9N 'Q@7>4>PO+8?/7H+R#JR^)?X%^! P:ZIU?4K3EG5^_$BXL
M+''9L!%M,&81]C#U^SWFDOMBO4! MYLNQ&D0.[G(<VGN.T]E?0H5SF>1VIL]
M[1'%3<"BP9=+$1KD)^?^5M9=2),S34P '4UM:_=:ET$@2IM,>50P?>&6^+QD
M?!E>#+.?C(IL;I63+9.4?\RV(JCBR ):YTM8Z)798,$NH&GG=N98$\..3=/X
MKHSF1QIXM!G59<DH"SF85O,QO&$'NST_BG!S*VAU#NY8-:O883ZH>VZ_TIL1
MKV%^F_$E^,D9;'NKM=GW!C#XG-1X4D@)188YZW)SBS2JCI!L,)!76?WD4<5>
M-$CY,L/NSYB"('VD D&Q'7V\BG,1+ISL0"RUE <ZI0J\=9^ +3-B:]^7_?9T
M18[F44">+=4-(,=VD'YP/2#8X]-1C1O#\E$*-*1%\*]J=4_G)B0VUS07M> $
MHHPNQ=E;:*L',EZ2^7LYCOX<.?T+ND(7@MURD*8;-P#RJT_.]&Q/FJ?;:+<N
M+%]VOIVT8I(H7O)B85$?4EI@5/Q9O%B9HUR$&WV!$:C28 OZF'=5M#<VX)=;
M\DG_@RR:$;^53OMGSZE-$!)C4K?P2>"1:%?CN>+D-M%0&YJ(_2S8'K<]"FI
MN$G)#:4\:C%&Z+0:U7.Y+<1D? ]*)P#J^"XGMN9>[.!L+^!))HB(K8*U"QM7
M106,8SRJ7T')/8=KMENHTHEENH2?8566!VS+2R:BJF8ED?ZH+<@0EUAH9"\G
M55UJV_16]*Y S69D9NRD:-Q31J_5@&N748;-E%3O@I!$0RRSW5QI2N[#Q6D9
MN@<P#I>#2A<=E?,8;?LFA"^GLU?YH^:L[8/<[3;#>/[SAT8;42Z$65RQ.S>
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M(/<B/+^7CY=C/=-ZGA_M8I8-#T#CEC1=>W74[;,>GY1%C&J\:X&Y?6)T_@W
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M[<1]#<9/"O>."I0+-(CBG< _!JGO+&S WWYHOO<XHK8%CH)7/'4\.[H!R-\
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M9,Z&=^*;:0Q5]6ES3N_"6VX 23> >XKM]&<91^PHDTOUV(&A;7ZU72JHUPU
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MG8O$<3WR-4BE_H7\4/$NE60.3-=.0EC#=B#%TB[P?G4FW;;ZL/[XK!ZCCO/
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M>MSN-NHO;:+^;@>L@H<F#<(H)9^BZ+<L]0B>%?OZ#]6>/1?Y1(W4#(_V/^#
MV'@DG]I.@_"2.BIFC< VT9JU9IH^)MR\,T.^1,IMF:*)]K/<=>,'K\85BB4S
MP8_TQWL".5H0YCZP>V4F2*-,1-S+-6Y\9IVZL@V:*QW%7,2Y(C34RYBQT7OP
M[*L"S4=#MF0:%CIDTLDWIY#S!SMMA!ZQDBX?RQP+(EMC'^(>V]80O)0;.U/!
M4_@ \2Y4)9*-=TV(=ZN^M85EV!1*R[9U711FSJTA"!488;D_]3=$!LA[LZ[6
M(VR6=94X+:F^EY9W8-C1'N\-(N2(7/.D)EI"@+NZE_HB0<Y1T,0#< V3.F6A
M2QGU#F^?%FR[\W@,8F;56/.J(55@K<K:/=O0$9CB9GP/45KD;=_>H=!8WI"Z
M@[GQZ(%1HB-S&$Q9CH66B&1M-D-GQG;SFE>[0J6A GX!(VN#2>AHAJNFDD7A
M47(S:D5P3^'7KWGLZL[B=,;3[W9O#+RI";XZM'%&JQ>'RKKZ!B4E3(_G#*HB
M7BC:SZXP8F]K/ 0N*QJ ,8"KNT8W %>BC5..!AG0'OI;R<Q3U* *P%]^RH/^
MD5"XN PF7N%B12_CK]TGP:_+MT?HE3-/>C*6YKV_H!1/UM\1$?ML:3\CIZZ-
M;;9V6NCR\)P/'(V] 8!N=VJNDN91P3+\L'NTU+B#K5;A\>>W6-Q!I J&'X@8
MXEJ^FG([*DC<87:T*7";:P8^+> .LKCZ@3WQ1FJ>%6#:1LCQNGAK%M+:D#>[
MXUGZI-TU8T0>8"+Q_2E41W%^2.S.O]/>_&Y8-KKD!K"8&_NG; \W%9A5J=D"
MB9KJ?U^!ZS\P?D?4CF\G@;_R8VC_;TI,^3WP;/\V[[GU;S-FV5"O!LP@)&I&
M=__1NK&8HT1@W@6Q%K$3I7DQ83C%C/5?:ZDD/Q7X9,_,.F1F?[KEBW70GP)D
MLH?*1J5(>4XA8EJQC!-ON9R(";4<'^MA9JM2T*@K%-B.;7>H)/Z8W$L&<*63
M/G\G"JCO,LQ-^4!)C-#I&-6O^6KC:U-G13B:H<G^DR]85H21Y03*A&@H*<JT
M76[ADY-/O/\0!JS"O\OY3?";7;-KYW2#F@:KFXVZYS-QQ@(%T^58/J6V4/^N
M6CQ^90PL\13&-D.MC^(\*TC+%-.1TU]3EG,,!IH8TR-'O><0._;%LC49/=U2
M\\)?ML[5H@$I-?EOYJ(,.BM*)/C>X8CC0H3"3CFB:YLR9,;S&ZP6K?PTN0VF
M72@';4>E?E1.=^@_!%VWN#N(&X4M;>)9+#5-"^\>3M6P?L%'*N'(EJ<JO#W-
MP+-E4H\;F7M"IC'Q$(=Q-MLTS]97[</V+=$^)5$/-N/1[;D/C?!-3,ZREI/<
MC<PO*[C.Y6]Z'/#Y.M^@*..SN5A%UF>/HJ5M4<>OQ8UQV?;>Q:ZY,-(/;.?S
MA.SK)-]J,3GL;3CWQQ:G[BT'/W\?QX3[50) @YOZE[B*OS?^X1>S6S<1_Y_)
MLF?[+<%7OU/3 5K_S#;X#XY_HJWG_\KQC\FF,^-S Y!8O@&TL=P HO(L-U$7
M(6A4-IK]BV44>^O \.4ASO4E$*5%S0/<;*:_6+L!'&EBF$5!*T_0?NTW@,#;
MYY'*_@4,H)M;NM=\ \B"@Y>2;@!=:G\-)T7&^A7Y5\]Y^U> JG?^OT7WB?4I
M+V"0Z85IMJ#\TK@9:<^.W6M 245;(YA=4.A"95U[ZPMN!C6RZ#C/'.R.UG*,
M^M?-_\&;V,K$@2FRYT(^09IF@N?T^FTRFD:9G9,_P4]!E[=,N.C+ZTM#^P"O
MC^W-HMKLD(_ZS2]Y;P##MSNB58GN3=M)W^V.23(@4=L'F:P_1WT";][R=.EI
M_)]G0Z)8SZ'EKA_1?P:52^)!'8.1:U-=)'XZOT3>_#T\$J5[-(7 /P&.K@W<
M ,2ST9<"%3)TD^>$&O1_ K0YMKR5(I7?H>^_<N/MD#AL\7\&Y??YMW=\JR97
M$Q"2W/,78/$_OV0M:]YL:_N_%O1_<$':792,)OTZ6:LD6E\Y! \.U$?^;D.@
M?Y6:^5>)GG_1[?]ANN6F;MR[]W"8QN(8JY[RRWV;?.QGV ^DUX@5I>Z0Z#!_
M0\G!T:$P;WZ\/A:D8>A+4;F/,*X++YK-SW'OSO(@(7G6!G_Q8OH*HV;OLZ3+
MQ+%.-#71W%'E5?B",ZHWJ]V6;Q^L46 G.!U,XY/U)JAV4WA(,ORXM'*8!)=*
M3_V9]YU?N(#$J#"Q)I^,MSK$8KX<P79V?^'$MQ*48J[^SD"!RE=]N<"?7VOW
M&0@5 T;C_:,F_^1_L=W'*L':E<+[XRU('S2\&UR+S#L!-]0[HHHQ]=E%K,,
M^&/Y)J?<WZU/BDKOJO9+J_/>V[+!^#<B?-O7,1YS%XBL49)=_/E:/F:0P>C7
M;LRUC%&P=QEDM3Y8)I%2553T<]CM-,F/7^[_3PB(YAF!@?+8$P4/KA=3_4(.
M7R_X.$WC#3$[W63V[O2SQV5"MD5[/EU_*IDQOM0]D1QTKGP[Y)*9ORH,3-&:
M]-=9N29TN5OT34__IY2D9N([A,3Y64\+1_[=+E+]#K7*20>R796FX)V%..QR
M>5J% U[V+ C,Z)$T>V-9J:W5 6\)YQ<^(M46^8O"A;H[):4RZN,> 6)ZM4CE
M3P%./O>$>;"#ODN&TQ+5* I<9U8?M4O,$ROQ7-4O2GV[ 4@I*]U:E1E,"1V4
MB3J:TI,?EXFZ$]ER,X4ZGLAG+\IB!R8#KEB+"QKK@H('Q-4J*#OJ[[YCSGWG
MRBOZ.P%,YW&Q_VOX^:?5>\W/79A[YO+=8QI[/HXN46O%N24EC! /,ZDWMH04
M#+5&L1;^5U$B)1W\*>A9.3_?GR#]D#Q13ACWBT5B "NF/@?P];0[Q).-::P&
MSZ\S)M0SM...9#AISBV6/LLXDB7.2*K3@6>8.>B1RAM ]@ 8>=6V*D5FDZ^M
MH]K;GAP33"A=\#]<80(6R&DW?<73L3NP+[BC:)^?R%#9[2S%C5$VVWRQ:HU*
MPKME^3X1.H8T5,?F>BF=F_H&8/3I$URC^Z*5>1QZNJ^_?^"T;_@Z45YV,[(>
MY2R'%N>(G Y\:N]U:XZ332M.6H>_-D! $EE[9W=H..@#>EBV9$R:EA!4/1V+
M+&-Q[5^W7>=ZY5"GE(9H^B;3@QJ:5GKT]S8XR\<,1Z<8+]=-Z/"S6>#AA[8X
M>\\V[^9T$!!A<7O6<Q=L9%P:H(9M$#VP72@>0IWB=#<L1*WE(Y-C^,8K8[UP
MM"AP62L-[M1U50N1K,CQ#MO0J^$0$>\ZB1\B%S,"+W/B7)\9@CL5KQ6[P.1/
M*D;?@JOC8L@=:EWC^E\J-"5T.Q=EKWQUMFL\#)/DF?$.[Q15'0-7%\R)VX ]
M>[\S"FF,K,1+V+'9G2%U;@#OC)3(,H%%""HZ=D0*%&$.6]C!VRX<VR][()#
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MU)>O8ETG&7F&P"1<07'3L[1#1?R-_FKU#QX=6\@6,02XVO,MXZ!"41IGX3>
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M% 6]SV(9$Z>%V%78KT.84L@$4G*MGE=6S+\'R _).:V4*.^#E+B%"O;+:MG
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M1T3!S1*PAB]I^N/H"3B;[G#F$P<<Z()I5DJ;#+?N[!1>T_S@E#L!7R>5VKB
MHE.U7F)^SP:O:XN(.M'NFPKX5&SA%OTO[2GB6!Y\@NKWO?G/F39=F(Z5[$:5
M!T#//8^%F\#O%^_59&XH$5 TIG0FR:](4PC?J9<,+]Z/&AE#W5G))%>>X.2_
M%NJKF3 _/D@:3FCN:J?H,Y/#]S6'N">K698?_'0B\M9X!<]_U)$[$Y J\DL\
M9-!K7NH[LO/6"-$@3H-Z>[T^DLRJI>J"SCJD2C.H/$_: +QSS:?;*!SCCZ;%
M4;RU-!B..9>'T^C.'1J8LG23)K+.?*,$:7\2/4!P="QRI-_W@ #W53!38B['
MGH[X #W"[#W4M# QCH/>291,J"MPO7?1R;[O3QS@/:V^%1&WZ<;)IT#U"+U3
MC@7O\O -S+ LT)4S-[4GK?EF?I_$/I2N;;-%_Y;NVE(+9]:D/O"T=O+I6 _N
MB(@#+]X._H0<X$$I (BOHU.T/:6O%*.M'U"M/56!SZ3&#;C=F<C)KZP*7 ^$
M G1O]^/W_TOR)?]G8NP=_K;XLL[?EF8N $9\>JN5&\7QY>?_KK"Z?]'M7W3[
MSZ<;</\<?'*!<XTB"6@=1@?^3BT)_J:FRMLVMW<#V#P@0B)8D0'9J.OV&P#X
MCF[N.X[K?P.+KYNY 0S/TU_ M6Y/]']-^/L30MRP>P=(CGJ_6^,N?[;ZIB9%
M4EQ:K7J'G7V?!.-U5),,0#VW;/3_R$6!WQ*HUJK-5X8!Y"EJ@&!B4##R+T1>
M3Z*^YNX=/"VS>.MTD-T?&WL]?JG=VHG>06N^53F KNO[@9[XO/GCLMH?>1K3
MO[(70/VQOR<6G[=*]_^#>7(UQX0:C+]3/#3_ *@Y9[G0.<XS WN V26@'UP_
M4?\E!P1: 6QL2Z%^A"R]5-OW#TGN_;6T $SY P 2\ >B/W#&VZ_1%,IVH[=O
M?_\&L-_[C4CV#YQ^((9UWC]22/X * 7]@4CP#YRSESAL"7_),=%'_H'H#YQT
MT[TB_UK<?_KB.'0Q&=\&BQS*Z ,(WQ$5D"9Y>;'9@&]F_@M02P,$%     @
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M\TXY&V-O1@W[5)NE4 9D13$1R^F'K0SZ*;&598QP&CQPG >G/V]CM,9]6O_
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M?ED<N(6L>?M/4$L! A0#%     @ Z(M)7%.]DQID$@  8\8  !$
M     ( !     &)R='@M,C R-3 Y,S N>'-D4$L! A0#%     @ Z(M)7'I]
MH0[K%0  !1 ! !4              ( !DQ(  &)R='@M,C R-3 Y,S!?8V%L
M+GAM;%!+ 0(4 Q0    ( .B+25S [:%<OT@  -7^!  5              "
M ;$H  !B<G1X+3(P,C4P.3,P7V1E9BYX;6Q02P$"% ,4    " #HBTE<\Y@D
M:[ES  "AYP8 %0              @ &C<0  8G)T>"TR,#(U,#DS,%]L86(N
M>&UL4$L! A0#%     @ Z(M)7->OWG,:7   #U & !4              ( !
MC^4  &)R='@M,C R-3 Y,S!?<')E+GAM;%!+ 0(4 Q0    ( .B+25PT&6$W
MR*(  (06!  +              "  =Q! 0!E>#$P+34P+FAT;5!+ 0(4 Q0
M   ( .B+25S )NKNR1@  +_+   )              "  <WD 0!E>#$P-RYH
M=&U02P$"% ,4    " #HBTE<CRDI:B0#   _$0  "@              @ &]
M_0$ 97@R,RTQ+FAT;5!+ 0(4 Q0    ( .B+25RCMV<;+$X  "83 @ )
M          "  0D! @!E>#0M,BYH=&U02P$"% ,4    " #HBTE<%&0-NH1*
M  "D]0$ "0              @ %<3P( 97@T+3,N:'1M4$L! A0#%     @
MZ(M)7#$ &8$44@  4R<"  D              ( !!YH" &5X-"TT+FAT;5!+
M 0(4 Q0    ( .B+25PLHYR_9 H  &=    )              "  4+L @!E
M>#4M,2YH=&U02P$"% ,4    " #HBTE<\/U'*WU/! #LM2D "P
M    @ '-]@( 9F]R;7,M,2YH=&U02P$"% ,4    " #HBTE<!Y[/;77, 0#[
M[P$ #P              @ %S1@< 9F]R;7,M,5\P,#$N:G!G4$L! A0#%
M  @ Z(M)7)_>B%#Q5 , :5X#  \              ( !%1,) &9O<FUS+3%?
M,# R+FIP9U!+ 0(4 Q0    ( .B+25Q_R#V@S=4  &#F   /
M  "  3-H# !F;W)M<RTQ7S P,RYJ<&=02P$"% ,4    " #HBTE<$M['[:A-
M  "%3P  #P              @ $M/@T 9F]R;7,M,5\P,#0N:G!G4$L! A0#
M%     @ Z(M)7.#C*D01_0  H3$!  \              ( ! HP- &9O<FUS
M+3%?,# U+FIP9U!+ 0(4 Q0    ( .B+25QO!<< IQ$  .P2   /
M      "  4")#@!F;W)M<RTQ7S P-BYJ<&=02P4&     !, $P!V!   %)L.
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>forms-1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:BRTX="http://biorestorative.com/20250930"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="brtx-20250930.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ATMSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BRTX:ATMSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_ATMSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BRTX:ATMSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BRTX:TwoThousandTwentyFourATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-10-082025-10-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-08</startDate>
            <endDate>2025-10-08</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-08_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-08</instant>
        </period>
    </context>
    <context id="AsOf2025-10-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-08</instant>
        </period>
    </context>
    <context id="From2024-11-062024-11-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2024-11-06</startDate>
            <endDate>2024-11-06</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-06_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="From2024-02-062024-02-06_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_AuctusFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-03-202025-03-20_us-gaap_CommonStockMember_custom_AuctusFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-20</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2025-03-20</instant>
        </period>
    </context>
    <context id="From2024-02-062024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="From2024-02-052024-02-05_us-gaap_CommonStockMember_custom_RothCapitalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="From2025-06-052025-06-05_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-05</startDate>
            <endDate>2025-06-05</endDate>
        </period>
    </context>
    <context id="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-13</startDate>
            <endDate>2025-10-13</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">BRTX:TwoThousandTwentyFourATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-06-162025-06-16_custom_BoardOfDirectorMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:BoardOfDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-16</startDate>
            <endDate>2025-06-16</endDate>
        </period>
    </context>
    <context id="From2025-09-302025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-08</instant>
        </period>
    </context>
    <context id="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-08</startDate>
            <endDate>2022-09-08</endDate>
        </period>
    </context>
    <context id="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-08</startDate>
            <endDate>2022-09-08</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-04</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-04</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-10</instant>
        </period>
    </context>
    <context id="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-10</instant>
        </period>
    </context>
    <context id="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-13</instant>
        </period>
    </context>
    <context id="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-13</instant>
        </period>
    </context>
    <context id="AsOf2024-07-22_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-22</instant>
        </period>
    </context>
    <context id="AsOf2024-07-23_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-23</instant>
        </period>
    </context>
    <context id="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_DemandSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:DemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-122023-07-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2023-07-12</startDate>
            <endDate>2023-07-13</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2023-07-13</instant>
        </period>
    </context>
    <context id="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="From2024-02-062024-02-06_us-gaap_CommonStockMember_custom_AuctusFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NewWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember20509234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember20509593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember20509640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember20509859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_EmployeeStockOptionMember20510484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember20510484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-302025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-12-312024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_custom_ExistingWarrantMember_custom_BlackScholesOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2024-02-08</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BlackScholesOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BlackScholesOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BlackScholesOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BlackScholesOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-10-062025-10-06_us-gaap_CommonStockMember_custom_SubscriptionAgreementsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-06</startDate>
            <endDate>2025-10-06</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-06_us-gaap_SubsequentEventMember_custom_SubscriptionAgreementsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-06</instant>
        </period>
    </context>
    <context id="AsOf2025-10-06_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-06</instant>
        </period>
    </context>
    <context id="From2025-10-062025-10-06_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-06</startDate>
            <endDate>2025-10-06</endDate>
        </period>
    </context>
    <context id="From2025-08-112025-08-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="From2025-10-272025-10-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-27</startDate>
            <endDate>2025-10-27</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-27</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-27</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ComputerSoftwareAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ComputerSoftwareAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20515187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SectionThreeHundredAndEightyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:SectionThreeHundredAndEightyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MelvilleLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>BRTX:Segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-09-30" id="Fact000004">0001505497</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0097"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0216"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueAbeyanceShares
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueAbeyanceShares
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueAbeyanceShares
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueAbeyanceShares
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueAbeyanceShares
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:NoncashLeaseExpense
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0675"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0679"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:ReclassificationOfDeferredOfferingCosts
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0691"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:DeferredOfferingCostsIncludedInAccountsPayable
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0694"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_us-gaap_ProductMember"
      id="xdx2ixbrl0754"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0965"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0973"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1012"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1013"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1014"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1108"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1110"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1124"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1132"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:DeferredOfferingCost
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1191"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1224"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1291"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GrantIncome
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1317"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1436"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1441"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1444"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1449"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1452"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1466"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl1477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1479"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1576"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1579"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1583"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:PaymentsForProceedsFromDeferredOfferingCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1586"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1607"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1609"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1610"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:IssuanceOfCommonStockHeldInAbeyance
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_ProductMember"
      id="xdx2ixbrl1657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1741"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31_custom_PatentsAndTrademarkMember"
      id="xdx2ixbrl1846"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_PatentsAndTrademarkMember"
      id="xdx2ixbrl1858"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2097"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20515187"
      id="xdx2ixbrl2181"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20515187"
      id="xdx2ixbrl2185"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl2187"
      unitRef="Shares"
      xsi:nil="true"/>
    <BRTX:DeferredTaxAssetsRightOfUseAsset
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2307"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2327"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2024-12-31" id="xdx2ixbrl2369">http://fasb.org/us-gaap/2025#OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2023-12-31" id="xdx2ixbrl2370">http://fasb.org/us-gaap/2025#OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl2459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl2461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl2467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl2469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl2473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl2475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl2481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl2483"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-09-30" id="Fact000013">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-09-30" id="Fact000014">BIORESTORATIVE THERAPIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-09-30" id="Fact000015">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-09-30" id="Fact000016">30-1341024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-09-30" id="Fact000017">40 Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-09-30" id="Fact000018">Suite One</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-09-30" id="Fact000019">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-09-30" id="Fact000020">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-09-30" id="Fact000021">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-09-30" id="Fact000022">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-09-30" id="Fact000023">760-8100</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="From2025-01-012025-09-30_dei_BusinessContactMember"
      id="Fact000024">Lance Alstodt</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2025-01-012025-09-30_dei_BusinessContactMember"
      id="Fact000025">40 Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2025-01-012025-09-30_dei_BusinessContactMember"
      id="Fact000026">Suite One</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="From2025-01-012025-09-30_dei_BusinessContactMember"
      id="Fact000027">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2025-01-012025-09-30_dei_BusinessContactMember"
      id="Fact000028">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2025-01-012025-09-30_dei_BusinessContactMember"
      id="Fact000029">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="From2025-01-012025-09-30_dei_BusinessContactMember"
      id="Fact000030">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2025-01-012025-09-30_dei_BusinessContactMember"
      id="Fact000031">760-8100</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-09-30" id="Fact000032">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-09-30" id="Fact000033">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-09-30" id="Fact000034">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000042"
      unitRef="USD">602444</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000043"
      unitRef="USD">547890</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000045"
      unitRef="USD">3887383</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000046"
      unitRef="USD">10184701</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000048"
      unitRef="USD">13400</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">188400</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000051"
      unitRef="USD">204237</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">223230</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000054"
      unitRef="USD">4707464</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">11144221</us-gaap:AssetsCurrent>
    <BRTX:DeferredOfferingCost
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000057"
      unitRef="USD">69066</BRTX:DeferredOfferingCost>
    <BRTX:DeferredOfferingCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">148697</BRTX:DeferredOfferingCost>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000060"
      unitRef="USD">309498</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">362936</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000066"
      unitRef="USD">556634</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">623945</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000069"
      unitRef="USD">5642662</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">12279799</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000078"
      unitRef="USD">859898</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">483070</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000081"
      unitRef="USD">607470</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">744485</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000087"
      unitRef="USD">1968315</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">2520851</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000090"
      unitRef="USD">3435683</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">3748406</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000105"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000107"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000109"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000111"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000113"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000115"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000117"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000119"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000121"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000102"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000128"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000130"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000132"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000134"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000136"
      unitRef="Shares">7978117</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000138"
      unitRef="Shares">7978117</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000140"
      unitRef="Shares">6919919</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000142"
      unitRef="Shares">6919919</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000125"
      unitRef="USD">797</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">692</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000144"
      unitRef="USD">168905254</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">164195434</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000147"
      unitRef="USD">-166713054</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000148"
      unitRef="USD">-155678715</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000150"
      unitRef="USD">2206979</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">8531393</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000153"
      unitRef="USD">5642662</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">12279799</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000156"
      unitRef="USD">11800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000157"
      unitRef="USD">233600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000158"
      unitRef="USD">340100</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000159"
      unitRef="USD">357700</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000161"
      unitRef="USD">10570</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000162"
      unitRef="USD">18243</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000163"
      unitRef="USD">22208</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000164"
      unitRef="USD">24733</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000166"
      unitRef="USD">1230</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">215357</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000168"
      unitRef="USD">317892</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000169"
      unitRef="USD">332967</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000176"
      unitRef="USD">2594750</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">1453363</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000178"
      unitRef="USD">7467532</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">5004794</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000181"
      unitRef="USD">1115491</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000182"
      unitRef="USD">1048987</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000183"
      unitRef="USD">4672192</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000184"
      unitRef="USD">4193225</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">3710241</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000187"
      unitRef="USD">2502350</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000188"
      unitRef="USD">12139724</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">9198019</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000191"
      unitRef="USD">-3709011</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000192"
      unitRef="USD">-2286993</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000193"
      unitRef="USD">-11821832</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000194"
      unitRef="USD">-8865052</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">57740</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000202"
      unitRef="USD">158547</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000203"
      unitRef="USD">231621</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000204"
      unitRef="USD">497089</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000211"
      unitRef="USD">930</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000212"
      unitRef="USD">566</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000213"
      unitRef="USD">3336</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000214"
      unitRef="USD">150498</us-gaap:OtherNonoperatingIncomeExpense>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000219"
      unitRef="USD">1711698</BRTX:GainLossOnExchangeOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000221"
      unitRef="USD">612064</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000222"
      unitRef="USD">1036464</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000223"
      unitRef="USD">552536</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000224"
      unitRef="USD">-837466</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">670734</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000227"
      unitRef="USD">1195577</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000228"
      unitRef="USD">787493</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000229"
      unitRef="USD">1521819</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000231"
      unitRef="USD">-3038277</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-1091416</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000233"
      unitRef="USD">-11034339</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000234"
      unitRef="USD">-7343233</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000236"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000238"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000240"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000242"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000244"
      unitRef="USDPShares">-1.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000246"
      unitRef="USDPShares">-1.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000248"
      unitRef="USDPShares">-0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000250"
      unitRef="USDPShares">-0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000252"
      unitRef="Shares">9116172</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000254"
      unitRef="Shares">9116172</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000256"
      unitRef="Shares">8121499</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000258"
      unitRef="Shares">8121499</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000260"
      unitRef="Shares">8742085</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000262"
      unitRef="Shares">8742085</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">7643437</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000266"
      unitRef="Shares">7643437</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000274"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000276"
      unitRef="Shares">6919919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000269"
      unitRef="USD">692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000270"
      unitRef="USD">164195434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000271"
      unitRef="USD">-155678715</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000272"
      unitRef="USD">8531393</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000284"
      unitRef="Shares">29249</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">3</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">42408</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">42411</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000292"
      unitRef="Shares">492087</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">49</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000288"
      unitRef="USD">901561</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000290"
      unitRef="USD">901610</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <BRTX:StockIssuedDuringPeriodSharesAbeyanceShares
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000300"
      unitRef="Shares">63525</BRTX:StockIssuedDuringPeriodSharesAbeyanceShares>
    <BRTX:StockIssuedDuringPeriodValueAbeyanceShares
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000295"
      unitRef="USD">6</BRTX:StockIssuedDuringPeriodValueAbeyanceShares>
    <BRTX:StockIssuedDuringPeriodValueAbeyanceShares
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000296"
      unitRef="USD">-6</BRTX:StockIssuedDuringPeriodValueAbeyanceShares>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000322"
      unitRef="USD">2009126</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000324"
      unitRef="USD">2009126</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-5339799</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-5339799</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000338"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000332"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000340"
      unitRef="Shares">7504780</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000333"
      unitRef="USD">750</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">167148523</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">-161018514</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000336"
      unitRef="USD">6144741</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000348"
      unitRef="Shares">473337</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000343"
      unitRef="USD">47</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000344"
      unitRef="USD">888091</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000346"
      unitRef="USD">888138</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">468708</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000360"
      unitRef="USD">468708</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">-2656263</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000366"
      unitRef="USD">-2656263</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000374"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000368"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000376"
      unitRef="Shares">7978117</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">797</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">168505322</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">-163674777</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000372"
      unitRef="USD">4845324</us-gaap:StockholdersEquity>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">399932</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000388"
      unitRef="USD">399932</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000393"
      unitRef="USD">-3038277</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000394"
      unitRef="USD">-3038277</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000402"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000404"
      unitRef="Shares">7978117</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000397"
      unitRef="USD">797</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000398"
      unitRef="USD">168905254</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000399"
      unitRef="USD">-166713054</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000400"
      unitRef="USD">2206979</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000412"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000406"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000414"
      unitRef="Shares">4706917</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000407"
      unitRef="USD">471</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000408"
      unitRef="USD">156689256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000409"
      unitRef="USD">-146699334</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000410"
      unitRef="USD">10004375</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000422"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000417"
      unitRef="USD">200</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000418"
      unitRef="USD">4742043</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000420"
      unitRef="USD">4742243</us-gaap:StockIssuedDuringPeriodValueOther>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000430"
      unitRef="Shares">-34825</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">-4</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-48406</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000428"
      unitRef="USD">-48410</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000444"
      unitRef="Shares">97827</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000439"
      unitRef="USD">10</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000440"
      unitRef="USD">985028</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000442"
      unitRef="USD">985038</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000448"
      unitRef="USD">1043336</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">1043336</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000455"
      unitRef="USD">-2223255</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">-2223255</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000464"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000458"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000466"
      unitRef="Shares">6769919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">677</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">163411257</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">-148922589</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">14503327</us-gaap:StockholdersEquity>
    <BRTX:StockIssuedDuringPeriodSharesAbeyanceShares
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000474"
      unitRef="Shares">150000</BRTX:StockIssuedDuringPeriodSharesAbeyanceShares>
    <BRTX:StockIssuedDuringPeriodValueAbeyanceShares
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000469"
      unitRef="USD">15</BRTX:StockIssuedDuringPeriodValueAbeyanceShares>
    <BRTX:StockIssuedDuringPeriodValueAbeyanceShares
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000470"
      unitRef="USD">-15</BRTX:StockIssuedDuringPeriodValueAbeyanceShares>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000484"
      unitRef="USD">324322</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000486"
      unitRef="USD">324322</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000491"
      unitRef="USD">-4028562</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000492"
      unitRef="USD">-4028562</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000500"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000494"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000502"
      unitRef="Shares">6919919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000495"
      unitRef="USD">692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000496"
      unitRef="USD">163735564</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000497"
      unitRef="USD">-152951151</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000498"
      unitRef="USD">10799087</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000510"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000504"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000512"
      unitRef="Shares">6919919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000505"
      unitRef="USD">692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000506"
      unitRef="USD">163735564</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000507"
      unitRef="USD">-152951151</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000508"
      unitRef="USD">10799087</us-gaap:StockholdersEquity>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000522"
      unitRef="USD">284245</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000524"
      unitRef="USD">284245</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000529"
      unitRef="USD">-1091416</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000530"
      unitRef="USD">-1091416</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000538"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000532"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000540"
      unitRef="Shares">6919919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000533"
      unitRef="USD">692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000534"
      unitRef="USD">164019809</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000535"
      unitRef="USD">-154042567</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000536"
      unitRef="USD">9991916</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000548"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000550"
      unitRef="Shares">6919919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000543"
      unitRef="USD">692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">164019809</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000545"
      unitRef="USD">-154042567</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000546"
      unitRef="USD">9991916</us-gaap:StockholdersEquity>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-03-31_custom_ATMSalesMember"
      decimals="0"
      id="Fact000553"
      unitRef="USD">1083915</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-012025-03-31_custom_ATMSalesMember"
      decimals="0"
      id="Fact000555"
      unitRef="USD">182305</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_custom_ATMSalesMember"
      decimals="0"
      id="Fact000557"
      unitRef="USD">901610</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-04-012025-06-30_custom_ATMSalesMember"
      decimals="0"
      id="Fact000560"
      unitRef="USD">927335</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-04-012025-06-30_custom_ATMSalesMember"
      decimals="0"
      id="Fact000562"
      unitRef="USD">39197</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30_custom_ATMSalesMember"
      decimals="0"
      id="Fact000564"
      unitRef="USD">888138</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000567"
      unitRef="Shares">3351580</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000569"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <BRTX:SharesHeldInAbeyance
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000571"
      unitRef="Shares">1351580</BRTX:SharesHeldInAbeyance>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000576"
      unitRef="USD">-11034339</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000577"
      unitRef="USD">-7343233</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000582"
      unitRef="USD">157149</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000583"
      unitRef="USD">138687</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000585"
      unitRef="USD">235878</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000586"
      unitRef="USD">492476</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000588"
      unitRef="USD">2877766</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000589"
      unitRef="USD">2636941</us-gaap:ShareBasedCompensation>
    <BRTX:NoncashLeaseExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000592"
      unitRef="USD">111750</BRTX:NoncashLeaseExpense>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000595"
      unitRef="USD">1711698</BRTX:GainLossOnExchangeOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000597"
      unitRef="USD">552536</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000598"
      unitRef="USD">-837466</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000603"
      unitRef="USD">-175000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000604"
      unitRef="USD">145700</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000606"
      unitRef="USD">-18993</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000607"
      unitRef="USD">-23124</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000609"
      unitRef="USD">357070</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000610"
      unitRef="USD">211990</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000612"
      unitRef="USD">-137015</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000613"
      unitRef="USD">-29449</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000616"
      unitRef="USD">-119903</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000618"
      unitRef="USD">-8373790</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000619"
      unitRef="USD">-5882501</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000624"
      unitRef="USD">9212343</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000625"
      unitRef="USD">17370243</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000627"
      unitRef="USD">2679147</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000628"
      unitRef="USD">18294566</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000630"
      unitRef="USD">36400</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000631"
      unitRef="USD">93755</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000633"
      unitRef="USD">6496796</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000634"
      unitRef="USD">-1018078</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000639"
      unitRef="USD">2011250</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000642"
      unitRef="USD">72805</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000645"
      unitRef="USD">42411</us-gaap:ProceedsFromStockOptionsExercised>
    <BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000652"
      unitRef="USD">7528027</BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1>
    <BRTX:PaymentsForProceedsFromDeferredOfferingCosts
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000654"
      unitRef="USD">49308</BRTX:PaymentsForProceedsFromDeferredOfferingCosts>
    <BRTX:PaymentsForProceedsFromDeferredOfferingCosts
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000655"
      unitRef="USD">22381</BRTX:PaymentsForProceedsFromDeferredOfferingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000657"
      unitRef="USD">1931548</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000658"
      unitRef="USD">7505646</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000660"
      unitRef="USD">54554</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000661"
      unitRef="USD">605067</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000663"
      unitRef="USD">547890</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000664"
      unitRef="USD">884377</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000666"
      unitRef="USD">602444</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000667"
      unitRef="USD">1489444</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000685"
      unitRef="USD">48410</BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:IssuanceOfCommonStockHeldInAbeyance
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000687"
      unitRef="USD">6</BRTX:IssuanceOfCommonStockHeldInAbeyance>
    <BRTX:IssuanceOfCommonStockHeldInAbeyance
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000688"
      unitRef="USD">15</BRTX:IssuanceOfCommonStockHeldInAbeyance>
    <BRTX:ReclassificationOfDeferredOfferingCosts
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000690"
      unitRef="USD">148697</BRTX:ReclassificationOfDeferredOfferingCosts>
    <BRTX:DeferredOfferingCostsIncludedInAccountsPayable
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000693"
      unitRef="USD">19758</BRTX:DeferredOfferingCostsIncludedInAccountsPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000696">&lt;p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zsU4hcvrI9i8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
1 &#x2013; &lt;span id="xdx_822_zOFIWkF7PVi9"&gt;BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Corporate
History&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#x201c;Stem Pearls&#x201d;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#x201c;BRT&#x201d; or the &#x201c;Company&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Business
Operations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#x2019;s
website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated
by reference into this Quarterly Report. BRT is currently developing a Disc/Spine Program referred to as &#x201c;brtxDISC&#x201d;. Its
lead cell therapy candidate, &lt;i&gt;BRTX-100&lt;/i&gt;, is a product formulated from autologous (or a person&#x2019;s own) cultured mesenchymal
stem cells collected from the patient&#x2019;s bone marrow. The product is intended to be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect
to a platform technology utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic
disorders and has labeled this initiative its ThermoStem Program. In addition, in continuation of BRT&#x2019;s mission of developing and
commercializing cell-based biologics, it is seeking to develop a biologics-based cosmetic products business. Pursuant to such business,
BRT would formulate, manufacture and sell products designed for cosmetic and aesthetic uses. Further, BRT has licensed a patented curved
needle device that is a needle system designed to deliver cells and/or other therapeutic products or material to the spine and discs
or other potential sites.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form
10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for
complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring
items) that are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company
as of September 30, 2025 and for the three and nine months then ended. The results of operations for the three and nine months ended
September 30, 2025 are not necessarily indicative of the operating results for the full year ending December 31, 2025 or any other period.
The December 31, 2024 consolidated balance sheet data were derived from audited financial statements but do not include all disclosures
required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and related disclosures of the Company as of December 31, 2024 and for the year then ended, which were filed with
the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 28, 2025 (the &#x201c;Form 10-K&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared on the basis that the Company will continue as
a going concern, which contemplates realization of assets and satisfying liabilities in the normal course of business. For the nine months
ended September 30, 2025, the Company had a net loss of $&lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250930_zOfSbFUsKVRj" title="Net loss"&gt;11.0&lt;/span&gt; million, and negative cash flows from operations of $&lt;span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250930_zLdueRSXo8hc" title="Cash flows from operations"&gt;8.4&lt;/span&gt; million, and as
of September 30, 2025, the Company had working capital of $&lt;span id="xdx_90D_ecustom--WorkingCapital_iI_pn5n6_c20250930_zFNA1zhTFMo" title="Working capital"&gt;1.3&lt;/span&gt; million. The Company anticipates that it will continue to incur net losses
and negative cash flows from operations as it executes its development plans during 2025 and beyond, as well as other potential strategic
and business development initiatives. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going
concern for at least twelve months after the issuance date of these financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable
securities and additional infusions of cash from equity and debt financing. During the nine months ended September 30, 2025, the Company
sold &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdCaEuIrsY41" title="Number of shares sold"&gt;965,424&lt;/span&gt; shares of its common stock under its at-the-market offering agreement (the &#x201c;2024 ATM&#x201d;) with Rodman &amp;amp; Renshaw
LLC (&#x201c;Rodman&#x201d;) and raised approximately $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPlQGqAjsPsd" title="Gross proceeds from sale of shares"&gt;2.0&lt;/span&gt; million of gross proceeds. On October 8, 2025, the Company closed on the sale
of an aggregate of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251008__20251008__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOOexdVmT2li" title="Number of shares sold"&gt;678,125&lt;/span&gt; shares of its common stock for aggregate gross proceeds of approximately $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjAihl2MxHXb" title="Gross proceeds from sale of shares"&gt;1.1&lt;/span&gt; million. Concurrently, the Company
issued to the investors warrants to purchase an aggregate of &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251008__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwRgmBQVTSx4" title="Warrants purchase"&gt;508,592&lt;/span&gt; shares of its common stock at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251008__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWG5Cpl1Q6c5" title="Exercise price"&gt;2.75&lt;/span&gt; per share.
See Note 6 &#x2013; Subsequent Events for additional details. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable
operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its
development, marketing and promotional activities, which would have a material adverse effect on the Company&#x2019;s business, financial
condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate
continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of
business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not
necessarily purport to represent realizable or settlement values. The accompanying unaudited condensed consolidated financial statements
do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="-5"
      id="Fact000698"
      unitRef="USD">-11000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="-5"
      id="Fact000700"
      unitRef="USD">-8400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <BRTX:WorkingCapital
      contextRef="AsOf2025-09-30"
      decimals="-5"
      id="Fact000702"
      unitRef="USD">1300000</BRTX:WorkingCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000704"
      unitRef="Shares">965424</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000706"
      unitRef="USD">2000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-10-082025-10-08_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000708"
      unitRef="Shares">678125</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000710"
      unitRef="USD">1100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-10-08_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000712"
      unitRef="Shares">508592</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-10-08_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000714"
      unitRef="USDPShares">2.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000716">&lt;p id="xdx_80B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zuAGmzPkV0Bb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
2 &#x2013; &lt;span id="xdx_82C_zl0oSPJPiYw"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zuoYoou5Mad5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
prior period statements of operations amounts have been reclassified to conform to the Company&#x2019;s fiscal 2025 presentation. These
reclassifications have no impact on the Company&#x2019;s previously reported net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zWKRFvYaCgp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#x201c;FDIC&#x201d;) coverage of $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20250930_zJD8tEm9PdDb" title="FDIC insured limit"&gt;250,000&lt;/span&gt; per banking institution. The Company had deposits in excess of FDIC coverage of $&lt;span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_c20250930_z4MdKwMJTX04" title="Cash in excess of FDIC limit"&gt;290,180&lt;/span&gt; and
$&lt;span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zox3igVmFcxj" title="Cash in excess of FDIC limit"&gt;252,801&lt;/span&gt; as of September 30, 2025 and December 31, 2024, respectively. As of September 30, 2025, the Company has not experienced losses
on this account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zA8EOTyYL9Ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Investments
Held in Marketable Securities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2025 and December 31, 2024, investments held in marketable securities consists of U.S. Treasury securities held in a
trust account. The Company&#x2019;s investments held in the trust account are presented on the unaudited condensed consolidated balance
sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities
are included in interest income in the accompanying unaudited condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zOKc1nRk6qEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Customer
and Revenue Concentrations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s contract service revenue is derived from one customer. Additionally, all of the Company&#x2019;s product sales
revenue is derived from one customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z0Iff1vBFCL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accounts
Receivable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of &lt;span style="background-color: white"&gt;September
30, 2025 &lt;/span&gt;and December 31, 2024, no allowances for credit losses were determined to be necessary. Management estimates the allowance
for credit losses based on existing economic conditions, the financial conditions of the customers, and the amount and age of past due
accounts. Receivables are considered past due if full payment is not received by the contractual due date. Past due accounts are generally
written off against the allowance for credit losses only after all collection attempts have been exhausted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--DeferredChargesPolicyTextBlock_zPTZ9bBDS0tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Deferred
Contract Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs relate
directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying performance obligations
in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as cost of revenues in the period
when the related revenue is recognized. Deferred contract costs consist of consumables and labor costs and are included in prepaid and
other current assets in the unaudited condensed consolidated balance sheets. The Company had $&lt;span id="xdx_902_eus-gaap--DeferredCosts_iI_c20250930_ztAqpn7wZG9" title="Deferred contract costs"&gt;7,491&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zlvqQHgH5kek" title="Deferred contract costs"&gt;10,250&lt;/span&gt; deferred contract costs
as of &lt;span style="background-color: white"&gt;September 30, 2025 &lt;/span&gt;and December 31, 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--DeferredOfferingCostsPolicyTextBlock_zUPPJ97vXR12" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Deferred
Offering Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
offering costs, which primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized
as non-current assets on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the
offering proceeds. If the completion of a contemplated financing was no longer probable, the related deferred offering costs would be
charged to general and administrative expense in the unaudited condensed consolidated financial statements. The Company had $&lt;span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20250930_z4s2RZanSigj" title="Deferred offering costs"&gt;69,066&lt;/span&gt; and
$&lt;span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20241231_zxOLA0MPGa7g" title="Deferred offering costs"&gt;148,697&lt;/span&gt; of deferred offering costs as of &lt;span style="background-color: white"&gt;September 30, 2025 &lt;/span&gt;and December 31, 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zZv6KZulSXol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Derivative
Financial Instruments &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated
statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option
pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zkANa1kvlmrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of &lt;span style="background-color: white"&gt;September 30, 2025 &lt;/span&gt;and
December 31, 2024, the carrying amount of cash and cash equivalents, investments held in marketable securities, accounts receivable,
and accounts payable approximate their fair value due to the relatively short period of time between their origination and their expected
realization or payment. The warrant liabilities are measured at fair value (see Note 5 &#x2013; Fair Value Measurement for additional
details).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zDWt9x0oUJT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &#x201c;Revenue from Contracts
with Customers&#x201d; (&#x201c;ASC 606&#x201d;). The core principle of ASC 606 requires that an entity recognize revenue to depict the
transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled
in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible
more judgment and estimates may be required within the revenue recognition process, including identifying performance obligations in
the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price
to each separate performance obligation. The Company recognizes revenue primarily from the following different types of contracts:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Product
    sales&lt;/b&gt; - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Royalty
    revenue&lt;/b&gt; - Revenue is recognized as a usage-based royalty from customers&#x2019; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#x2019;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    reason for the bill-and-hold arrangement is substantive &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    customer has requested the product be warehoused&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product has been identified as separately belonging to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product is currently ready for physical transfer to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    Company does not have the ability to use the product or direct it to another customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zUp6hfR82OB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s revenue recognized in its unaudited condensed consolidated statements of operations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_z0f5J2lLd7qj" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNIZED&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250701__20250930_zmrJbKyBvxUd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240701__20240930_zDeGk3t9GU94" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250930_zqyeKJkPHFF6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20240930_z6BY4V2rHPqk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zayVoAdXqGSe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;230,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zSCqOCQLgYXg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;57,700&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zuuQYkToU9Ka" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;233,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;340,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;357,700&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zjMjD1SO5q28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z0O1dsrwFqPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Net
Loss Per Common Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. For the three and nine months ended &lt;span style="background-color: white"&gt;September&lt;/span&gt;
30, 2025, the Company had &lt;span id="xdx_903_ecustom--SharesHeldInAbeyance_iI_pid_c20250930_z56gNeuQxRLa" title="Shares held in abeyance"&gt;1,138,055&lt;/span&gt; shares held in abeyance included in basic loss per share given that they are issuable for no additional
consideration. For the three and nine months ended &lt;span style="background-color: white"&gt;September&lt;/span&gt; 30, 2024, the Company had &lt;span id="xdx_90B_ecustom--SharesHeldInAbeyance_iI_pid_c20240930_zrGTXIJeWwD5" title="Shares held in abeyance"&gt;1,201,580&lt;/span&gt;
shares held in abeyance included in basic loss per share given that they are issuable for no additional consideration (see Note 4 &#x2013;
Stockholders&#x2019; Equity for additional details). The dilutive effect, if any, of stock options and warrants are calculated using the
treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning of the period or at the
time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect
to losses, options, warrants, restricted stock units (&#x201c;RSUs&#x201d;) and convertible preferred stock have been excluded from the
Company&#x2019;s computation of diluted net loss per common share for the three and nine months ended &lt;span style="background-color: white"&gt;September
30, 2025 &lt;/span&gt;and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zlziMoWXAXQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_zOfUfoHaWSgi" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three and Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z0ddViGBv088" title="Antidilutive shares"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zbwOLXMER4jb" title="Antidilutive shares"&gt;5,262,973&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zYLGQoxDHrqk" title="Antidilutive shares"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zGzgyZjSdSIg" title="Antidilutive shares"&gt;3,401,608&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOdb46xTIhE6" title="Antidilutive shares"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zMTo0rnFgyg8" title="Antidilutive shares"&gt;3,951,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z7e261Idjqe2" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2gQOA9BOJdi" title="Antidilutive shares"&gt;3,952,504&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zoAdP24LL9se" title="Antidilutive shares"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zxbicpBg5Pw7" title="Antidilutive shares"&gt;1,398,158&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBhtwPFuQYH2" title="Antidilutive shares"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjFYUbw8vdZ1" title="Antidilutive shares"&gt;1,398,158&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930_zw7VAXrfvgbh" title="Antidilutive shares"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zLSC5ZNyZcJk" title="Antidilutive shares"&gt;10,612,515&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930_zU0LwLcMz8y8" title="Antidilutive shares"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zZuTFrCR4u39" title="Antidilutive shares"&gt;8,752,270&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zJWezSIb5gNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkl4bVbUTfu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has &lt;span id="xdx_908_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20250101__20250930_z6uvo58Te011" title="Number of operating segments"&gt;&lt;span id="xdx_90F_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20250101__20250930_zVqE0Gyb38X7" title="Number of reporting segments"&gt;one&lt;/span&gt;&lt;/span&gt; operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#x2019;s Chief Executive Officer serves as
the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial performance.
The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated expense
data beyond what is included in the unaudited condensed consolidated statements of operations is not provided to the CODM. Since the
Company&#x2019;s operations consist of a single reporting segment, the segment assets are presented on the accompanying unaudited condensed
consolidated balance sheets as total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFqg54WqZt0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; (&#x201c;ASU
2023-09&#x201d;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09
should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of this
update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU No. 2024-03, &#x201c;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; (&#x201c;ASU 2024-03&#x201d;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--TaxLawChangePolicyTextBlock_zJjlyrjJprU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Tax
Law Change&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 4th, 2025, the President signed into law significant federal tax legislation, H.R.1 (the &#x201c;Tax Reform Act of 2025&#x201d;).
The legislation includes numerous changes to U.S. corporate income tax law, including but not limited to: permanent 100% bonus
depreciation for qualified property, immediate expensing of domestic research and experimental expenditures, modifications to the
limitation on business interest expense, increased Section 179 expensing limits, changes to the international tax regime, and
expanded limitations on the deductibility of executive compensation under IRC Section 162(m). Most provisions are effective for tax
years beginning after December 31, 2024, with certain transition rules and exceptions. &lt;/span&gt;The Company does not expect the
enactment of the Tax Reform Act of 2025 to have a material impact on its  consolidated financial statements. &lt;/p&gt;

&lt;p id="xdx_857_zj3PHAK8EAmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2025-01-01to2025-09-30" id="Fact000718">&lt;p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zuoYoou5Mad5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
prior period statements of operations amounts have been reclassified to conform to the Company&#x2019;s fiscal 2025 presentation. These
reclassifications have no impact on the Company&#x2019;s previously reported net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000720">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zWKRFvYaCgp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#x201c;FDIC&#x201d;) coverage of $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20250930_zJD8tEm9PdDb" title="FDIC insured limit"&gt;250,000&lt;/span&gt; per banking institution. The Company had deposits in excess of FDIC coverage of $&lt;span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_c20250930_z4MdKwMJTX04" title="Cash in excess of FDIC limit"&gt;290,180&lt;/span&gt; and
$&lt;span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zox3igVmFcxj" title="Cash in excess of FDIC limit"&gt;252,801&lt;/span&gt; as of September 30, 2025 and December 31, 2024, respectively. As of September 30, 2025, the Company has not experienced losses
on this account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000722"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000724"
      unitRef="USD">290180</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000726"
      unitRef="USD">252801</us-gaap:CashUninsuredAmount>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2025-01-01to2025-09-30" id="Fact000728">&lt;p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zA8EOTyYL9Ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Investments
Held in Marketable Securities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2025 and December 31, 2024, investments held in marketable securities consists of U.S. Treasury securities held in a
trust account. The Company&#x2019;s investments held in the trust account are presented on the unaudited condensed consolidated balance
sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities
are included in interest income in the accompanying unaudited condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-09-30" id="Fact000730">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zOKc1nRk6qEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Customer
and Revenue Concentrations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s contract service revenue is derived from one customer. Additionally, all of the Company&#x2019;s product sales
revenue is derived from one customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2025-01-01to2025-09-30" id="Fact000732">&lt;p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z0Iff1vBFCL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accounts
Receivable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of &lt;span style="background-color: white"&gt;September
30, 2025 &lt;/span&gt;and December 31, 2024, no allowances for credit losses were determined to be necessary. Management estimates the allowance
for credit losses based on existing economic conditions, the financial conditions of the customers, and the amount and age of past due
accounts. Receivables are considered past due if full payment is not received by the contractual due date. Past due accounts are generally
written off against the allowance for credit losses only after all collection attempts have been exhausted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000734">&lt;p id="xdx_848_eus-gaap--DeferredChargesPolicyTextBlock_zPTZ9bBDS0tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Deferred
Contract Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs relate
directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying performance obligations
in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as cost of revenues in the period
when the related revenue is recognized. Deferred contract costs consist of consumables and labor costs and are included in prepaid and
other current assets in the unaudited condensed consolidated balance sheets. The Company had $&lt;span id="xdx_902_eus-gaap--DeferredCosts_iI_c20250930_ztAqpn7wZG9" title="Deferred contract costs"&gt;7,491&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zlvqQHgH5kek" title="Deferred contract costs"&gt;10,250&lt;/span&gt; deferred contract costs
as of &lt;span style="background-color: white"&gt;September 30, 2025 &lt;/span&gt;and December 31, 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredCosts
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000736"
      unitRef="USD">7491</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000738"
      unitRef="USD">10250</us-gaap:DeferredCosts>
    <BRTX:DeferredOfferingCostsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000740">&lt;p id="xdx_842_ecustom--DeferredOfferingCostsPolicyTextBlock_zUPPJ97vXR12" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Deferred
Offering Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
offering costs, which primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized
as non-current assets on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the
offering proceeds. If the completion of a contemplated financing was no longer probable, the related deferred offering costs would be
charged to general and administrative expense in the unaudited condensed consolidated financial statements. The Company had $&lt;span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20250930_z4s2RZanSigj" title="Deferred offering costs"&gt;69,066&lt;/span&gt; and
$&lt;span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20241231_zxOLA0MPGa7g" title="Deferred offering costs"&gt;148,697&lt;/span&gt; of deferred offering costs as of &lt;span style="background-color: white"&gt;September 30, 2025 &lt;/span&gt;and December 31, 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</BRTX:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000742"
      unitRef="USD">69066</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000744"
      unitRef="USD">148697</us-gaap:DeferredOfferingCosts>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-09-30" id="Fact000746">&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zZv6KZulSXol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Derivative
Financial Instruments &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated
statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option
pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000748">&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zkANa1kvlmrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of &lt;span style="background-color: white"&gt;September 30, 2025 &lt;/span&gt;and
December 31, 2024, the carrying amount of cash and cash equivalents, investments held in marketable securities, accounts receivable,
and accounts payable approximate their fair value due to the relatively short period of time between their origination and their expected
realization or payment. The warrant liabilities are measured at fair value (see Note 5 &#x2013; Fair Value Measurement for additional
details).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000750">&lt;p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zDWt9x0oUJT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &#x201c;Revenue from Contracts
with Customers&#x201d; (&#x201c;ASC 606&#x201d;). The core principle of ASC 606 requires that an entity recognize revenue to depict the
transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled
in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible
more judgment and estimates may be required within the revenue recognition process, including identifying performance obligations in
the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price
to each separate performance obligation. The Company recognizes revenue primarily from the following different types of contracts:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Product
    sales&lt;/b&gt; - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Royalty
    revenue&lt;/b&gt; - Revenue is recognized as a usage-based royalty from customers&#x2019; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#x2019;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    reason for the bill-and-hold arrangement is substantive &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    customer has requested the product be warehoused&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product has been identified as separately belonging to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product is currently ready for physical transfer to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    Company does not have the ability to use the product or direct it to another customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zUp6hfR82OB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s revenue recognized in its unaudited condensed consolidated statements of operations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_z0f5J2lLd7qj" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNIZED&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250701__20250930_zmrJbKyBvxUd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240701__20240930_zDeGk3t9GU94" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250930_zqyeKJkPHFF6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20240930_z6BY4V2rHPqk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zayVoAdXqGSe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;230,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zSCqOCQLgYXg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;57,700&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zuuQYkToU9Ka" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;233,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;340,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;357,700&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zjMjD1SO5q28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000752">&lt;p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zUp6hfR82OB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s revenue recognized in its unaudited condensed consolidated statements of operations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_z0f5J2lLd7qj" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNIZED&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250701__20250930_zmrJbKyBvxUd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240701__20240930_zDeGk3t9GU94" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250930_zqyeKJkPHFF6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20240930_z6BY4V2rHPqk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zayVoAdXqGSe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;230,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zSCqOCQLgYXg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;57,700&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zuuQYkToU9Ka" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;233,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;340,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;357,700&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30_us-gaap_ProductMember"
      decimals="0"
      id="Fact000755"
      unitRef="USD">230700</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_us-gaap_ProductMember"
      decimals="0"
      id="Fact000756"
      unitRef="USD">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30_us-gaap_ProductMember"
      decimals="0"
      id="Fact000757"
      unitRef="USD">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_us-gaap_RoyaltyMember"
      decimals="0"
      id="Fact000759"
      unitRef="USD">11800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30_us-gaap_RoyaltyMember"
      decimals="0"
      id="Fact000760"
      unitRef="USD">2900</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_us-gaap_RoyaltyMember"
      decimals="0"
      id="Fact000761"
      unitRef="USD">40100</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30_us-gaap_RoyaltyMember"
      decimals="0"
      id="Fact000762"
      unitRef="USD">57700</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000764"
      unitRef="USD">11800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000765"
      unitRef="USD">233600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000766"
      unitRef="USD">340100</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000767"
      unitRef="USD">357700</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000769">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z0O1dsrwFqPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Net
Loss Per Common Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. For the three and nine months ended &lt;span style="background-color: white"&gt;September&lt;/span&gt;
30, 2025, the Company had &lt;span id="xdx_903_ecustom--SharesHeldInAbeyance_iI_pid_c20250930_z56gNeuQxRLa" title="Shares held in abeyance"&gt;1,138,055&lt;/span&gt; shares held in abeyance included in basic loss per share given that they are issuable for no additional
consideration. For the three and nine months ended &lt;span style="background-color: white"&gt;September&lt;/span&gt; 30, 2024, the Company had &lt;span id="xdx_90B_ecustom--SharesHeldInAbeyance_iI_pid_c20240930_zrGTXIJeWwD5" title="Shares held in abeyance"&gt;1,201,580&lt;/span&gt;
shares held in abeyance included in basic loss per share given that they are issuable for no additional consideration (see Note 4 &#x2013;
Stockholders&#x2019; Equity for additional details). The dilutive effect, if any, of stock options and warrants are calculated using the
treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning of the period or at the
time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect
to losses, options, warrants, restricted stock units (&#x201c;RSUs&#x201d;) and convertible preferred stock have been excluded from the
Company&#x2019;s computation of diluted net loss per common share for the three and nine months ended &lt;span style="background-color: white"&gt;September
30, 2025 &lt;/span&gt;and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zlziMoWXAXQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_zOfUfoHaWSgi" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three and Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z0ddViGBv088" title="Antidilutive shares"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zbwOLXMER4jb" title="Antidilutive shares"&gt;5,262,973&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zYLGQoxDHrqk" title="Antidilutive shares"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zGzgyZjSdSIg" title="Antidilutive shares"&gt;3,401,608&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOdb46xTIhE6" title="Antidilutive shares"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zMTo0rnFgyg8" title="Antidilutive shares"&gt;3,951,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z7e261Idjqe2" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2gQOA9BOJdi" title="Antidilutive shares"&gt;3,952,504&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zoAdP24LL9se" title="Antidilutive shares"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zxbicpBg5Pw7" title="Antidilutive shares"&gt;1,398,158&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBhtwPFuQYH2" title="Antidilutive shares"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjFYUbw8vdZ1" title="Antidilutive shares"&gt;1,398,158&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930_zw7VAXrfvgbh" title="Antidilutive shares"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zLSC5ZNyZcJk" title="Antidilutive shares"&gt;10,612,515&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930_zU0LwLcMz8y8" title="Antidilutive shares"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zZuTFrCR4u39" title="Antidilutive shares"&gt;8,752,270&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zJWezSIb5gNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <BRTX:SharesHeldInAbeyance
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000771"
      unitRef="Shares">1138055</BRTX:SharesHeldInAbeyance>
    <BRTX:SharesHeldInAbeyance
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000773"
      unitRef="Shares">1201580</BRTX:SharesHeldInAbeyance>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000775">&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zlziMoWXAXQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_zOfUfoHaWSgi" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three and Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z0ddViGBv088" title="Antidilutive shares"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zbwOLXMER4jb" title="Antidilutive shares"&gt;5,262,973&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zYLGQoxDHrqk" title="Antidilutive shares"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zGzgyZjSdSIg" title="Antidilutive shares"&gt;3,401,608&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOdb46xTIhE6" title="Antidilutive shares"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zMTo0rnFgyg8" title="Antidilutive shares"&gt;3,951,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z7e261Idjqe2" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2gQOA9BOJdi" title="Antidilutive shares"&gt;3,952,504&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zoAdP24LL9se" title="Antidilutive shares"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zxbicpBg5Pw7" title="Antidilutive shares"&gt;1,398,158&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBhtwPFuQYH2" title="Antidilutive shares"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjFYUbw8vdZ1" title="Antidilutive shares"&gt;1,398,158&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930_zw7VAXrfvgbh" title="Antidilutive shares"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zLSC5ZNyZcJk" title="Antidilutive shares"&gt;10,612,515&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20240930_zU0LwLcMz8y8" title="Antidilutive shares"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zZuTFrCR4u39" title="Antidilutive shares"&gt;8,752,270&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Shares">5262973</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000779"
      unitRef="Shares">5262973</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">3401608</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000783"
      unitRef="Shares">3401608</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000785"
      unitRef="Shares">3951384</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000787"
      unitRef="Shares">3951384</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-012024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000789"
      unitRef="Shares">3952504</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Shares">3952504</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000793"
      unitRef="Shares">1398158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000795"
      unitRef="Shares">1398158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-012024-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Shares">1398158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000799"
      unitRef="Shares">1398158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000801"
      unitRef="Shares">10612515</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000803"
      unitRef="Shares">10612515</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000805"
      unitRef="Shares">8752270</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000807"
      unitRef="Shares">8752270</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000809">&lt;p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkl4bVbUTfu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has &lt;span id="xdx_908_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20250101__20250930_z6uvo58Te011" title="Number of operating segments"&gt;&lt;span id="xdx_90F_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20250101__20250930_zVqE0Gyb38X7" title="Number of reporting segments"&gt;one&lt;/span&gt;&lt;/span&gt; operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#x2019;s Chief Executive Officer serves as
the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial performance.
The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated expense
data beyond what is included in the unaudited condensed consolidated statements of operations is not provided to the CODM. Since the
Company&#x2019;s operations consist of a single reporting segment, the segment assets are presented on the accompanying unaudited condensed
consolidated balance sheets as total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000811"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000813"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000815">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFqg54WqZt0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; (&#x201c;ASU
2023-09&#x201d;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09
should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of this
update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU No. 2024-03, &#x201c;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; (&#x201c;ASU 2024-03&#x201d;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <BRTX:TaxLawChangePolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000817">&lt;p id="xdx_849_ecustom--TaxLawChangePolicyTextBlock_zJjlyrjJprU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Tax
Law Change&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 4th, 2025, the President signed into law significant federal tax legislation, H.R.1 (the &#x201c;Tax Reform Act of 2025&#x201d;).
The legislation includes numerous changes to U.S. corporate income tax law, including but not limited to: permanent 100% bonus
depreciation for qualified property, immediate expensing of domestic research and experimental expenditures, modifications to the
limitation on business interest expense, increased Section 179 expensing limits, changes to the international tax regime, and
expanded limitations on the deductibility of executive compensation under IRC Section 162(m). Most provisions are effective for tax
years beginning after December 31, 2024, with certain transition rules and exceptions. &lt;/span&gt;The Company does not expect the
enactment of the Tax Reform Act of 2025 to have a material impact on its  consolidated financial statements. &lt;/p&gt;

</BRTX:TaxLawChangePolicyTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000819">&lt;p id="xdx_800_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zeyEgGadysl5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
3 - &lt;span id="xdx_82D_zKZw4PePgXI9"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zIgMfJkz32R9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B1_z1vUJk1Sfkua" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250930_zjbaifrt9Od1" style="font-weight: bold; text-align: center"&gt;September 30 ,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zzBgOOifDuWf" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALAOLzJ5Y_zQfcVLxZ3IUf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued bonuses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;538,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;704,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_z5TEQmTk5Bmb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;68,595&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtALAOLzJ5Y_zKbjZiqer5me" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;607,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;744,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zQLHNtTM2Af1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000821">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zIgMfJkz32R9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B1_z1vUJk1Sfkua" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250930_zjbaifrt9Od1" style="font-weight: bold; text-align: center"&gt;September 30 ,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zzBgOOifDuWf" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALAOLzJ5Y_zQfcVLxZ3IUf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued bonuses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;538,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;704,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_z5TEQmTk5Bmb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;68,595&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtALAOLzJ5Y_zKbjZiqer5me" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;607,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;744,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000823"
      unitRef="USD">538875</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000824"
      unitRef="USD">704000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <BRTX:AccruedGeneralAndAdministrativeExpenses
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000826"
      unitRef="USD">68595</BRTX:AccruedGeneralAndAdministrativeExpenses>
    <BRTX:AccruedGeneralAndAdministrativeExpenses
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000827"
      unitRef="USD">40485</BRTX:AccruedGeneralAndAdministrativeExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000829"
      unitRef="USD">607470</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000830"
      unitRef="USD">744485</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000832">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zHG5tvmySONa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
4 - &lt;span id="xdx_821_zhU25ADtybPh"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
Exercise and Issuance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 6, 2024, the Company entered into agreements with certain holders of its existing warrants exercisable for an aggregate of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx5gSnUYYHZ" title="Warrants exercisable"&gt;3,351,580&lt;/span&gt;
shares of its Common Stock (collectively, the &#x201c;Existing Warrants&#x201d;), to exercise their warrants at a reduced exercise price
of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAtgLyiYvwt2" title="Exercise price"&gt;2.33&lt;/span&gt; per share, in exchange for the issuance of new warrants (the &#x201c;New Warrants&#x201d;) as described below (the &#x201c;Warrant
Exercise and Issuance&#x201d;). The aggregate gross proceeds from the exercise of the Existing Warrants and the payment of the New Warrants,
as described below, was approximately $&lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGq6BKn2nqkc" title="Proceeds from exercise of warrants"&gt;8.1&lt;/span&gt; million, before deducting cash issuance costs in the amount of $&lt;span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZCTpSpST2xl" title="Cash issuance costs"&gt;595,364&lt;/span&gt;. The reduction of
the exercise price of the Existing Warrants and the issuance of the New Warrants was structured as an at-market transaction under Nasdaq
rules. Of the &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZGqM0uZWQdb" title="Warrants exercisable"&gt;3,351,580&lt;/span&gt; shares of Common Stock underlying the Existing Warrants, &lt;span id="xdx_904_ecustom--SharesHeldInAbeyance_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zDzEd4E6Vyw8" title="Shares held in abeyance"&gt;1,201,580&lt;/span&gt; shares issuable to Auctus Fund, LLC (&#x201c;Auctus&#x201d;)
were held in abeyance as of December 31, 2024, due to Auctus&#x2019; maximum beneficial ownership limitation &lt;span style="background-color: white"&gt;(the
&#x201c;Abeyance Shares&#x201d;)&lt;/span&gt;. On March 20, 2025, the Company issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20250320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zjDxgAVSTwd7" title="Warrants exercisable"&gt;63,525&lt;/span&gt; of these shares, reducing the remaining Abeyance
Shares to &lt;span id="xdx_90A_ecustom--SharesHeldInAbeyance_iI_pid_c20250320_zdbB6qiEiMn4" title="Shares held in abeyance"&gt;1,138,055&lt;/span&gt;. As of &lt;span style="background-color: white"&gt;September&lt;/span&gt; 30, 2025, the Company had issued an aggregate of &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Pv2ppO2EI7" title="Shares issued"&gt;2,213,525&lt;/span&gt;
shares of Common Stock. Such Abeyance Shares have been fully paid for and are issuable upon notice from Auctus to the Company. See Note
6 &#x2013; Subsequent Events &#x2013; for additional details regarding shares issued to Auctus subsequent to September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 6pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for the immediate exercise of the Existing Warrants for cash and the payment of $&lt;span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWpB6FU3W7G7" title="Warrants for cash and the payment"&gt;0.125&lt;/span&gt; per share underlying the New Warrants,
the exercising holders received the New Warrants to purchase shares of Common Stock in a private placement pursuant to Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The New Warrants will be exercisable for a period of five
years into an aggregate of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zhVPmr7uhBbe" title="Warrants exercisable"&gt;2,513,686&lt;/span&gt; shares of Common Stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zXqt8vRCbOyj" title="Exercise price"&gt;2.43&lt;/span&gt; per share. The securities offered in the private
placement have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company agreed to file
a resale registration statement with the SEC to register the resale of the shares of Common Stock underlying the New Warrants issued
in the private placement. Such resale registration statement was filed and was declared effective by the SEC on April 18, 2024. In connection
with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5, 2024, with
Roth Capital Partners, LLC (&#x201c;Roth&#x201d;), pursuant to which the Company has paid Roth a cash fee of approximately $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240205__20240205__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zFmR4GeV6Rh6" title="Cash fee for services"&gt;528,000&lt;/span&gt; for
its services, in addition to reimbursement for certain expense. During the nine months ended &lt;span style="background-color: white"&gt;September&lt;/span&gt;
30, 2024, the Company incurred an aggregate of $&lt;span id="xdx_90A_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zCgxSb4KVd5h" title="Issuance costs"&gt;595,364&lt;/span&gt; of cash issuance costs related to the Warrant Exercise and Issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Prior
to the Warrant Exercise and Issuance, the Existing Warrants were classified as derivative liabilities. Additionally, the Company analyzed
the form of the New Warrants and determined that they should be classified as derivative liabilities&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
accordance with ASC 815-40, Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity. Under the New Warrants, the Company
does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the New Warrants and
not result in a change of control of the Company. As a result, such New Warrants do not meet the criteria for equity treatment. Additionally,
certain New Warrants contain adjustments to the settlement amount based on a variable that is not an input to the fair value of a &#x201c;fixed-for-fixed&#x201d;
option as defined under ASC 815-40 and, accordingly, such New Warrants are not considered indexed to the Company&#x2019;s own stock and
are not eligible for an exception from derivative accounting. &lt;span style="background-color: white"&gt;See Note 5 &#x2013; Fair Value Measurement
for details regarding the valuation of warrants accounted for as derivative liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;See
Note 5 &#x2013; Fair Value of Financial Instruments for details regarding the valuation of warrants accounted for as derivative liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zo19fZvsrdp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s warrant activity and related information follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BF_zZ3PlS8QnNqe" style="display: none"&gt;SCHEDULE OF WARRANT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zULU5j9OkiMg" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning balance"&gt;3,951,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDQmWH9JHqqe" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance"&gt;5.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znMqdO0blV22" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired"&gt;(250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJvBG1DUXmO2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;60.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy0i7C8bnsd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending balance"&gt;3,951,384&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKtxZKhWUYia" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance"&gt;5.21&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJq4qX3eMsTb" title="Weighted Average Remaining Life In Years, Outstanding"&gt;2.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRx5Q2Zfx1zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable"&gt;3,951,384&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIJFLzpYIhEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;5.21&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7joyKclZvt3" title="Weighted Average Remaining Life In Years, Exercisable"&gt;2.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_za5lKfk8sxSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2025, the Company granted options to purchase an aggregate of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zGPLhmcTQmWj" title="Options granted"&gt;2,152,908&lt;/span&gt; shares of the Company&#x2019;s common stock at an
exercise price of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlj9v5UYoXb2" title="Exercise price of options granted"&gt;2.46&lt;/span&gt; per share to employees, the Company&#x2019;s board of directors and a member of the Company&#x2019;s Scientific
Advisory Board. The options had an aggregate grant date fair value of $&lt;span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWQIcTolxNzg" title="Grant date fair value of options granted"&gt;4,044,250&lt;/span&gt; and &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250214__20250214__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zBVsBX5FSfXa" title="Vesting of options description"&gt;vest as follows: (i) options to purchase an aggregate
323,459 shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of 1,829,449 shares of common stock
vest to the extent of 50% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant.&lt;/span&gt;
The Company is recognizing the grant date fair value of the options on a straight-line basis over the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 5, 2025, the Company granted an option to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0ZuBXJ7t5ne" title="Options granted"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zimgpjmGrocl" title="Exercise price of options granted"&gt;1.78&lt;/span&gt;
per share to an employee. The option had a grant date fair value of $&lt;span id="xdx_90E_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNV5n0akZLDa" title="Grant date fair value of options granted"&gt;34,250&lt;/span&gt; and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250605__20250605__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQzCyRduK3gk" title="Vesting of options description"&gt;vests to the extent of 50% immediately with the remainder
vesting quarterly over two years commencing one year from the date of grant.&lt;/span&gt; The Company is recognizing the grant date fair value of
the option on a straight-line basis over the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 13, 2025, the Company granted an option to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpoibAmWqss3" title="Options granted"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise price of
$&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuL7CY8ZzLY8" title="Exercise price of options granted"&gt;1.62&lt;/span&gt; per share to an employee. See Note 6 &#x2013; Subsequent Events for additional details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znYuBL1ziLZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B8_z1wWVGt9vlj2" style="display: none"&gt;SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z37XMit7f4ka" title="Risk free interest rate"&gt;4.03&lt;/span&gt; - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxfdSV77vPHc" title="Risk free interest rate"&gt;4.40&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zz2zKecFH9Ic" title="Risk free interest rate"&gt;4.14&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zy4srh72s6Ag" title="Risk free interest rate"&gt;4.30&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zw2WookFhCm4" title="Expected term (years)"&gt;2.77&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziuM2v5u7cOj" title="Expected term (years)"&gt;5.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjyJG6PA6aS9" title="Expected term (years)"&gt;2.77&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zQR6mDHTPdJi" title="Expected term (years)"&gt;5.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zoRgnEW4J5qk" title="Expected volatility"&gt;98.14&lt;/span&gt; - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zgMcQ5QsoGw9" title="Expected volatility"&gt;99.22&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_ze1M3w366Qp5" title="Expected volatility"&gt;101&lt;/span&gt; - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziXN0JVmgKc5" title="Expected volatility"&gt;102&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHhTEVNeZJ58" style="width: 18%; text-align: center"&gt;0.00%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaogLqcGvEN" style="width: 18%; text-align: center" title="Expected dividends"&gt;0.00%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z4yJkz1L6Zk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_do_c20250701__20250930_zaJ7QgaILCP3" title="Weighted average grant date fair value of stock options granted"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_do_c20240701__20240930_zLmTZh77Jbza" title="Weighted average grant date fair value of stock options granted"&gt;no&lt;/span&gt;&lt;/span&gt; stock options granted during the three months ended September 30, 2025 or 2024. Options granted during the nine months ended
&lt;span style="background-color: white"&gt;September&lt;/span&gt; 30, 2025 and 2024 had a weighted average grant date fair value per share of &lt;span style="background-color: white"&gt;$&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250930_zxPzPvInIHY" title="Weighted average grant date fair value of stock options granted"&gt;1.87&lt;/span&gt;
&lt;/span&gt;and $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zWohCJHGjAC5" title="Weighted average grant date fair value of stock options granted"&gt;1.11&lt;/span&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWv2M3qYRMph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity during the nine months ended &lt;span style="background-color: white"&gt;September 30, 2025 &lt;/span&gt;is
presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zlBKQWNVMBRg" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhd1fbMc1OAf" style="width: 12%; text-align: right" title="Number of Options, Outstanding Beginning"&gt;3,263,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyqcbmh3G9A4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning"&gt;2.63&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYJikieUBiU1" style="text-align: right" title="Number of Options, Granted"&gt;2,177,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Utpi7z1E8a" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: #0D0D0D"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcjxWNpZEXC2" style="text-align: right" title="Number of Options, Exercised"&gt;(29,249&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: #0D0D0D"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4LZRf2tNRW8" style="color: #0D0D0D; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;1.45&lt;/td&gt;&lt;td style="color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbFGtbkRLn" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(149,153&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY5MaYv8AMn1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;2.23&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMyvapoNh9d" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding Ending"&gt;5,262,973&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNC1OSsrXyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending"&gt;2.58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlT9rvVz6pDg" title="Weighted Average Remaining Life in Years, Outstanding"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4ggKcamAFA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxCRQYm4YeMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable"&gt;3,805,964&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1EzeOBaB595" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable"&gt;2.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCLZZ4ZLn9q8" title="Weighted Average Remaining Life in Years, Exercisable"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zy6EeZ7DMJXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zcOQfjQkTMcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-Based
Compensation Expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zSDcZLOPTYXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock-based compensation expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8B2_zKoGZ1kN5cRa" style="display: none"&gt;SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250701__20250930_zdcPCx4xRGV3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240701__20240930_zLNJc59cbcLh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20250930_zsq10U8gkd72" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20240930_zLqIBApcfsX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrecognized at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average Remaining Amortization&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt; Period&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJ3sW3wPgOJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;175,398&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;133,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,308,322&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,314,298&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYpkGCwTTDmi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;224,535&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150,912&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,569,444&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,322,643&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_ztRikAHkmre9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;399,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;284,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,877,766&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,636,941&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20250930_zQSnElFKLth" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense"&gt;1,878,612&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930_zyXAPbw3kbTa" title="Weighted average remaining amortization period (years)"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zgACj4pdDPxa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;399,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;284,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,877,766&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,636,941&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20250930_z5a460ZK7FN7" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense"&gt;1,878,612&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930_zjo2gjtyVdXi" title="Weighted average remaining amortization period (years)"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_zFjpcsrR5B6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock_zsBI1ipxGnoh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents stock-based compensation by award type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_zvDA3KujAUgd" style="display: none"&gt;SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250701__20250930_z6ZTqHehz6Vi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240701__20240930_zn2OOoEhzk98" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250930_zFXjSdEXksPb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930_zTjmJ2NseNQ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV3WJPGewlZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;399,932&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;284,245&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,877,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,651,903&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zd3IddrYGPx2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1013"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;985,038&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_z91a9z3GNKxg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;399,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;284,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,877,766&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,636,941&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zp3s2uAPl9o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ATM
Sales&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2025, there were &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_do_c20250701__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL1oEMYxf3bk" title="Number of shares sold"&gt;no&lt;/span&gt; sales of common stock under the 2024 ATM. During the nine months ended September
30, 2025, the Company sold &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztj50j89INd7" title="Number of shares sold"&gt;965,424&lt;/span&gt; shares of its common stock under the 2024 ATM, generating gross proceeds of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0o9TgpNyNj4" title="Gross proceeds from shares sold"&gt;2,011,250&lt;/span&gt;. For the nine
months ended September 30, 2025, the total commissions and related legal and accounting fees incurred were $&lt;span id="xdx_904_ecustom--PaymentsForCommissionsLegalAndAccountingFees_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcd44cifUHC4" title="Commissions, legal and accounting fees"&gt;72,805&lt;/span&gt;, resulting in net
proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourATMProgramMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMoj4wiTQdof" title="Net proceeds from shares sold"&gt;1,938,445&lt;/span&gt;. During the nine months ended September 30, 2025, the Company reclassified previously capitalized deferred offering
costs of $&lt;span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20250101__20250930_zHf4xVAtpgtl" title="Deferred offering costs reclassified to additional paid-in capital"&gt;148,697&lt;/span&gt; to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock Repurchase Program&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 16, 2025, the Company&#x2019;s Board of Directors authorized a common stock repurchase program under which the Company may repurchase
up to $&lt;span id="xdx_90F_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20250616__20250616__srt--TitleOfIndividualAxis__custom--BoardOfDirectorMember__srt--RangeAxis__srt--MinimumMember_zcltBrP2zzyl" title="Repurchase of common stock"&gt;2,000,000&lt;/span&gt; of its outstanding common stock through June 16, 2026. &lt;span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfCommonStock_do_c20250930__20250930_zVnjpa6GnRNa" title="Repurchase of common stock"&gt;No&lt;/span&gt; repurchases have been made as of September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock Issuances&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2025, there were &lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesAbeyanceShares_do_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKFJ7f2cOdH9" title="Abeyance shares issued"&gt;no&lt;/span&gt; issuances of common stock by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2025, the Company issued &lt;span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesAbeyanceShares_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8WVx7DEr5j2" title="Abeyance shares issued"&gt;63,525&lt;/span&gt; shares of common stock to Auctus Fund, LLC in partial satisfaction
of shares held in abeyance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2025, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztYvkBJs1qg4" title="Shares issued upon exercise of options"&gt;29,249&lt;/span&gt; shares of common stock related to the exercise of an option at an
exercise price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU4nhYmNIsRh" title="Exercise price of options exercised"&gt;1.45&lt;/span&gt; per share, which resulted in gross cash proceeds to the Company of $&lt;span id="xdx_903_eus-gaap--ProceedsFromStockOptionsExercised_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHs8DohRpmCl" title="Gross proceeds from exercise of options"&gt;42,411&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000834"
      unitRef="Shares">3351580</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000836"
      unitRef="USDPShares">2.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000838"
      unitRef="USD">8100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000840"
      unitRef="USD">595364</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000842"
      unitRef="Shares">3351580</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <BRTX:SharesHeldInAbeyance
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_AuctusFundLLCMember"
      decimals="INF"
      id="Fact000844"
      unitRef="Shares">1201580</BRTX:SharesHeldInAbeyance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-202025-03-20_us-gaap_CommonStockMember_custom_AuctusFundLLCMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Shares">63525</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <BRTX:SharesHeldInAbeyance
      contextRef="AsOf2025-03-20"
      decimals="INF"
      id="Fact000848"
      unitRef="Shares">1138055</BRTX:SharesHeldInAbeyance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000850"
      unitRef="Shares">2213525</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000852"
      unitRef="USDPShares">0.125</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000854"
      unitRef="Shares">2513686</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000856"
      unitRef="USDPShares">2.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-02-052024-02-05_us-gaap_CommonStockMember_custom_RothCapitalPartnersLLCMember"
      decimals="0"
      id="Fact000858"
      unitRef="USD">528000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember"
      decimals="0"
      id="Fact000860"
      unitRef="USD">595364</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000862">&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zo19fZvsrdp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s warrant activity and related information follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BF_zZ3PlS8QnNqe" style="display: none"&gt;SCHEDULE OF WARRANT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zULU5j9OkiMg" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning balance"&gt;3,951,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDQmWH9JHqqe" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance"&gt;5.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znMqdO0blV22" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired"&gt;(250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJvBG1DUXmO2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;60.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy0i7C8bnsd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending balance"&gt;3,951,384&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKtxZKhWUYia" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance"&gt;5.21&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJq4qX3eMsTb" title="Weighted Average Remaining Life In Years, Outstanding"&gt;2.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRx5Q2Zfx1zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable"&gt;3,951,384&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIJFLzpYIhEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;5.21&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7joyKclZvt3" title="Weighted Average Remaining Life In Years, Exercisable"&gt;2.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000864"
      unitRef="Shares">3951634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000866"
      unitRef="USDPShares">5.22</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember20509593"
      decimals="INF"
      id="Fact000868"
      unitRef="Shares">250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember20509593"
      decimals="INF"
      id="Fact000870"
      unitRef="USDPShares">60.00</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000872"
      unitRef="Shares">3951384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000874"
      unitRef="USDPShares">5.21</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember20509593"
      id="Fact000876">P2Y6M18D</BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Shares">3951384</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000880"
      unitRef="USDPShares">5.21</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember20509593"
      id="Fact000882">P2Y6M18D</BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-02-142025-02-14_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">2152908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-02-142025-02-14_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact000886"
      unitRef="USDPShares">2.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2025-02-142025-02-14_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="0"
      id="Fact000888"
      unitRef="USD">4044250</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2025-02-142025-02-14_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact000890">vest as follows: (i) options to purchase an aggregate
323,459 shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of 1,829,449 shares of common stock
vest to the extent of 50% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-06-052025-06-05_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact000892"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-06-052025-06-05_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact000894"
      unitRef="USDPShares">1.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2025-06-052025-06-05_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="0"
      id="Fact000896"
      unitRef="USD">34250</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2025-06-052025-06-05_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact000898">vests to the extent of 50% immediately with the remainder
vesting quarterly over two years commencing one year from the date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000902"
      unitRef="USDPShares">1.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000904">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znYuBL1ziLZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B8_z1wWVGt9vlj2" style="display: none"&gt;SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z37XMit7f4ka" title="Risk free interest rate"&gt;4.03&lt;/span&gt; - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxfdSV77vPHc" title="Risk free interest rate"&gt;4.40&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zz2zKecFH9Ic" title="Risk free interest rate"&gt;4.14&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zy4srh72s6Ag" title="Risk free interest rate"&gt;4.30&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zw2WookFhCm4" title="Expected term (years)"&gt;2.77&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziuM2v5u7cOj" title="Expected term (years)"&gt;5.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjyJG6PA6aS9" title="Expected term (years)"&gt;2.77&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zQR6mDHTPdJi" title="Expected term (years)"&gt;5.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zoRgnEW4J5qk" title="Expected volatility"&gt;98.14&lt;/span&gt; - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zgMcQ5QsoGw9" title="Expected volatility"&gt;99.22&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_ze1M3w366Qp5" title="Expected volatility"&gt;101&lt;/span&gt; - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziXN0JVmgKc5" title="Expected volatility"&gt;102&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHhTEVNeZJ58" style="width: 18%; text-align: center"&gt;0.00%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaogLqcGvEN" style="width: 18%; text-align: center" title="Expected dividends"&gt;0.00%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000906"
      unitRef="Pure">0.0403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000908"
      unitRef="Pure">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000910"
      unitRef="Pure">0.0414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000912"
      unitRef="Pure">0.0430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      id="Fact000914">P2Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      id="Fact000916">P5Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      id="Fact000918">P2Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      id="Fact000920">P5Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000922"
      unitRef="Pure">0.9814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000924"
      unitRef="Pure">0.9922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000926"
      unitRef="Pure">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000928"
      unitRef="Pure">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="INF"
      id="Fact000929"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember20509859"
      decimals="INF"
      id="Fact000931"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000933"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000935"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000937"
      unitRef="USDPShares">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000939"
      unitRef="USDPShares">1.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000941">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWv2M3qYRMph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity during the nine months ended &lt;span style="background-color: white"&gt;September 30, 2025 &lt;/span&gt;is
presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zlBKQWNVMBRg" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhd1fbMc1OAf" style="width: 12%; text-align: right" title="Number of Options, Outstanding Beginning"&gt;3,263,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyqcbmh3G9A4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning"&gt;2.63&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYJikieUBiU1" style="text-align: right" title="Number of Options, Granted"&gt;2,177,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Utpi7z1E8a" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: #0D0D0D"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcjxWNpZEXC2" style="text-align: right" title="Number of Options, Exercised"&gt;(29,249&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: #0D0D0D"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4LZRf2tNRW8" style="color: #0D0D0D; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;1.45&lt;/td&gt;&lt;td style="color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbFGtbkRLn" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(149,153&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY5MaYv8AMn1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;2.23&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMyvapoNh9d" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding Ending"&gt;5,262,973&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNC1OSsrXyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending"&gt;2.58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlT9rvVz6pDg" title="Weighted Average Remaining Life in Years, Outstanding"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4ggKcamAFA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxCRQYm4YeMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable"&gt;3,805,964&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1EzeOBaB595" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable"&gt;2.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCLZZ4ZLn9q8" title="Weighted Average Remaining Life in Years, Exercisable"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zy6EeZ7DMJXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000943"
      unitRef="Shares">3263467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000945"
      unitRef="USDPShares">2.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="INF"
      id="Fact000947"
      unitRef="Shares">2177908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="INF"
      id="Fact000949"
      unitRef="USDPShares">2.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="INF"
      id="Fact000951"
      unitRef="Shares">29249</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="INF"
      id="Fact000953"
      unitRef="USDPShares">1.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="INF"
      id="Fact000955"
      unitRef="Shares">149153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="INF"
      id="Fact000957"
      unitRef="USDPShares">2.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000959"
      unitRef="Shares">5262973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000961"
      unitRef="USDPShares">2.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      id="Fact000963">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000967"
      unitRef="Shares">3805964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000969"
      unitRef="USDPShares">2.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      id="Fact000971">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000975">&lt;p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zSDcZLOPTYXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock-based compensation expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8B2_zKoGZ1kN5cRa" style="display: none"&gt;SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250701__20250930_zdcPCx4xRGV3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240701__20240930_zLNJc59cbcLh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20250930_zsq10U8gkd72" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20240930_zLqIBApcfsX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrecognized at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average Remaining Amortization&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt; Period&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJ3sW3wPgOJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;175,398&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;133,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,308,322&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,314,298&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYpkGCwTTDmi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;224,535&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150,912&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,569,444&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,322,643&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_ztRikAHkmre9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;399,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;284,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,877,766&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,636,941&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20250930_zQSnElFKLth" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense"&gt;1,878,612&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930_zyXAPbw3kbTa" title="Weighted average remaining amortization period (years)"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zgACj4pdDPxa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;399,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;284,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,877,766&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,636,941&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20250930_z5a460ZK7FN7" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense"&gt;1,878,612&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930_zjo2gjtyVdXi" title="Weighted average remaining amortization period (years)"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000977"
      unitRef="USD">175398</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000978"
      unitRef="USD">133333</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000979"
      unitRef="USD">1308322</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000980"
      unitRef="USD">1314298</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000982"
      unitRef="USD">224535</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000983"
      unitRef="USD">150912</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000984"
      unitRef="USD">1569444</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000985"
      unitRef="USD">1322643</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000987"
      unitRef="USD">399932</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000988"
      unitRef="USD">284245</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000989"
      unitRef="USD">2877766</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000990"
      unitRef="USD">2636941</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000992"
      unitRef="USD">1878612</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2025-01-01to2025-09-30" id="Fact000994">P1Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000996"
      unitRef="USD">399932</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000997"
      unitRef="USD">284245</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000998"
      unitRef="USD">2877766</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000999"
      unitRef="USD">2636941</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001001"
      unitRef="USD">1878612</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2025-01-01to2025-09-30" id="Fact001003">P1Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <BRTX:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001005">&lt;p id="xdx_89C_ecustom--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock_zsBI1ipxGnoh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents stock-based compensation by award type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_zvDA3KujAUgd" style="display: none"&gt;SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE BY AWARD TYPE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250701__20250930_z6ZTqHehz6Vi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240701__20240930_zn2OOoEhzk98" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250930_zFXjSdEXksPb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930_zTjmJ2NseNQ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV3WJPGewlZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;399,932&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;284,245&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,877,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,651,903&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zd3IddrYGPx2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1013"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;985,038&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_z91a9z3GNKxg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;399,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;284,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,877,766&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,636,941&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BRTX:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByAwardTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30_us-gaap_EmployeeStockOptionMember20510484"
      decimals="0"
      id="Fact001007"
      unitRef="USD">399932</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember20510484"
      decimals="0"
      id="Fact001008"
      unitRef="USD">284245</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="0"
      id="Fact001009"
      unitRef="USD">2877766</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember20509859"
      decimals="0"
      id="Fact001010"
      unitRef="USD">1651903</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001015"
      unitRef="USD">985038</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001017"
      unitRef="USD">399932</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001018"
      unitRef="USD">284245</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001019"
      unitRef="USD">2877766</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001020"
      unitRef="USD">2636941</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001022"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001024"
      unitRef="Shares">965424</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001026"
      unitRef="USD">2011250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <BRTX:PaymentsForCommissionsLegalAndAccountingFees
      contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001028"
      unitRef="USD">72805</BRTX:PaymentsForCommissionsLegalAndAccountingFees>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyFourATMProgramMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001030"
      unitRef="USD">1938445</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001032"
      unitRef="USD">148697</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2025-06-162025-06-16_custom_BoardOfDirectorMember_srt_MinimumMember"
      decimals="0"
      id="Fact001034"
      unitRef="USD">2000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2025-09-302025-09-30"
      decimals="0"
      id="Fact001036"
      unitRef="USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <BRTX:StockIssuedDuringPeriodSharesAbeyanceShares
      contextRef="From2025-07-012025-09-30_custom_AuctusFundLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001038"
      unitRef="Shares">0</BRTX:StockIssuedDuringPeriodSharesAbeyanceShares>
    <BRTX:StockIssuedDuringPeriodSharesAbeyanceShares
      contextRef="From2025-01-012025-09-30_custom_AuctusFundLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001040"
      unitRef="Shares">63525</BRTX:StockIssuedDuringPeriodSharesAbeyanceShares>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="INF"
      id="Fact001042"
      unitRef="Shares">29249</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="INF"
      id="Fact001044"
      unitRef="USDPShares">1.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember20508593"
      decimals="0"
      id="Fact001046"
      unitRef="USD">42411</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001048">&lt;p id="xdx_80B_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zWIei0oZrkef" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
5 &#x2013; &lt;span id="xdx_825_zVWiYOnlMsV5"&gt;FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 30, 2025 and December 31, 2024, the Company estimated the aggregate fair value of warrants that are accounted for as warrant
liabilities to be $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJcqWDj8PgBd" title="Fair value of warrants"&gt;1,968,315&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20241231__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAEe4M7r7e25" title="Fair value of warrants"&gt;2,520,851&lt;/span&gt;, respectively, using the Black-Scholes option price model (Level 3 inputs). The Company recognized
a gain on the change in fair value of these warrant liabilities of $&lt;span id="xdx_901_eus-gaap--DerivativeGainLossOnDerivativeNet_c20250701__20250930_z30hwbndc2y6" title="Change in fair value of warrant liability"&gt;612,064&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--DerivativeGainLossOnDerivativeNet_c20250101__20250930_zvlwGBvcD9K3" title="Change in fair value of warrant liability"&gt;552,536&lt;/span&gt; for the three and nine months ended September
30, 2025, respectively. The Company recognized a gain (loss) on the change in fair value of these warrant liabilities of $&lt;span id="xdx_90E_eus-gaap--DerivativeGainLossOnDerivativeNet_c20240701__20240930_zYATYdoL83V1" title="Change in fair value of warrant liability"&gt;1,036,464&lt;/span&gt; and
&lt;span id="xdx_90E_eus-gaap--DerivativeGainLossOnDerivativeNet_c20240101__20240930_zmWrjebF3sBf" title="Change in fair value of warrant liability"&gt;($837,466)&lt;/span&gt; for the three and nine months ended September 30, 2024, respectively. The following table shows the detail of the valuation
assumptions used as of September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zYbR150SpqHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_zcgeC8MqrZ5" style="display: none"&gt;SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zxEA6d76kmYb" title="Risk free interest rate, minimum"&gt;3.63&lt;/span&gt;%-&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2LyC3yTSKN2" title="Risk free interest rate, maximum"&gt;3.68&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zEjOyYzWXZL1" title="Expected term (years)"&gt;1.11&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zs74j345MWhg" title="Expected term (years)"&gt;3.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zChsDNjScRgl" title="Risk free interest rate, minimum"&gt;71&lt;/span&gt;% - &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zNNZYtdpL4bk" title="Risk free interest rate, maximum"&gt;95&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znlFqfExj7h4" title="Fair value measurement input"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zRfP3IV2E5k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: left; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z0molxKWjZA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_z9xuaMvT1xX2" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the three months ended September 30, 2025 and three months ended September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250701__20250930_zeCR0vBVgfgi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240701__20240930_zYoNyQCUs5b5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Three Months Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DerivativeLiabilitiesCurrent_iS_zxmARxdlRPSa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Balance, July 1,&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,580,379&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,491,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfWarrants_zmQMZLHyGDHg" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt"&gt;Issuance of warrants&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--ProceedsFromWarrantExercises_zdS9hwqjGvhf" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt"&gt;Exercise of warrants&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zqccaL1gKsq8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;(612,064&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;(1,036,464&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DerivativeLiabilitiesCurrent_iE_zPCfqZ6CcHFa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance, September 30,&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,968,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,455,505&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the nine months ended September 30, 2025 and nine months ended September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20250930_zyDniDIA96xf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20240930_z1eIEDR8hka7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Nine Months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DerivativesLiabilities_iS_zDuXqE4pQ9I1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Balance, January 1,&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,520,851&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,618,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zOrza3ZtG34b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;(552,536&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;837,466&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DerivativesLiabilities_iE_zf8kCHzACY72" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance, September 30,&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,968,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,455,505&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_ze9GaU9FQCCj" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zJgEq6fVipC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
and liabilities measured at fair value on a recurring basis are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BE_z9AJ9ruwatC" style="display: none"&gt;SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements at reporting date using:&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets for identical liabilities (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant unobservable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%"&gt;Marketable securities as of September 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx0XRgOrIwVj" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;3,887,383&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXy6QSa4CiKj" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAfGqdOs7p1c" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1110"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250930_zDJYVBVmVbjk" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;3,887,383&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Marketable securities as of December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsnvRgnScII4" style="text-align: right" title="Marketable securities, fair value"&gt;10,184,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXWj3LcyLswf" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIV6QKf55UAg" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20241231_z2kNUxQuWnph" style="text-align: right" title="Marketable securities, fair value"&gt;10,184,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrant liabilities as of September 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zlbrjHmcywRe" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNRVZ9KTxIxe" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1124"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdIugE6kW3E7" style="text-align: right" title="Warrant liabilities, fair value"&gt;1,968,315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930_zRmBTjm57Jcc" style="text-align: right" title="Warrant liabilities, fair value"&gt;1,968,315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrant liabilities as of December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXF2LovcwaF1" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1130"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl1rAwhJDX96" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1132"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDK5hyhn8tm4" style="text-align: right" title="Warrant liabilities, fair value"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231_zPIjIUPYLfFk" style="text-align: right" title="Warrant liabilities, fair value"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zeUnMi7Tq9Q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-09-302025-09-30_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001050"
      unitRef="USD">1968315</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-12-312024-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001052"
      unitRef="USD">2520851</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001054"
      unitRef="USD">612064</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001056"
      unitRef="USD">552536</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001058"
      unitRef="USD">1036464</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001060"
      unitRef="USD">-837466</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001062">&lt;p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zYbR150SpqHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_zcgeC8MqrZ5" style="display: none"&gt;SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zxEA6d76kmYb" title="Risk free interest rate, minimum"&gt;3.63&lt;/span&gt;%-&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2LyC3yTSKN2" title="Risk free interest rate, maximum"&gt;3.68&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zEjOyYzWXZL1" title="Expected term (years)"&gt;1.11&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zs74j345MWhg" title="Expected term (years)"&gt;3.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zChsDNjScRgl" title="Risk free interest rate, minimum"&gt;71&lt;/span&gt;% - &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zNNZYtdpL4bk" title="Risk free interest rate, maximum"&gt;95&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znlFqfExj7h4" title="Fair value measurement input"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001064"
      unitRef="Pure">3.63</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001066"
      unitRef="Pure">3.68</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_us-gaap_WarrantMember_srt_MinimumMember"
      id="Fact001068">P1Y1M9D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_us-gaap_WarrantMember_srt_MaximumMember"
      id="Fact001070">P3Y4M9D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001072"
      unitRef="Pure">71</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001074"
      unitRef="Pure">95</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001076"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001078">&lt;p id="xdx_89B_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z0molxKWjZA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_z9xuaMvT1xX2" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the three months ended September 30, 2025 and three months ended September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250701__20250930_zeCR0vBVgfgi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240701__20240930_zYoNyQCUs5b5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Three Months Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DerivativeLiabilitiesCurrent_iS_zxmARxdlRPSa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Balance, July 1,&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,580,379&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,491,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfWarrants_zmQMZLHyGDHg" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt"&gt;Issuance of warrants&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--ProceedsFromWarrantExercises_zdS9hwqjGvhf" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt"&gt;Exercise of warrants&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zqccaL1gKsq8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;(612,064&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;(1,036,464&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DerivativeLiabilitiesCurrent_iE_zPCfqZ6CcHFa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance, September 30,&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,968,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,455,505&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the nine months ended September 30, 2025 and nine months ended September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20250930_zyDniDIA96xf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20240930_z1eIEDR8hka7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Nine Months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DerivativesLiabilities_iS_zDuXqE4pQ9I1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Balance, January 1,&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,520,851&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,618,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zOrza3ZtG34b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: #0D0D0D; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;(552,536&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: #0D0D0D; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; color: #0D0D0D; text-align: right"&gt;837,466&lt;/td&gt;&lt;td style="padding-bottom: 1pt; color: #0D0D0D; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DerivativesLiabilities_iE_zf8kCHzACY72" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance, September 30,&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,968,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,455,505&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001080"
      unitRef="USD">2580379</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001081"
      unitRef="USD">4491969</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001089"
      unitRef="USD">612064</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001090"
      unitRef="USD">1036464</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001092"
      unitRef="USD">1968315</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001093"
      unitRef="USD">3455505</us-gaap:DerivativeLiabilitiesCurrent>
    <BRTX:DerivativesLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001095"
      unitRef="USD">2520851</BRTX:DerivativesLiabilities>
    <BRTX:DerivativesLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001096"
      unitRef="USD">2618039</BRTX:DerivativesLiabilities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001098"
      unitRef="USD">552536</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001099"
      unitRef="USD">-837466</us-gaap:DerivativeGainLossOnDerivativeNet>
    <BRTX:DerivativesLiabilities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001101"
      unitRef="USD">1968315</BRTX:DerivativesLiabilities>
    <BRTX:DerivativesLiabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001102"
      unitRef="USD">3455505</BRTX:DerivativesLiabilities>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001104">&lt;p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zJgEq6fVipC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
and liabilities measured at fair value on a recurring basis are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BE_z9AJ9ruwatC" style="display: none"&gt;SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements at reporting date using:&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets for identical liabilities (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant unobservable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%"&gt;Marketable securities as of September 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx0XRgOrIwVj" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;3,887,383&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXy6QSa4CiKj" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAfGqdOs7p1c" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1110"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250930_zDJYVBVmVbjk" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;3,887,383&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Marketable securities as of December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsnvRgnScII4" style="text-align: right" title="Marketable securities, fair value"&gt;10,184,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXWj3LcyLswf" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIV6QKf55UAg" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20241231_z2kNUxQuWnph" style="text-align: right" title="Marketable securities, fair value"&gt;10,184,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrant liabilities as of September 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zlbrjHmcywRe" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNRVZ9KTxIxe" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1124"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdIugE6kW3E7" style="text-align: right" title="Warrant liabilities, fair value"&gt;1,968,315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250930_zRmBTjm57Jcc" style="text-align: right" title="Warrant liabilities, fair value"&gt;1,968,315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrant liabilities as of December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXF2LovcwaF1" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1130"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl1rAwhJDX96" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1132"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDK5hyhn8tm4" style="text-align: right" title="Warrant liabilities, fair value"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231_zPIjIUPYLfFk" style="text-align: right" title="Warrant liabilities, fair value"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001106"
      unitRef="USD">3887383</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001112"
      unitRef="USD">3887383</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001114"
      unitRef="USD">10184701</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001120"
      unitRef="USD">10184701</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001126"
      unitRef="USD">1968315</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001128"
      unitRef="USD">1968315</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001134"
      unitRef="USD">2520851</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001136"
      unitRef="USD">2520851</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001138">&lt;p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_znPakqqd9Om6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
6 &#x2013; &lt;span id="xdx_821_z4TzsZfGHP7e"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Registered
Offering and Private Placement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 6, 2025, the Company entered into subscription agreements (the &#x201c;Subscription Agreements&#x201d;) with several investors
(the &#x201c;Purchasers&#x201d;) pursuant to which the Company agreed to sell and issue to the Purchasers an aggregate of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251006__20251006__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlzNCmTpDIOh" title="Sold shares of common stock"&gt;678,125&lt;/span&gt; shares
of the Company&#x2019;s common stock in a registered direct offering at an offering price of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQmPGfkniFB3" title="Offering price"&gt;1.60&lt;/span&gt; per share (the &#x201c;Registered Offering&#x201d;)
for aggregate gross proceeds of approximately $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20251006__20251006__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zQJfYMcLg6A6" title="Gross proceeds from sale of shares"&gt;1.1&lt;/span&gt; million. Pursuant to the Subscription Agreements, in a concurrent private placement
offering (the &#x201c;Private Placement&#x201d;), the Company agreed to issue to the Purchasers unregistered warrants to purchase up to
an aggregate of &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251006__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zrbksF93MJw3" title="Warrants exercisable"&gt;508,592&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPb5B4OeqpL6" title="Exercise price"&gt;2.75&lt;/span&gt; per share. The Registered Offering and
the Private Placement closed on October 8, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SaleOfStockDescriptionOfTransaction_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkCj8neueAD8" title="Description on sale of stock"&gt;In
connection with the offering, the Company entered into an engagement letter, dated August 11, 2025, with Alere Financial Partners (a
division of Cova Capital Partners, LLC) (the &#x201c;Placement Agent&#x201d;), pursuant to which the Company agreed to pay the Placement
Agent a cash fee equal to 6% of the gross proceeds of the offering from investors introduced to the Company by the Placement Agent (the
&#x201c;Placement Agent Investors&#x201d;) (4% for other investors).&lt;/span&gt; The Company has also agreed to reimburse the Placement Agent approximately
$&lt;span id="xdx_908_ecustom--LegalFeesAndOtherExpenses_c20250811__20250811_z4Ue4YpUWl03" title="Legal fees and other expenses"&gt;8,300&lt;/span&gt; for out-of-pocket expenses for legal fees and other expenses. In addition, the Company agreed to issue to the Placement Agent,
at the closing of the offering, a warrant exercisable commencing six months from the date of issuance until the five year anniversary
of the date of issuance to purchase up to 6% of the number of Shares sold in the Registered Offering to Placement Agent Investors (4%
for other investors), at a per share exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkv2vIYEvaBg" title="Exercise price"&gt;2.75&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Option
Grants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 13, 2025, the Company granted an option to purchase &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zam1vFGvqj64" title="Options granted"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise price of
$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6s4OO6iNKok" title="Exercise price of options granted"&gt;1.62&lt;/span&gt; per share to an employee. The option &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20251013__20251013__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zORSOjGXk9u9" title="Vesting of options description"&gt;vests as follows: (i) 50% immediately, and (ii) the remainder quarterly over two years commencing
one year from the date of grant.&lt;/span&gt; The Company will recognize the grant date fair value of the option on a straight-line basis over vesting
period.&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock Issuance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 27, 2025, the Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251027__20251027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zgQcx7pN8rN3" title="Number of shares of common stock"&gt;220,000&lt;/span&gt; shares of common stock to Auctus Fund, LLC in partial satisfaction of shares held by abeyance.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-10-062025-10-06_us-gaap_CommonStockMember_custom_SubscriptionAgreementsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001140"
      unitRef="Shares">678125</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-10-06_us-gaap_SubsequentEventMember_custom_SubscriptionAgreementsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001142"
      unitRef="USDPShares">1.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-10-062025-10-06_us-gaap_CommonStockMember_custom_SubscriptionAgreementsMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001144"
      unitRef="USD">1100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-10-06_us-gaap_SubsequentEventMember_custom_SubscriptionAgreementsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001146"
      unitRef="Shares">508592</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-10-06_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001148"
      unitRef="USDPShares">2.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockDescriptionOfTransaction
      contextRef="From2025-10-062025-10-06_us-gaap_SubsequentEventMember"
      id="Fact001150">In
connection with the offering, the Company entered into an engagement letter, dated August 11, 2025, with Alere Financial Partners (a
division of Cova Capital Partners, LLC) (the &#x201c;Placement Agent&#x201d;), pursuant to which the Company agreed to pay the Placement
Agent a cash fee equal to 6% of the gross proceeds of the offering from investors introduced to the Company by the Placement Agent (the
&#x201c;Placement Agent Investors&#x201d;) (4% for other investors).</us-gaap:SaleOfStockDescriptionOfTransaction>
    <BRTX:LegalFeesAndOtherExpenses
      contextRef="From2025-08-112025-08-11"
      decimals="0"
      id="Fact001152"
      unitRef="USD">8300</BRTX:LegalFeesAndOtherExpenses>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-10-06_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001154"
      unitRef="USDPShares">2.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001158"
      unitRef="USDPShares">1.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2025-10-132025-10-13_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventMember"
      id="Fact001160">vests as follows: (i) 50% immediately, and (ii) the remainder quarterly over two years commencing
one year from the date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-10-272025-10-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember"
      decimals="INF"
      id="Fact001162"
      unitRef="Shares">220000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001170"
      unitRef="USD">547890</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001171"
      unitRef="USD">884377</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001173"
      unitRef="USD">10184701</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001174"
      unitRef="USD">10181618</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001176"
      unitRef="USD">188400</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001177"
      unitRef="USD">19300</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001179"
      unitRef="USD">223230</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001180"
      unitRef="USD">305231</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001182"
      unitRef="USD">11144221</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001183"
      unitRef="USD">11390526</us-gaap:AssetsCurrent>
    <BRTX:DeferredOfferingCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001185"
      unitRef="USD">148697</BRTX:DeferredOfferingCost>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001188"
      unitRef="USD">362936</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001189"
      unitRef="USD">356055</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001192"
      unitRef="USD">151447</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001194"
      unitRef="USD">623945</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001195"
      unitRef="USD">713692</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001197"
      unitRef="USD">12279799</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001198"
      unitRef="USD">12611720</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001206"
      unitRef="USD">483070</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001207"
      unitRef="USD">189389</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001209"
      unitRef="USD">744485</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001210"
      unitRef="USD">711686</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001213"
      unitRef="USD">162317</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001215"
      unitRef="USD">2520851</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001216"
      unitRef="USD">1543953</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001218"
      unitRef="USD">3748406</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001219"
      unitRef="USD">2607345</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001221"
      unitRef="USD">3748406</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001222"
      unitRef="USD">2607345</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001230"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001232"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001234"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001236"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001241"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001243"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001245"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001247"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001249"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001251"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001238"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001239"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001253"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001254"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001259"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001261"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001263"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001265"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001267"
      unitRef="Shares">6919919</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001269"
      unitRef="Shares">6919919</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001271"
      unitRef="Shares">4706917</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001273"
      unitRef="Shares">4706917</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001256"
      unitRef="USD">692</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001257"
      unitRef="USD">471</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001275"
      unitRef="USD">164195434</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001276"
      unitRef="USD">156689256</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001278"
      unitRef="USD">-155678715</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001279"
      unitRef="USD">-146699334</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001281"
      unitRef="USD">8531393</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001282"
      unitRef="USD">10004375</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001284"
      unitRef="USD">12279799</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001285"
      unitRef="USD">12611720</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001287"
      unitRef="USD">401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001288"
      unitRef="USD">145800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001290"
      unitRef="USD">28072</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001293"
      unitRef="USD">372928</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001294"
      unitRef="USD">145800</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001299"
      unitRef="USD">5348709</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001300"
      unitRef="USD">4034591</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001302"
      unitRef="USD">6579413</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001303"
      unitRef="USD">11331983</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001305"
      unitRef="USD">11928122</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001306"
      unitRef="USD">15366574</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001308"
      unitRef="USD">-11555194</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001309"
      unitRef="USD">-15220774</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001314"
      unitRef="USD">616077</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001315"
      unitRef="USD">552293</us-gaap:InterestIncomeExpenseNet>
    <BRTX:GrantIncome
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001318"
      unitRef="USD">83333</BRTX:GrantIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001320"
      unitRef="USD">150850</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001321"
      unitRef="USD">169664</us-gaap:OtherNonoperatingIncomeExpense>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001323"
      unitRef="USD">1711698</BRTX:GainLossOnExchangeOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001326"
      unitRef="USD">97188</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001327"
      unitRef="USD">3997780</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001329"
      unitRef="USD">2575813</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001330"
      unitRef="USD">4803070</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001332"
      unitRef="USD">-8979381</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001333"
      unitRef="USD">-10417704</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001335"
      unitRef="USDPShares">-1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001337"
      unitRef="USDPShares">-1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001339"
      unitRef="USDPShares">-2.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001341"
      unitRef="USDPShares">-2.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001343"
      unitRef="Shares">7763932</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001345"
      unitRef="Shares">7763932</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001347"
      unitRef="Shares">4218347</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">4218347</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001357"
      unitRef="Shares">1518158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001351"
      unitRef="USD">15182</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001359"
      unitRef="Shares">3677775</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001352"
      unitRef="USD">369</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001353"
      unitRef="USD">146556418</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001354"
      unitRef="USD">-136281630</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001355"
      unitRef="USD">10290339</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001373"
      unitRef="Shares">89840</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001368"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001369"
      unitRef="USD">4633655</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001371"
      unitRef="USD">4633664</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001377"
      unitRef="USD">3141803</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001379"
      unitRef="USD">3141803</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001387"
      unitRef="Shares">1442</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001383"
      unitRef="USD">7500</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001385"
      unitRef="USD">7500</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001395"
      unitRef="Shares">-120000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001389"
      unitRef="USD">-1200</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001397"
      unitRef="Shares">120000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001390"
      unitRef="USD">12</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001391"
      unitRef="USD">1188</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001405"
      unitRef="Shares">817860</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001400"
      unitRef="USD">81</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001401"
      unitRef="USD">2348692</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001403"
      unitRef="USD">2348773</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001410"
      unitRef="USD">-10417704</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001411"
      unitRef="USD">-10417704</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001419"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001413"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001421"
      unitRef="Shares">4706917</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001414"
      unitRef="USD">471</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001415"
      unitRef="USD">156689256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001416"
      unitRef="USD">-146699334</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001417"
      unitRef="USD">10004375</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001429"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001423"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001431"
      unitRef="Shares">4706917</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001424"
      unitRef="USD">471</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001425"
      unitRef="USD">156689256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001426"
      unitRef="USD">-146699334</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001427"
      unitRef="USD">10004375</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001439"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001434"
      unitRef="USD">200</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001435"
      unitRef="USD">4742043</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001437"
      unitRef="USD">4742243</us-gaap:StockIssuedDuringPeriodValueOther>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001447"
      unitRef="Shares">-34825</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001442"
      unitRef="USD">-4</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001443"
      unitRef="USD">-48406</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001445"
      unitRef="USD">-48410</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001455"
      unitRef="Shares">150000</BRTX:StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares>
    <BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001450"
      unitRef="USD">15</BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares>
    <BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001451"
      unitRef="USD">-15</BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001469"
      unitRef="Shares">97827</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001464"
      unitRef="USD">10</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001465"
      unitRef="USD">985028</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001467"
      unitRef="USD">985038</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001473"
      unitRef="USD">1827528</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001475"
      unitRef="USD">1827528</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001480"
      unitRef="USD">-8979381</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001481"
      unitRef="USD">-8979381</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001489"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001483"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001491"
      unitRef="Shares">6919919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001484"
      unitRef="USD">692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001485"
      unitRef="USD">164195434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001486"
      unitRef="USD">-155678715</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001487"
      unitRef="USD">8531393</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001499"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001493"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001501"
      unitRef="Shares">6919919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001494"
      unitRef="USD">692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001495"
      unitRef="USD">164195434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001496"
      unitRef="USD">-155678715</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001497"
      unitRef="USD">8531393</us-gaap:StockholdersEquity>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001504"
      unitRef="Shares">3351580</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001506"
      unitRef="Shares">2150000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <BRTX:SharesHeldInAbeyance
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001508"
      unitRef="Shares">1201580</BRTX:SharesHeldInAbeyance>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001513"
      unitRef="USD">-8979381</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001514"
      unitRef="USD">-10417704</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001519"
      unitRef="USD">189056</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001520"
      unitRef="USD">165735</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001522"
      unitRef="USD">623801</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001523"
      unitRef="USD">569068</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001525"
      unitRef="USD">2812566</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001526"
      unitRef="USD">7782967</us-gaap:ShareBasedCompensation>
    <BRTX:NoncashLeaseExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001528"
      unitRef="USD">151447</BRTX:NoncashLeaseExpense>
    <BRTX:NoncashLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001529"
      unitRef="USD">90313</BRTX:NoncashLeaseExpense>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001531"
      unitRef="USD">1711698</BRTX:GainLossOnExchangeOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001534"
      unitRef="USD">97188</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001535"
      unitRef="USD">3997780</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001540"
      unitRef="USD">169100</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001541"
      unitRef="USD">3300</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001543"
      unitRef="USD">-33591</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001544"
      unitRef="USD">-57851</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001546"
      unitRef="USD">293680</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001547"
      unitRef="USD">18487</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001549"
      unitRef="USD">32799</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001550"
      unitRef="USD">581616</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001552"
      unitRef="USD">-162317</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001553"
      unitRef="USD">-139328</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001555"
      unitRef="USD">-8230346</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001556"
      unitRef="USD">-6430211</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001561"
      unitRef="USD">21508641</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001562"
      unitRef="USD">20964373</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001564"
      unitRef="USD">20887923</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001565"
      unitRef="USD">17541287</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001567"
      unitRef="USD">106189</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001568"
      unitRef="USD">171043</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001570"
      unitRef="USD">514529</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001571"
      unitRef="USD">3252043</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001577"
      unitRef="USD">494783</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001580"
      unitRef="USD">1853990</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001582"
      unitRef="USD">7528027</BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1>
    <BRTX:PaymentsForProceedsFromDeferredOfferingCosts
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001585"
      unitRef="USD">148697</BRTX:PaymentsForProceedsFromDeferredOfferingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001588"
      unitRef="USD">7379330</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001589"
      unitRef="USD">2348773</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001591"
      unitRef="USD">-336487</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001592"
      unitRef="USD">-829395</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001594"
      unitRef="USD">884377</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001595"
      unitRef="USD">1713772</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001597"
      unitRef="USD">547890</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001598"
      unitRef="USD">884377</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <BRTX:IssuanceOfCommonStockHeldInAbeyance
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001615"
      unitRef="USD">15</BRTX:IssuanceOfCommonStockHeldInAbeyance>
    <BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001618"
      unitRef="USD">48410</BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001619"
      unitRef="USD">39308</BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001622"
      unitRef="USD">8123391</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001624"
      unitRef="USD">595364</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact001626">&lt;p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zad1yrVgoFC6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
1 - &lt;span&gt;ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span id="xdx_823_zt5CeRGTE1T3" style="display: none"&gt;BUSINESS ORGANIZATION, NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Corporate
History&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#x201c;Stem Pearls&#x201d;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#x201c;BRT&#x201d; or the &#x201c;Company&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which
contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2024,
the Company had a net loss of $&lt;span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zpyfxt7l3Ml4" title="Net loss"&gt;9.0&lt;/span&gt; million, negative cash flows from operations of $&lt;span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zbxaUj3RB9Eg" title="Cash flows from operations"&gt;8.2&lt;/span&gt; million and working capital of $&lt;span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_c20241231_z46fDtgeQMRg" title="Working capital"&gt;7.4&lt;/span&gt; million.
The Company anticipates that it will continue to incur net losses and negative cash flows from operations as it executes its development
plans for 2025 and beyond, as well as other potential strategic and business development initiatives. These conditions raise substantial
doubt about the Company&#x2019;s ability to continue as a going concern for at least twelve months after the issuance date of these financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable
securities and additional infusions of cash from equity and debt financing. During the year ended December 31, 2024, the Company raised
net proceeds of approximately $&lt;span id="xdx_903_ecustom--ProceedsFromWarrantExercisesNet_iI_pn5n6_c20240101__20241231_zN7GIeS7Bo81" title="Proceeds from warrant exercises, net"&gt;7.5&lt;/span&gt; million in connection with a warrant exercise program which is further discussed in Note 6 &#x2013;
Stockholders&#x2019; Equity. On November 6, 2024, the Company entered into an at-the-market offering agreement (the &#x201c;2024 ATM&#x201d;)
pursuant to which the Company has an ability to issue and sell shares of its common stock up to an aggregate offering price of $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241106__20241106_zicrnDnE8Hjb" title="Offering price"&gt;3,614,170&lt;/span&gt;.
Subsequent to December 31, 2024, the Company sold &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zD3UaD052txg" title="Sold shares of common stock"&gt;492,000&lt;/span&gt; shares of its common stock under the 2024 ATM and raised approximately $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z22hnIqNkwu3" title="Offering price"&gt;1,084,000&lt;/span&gt;
of gross proceeds See Note 10 &#x2013; Subsequent Events for additional details regarding sales of the Company&#x2019;s common under the
2024 ATM subsequent to December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable
operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its
development, marketing and promotional activities, which would have a material adverse effect on the Company&#x2019;s business, financial
condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;), which contemplate continuation of the Company as a going concern and the realization
of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented
in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying consolidated
financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Business
Operations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#x2019;s
website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated
by reference into this Annual Report. BRT is currently developing a Disc/Spine Program referred to as &#x201c;brtxDISC&#x201d;. Its lead
cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person&#x2019;s own) cultured mesenchymal stem cells collected
from the patient&#x2019;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders
or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect to a platform technology
utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled
this initiative its ThermoStem Program. In addition, in continuation of BRT&#x2019;s mission of developing and commercializing cell-based
biologics, it is seeking to develop a biologics-based cosmetic products business. Pursuant to such business, BRT would formulate, manufacture
and sell products designed for cosmetic and aesthetic uses. Further, BRT has licensed a patented curved needle device that is a needle
system designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001628"
      unitRef="USD">-9000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001630"
      unitRef="USD">-8200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <BRTX:WorkingCapital
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001632"
      unitRef="USD">7400000</BRTX:WorkingCapital>
    <BRTX:ProceedsFromWarrantExercisesNet
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001634"
      unitRef="USD">7500000</BRTX:ProceedsFromWarrantExercisesNet>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-11-062024-11-06"
      decimals="0"
      id="Fact001636"
      unitRef="USD">3614170</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001638"
      unitRef="Shares">492000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001640"
      unitRef="USD">1084000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-01-012024-12-31" id="Fact001642">&lt;p id="xdx_80B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKzKY88P6szc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
2 - &lt;span id="xdx_828_zMyXsBBEEUzi"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zntv9Aiyyqwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zdk4PxG1qrLi"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#x2019;s consolidated financial statements. Such consolidated
financial statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity
and objectivity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zxDKCiAlpgg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_z0fNjlbqN8zj"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany
accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zEU1sFsNaugc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z4poG7D1ldXh"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#x2019;s future results to be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkkM4rTKhXL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_z3GH9BVMoxqk"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has one operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#x2019;s Chief Executive Officer, serves
as the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial
performance. The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated
expense data beyond what is included in the consolidated statements of operations is not provided to the CODM. Since the Company&#x2019;s
operations consist of a single reporting segment, the segment assets are presented on the accompanying consolidated balance sheet as
total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zutuEXoDmQC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zLcOVvLUxfTa"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue in accordance with ASC Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;).
The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC
606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required
within the revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable
consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company
recognizes revenue primarily from the following different types of contracts:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Product
    sales&lt;/b&gt; - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Royalty
    revenue&lt;/b&gt; - Revenue is recognized as a usage-based royalty from customers&#x2019; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#x2019;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    reason for the bill-and-hold arrangement is substantive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    customer has requested the product be warehoused&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product has been identified as separately belonging to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product is currently ready for physical transfer to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    Company does not have the ability to use the product or direct it to another customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s revenue recognized in its consolidated statements of operations:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z7tV6GJV8wQe" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNIZED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;401,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zucK4GFra5g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z82RXuAQ9m83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zPY8JAe2pUG9"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#x201c;FDIC&#x201d;) coverage of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zd4LGIJOhtt9" title="FDIC insured limit"&gt;250,000&lt;/span&gt; per banking institution. The Company had deposits in excess of FDIC coverage of $&lt;span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zkZR8JFpwxA1" title="FDIC amount"&gt;252,801&lt;/span&gt; and
$&lt;span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zuUVXiGB8vo1" title="FDIC amount"&gt;604,226&lt;/span&gt; as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has not experienced losses on this account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrHslI4Q5v9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zMa1AmFIfaIk"&gt;Customer
and Revenue Concentrations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s royalty revenue is derived from one customer. Additionally, all of the Company&#x2019;s product sales revenue is
derived from one customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z96cN1ak7Q7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zjqSBcHeCS88"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of December 31, 2024 and 2023, no allowances
for credit losses were determined to be necessary. Management estimates the allowance for credit losses based on existing economic conditions,
the financial conditions of the customers, and the amount and age of past due accounts. Receivables are considered past due if full payment
is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only
after all collection attempts have been exhausted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--DeferredContractCostsPolicyTextBlock_zBfyPacgQe1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_z9v0S1hZqQUi"&gt;Deferred
Contract Costs&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs
relate directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying
performance obligations in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as
cost of revenues in the period when the related revenue is recognized. Deferred contract costs consist of consumables and labor
costs and are included within prepaid &amp;amp; other current assets in the consolidated balance sheets. The Company had $&lt;span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zZfVwr6cQXkb" title="Deferred contract costs"&gt;10,250&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--DeferredCosts_iI_c20231231_zdJ4p8ov21Hk" title="Deferred contract costs"&gt;0 &lt;/span&gt;deferred contract
costs as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--DeferredOfferingCostsPolicyTextBlock_zCSW2VIkUIsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86C_zv1g22C3EyB3"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Deferred offering costs, which
primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized as non-current assets
on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the offering proceeds. If
the completion of a contemplated financing was no longer probable, the related deferred offering costs would be charged to general and
administrative expense in the consolidated financial statements. The Company had $&lt;span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_c20241231_zRqgz5xgN36j" title="Deferred offering costs"&gt;148,697&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20231231_zQ0rJYVdgKF6" title="Deferred offering costs"&gt;0&lt;/span&gt; deferred offering costs as of December
31, 2024 and 2023, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrNWYT5nz4ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zheceqDJFsi8"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_z7kFHq54efw8" style="display: none" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt;three to &lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_z9lXBJdFqlhj" title="Property plant and equipment estimated useful lives"&gt;fifteen years&lt;/span&gt;. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfnq9MSy6d45" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt; years. Medical equipment costs
are capitalized and depreciated over &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZ4jRpsDJgA6" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years, while furniture and fixtures are depreciated over &lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjMrGwd0Prad" title="Property plant and equipment estimated useful lives"&gt;4&lt;/span&gt; years. Office equipment is depreciated
over a period of &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zFxufD0aVXDh" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcK9bTYPatcf" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years, and manufacturing equipment over &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRGoTgdUsUR5" title="Property plant and equipment estimated useful lives"&gt;4&lt;/span&gt; to &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNoLqgQf3lLh" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zvYszRC8Li8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zEt2msSsRFC2"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records its intangible assets at cost in accordance with ASC 350, &lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;. Definite lived intangible
assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over
which the cash flows from the asset are expected to be generated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhNRS1Aqq6jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zFhYORrqYOJc"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, the Company determined that
there was &lt;span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20240101__20241231_zkUKhwWoBDvg" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20230101__20231231_zJwaUYA1d6li" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment charge for its long-lived assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--WarrantAndOptionValuationPolicyTextBlock_zI9N9CDazI73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zUd3lVu9E2Sd"&gt;Warrant
and Option Valuation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#x201c;simplified&#x201d;
method to develop an estimate of the expected term of &#x201c;plain vanilla&#x201d; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry blended with the Company&#x2019;s historical
volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining
term consistent with the expected term of the instrument being valued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQ9biVqlTD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span id="xdx_86F_z6RhMrU5RzF3"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option pricing model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGbcb7LJWe47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zhJEhRPQrt7k"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of December 31, 2024 and 2023, the carrying amount of cash and cash equivalents,
investments held in marketable securities, accounts receivable, and accounts payable approximate their fair value due to the relatively
short period of time between their origination and their expected realization or payment. The warrant liabilities are measured at fair
value (see Note 9 &#x2013; Fair Value Measurement for additional details).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company recognized aggregate dividend and interest income of $&lt;span id="xdx_90C_eus-gaap--InterestAndDividendIncomeOperating_c20240101__20241231_zg5oD0W09dNe" title="Dividend and interest income"&gt;623,801&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--InterestAndDividendIncomeOperating_c20230101__20231231_zU0r2WazoLE7" title="Dividend and interest income"&gt;569,068&lt;/span&gt; respectively,
on its marketable securities, which was included within other income on its consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zV62cxfcykAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zSfIv1elO46k"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The Company has &lt;span id="xdx_90D_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zLHCITQpABQj" title="Shares held in abeyance"&gt;1,201,580&lt;/span&gt; shares held in abeyance included
in basic loss per share given that they are issuable for no additional consideration (see Note 6 &#x2013; Stockholders&#x2019; Equity for
additional details). The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding
convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant
to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants,
restricted stock units (&#x201c;RSUs&#x201d;) and convertible preferred stock have been excluded from the Company&#x2019;s computation of
diluted net loss per common share for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1GIc8cffMY8" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total"&gt;3,263,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total"&gt;1,466,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares"&gt;3,951,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares"&gt;4,791,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unvested RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1741"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested"&gt;97,827&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;8,613,259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;7,753,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zh9UmzbEuc23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4rqRiibYMW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zXmhvArh15nb"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be
provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified
warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction
of amounts previously expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zyorW7NGWskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_zwBN5Q5WlHH"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes ASC 740, &#x201c;Income Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#x201c;more likely-than-not&#x201d;
that a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zUyYKWUBRBq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zvsoDK4W79Yj"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;)
assets and operating lease liabilities in our consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value
of lease payments over the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement
date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company&#x2019;s lease terms
may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for
lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXTkrjpty3U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zpKTHgzD4l67"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07,
&#x201c;Improvements to Reportable Segments Disclosures (Topic 280)&#x201d; (&#x201c;ASU 2023-07&#x201d;), which updates reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis.
The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after
December 15, 2024, with early adoption permitted. The adoption of this accounting standard on a retrospective basis did not have a material
impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zmtEdleuNQYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zNfZlr2uXiec"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; (&#x201c;ASU
2023-09&#x201d;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU No. 2024-03, &#x201c;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; (&#x201c;ASU 2024-03&#x201d;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_850_zSD8QCfCQlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001644">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zntv9Aiyyqwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zdk4PxG1qrLi"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#x2019;s consolidated financial statements. Such consolidated
financial statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity
and objectivity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001646">&lt;p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zxDKCiAlpgg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_z0fNjlbqN8zj"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany
accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-012024-12-31" id="Fact001648">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zEU1sFsNaugc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z4poG7D1ldXh"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#x2019;s future results to be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001650">&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkkM4rTKhXL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_z3GH9BVMoxqk"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has one operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#x2019;s Chief Executive Officer, serves
as the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial
performance. The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated
expense data beyond what is included in the consolidated statements of operations is not provided to the CODM. Since the Company&#x2019;s
operations consist of a single reporting segment, the segment assets are presented on the accompanying consolidated balance sheet as
total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001652">&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zutuEXoDmQC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zLcOVvLUxfTa"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue in accordance with ASC Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;).
The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC
606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required
within the revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable
consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company
recognizes revenue primarily from the following different types of contracts:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Product
    sales&lt;/b&gt; - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Royalty
    revenue&lt;/b&gt; - Revenue is recognized as a usage-based royalty from customers&#x2019; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#x2019;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    reason for the bill-and-hold arrangement is substantive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    customer has requested the product be warehoused&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product has been identified as separately belonging to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product is currently ready for physical transfer to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    Company does not have the ability to use the product or direct it to another customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s revenue recognized in its consolidated statements of operations:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z7tV6GJV8wQe" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNIZED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;401,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zucK4GFra5g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="From2024-01-012024-12-31" id="Fact001654">&lt;p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z7tV6GJV8wQe" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNIZED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;401,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_ProductMember"
      decimals="0"
      id="Fact001656"
      unitRef="USD">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_RoyaltyMember"
      decimals="0"
      id="Fact001659"
      unitRef="USD">101000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_RoyaltyMember"
      decimals="0"
      id="Fact001660"
      unitRef="USD">145800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001662"
      unitRef="USD">401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001663"
      unitRef="USD">145800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001665">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z82RXuAQ9m83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zPY8JAe2pUG9"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#x201c;FDIC&#x201d;) coverage of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zd4LGIJOhtt9" title="FDIC insured limit"&gt;250,000&lt;/span&gt; per banking institution. The Company had deposits in excess of FDIC coverage of $&lt;span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zkZR8JFpwxA1" title="FDIC amount"&gt;252,801&lt;/span&gt; and
$&lt;span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zuUVXiGB8vo1" title="FDIC amount"&gt;604,226&lt;/span&gt; as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has not experienced losses on this account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001667"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001669"
      unitRef="USD">252801</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001671"
      unitRef="USD">604226</us-gaap:CashUninsuredAmount>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-012024-12-31" id="Fact001673">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrHslI4Q5v9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zMa1AmFIfaIk"&gt;Customer
and Revenue Concentrations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s royalty revenue is derived from one customer. Additionally, all of the Company&#x2019;s product sales revenue is
derived from one customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2024-01-012024-12-31" id="Fact001675">&lt;p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z96cN1ak7Q7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zjqSBcHeCS88"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of December 31, 2024 and 2023, no allowances
for credit losses were determined to be necessary. Management estimates the allowance for credit losses based on existing economic conditions,
the financial conditions of the customers, and the amount and age of past due accounts. Receivables are considered past due if full payment
is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only
after all collection attempts have been exhausted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <BRTX:DeferredContractCostsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001677">&lt;p id="xdx_841_ecustom--DeferredContractCostsPolicyTextBlock_zBfyPacgQe1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_z9v0S1hZqQUi"&gt;Deferred
Contract Costs&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs
relate directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying
performance obligations in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as
cost of revenues in the period when the related revenue is recognized. Deferred contract costs consist of consumables and labor
costs and are included within prepaid &amp;amp; other current assets in the consolidated balance sheets. The Company had $&lt;span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zZfVwr6cQXkb" title="Deferred contract costs"&gt;10,250&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--DeferredCosts_iI_c20231231_zdJ4p8ov21Hk" title="Deferred contract costs"&gt;0 &lt;/span&gt;deferred contract
costs as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</BRTX:DeferredContractCostsPolicyTextBlock>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001679"
      unitRef="USD">10250</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001681"
      unitRef="USD">0</us-gaap:DeferredCosts>
    <BRTX:DeferredOfferingCostsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001683">&lt;p id="xdx_844_ecustom--DeferredOfferingCostsPolicyTextBlock_zCSW2VIkUIsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86C_zv1g22C3EyB3"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Deferred offering costs, which
primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized as non-current assets
on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the offering proceeds. If
the completion of a contemplated financing was no longer probable, the related deferred offering costs would be charged to general and
administrative expense in the consolidated financial statements. The Company had $&lt;span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_c20241231_zRqgz5xgN36j" title="Deferred offering costs"&gt;148,697&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20231231_zQ0rJYVdgKF6" title="Deferred offering costs"&gt;0&lt;/span&gt; deferred offering costs as of December
31, 2024 and 2023, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</BRTX:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001685"
      unitRef="USD">148697</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001687"
      unitRef="USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001689">&lt;p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrNWYT5nz4ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zheceqDJFsi8"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_z7kFHq54efw8" style="display: none" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt;three to &lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_z9lXBJdFqlhj" title="Property plant and equipment estimated useful lives"&gt;fifteen years&lt;/span&gt;. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfnq9MSy6d45" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt; years. Medical equipment costs
are capitalized and depreciated over &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZ4jRpsDJgA6" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years, while furniture and fixtures are depreciated over &lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjMrGwd0Prad" title="Property plant and equipment estimated useful lives"&gt;4&lt;/span&gt; years. Office equipment is depreciated
over a period of &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zFxufD0aVXDh" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcK9bTYPatcf" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years, and manufacturing equipment over &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRGoTgdUsUR5" title="Property plant and equipment estimated useful lives"&gt;4&lt;/span&gt; to &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNoLqgQf3lLh" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      id="Fact001691">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      id="Fact001693">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact001695">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_MedicalEquipmentMember"
      id="Fact001697">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact001699">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember"
      id="Fact001701">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember"
      id="Fact001703">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MinimumMember"
      id="Fact001705">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MaximumMember"
      id="Fact001707">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-01-012024-12-31" id="Fact001709">&lt;p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zvYszRC8Li8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zEt2msSsRFC2"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records its intangible assets at cost in accordance with ASC 350, &lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;. Definite lived intangible
assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over
which the cash flows from the asset are expected to be generated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001711">&lt;p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhNRS1Aqq6jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zFhYORrqYOJc"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, the Company determined that
there was &lt;span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20240101__20241231_zkUKhwWoBDvg" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20230101__20231231_zJwaUYA1d6li" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment charge for its long-lived assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001713"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001715"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <BRTX:WarrantAndOptionValuationPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001717">&lt;p id="xdx_846_ecustom--WarrantAndOptionValuationPolicyTextBlock_zI9N9CDazI73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zUd3lVu9E2Sd"&gt;Warrant
and Option Valuation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#x201c;simplified&#x201d;
method to develop an estimate of the expected term of &#x201c;plain vanilla&#x201d; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry blended with the Company&#x2019;s historical
volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining
term consistent with the expected term of the instrument being valued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</BRTX:WarrantAndOptionValuationPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-012024-12-31" id="Fact001719">&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQ9biVqlTD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span id="xdx_86F_z6RhMrU5RzF3"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option pricing model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001721">&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGbcb7LJWe47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zhJEhRPQrt7k"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of December 31, 2024 and 2023, the carrying amount of cash and cash equivalents,
investments held in marketable securities, accounts receivable, and accounts payable approximate their fair value due to the relatively
short period of time between their origination and their expected realization or payment. The warrant liabilities are measured at fair
value (see Note 9 &#x2013; Fair Value Measurement for additional details).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company recognized aggregate dividend and interest income of $&lt;span id="xdx_90C_eus-gaap--InterestAndDividendIncomeOperating_c20240101__20241231_zg5oD0W09dNe" title="Dividend and interest income"&gt;623,801&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--InterestAndDividendIncomeOperating_c20230101__20231231_zU0r2WazoLE7" title="Dividend and interest income"&gt;569,068&lt;/span&gt; respectively,
on its marketable securities, which was included within other income on its consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001723"
      unitRef="USD">623801</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001725"
      unitRef="USD">569068</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001727">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zV62cxfcykAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zSfIv1elO46k"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The Company has &lt;span id="xdx_90D_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zLHCITQpABQj" title="Shares held in abeyance"&gt;1,201,580&lt;/span&gt; shares held in abeyance included
in basic loss per share given that they are issuable for no additional consideration (see Note 6 &#x2013; Stockholders&#x2019; Equity for
additional details). The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding
convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant
to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants,
restricted stock units (&#x201c;RSUs&#x201d;) and convertible preferred stock have been excluded from the Company&#x2019;s computation of
diluted net loss per common share for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1GIc8cffMY8" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total"&gt;3,263,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total"&gt;1,466,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares"&gt;3,951,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares"&gt;4,791,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unvested RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1741"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested"&gt;97,827&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;8,613,259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;7,753,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zh9UmzbEuc23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <BRTX:SharesHeldInAbeyance
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001729"
      unitRef="Shares">1201580</BRTX:SharesHeldInAbeyance>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001731">&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1GIc8cffMY8" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total"&gt;3,263,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total"&gt;1,466,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares"&gt;3,951,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares"&gt;4,791,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unvested RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1741"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested"&gt;97,827&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;8,613,259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;7,753,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001733"
      unitRef="Shares">3263467</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001735"
      unitRef="Shares">1466892</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001737"
      unitRef="Shares">3951634</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001739"
      unitRef="Shares">4791019</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001743"
      unitRef="Shares">97827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001745"
      unitRef="Shares">1398158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001747"
      unitRef="Shares">1398158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001749"
      unitRef="Shares">8613259</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001751"
      unitRef="Shares">7753896</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-012024-12-31" id="Fact001753">&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4rqRiibYMW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zXmhvArh15nb"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be
provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified
warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction
of amounts previously expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001755">&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zyorW7NGWskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_zwBN5Q5WlHH"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes ASC 740, &#x201c;Income Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#x201c;more likely-than-not&#x201d;
that a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001757">&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zUyYKWUBRBq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zvsoDK4W79Yj"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;)
assets and operating lease liabilities in our consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value
of lease payments over the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement
date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company&#x2019;s lease terms
may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for
lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001759">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXTkrjpty3U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zpKTHgzD4l67"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07,
&#x201c;Improvements to Reportable Segments Disclosures (Topic 280)&#x201d; (&#x201c;ASU 2023-07&#x201d;), which updates reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis.
The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after
December 15, 2024, with early adoption permitted. The adoption of this accounting standard on a retrospective basis did not have a material
impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <BRTX:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact001761">&lt;p id="xdx_845_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zmtEdleuNQYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zNfZlr2uXiec"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; (&#x201c;ASU
2023-09&#x201d;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU No. 2024-03, &#x201c;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; (&#x201c;ASU 2024-03&#x201d;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

</BRTX:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact001763">&lt;p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zEvV1FTo67xk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
3 - &lt;span id="xdx_829_zsg9IrEIAfo9"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2ZdwaDNWsb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zRiW19Duyqmj" style="display: none"&gt;SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zcvb0j2Mshvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zCrUODQYb0Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zLOXDxjVNdhb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zHKi6c2fM66c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zTPXuLfpmrf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer software and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdSPeVh24a7d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zHLEEhyimZOi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Manufacturing equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;501,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;395,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb0uKt79Uwyg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;342,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;342,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzKiZ_z4su14VN8qy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
    plant and equipment gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,474,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,367,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKiZ_zeJSxm1HRBa4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,111,136&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,011,828&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKiZ_zPMObeOSxMXd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;362,936&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zZiYqaFLPewe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
depreciation expense for the years ended December 31, 2024 and 2023 was $&lt;span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zvtQEHghKRO7" title="Depreciation"&gt;99,309&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zi5SeumhaRl8" title="Depreciation"&gt;75,989&lt;/span&gt;, respectively. Depreciation expense is reflected
in general and administrative expenses and research and development expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-012024-12-31" id="Fact001765">&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2ZdwaDNWsb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zRiW19Duyqmj" style="display: none"&gt;SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zcvb0j2Mshvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zCrUODQYb0Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zLOXDxjVNdhb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zHKi6c2fM66c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zTPXuLfpmrf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer software and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdSPeVh24a7d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zHLEEhyimZOi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Manufacturing equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;501,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;395,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb0uKt79Uwyg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;342,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;342,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzKiZ_z4su14VN8qy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
    plant and equipment gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,474,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,367,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKiZ_zeJSxm1HRBa4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,111,136&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,011,828&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKiZ_zPMObeOSxMXd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;362,936&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001767"
      unitRef="USD">352133</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001768"
      unitRef="USD">352133</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact001770"
      unitRef="USD">123486</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact001771"
      unitRef="USD">123486</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_ComputerSoftwareAndEquipmentMember"
      decimals="0"
      id="Fact001773"
      unitRef="USD">136205</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ComputerSoftwareAndEquipmentMember"
      decimals="0"
      id="Fact001774"
      unitRef="USD">136205</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact001776"
      unitRef="USD">18779</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact001777"
      unitRef="USD">18779</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember"
      decimals="0"
      id="Fact001779"
      unitRef="USD">501421</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ManufacturingEquipmentMember"
      decimals="0"
      id="Fact001780"
      unitRef="USD">395232</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact001782"
      unitRef="USD">342048</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact001783"
      unitRef="USD">342048</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001785"
      unitRef="USD">1474072</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001786"
      unitRef="USD">1367883</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001788"
      unitRef="USD">1111136</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001789"
      unitRef="USD">1011828</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001791"
      unitRef="USD">362936</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001792"
      unitRef="USD">356055</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001794"
      unitRef="USD">99309</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001796"
      unitRef="USD">75989</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact001798">&lt;p id="xdx_80E_eus-gaap--IntangibleAssetsDisclosureTextBlock_z7XcTOpi2I3c" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
4 - &lt;span id="xdx_82E_z8jFnJ0P8vsc"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a license agreement with the SCTC (as amended) (the &#x201c;SCTC Agreement&#x201d;). Pursuant to the SCTC Agreement,
the Company obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from the SCTC
to utilize or sublicense a certain method for culturing cells and a worldwide, exclusive, royalty-bearing license from the SCTC to utilize
or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine
(and other parts of the body).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2017, the Company received authorization from the Food and Drug Administration (the &#x201c;FDA&#x201d;) to proceed with a Phase
2 clinical trial. In February 2022, the Company announced that the United States Patent and Trademark Office issued a notice of allowance
for a patent application relating to the Company&#x2019;s BRTX-100 clinical program. This patent was issued in March 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdsSzvPsMxw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zovX5FmRjKn8" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zMa8DpLEhmyh" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgkIpLlGFbo2" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"&gt;1,593,530&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zqY3dA0k41Sl" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"&gt;(793,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20230101__20231231_z6h1cAws7Od" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"&gt;803,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zDUNrjLtHqbj" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231_zRrGfdmJ09Eb" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zTRGfffLeNbf" style="text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBVozX7VDJlj" style="text-align: right" title="Beginning Balance"&gt;1,593,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXRYXWxN8sRe" style="text-align: right" title="Beginning Balance"&gt;(883,514&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20240101__20241231_zqwLjk2xJY0j" style="text-align: right" title="Beginning Balance"&gt;713,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zytthitOTw2k" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231_zAM5NMN8yS06" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zQuRKUBmR8mh" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zoYjoWDb33X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"&gt;1,593,530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztG665tY4AIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance"&gt;(973,261&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_pp0p0_c20240101__20241231_zjzg3CCnlNxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, Ending Balance"&gt;623,945&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average remaining amortization period at December 31, 2024 (in years)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zFTAQg0U6qf8" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zWn6aGIbVlz8" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;10.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zQnJWoLGRUxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zyr8t0Ym6OWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
of intangible assets consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B1_zIE3bG4EPzp9" style="display: none"&gt;SCHEDULE OF FINITE LIVED
INTANGIBLE ASSETS AMORTIZATION EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zAQRVTNxCnRa" style="width: 14%; text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zTV1EfXZQxkj" style="width: 14%; text-align: right" title="Beginning Balance"&gt;790,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuMtebEZOmgf" style="width: 14%; text-align: right" title="Beginning Balance"&gt;793,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zY8aapJwfbif" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1846"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgEjKj6jTWI5" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2rXVJBGP7il" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zgRAH3stiYi7" style="text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDe9KaWcOYI7" style="text-align: right" title="Beginning Balance"&gt;879,838&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXVvp6oFTRTa" style="text-align: right" title="Beginning Balance"&gt;883,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zuHhehAQNkik" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6qgnUqvdCNe" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zygSxwRoDT8e" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zpDaKpFlcUXl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_ziQYvOYoF2Vh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;969,585&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z21atXqH7Mrd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;973,261&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zXJeZ8EsBx54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zO5E84hy3qC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense for the next five years is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zDxhPMghSJb7" style="display: none"&gt;SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom"&gt;For the Years Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zLqGmLhSvkA" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz89Q_z1vNDKxW98G5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz89Q_za7zLx3utHS9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz89Q_z9FWK80aZ1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz89Q_zCZfaJK7po9f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz89Q_zlr2Quf6AHf9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 1pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz89Q_zivgdmaXPRBi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;448,730&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zRFY1LD10kBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001800">&lt;p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdsSzvPsMxw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zovX5FmRjKn8" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zMa8DpLEhmyh" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgkIpLlGFbo2" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"&gt;1,593,530&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zqY3dA0k41Sl" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"&gt;(793,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20230101__20231231_z6h1cAws7Od" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"&gt;803,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zDUNrjLtHqbj" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231_zRrGfdmJ09Eb" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zTRGfffLeNbf" style="text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBVozX7VDJlj" style="text-align: right" title="Beginning Balance"&gt;1,593,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXRYXWxN8sRe" style="text-align: right" title="Beginning Balance"&gt;(883,514&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20240101__20241231_zqwLjk2xJY0j" style="text-align: right" title="Beginning Balance"&gt;713,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zytthitOTw2k" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231_zAM5NMN8yS06" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zQuRKUBmR8mh" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zoYjoWDb33X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"&gt;1,593,530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztG665tY4AIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance"&gt;(973,261&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_pp0p0_c20240101__20241231_zjzg3CCnlNxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, Ending Balance"&gt;623,945&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average remaining amortization period at December 31, 2024 (in years)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zFTAQg0U6qf8" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zWn6aGIbVlz8" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;10.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_custom_PatentsAndTrademarksMember"
      decimals="0"
      id="Fact001802"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact001804"
      unitRef="USD">1593530</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact001806"
      unitRef="USD">793768</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001808"
      unitRef="USD">803438</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact001810"
      unitRef="USD">89746</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001812"
      unitRef="USD">89746</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_PatentsAndTrademarksMember"
      decimals="0"
      id="Fact001814"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact001816"
      unitRef="USD">1593530</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact001818"
      unitRef="USD">883514</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001820"
      unitRef="USD">713692</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact001822"
      unitRef="USD">89747</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001824"
      unitRef="USD">89747</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_PatentsAndTrademarksMember"
      decimals="0"
      id="Fact001826"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact001828"
      unitRef="USD">1593530</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact001830"
      unitRef="USD">973261</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001832"
      unitRef="USD">623945</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="AsOf2024-12-31_us-gaap_LicenseMember"
      id="Fact001836">P10Y3M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001838">&lt;p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zyr8t0Ym6OWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
of intangible assets consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B1_zIE3bG4EPzp9" style="display: none"&gt;SCHEDULE OF FINITE LIVED
INTANGIBLE ASSETS AMORTIZATION EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zAQRVTNxCnRa" style="width: 14%; text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zTV1EfXZQxkj" style="width: 14%; text-align: right" title="Beginning Balance"&gt;790,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuMtebEZOmgf" style="width: 14%; text-align: right" title="Beginning Balance"&gt;793,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zY8aapJwfbif" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1846"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgEjKj6jTWI5" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2rXVJBGP7il" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zgRAH3stiYi7" style="text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDe9KaWcOYI7" style="text-align: right" title="Beginning Balance"&gt;879,838&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXVvp6oFTRTa" style="text-align: right" title="Beginning Balance"&gt;883,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zuHhehAQNkik" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6qgnUqvdCNe" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zygSxwRoDT8e" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zpDaKpFlcUXl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_ziQYvOYoF2Vh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;969,585&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z21atXqH7Mrd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;973,261&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_PatentsAndTrademarkMember"
      decimals="0"
      id="Fact001840"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact001842"
      unitRef="USD">790092</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact001844"
      unitRef="USD">793768</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact001848"
      unitRef="USD">89746</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact001850"
      unitRef="USD">89746</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_custom_PatentsAndTrademarkMember"
      decimals="0"
      id="Fact001852"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact001854"
      unitRef="USD">879838</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact001856"
      unitRef="USD">883514</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact001860"
      unitRef="USD">89747</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact001862"
      unitRef="USD">89747</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_custom_PatentsAndTrademarkMember"
      decimals="0"
      id="Fact001864"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact001866"
      unitRef="USD">969585</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact001868"
      unitRef="USD">973261</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001870">&lt;p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zO5E84hy3qC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense for the next five years is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zDxhPMghSJb7" style="display: none"&gt;SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom"&gt;For the Years Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zLqGmLhSvkA" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz89Q_z1vNDKxW98G5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz89Q_za7zLx3utHS9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz89Q_z9FWK80aZ1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz89Q_zCZfaJK7po9f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz89Q_zlr2Quf6AHf9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 1pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz89Q_zivgdmaXPRBi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;448,730&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001872"
      unitRef="USD">89746</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001874"
      unitRef="USD">89746</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001876"
      unitRef="USD">89746</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001878"
      unitRef="USD">89746</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001880"
      unitRef="USD">89746</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001882"
      unitRef="USD">448730</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2024-01-012024-12-31" id="Fact001884">&lt;p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zcCzM4pARQo3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
5 - &lt;span id="xdx_820_zMsUx2ILh5Tl"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7ve0gvNg4Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z3T5qunqNukl" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zEWk23Yc0nC" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zeM88DjmnpU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALAOLzJ5Y_zfKjliCICsKd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accrued bonuses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;704,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;638,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zWjZXZQ1wT92" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;73,686&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtALAOLzJ5Y_zh0kRlaqDaTb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;744,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;711,686&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_ziyjOByjOsNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001886">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7ve0gvNg4Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z3T5qunqNukl" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zEWk23Yc0nC" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zeM88DjmnpU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALAOLzJ5Y_zfKjliCICsKd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accrued bonuses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;704,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;638,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zWjZXZQ1wT92" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;73,686&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtALAOLzJ5Y_zh0kRlaqDaTb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;744,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;711,686&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001888"
      unitRef="USD">704000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001889"
      unitRef="USD">638000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <BRTX:AccruedGeneralAndAdministrativeExpenses
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001891"
      unitRef="USD">40485</BRTX:AccruedGeneralAndAdministrativeExpenses>
    <BRTX:AccruedGeneralAndAdministrativeExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001892"
      unitRef="USD">73686</BRTX:AccruedGeneralAndAdministrativeExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001894"
      unitRef="USD">744485</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001895"
      unitRef="USD">711686</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact001897">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJPEBtlN7YIk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
6 - &lt;span id="xdx_82B_zUgzUG841pcg"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
A Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 8, 2021, in connection with the Company&#x2019;s public offering, the Company&#x2019;s Board of Directors adopted a resolution
allowing for the designation and issuance of &lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAv4O5ACYYm2" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of the Company&#x2019;s Preferred Stock, $&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQNlJEUEDcQa" title="Preferred stock, par value"&gt;.01&lt;/span&gt; par value per share, designated
as Series A Preferred Stock (&#x201c;Series A&#x201d;). The Series A had a liquidation preference of $&lt;span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3hczMMtKpU8" title="Preferred stock, liquidation preference"&gt;0.001&lt;/span&gt; per share. On September 8,
2022, the Company issued &lt;span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zo0GcvUNCdN2" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of Series B Preferred Stock (&#x201c;Series B&#x201d;) to Auctus Fund, LLC (&#x201c;Auctus&#x201d;)
in exchange for an equal number of shares of the Company&#x2019;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#x2019;s Board
of Directors cancelled the Series A.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
B Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 8, 2022, the Company issued &lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYC3O1qRrCy6" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of Series B to Auctus in exchange for an equal number of shares of the Company&#x2019;s
outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is &lt;span id="xdx_90D_eus-gaap--PreferredStockVotingRights_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKAmHWfyKJBh" title="Preferred stock voting rights"&gt;9.99&lt;/span&gt;% of the then outstanding Common Stock of the Company instead of &lt;span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuT87XMZHkJ6" title="Preferred stock voting rights"&gt;4.99&lt;/span&gt;% as
provided for the Series A. The Company is required, at all times, to reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to
redemption by the Company or any Series B holder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Dividends&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Voting
Rights&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than &lt;span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7GqZ3KTuVV4" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the then outstanding shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Conversion&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Optional
Conversion - &lt;span id="xdx_902_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zL2VXQ8WU4De" title="Preferred stock conversion term"&gt;Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock;&lt;/span&gt; provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than &lt;span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znCDeplQWuW5" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the outstanding
shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Automatic
Conversion - From time to time, in the event that an event occurs which has the effect of reducing a Series B holder&#x2019;s beneficial
ownership of shares of Common Stock to less than &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zphxO48CaFTi" title="Ownership percentage"&gt;9.5&lt;/span&gt;% of the then publicly disclosed outstanding shares of Common Stock, then, within
five business days, the Series B holder is required to provide notice to the Company to such effect, which notice shall state the number
of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard thereto, including
the number of derivative securities compromising a portion of such beneficial share amount. Such notice shall have the effect of a notice
of conversion with respect to the conversion of such number of shares of Series B as would increase the Series B holder&#x2019;s beneficial
ownership of Common Stock to &lt;span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zf50yJldC0Qg" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the then publicly disclosed outstanding shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 25, 2022, Auctus converted &lt;span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_z5AXhJwz8bFi" title="Debt conversion, converted instrument, shares issued"&gt;25,000&lt;/span&gt; shares of Series B into &lt;span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zlLsZqLS1tRe" title="Debt conversion, converted instrument, shares issued"&gt;25,000&lt;/span&gt; shares of Common Stock. The number of shares of Series B remaining
outstanding after this conversion was &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLoD9gwPh8vg" title="Conversion of stock shares"&gt;1,518,158&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 4, 2023, Auctus converted &lt;span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zFD1ODMs5Buk" title="Number of shares converted"&gt;120,000&lt;/span&gt; shares of Series B into &lt;span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUB0LKFisLvh" title="Number of shares issued in conversion"&gt;120,000&lt;/span&gt; shares of Common Stock. As of December 31, 2024, the number of
shares of Series B remaining outstanding after giving effect to such conversion was &lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zveV0mvbGEcl" title="Preferred stock, shares outstanding"&gt;1,398,158&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2021
Stock Incentive Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2021, the Company&#x2019;s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &#x201c;2021
Plan&#x201d;). The 2021 Plan was approved by the Company&#x2019;s stockholders on August 17, 2021. Pursuant to the 2021 Plan, a total of
&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210318__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember_zQB2Po9BLkKg" title="Number of shares of common stock authorized"&gt;1,175,000&lt;/span&gt; shares of common stock were initially authorized to be issued pursuant to the grant of stock options, restricted stock units,
restricted stock, stock appreciation rights and other incentive awards. On December 10, 2021, the Company&#x2019;s Board of Directors
approved an amendment to increase the number of shares of Common Stock authorized to be issued from &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zVPMbYgrWnQ2" title="Common stock shares authorized"&gt;1,175,000&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zncC5eiUPWt1" title="Common stock shares authorized"&gt;2,500,000&lt;/span&gt;. Such amendment
was approved by the Company&#x2019;s stockholders on November 3, 2022. On July 13, 2023, the Company&#x2019;s Board of Directors approved
an amendment to the 2021 Plan to increase the number of shares of Common Stock authorized to be issued from &lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zo1X1po4yASk" title="Common stock shares authorized"&gt;2,500,000&lt;/span&gt; to &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zVCTDa6pQi4" title="Common stock shares authorized"&gt;3,850,000&lt;/span&gt;. Such
amendment was approved by the Company&#x2019;s stockholders on September 13, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 23, 2024, the Company&#x2019;s Board of Directors approved an amendment to the Company&#x2019;s 2021 Plan to increase the number of
shares of common stock authorized to be issued under the 2021 Plan from &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240722__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zVT1EXT7QkA9" title="Common stock authorized to issue"&gt;3,850,000&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240723__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_z0fNr8c0ddHb" title="Common stock authorized to issue"&gt;6,850,000&lt;/span&gt;. Such amendment was approved by the Company&#x2019;s
stockholders on September 19, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Compensatory
Common Stock Issuance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231_ztpy3rsk930e" title="Vested common stock, shares"&gt;1,442&lt;/span&gt; shares of immediately vested common stock with a value of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231_zKuKeGD0i2fd" title="Aggregate common stock services rendered"&gt;7,500&lt;/span&gt; to a consultant
for services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sales
of Common Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2023, the Company entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (&#x201c;JonesTrading&#x201d;)
under which the Company had the ability to issue and sell shares of its Common Stock, from time to time, through JonesTrading, up to
an aggregate offering price of approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--DemandSalesAgreementMember_z2vE6NAiKWPj"&gt;6,109,000&lt;/span&gt; in what is commonly referred to as an &#x201c;at-the-market&#x201d; (&#x201c;ATM&#x201d;)
program. During the year ended December 31, 2023, the Company sold &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zXplo7pD9iOk" title="Sold shares of common stock"&gt;132,827&lt;/span&gt; shares of its Common Stock at a weighted average price of
$&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zpEUTC3wNX2l" title="Weighted average price"&gt;4.68&lt;/span&gt; per share and raised $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zunGcHy30dsd"&gt;494,782&lt;/span&gt; in net proceeds under the JonesTrading ATM program. In November 2024, in connection with the ATM
program with Rodman &amp;amp; Renshaw LLC (&#x201c;Rodman&#x201d;) discussed below, the Company terminated the Capital on Demand Sales Agreement
with JonesTrading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 13, 2023, the Company sold an aggregate of 	&lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713_zGeXKDbsQOZf" title="Sale of aggregate shares"&gt;685,033&lt;/span&gt; shares of Common Stock to several institutional buyers and accredited investors
in a registered direct offering at an offering price of $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230713_zcVAT4OtM4yi" title="Offering price"&gt;3.03&lt;/span&gt; per share. The offering closed on July 13, 2023 with net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230712__20230713_zP7zaht68Fhf" title="Net proceeds offering price"&gt;1,853,990&lt;/span&gt;.
The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy
candidate, BRTX-100, pre-clinical research and development with respect to its metabolic ThermoStem Program and for general corporate
purposes and working capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the Company entered into an At The Market Offering Agreement with Rodman, under which the Company currently has the ability
to issue and sell shares of its Common Stock, from time to time, through Rodman, up to an aggregate offering price of approximately $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zH6H9vwuMDQa" title="Sold value of common stock"&gt;3,614,000&lt;/span&gt;
in an ATM program. See Note 10 - Subsequent Events &#x2013; Common Stock Sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
Exercise and Issuance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 6, 2024, the Company entered into agreements with certain holders of its existing warrants exercisable for an aggregate of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJLLRuKcXiXh" title="Warrants exercisable"&gt;3,351,580&lt;/span&gt;
shares of its Common Stock (collectively, the &#x201c;Existing Warrants&#x201d;), to exercise their warrants at a reduced exercise price
of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWIprX6rqLng" title="Exercise price"&gt;2.33&lt;/span&gt; per share, in exchange for the issuance of new warrants (the &#x201c;New Warrants&#x201d;) as described below (the &#x201c;Warrant
Exercise and Issuance&#x201d;). The aggregate gross proceeds from the exercise of the Existing Warrants and the payment of the New Warrants,
as described below, was approximately $&lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLxbdAHUuGN7" title="Proceeds from exercise of warrants"&gt;8.1&lt;/span&gt; million, before deducting cash issuance costs in the amount of $&lt;span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAFNeSFqflDl" title="Cash issuance costs"&gt;595,364&lt;/span&gt;. The reduction of
the exercise price of the Existing Warrants and the issuance of the New Warrants was structured as an at-market transaction under Nasdaq
rules. Of the &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzsKaWfvjyT2" title="Warrants exercisable"&gt;3,351,580&lt;/span&gt; shares of Common Stock issuable upon the exercise of the Existing Warrants, through December 31, 2024, the Company
had issued an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z68Q6vqjUh11" title="Warrants exercisable"&gt;2,150,000&lt;/span&gt; shares of Common Stock. The remaining &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zvVWO1PSwBY4" title="Warrants exercisable"&gt;1,201,580&lt;/span&gt; shares of Common Stock, which are issuable to Auctus
Fund, LLC (&#x201c;Auctus&#x201d;), are being held in abeyance due to Auctus&#x2019; maximum beneficial ownership limitation (the &#x201c;Abeyance
Shares&#x201d;). Such Abeyance Shares have been fully paid for and are issuable upon notice from Auctus to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for the immediate exercise of the Existing Warrants for cash and the payment of $&lt;span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zBxG29Eh8Uv" title="Warrants for cash and the payment"&gt;0.125&lt;/span&gt; per share underlying the New Warrants,
the exercising holders received the New Warrants to purchase shares of Common Stock in a private placement pursuant to Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The New Warrants will be exercisable for a period of five
years into an aggregate of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNlyN1DFbIFj" title="Warrants exercisable"&gt;2,513,686&lt;/span&gt; shares of Common Stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRsdklXiIqW9" title="Exercise price"&gt;2.43&lt;/span&gt; per share. The securities offered in the private
placement have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company agreed to file
a resale registration statement with the SEC to register the resale of the shares of Common Stock underlying the New Warrants issued
in the private placement. Such resale registration statement was filed and was declared effective by the SEC on April 18, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5,
2024, with Roth Capital Partners, LLC (&#x201c;Roth&#x201d;), pursuant to which the Company has paid Roth a cash fee of approximately $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240205__20240205__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zzl7n2lB0Vtl" title="Cash fee for services"&gt;528,000&lt;/span&gt;
for its services, in addition to reimbursement for certain expense. During the year ended December 31, 2024, the Company incurred an
aggregate of $&lt;span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zT0D139u7t1a" title="Issuance costs"&gt;595,364&lt;/span&gt; of cash issuance costs related to the Warrant Exercise and Issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the Warrant Exercise and Issuance, the Existing Warrants were classified as derivative liabilities. Additionally, the Company analyzed
the form of the New Warrants and determined that they should be classified as derivative liabilities in accordance with ASC 815-40, Derivatives
and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity. Under the New Warrants, the Company does not control the occurrence of events,
such as a tender offer or exchange, that may trigger cash settlement of the New Warrants and not result in a change of control of the
Company. As a result, such New Warrants do not meet the criteria for equity treatment. Additionally, certain New Warrants contain adjustments
to the settlement amount based on a variable that is not an input to the fair value of a &#x201c;fixed-for-fixed&#x201d; option as defined
under ASC 815-40 and, accordingly, such New Warrants are not considered indexed to the Company&#x2019;s own stock and are not eligible
for an exception from derivative accounting. See Note 9&#x2013; Fair Value Measurement for details regarding the valuation of the Existing
Warrants and New Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined the Warrant Exercise and Issuance to be an exchange by investors of Existing Warrants with an aggregate fair value
of $&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zwsYJKgpvCMb" title="Fair value of adjustment"&gt;1,115,334&lt;/span&gt; along with aggregate cash consideration of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zfFm1YZsZXZc" title="Proceeds from issuance of warrants"&gt;8,123,392&lt;/span&gt; (consisting of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zCSVqe8YkOf2" title="Proceeds from issuance of warrants"&gt;7,809,181&lt;/span&gt; paid to exercise the Existing Warrants
and $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zbHEcEn03OHl" title="Proceeds from issuance of warrants"&gt;314,211&lt;/span&gt; paid for the New Warrants) for an aggregate of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zF7lId3Nr2Q7" title="Stock issued during period shares new issues"&gt;3,351,580&lt;/span&gt; shares of common stock with an aggregate fair value of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zefA77ZQfLn9" title="Stock issued during period value new issues"&gt;4,742,244&lt;/span&gt;,
New Warrants with an aggregate fair value of $&lt;span id="xdx_909_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zk6OWlB7V2rb" title="Stock issued during period value warrants"&gt;2,189,420&lt;/span&gt; and aggregate cash issuance costs of $&lt;span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zWjJHU1kOYy9" title="Issuance costs"&gt;595,364&lt;/span&gt; and, accordingly, the Company recorded
a gain on exchange of warrants of $&lt;span id="xdx_907_ecustom--GainLossOnExchangeOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zoVcOH6TDVVd" title="Gain on exchange of warrants"&gt;1,711,698&lt;/span&gt; during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
Activity Summary&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zSZin8yUZKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the warrant activity during the year ended December 31, 2024 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zGJJPKtZyAE5" style="display: none"&gt;SCHEDULE OF WARRANT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Outstanding, January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znAqvvT4Qbx9" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding Beginning"&gt;4,791,019&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z87TDq6moIv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price,  Outstanding beginning balance"&gt;10.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdjrTKuhx9z6" style="text-align: right" title="Number of Warrants, Granted"&gt;2,513,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjdzOfyxLbwc" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzgG1cCZ4vr1" style="text-align: right" title="Number of Warrants, Exercised"&gt;(3,351,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zki4H944FIMe" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;2.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOsoduSVUaRk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired"&gt;(1,491&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrBkx7PzwuQk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;1,770&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfvfXo0Eesnl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding Ending"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsOAZv5WGZd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding ending balance"&gt;5.22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZ3LPAMieATi" title="Weighted Average Remaining Life In Years, Outstanding"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSXFmGrNy028" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable Ending"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlHDUWyygGWc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;5.22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4jobdqNbrP3" title="Weighted Average Remaining Life In Years, Exercisable"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zXSUQ9QnVqc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average estimated fair value of the warrants granted during the year ended December 31, 2024 was $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDO6RUoak3l1" title="Weighted average estimated fair value of warrants granted"&gt;0.87 &lt;/span&gt;per warrant. See Note
9 &#x2013; Fair Value Measurement &#x2013; for details regarding the fair value estimates of the Warrants that are classified as derivative
liabilities. The Company did not issue any warrants during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zpOFtra6fg6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock warrants at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zJhgTLHPR6Ie" style="display: none"&gt;SCHEDULE
OF STOCK WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBIP5ZD4QC56" style="width: 22%; text-align: right" title="Warrants outstanding, exercise price"&gt;2.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl2Jku2lXkle" style="width: 22%; text-align: right" title="Warrants outstanding, number of warrants"&gt;2,513,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zU6Nhvq6d4e2" title="Warrants exercisable, weighted average remaining life in years"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zC60jbXs1afd" style="width: 21%; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;2,513,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z17wx76SisWa" style="text-align: right" title="Warrants outstanding, exercise price"&gt;2.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUseg3QpPL84" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyTCTVYqM8Mh" title="Warrants exercisable, weighted average remaining life in years"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zwoRloxfJKD9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuBvZFdF9pE2" style="text-align: right" title="Warrants outstanding, exercise price"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWunI15vUYcb" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;1,150,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOE3aHbPJii4" title="Warrants exercisable, weighted average remaining life in years"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCyYxBCsyVJe" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;1,150,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zroKiGu0kyKh" style="text-align: right" title="Warrants outstanding, exercise price"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvBqal267Qf4" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zsRzI4SStm05" title="Warrants exercisable, weighted average remaining life in years"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zjlWnxsI3Tue" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcUo7cIEyFd6" style="padding-bottom: 1pt; text-align: right" title="Warrants outstanding, exercise price"&gt;60.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4H9FGqoOWtj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, number of warrants"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlijR7PFbo2l" title="Warrants exercisable, weighted average remaining life in years"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJksqF3ibGo6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zMTGD0WHNxH" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, number of warrants"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zfJ2T3TGfPA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_za7feX7DXOtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfNfCP9eNvD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the option activity during the year ended December 31, 2024 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zrN9b2GV9bbk" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding, January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTvM4oSXln82" style="width: 12%; text-align: right" title="Number of Options, Outstanding beginning"&gt;1,466,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zoDROm8SpfK" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning"&gt;4.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z1Abs0lPnAC2" style="text-align: right" title="Number of Options, Granted"&gt;1,934,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zf56QyHtDan2" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zBqFaBP2hRrg" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2097"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zQdf2naQfNwc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(138,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zPDXmZhZIG01" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;1.76&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zcyRTNE1DYVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding ending"&gt;3,263,467&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z6AUvmyFe4hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending"&gt;2.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zTVIyvLVQU9e" title="Weighted Average Remaining Life in Years Outstanding Ending"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_z0jhmSrRb99" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z6OaUmtzPBzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable Ending"&gt;2,499,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zLxmZKqE199h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending"&gt;2.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zv88ELOpOHR9" title="Weighted Average Remaining Life in Years Exercisable Ending"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231_z0nAmGqFN17c" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2117"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zoAlkje3gnuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average grant date fair value of the stock options granted during the years ended December 31, 2024 and 2023 was $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zHbmqifX8bie" title="Weighted average grant date fair value of stock options granted"&gt;1.45&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zRFePEuvUmbe" title="Weighted average grant date fair value of stock options granted"&gt;3.00&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRtaMfXkznRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock options at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_ztcIUlTEysz5" style="display: none"&gt;SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeGpMtvcx146" style="width: 22%; text-align: right" title="Options Outstanding, Exercise Price"&gt;1.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFR9VoHQVghd" style="width: 22%; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;1,825,067&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBesCUmhfgB8" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOElztZCIEXk" style="width: 21%; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;1,138,579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zlN1nxbD5Qm7" style="text-align: right" title="Options Outstanding, Exercise Price"&gt;2.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z5su5TfUL9I1" style="text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;626,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmxifRgIyVvh" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrvHndT1tcGc" style="text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;548,368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGAMtsYhR5eh" style="padding-bottom: 1pt; text-align: right" title="Options Outstanding, Exercise Price"&gt;5.08&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoR8Y98253Y8" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;812,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1xz1zj7zjja" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIZKhcRWSsw5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;812,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231_zbocWCIXa5Vc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;3,263,467&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_ziXBWM6T6LZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;2,499,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zrKbEgsvNC01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzhvGPbrfrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zZxbFDb2dxqf" style="display: none"&gt;SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zGOcrqNV9u6b" title="Risk free interest rate"&gt;4.14&lt;/span&gt; -&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zlS2vh9EUFd4" title="Risk free interest rate"&gt; 4.30&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoHTrUNaM9yc" title="Risk free interest rate"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z1KylLmbD0Dj" title="Expected term (years)"&gt;2.77&lt;/span&gt; - &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zar0bL5bcuah" title="Expected term (years)"&gt;5.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx5RjK2kIGab" title="Expected term (years)"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zWWPgchvXA8e" title="Expected volatility"&gt;101&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_znbbAp1dPtUe" title="Expected volatility"&gt;102&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEkATAdzvs76" title="Expected volatility"&gt;175.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zauNMGbqKima" style="text-align: right" title="Expected dividends"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0OQS4xjFub7" style="text-align: right" title="Expected dividends"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zjeFEbC9TUoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the 2021 Plan, the Company may grant restricted stock units (&#x201c;RSUs&#x201d;) to employees, consultants or non-employee directors
(&#x201c;Eligible Recipients&#x201d;). The number, terms and conditions of the RSUs that are granted to Eligible Recipients are determined
on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Recipient one
unrestricted, fully transferable share of the Company&#x2019;s common stock (or the fair market value of one such share in cash) for each
vested and nonforfeitable RSU.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zbjCRCDfsw47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the unvested RSUs as of December 31, 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z7qX6TjqzmYg" style="display: none"&gt;SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;Non-vested at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z54caD9t4qNf" style="width: 22%; text-align: right" title="Number of shares outstanding beginning"&gt;97,827&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7rNzZRrwG7c" style="text-align: right" title="Number of shares granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2181"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6DHLnyY2Zc" style="text-align: right" title="Number of shares forfeited"&gt;(97,827&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVJwCiRoFDV8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2185"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-vested at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z984AZuQj4Zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zHAVwHeWUTFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-Based
Compensation Expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zKMX8JsmytWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock-based compensation expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zNmDZQdJkQIj" style="display: none"&gt;SCHEDULE OF STOCK OPTION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;Unrecognized at December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;Weighted Average Remaining
    Amortization Period&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8mg1PWdtnvh" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense"&gt;2,812,566&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0lPbAx67Oo4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense"&gt;7,782,967&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAfZqmoXHmha" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Unrecognized expense"&gt;774,470&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbb2sY1Dla3" title="Weighted average remaining amortization period (years)"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231_zbrAVj7QZ22e" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense"&gt;2,812,566&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231_zf5gaaCKHH4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense"&gt;7,782,967&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231_zZzUIJJBw2k1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense"&gt;774,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zOzUVTj3znM8" title="Weighted average remaining amortization period (years)"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zFWRUvqoB1Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001899"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001901"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001903"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001905"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001907"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockVotingRights
      contextRef="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember"
      id="Fact001909">9.99</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockVotingRights
      contextRef="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember"
      id="Fact001911">4.99</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001913"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      id="Fact001915">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock;</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001917"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember"
      decimals="INF"
      id="Fact001919"
      unitRef="Pure">0.095</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember"
      decimals="INF"
      id="Fact001921"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember"
      decimals="INF"
      id="Fact001923"
      unitRef="Shares">25000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact001925"
      unitRef="Shares">25000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact001927"
      unitRef="Shares">1518158</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001929"
      unitRef="Shares">120000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001931"
      unitRef="Shares">120000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001933"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember"
      decimals="INF"
      id="Fact001935"
      unitRef="Shares">1175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001937"
      unitRef="Shares">1175000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001939"
      unitRef="Shares">2500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001941"
      unitRef="Shares">2500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001943"
      unitRef="Shares">3850000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-07-22_custom_TwoThousandAndTwentyOneStockIncentivePlanMember"
      decimals="INF"
      id="Fact001945"
      unitRef="Shares">3850000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-07-23_custom_TwoThousandAndTwentyOneStockIncentivePlanMember"
      decimals="INF"
      id="Fact001947"
      unitRef="Shares">6850000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001949"
      unitRef="Shares">1442</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001951"
      unitRef="USD">7500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_DemandSalesAgreementMember"
      decimals="0"
      id="Fact001952"
      unitRef="USD">6109000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember"
      decimals="INF"
      id="Fact001954"
      unitRef="Shares">132827</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember"
      decimals="INF"
      id="Fact001956"
      unitRef="USDPShares">4.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember"
      decimals="0"
      id="Fact001957"
      unitRef="USD">494782</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-122023-07-13"
      decimals="INF"
      id="Fact001959"
      unitRef="Shares">685033</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-07-13"
      decimals="INF"
      id="Fact001961"
      unitRef="USDPShares">3.03</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-07-122023-07-13"
      decimals="0"
      id="Fact001963"
      unitRef="USD">1853990</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_ATMProgramMember"
      decimals="0"
      id="Fact001965"
      unitRef="USD">3614000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001967"
      unitRef="Shares">3351580</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001969"
      unitRef="USDPShares">2.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001971"
      unitRef="USD">8100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001973"
      unitRef="USD">595364</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001975"
      unitRef="Shares">3351580</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001977"
      unitRef="Shares">2150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember_custom_AuctusFundLLCMember"
      decimals="INF"
      id="Fact001979"
      unitRef="Shares">1201580</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001981"
      unitRef="USDPShares">0.125</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001983"
      unitRef="Shares">2513686</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001985"
      unitRef="USDPShares">2.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-02-052024-02-05_us-gaap_CommonStockMember_custom_RothCapitalPartnersLLCMember"
      decimals="0"
      id="Fact001987"
      unitRef="USD">528000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember"
      decimals="0"
      id="Fact001989"
      unitRef="USD">595364</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember"
      decimals="0"
      id="Fact001991"
      unitRef="USD">1115334</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember"
      decimals="0"
      id="Fact001993"
      unitRef="USD">8123392</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31_custom_ExistingWarrantMember"
      decimals="0"
      id="Fact001995"
      unitRef="USD">7809181</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember"
      decimals="0"
      id="Fact001997"
      unitRef="USD">314211</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember"
      decimals="INF"
      id="Fact001999"
      unitRef="Shares">3351580</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember"
      decimals="0"
      id="Fact002001"
      unitRef="USD">4742244</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact002003"
      unitRef="USD">2189420</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact002005"
      unitRef="USD">595364</us-gaap:PaymentsOfDebtIssuanceCosts>
    <BRTX:GainLossOnExchangeOfWarrants
      contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact002007"
      unitRef="USD">1711698</BRTX:GainLossOnExchangeOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-012024-12-31" id="Fact002009">&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zSZin8yUZKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the warrant activity during the year ended December 31, 2024 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zGJJPKtZyAE5" style="display: none"&gt;SCHEDULE OF WARRANT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Outstanding, January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znAqvvT4Qbx9" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding Beginning"&gt;4,791,019&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z87TDq6moIv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price,  Outstanding beginning balance"&gt;10.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdjrTKuhx9z6" style="text-align: right" title="Number of Warrants, Granted"&gt;2,513,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjdzOfyxLbwc" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzgG1cCZ4vr1" style="text-align: right" title="Number of Warrants, Exercised"&gt;(3,351,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zki4H944FIMe" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;2.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOsoduSVUaRk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired"&gt;(1,491&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrBkx7PzwuQk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;1,770&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfvfXo0Eesnl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding Ending"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsOAZv5WGZd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding ending balance"&gt;5.22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZ3LPAMieATi" title="Weighted Average Remaining Life In Years, Outstanding"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSXFmGrNy028" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable Ending"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlHDUWyygGWc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;5.22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4jobdqNbrP3" title="Weighted Average Remaining Life In Years, Exercisable"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002011"
      unitRef="Shares">4791019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002013"
      unitRef="USDPShares">10.57</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640"
      decimals="0"
      id="Fact002015"
      unitRef="Shares">2513686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640"
      decimals="INF"
      id="Fact002017"
      unitRef="USDPShares">2.43</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640"
      decimals="INF"
      id="Fact002019"
      unitRef="Shares">3351580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640"
      decimals="INF"
      id="Fact002021"
      unitRef="USDPShares">2.33</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640"
      decimals="INF"
      id="Fact002023"
      unitRef="Shares">1491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640"
      decimals="INF"
      id="Fact002025"
      unitRef="USDPShares">1770</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002027"
      unitRef="Shares">3951634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002029"
      unitRef="USDPShares">5.22</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640"
      id="Fact002031">P3Y3M18D</BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002033"
      unitRef="Shares">3951634</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002035"
      unitRef="USDPShares">5.22</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509640"
      id="Fact002037">P3Y3M18D</BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember20509234"
      decimals="INF"
      id="Fact002039"
      unitRef="USDPShares">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002041">&lt;p id="xdx_899_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zpOFtra6fg6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock warrants at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zJhgTLHPR6Ie" style="display: none"&gt;SCHEDULE
OF STOCK WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBIP5ZD4QC56" style="width: 22%; text-align: right" title="Warrants outstanding, exercise price"&gt;2.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl2Jku2lXkle" style="width: 22%; text-align: right" title="Warrants outstanding, number of warrants"&gt;2,513,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zU6Nhvq6d4e2" title="Warrants exercisable, weighted average remaining life in years"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zC60jbXs1afd" style="width: 21%; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;2,513,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z17wx76SisWa" style="text-align: right" title="Warrants outstanding, exercise price"&gt;2.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUseg3QpPL84" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyTCTVYqM8Mh" title="Warrants exercisable, weighted average remaining life in years"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zwoRloxfJKD9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuBvZFdF9pE2" style="text-align: right" title="Warrants outstanding, exercise price"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWunI15vUYcb" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;1,150,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOE3aHbPJii4" title="Warrants exercisable, weighted average remaining life in years"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCyYxBCsyVJe" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;1,150,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zroKiGu0kyKh" style="text-align: right" title="Warrants outstanding, exercise price"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvBqal267Qf4" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zsRzI4SStm05" title="Warrants exercisable, weighted average remaining life in years"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zjlWnxsI3Tue" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcUo7cIEyFd6" style="padding-bottom: 1pt; text-align: right" title="Warrants outstanding, exercise price"&gt;60.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4H9FGqoOWtj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, number of warrants"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlijR7PFbo2l" title="Warrants exercisable, weighted average remaining life in years"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJksqF3ibGo6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zMTGD0WHNxH" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, number of warrants"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zfJ2T3TGfPA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact002043"
      unitRef="USDPShares">2.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact002045"
      unitRef="Shares">2513686</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      id="Fact002047">P4Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact002049"
      unitRef="Shares">2513686</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact002051"
      unitRef="USDPShares">2.92</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact002053"
      unitRef="Shares">51370</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      id="Fact002055">P2Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact002057"
      unitRef="Shares">51370</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact002059"
      unitRef="USDPShares">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact002061"
      unitRef="Shares">1150358</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      id="Fact002063">P1Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact002065"
      unitRef="Shares">1150358</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact002067"
      unitRef="USDPShares">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact002069"
      unitRef="Shares">235970</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      id="Fact002071">P1Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact002073"
      unitRef="Shares">235970</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact002075"
      unitRef="USDPShares">60.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact002077"
      unitRef="Shares">250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      id="Fact002079">P0Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact002081"
      unitRef="Shares">250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002083"
      unitRef="Shares">3951634</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002085"
      unitRef="Shares">3951634</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002087">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfNfCP9eNvD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the option activity during the year ended December 31, 2024 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zrN9b2GV9bbk" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding, January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTvM4oSXln82" style="width: 12%; text-align: right" title="Number of Options, Outstanding beginning"&gt;1,466,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zoDROm8SpfK" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning"&gt;4.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z1Abs0lPnAC2" style="text-align: right" title="Number of Options, Granted"&gt;1,934,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zf56QyHtDan2" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zBqFaBP2hRrg" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2097"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zQdf2naQfNwc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(138,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zPDXmZhZIG01" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;1.76&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zcyRTNE1DYVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding ending"&gt;3,263,467&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z6AUvmyFe4hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending"&gt;2.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zTVIyvLVQU9e" title="Weighted Average Remaining Life in Years Outstanding Ending"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_z0jhmSrRb99" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z6OaUmtzPBzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable Ending"&gt;2,499,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zLxmZKqE199h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending"&gt;2.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zv88ELOpOHR9" title="Weighted Average Remaining Life in Years Exercisable Ending"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231_z0nAmGqFN17c" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2117"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact002089"
      unitRef="Shares">1466892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact002091"
      unitRef="USDPShares">4.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002093"
      unitRef="Shares">1934716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002095"
      unitRef="USDPShares">1.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002099"
      unitRef="Shares">138141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002101"
      unitRef="USDPShares">1.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002103"
      unitRef="Shares">3263467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002105"
      unitRef="USDPShares">2.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-012024-12-31" id="Fact002107">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002111"
      unitRef="Shares">2499132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002113"
      unitRef="USDPShares">2.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-012024-12-31" id="Fact002115">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002119"
      unitRef="USDPShares">1.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002121"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2024-01-012024-12-31" id="Fact002123">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRtaMfXkznRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock options at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_ztcIUlTEysz5" style="display: none"&gt;SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeGpMtvcx146" style="width: 22%; text-align: right" title="Options Outstanding, Exercise Price"&gt;1.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFR9VoHQVghd" style="width: 22%; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;1,825,067&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBesCUmhfgB8" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOElztZCIEXk" style="width: 21%; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;1,138,579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zlN1nxbD5Qm7" style="text-align: right" title="Options Outstanding, Exercise Price"&gt;2.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z5su5TfUL9I1" style="text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;626,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmxifRgIyVvh" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrvHndT1tcGc" style="text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;548,368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGAMtsYhR5eh" style="padding-bottom: 1pt; text-align: right" title="Options Outstanding, Exercise Price"&gt;5.08&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoR8Y98253Y8" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;812,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1xz1zj7zjja" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIZKhcRWSsw5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;812,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231_zbocWCIXa5Vc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;3,263,467&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_ziXBWM6T6LZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;2,499,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact002125"
      unitRef="USDPShares">1.45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact002127"
      unitRef="Shares">1825067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeOneMember"
      id="Fact002129">P8Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact002131"
      unitRef="Shares">1138579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact002133"
      unitRef="USDPShares">2.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact002135"
      unitRef="Shares">626215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeTwoMember"
      id="Fact002137">P6Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact002139"
      unitRef="Shares">548368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact002141"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact002143"
      unitRef="Shares">812185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeThreeMember"
      id="Fact002145">P5Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact002147"
      unitRef="Shares">812185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002149"
      unitRef="Shares">3263467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002151"
      unitRef="Shares">2499132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002153">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzhvGPbrfrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zZxbFDb2dxqf" style="display: none"&gt;SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zGOcrqNV9u6b" title="Risk free interest rate"&gt;4.14&lt;/span&gt; -&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zlS2vh9EUFd4" title="Risk free interest rate"&gt; 4.30&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoHTrUNaM9yc" title="Risk free interest rate"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z1KylLmbD0Dj" title="Expected term (years)"&gt;2.77&lt;/span&gt; - &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zar0bL5bcuah" title="Expected term (years)"&gt;5.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx5RjK2kIGab" title="Expected term (years)"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zWWPgchvXA8e" title="Expected volatility"&gt;101&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_znbbAp1dPtUe" title="Expected volatility"&gt;102&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEkATAdzvs76" title="Expected volatility"&gt;175.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zauNMGbqKima" style="text-align: right" title="Expected dividends"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0OQS4xjFub7" style="text-align: right" title="Expected dividends"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002155"
      unitRef="Pure">0.0414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002157"
      unitRef="Pure">0.0430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact002159"
      unitRef="Pure">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember"
      id="Fact002161">P2Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember"
      id="Fact002163">P5Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      id="Fact002165">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002167"
      unitRef="Pure">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002169"
      unitRef="Pure">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact002171"
      unitRef="Pure">1.7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact002173"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact002175"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002177">&lt;p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zbjCRCDfsw47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the unvested RSUs as of December 31, 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z7qX6TjqzmYg" style="display: none"&gt;SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;Non-vested at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z54caD9t4qNf" style="width: 22%; text-align: right" title="Number of shares outstanding beginning"&gt;97,827&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7rNzZRrwG7c" style="text-align: right" title="Number of shares granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2181"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6DHLnyY2Zc" style="text-align: right" title="Number of shares forfeited"&gt;(97,827&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVJwCiRoFDV8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2185"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-vested at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z984AZuQj4Zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002179"
      unitRef="Shares">97827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20515187"
      decimals="INF"
      id="Fact002183"
      unitRef="Shares">97827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002189">&lt;p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zKMX8JsmytWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock-based compensation expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zNmDZQdJkQIj" style="display: none"&gt;SCHEDULE OF STOCK OPTION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;Unrecognized at December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;Weighted Average Remaining
    Amortization Period&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8mg1PWdtnvh" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense"&gt;2,812,566&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0lPbAx67Oo4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense"&gt;7,782,967&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAfZqmoXHmha" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Unrecognized expense"&gt;774,470&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbb2sY1Dla3" title="Weighted average remaining amortization period (years)"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231_zbrAVj7QZ22e" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense"&gt;2,812,566&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231_zf5gaaCKHH4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense"&gt;7,782,967&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231_zZzUIJJBw2k1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense"&gt;774,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zOzUVTj3znM8" title="Weighted average remaining amortization period (years)"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact002191"
      unitRef="USD">2812566</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact002193"
      unitRef="USD">7782967</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact002195"
      unitRef="USD">774470</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      id="Fact002197">P0Y11M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002199"
      unitRef="USD">2812566</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002201"
      unitRef="USD">7782967</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002203"
      unitRef="USD">774470</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2024-01-012024-12-31" id="Fact002205">P0Y11M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact002207">&lt;p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zVozmWE0SJyc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
7 - &lt;span id="xdx_826_zR22wSIZcwLf"&gt;INCOME TAXES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company identified its federal and New York tax returns as its &#x201c;major&#x201d; tax jurisdictions. The Company is no longer subject
to income tax income examinations by these tax authorities for taxable years ended December 31, 2020, and prior. The Company reviewed
the prior New York state income tax filings and concluded that the prior year return will be amended to change the apportionment from
zero to &lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20240101__20241231_zUkrmcjJv7h4" title="Prior year income taxes, percentage"&gt;100&lt;/span&gt;%. The Company believes its income tax filing positions and deductions will be sustained on audit, and it does not anticipate
any adjustments that would result in a material change to its financial position. Therefore, no liabilities for uncertain tax positions
have been recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, the Company had approximately $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zePnVp7cedXh" title="Operating loss carry forwards"&gt;68,200,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zRa5IkvBOzVf" title="Operating loss carry forwards"&gt;51,800,000&lt;/span&gt;, respectively, of federal and state net operating losses
that may be available to offset future taxable income. As a result of the Tax Cuts and Jobs Act of 2017 (the &#x201c;Tax Act&#x201d;),
certain future carryforwards do not expire. At December 31, 2024, approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_c20241231__srt--StatementScenarioAxis__custom--ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_zDqomiSyERfd" title="Operating loss carry-forwards subject to expiration"&gt;7,800,000&lt;/span&gt; of federal net operating losses will expire
from 2030 to 2038 and approximately $&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_c20241231_zXc6BzRqcNMd" title="Operating loss carry-forwards not subject to expiration"&gt;60,400,000&lt;/span&gt; have no expiration but are subject to a utilization limit equal to 80% of current taxable
income. &lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_z84EZ3UauGO9" title="Net operating loss description"&gt;The state net operating losses have a 20 year carryforward period and will begin to expire beginning 2035.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zywpKWkgXOba" title="Income tax examination, description"&gt;In
accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#x2019;s net operating loss carryforwards are subject
to annual limitations due to several greater than 50% ownership changes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not performed a formal analysis for the year ended December 31, 2024, but it believes its ability to use such net operating
losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections
382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit
use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred
over the three-year period ended December 31, 2024. For the period ended December 31, 2024, the Company has recorded a full valuation
allowance against the gross deferred tax asset balance as management believes that it is more likely than not that the results of operations
will not generate sufficient taxable income to realize any of the deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of this filing, the Company has not filed its 2024 federal and state corporate income tax returns. The Company expects to
file these documents as soon as practicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOmgaPOBaQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zZUwWPmupGV3" style="display: none"&gt;SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zL9QFC7L3Yig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zhbF1s19zvl7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zEjIVolmYEU6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzcBK_zW8G8vTtyQJk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;18,004,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;14,311,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGzcBK_zFIFQbADeNHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,695,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,788,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTAGzcBK_zdxqp5f1BD88" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,694,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,676,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGzcBK_zOXQBzh1v0Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsRightOfUseAsset_i01I_maDTAGzcBK_zZJt7OwUWjwa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2240"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcBK_zwScf9aTi8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;600&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGzcBK_maDTALNz6jW_zRxljnsv5rrj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total Deferred Tax Assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;29,724,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;32,134,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zlws6xNcz8z3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxLiabilitiesDepreciation_i01NI_pp0p0_di_maDITLz8iB_zvhfLWJlS6a1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(153,200&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_maDITLz8iB_zMvdEk1EX2Mf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41,700&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_i01NI_pp0p0_di_maDITLz8iB_z5JN7o7R2Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2258"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLz8iB_z626f9pOcRZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(95,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(86,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pp0p0_di_mtDITLz8iB_msDTALNz6jW_z5ov3kRZfdYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total Deferred Tax Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(289,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(294,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNz6jW_zDuuMmzJjzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net Deferred Tax Asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,434,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,840,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8Hs2v6wALU5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,434,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(31,840,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_z8GkK0NwV2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred Tax Asset, Net of Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2273"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2274"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20240101__20241231_zmS2WbGfj5n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;2,405,900&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20230101__20231231_zc9ckzJO7A9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;(4,064,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zgRHuIkbL9D3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zltwcQOflIb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision (benefit) as of December 31, 2024 and 2023 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zewWuR64PcD5" style="display: none"&gt;SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zRwhUVQspGih" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zxkSMrPCvzR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlI2aJg7XIZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maDFSALzNuk_zO5ShPfW6jN4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2285"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2286"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zk51qR840bie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 64%"&gt;Deferred&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,567,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(3,090,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zTDgkAmF6Uzj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;State &amp;amp; Local:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maDFSALzNuk_z2FcUaberu53" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2294"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2295"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zRDQK8KB7bX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Deferred&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,161,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(974,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBz5Bf_mtDFSALzNuk_zPjhdL5jZTtd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,405,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,064,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ChangeInValuationAllowance_i01N_di_msITEBz5Bf_zhzlgQSBeSpj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,405,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,064,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz5Bf_zTflNXI3Iww2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2306"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2307"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zE62j2LkqvZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbnotrZxBuda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zkPZz0PDfa4f" style="display: none"&gt;SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zIN1SWuTCKCd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zYoEk77mdqyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR_zoD8GqfTv0Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR_zBasGeNwUdq5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax, net of valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR_ztCkHqhYvo49" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_maETR_zeaqqe9LYYr1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax return to provision adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR_zu0T4TNCIfFa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in federal valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;39.7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-29.7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_pid_dp_uPure_maETR_z06HeVNrY5Z7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Adjustment for stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;-62.1&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2327"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR_z9fAJvH2U32l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zWRkjNmqbrWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002209"
      unitRef="Pure">1</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact002211"
      unitRef="USD">68200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact002213"
      unitRef="USD">51800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="AsOf2024-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember"
      decimals="0"
      id="Fact002215"
      unitRef="USD">7800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002217"
      unitRef="USD">60400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2024-01-012024-12-31" id="Fact002219">The state net operating losses have a 20 year carryforward period and will begin to expire beginning 2035.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:IncomeTaxExaminationDescription
      contextRef="From2024-01-012024-12-31_custom_SectionThreeHundredAndEightyTwoMember"
      id="Fact002221">In
accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#x2019;s net operating loss carryforwards are subject
to annual limitations due to several greater than 50% ownership changes.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002223">&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOmgaPOBaQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zZUwWPmupGV3" style="display: none"&gt;SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zL9QFC7L3Yig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zhbF1s19zvl7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zEjIVolmYEU6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzcBK_zW8G8vTtyQJk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;18,004,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;14,311,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGzcBK_zFIFQbADeNHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,695,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,788,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTAGzcBK_zdxqp5f1BD88" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,694,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,676,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGzcBK_zOXQBzh1v0Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsRightOfUseAsset_i01I_maDTAGzcBK_zZJt7OwUWjwa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2240"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcBK_zwScf9aTi8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;600&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGzcBK_maDTALNz6jW_zRxljnsv5rrj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total Deferred Tax Assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;29,724,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;32,134,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zlws6xNcz8z3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxLiabilitiesDepreciation_i01NI_pp0p0_di_maDITLz8iB_zvhfLWJlS6a1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(153,200&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_maDITLz8iB_zMvdEk1EX2Mf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41,700&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_i01NI_pp0p0_di_maDITLz8iB_z5JN7o7R2Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2258"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLz8iB_z626f9pOcRZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(95,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(86,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pp0p0_di_mtDITLz8iB_msDTALNz6jW_z5ov3kRZfdYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total Deferred Tax Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(289,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(294,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNz6jW_zDuuMmzJjzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net Deferred Tax Asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,434,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,840,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8Hs2v6wALU5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,434,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(31,840,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_z8GkK0NwV2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred Tax Asset, Net of Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2273"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2274"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20240101__20241231_zmS2WbGfj5n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;2,405,900&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20230101__20231231_zc9ckzJO7A9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;(4,064,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002228"
      unitRef="USD">18004100</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002229"
      unitRef="USD">14311000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002231"
      unitRef="USD">8695100</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002232"
      unitRef="USD">15788000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002234"
      unitRef="USD">2694200</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002235"
      unitRef="USD">1676000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002237"
      unitRef="USD">330000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002238"
      unitRef="USD">330000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <BRTX:DeferredTaxAssetsRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002241"
      unitRef="USD">25000</BRTX:DeferredTaxAssetsRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002243"
      unitRef="USD">600</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002244"
      unitRef="USD">4000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002246"
      unitRef="USD">29724000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002247"
      unitRef="USD">32134000</us-gaap:DeferredTaxAssetsGross>
    <BRTX:DeferredTaxLiabilitiesDepreciation
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002252"
      unitRef="USD">153200</BRTX:DeferredTaxLiabilitiesDepreciation>
    <BRTX:DeferredTaxLiabilitiesDepreciation
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002253"
      unitRef="USD">122000</BRTX:DeferredTaxLiabilitiesDepreciation>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002255"
      unitRef="USD">41700</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002256"
      unitRef="USD">47000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002259"
      unitRef="USD">39000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002261"
      unitRef="USD">95000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002262"
      unitRef="USD">86000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002264"
      unitRef="USD">289900</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002265"
      unitRef="USD">294000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002267"
      unitRef="USD">29434100</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002268"
      unitRef="USD">31840000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002270"
      unitRef="USD">29434100</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002271"
      unitRef="USD">31840000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002276"
      unitRef="USD">-2405900</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002278"
      unitRef="USD">4064000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002280">&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zltwcQOflIb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision (benefit) as of December 31, 2024 and 2023 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zewWuR64PcD5" style="display: none"&gt;SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zRwhUVQspGih" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zxkSMrPCvzR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlI2aJg7XIZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maDFSALzNuk_zO5ShPfW6jN4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2285"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2286"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zk51qR840bie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 64%"&gt;Deferred&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,567,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(3,090,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zTDgkAmF6Uzj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;State &amp;amp; Local:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maDFSALzNuk_z2FcUaberu53" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2294"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2295"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zRDQK8KB7bX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Deferred&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,161,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(974,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBz5Bf_mtDFSALzNuk_zPjhdL5jZTtd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,405,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,064,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ChangeInValuationAllowance_i01N_di_msITEBz5Bf_zhzlgQSBeSpj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,405,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,064,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz5Bf_zTflNXI3Iww2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2306"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2307"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002288"
      unitRef="USD">3567000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002289"
      unitRef="USD">-3090000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002297"
      unitRef="USD">-1161100</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002298"
      unitRef="USD">-974000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002300"
      unitRef="USD">2405900</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002301"
      unitRef="USD">-4064000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <BRTX:ChangeInValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002303"
      unitRef="USD">2405900</BRTX:ChangeInValuationAllowance>
    <BRTX:ChangeInValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002304"
      unitRef="USD">-4064000</BRTX:ChangeInValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002309">&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbnotrZxBuda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zkPZz0PDfa4f" style="display: none"&gt;SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zIN1SWuTCKCd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zYoEk77mdqyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR_zoD8GqfTv0Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR_zBasGeNwUdq5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax, net of valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR_ztCkHqhYvo49" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_maETR_zeaqqe9LYYr1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax return to provision adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR_zu0T4TNCIfFa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in federal valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;39.7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-29.7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_pid_dp_uPure_maETR_z06HeVNrY5Z7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Adjustment for stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;-62.1&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2327"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR_z9fAJvH2U32l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002311"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002312"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002314"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002315"
      unitRef="Pure">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002317"
      unitRef="Pure">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002318"
      unitRef="Pure">0.072</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002320"
      unitRef="Pure">0.004</BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment>
    <BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002321"
      unitRef="Pure">-0.002</BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002323"
      unitRef="Pure">0.397</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002324"
      unitRef="Pure">-0.297</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <BRTX:EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002326"
      unitRef="Pure">-0.621</BRTX:EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002329"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002330"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-012024-12-31" id="Fact002332">&lt;p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zgcg9trQLw4b" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
8 &#x2013; &lt;span id="xdx_82A_zZqO5mhrGS0j"&gt;LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a lease for &lt;span id="xdx_90B_eus-gaap--AreaOfLand_iI_usqft_c20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zh4cxmaJnd2j" title="Area of land"&gt;6,800&lt;/span&gt; square feet of space located in Melville, New York (the &#x201c;Melville Lease&#x201d;) with respect
to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zmpZ4l7IQSC6" title="Rent expense"&gt;132,600&lt;/span&gt; and
$&lt;span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zOjbIvPdVbN8" title="Rent expense"&gt;149,260&lt;/span&gt;. In June 2019, &lt;span id="xdx_908_eus-gaap--LessorOperatingLeaseOptionToExtend_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_z4SYxbAeZm8h" title="Lease extension description"&gt;the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zIdUhKaj4omk" title="Rent expense"&gt;153,748&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zAvMxkpiKrlg" title="Rent expense"&gt;173,060&lt;/span&gt;.&lt;/span&gt; The lease
expired on December 31, 2024 and the Company is currently leasing the premises on a month-to-month basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was &lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zrQlabrxcXu" title="Weighted average incremental borrowing rate"&gt;12&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zfhOXOmxfDS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents net lease cost and other supplemental lease information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_8BA_zYd7fINKNxyl" style="display: none"&gt;SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zAim7KPlS8Vd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_zJY5zkeqo6Qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease Costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzEnl_zdxX3SOKOhwd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt"&gt;Operating lease cost (cost resulting from lease payments)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zNJI74DdZmgh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zaVUvxrI8Xgk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating lease - operating cash flows (fixed payments)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--OperatingLeaseLiabilityReduction_zlA1fMwWsVF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease - operating cash flows (liability reduction)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;162,317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;139,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-current leases - right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20241231_zlGR7yPRwte5" style="text-align: right" title="Non-current leases - right of use assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2362"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_z3Cs3WdUJgzk" style="text-align: right" title="Non-current leases - right of use assets"&gt;151,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities - operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20241231_zait734oCTT3" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2366"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_z5SMTMDgFzqf" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;162,317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zXJzCNst9qGg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23OperatingLeaseLiabilityCurrent"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zRFYux9HxGJ8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23OperatingLeaseLiabilityCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2369"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2370"&gt;Non-current liabilities - operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20241231_zqhxJYXaknKk" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2372"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_zSdrEeHsTO37" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2374"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zHFgvhk3iHe6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are no future minimum payments under non-cancelable leases following the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2024-12-31_custom_MelvilleLeaseMember"
      decimals="INF"
      id="Fact002334"
      unitRef="sqft">6800</us-gaap:AreaOfLand>
    <us-gaap:PaymentsForRent
      contextRef="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MinimumMember"
      decimals="0"
      id="Fact002336"
      unitRef="USD">132600</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MaximumMember"
      decimals="0"
      id="Fact002338"
      unitRef="USD">149260</us-gaap:PaymentsForRent>
    <us-gaap:LessorOperatingLeaseOptionToExtend
      contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember"
      id="Fact002340">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $153,748 and $173,060.</us-gaap:LessorOperatingLeaseOptionToExtend>
    <us-gaap:PaymentsForRent
      contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember"
      decimals="0"
      id="Fact002342"
      unitRef="USD">153748</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember"
      decimals="0"
      id="Fact002344"
      unitRef="USD">173060</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002346"
      unitRef="Pure">0.12</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002348">&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zfhOXOmxfDS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents net lease cost and other supplemental lease information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_8BA_zYd7fINKNxyl" style="display: none"&gt;SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zAim7KPlS8Vd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_zJY5zkeqo6Qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease Costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzEnl_zdxX3SOKOhwd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt"&gt;Operating lease cost (cost resulting from lease payments)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zNJI74DdZmgh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zaVUvxrI8Xgk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating lease - operating cash flows (fixed payments)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--OperatingLeaseLiabilityReduction_zlA1fMwWsVF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease - operating cash flows (liability reduction)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;162,317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;139,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-current leases - right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20241231_zlGR7yPRwte5" style="text-align: right" title="Non-current leases - right of use assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2362"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_z3Cs3WdUJgzk" style="text-align: right" title="Non-current leases - right of use assets"&gt;151,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities - operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20241231_zait734oCTT3" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2366"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_z5SMTMDgFzqf" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;162,317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_zXJzCNst9qGg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23OperatingLeaseLiabilityCurrent"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zRFYux9HxGJ8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23OperatingLeaseLiabilityCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2369"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2370"&gt;Non-current liabilities - operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20241231_zqhxJYXaknKk" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2372"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_zSdrEeHsTO37" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2374"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002350"
      unitRef="USD">173060</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002351"
      unitRef="USD">168028</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002353"
      unitRef="USD">173060</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002354"
      unitRef="USD">168028</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002356"
      unitRef="USD">173060</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002357"
      unitRef="USD">168028</us-gaap:OperatingLeasePayments>
    <BRTX:OperatingLeaseLiabilityReduction
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002359"
      unitRef="USD">162317</BRTX:OperatingLeaseLiabilityReduction>
    <BRTX:OperatingLeaseLiabilityReduction
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002360"
      unitRef="USD">139328</BRTX:OperatingLeaseLiabilityReduction>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002364"
      unitRef="USD">151447</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002368"
      unitRef="USD">162317</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact002376">&lt;p id="xdx_80B_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zltmBzWqEc73" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
9 &#x2013; &lt;span id="xdx_822_zkzDTDJn5Zsa"&gt;FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the Warrants as liabilities in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging &#x2014;
Contracts in Entity&#x2019;s Own Equity. For certain Warrants, the Company does not control the occurrence of events, such as a tender
offer or exchange, that may trigger cash settlement of the Warrants and not result in a change of control of the Company. As a result,
such Warrants do not meet the criteria for equity treatment and the Warrants must be recorded as a derivative liability. Additionally,
certain other Warrants contain adjustments to the settlement amount based on a variable that is not an input to the fair value of a &#x201c;fixed-for-fixed&#x201d;
option as defined under ASC 815-40 and, accordingly, such Warrants are not considered indexed to the Company&#x2019;s own stock and are
not eligible for an exception from derivative accounting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2024, in connection with the Warrant Exercise and Issuance, the Company estimated the aggregate fair value of the Existing
Warrants (see Note 6- Stockholders&#x2019; Equity for details) to be $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20240208__20240208__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_ziBScYzZ13xb" title="Fair value of adjustment"&gt;1,115,334&lt;/span&gt; using the Black-Scholes option pricing model (Level 3
inputs). The following table shows the detail of the valuation assumptions used:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-ZMNRFLS_zGWiyj8eGB08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zy4Lx3EQdX9j" style="display: none"&gt;SCHEDULE
OF FAIR VALUE VALUATION ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;February 8, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_z3vjeUokVdy1" title="Risk free interest rate, minimum"&gt;4.20&lt;/span&gt; - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zsQwgnRfo9ne" title="Risk free interest rate, maximum"&gt;4.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zqcGcNRJo4Xb" title="Expected term (years)"&gt;2.75&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zMr7mo2LgO82" title="Expected term (years)"&gt;2.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zT7MOzpWsO63" title="Expected volatility"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zByUcEfDP6Vl" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zWTVHDTVNATa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2024, the Company estimated the aggregate issuance date fair value of the warrant liability related to the New Warrants (see
Note 4 - Stockholders&#x2019; Equity for details) as $&lt;span id="xdx_909_eus-gaap--DerivativeLiabilities_iI_c20240208_zaZ4oNIOeEXf" title="Derivative liabilities"&gt;2,189,420&lt;/span&gt; using the Black-Scholes option pricing model (Level 3 inputs). The following
table shows the detail of the valuation assumptions used:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_zFEXuwxSsfh3"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C07_gL3FVAALMORAN-ZMNRFLS_z9jIJ08bBYOb"&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_300_zBSJWV5SGvha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;February 8, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zD3oN4V56Q5b" title="Risk free interest rate"&gt;4.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8SRKjJEIcZ3" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0OvHJjsBvog" title="Expected volatility"&gt;101&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmGV2nd8un74" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_C04_gL3FVAALMORAN-ZMNRFLS_zRoWvOb3mFlc"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 31, 2024 and 2023, the Company estimated the aggregate fair value of the warrants classified as derivative liabilities to purchase
an aggregate of &lt;span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zLLHtFGQXIk2" title="Fair value of adjustment"&gt;3,900,014&lt;/span&gt; and &lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_z5RerJc1v6T2" title="Fair value of adjustment"&gt;4,737,908&lt;/span&gt; shares of common stock, respectively, to be $&lt;span id="xdx_907_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zC0D4h0jC5k6" title="Fair value of derivative liabilitiy"&gt;2,520,851&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zSAOIQsG5Qm9" title="Fair value of derivative liabilitiy"&gt;1,543,953&lt;/span&gt;, respectively, using the
Black-Scholes option pricing model (Level 3 inputs) using the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_z6Jk0lFnAFsd"&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_307_zKLVcIhIzVE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv7eKFqVeiu7" title="Risk free interest rate, Minimum"&gt;4.12%&lt;/span&gt; - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBHAeic1Mmv" title="Risk free interest rate, Maximum"&gt;4.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvyycNHmduL7" title="Risk free interest rate, Minimum"&gt;4.04&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zA8LVCxdYpp9" title="Expected term (years)"&gt;1.86&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMhtVWrrmuYj" title="Expected term (years)"&gt;4.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z570pw5hpvj8" title="Expected term (years)"&gt;2.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCRrHeM4Aqyi" title="Expected volatility"&gt;97&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zQRlaizdtMj2" title="Expected volatility"&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmLHGhk0izj8" title="Expected volatility"&gt;87.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1AoHDe9wf58" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4BAeX5Y6SXd" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_C01_gL3FVAALMORAN-ZMNRFLS_zQgLe4Ufswxb"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMC0qycoxwah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zKAQQdINnHu1" style="display: none"&gt;SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance, January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_c20230101__20231231_zq0KZ6eETEId" style="width: 16%; text-align: right" title="Balance, January 1, 2023"&gt;5,541,733&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20230101__20231231_zzNM3R7N5ZQa" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;(3,997,780&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance, January 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_c20240101__20241231_z9mQLh7c0ln7" style="text-align: right" title="Balance, January 1, 2024"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231_zKGDn9WG9Bhf" title="Issuance of warrants"&gt;2,189,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_iN_di_c20240101__20241231_zF9LX4FrXUh9" title="Exercise of warrants"&gt;(1,115,334&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20240101__20241231_zpDBZORmgt8b" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;(97,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_iE_c20240101__20241231_zNGCeauSjfRl" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, december 30, 2024"&gt;2,520,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z3mL6NzRpPKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
and liabilities measured at fair value on a recurring basis are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6tGfwS6kgK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z5r5D5GaLK3d" style="display: none"&gt;&lt;span&gt;SCHEDULE
OF FAIR VALUE RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements at reporting date using:&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets for identical liabilities (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant unobservable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%"&gt;Marketable securities as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4WzJJjC4wS1" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;10,184,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxeusrZDKjP6" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl2459"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2rpFzeBYrv1" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2461"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_c20241231_zmKh1dwd0rfe" style="width: 12%; text-align: right" title="Marketable securities"&gt;10,184,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Marketable securities as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zC3pfJMA2Vod" style="text-align: right" title="Marketable securities, fair value"&gt;10,181,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFxBE74S8NCj" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2467"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUaeaX3Cxbrj" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2469"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zkPmSxUWuL6e" style="text-align: right" title="Marketable securities"&gt;10,181,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrant liabilities as of December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaDiGqMl6dni" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2473"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZUD9addK6D7" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2475"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlzurmG7ynm" style="text-align: right" title="Warrant liabilities, fair value"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_ziSFoXIxNsge" style="text-align: right" title="Warrant liabilities"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrant liabilities as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRXvDdOz7IR8" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2481"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWQ1XwDflpwh" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2483"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzV5BGldJR4" style="text-align: right" title="Warrant liabilities, fair value"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231_zyQUQAE5wWT5" style="text-align: right" title="Warrant liabilities"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zHZFVjyZEVW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-02-082024-02-08_custom_ExistingWarrantMember_custom_BlackScholesOptionMember"
      decimals="0"
      id="Fact002378"
      unitRef="USD">1115334</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002385">&lt;p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-ZMNRFLS_zGWiyj8eGB08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zy4Lx3EQdX9j" style="display: none"&gt;SCHEDULE
OF FAIR VALUE VALUATION ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;February 8, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_z3vjeUokVdy1" title="Risk free interest rate, minimum"&gt;4.20&lt;/span&gt; - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zsQwgnRfo9ne" title="Risk free interest rate, maximum"&gt;4.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zqcGcNRJo4Xb" title="Expected term (years)"&gt;2.75&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zMr7mo2LgO82" title="Expected term (years)"&gt;2.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zT7MOzpWsO63" title="Expected volatility"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zByUcEfDP6Vl" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_300_zBSJWV5SGvha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;February 8, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zD3oN4V56Q5b" title="Risk free interest rate"&gt;4.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8SRKjJEIcZ3" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0OvHJjsBvog" title="Expected volatility"&gt;101&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmGV2nd8un74" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;&lt;table cellpadding="0" cellspacing="0" id="xdx_307_zKLVcIhIzVE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv7eKFqVeiu7" title="Risk free interest rate, Minimum"&gt;4.12%&lt;/span&gt; - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBHAeic1Mmv" title="Risk free interest rate, Maximum"&gt;4.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvyycNHmduL7" title="Risk free interest rate, Minimum"&gt;4.04&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zA8LVCxdYpp9" title="Expected term (years)"&gt;1.86&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMhtVWrrmuYj" title="Expected term (years)"&gt;4.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z570pw5hpvj8" title="Expected term (years)"&gt;2.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCRrHeM4Aqyi" title="Expected volatility"&gt;97&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zQRlaizdtMj2" title="Expected volatility"&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmLHGhk0izj8" title="Expected volatility"&gt;87.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1AoHDe9wf58" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4BAeX5Y6SXd" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember"
      decimals="INF"
      id="Fact002387"
      unitRef="Pure">0.0420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember"
      decimals="INF"
      id="Fact002389"
      unitRef="Pure">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_ExistingWarrantMember"
      id="Fact002391">P2Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_ExistingWarrantMember"
      id="Fact002393">P2Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_custom_ExistingWarrantMember"
      decimals="INF"
      id="Fact002395"
      unitRef="Pure">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ExistingWarrantMember"
      decimals="INF"
      id="Fact002397"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-02-08"
      decimals="0"
      id="Fact002399"
      unitRef="USD">2189420</us-gaap:DerivativeLiabilities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact002401"
      unitRef="Pure">0.0412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member"
      id="Fact002403">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact002405"
      unitRef="Pure">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact002407"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_BlackScholesOptionMember"
      decimals="0"
      id="Fact002409"
      unitRef="USD">3900014</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_BlackScholesOptionMember"
      decimals="0"
      id="Fact002411"
      unitRef="USD">4737908</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2024-12-31_custom_BlackScholesOptionMember"
      decimals="0"
      id="Fact002413"
      unitRef="USD">2520851</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2023-12-31_custom_BlackScholesOptionMember"
      decimals="0"
      id="Fact002415"
      unitRef="USD">1543953</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact002417"
      unitRef="Pure">0.0412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact002419"
      unitRef="Pure">0.0434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact002421"
      unitRef="Pure">0.0404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember"
      id="Fact002423">P1Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember"
      id="Fact002425">P4Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact002427">P2Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002429"
      unitRef="Pure">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002431"
      unitRef="Pure">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact002433"
      unitRef="Pure">0.8700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact002435"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact002437"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002439">&lt;p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMC0qycoxwah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zKAQQdINnHu1" style="display: none"&gt;SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance, January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_c20230101__20231231_zq0KZ6eETEId" style="width: 16%; text-align: right" title="Balance, January 1, 2023"&gt;5,541,733&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20230101__20231231_zzNM3R7N5ZQa" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;(3,997,780&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance, January 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_c20240101__20241231_z9mQLh7c0ln7" style="text-align: right" title="Balance, January 1, 2024"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231_zKGDn9WG9Bhf" title="Issuance of warrants"&gt;2,189,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_iN_di_c20240101__20241231_zF9LX4FrXUh9" title="Exercise of warrants"&gt;(1,115,334&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20240101__20241231_zpDBZORmgt8b" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;(97,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_iE_c20240101__20241231_zNGCeauSjfRl" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, december 30, 2024"&gt;2,520,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002441"
      unitRef="USD">5541733</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002443"
      unitRef="USD">3997780</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002445"
      unitRef="USD">1543953</us-gaap:DerivativeLiabilities>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002447"
      unitRef="USD">2189420</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002449"
      unitRef="USD">1115334</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact002451"
      unitRef="USD">97188</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002453"
      unitRef="USD">2520851</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact002455">&lt;p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6tGfwS6kgK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z5r5D5GaLK3d" style="display: none"&gt;&lt;span&gt;SCHEDULE
OF FAIR VALUE RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements at reporting date using:&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets for identical liabilities (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant unobservable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%"&gt;Marketable securities as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4WzJJjC4wS1" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;10,184,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxeusrZDKjP6" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl2459"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2rpFzeBYrv1" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2461"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_c20241231_zmKh1dwd0rfe" style="width: 12%; text-align: right" title="Marketable securities"&gt;10,184,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Marketable securities as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zC3pfJMA2Vod" style="text-align: right" title="Marketable securities, fair value"&gt;10,181,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFxBE74S8NCj" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2467"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUaeaX3Cxbrj" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2469"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zkPmSxUWuL6e" style="text-align: right" title="Marketable securities"&gt;10,181,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrant liabilities as of December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaDiGqMl6dni" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2473"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZUD9addK6D7" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2475"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlzurmG7ynm" style="text-align: right" title="Warrant liabilities, fair value"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_ziSFoXIxNsge" style="text-align: right" title="Warrant liabilities"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrant liabilities as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRXvDdOz7IR8" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2481"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWQ1XwDflpwh" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2483"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzV5BGldJR4" style="text-align: right" title="Warrant liabilities, fair value"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231_zyQUQAE5wWT5" style="text-align: right" title="Warrant liabilities"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact002457"
      unitRef="USD">10184701</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002463"
      unitRef="USD">10184701</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact002465"
      unitRef="USD">10181618</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002471"
      unitRef="USD">10181618</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002477"
      unitRef="USD">2520851</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002479"
      unitRef="USD">2520851</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002485"
      unitRef="USD">1543953</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002487"
      unitRef="USD">1543953</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-012024-12-31" id="Fact002489">&lt;p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zQwk95xqwdn2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
10 - &lt;span id="xdx_827_z8pGpu2YREya"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock Sales&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to the year ended December 31, 2024, the Company sold &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKg7Zk2AAER1" title="Sold shares of common stock"&gt;492,000&lt;/span&gt; shares of its common stock under the Rodman ATM program with a weighted-average
gross price of approximately $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFw7mnG04Qni" title="Share price"&gt;2.20&lt;/span&gt; per share and raised approximately $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zus5kgmQYQ7" title="Gross proceeds"&gt;1,084,000&lt;/span&gt; of gross proceeds. The total commissions and related
legal and accounting fees were approximately $&lt;span id="xdx_904_eus-gaap--PaymentsForLegalSettlements_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuIqcQVJa93f" title="Legal settlements paid"&gt;178,000&lt;/span&gt; and the Company received net proceeds of approximately $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zfCSxkZoeUo1" title="Net proceeds"&gt;906,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Option
Grants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to December 31, 2024, the Company granted options to purchase an aggregate &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9OxoGbvnv17" title="Grant options shares"&gt;2,152,908&lt;/span&gt; shares of the Company&#x2019;s common stock at an
exercise price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8mtyATWWQi7" title="Exercise price"&gt;2.46&lt;/span&gt; per share to employees, the Company&#x2019;s board of directors and a member of the Company&#x2019;s scientific
advisory board. The options had an aggregate grant date fair value of $&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP0528XPAvEi" title="Grant options shares"&gt;4,044,250&lt;/span&gt; and vest as follows: (i) options to purchase an aggregate
&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zA3ysS42tju2" title="Options to purchase shares"&gt;323,459&lt;/span&gt; shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoMpjuVT8AZf" title="Purchase of common shares"&gt;1,829,449&lt;/span&gt; shares of common stock
vest &lt;span id="xdx_908_ecustom--CommonStockVestRemainderPercentage_iI_pid_dp_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSBDnzWykyNg" title="Purchase of common shares"&gt;50&lt;/span&gt;% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant. The Company will
recognize the grant date fair value of the options proportionate to the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Common Stock Issuance&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent to the year ended December 31, 2024, the
Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zn754CUGeFkd" title="Number of shares of common stock"&gt;63,525&lt;/span&gt; shares of common stock to Auctus Fund, LLC in partial satisfaction of shares held by abeyance.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002491"
      unitRef="Shares">492000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002493"
      unitRef="USDPShares">2.20</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact002495"
      unitRef="USD">1084000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact002497"
      unitRef="USD">178000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember"
      decimals="0"
      id="Fact002499"
      unitRef="USD">906000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002501"
      unitRef="Shares">2152908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002503"
      unitRef="USDPShares">2.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002505"
      unitRef="USD">4044250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002507"
      unitRef="Shares">323459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002509"
      unitRef="Shares">1829449</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <BRTX:CommonStockVestRemainderPercentage
      contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002511"
      unitRef="Pure">0.50</BRTX:CommonStockVestRemainderPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember"
      decimals="INF"
      id="Fact002513"
      unitRef="Shares">63525</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl0286"
          xlink:label="xdx2ixbrl0286"
          xlink:type="locator"/>
        <link:footnote id="Footnote000551" xlink:label="Footnote000551" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the
gross proceeds of $<xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zPkGpeUXA026"
  title="Gross proceeds">1,083,915</xhtml:span>, less issuance costs of $<xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_z11HcIisOgnd"
  title="Issuance costs">182,305</xhtml:span>, resulting in net proceeds of $<xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zlB0kglfAiyl"
  title="Net proceeds">901,610</xhtml:span>. See Note 4 - Stockholders&#x2019;
Equity - ATM Sales for additional details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0286"
          xlink:to="Footnote000551"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000287"
          xlink:label="Fact000287"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000287"
          xlink:to="Footnote000551"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000288"
          xlink:label="Fact000288"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000288"
          xlink:to="Footnote000551"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0289"
          xlink:label="xdx2ixbrl0289"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0289"
          xlink:to="Footnote000551"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000290"
          xlink:label="Fact000290"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000290"
          xlink:to="Footnote000551"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000292"
          xlink:label="Fact000292"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000292"
          xlink:to="Footnote000551"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0342"
          xlink:label="xdx2ixbrl0342"
          xlink:type="locator"/>
        <link:footnote id="Footnote000558" xlink:label="Footnote000558" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the
gross proceeds of $<xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zKw9V4fZzg5l"
  title="Gross proceeds">927,335</xhtml:span>, less issuance costs of $<xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxsQLuhgdqDh"
  title="Issuance costs">39,197</xhtml:span>, resulting in net proceeds of $<xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250401__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSalesMember_zxHhFmIh8c7k"
  title="Net proceeds">888,138</xhtml:span>. See Note 4 - Stockholders&#x2019; Equity
- ATM Sales for additional details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0342"
          xlink:to="Footnote000558"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000343"
          xlink:label="Fact000343"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000343"
          xlink:to="Footnote000558"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000344"
          xlink:label="Fact000344"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000344"
          xlink:to="Footnote000558"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0345"
          xlink:label="xdx2ixbrl0345"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0345"
          xlink:to="Footnote000558"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000346"
          xlink:label="Fact000346"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000346"
          xlink:to="Footnote000558"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000348"
          xlink:label="Fact000348"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000348"
          xlink:to="Footnote000558"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0416"
          xlink:label="xdx2ixbrl0416"
          xlink:type="locator"/>
        <link:footnote id="Footnote000565" xlink:label="Footnote000565" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the
aggregate fair value of <xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHaF4Odvuz81"
  title="Aggregate fair value of common stock">3,351,580</xhtml:span> shares of common stock, which includes <xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI9x89Qv0BMb"
  title="Shares issued">2,000,000</xhtml:span> shares that were issued at the time of the warrant
exchange and <xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_907_ecustom--SharesHeldInAbeyance_iI_pid_c20240331_z1PxY0VQzHHb"
  title="Shares held in abeyance">1,351,580</xhtml:span> shares that were held in abeyance at the time of the warrant exchange. See Note 4 - Stockholders&#x2019; Equity
- Warrant Exercise and Issuance and Note 5 - Fair Value Measurement for additional details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0416"
          xlink:to="Footnote000565"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000417"
          xlink:label="Fact000417"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000417"
          xlink:to="Footnote000565"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000418"
          xlink:label="Fact000418"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000418"
          xlink:to="Footnote000565"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000420"
          xlink:label="Fact000420"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000420"
          xlink:to="Footnote000565"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000422"
          xlink:label="Fact000422"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000422"
          xlink:to="Footnote000565"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1433"
          xlink:label="xdx2ixbrl1433"
          xlink:type="locator"/>
        <link:footnote id="Footnote001502" xlink:label="Footnote001502" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the
aggregate fair value of <xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpPD4xdmm3mj"
  title="Aggregate fair value of common stock">3,351,580</xhtml:span> shares of common stock, which includes <xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5nhgzoqroak"
  title="Warrants exercisable">2,150,000</xhtml:span> shares that have been issued and <xhtml:span
  class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENoYW5nZXMgaW4gU3RvY2tob2xkZXJzJyBFcXVpdHkgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90E_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zQNmiOi5AQNa"
  title="Shares held in abeyance">1,201,580</xhtml:span> shares
held in abeyance. See Note 6 - Stockholders&#x2019; Equity - Warrant Exercise and Issuance and Note 9 - Fair Value Measurement for additional
details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1433"
          xlink:to="Footnote001502"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001434"
          xlink:label="Fact001434"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001434"
          xlink:to="Footnote001502"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001435"
          xlink:label="Fact001435"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001435"
          xlink:to="Footnote001502"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1436"
          xlink:label="xdx2ixbrl1436"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1436"
          xlink:to="Footnote001502"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001437"
          xlink:label="Fact001437"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001437"
          xlink:to="Footnote001502"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001439"
          xlink:label="Fact001439"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001439"
          xlink:to="Footnote001502"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001582"
          xlink:label="Fact001582"
          xlink:type="locator"/>
        <link:footnote id="Footnote001620" xlink:label="Footnote001620" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes gross
proceeds of $<xhtml:span
  id="xdx_90B_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20240101__20241231_zSqmWfzB3Fwf"
  title="Proceeds from debt issuance costs">8,123,391</xhtml:span>, less issuance costs of $<xhtml:span
  id="xdx_908_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231_zFrZALfkTkQg"
  title="Issuance costs">595,364</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001582"
          xlink:to="Footnote001620"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1583"
          xlink:label="xdx2ixbrl1583"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1583"
          xlink:to="Footnote001620"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>ex107_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="AsOf2026-02-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2026-02-09</startDate>
            <endDate>2026-02-09</endDate>
        </period>
    </context>
    <context id="From2026-02-092026-02-09_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-09</startDate>
            <endDate>2026-02-09</endDate>
        </period>
    </context>
    <context id="From2026-02-092026-02-09_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-09</startDate>
            <endDate>2026-02-09</endDate>
        </period>
    </context>
    <context id="From2026-02-092026-02-09_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-09</startDate>
            <endDate>2026-02-09</endDate>
        </period>
    </context>
    <context id="From2026-02-092026-02-09_4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-09</startDate>
            <endDate>2026-02-09</endDate>
        </period>
    </context>
    <context id="From2026-02-092026-02-09_5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-09</startDate>
            <endDate>2026-02-09</endDate>
        </period>
    </context>
    <context id="From2026-02-092026-02-09_6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>6</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-09</startDate>
            <endDate>2026-02-09</endDate>
        </period>
    </context>
    <context id="From2026-02-092026-02-09_7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>7</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-09</startDate>
            <endDate>2026-02-09</endDate>
        </period>
    </context>
    <context id="From2026-02-092026-02-09_8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>8</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-09</startDate>
            <endDate>2026-02-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-02-09" id="Fact000003">0001505497</dei:EntityCentralIndexKey>
    <ffd:FeeExhibitTp contextRef="AsOf2026-02-09" id="xdx2ixbrl0009">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:FeeRate
      contextRef="From2026-02-092026-02-09_1"
      id="xdx2ixbrl0014"
      unitRef="Ratio"
      xsi:nil="true"/>
    <ffd:AmtSctiesRegd
      contextRef="From2026-02-092026-02-09_1"
      id="xdx2ixbrl0018"
      unitRef="Shares"
      xsi:nil="true"/>
    <ffd:MaxOfferingPricPerScty
      contextRef="From2026-02-092026-02-09_1"
      id="xdx2ixbrl0019"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ffd:FeeRate
      contextRef="From2026-02-092026-02-09_3"
      id="xdx2ixbrl0028"
      unitRef="Ratio"
      xsi:nil="true"/>
    <ffd:AmtSctiesRegd
      contextRef="From2026-02-092026-02-09_3"
      id="xdx2ixbrl0032"
      unitRef="Shares"
      xsi:nil="true"/>
    <ffd:MaxOfferingPricPerScty
      contextRef="From2026-02-092026-02-09_3"
      id="xdx2ixbrl0033"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ffd:FeeRate
      contextRef="From2026-02-092026-02-09_5"
      id="xdx2ixbrl0042"
      unitRef="Ratio"
      xsi:nil="true"/>
    <ffd:AmtSctiesRegd
      contextRef="From2026-02-092026-02-09_5"
      id="xdx2ixbrl0046"
      unitRef="Shares"
      xsi:nil="true"/>
    <ffd:MaxOfferingPricPerScty
      contextRef="From2026-02-092026-02-09_5"
      id="xdx2ixbrl0047"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ffd:FeeRate
      contextRef="From2026-02-092026-02-09_7"
      id="xdx2ixbrl0056"
      unitRef="Ratio"
      xsi:nil="true"/>
    <ffd:AmtSctiesRegd
      contextRef="From2026-02-092026-02-09_7"
      id="xdx2ixbrl0060"
      unitRef="Shares"
      xsi:nil="true"/>
    <ffd:MaxOfferingPricPerScty
      contextRef="From2026-02-092026-02-09_7"
      id="xdx2ixbrl0061"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ffd:OfferingSctyTp contextRef="From2026-02-092026-02-09_8" id="xdx2ixbrl0066">Equity</ffd:OfferingSctyTp>
    <ffd:TtlPrevslyPdAmt
      contextRef="AsOf2026-02-09"
      id="xdx2ixbrl0079"
      unitRef="USD"
      xsi:nil="true"/>
    <ffd:FormTp contextRef="AsOf2026-02-09" id="Fact000010">S-1</ffd:FormTp>
    <ffd:SubmissnTp contextRef="AsOf2026-02-09" id="Fact000011">S-1</ffd:SubmissnTp>
    <dei:EntityRegistrantName contextRef="AsOf2026-02-09" id="Fact000012">BIORESTORATIVE THERAPIES, INC.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="From2026-02-092026-02-09_1" id="Fact000016">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-02-092026-02-09_1" id="Fact000013">Units, consisting of</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="From2026-02-092026-02-09_1" id="Fact000017">true</ffd:FeesOthrRuleFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-02-092026-02-09_1"
      decimals="INF"
      id="Fact000020"
      unitRef="USD">-0</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="From2026-02-092026-02-09_1"
      decimals="INF"
      id="Fact000015"
      unitRef="USD">-0</ffd:FeeAmt>
    <ffd:OfferingSctyTp contextRef="From2026-02-092026-02-09_2" id="Fact000024">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-02-092026-02-09_2" id="Fact000021">Common Stock, par value $0.0001 per share(2)</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="From2026-02-092026-02-09_2" id="Fact000025">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-02-092026-02-09_2"
      decimals="INF"
      id="Fact000026"
      unitRef="USD">10000000.14</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="From2026-02-092026-02-09_2"
      decimals="INF"
      id="Fact000022"
      unitRef="Ratio">0.00013810</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="From2026-02-092026-02-09_2"
      decimals="INF"
      id="Fact000023"
      unitRef="USD">1381.00</ffd:FeeAmt>
    <ffd:OfferingSctyTp contextRef="From2026-02-092026-02-09_3" id="Fact000030">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-02-092026-02-09_3" id="Fact000027">Pre-Funded Warrants to purchase shares of Common Stock (4)</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="From2026-02-092026-02-09_3" id="Fact000031">true</ffd:FeesOthrRuleFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-02-092026-02-09_3"
      decimals="INF"
      id="Fact000034"
      unitRef="USD">-0</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="From2026-02-092026-02-09_3"
      decimals="INF"
      id="Fact000029"
      unitRef="USD">-0</ffd:FeeAmt>
    <ffd:OfferingSctyTp contextRef="From2026-02-092026-02-09_4" id="Fact000038">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-02-092026-02-09_4" id="Fact000035">Common Stock issuable upon exercise of the Pre-Funded Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="From2026-02-092026-02-09_4" id="Fact000039">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-02-092026-02-09_4"
      decimals="INF"
      id="Fact000040"
      unitRef="USD">-0</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="From2026-02-092026-02-09_4"
      decimals="INF"
      id="Fact000036"
      unitRef="Ratio">0.00013810</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="From2026-02-092026-02-09_4"
      decimals="INF"
      id="Fact000037"
      unitRef="USD">-0</ffd:FeeAmt>
    <ffd:OfferingSctyTp contextRef="From2026-02-092026-02-09_5" id="Fact000044">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-02-092026-02-09_5" id="Fact000041">Warrants to purchase shares of Common Stock (4)</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="From2026-02-092026-02-09_5" id="Fact000045">true</ffd:FeesOthrRuleFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-02-092026-02-09_5"
      decimals="INF"
      id="Fact000048"
      unitRef="USD">-0</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="From2026-02-092026-02-09_5"
      decimals="INF"
      id="Fact000043"
      unitRef="USD">-0</ffd:FeeAmt>
    <ffd:OfferingSctyTp contextRef="From2026-02-092026-02-09_6" id="Fact000052">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-02-092026-02-09_6" id="Fact000049">Common Stock, par value $0.0001 per share, issuable upon exercise of Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="From2026-02-092026-02-09_6" id="Fact000053">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-02-092026-02-09_6"
      decimals="INF"
      id="Fact000054"
      unitRef="USD">10000000.14</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="From2026-02-092026-02-09_6"
      decimals="INF"
      id="Fact000050"
      unitRef="Ratio">0.00013810</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="From2026-02-092026-02-09_6"
      decimals="INF"
      id="Fact000051"
      unitRef="USD">1381.00</ffd:FeeAmt>
    <ffd:OfferingSctyTp contextRef="From2026-02-092026-02-09_7" id="Fact000058">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-02-092026-02-09_7" id="Fact000055">Placement Agent Warrants (4)</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="From2026-02-092026-02-09_7" id="Fact000059">true</ffd:FeesOthrRuleFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-02-092026-02-09_7"
      decimals="INF"
      id="Fact000062"
      unitRef="USD">-0</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="From2026-02-092026-02-09_7"
      decimals="INF"
      id="Fact000057"
      unitRef="USD">-0</ffd:FeeAmt>
    <ffd:OfferingSctyTitl contextRef="From2026-02-092026-02-09_8" id="Fact000063">Common Stock, par value $0.0001 per share, issuable upon exercise of Placement Agent Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="From2026-02-092026-02-09_8" id="Fact000067">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-02-092026-02-09_8"
      decimals="INF"
      id="Fact000068"
      unitRef="USD">875000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="From2026-02-092026-02-09_8"
      decimals="INF"
      id="Fact000064"
      unitRef="Ratio">0.00013810</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="From2026-02-092026-02-09_8"
      decimals="INF"
      id="Fact000065"
      unitRef="USD">120.83</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="AsOf2026-02-09"
      decimals="INF"
      id="Fact000069"
      unitRef="USD">20875000.14</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="AsOf2026-02-09"
      decimals="INF"
      id="Fact000070"
      unitRef="USD">2882.83</ffd:TtlFeeAmt>
    <ffd:PrevslyPdFlg contextRef="From2026-02-092026-02-09_1" id="Fact000071">false</ffd:PrevslyPdFlg>
    <ffd:PrevslyPdFlg contextRef="From2026-02-092026-02-09_2" id="Fact000072">false</ffd:PrevslyPdFlg>
    <ffd:PrevslyPdFlg contextRef="From2026-02-092026-02-09_3" id="Fact000073">false</ffd:PrevslyPdFlg>
    <ffd:PrevslyPdFlg contextRef="From2026-02-092026-02-09_4" id="Fact000074">false</ffd:PrevslyPdFlg>
    <ffd:PrevslyPdFlg contextRef="From2026-02-092026-02-09_5" id="Fact000075">false</ffd:PrevslyPdFlg>
    <ffd:PrevslyPdFlg contextRef="From2026-02-092026-02-09_6" id="Fact000076">false</ffd:PrevslyPdFlg>
    <ffd:PrevslyPdFlg contextRef="From2026-02-092026-02-09_7" id="Fact000077">false</ffd:PrevslyPdFlg>
    <ffd:PrevslyPdFlg contextRef="From2026-02-092026-02-09_8" id="Fact000078">false</ffd:PrevslyPdFlg>
    <ffd:TtlOffsetAmt
      contextRef="AsOf2026-02-09"
      decimals="INF"
      id="Fact000080"
      unitRef="USD">0</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="AsOf2026-02-09"
      decimals="INF"
      id="Fact000081"
      unitRef="USD">2882.83</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="From2026-02-092026-02-09_1" id="Fact000084">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.&lt;span id="xdx_C0F_gIFON-DYDU_zB3f64l95Zvf"&gt;&lt;span id="xdx_C0E_gIFON-GHQRUYJ_zf49cdNGa2I4"&gt;&lt;span id="xdx_C08_gIFON-SKI_zIhKc3G4tQfe"&gt;&lt;span id="xdx_C0B_gIFON-UEJ_zZfXxrlNQts7"&gt;&lt;span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"&gt;&lt;span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"&gt;&lt;span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc"&gt;Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_C0E_gIFON-DYDU_zpg86F7pLEj8"&gt;&lt;span id="xdx_C02_gIFON-GHQRUYJ_zQSy3JjIeSN4"&gt;&lt;span id="xdx_C04_gIFON-SKI_zqVRBVBoDev9"&gt;&lt;span id="xdx_C03_gIFON-UEJ_zjgS3N808BA5"&gt;&lt;span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"&gt;&lt;span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"&gt;&lt;span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6"&gt;Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-02-092026-02-09_2" id="Fact000087">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.&lt;span id="xdx_C0E_gIFON-GHQRUYJ_zf49cdNGa2I4"&gt;&lt;span id="xdx_C08_gIFON-SKI_zIhKc3G4tQfe"&gt;&lt;span id="xdx_C0B_gIFON-UEJ_zZfXxrlNQts7"&gt;&lt;span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"&gt;&lt;span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"&gt;&lt;span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc"&gt;Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_C02_gIFON-GHQRUYJ_zQSy3JjIeSN4"&gt;&lt;span id="xdx_C04_gIFON-SKI_zqVRBVBoDev9"&gt;&lt;span id="xdx_C03_gIFON-UEJ_zjgS3N808BA5"&gt;&lt;span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"&gt;&lt;span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"&gt;&lt;span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6"&gt;Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-02-092026-02-09_3" id="Fact000091">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.&lt;span id="xdx_C08_gIFON-SKI_zIhKc3G4tQfe"&gt;&lt;span id="xdx_C0B_gIFON-UEJ_zZfXxrlNQts7"&gt;&lt;span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"&gt;&lt;span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"&gt;&lt;span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc"&gt;Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_C04_gIFON-SKI_zqVRBVBoDev9"&gt;&lt;span id="xdx_C03_gIFON-UEJ_zjgS3N808BA5"&gt;&lt;span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"&gt;&lt;span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"&gt;&lt;span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6"&gt;Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_C04_gIFON-UEJ_zuQ987MkBvlb"&gt;&lt;span id="xdx_C05_gIFON-EBFK_zHHgbUJ57zx2"&gt;No
    separate registration fee required pursuant to Rule 457(g) under the Securities Act,&lt;/span&gt;&lt;/span&gt;</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-02-092026-02-09_4" id="Fact000094">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.&lt;span id="xdx_C0B_gIFON-UEJ_zZfXxrlNQts7"&gt;&lt;span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"&gt;&lt;span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"&gt;&lt;span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc"&gt;Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_C03_gIFON-UEJ_zjgS3N808BA5"&gt;&lt;span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"&gt;&lt;span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"&gt;&lt;span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6"&gt;Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-02-092026-02-09_5" id="Fact000098">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.&lt;span id="xdx_C02_gIFON-XDHX_z0NAxRbkpHi1"&gt;&lt;span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"&gt;&lt;span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc"&gt;Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_C05_gIFON-XDHX_zqTLVeIViDu1"&gt;&lt;span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"&gt;&lt;span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6"&gt;Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_C05_gIFON-EBFK_zHHgbUJ57zx2"&gt;No
    separate registration fee required pursuant to Rule 457(g) under the Securities Act,&lt;/span&gt;</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-02-092026-02-09_6" id="Fact000101">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.&lt;span id="xdx_C05_gIFON-EBFK_znZcXsPzeVVk"&gt;&lt;span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc"&gt;Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_C05_gIFON-EBFK_zoItznNwNw5"&gt;&lt;span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6"&gt;Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.&lt;/span&gt;&lt;/span&gt;</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-02-092026-02-09_7" id="Fact000105">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.&lt;span id="xdx_C0C_gIFON-CBJI_zKrp0cAIzelc"&gt;Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.&lt;/span&gt;&lt;span id="xdx_C05_gIFON-CBJI_zDbCmVjJgpH6"&gt;Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.&lt;/span&gt;No
    separate registration fee required pursuant to Rule 457(g) under the Securities Act,</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-02-092026-02-09_8" id="Fact000108">Pursuant
    to Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the shares of Common Stock being registered
    hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock
    being registered hereunder as a result of stock splits, stock dividends or similar transactions.Pursuant
    to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may
    be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.Calculated
    pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.</ffd:OfferingNote>
    <ffd:OffsetTableNa contextRef="AsOf2026-02-09" id="Fact000109">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="AsOf2026-02-09" id="Fact000110">N/A</ffd:CombinedProspectusTableNa>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
